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The present book gives an exceptional overview of molecular imaging. Practical 
approach represents the red thread through the whole book, covering at the same time 
detailed background information that goes very deep into molecular as well as cellular 
level. Ideas how molecular imaging will develop in the near future present a special 
delicacy. This should be of special interest as the contributors are members of leading 





 MOLECULAR IMAGING 
 
Edited by Bernhard Schaller 
 
  
 MOLECULAR IMAGING 
 





Edited by Bernhard Schaller
Contributors
Yasumi Uchida, Bernhard Schaller, Fatemeh Momen-Heravi, Marisa Martin-Fernandez, David Clarke, Sarah Rebecca 
Needham, Selene K. Roberts, Daniel J. Rolfe, Christopher J. Tynan, Stephen E.D. Webb, Martyn Winn, Michael Hirsch, 
Laura Zanetti Domingues, Tetsuya Yuasa, Tohoru Takeda, Haibiao Gong, Lakshmi Sampath, Joy Kovar, D. Mike Olive, 
Nanguang Chen, Guangjun Gao, Shau Poh Chong, Guillermina Ferro-Flores, Enrique Morales-Avila, Blanca E Ocampo-
Garcia, Flor De Maria Ramirez, Bernard Te Boekhorst, Klaas Nicolay, Pirkko-Liisa Kellokumpu-Lehtinen, Xingchen Wu, 
Wenbin Zeng, Zhiguo Liu, Wei Wang, Alexander Guimaraes, Shaunagh McDermott, Manuel Freiberger, Hermann 
Scharfetter, Lorena Favaro Pavon, Luciana Marti, Tatiana TaÃ s Sibov, Maria Izabel Camargo-Mathias, Edson Amaro Jr., 
Lionel Gamarra, Laura Cerchia, Vittorio De Franciscis, Anna Rienzo, Mahaveer Swaroop Bhojani, Marcian Van Dort, 
Abass Alavi, Babak Saboury, Dimiter Prodanov, Kris Verstreken
© The Editor(s) and the Author(s) 2012
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2012 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Molecular Imaging
Edited by Bernhard Schaller
p. cm.
ISBN 978-953-51-0359-2
eBook (PDF) ISBN 978-953-51-6922-2
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Bernhard Schaller (MD, PhD, DSC) studied Medicine in Switzerland and 
Biochemistry in Sweden and Great Britain. In later years, he developed 
an interest in Molecular Imaging and since than has been integrating this 
method into his other research activities. His principal contributions are 
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Molecular Imaging represents a unique project that was only possible by the exceptional 
InTech support. The authors of the book give therefore an overview of the relatively 
new topic of molecular imaging, with broad background to basic but also clinical 
sciences. The present book is best suited not only for the beginners in the area to gain 
some overview of the feature, but also for professionals to see trends of other groups 
from all over the world. 
Molecular imaging has rapidly gained influence in medicine, not only for different 
research projects, but also in the view of personalized medicine. The door for 
personalized medicine is now widely open. Also in this direction, the present book 
gives more than only a little food for thought. 
Even if Molecular Imaging covers a broad part of the whole topic, it was and it is not 
our goal to be comprehensive. Such a project can never be complete, and different 
authors from all over the world can only give some insights of their daily work. Ideas 
how molecular imaging will develop in the near future present a special delicacy. 
We hope that readers will enjoy this book. I would like to thank all those who made 
the project possible, especially Ms Pantar and Mrs Durovic from InTech. They both 
were angels for the authors. 
Prof. Bernhard Schaller, MD, PhD, DSC 
Department of Neurosurgery, 
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1
Modern Quantitative Techniques for
PET/CT/MR Hybrid Imaging 
Babak Saboury*, Mateen Moghbel*, Sandip Basu and Abass Alavi 
Radiology Department, School of Medicine, University of Pennsylvania, 
USA 
1. Introduction 
The relentless progress that is being made in tomographic imaging modalities is inexorably 
expanding the application of positron emission tomography (PET) in the clinical field. Some 
of the most noteworthy advances involve innovations in quantitative techniques for hybrid 
imaging modalities such as PET/Computed Tomography (CT) and PET/Magnetic 
Resonance Imaging (MRI), which have greatly improved the ability to segment and analyze 
functional images produced with radiotracers such as (18F) Fluorodeoxyglucose (FDG). With 
continued technological progress, quantitative approaches can supplant the more subjective 
qualitative and semi-quantitative techniques that currently dominate the clinical use of PET. 
Although it does not meet the rigorous standards for objectivity in medical research, the 
qualitative method of visual assessment continues to be very prevalent in the clinical field. 
The benefits of this technique’s simplicity are offset by its immense subjectivity and the 
consequent lack of reproducibility and pervasiveness of inter-reader variability. These 
limitations are mitigated in the somewhat more consistent semi-quantitative technique of 
standardized uptake value (SUV), but concerns about reproducibility still linger. The 
manual delineation of the regions of interest (ROIs) within an image maintains a degree of 
subjectivity that hinders the reproducibility of the analysis. Therefore, while these 
methodologies may be less demanding, they open the door to the possibility of variability. 
Using structural and functional imaging, namely PET/CT and PET/MRI, and combining 
structural information with functional data by various quantitative techniques provide a far 
more objective method of image analysis, but also carry their own set of inherent difficulties. 
This method of quantification is far more technically demanding and requires complex 
mathematical computations1,2.  
Despite its limitations, it appears likely that quantitative analysis of hybrid imaging will 
become the method of choice in the future. Recent developments in tomographic imaging 
have improved the ability of PET to accurately assess global function in addition to the more 
conventional ROI analysis. Global assessment, which combines data on the activity of a 
lesion measured by PET and its segmented volume defined by CT, has wide-reaching 
applications in a diverse range of medical fields. The viability of this alternative method 
* Co-First Authors 
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depends on the accuracy of segmentation and quantification, as well as the alleviation of 
some of the inherent obstacles of hybrid imaging. 
2. Classifications of PET data analysis 
The techniques employed for the analysis of functional images can be subdivided into three 
categories: qualitative, semi-quantitative, and quantitative. The first of these three is by far 
the most subjective, and entails the visual interpretation of data by human observers. The 
second utilizes indices such as SUV and lesion-to-background ratio to measure activity in 
assigned regions of interest. Lastly, the third employs more complex mathematical and 
technical processes, such as non-linear regression and Patlak-Gjedde graphical analysis. 
Despite the superior reproducibility and objectivity it provides, this final technique is 
arguably rendered impractical for clinical use by its technical rigors. On the other hand, the 
other two techniques are far more susceptible to both inter-reader and intra-reader 
variability, but are widely employed due to their simplicity.  
3. Models for quantifying absolute glucose metabolic rate 
The metabolic rate of glucose is estimated with the aid of FDG, an analog of glucose that is 
currently the most widely used PET radiotracer3,4,5. The metabolism of FDG is in turn 
measured through kinetic modeling of the data6. This process reveals a series of rate 
constants that shed light not only on the absolute metabolic rate, but also the steps within 
glucose metabolism. 
 
Fig. 1. The three-compartment model involves the transport of FDG from the plasma to the 
cell, as well as the phosphorylation and dephosphorylation of FDG within the cell. Simpler 
models ignore the dephosphorylation of FDG, thereby eliminating the k4 rate constant. 
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When dealing with FDG, the tracer kinetic model comprises three compartments that 
encompass the processes of transportation and phosphorylation. More specifically, these 
compartments demarcate the FDG in the blood plasma, the FDG in the cell, and the FDG-6-
phosphate in the cell (Fig. 1). The first compartment (C1) is assumed to be open, with free 
exchange with other tissues in the body. It is for this reason that the input function of this 
compartment (i.e., FDG levels in the plasma) cannot be calculated and must be measured by 
arterial sampling. The second compartment (C2) refers to FDG that is in the tissue and not in 
the vasculature. These pools of FDG in the cell are available for phosphorylation by 
hexokinase. Once FDG is in its phosphorylated form, it occupies the third compartment 
(C3).  
If a kinetic model accounts for the dephosphorylation of FDG-6-phosphate by glucose-6-
phosphatase in addition to transportation and phosphorylation, it is termed “reversible.”7 
However, this three-compartment model is far from the only one in use; more simplified 
“irreversible” models often ignore the dephosphorylation of FDG on the assumption that 
the incorporation of fewer parameters will lower variance.1 These methods include non-
linear regression analysis, which estimates a single rate constant Ki in the place of k1, k2, and 
k3, and Patlak-Gjedde graphical analysis, which calculates activity as a function of the 
concentration, distribution volume, and net rate of influx of FDG.8  
By applying this simplified irreversible model to dynamic PET data, non-linear regression 
analysis can estimate the net rate of FDG influx. The advantages of this method of 
quantification include its lack of dependence on the length of time over which uptake occurs 
and its ability to provide insight into the rate constants behind glucose metabolism. But on 
the other hand, the technical complexity of the method makes it demanding and time-
consuming, with the required arterial sampling only exacerbating these issues.  
In comparison to non-linear regression, the method of Patlak-Gjedde graphical analysis is 
more robust due to a simpler scanning protocol that is less susceptible to noise. This 
technique, which also has the ability to produce parametric images, is modeled by the 
following equation: 
      
0
t
p i pc t c t K c d        
where  
c(t) = activity in the tissue as measured by the PET scanner at time t, 
cp(t) = concentration of FDG in the plasma, 
λ = distribution volume of FDG, 
Ki = net rate of FDG influx into the tissue, and 
 is a dummy integration variable 
Unlike non-linear regression, Patlak-Gjedde graphical analysis cannot calculate individual 
rate constants for the metabolism of glucose. But similar to non-linear regression, it requires 
dynamic scanning, which carries with it a host of limitations.  
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Dynamic scanning, which is crucial to both non-linear regression and Patlak-Gjedde 
graphical analysis, entails an extended sequence of acquisitions that are subsequently 
reconstructed. The high availability of dynamic data, which is comparatively less dependent 
on imaging time, works to the advantage of these quantitative techniques. On the other 
hand, the rigors of the procedure make it technically demanding and time-consuming. 
Moreover, since only one bed position can be assumed per scan, each lesion may have to be 
acquired separately. The need to quantify FDG concentration in the plasma also necessitates 
arterial blood sampling at several points during the scan.  
The arterial sampling performed during dynamic scans allows for the extrapolation of time-
vs.-activity curves, which can yield rate constants through non-linear least squares 
approximation. This approach to quantifying FDG activity is certainly more objective than 
more popular alternatives such as SUV and visual assessment, but is far from immune to 
error. First and foremost, the assumption that FDG-6-phosphate is not dephosphorylated 
once it is inside the cell is overly simplistic and can lead to inaccurate estimates. Variance 
due to imaging noise and partial-volume effects further limit these methods of 
quantification. 
In addition to non-linear regression and Patlak-Gjedde graphical analysis, there exist other, 
more simplified kinetic methods for quantifying the rate of glucose metabolism. This is done 
using only a single static scan, albeit with somewhat lower accuracy. An autoradiographic 
method developed by Sokoloff et al. is one such single-scan method, but is still limited by 
the need of arterial sampling to determine FDG concentration9,10. A similar technique 
devised by Hunter et al. is able to quantify metabolic rates with the aid of limited venous 
blood sampling11.  
4. Quantification of activity through SUV 
Standardized uptake value (SUV)—also known as differential absorption ratio (DAR), 
differential uptake ratio (DUR), and standardized uptake ratio (SUR)—is currently the most 
common semi-quantitative index employed in the clinical field. It has the ability to measure 
FDG metabolism through tracer concentration in the tissue. It is calculated according to the 
following formula: 
 18
( / ) 1
( ) ( )
MeanROI concentration MBq mlSUV
Injecteddose MBq Bodyweight g decay factor of F
    
The advantages of SUV lie in its ease of use; when compared to the aforementioned kinetic 
models, SUV is far less technically demanding and computationally complex. The fact that 
its values are automatically estimated by software makes the SUV method highly expedient 
for clinical use. The lack of dependency on arterial sampling and the comparatively short 
scanning time also work in its favor. In spite of these shortcuts, kinetic modeling reveals a 
strong correlation between SUV and glucose metabolic rate. However, that is not to say that 
SUV measurements are not just as—if not more—prone to error than kinetic modeling 
(Table 1). 
Currently, PET scanners are most often normalized to the body weight of the patient. This 
causes the systematic overestimation of SUV in obese patients, since adipose tissue 
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demonstrates comparatively low FDG uptake because of its dampened metabolic activity. 
Studies that employed the parameters of lean body mass and body surface area instead of 
body weight were found to be more accurate12,13,14.  
a. Patient-Related Factors 
Factor Effects Corrective measures 
Body size and habitus 
(3.3) 
SUV in obese patients 
overestimates FDG uptake relative 
to normal patients 
Use of lean body mass 
(SUVLBM) or body surface 
area (SUVBSA)  
Serum glucose levels 
(3.4) 
Reduced FDG uptake in target 
tissues with increasing blood 
glucose levels 
Control of blood glucose 
before administering FDG 
and applying correction 
factor for glucose level 
Organ and lesion motion Reduction of SUV Respiratory gating or 4D 
reconstruction 
b. Technical Factors 
Factor Effects Corrective measures 
Duration of uptake 
period (3.5) 
Increase in SUV with increasing 
time in malignant lesions  
Standardization of time of 
image acquisition  
Attenuation correction 
and reconstruction 
methods (spatial filter 
kernel, image resolution, 
number of iterations) 
Underestimation of SUV with 






Underestimation of SUV in lesions 
with diameters smaller than 2-3 × 
spatial resolution  
Adopt an optimal partial 
volume correction factor 
Size of the ROI and non- 
uniformity of tracer 
distribution in the lesion 
Low SUVmean for large ROIs and 
high random errors in smaller 
ROIs 
Standard size ROIs placed 
reproducibly in the same 
location, SUVmax preferable 
to SUVmean. 
Organ and lesion motion Mismatch between EM and CT 
data 
Respiratory gating or 4D 
reconstruction 
Table 1. Factors influencing standardized uptake value (SUV) determination for FDG at 
intended regions of interest, their undesirable effects, and associated required corrective 
measures. (Based on Basu et al. [95] with permission from Elsevier Inc.). 
5. Effect of respiratory motion on SUV 
The accuracy of quantification through PET/CT imaging is affected by several factors. 
Historically, one of the most problematic factors—especially in the scanning of thoracic lesions 
or non-small cell cancers—has been respiratory motion, which impacts diagnostic and staging 
accuracy. Misregistration due to respiratory motion in the thorax and abdomen between data 
acquired through PET and CT was reported soon after commercial introduction of PET/CT 
and has been one of the most challenging research topics in the field.  
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The advantages of SUV lie in its ease of use; when compared to the aforementioned kinetic 
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demonstrates comparatively low FDG uptake because of its dampened metabolic activity. 
Studies that employed the parameters of lean body mass and body surface area instead of 
body weight were found to be more accurate12,13,14.  
a. Patient-Related Factors 
Factor Effects Corrective measures 
Body size and habitus 
(3.3) 
SUV in obese patients 
overestimates FDG uptake relative 
to normal patients 
Use of lean body mass 
(SUVLBM) or body surface 
area (SUVBSA)  
Serum glucose levels 
(3.4) 
Reduced FDG uptake in target 
tissues with increasing blood 
glucose levels 
Control of blood glucose 
before administering FDG 
and applying correction 
factor for glucose level 
Organ and lesion motion Reduction of SUV Respiratory gating or 4D 
reconstruction 
b. Technical Factors 
Factor Effects Corrective measures 
Duration of uptake 
period (3.5) 
Increase in SUV with increasing 
time in malignant lesions  
Standardization of time of 
image acquisition  
Attenuation correction 
and reconstruction 
methods (spatial filter 
kernel, image resolution, 
number of iterations) 
Underestimation of SUV with 






Underestimation of SUV in lesions 
with diameters smaller than 2-3 × 
spatial resolution  
Adopt an optimal partial 
volume correction factor 
Size of the ROI and non- 
uniformity of tracer 
distribution in the lesion 
Low SUVmean for large ROIs and 
high random errors in smaller 
ROIs 
Standard size ROIs placed 
reproducibly in the same 
location, SUVmax preferable 
to SUVmean. 
Organ and lesion motion Mismatch between EM and CT 
data 
Respiratory gating or 4D 
reconstruction 
Table 1. Factors influencing standardized uptake value (SUV) determination for FDG at 
intended regions of interest, their undesirable effects, and associated required corrective 
measures. (Based on Basu et al. [95] with permission from Elsevier Inc.). 
5. Effect of respiratory motion on SUV 
The accuracy of quantification through PET/CT imaging is affected by several factors. 
Historically, one of the most problematic factors—especially in the scanning of thoracic lesions 
or non-small cell cancers—has been respiratory motion, which impacts diagnostic and staging 
accuracy. Misregistration due to respiratory motion in the thorax and abdomen between data 
acquired through PET and CT was reported soon after commercial introduction of PET/CT 
and has been one of the most challenging research topics in the field.  
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Fast gantry rotation of less than one second per revolution and sizeable detector coverage of 
over 2 cm enable CT systems to scan over 100 cm in the cranial-caudal direction in 20 
seconds. By comparison, PET typically requires 2 to 5 minutes to scan 15 cm. The temporal 
resolutions of CT and PET are also disparate: less than 1 second for CT and about one 
respiratory cycle for PET. This discrepancy in temporal resolution may lead to a 
misalignment of the tumor position between the CT and PET data, and may compromise the 
quantification process. 
These issues with misregistration due to motion can be remedied by respiratory gating. 4D-
PET can also be performed on this PET/CT for RT, but its application has been limited due 
to the total acquisition time of approximately 40 minutes. Most patients cannot hold their 
arms over their heads for such a long period of time, and the inevitable motion that results 
compromises the PET data. Moreover, the splitting of coincident events into multiple bins or 
phases and the low spatial resolution of 5 to 10 mm further hinder the applicability of 4D-
PET. When combined with respiratory gating, this technique of 4D-PET yields higher SUVs 
and more consistent tumor volumes between PET and CT.  
6. Factors affecting SUV measurements 
The SUVs of malignant lesion are heavily dependent on glycemic status. Hyperinsulinemia 
causes enhanced glycolysis in adipose tissue and muscles, leading to comparatively low 
SUVs elsewhere. For this reason, the glucose level of patients undergoing PET is normally 
capped at 150 to 200 mg/dl. Studies have shown the elevated blood glucose levels (up to 250 
mg/dl) do not affect SUV in inflammatory or benign lesions.  
Most centers measure SUV at a single time point by assigning ROIs. Variation in the time 
interval between tracer injection and image acquisition, which have a significant effect on 
SUV, is unavoidable to some extent. The confounding effect can be minimized by 
standardizing protocols outlining the time and direction of the scan. The SUV of tumors 
continues to rise for several hours after injection, whereas that of the surrounding non-
malignant tissue can actually fall. As a result, delayed PET scans often demonstrate better 
contrast than early PET scans because of an increased lesion-to-background ratio.  
The overlap between inflammatory and malignant lesions precludes SUV from being able to 
distinguish between them. Dual-time point imaging has been used instead to assess 
malignancies in the head, neck, lungs, breast, cervix, gallbladder, and CNS. The lack of 
glucose-6-phosphatase in the tumor cells relative to normal cells slows the dephosphorylation 
of FDG. This leads to increased contrast between tumor and normal cells over time. This 
also provides a means of differentiating between benign and malignant lesions. 
In many studies of various malignancies, dual-time point imaging improved the sensitivity 
and specificity of PET. The higher specificity is due to the increasing difference in FDG 
uptake over time between malignant and benign lesions. On the other hand, the higher 
sensitivity is due to increased lesion-to-background ratio that results from increased uptake 
in malignancies and the clearance of FDG in other tissues. 
7. Future Implications for SUV 
It has been suggested that SUV is not optimal for classifying tumors. Dual-time point 
imaging and delayed PET imaging may be embraced as a more accurate method in the 
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future. As structural and functional imaging become increasingly fused, it is likely that 
PET/CTs and PET/MRIs will be integral in the assessment of pathophysiological processes.  
8. Correcting for Partial-Volume Effects 
The partial-volume effect (PVE) affects objects that are less than 2 to 3 times the spatial 
resolution of the PET scanner. PVE causes the systematic underestimation of SUVs yielded 
from PET data. Physiological and patient motion also cause the degradation of spatial 
resolution and exacerbate PVE. These difficulties can be compensated for with 4D 
respiratory gated PET/CT. Studies have shown that using anatomic imaging (namely CT) to 
measure the true size of lesions also causes substantial increases in the accuracy of PET data. 
The best resolution that can be achieved by modern clinical whole-body scanners is 4 mm. 
In the field, spatial resolution is normally worse by a significant margin. Structures that are 
less than 2 to 3 times the spatial resolution of the system, as measured by the full-width at 
half-maximum, are subject to PVE. Contrast between a lesion and the background decreases 
the smaller the region is. There are three broadly-defined approaches to minimizing PVE: 
1. Correcting for the loss of resolution after reconstruction; 
2. Incorporating PVE modeling into the reconstruction process; 
3. Using the size of a lesion as determined by anatomic imaging to correct for PVE. 
Correction of PVE was broached as early as the 1980s when CT and PET were used to 
examine patients with AD and other CNS disorders that cause cerebral atrophy. High 
resolution MR imaging has since led to accurate segmentation and measurement in the gray 
matter, white matter, and cerebrospinal fluid (CSF).  
9. Factors affecting recovery coefficients 
The recovery coefficient (RC) is the ratio of observed activity to true activity in PET. It is 
affected by lesion-to-background ratio, matrix size, etc. RC is usually measured in a static 
condition, but is subsequently applied in the field to scans with physiological and patient 
motion. A study carried out by Hickeson et al. reported an increase from 58% to 89% in the 
accuracy of metabolic activity measurements in lung nodues smaller than 2 cm when 
partial-volume effects were corrected for and a threshold SUV of 2.5 was used to 
differentiate between malignant and benign lesions15. 
10. Assessing global metabolic activity 
Global metabolic activity is calculated by multiplying partial-volume corrected SUV and the 
volume of the organ of interest, as determined by CT or MRI. The ability to segment images 
into organs and even subcomponents of organs will no doubt have enormous value in the 
field of oncology. The therapeutic efficacy of treatment on multiple malignancies can be 
better measured in this manner.  
The assessment of disease through global metabolic activity is particularly useful in 
neuropsychiatric disorders, where the measurement of glucose metabolism in the entire 
brain can be a more reliable indicator of disease than that of a single region of interest. 
Atrophy-corrected whole brain metabolism shows a high degree of sensitivity to and 
correlates well with cognitive function, as measured by mini-mental status examinations16.  
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MeanCMRGlcAtrophy corrected average CMRGlc percentageof brain tissuein theintracranialvolume  
Global metabolic activity was first measured in studies of AD by Alavi et al.1. It was 
calculated by multiplying segmented brain volumes—as determined by MR—by the mean 
metabolic rate for glucose to yield metabolic volumetric product (MVP). Volume has to be 
measured accurately by algorithms on computers, while metabolic rate has to be corrected 
for partial-volume effects to be on target. Quantitative approaches that employ either 
structural or functional imaging are prone to more inaccuracy and variability than those 
utilizing both modalities.  
The extent of athereosclerosis in the aorta can also be quantified by multiplying SUV in the 
aortic wall with volumetric data of the aortic wall, as determined by CT. The resulting MVP 
value is representative of the atheroscleoritc burden in each segment of the aorta17. The same 
principles can be applied to the diffuse hepatic steatosis; hepatic MVP can be calculated by 
multiplying the mean hepatic SUV by the liver volume measured by MRI18. 
Perhaps one of the most valuable applications of global metabolic activity is in the field of 
oncology. This technique of analysis can determine the metabolic burden of individual 
lesions. Metabolic burden (MB) is calculated by multiplying the partial-volume corrected 
SUV by the volume of the lesion measured by CT and dividing the product by the recovery 
coefficient.  
 meanCT CTMB SUV V RC  
Metabolic burden is a promising method of assessing total body tumor burden, but there are 
other techniques that also draw from the concept of global metabolic activity. The measure 
of Total Lesion Glycolysis (TLG) multiplies SUV by lesion volume without accounting for 
the recovery coefficient.  
11. Image segmentation in quantitative PET imaging 
Segmentation, a crucial step in analyzing structural images, groups voxels into sets of 
distinct classes. Despite its technical complexity, the process of segmentation has breached 
the clinical field. Through segmentation, organ and tumor volume can be accurately 
measured, target treatment volumes can be defined, attenuation maps can be generated, and 
voxel-based anthropomorphic phantoms can be constructed from high resolution anatomical 
images. Approaches to segmentation are myriad, and include: 
 Thresholding 
 Region growing 
 Classifiers 
 Clustering 
 Edge detection 
 Markov random field models 
 Artificial neutral networks 
 Deformable models 
 Atlas guidance 
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The process of segmenting CT images of regions such as the lungs is normally preceded by 
inhomogeneity correction and intensity standardization, and can be accomplished through 
thresholding and the construction of masks. Subtracting masks from one another allows for 
the segmentation of smaller structures. Lesion detectability is enhanced by similarity 
measures (e.g., cross-B-energy operator), while the reliability of the algorithms behind 
partial-volume correction is dependent on the accuracy of segmentation and coregistration. 
Errors in segmentation only affect the partial-volume correction of the mis-segmented 
region19. It is believed that errors in segmentation carry greater weight in measuring the true 
tracer concentration of a region in comparison to errors in coregistration. 
12. Novel approaches to segmentation 
Image segmentation is necessary for the quantification of tumor activity, assessment of 
tumor response to treatment, and definition of target volumes for treatment20,21. 
Demarcating target regions in noisy functional images is one of the most challenging aspects 
of the oncological applications of PET. Delineating target volumes is normally operator-
dependent in the clinical setting. Since this methodology opens the door to high inter-reader 
variability, moving towards automated techniques would reduce subjectivity.  
A method for automated segmentation involving Expectation Maximization-based mixture 
modeling using k-means clustering has been proposed. A multiscale Markov model can 
refine segmentation by modeling spatial correlations between neighboring image voxels22. 
Anthropomorphic phantom experiments evaluated the proposed segmentation algorithm. 
Segmentation using the Markov Random Field Model was shown to reduce relative error. 
13. Conclusions 
The incorporation of functional imaging such as MR and CT into PET analysis has expended 
and strengthened its applications in the medical field. Measures of global metabolic activity 
that can be made with PET/CT and PET/MRI may be superior to those of SUVmax, 
especially in oncology. Further refinements might prove invaluable for the optimal 
utilization of this powerful imaging technology. 
14. View to the future  
We believe that the future of imaging is going to shift rapidly from a single modality 
approach to hybrid imaging with heavy emphasis on PET-CT and possibly PET-MRI. 
Clearly, the impact of PET-CT has been substantial in many domains. In particular, this 
approach has revolutionized the practice of oncology and other disciplines with regard to 
monitoring the effects of various interventions. In particular, PET-CT has been critical in the 
preoperative assessment of the staging of disease and optimal characterization of the 
structural abnormalities noted before surgery. Similarly, the field of radiation oncology has 
rapidly adopted PET-CT imaging for effective control of a variety of cancers, in particular, 
those that originate in the lungs and the head/neck regions. The role of contrast enhanced 
CT can be expected to decline if PET data indicates that this extra step may be redundant 
and will not substantially alter the results generated from PET alone. The role of PET-MRI is 
unclear at this time. However, its applications in the brain will obviate the need for PET-CT 
for this anatomic site. This is mainly due to the fact that information provided by CT for 
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central nervous disorders is suboptimal and therefore combined PET-MRI will provide 
superior data in the brain. It is possible that orthopedic applications of PET may 
substantially improve by combining PET and MRI, particularly in the structures of the feet 
and the knees. It is unclear whether PET-MRI will be as successful in assessing disease 
activity in the chest and abdomen. This is primarily due to the fact that attenuation 
correction in these anatomic sites is complex and may not be feasible with MR approaches 
alone. Efforts are on the way to estimate the degree of attenuation at these sites but we are 
uncertain that this will lead to overcoming the difficulties that exist in this particular 
domain. Finally, the use of hybrid imaging has substantially improved our ability to 
optimally quantify PET data. This will further enhance the role of functional imaging for 
accurate characterization of lesions and response to therapy.  
15. Summary 
The information provided in this chapter reveals a paradigm shift in medical imaging and 
has described in detail the need for hybrid imaging with an emphasis on PET-CT as major 
modality for the future in medicine. Therefore, practitioners of medicine must make every 
effort to amiliarize themselves with the capabilities of these modalities in order to optimize 
treatments and care for their patients.  
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central nervous disorders is suboptimal and therefore combined PET-MRI will provide 
superior data in the brain. It is possible that orthopedic applications of PET may 
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15. Summary 
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1. Introduction 
Molecular imaging (MI) comprises non-invasive monitoring of functional and 
spatiotemporal processes at molecular and cellular levels in humans and other living 
systems. In contrast to conventional diagnostic imaging, MI seeks to probe the molecular 
abnormalities that are the basis of disease rather than capture the images of the end effects 
of the molecular alterations. Imaging techniques such as magnetic resonance imaging (MRI), 
single photon emission computed tomography (SPECT), positron emission tomography 
(PET) and optical fluorescence imaging (OI) have been used to monitor such processes. 
Radionuclide-based imaging methods, such as SPECT and PET, use internal radiation that is 
administered through a target-specific molecule labeled with a radionuclide at doses free of 
pharmacologic side effects. Nuclear imaging is an established clinical MI modality that, 
compared to other modalities, offers better sensitivity and has no tissue penetration limits 
(Massoud & Gamghir, 2003; Ferro-Flores et. al., 2010a). Nuclear technologies have been 
evolving toward greater sensitivity due to enhanced hardware development, such as multi-
pinhole acquisitions methods or pixelated semiconductor detectors. In parallel with the 
hardware advances, steady progress is being made in image-processing algorithms, and 
such algorithms may soon provide substantial reduction in SPECT acquisition times without 
sacrificing diagnostic quality (Madsen, 2007). The fusion of nuclear and anatomical images 
from computed tomography (CT) into a single imaging device (SPECT/CT and PET/CT) 
has been very useful for clinical oncology (Hong et al., 2009a). 
According to the American Society for Testing and Materials (ASTM), the term 
nanoparticles describes a sub-classification of ultra-fine solids with dimensions from 1 nm to 
100 nm and novel properties that distinguish them from the bulk material (ASTM, 2006). 
Nanoparticles produce multivalent effects due to multiple simultaneous interactions 
between the biomolecules conjugated to the nanoparticle surface and specific receptors for 
those biomolecules on the cell surface (Montet et al., 2006). Nanoparticles can be near 
infrared (NIR)-fluorescent (e.g. nanocrystals or quantum dots) or can have magnetic 
properties (e.g. iron oxide nanoparticles).  
Therefore, the first aim during the development of radiolabeled nanoparticles is to 
maximize the binding affinity via multimeric receptor-specific biomolecules based on the 
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multivalency principle. Large numbers of antibodies, peptides or any molecule with 
biological activity can be linked to the surface of a single radiolabeled nanocrystal (quantum 
dot), metal nanoparticle (iron oxide and gold) or single-walled carbon nanotube (SWNT) to 
improve imaging of tumors over-expressing those specific antigens or receptors. 
In general, different imaging techniques are complementary rather than competitive. 
Consequently, the second aim of engineering radiolabeled nanoparticles is to develop dual-
labeled imaging agents that target the same ligand. This allows for cross validation between 
nuclear and fluorescence optical images, MRI and nuclear images, or trimodal nuclear-MRI-
fluorescence images. 
The third aim is related to therapeutic properties. Gold nanoparticles and SWNT, which are 
designed to absorb in the NIR spectrum, cause irreversible thermal cellular destruction 
when they are irradiated using a laser (NIR light). It is important to remember that “the 
magic bullet does not exist” when it comes to cancer therapy; therefore, increasing the 
therapeutic response requires the application of combined modalities with multiple 
therapeutic agents. For example, gold nanoparticles or SWNT radiolabeled with beta-
particle emitters could represent a unique, multifunctional and target-specific 
pharmaceutical that could be administered as a single drug. This pharmaceutical would be 
capable of functioning, simultaneously, as both a targeted radiotherapy system and a 
photothermal therapy system.  
This chapter covers recent major advancements in design, synthesis, physicochemical 
characterization and molecular recognition assessment of radiolabeled synthetic 
nanoparticles for molecular imaging and highlights the therapeutic possibilities of these 
nanosystems. 
2. General aspects of radiolabeled nanoparticles 
Multivalent interactions regulate a wide variety of cellular processes, such as cell surface 
recognition events that involve inflammation and tumor metastasis. Multivalency is a 
design principle by which organized arrays amplify the strength of a binding process, e.g. 
the binding of multimeric peptides to specific receptors on a cell surface (Ocampo-Garcia et 
al., 2011a). 
Nanoparticles can be design as multimeric systems to produce multivalent effects. The 
physical and chemical properties of nanoparticles play an important role in determining 
particle-cell interactions, cellular trafficking mechanisms, biodistribution, pharmacokinetics 
and optical properties. Important nanoparticle properties include chemical composition of 
the core, size, shape, surface charge and surface chemistry.  
The synthesis of nanoparticles with a variety of physicochemical properties has led to 
important advances. Among these, gold nanoparticles are of particular importance to 
SPECT/CT or PET/CT molecular imaging due to the relative ease of surface modification 
and radiolabeling, their biocompatibility, resistance to oxidation and extraordinary optical 
properties (Giljohann et al., 2010).  
Nanoparticles of semiconductors are densely packed inorganic fluorescent semiconductor 
crystals with excellent optical properties, and these can be radiolabeled for PET/NIR 
imaging (Erathodiyil & Ying, 2011).  
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Radiolabeled iron oxide nanoparticles have been designed for use in SPECT/MRI and 
PET/MRI dual techniques (Torres et al., 2011; Jarret et al., 2008). Other radiolabeled 
nanosystems have also been proposed for biomedical applications, and these include single 
wall carbon nanotubes (Hong et al., 2009b), fullerenes (Qingnuan et al., 2002), multiwall 
carbon nanotubes (Guo et al., 2007) and CuS nanoparticles (Zhou et al., 2010). 
Radiolabeled nanoparticles conjugated to target specific molecules can be directly used as 
agents for diagnosis. The most common radionuclides for SPECT imaging include 99mTc 
(t1/2= 6 h) and 111In (t1/2=2.8 days), and the most common for PET are 64Cu (t1/2 =12.7 h), 18F 
(t1/2=109.8 min) and 68Ga (t1/2= 68.1 min). Moreover, radiolabeling is used to study the 
biokinetics of new devices based on nanoparticles that comprise radiopharmaceuticals, 
drug/gene delivery systems or plasmonic photothermal therapy enhancers. Many types of 
radiolabeled nanoparticles have three main components: the core, the targeting biomolecule 
and the radiotracer group (Fig. 1). The targeting biomolecule includes a component with 
high affinity for target epitopes; radiolabeling can be performed with or without slight 
modifications of the original nanoparticle (NP) surface. For ligands to bind effectively, each 
radionuclide can be conjugated directly on the NP surface, with or without a spacer, or can 
be attached to the NP during chemical synthesis. The spacer groups between the NP surface 
and the radionuclide or the biomolecule can be a simple hydrocarbon chain, a peptide 
sequence or a poly-ethyleneglycol linker. 
 
Fig. 1. Schematic structure of a radiolabeled nanoparticle design for molecular imaging 
3. Radiolabeled nanoparticles for SPECT molecular imaging 
Peptide receptors are proteins that are overexpressed in numerous human cancer cells. 
These receptors have been used as molecular targets, allowing radiolabeled peptides to 
identify tumors. The gastrin-releasing peptide receptor (GRP-r) is overexpressed in prostate 
and breast cancer, and 99mTc-Lys3-bombesin has been reported as a radiopharmaceutical with 
specific binding to cells expressing GRP-r (Ferro-Flores et al., 2006; Santos-Cuevas et al., 2008). 
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(RGD) peptides have been used for noninvasive imaging of tumor αVβ3 expression (Liu, 2008, 
2009). Mannosylated macromolecules labeled with 99mTc have displayed properties suitable for 
use in sentinel lymph node detection; these radiopharmaceuticals are considered target-
specific because they exhibit specific binding to mannose receptors that are expressed on 
lymph node macrophages (Vera et al., 2001; Takagi et al., 2004). 
Based on the observations above, 99mTc-labeled gold nanoparticles conjugated to Lys3-
bombesin, RGD peptides or thiol-mannose have been prepared as multimeric systems 
showing properties suitable for use as target-specific agents for molecular imaging of GRP 
receptor-positive tumors, tumor αVβ3 expression and sentinel lymph node detection, 
respectively. 99mTc- and 111In-labeled carbon nanotubes, 125I-labeled silver nanoparticles and 
99mTc-labeled iron oxide nanoparticles have also been reported for SPECT imaging (Table 1). 
The strategies of synthesis and functionalization for these nanoparticles are discussed in the 
following sections. 
3.1 Synthesis of NP cores 
The most common nanomaterials reported for SPECT imaging are iron oxide NPs, gold 
NPs, silver NPs and carbon nanotubes. NPs usually have optical or magnetic properties that 
can be used for molecular imaging, whereas polymer- or liposome-based NPs do not 
produce imaging signals by themselves.  
NP core synthesis generally follows standardized strategies; for example, the most popular 
method of synthesis for gold nanoparticles (AuNPs) is based on the use of HAuCl4 (Au III) 
salt, which is reduced to metallic Au(0) in aqueous solution and stabilized with a chemical 
agent. The classical sodium citrate reduction is the oldest and most widely used method 
(Daniel & Astruc, 2004), but there are different techniques to produce AuNPs with different 
sizes and shapes using reduction agents stronger than citrate (such as NaBH4), different 
organic solvents and/or different stabilizer surfactants. Most of the stabilizer surfactants are 
quaternary ammonium salts, such as cetyltrimethylammonium bromide (CTAB), 
didodecyldimethylammonium bromide (DDAB) and tetradodecylammonium bromide 
(TTAB). Anionic surfactant syntheses have also been reported (Zhang et al., 2006). 
Anisometric gold colloids (rods) can be prepared by adding gold nuclei to HAuCl4 growth 
solutions (formed by reduction of HAuCl4 with phosphorus), and the growth of the gold 
nanorods is initiate with the addition of H2O2 (Huang et al., 2009). Electrochemical and 
photochemical reduction, microwave, ultrasound and laser ablation have also been used for 
AuNP synthesis (Ferro-Flores et al., 2010b; Huang et al., 2009). The Au(0) core is essentially 
inert and non-toxic (Connor et al., 2005). AuNPs exhibit narrow and intense absorption and 
scattering bands due to the phenomenon of plasmon resonance. This occurs at the resonance 
condition of the collective oscillation that the conduction electrons experience in an 
electromagnetic field of the appropriate wavelength. The plasmon resonance band for 
ordinary 20 nm gold nanospheres is at 520 nm, in the middle of the visible spectrum, but 
this can be red-shifted into the NIR spectrum. Rod-shaped NPs exhibit two plasmon 
resonance bands due to oscillation of the conduction electrons along the short axis and the 
long axis of the particles. The former plasmon band is called the transverse resonance and 
the latter the longitudinal resonance. While the transverse plasmon band occurs in the 
neighborhood of 520 nm, the longitudinal band is red-shifted between 675–850 nm in the 
interest of optical imaging. This occupies the most important part of the “optical imaging 
window” where light penetration in tissue is high due to reduced scattering and absorption 
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coefficients. Optical imaging techniques that rely on scattering and/or absorption contrast 
to detect pathological tissue could benefit from the use of gold nanoparticles with targeting 
capability (Huang et al., 2009). 
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coefficients. Optical imaging techniques that rely on scattering and/or absorption contrast 
to detect pathological tissue could benefit from the use of gold nanoparticles with targeting 
capability (Huang et al., 2009). 
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Iron oxide NPs can be synthesized via the coprecipitation of Fe2+ and Fe3+ aqueous salt 
solutions, which results in the addition of a base. The size, shape and composition of NPs 
depend on a number of factors, including: the type of salts used (e.g., chlorides, sulfates, 
nitrates or perchlorates), the Fe2+ and Fe3+ ratio, pH and ionic strength of the media. A 
variety of other methods, based on the principle of precipitation in highly constrained 
domains, have been developed and these include sol–gel preparation, polymer matrix-
mediated synthesis and precipitation using microemulsions and vesicles (Kogan et al., 2007). 
Silver nanoparticles can be synthesized in large quantities by reducing silver nitrate with 
ethylene glycol in the presence of poly(vinyl pyrrolidone) (PVP). The presence of PVP and 
its molar ratio relative to silver nitrate is important in determining the geometric shape and 
size of the product. The size, shape, and structure of metal nanoparticles are important 
because there is a strong correlation between these parameters and optical, electrical, and 
catalytic AgNP properties (Sun & Xia, 2002).  
Carbon nanotubes (CNT) are essentially hexagonal networks of carbon atoms arranged like 
a layer of graphite rolled into a cylinder consisting of pure carbon units, the C60 fullerene. 
Methods such as electric arc discharge, laser vaporization and chemical vapor deposition 
techniques are well known to produce a wide variety of single- (SWNT) and multi-walled 
(MWNT) CNTs. Catalytic chemical vapor deposition is the most commonly used, whereas 
the water-assisted synthesis method for NTs produces highly organized intrinsic nanotube 
structures. The water-stimulated synthesis enhances catalytic activity resulting in massive 
growth of super-dense and vertically aligned nanotubes (Hata et al., 2004). SWNTs produce 
high optical absorbance in the NIR (Kam et al., 2005). It has been well documented that 
water-solubilized nanotubes with high hydrophilicity are non-toxic, even at high 
concentrations (Dumortier et al., 2006). 
3.2 Preparation of radiolabeled NP-conjugates 
To achieve recognition of the molecular target, specific biomolecules are used as ligands and 
these are conjugated to the AuNP surface. These ligands include sugars, antibodies, nucleic 
acids, proteins and peptides. All of these biomolecules must offer low nonspecific binding, 
high affinity to their binding sites, no immunogenicity, fast accumulation at the target, fast 
blood clearance, and preferably exhibit no peripheral metabolic activity or toxicity. The 
biomolecules are frequently attached to the surface of the nanoparticle via electrostatic 
interactions; however, a covalent bond is preferred to prevent release of the attached 
biomolecules in vivo. The chemical bond occurs between the AuNP surface and the peptide 
containing sulfhydryl (–SH) groups (usually from cysteine) with high affinity toward the 
gold atoms. The -SH group forms a ‘staple motif’ chemical model comprised of two thiol 
groups interacting with three gold atoms in a bridge conformation (Jadzinsky et al., 2009).  
Two main strategies for binding peptides to AuNPs are commonly used. The first is the 
direct conjugation of the peptide by means of a terminal thiol (cysteine) or an N-terminal 
primary amine (Levy et al., 2004; Porta et al., 2007), and the second is an indirect conjugation 
with a linker that contains both a thiol group (that binds the nanoparticle) and a carbonyl 
terminal group, that is activated and conjugated to biological active peptides using the 
carbodiimide-coupling chemistry (Wang et al., 2005; Cheung et al., 2009). An advantage of 
the direct conjugation strategy is that it does not require the use of linkers with long chains 
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as spacers between the NP and the conjugated peptides. This is important because the 
introduction of spacers and an increase in linker length has been proven to significantly alter 
the peptide-multivalency effect, which may correlate to a decrease in the effective peptide 
molarity (Kubas et al., 2010).  
Current methodologies for SPECT molecular imaging require an additional ligand that is 
appended to the AuNP surface, and this ligand functions as a chelator of the radiometal. 
Two different kinds of molecules can be bound to the AuNP surface to produce hybrid 
radiolabeled AuNP-peptide systems. In our research, we have reported two different 
radionuclide chelators to generate radiolabeled gold nanoparticles. Mendoza-Sanchez et al., 
(2010), Ocampo-Garcia et al., (2011b) and Morales-Avila et al., (2011) demonstrated 
radiolabeling of AuNPs using 6-hydrazinopyridine-3-carboxylic(HYNIC)-GGC peptide. 
With this approach, HYNIC was added as a 99mTc chelator group, -Gly-Gly- as a spacer 
group and -Cys as the active group that interacted with the nanoparticle surface (Fig. 2). In 
the second approach, the HYNIC-Tyr3-Octreotide (HYNIC-TOC) was used for AuNP 
radiolabeling, whereby the HYNIC group was the 99mTc chelator and the cysteine contained 
in the disulphide bridge or the ε-amine of lysine was the reactive group for AuNP 
conjugation (Ocampo-Garcia et al., 2011a) (Fig. 3). 
 
Fig. 2. Radiolabeling of gold nanoparticles conjugated to biomolecules using HYNIC-GGG 
as 99mTc chelator: a) radiolabeling after biomolecule conjugation to AuNP and b) conjugation 
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Fig. 2. Radiolabeling of gold nanoparticles conjugated to biomolecules using HYNIC-GGG 
as 99mTc chelator: a) radiolabeling after biomolecule conjugation to AuNP and b) conjugation 
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Mendoza-Sanchez et al., (2010) and Ocampo-Garcia et al., (2011b) conjugated peptides to the 
gold nanoparticle surface using a posterior radiolabeling process. This process was 
conducted by adding ethylenediaminediacetic acid (EDDA)/Tricine, SnCl2 (as reducing 
agent) and 99mTc-pertechnetate to 1 mL of HYNIC-GGC-AuNP followed by incubation at 
100 °C for 20 min. The mixture was purified by size-exclusion chromatography (PD-10 
column, Sephadex G-25) using injectable grade water as the eluent by collecting 0.5 mL 
fractions. The first peak (3.0–4.0 mL) corresponded to the void volume of the column and 
contained 99mTc-EDDA/HYNIC-GGC-AuNP (a radioactive red color solution), while the 
second peak corresponded to 99mTc-EDDA (6.0–8.0 mL). Free 99mTcO4– and 99mTc-colloid 
remained in the PD-10 column (Fig. 2a). In a second approach (Morales-Avila et al., 2011), 
the peptide conjugation to AuNPs and the radiolabeling were carried out in a single step 
without further purification (Fig. 2b). 
 
Fig. 3. Radiolabeling of gold nanoparticles conjugated to biomolecules using HYNIC-TOC as 
99mTc chelator . 
Zhang et al. (2009) obtained 111In-labeled polyethylene-glycol (PEG)-AuNPs using 
diethylenetriaminepentaacetic acid–thioctic acid (DTPA-TA) as radiometal chelator. They 
found a strong dependency between pharmacokinetics/biodistribution and the size and 
density of PEG coating on the AuNP surface.  
Chan et al. (2004) prepared carbon-encapsulated 99mTc nanoparticles. Fullerenes can be 
directly labeled with 99mTc using ascorbic acid/SnCl2 as reducing agents to form 
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99mTc-C60(OH)X, however, biodistribution studies indicated that the radionanoparticles were 
distributed in all tissues (Qingnuan et al., 2002). The 99mTc-glucosamine-MWNT, also labeled 
by the direct method, is water-soluble, and further modification of this system may allow 
the development of a versatile delivery system for molecular targeting (Guo et al., 2007).  
111In-labeled carbon nanotubes were synthesized by Singh et al. (2006). The ammonium-
functionalized CNTs (single- and multi-walled) were prepared following the 1,3-dipolar 
cycle addition method to be covalently bound to DTPA. Biodistribution studies showed a 
rapid blood clearance (half-life=3 h) with renal excretion. Radiolabeling of CNTs with 111In 
has also been reported by McDevitt et al., 2007. In general, CNTs are functionalized with 2-
(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic (DOTA-NCS) 
via thiolurea bonding and radiolabeled by adding 111In chloride to the DOTA-CNT 
conjugate.  
Chrastina & Schnitzer (2010) reported the synthesis of silver nanoparticles labeled with 
iodine-125 to track in vivo tissue targeting with SPECT images. Poly(N-vinyl-2-pyrrolidone)-
capped silver nanoparticles (average size 12 nm) were labeled by chemisorptions, whereby 
chloramine-T (N-chlorobenzenesulfonamide) was immobilized on a polystyrene backbone. 
The radio-solution was removed and added to a dispersion of unfunctionalized Ag 
nanoparticles. Unbound iodide-125 was removed by size exclusion chromatography on 
Sephadex G-25 columns. Radiochemical yields higher than 95% were obtained. 
Radiolabeled AgNPs were characterized by UV-Vis spectrometry (410 nm). 
Torres et al., (2011) reported the development of a new class of dual-modality imaging 
agents based on the conjugation of radiolabeled bisphosphonates (BP) directly to the surface 
of superparamagnetic iron oxide (SPIO) nanoparticles (5 nm, Fe₃O₄ core). The SPIO labeling 
with 99mTc-DTPA-alendronate was performed in a single step at room temperature. The 
radiolabeled nanoparticles showed excellent stability, making the conjugate suitable for 
SPECT-CT/MRI imaging. 
3.3 Structural, chemical and radiochemical characterization  
Several methods have been used for the structural characterization of nanoparticles, 
including X-ray diffraction (XRD), small-angle X-ray scattering (SAXS), microscopic 
techniques such as scanning electron microscopy (SEM), high-resolution transmission 
microscopy (HRTEM) and scanning probe microscopy (SPM). For the chemical 
characterization of the biomolecule-nanoparticle conjugate, spectroscopic methods have 
been applied to confirm the chemical interaction and functionalization of NPs with the 
biomolecules. These methods include UV-Vis, infrared, Raman, fluorescence and XPS 
spectroscopy. For example, in the case of peptides conjugated to AuNPs, the vibrational 
spectroscopic techniques can be used to confirm that the biomolecule displaces the 
carboxylate groups of the citrate on the AuNP surface. The structured spectra can be used to 
confirm that AuNPs were functionalized with peptides, because several well defined bands 
with vibrational frequencies in the region of those associated with the main functional 
groups of the peptides can be observed in the AuNP-peptide conjugate, even though these 
will have characteristics of the AuNP-peptide because the bands shift to lower or higher 
energies and increase in intensities (Surujpaul et al., 2008; Morales-Avila et al., 2011). 
Additionally, the Au-S bond shows a characteristic band at 279 ± 1 cm-1 identified by far-
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infrared spectroscopy (Ocampo-Garcia et al., 2011a). In UV-Vis spectroscopy a red shift in 
the maximum absorbance of the AuNP is representative of the peptide conjugation process, 
while the small change in the surface plasmon resonance position occurs as the result of the 
peptide adsorption on the AuNP surface (Kogan et al., 2007; Ferro-Flores et al. 2010b). The 
orbital energies of Au-Au or AuNP (Au0) and Au-S (Au+1) bonds are related to changes in 
the oxidative states (Au0 to Au+1); therefore, in XPS analyses the shift of electron binding 
energies to higher values in the AuNP-peptide conjugates, with respect to AuNPs, is an 
intrinsic property of the interaction between gold core electrons and the peptide (Mendoza-
Sanchez et al., 2010; Ocampo-Garcia et al., 2011b).  
The methods frequently used to determine radiochemical purity and assess quality control 
of the radiolabelled nanoparticles include instant thin layer chromatography (ITLC), which 
has the advantage of being very quick and easy to use, and size-exclusion high performance 
liquid chromatography (SE-HPLC) that can be used as an accurate method depending on 
the NPs size. PD-10 columns and ultrafiltration can be used as easy purification methods 
and to determine radiochemical purity (Ocampo-Garcia et al., 2011a).  
3.4 Biological recognition  
It has been demonstrated that multimeric systems of 99mTc-AuNP-biomolecules exhibit 
properties that make them suitable for use as target-specific agents for molecular imaging of 
tumors and sentinel lymph node detection. For example, in vitro binding studies of 
99mTc-AuNP-RGD conducted in αVβ3 receptor positive C6 glioma cancer cells showed 
specific recognition for those receptors (Morales-Avila et. al., 2011). Moreover, 99mTc-AuNP-
Lys3-bombesin showed specific recognitions for GRP receptors in PC3 cancer cells 
(Mendoza-Sanchez, et al., 2010) and 99mTc-AuNP-mannose demonstrated specificity for 
mannose receptors (Ocampo-Garcia et al., 2011a). Micro-SPECT/CT images of these 
radiopharmaceuticals have shown a clear tumor uptake or lymph node accumulation 
(Fig. 4). 
      
 
99mTc-AuNP-Mannose 99mTc-AuNP-RGD 99mTc-AuNP-Lys3-bombesin 
 
Fig. 4. Micro-SPECT/CT images of 99mTc-labeled gold nanoparticles in mice with induced 
tumors (conjugates of Lys3-bombesin and RGD) and in Wistar rat (mannose conjugate). 
The 111In-DTPA-TA-AuNP-PEG system has shown a prolonged blood circulation and 
significant tumor uptake by the enhanced permeability and retention effect, making of the 
radiolabeled AuNPs a promising drug delivery vehicle and diagnostic imaging agent 
(Zhang et al., 2009). 
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The multifunctional system of carbon nanotubes, conjugated to both anti-CD20 (Rituximab) 
and 111In-DOTA-NCS, demonstrated ability of this double conjugate to specifically target 
tumor cells in vitro (in CD20+ specific Daudi cells) and tumors in vivo using a murine model 
of disseminated Lymphoma (McDevitt et al. 2007). 
4. Radiolabeled nanoparticles for PET molecular imaging 
PET is a nuclear imaging technique used to map biological and physiological processes in 
living subjects following the administration of radiolabeled probes. In PET, the radionuclide 
decays and the resulting positrons subsequently interact with nearby electrons after 
travelling a short distance (~1 mm) within the body. Each positron-electron transmutation 
produces two 511-keV gamma photons in opposite trajectories, and these two gamma 
photons may be detected by the detectors surrounding the subject to precisely locate the 
source of the decay event. Subsequently, the “coincidence events” data can be processed by 
computers to reconstruct the spatial distribution of the radiotracer (Chen & Conti, 2011). 
Several positron-emitting radionuclides have been used in the development of radiolabeled 
nanoparticles. These radionuclides include 64Cu (Emax 657 keV), 18F (Emax 635 keV) and 68Ga 
(Emax 1.90 MeV), which are described in the following sections. 
4.1 64Cu-labeled nanoparticles 
The 64Cu radionuclide can be effectively produced using both reactor- and accelerator-based 
methods. Its use as a positron emitter has grown, and it has been reported to be suitable for 
the radiolabeling of proteins, antibodies and peptides. In addition, 64Cu has been 
investigated as a promising radiotracer for real-time PET monitoring of regional drug 
concentration and for pharmacokinetics applications. Its integration as a structural 
component of nanoparticles produces multimeric systems suitable for therapy and PET 
imaging (Zhou et al., 2010).  
To date, nanocrystals (quantum dot), iron oxide nanoparticles, SWNT and gold 
nanoparticles (nanoshells) have been functionalized with 64Cu ligands for PET/MRI or 
PET/NIR fluorescence imaging and therapy. In these multiple combinations, the same 
molecular target can be evaluated with two different imaging modalities. These groupings 
allow the strengths of each to improve the overall diagnostic accuracy, and this approach 
provides a synergistic effect, increasing expectations for high sensitive and high-resolution 
imaging (Hong, 2009). 
Quantum dots (QDs) or nanocrystals are fluorescent semiconductor nanoparticles (2-10 nm) 
with many unique optical properties including bright fluorescence, resistance to 
photobleaching, and a narrow emission bandwidth (Ferro-Flores et al., 2010a). Their 
fluorescence emission wavelength can be continuously tuned from 400 nm to 2000 nm by 
changing both the particle size and chemical composition. Their quantum yields are as high 
as 85 %. The particles are generally made from hundreds to thousands of atoms (~200-10,000 
atoms) of IIB and VIA family elements (e.g. CdSe and CdTe) or IIIA and VA family elements 
(e.g. InP and InAs). Recent advances have allowed the precise control of particle size, shape 
and internal structure (core-shell, gradient alloy or homogenous alloy) (Yu et al., 2003). As 
cadmium is potentially toxic, Gao et al. (2004) developed a class of QD conjugates that 
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Fig. 4. Micro-SPECT/CT images of 99mTc-labeled gold nanoparticles in mice with induced 
tumors (conjugates of Lys3-bombesin and RGD) and in Wistar rat (mannose conjugate). 
The 111In-DTPA-TA-AuNP-PEG system has shown a prolonged blood circulation and 
significant tumor uptake by the enhanced permeability and retention effect, making of the 
radiolabeled AuNPs a promising drug delivery vehicle and diagnostic imaging agent 
(Zhang et al., 2009). 
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The multifunctional system of carbon nanotubes, conjugated to both anti-CD20 (Rituximab) 
and 111In-DOTA-NCS, demonstrated ability of this double conjugate to specifically target 
tumor cells in vitro (in CD20+ specific Daudi cells) and tumors in vivo using a murine model 
of disseminated Lymphoma (McDevitt et al. 2007). 
4. Radiolabeled nanoparticles for PET molecular imaging 
PET is a nuclear imaging technique used to map biological and physiological processes in 
living subjects following the administration of radiolabeled probes. In PET, the radionuclide 
decays and the resulting positrons subsequently interact with nearby electrons after 
travelling a short distance (~1 mm) within the body. Each positron-electron transmutation 
produces two 511-keV gamma photons in opposite trajectories, and these two gamma 
photons may be detected by the detectors surrounding the subject to precisely locate the 
source of the decay event. Subsequently, the “coincidence events” data can be processed by 
computers to reconstruct the spatial distribution of the radiotracer (Chen & Conti, 2011). 
Several positron-emitting radionuclides have been used in the development of radiolabeled 
nanoparticles. These radionuclides include 64Cu (Emax 657 keV), 18F (Emax 635 keV) and 68Ga 
(Emax 1.90 MeV), which are described in the following sections. 
4.1 64Cu-labeled nanoparticles 
The 64Cu radionuclide can be effectively produced using both reactor- and accelerator-based 
methods. Its use as a positron emitter has grown, and it has been reported to be suitable for 
the radiolabeling of proteins, antibodies and peptides. In addition, 64Cu has been 
investigated as a promising radiotracer for real-time PET monitoring of regional drug 
concentration and for pharmacokinetics applications. Its integration as a structural 
component of nanoparticles produces multimeric systems suitable for therapy and PET 
imaging (Zhou et al., 2010).  
To date, nanocrystals (quantum dot), iron oxide nanoparticles, SWNT and gold 
nanoparticles (nanoshells) have been functionalized with 64Cu ligands for PET/MRI or 
PET/NIR fluorescence imaging and therapy. In these multiple combinations, the same 
molecular target can be evaluated with two different imaging modalities. These groupings 
allow the strengths of each to improve the overall diagnostic accuracy, and this approach 
provides a synergistic effect, increasing expectations for high sensitive and high-resolution 
imaging (Hong, 2009). 
Quantum dots (QDs) or nanocrystals are fluorescent semiconductor nanoparticles (2-10 nm) 
with many unique optical properties including bright fluorescence, resistance to 
photobleaching, and a narrow emission bandwidth (Ferro-Flores et al., 2010a). Their 
fluorescence emission wavelength can be continuously tuned from 400 nm to 2000 nm by 
changing both the particle size and chemical composition. Their quantum yields are as high 
as 85 %. The particles are generally made from hundreds to thousands of atoms (~200-10,000 
atoms) of IIB and VIA family elements (e.g. CdSe and CdTe) or IIIA and VA family elements 
(e.g. InP and InAs). Recent advances have allowed the precise control of particle size, shape 
and internal structure (core-shell, gradient alloy or homogenous alloy) (Yu et al., 2003). As 
cadmium is potentially toxic, Gao et al. (2004) developed a class of QD conjugates that 





molecules for improving biocompatibility and circulation. InAs/InP/ZnSe Core/Shell/Shell 
quantum dots without Cd have significantly lower intrinsic toxicity compared to QDs 
containing elements such as cadmium (Xie et al., 2008). 
A dual-modality PET/NIR fluorescent peptide has been recently reported (Cai et al., 2007; 
Chen et al., 2010). A QD (QD705; emission maximum, 705 nm) with an amine-functionalized 
surface was modified with RGD (90 peptides per QD) or the vascular endothelial growth 
factor (VEGF) and 1,4,7,10-tetraazacyclodocecane-N,N',N'',N'''-tetraacetic acid (DOTA) 
chelator for integrin-αvβ3 or VEGF imaging. PET/NIR imaging, tissue homogenate 
fluorescence measurement, and immunofluorescence staining were performed with U87MG 
human glioblastoma tumor-bearing mice to quantify the 64Cu-DOTA-QD-RGD and 64Cu-
DOTA-QD-VEGF uptake in tumor and major organs. Excellent linear correlation was 
obtained between the results measured by in vivo PET imaging and those measured by ex 
vivo NIR fluorescent imaging and tissue homogenate fluorescence. Histologic examination 
revealed that 64Cu-DOTA-QD-RGD targets primarily the tumor vasculature through a RGD-
integrin interaction, with little extravasation. The authors concluded that this dual-function 
probe has significantly reduced potential toxicity and overcomes the tissue penetration 
limitation of optical imaging, requisite for quantitative targeted imaging in deep tissue.  
Iron oxide nanoparticles have magnetic properties and have been extensively investigated 
for biomedical applications due to their excellent biocompatibility and ease of synthesis. 
Jarrett et al. (2008) recently reported a dual-mode imaging probe for PET/MRI that was 
designed for vascular inflammation, and this probe was based on iron oxide nanoparticles 
coupled to 64Cu. The labeling of SPIONs was made by coordination of 64Cu to the chelating 
bifunctional ligand S-2-(4- isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (p-SCNBz-DOTA) and followed by conjugation to the nanoparticle. For the 
dextran sulfate coated nanoparticles, the particle surface was modified to contain aldehyde 
groups that can be conjugated to the amine-reactive p-SCN-Bz-DOTA chelator. Xie et al. 
(2010) encapsulated iron oxide nanoparticles (IONPs) into human serum albumin (HSA) 
matrices. The HSA coated IONPs (HSA-IONPs) were dually labeled with 64Cu-DOTA and 
Cy5.5, and tested in a subcutaneous U87MG xenograft mouse model. In vivo PET/NIR 
fluorescence/MRI tri-modality imaging showed massive accumulation in lesions, high 
extravasation rate, and low uptake of the particles by macrophages at the tumor area. Glaus 
et al. (2010) prepared 64Cu-DOTA-PEG-SPIOs which demonstrated strong MR and PET 
signals and high stability in mouse serum for 24 h at 37 °C. 
To image Vβ3 expression, multifunctional 64Cu-labeled IONPs conjugated to RGD have 
been reported. Lee et al. (2008) developed the 64Cu-DOTA-IO-RGD system (diameter: 45 ± 
10 nm) containing 35 RGD peptide molecules and 30 DOTA chelating units per 
nanoparticle. The receptor-binding affinity studies for vβ3 integrin in U87MG cells showed 
an IC50 value of 34 ± 5 nM. cRGDfC and the macrocyclic 1,4,7-triazacyclononane-N,N’,N’’-
triacetic-thiol derivative (NOTA-SH) were conjugated onto the iron oxide nanoparticles. 
64Cu-labeled SPIONs conjugated to cRGDfC demonstrated a good U87MG tumor-targeting 
capability and tumor contrast by PET/MRI dual-modality imaging (Yang et al., 2011).  
Liu et al. (2007) investigated the biodistribution of 64Cu-labeled SWNTs conjugated to 
polyethylene-glycol-DOTA and RGD in mice with U87MG-induced tumors using PET, ex 
vivo biodistribution and Raman spectroscopy. The results showed a high 64Cu-DOTA-PEG-
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SWNT-RGD tumor accumulation (∼7% at 1 h) that was attributed to the multivalent effect 
of the SWNTs. 
Gold nanoshells (NSs) are core/shell particles comprised of a gold shell and a dielectric 
silica core with peak plasmon resonances tunable to desired wavelengths by adjusting the 
relative core and shell thicknesses. At NIR wavelengths, light penetrates up to several 
centimeters in tissue. NSs absorb in the NIR wavelength and efficiently convert incident 
light to heat (eg, a 120-nm core diameter and a 14-nm-thick shell result in an absorption 
peak between 780 nm and 800 nm). Xie et al. (2011) reported the preparation of 64Cu-DOTA 
labeled NSs conjugated to cRGDfK and evaluated the in vivo biodistribution and tumor 
specificity of these in live nude rats bearing head and neck squamous cell carcinoma 
(HNSCC) xenografts. The potential therapeutic properties were also evaluated by 
subablative thermal therapy of tumors. PET/CT imaging showed a high tumor uptake even 
at ~20 h postinjection and the thermal therapy study showed a high degree of tumor 
necrosis. 
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Table 2. 64Cu-labeled nanoparticles for PET imaging 
4.2 18F labeled iron oxide nanoparticles for PET/MRI 
The main requirement for MRI is the efficient capture of magnetic nanoparticles by the cell, 
and when a cell is sufficiently loaded with magnetic material, MRI can also be used for cell 
tracking. The synthesis and in vivo characterization of iron oxide nanoparticles labeled with 
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SWNT-RGD tumor accumulation (∼7% at 1 h) that was attributed to the multivalent effect 
of the SWNTs. 
Gold nanoshells (NSs) are core/shell particles comprised of a gold shell and a dielectric 
silica core with peak plasmon resonances tunable to desired wavelengths by adjusting the 
relative core and shell thicknesses. At NIR wavelengths, light penetrates up to several 
centimeters in tissue. NSs absorb in the NIR wavelength and efficiently convert incident 
light to heat (eg, a 120-nm core diameter and a 14-nm-thick shell result in an absorption 
peak between 780 nm and 800 nm). Xie et al. (2011) reported the preparation of 64Cu-DOTA 
labeled NSs conjugated to cRGDfK and evaluated the in vivo biodistribution and tumor 
specificity of these in live nude rats bearing head and neck squamous cell carcinoma 
(HNSCC) xenografts. The potential therapeutic properties were also evaluated by 
subablative thermal therapy of tumors. PET/CT imaging showed a high tumor uptake even 
at ~20 h postinjection and the thermal therapy study showed a high degree of tumor 
necrosis. 
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4.2 18F labeled iron oxide nanoparticles for PET/MRI 
The main requirement for MRI is the efficient capture of magnetic nanoparticles by the cell, 
and when a cell is sufficiently loaded with magnetic material, MRI can also be used for cell 
tracking. The synthesis and in vivo characterization of iron oxide nanoparticles labeled with 





molecules held together in core-shell formation by a superparamagnetic iron oxide core and 
functionalized with the radionuclide 18F in high yield, via “click” chemistry. Such 
nanoparticles could accurately detect lymph nodes (LNs), which are critical for assessing 
cancer metastasis. In vivo PET/MRI images could clearly identify small (~1 mm) LNs along 
with precise anatomical information. 
4.3 68Ga labeled nanoparticles  
Stelter et al. (2009) covalently bound the transfection agent HIV-1 Tat (peptide derived from 
the transcription protein transactivator of the human immunodeficiency virus), the 
fluorescent dye fluorescein isothiocyanate and 68Ga to the aminosilane-coated 
superparamagnetic nanoparticle. PET imaging and MRI revealed increasing hepatic and 
splenic accumulation of the particles over 24 h in Wistar rats. Hepatogenic HuH7 cells were 
labeled with the radionanoparticles and injected them intravenously into rats, followed by 
animal PET and MRI imaging. In vitro studies in hepatogenic HuH7 cells showed a rapid 
intracellular accumulation of the labeled nanoparticles and without any signs of toxicity. In 
vivo dissemination of the labeled cells was followed by dynamic biodistribution studies. 
This radionanoconjugate can be applicable to efficient cell labeling and subsequent 
multimodal molecular imaging. Moreover, their multiple free amino groups suggest the 
possibility of further modifications and might provide interesting opportunities for various 
research fields. 
A quadruple imaging modality made using nanoparticles that is capable of concurrent 
fluorescence, bioluminescence, bioluminescence resonance energy transfer (BRET), PET and 
MRI has been reported (Hwang et al., 2009). A cobalt–ferrite nanoparticle surrounded by 
rhodamine (MF) was conjugated with luciferase (MFB) and p-SCNbnNOTA (2-(4-
isothiocyanatobenzyl)-1,4,7-triazacyclonane-1,4,7-triacetic acid) followed by 68GaCl3 
(magnetic-fluorescent-bioluminescent-radioisotopic particle, MFBR). Confocal microscopy 
revealed good transfection efficiency of MFB into cells and BRET was also observed in MFB. 
A good correlation among rhodamine, luciferase, and 68GaCl3 was found in MFBR, and the 
activities of each imaging modality increased dose-dependently with the amount of MFBR 
in the C6 cells. In vivo optical images were acquired from the thighs of mice after 
intramuscular and subcutaneous injections of MFBR-laden cells. MicroPET and MR images 
showed intense radioactivity and ferromagnetic intensities with MFBR-laden cells. The 
multimodal imaging strategy could be used as a potential imaging tool to improve the 
diagnostic accuracy. 
5. Radiolabeled nanoparticle for therapy 
Radiolabeled nanoparticles represent novel agents with huge potential for clinical 
radiotherapy applications. McDevitt et al. (2010) proposed the radiolabeling of carbon 
nanotubes (DOTA-NTs, diameter of 1.4 nm.) functionalized by the anti-CD20 monoclonal 
antibody (Rituximab), the α-particle emitter 225Ac and the -particle emitter 90Y. Alpha-
emitters can be efficient therapeutics against small-volume tumors and micrometastatic 
cancers due to the linear energy transfer that is 500 times greater than that of  particles; 
hence, damaged cells have inadequate capability to repair DNA injure, and cell death may 
result. Beta-particle emitters are the most widely used radionuclides among the cancer 
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therapeutic agents because the localized decay in target cells generates DNA damaging free 
radicals, which can induce apoptosis (Fig. 4). Kucka et al. (2006) have also proposed the 
astatination of silver nanoparticles conjugated to poly(ethylene oxide) as possible carriers of 
the α-particle emitter 211At. 
 
Fig. 4. Schematic representation of radiolabeled nanoparticles for therapeutic applications 
The impermeable nature of the cell plasma membrane limits the therapeutic uses of many 
macromolecules. Several cell penetrating peptides, such as the HIV-1 Tat peptide, have been 
shown to traverse the cell membrane (where integral protein transduction domains (PTDs) 
are responsible for cellular uptake) and to reach the nucleus while retaining biological 
activity. PTDs can enable the cellular delivery of conjugated biomolecules and even 
nanoparticles, but nuclear delivery needs other strategies. Berry et al. (2007) developed 
biocompatible gold nanoparticles of differing sizes, functionalized with the HIV Tat-PTD, 
with the aim of producing nuclear targeting agents. The particles were subsequently tested 
in vitro on a human fibroblast cell line, and the results demonstrated successful nanoparticle 
transfer across the plasma membrane with 5 nm particles achieving nuclear entry while 
larger 30 nm particles were retained in the cytoplasm, suggesting entry was blocked via 
nuclear pores dimensions. 99mTc internalized in cancer cell nuclei acts as an effective system 
of targeted radiotherapy because of the Auger and internal conversion electron emissions 
near DNA. The HIV Tat(49-57) is a cell penetrating peptide that reaches DNA (Santos-
Cuevas et al., 2011). Therefore, 99mTc-labeled gold nanoparticles (5nm) prepared by the 
methods previously described (Ocampo-Garcia et al., 2011b; Morales-Avila et al., 2011) and 
conjugated to the HIV Tat(49-57) peptide, could potentially be a multifunctional system with 
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The -particle emitter 188Re has been conjugated to NPs for radiotherapy purposes. In 2004, 
Cao et al. prepared silica-coated magnetite nanoparticles immobilized with histidine. 188Re 
was linked on their surface by the complexation of [188Re(CO)3(H2O)3]+ to the imidazolyl 
groups of histidine, obtaining a labeling yield of 91%. A direct labeling method has also 
been reported that radiolabels SPIONs with rhenium-188 (Liang et al., 2007). The 
radiolabeling efficiency was about 90%, with good in vitro stability. 188Re labeled SPIONs 
demonstrated the ability to kill SMMC-7721 liver cancer cells.  
Photothermal ablation (PTA) therapy is a minimally invasive alternative to conventional 
approaches for cancer treatment. NPs, primarily gold nanostructures such as gold 
nanoshells, nanorods, nanocages and hollow nanospheres but also carbon nanotubes, have 
been investigated as photothermal coupling agents to enhance the efficacy of PTA therapy. 
These plasmonic nanomaterials exhibit strong absorption in the NIR region (700-1100 nm) 
and offer the opportunity to convert optical energy into thermal energy, enabling the 
deposition of otherwise benign optical energy into tumors for thermal ablation of tumor 
cells, as recently demonstrated Xie et al. (2011). Furthermore, AuNPs can be labeled with α- 
or β-particle emitter radionuclides and linked to target specific biomolecules to produce 
both thermotherapy and radiotheraphy effects on cancer cells.  
Zhou et al. (2010) synthesized and evaluated a novel class of chelator-free [64Cu]CuS 
nanoparticles (NPs) suitable both for PET imaging and as photothermal coupling agents for 
photothermal ablation. [64Cu]CuS NPs possess excellent stability, and allow robust 
noninvasive micro-PET imaging. The CuS NPs display strong absorption in the near-
infrared (NIR) region (peak at 930 nm); passive targeting prefers the tumor site, and 
mediated ablation of U87MG tumor cells occurs upon exposure to NIR light both in vitro 
and in vivo after either intratumoral or intravenous injection. The combination of small 
diameter (11 nm), strong NIR absorption, and integration of 64Cu as a structural component 
makes these [64Cu]CuS NPs suited for multifunctional molecular imaging and therapy. 
6. View to the future 
Looking into the future of the field of nuclear molecular imaging, we have to think about the 
development of the next generation of radiopharmaceuticals combining variety of 
properties and allowing for the simultaneous performance of multiple functions. The great 
diversity of nanoparticle cores and biomolecules that can be attached to the nanoparticle 
surface, offers the possibility of creating multifunctional devices to be used in hybrid 
imaging platforms.  
In the field of molecular therapy, some nanoparticles offer novel proposals for the delivery 
of therapeutic and target-specific drugs. Multifunctional radiolabeled nanoparticles can 
combine imaging and therapeutic agents in one preparation and specifically target the site 
of the disease (accumulate there) via both non-specific and specific mechanisms, such as the 
enhanced permeability and retention (EPR) effect for macromolecules (Maeda et al., 2000) 
and the ligand-mediated recognition.  
In all clinically relevant imaging modalities, contrast agents are used to absorb certain types 
of signal much stronger than do the surrounding tissues. To still further increase a local 
spatial concentration of a contrast agent for better imaging, it is a natural progression to use 
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nanoparticles to carry multiple contrast moieties for an efficient enhancing of the signal 
from these areas (Torchilin, 2006). 
A nanoparticle that has intrinsic imaging and therapeutic properties is advantageous. For 
gold and SWNT nanoparticles, the composition itself produces imaging contrast (optical 
imaging). Moreover, these nanoparticles have thermoablative properties. Local application 
of heat is a known concept in therapeutic medicine that has been extensively explored for 
cancer treatment and other conditions. Excitation sources, such as infrared lamps, 
ultrasound or lasers, can be used in the process, but there is always the problem of limiting 
the heat generated to just the area of the target tissue. This problem could be solved by 
using nanoparticles designed to absorb in the NIR region so that the resulting localized 
heating causes irreversible thermal cellular destruction. A laser irradiation (NIR light) of 
SWNT or gold nanoparticles leads to a rise in the temperature of the target regions from 
40°C to 50°C, which selectively could destroy a carcinoma (Pissuwan et al., 2006).  
An important benefit of receptor-specific radiopharmaceuticals is their use for targeted 
radiotherapy. Multiple specific biomolecules to target breast cancer cells, appended to one 
gold nanoparticle and labeled with an imaging radionuclide such as 99mTc as well as a 
β-particle-emitting radionuclide such as 90Y, 177Lu or 188Re, could be a multifunctional 
system useful for the identification of malignant tumors (SPECT/NIR fluorescence imaging) 
and metastatic sites (avoiding immunohistochemistry studies), for targeted radiotherapy 
(high β-particle-energy delivered per unit of targeted mass) and for photothermal therapy 
(localized heating). Furthermore, 99mTc internalized in cancer cell nuclei acts as an effective 
system of targeted radiotherapy because of the Auger and internal conversion electron 
emissions near DNA. 99mTc-labeled gold nanoparticles described above and also conjugated 
to the HIV Tat(49-57) peptide to reach DNA, could potentially be a radiotherapeutic system 
at cellular level. However, for therapeutic purposes NPs should be administered by 
intratumoral injection or into a selective artery to avoid a high uptake by organs of the 
reticuloendothelial system because of the NPs’ colloidal nature.  
The traditional concept of separating diagnosis and treatment could conclude. The use of 
multifunctional radiolabeled nanoparticles that can simultaneously detect, image, and treat 
diseases may one day become the first alternative instead of the exception. 
7. Conclusions 
In our research we have demonstrated that it is possible to prepare stable hybrid 
radiolabeled gold nanoparticles. Multimeric systems of 99mTc-labeled gold nanoparticles 
conjugated to peptides or mannose can be prepared from kit formulations with high 
radiochemical purities (>94%). 99mTc-AuNP-Lys3-bombesin, 99mTc-AuNP-c[RDGfK(C)] and 
99mTc-AuNP-mannose show properties suitable for use as target-specific agents for 
molecular imaging of GRP receptor-positive tumors, tumor αVβ3 expression and sentinel 
lymph node detection, respectively, with the possibility to be used as photothermal 
therapeutic systems. 
Multifunctional nanoparticles can combine diagnostic and therapeutic capabilities for 
targeted-specific diagnosis and the treatment of disease. Medical imaging modalities such as 
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at cellular level. However, for therapeutic purposes NPs should be administered by 
intratumoral injection or into a selective artery to avoid a high uptake by organs of the 
reticuloendothelial system because of the NPs’ colloidal nature.  
The traditional concept of separating diagnosis and treatment could conclude. The use of 
multifunctional radiolabeled nanoparticles that can simultaneously detect, image, and treat 
diseases may one day become the first alternative instead of the exception. 
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In our research we have demonstrated that it is possible to prepare stable hybrid 
radiolabeled gold nanoparticles. Multimeric systems of 99mTc-labeled gold nanoparticles 
conjugated to peptides or mannose can be prepared from kit formulations with high 
radiochemical purities (>94%). 99mTc-AuNP-Lys3-bombesin, 99mTc-AuNP-c[RDGfK(C)] and 
99mTc-AuNP-mannose show properties suitable for use as target-specific agents for 
molecular imaging of GRP receptor-positive tumors, tumor αVβ3 expression and sentinel 
lymph node detection, respectively, with the possibility to be used as photothermal 
therapeutic systems. 
Multifunctional nanoparticles can combine diagnostic and therapeutic capabilities for 
targeted-specific diagnosis and the treatment of disease. Medical imaging modalities such as 





probes with multivalent properties can provide multimodal images with enhanced signal 
and sensitivity. Developments of radioactive QD-, AuNP-, SWNT-, CuS- or IO-target-
specific biomolecules can be further developed to provide a visual guide during surgery. 
Radiolabeled SWNT and gold nanoparticles have a variety of real or potential applications 
in medical diagnosis and therapeutic treatments, due to their particularly combination of 
optical and photothermal properties. However, the work in this field is still in its infancy, 
and the achievement of more in vivo preclinical and clinical trials is required. 
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Presently, nuclear imaging techniques such as positron emission tomography (PET), and 
single photon emission CT (SPECT) are quite vital tools in clinical medicine as molecular 
imaging modalities to investigate the cause, diagnosis and therapy of diseases, e.g., 
Alzheimer’s disease, Parkinson’s disease, ischemic heart disease, cardiomyopathy and 
cancer, from the viewpoint of molecule. On the other hand, recent advance in genetic 
engineering have generated rodent models of human diseases that afford important clues to 
their causes, diagnoses and treatment. Studies using mouse and rat as the animal models 
have become important in most areas, such in molecular biology, toxicology, and drug 
discovery research. Hypotheses about the onset of disease and the effectiveness of treatment 
can be tested with the animals before terminal studies for human. Mice and rats have 
become key animal models for the study of development of human disease. They offer the 
possibility to manipulate their genome and produce accurate models of many human 
disorders resulting in significant progress in the understandings of human diseases. Also 
here, the molecular imaging techniques are quite important tools for observing the 
physiological and pathological status in vivo. However, they still suffer from insufficient 
spatial resolution. In addition, they must require radio-active imaging agency, resulting in 
being an intractable measurement method. So, the invention of a novel molecular imaging 
technique using non-radioactive imaging agencies with high-contrast and high spatial 
resolutions has been eagerly waited for. 
X-ray fluorescence analysis (XRF) is one of the most sensitive physicochemical analysis 
methods to identify trace elements with high sensitivity and high quantitativeness by 
detecting the fluorescent x-ray emitted from them. Use of synchrotron x-ray as the light 
source empowers it to detect trace elements with much higher sensitivity, because 
synchrotron x-ray has some excellent properties for XRF. Then, fluorescent x-ray scanning 
tomography (FXST) has been developed based on XRF to investigate a 2-dimensional 
distributions of specific elements. SR-FXST at the first stage was employed in planar mode 
to evaluate very low contents of medium- or high-atomic-number trace elements up to the 
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usually limited to scanning either the surface of the object or thin slices of samples with a 
perpendicular x-ray beam. Fluorescent x-ray computed tomography (FXCT) method 
combining SR-XRF with computed tomography technique bypasses this restriction. Hogan 
et al. (Hogan et al., 1991) theoretically discussed this approach and we were the first to 
implement it by using synchrotron radiation (Takeda, et al., 1996; —, 1998). 
SR-FXCT enables us to establish a low-invasive or non-destructive cross-sectional imaging 
method for biomedical use at high sensitivity and at high spatial resolution. The SR-FXCT is 
being developed to depict the distribution of specific elements inside the biomedical object 
(Takeda, et al., 2000; —, 2001). So far, we have successfully imaged myocardinal fatty acid 
metabolism of cardiomyopathic animal model ex vivo (Thet-Thet-Lwin, et al., 2007; —, 
2008), and cerebral perfusion of small rodents ex vivo (Takeda et al., 2009) after injecting 
non-radioactive iodine labeled cerebral perfusion agent (IMP), and fatty acid metabolic 
agent (BMIPP), respectively. 
Although SR-FXCT allows sub-millimeter resolution, this approach is hampered by the long 
measurement time required, as conventional FXCT is based on the first generation type of 
computed tomography (CT), which acquires a set of projections by translational and 
rotational scans using pencil-beam geometry. In order to complete the measurements during 
the course of anesthesia, the number of projections and the data acquisition time for each 
data point need to be reduced, resulting in a reduction in image quality. Thus, just a few 
slices can be obtained for in vivo imaging of a rat head, while under anesthesia (Takeda, et 
al., 2009). Therefore, conventional FXCT cannot substitute for PET or SPECT, which can 
obtain 3-D tomographic images. In order to overcome the difficulty, the parallel data 
acquisition scheme has been proposed (Huo, et al., 2008; —, 2009). 
This chapter is organized as follows. In Section 2, we present some background materials on 
SR-FXCT. Section 3 first describes SR-FXCT of the first generation based on pencil-beam 
geometry in its imaging protocol, reconstruction method, and applications, then points out 
the difficulty to prevent the SR-FXCT from being a molecular imaging modality. A novel 
type of SR-FXCT based on sheet-beam geometry for overcoming the difficulty is presented 
in Sections 4. Section 5 discusses the imaging properties of the SR-FXCT based on 
experimental results. Finally, some concluding remarks are given in Section 6. 
2. Backgrounds 
In this section, we will introduce the fundamental items indispensable for discussion in the 
following sections. 
2.1 Fluorescent X-ray 
When materials are exposed by short-wavelength x-rays or gamma rays, photoelectric effect 
will take place. The photoelectric effect is a phenomenon in which electrons are emitted 
from matter after the absorption of energy from electromagnetic radiation. With the removal 
of an electron in this way, the electronic structure of the atom is unstable, and electrons in 
higher orbitals “fall” into the lower orbital to fill the hole left behind. In falling, energy is 
released in the form of a photon, the energy of which is equal to the energy difference of the 
two orbitals involved. Thus, the fluorescence x-rays will be emitted isotropically (Fig. 1). 
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There are a limited number of ways in which this can happen, L→K transition is called Kα, 
an M→K transition is called Kβ, an M→L transition is called Lα, and so on (Fig. 2). Since each 
element has characteristic energy of electronic orbitals, the kind of elements can be 
investigated by analyzing fluorescent x-ray energy. Furthermore, the intensity of each 
characteristic radiation is proportional to the amount of elements, so the amount of elements 
can be investigated from the intensity. 
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Fig. 2. Characteristics of fluorescent x rays 
X-ray fluorescence analysis (XRF) is one of the most sensitive physicochemical analysis 
methods to identify trace elements with high sensitivity by detecting the fluorescent x ray 
emitted from them. Use of synchrotron x ray as the light source empowers it to detect trace 
elements with much higher sensitivity, because synchrotron x-ray has some excellent 
properties for XRF. In addition, combining XRF with computed tomography technique 
enable us to establish a low-invasive or non-destructive cross-sectional imaging method for 
biomedical use at high sensitivity and at high spatial resolution. 
2.2 Synchrotron radiation 
Synchrotron radiation is electromagnetic radiation from electrons accelerated to high speed 
in several stages to achieve a final energy that is typically in the GeV range. Then, the 
electrons are forced to travel in a closed path in a storage ring by strong magnetic fields of a 
few T. The synchrotron radiation is projected at a tangent to the electron storage ring and 
captured as beamlines. These beamlines may originate at bending magnets, which mark the 
corners of the storage ring; or insertion devices, which are located in the straight sections of 
the storage ring. Beamline is consisted by some optical devices which control the 
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The synchrotron radiation has some excellent properties as follows: 
A. High brightness and high intensity, many orders of magnitude larger than those of x-
rays produced by conventional x-ray tubes. 
B. High level of polarization (linear or elliptical). 
C. High collimation, i.e. small angular divergence of the beam. 
D. Low emittance, i.e. the product of source cross section and solid angle of emission is small. 
E. Wide tunability in energy/wavelength by monochromatization (sub eV up to the MeV 
range). 
F. High brilliance, exceeding other natural and artificial light sources by many orders of 
magnitude. 
The major applications of synchrotron light are in condensed matter physics, materials 
science, biology and medicine.  
2.3 Computed tomography 
In 1972, the first viable computed tomography (CT) scanner was invented by Honsfield 
using x rays, which can be used to investigate the structures inside bodies with various 
planes or even as volumetric (3D) representations. Here, we consider a 2-dimensional case 
using parallel incident beams. We introduce the typical coordinate systems for CT 
measurements. The xy- and st-coordinate systems are fixed to the object and the incident 
ray, as shown in Fig. 3, respectively. Here, the st-coordinate system is obtained by rotating 
the xy-coordinate system by  about the origin in the counter-clockwise direction. X-ray CT 
is a technique for probing the attenuation coefficient of an object by use of multiple x rays. 
Each ray is assumed to travel through the object without changing its direction. Measured 
quantity at each point is described as  
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Fig. 3. CT geometry 
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using the Beer’s law. Here, It and Io are the transmitted and the incident x-ray intensities, 
respectively:  is a distribution of linear attenuation coefficients, and the shoulder of exponential 
function means a line integral of  along the linear trajectory of the incident x ray, R(s,).  
In order to reconstruct 2-D function (x, y), we need the line integral along the x-ray path 
with respect to r and . By taking logarithm against Eq. (1), we obtain line integrals, i.e., 
projections. Projections along multiple x rays in multiple directions are measured. Then, 
applying a reconstruction algorithm to the projections, such as the filtered backprojection 
method, the distribution of the attenuation coefficient (x, y) is to be estimated. Here, we 
notice that the measurements required for CT reconstruction are not x-ray transmittance but 
the line integral. Therefore, CT measurement is a measurement protocol to systematically 
collect a series of line integrals of quantity of interest from multiple directions. 
2.4 Fluorescent X-ray computed tomography using synchrotron radiation 
Fluorescent x-ray computed tomography is a hybrid technique between XRF, which is a 
physicochemical analysis with high sensitivity and high quantitativeness, and CT, which 
obtains inside information non-destructively. We give a rough sketch of FXCT here, while 
the quantitative consideration is given in the next section. 
Suppose that a beam of monochromatic x ray is incident on an object containing specific 
element such as iodine. The advantageous properties of synchrotron radiation for 
fluorescent x-ray analysis are its broad energy spectrum that allows beam energy 
tunableness, its high brightness, and its natural forwardly collimation, as described in 
section 2.2. Thereby, we obtain a high-quality parallel monochromatic beam as an incident 
beam. The atoms locating on the beam path isotropically emit fluorescent x-ray photons 
having energy peculiar to the element according to their concentration. Since the amount of 
fluorescent x-ray photons from each site on the beam path depends on the concentration of 
the element, we can obtain the line integral of the concentration by acquiring the fluorescent 
photons efficiently and precisely. For this purpose, we must consider the problem where 
and how the detector should be set. 
We aggressively utilize a linear polarization property of SR. SR is linearly polarized in the 
plane of the electron storage ring. Ideally, Compton scattered radiation, which is dominant 
as noise source in hard x-ray regions, is not emitted in a direction at a right angle to the 
incident beam in the polarization plane (Yuasa et al., 1997; —, 1997). Therefore, the 
polarized nature of SR allows the maximal reduction of the spectral background originating 
from Compton scattering in the plane of the storage ring by positioning the detector at 90 
degrees to the beam in the plane of the polarization. Preparing an ideal detector having a 
detective surface with infinitely thin height and infinitely long width, we achieve the 
objective. 
As aforementioned, we can collect the fluorescent x-ray photons with high signal to noise 
ratio using SR as an incident beam. Projections are acquired at constant angular steps using 
a translation-rotation motion of the object over 180 degrees. 
3. SR-FXCT based on pencil beam geometry 
The x-ray fluorescence analysis method has been used in tracer element detection studies, 





The synchrotron radiation has some excellent properties as follows: 
A. High brightness and high intensity, many orders of magnitude larger than those of x-
rays produced by conventional x-ray tubes. 
B. High level of polarization (linear or elliptical). 
C. High collimation, i.e. small angular divergence of the beam. 
D. Low emittance, i.e. the product of source cross section and solid angle of emission is small. 
E. Wide tunability in energy/wavelength by monochromatization (sub eV up to the MeV 
range). 
F. High brilliance, exceeding other natural and artificial light sources by many orders of 
magnitude. 
The major applications of synchrotron light are in condensed matter physics, materials 
science, biology and medicine.  
2.3 Computed tomography 
In 1972, the first viable computed tomography (CT) scanner was invented by Honsfield 
using x rays, which can be used to investigate the structures inside bodies with various 
planes or even as volumetric (3D) representations. Here, we consider a 2-dimensional case 
using parallel incident beams. We introduce the typical coordinate systems for CT 
measurements. The xy- and st-coordinate systems are fixed to the object and the incident 
ray, as shown in Fig. 3, respectively. Here, the st-coordinate system is obtained by rotating 
the xy-coordinate system by  about the origin in the counter-clockwise direction. X-ray CT 
is a technique for probing the attenuation coefficient of an object by use of multiple x rays. 
Each ray is assumed to travel through the object without changing its direction. Measured 
quantity at each point is described as  
 ( , )
( , )
( , ) e R s
x y dl
t oI s I 

    (1) 
 
Fig. 3. CT geometry 
Fluorescent X-Ray Computed Tomography 
Using Synchrotron RadiationTowards Molecular Imaging 
 
43 
using the Beer’s law. Here, It and Io are the transmitted and the incident x-ray intensities, 
respectively:  is a distribution of linear attenuation coefficients, and the shoulder of exponential 
function means a line integral of  along the linear trajectory of the incident x ray, R(s,).  
In order to reconstruct 2-D function (x, y), we need the line integral along the x-ray path 
with respect to r and . By taking logarithm against Eq. (1), we obtain line integrals, i.e., 
projections. Projections along multiple x rays in multiple directions are measured. Then, 
applying a reconstruction algorithm to the projections, such as the filtered backprojection 
method, the distribution of the attenuation coefficient (x, y) is to be estimated. Here, we 
notice that the measurements required for CT reconstruction are not x-ray transmittance but 
the line integral. Therefore, CT measurement is a measurement protocol to systematically 
collect a series of line integrals of quantity of interest from multiple directions. 
2.4 Fluorescent X-ray computed tomography using synchrotron radiation 
Fluorescent x-ray computed tomography is a hybrid technique between XRF, which is a 
physicochemical analysis with high sensitivity and high quantitativeness, and CT, which 
obtains inside information non-destructively. We give a rough sketch of FXCT here, while 
the quantitative consideration is given in the next section. 
Suppose that a beam of monochromatic x ray is incident on an object containing specific 
element such as iodine. The advantageous properties of synchrotron radiation for 
fluorescent x-ray analysis are its broad energy spectrum that allows beam energy 
tunableness, its high brightness, and its natural forwardly collimation, as described in 
section 2.2. Thereby, we obtain a high-quality parallel monochromatic beam as an incident 
beam. The atoms locating on the beam path isotropically emit fluorescent x-ray photons 
having energy peculiar to the element according to their concentration. Since the amount of 
fluorescent x-ray photons from each site on the beam path depends on the concentration of 
the element, we can obtain the line integral of the concentration by acquiring the fluorescent 
photons efficiently and precisely. For this purpose, we must consider the problem where 
and how the detector should be set. 
We aggressively utilize a linear polarization property of SR. SR is linearly polarized in the 
plane of the electron storage ring. Ideally, Compton scattered radiation, which is dominant 
as noise source in hard x-ray regions, is not emitted in a direction at a right angle to the 
incident beam in the polarization plane (Yuasa et al., 1997; —, 1997). Therefore, the 
polarized nature of SR allows the maximal reduction of the spectral background originating 
from Compton scattering in the plane of the storage ring by positioning the detector at 90 
degrees to the beam in the plane of the polarization. Preparing an ideal detector having a 
detective surface with infinitely thin height and infinitely long width, we achieve the 
objective. 
As aforementioned, we can collect the fluorescent x-ray photons with high signal to noise 
ratio using SR as an incident beam. Projections are acquired at constant angular steps using 
a translation-rotation motion of the object over 180 degrees. 
3. SR-FXCT based on pencil beam geometry 
The x-ray fluorescence analysis method has been used in tracer element detection studies, 





However, these measurements require a thin sample and, therefore, are limited to 
measurements near the surface. Then, fluorescent x-ray scanning tomography was 
developed in order to investigate spatial distributions of specific elements. Fluorescent x-ray 
scanning tomography employing an x-ray tube has been used to study iodine in samples of 
several millimeters in diameter (Cesareo & Mascarenhas, 1989), while x-ray fluorescence 
scanning microtomography employing synchrotron radiation has been used in studies of Fe 
and Ti in 8-mm samples and in the detection of iron in a bee head (Boisseau & Grodzins, 
1987). However, 2-dimensionally scanning a sample is time-consuming. In addition, since 
the scanning tomography also requires a thin sample, spatial distributions of specific 
elements in a massive sample cannot be measured (Recently, in order to obtain 3-
dimensional tomogram, scanning tomography using a confocal collimator was proposed 
(Chukalina, et al., 2007)). In order to overcome the problems, Hogan et al. proposed an 
imaging scheme based on CT concept (Hogan, et al., 1991).  
3.1 SR-FXCT imaging system with pencil beam geometry 
The schematic diagram of a typical SR-FXCT system of the first generation is shown in Fig. 4. 
A white x-ray beam from a source is monochromatized using a monochromator, which in 
our system is a two-crystal Bragg–Bragg device employing Si crystals. It is collimated into a 
thin beam using a slit before impinging on the subject. Fluorescent x ray is emitted 
isotropically by the de-exciting contrast atoms along the line of the incident beam, with 
intensity proportional to the product of the iodine concentration in the incident beam and 
the incident x-ray flux rate. It is detected in a solid state detector (an HPGe detector) 
operating in a photon-counting mode. While in this article FXCT from a single kind of 
imaging agent is discussed, different FXCT images from multiple kinds of imaging agents 
can be simultaneously obtained by setting the corresponding energy windows (Yu, et al., 
2001; Golosio, et al., 2003; Deng, et al., 2007; —, 2011). The detector is collimated to reduce 
the amount of stray radiation being detected, and is positioned perpendicular to the incident  
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beam for reducing the Compton scattering background in the spectrum. The energy of the 
incident beam is carefully tuned so that the fluorescent spectral line does not overlap with 
the Compton scatter peak. Despite these precautions, the detected signal contains some 
scattered photons.  
In studies of phantom and plant (Simionovici, et al., 2000; —, 2001) and sediment particles, 
micro-FXCT images were obtained with a spatial resolution of less than 0.01 mm. Our FXCT 
system, designed for biomedical study, improved the spatial resolution from 1 mm to 0.025 
mm. Compared with recent molecular imaging techniques such as micro-PET (positron 
emission tomography) and micro-SPECT (single photon emission computed tomography), 
FXCT has the advantage of not requiring the use of a radioactive agent limiting easy 
preparation of the object (Takeda, et al., 2001). In addition, FXCT has high quantitativeness. 
3.2 Principle and formulation 
The principles of the fluorescent X-ray CT is depicted in Fig. 4 (Hogan, et al., 1991; Yuasa, et 
al., 1997). The coordinate system (x, y) is fixed in the reference frame of the sample. The 
system (s, t) is represents the rotating coordinate system associated with the specimen, and 
they are related to system (x, y) by a rotation of an angel θ. The two coordinate systems are 
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The points P, Q, and R represent the intersection of the incident x-ray beam with the object’s 
surface, the point of interest, and an intersection of a single emitted fluorescent x-ray with 
the object’s surface, respectively. An incident x-ray with an initial intensity I0 travels 
through the point P, and arrives at the point Q, and then fluorescent emitted isotropically x 
ray from the iodine atoms excited at the point Q. The interaction of the beam with the object 
can be depicted with three steps in the following: 
Step 1: Incident radiation travels from P to Q while receiving attenuation by the object. The 
process for a single ray at position s and projection angle θ can be given by 
 ' '1 0( , ) exp( ( , ) )
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where I0 is the intensity of incident beam and ( , )I s t  is the linear absorption coefficient for 
the energy of the incident x-ray. The integration proceeds along the line segment PQ. 
Step 2: The fluorescent x-ray fluxes are emitted isotropically at position Q in quantity 
proportional to the product of the incident intensity and the concentration of imaging agents 
d(s, t). The fluorescent x-ray emitted fluxes from the point Q, I2 can be given by 
 ' '2 0( , ) exp( ( , ) ) ( , )
t I
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where ph  is the photoelectric linear attenuation coefficient,  is the fluorescent yield of the K 
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beam for reducing the Compton scattering background in the spectrum. The energy of the 
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where I0 is the intensity of incident beam and ( , )I s t  is the linear absorption coefficient for 
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 ( m M    ) denotes the angle between a single ray inside the fan-shaped emitted 
fluorescence photon and the t-axis (Fig. 4) and ( , )F s t  is the linear attenuation coefficient of 
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( , ) exp( ( , ) ) ( , )





I s t I s t dt d s t








   

 
  (6) 
The total fluorescent flux to the detective surface I, is obtained by integrating I3 with respect 
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The ( , , )f s u  represents the incident radiation intensity attenuated reaches the point Q, 
and ( , , )g s u  represents the fluorescent radiation intensity attenuated were detected by a 
detector, respectively. The goal of image reconstruction in FXCT is to solve the d(s, u). We 
can estimate the d(s, u) from eq. (7) when the distributions of the linear attenuation 
coefficients of the object at the energies of the incident and fluorescent x-
ray, ( , )I s u and ( , )F s u are known. 
3.3 Reconstruction 
As seen in the previous section, the measurement process is relatively complicated. So, 
analytical solutions may not be available without some approximation (Hogan, et al., 1991; 
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Brunetti, et al., 2001; La Riviere, 2004; Miqueles, et al. 2010). To numerically solve (7), we 
need to discretize it. The object is assumed to be two dimensional. Here, we adopt the xy-
coordinate system fixed to the object for discretization. Three matrices, dj, Ij and , Fj (j = 1, 
2, …, N) fixed to the xy-coordinate system are prepared, corresponding to the functions d(s, 
t), I(s, t) and F(s, t), where j (j = 1, 2, …, N) is the index identifying the pixel. Note that Ij 
and Fj are known. Also, let us number each incident x-ray Si with the index i that runs from 
1 to M. Si is then the set consisting of the indexes identifying pixels which are intersected by 
the ith ray (Fig. 5). Taking note of the jth pixel being struck by beam Si, let us follow the 
process described in the previous section using Fig. 6. 
  
Fig. 5. Example of a set Si defined for the ith incident X-ray. 
  
Fig. 6. Example of a set Sij defined for the ith incident X-ray and the jth pixel. 
Step 1: The incident x-ray is attenuated by the shaded pixels in Fig. 6. Here, Sij is defined as 
the set of the indices denoting these pixels, which is apparently the subset of the set Si. 
Defining the length of the line segment such that the ith xray is intersected with the kth pixel 
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which corresponds to (8). 
Step 2: The fluorescent x-ray is radiated isotropically, whose absorbed flux rate is in 
proportion to the product of the flux rate of the x-ray entering the jth pixel and concerning 
this phenomenon, ph fij LIij, and the iodine concentration, dj. Let us define the angle at 
which the jth pixel is viewed by the detector as  (Fig. 7). The x-ray absorbed flux rate 
corresponding to (4) is (/ 2)ph fij LIij dj. 
  
Fig. 7. Definition of angle . 
 
Fig. 8. Example of a set Tijl defined for the ith incident X-ray and the jth pixel and the lth 
fluorescent X-ray. 
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Step 3: We consider the attenuation process up to the detector. For a predefined integer, K, 
let  =  / K. Here, the fan-shaped fluorescent x-ray is approximated by K individual x-
rays. We define the index identifying the angle of the fluorescent x-rays as l (1 lK). 
Considering the jth pixel (j Si) and the lth fluorescent x-ray, we consider the attenuation 
from the lth ray from the jth pixel to the detector (Fig. 8). Let Tijl be a set of indexes 
consisting of the pixels which are intersected with the lth fluorescent x-ray. These pixels, 
denoted as the shaded pixels in Fig. 8, attenuate the lth fluorescence x-ray before they reach 
the detector. Let LFijm be the length of the line segment such that the lth ray is intersected 
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where 
 Ii j ij ij ijh f g L   (13) 
The matrix representation of (12) is 
 I Hd   (14) 
where 
    1 , 1ijh i M j N    H   (15) 
    1iI i M  I   (16) 
and 
    1jd j N  d   (17) 
As a result, in order to reconstruct a cross section, you should solve the matrix equation. A 
















   (10) 
which corresponds to (8). 
Step 2: The fluorescent x-ray is radiated isotropically, whose absorbed flux rate is in 
proportion to the product of the flux rate of the x-ray entering the jth pixel and concerning 
this phenomenon, ph fij LIij, and the iodine concentration, dj. Let us define the angle at 
which the jth pixel is viewed by the detector as  (Fig. 7). The x-ray absorbed flux rate 
corresponding to (4) is (/ 2)ph fij LIij dj. 
  
Fig. 7. Definition of angle . 
 
Fig. 8. Example of a set Tijl defined for the ith incident X-ray and the jth pixel and the lth 
fluorescent X-ray. 
Fluorescent X-Ray Computed Tomography 
Using Synchrotron RadiationTowards Molecular Imaging 
 
49 
Step 3: We consider the attenuation process up to the detector. For a predefined integer, K, 
let  =  / K. Here, the fan-shaped fluorescent x-ray is approximated by K individual x-
rays. We define the index identifying the angle of the fluorescent x-rays as l (1 lK). 
Considering the jth pixel (j Si) and the lth fluorescent x-ray, we consider the attenuation 
from the lth ray from the jth pixel to the detector (Fig. 8). Let Tijl be a set of indexes 
consisting of the pixels which are intersected with the lth fluorescent x-ray. These pixels, 
denoted as the shaded pixels in Fig. 8, attenuate the lth fluorescence x-ray before they reach 
the detector. Let LFijm be the length of the line segment such that the lth ray is intersected 












    








ij ph m ijm
l m T






    (11) 
















  (12) 
where 
 Ii j ij ij ijh f g L   (13) 
The matrix representation of (12) is 
 I Hd   (14) 
where 
    1 , 1ijh i M j N    H   (15) 
    1iI i M  I   (16) 
and 
    1jd j N  d   (17) 
As a result, in order to reconstruct a cross section, you should solve the matrix equation. A 





et al., 2011; La Riviere, et al., 2010). If data amount is not so huge, you may solve it through a 
direct matrix calculation. If so, you should take an iterative reconstruction method. In 
addition, if a signal to noise ratio is not high, you should select a statistical reconstruction 
method such as EM algorithm (Rust, et al., 1998). On the other hand, while we discussed 
reconstruction when distributions of I and F are known, in order to obtain these 
distributions additional CT measurements are required. Approaches to circumvent this 
problem have been proposed (Schroer, et al., 2001; La Riviere, et al., 2006; —, 2006; ). 
3.4 Imaging experiments 
Here, we introduce the actual experimental results, which show that SR-FXCT has high 
sensitivity and spatial resolution as well as quantitativeness, and offers useful knowledges 
to biomedical sciences. 
3.4.1 Imaging setup 
The experiment was carried out at the bending magnet beam line BLNE-5A in KEK, Japan 
(Fig. 9). The photon flux rate in front of the subject was approximately 108 
photons/mm2/sec at a beam current of 40 mA with 6.5 GeV. The FXCT system consists of a  
 
Fig. 9. Schematic of fluorescent x-ray CT system 
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silicon (220) double-crystal monochromator, an x-ray slit system, a scanning table for the  
target object, a highly purified germanium (HPGe) detector (IGRET, EG&G Ortec, USA) 
with a parallel collimator, two pindiode detectors and a computer system. The white x-ray 
beam was monochromated at 37 keV using the silicon double-crystal monochromator. The 
incident monochromatic x-ray beam was collimated into a pencil beam with square cross 
section (0.25 mm 0.5 mm) using the x-ray slit system. Fluorescent x-rays were detected by 
the HPGe detector in photon-counting mode. To reduce the amount of Compton radiation 
captured by the detector, the HPGe detector was positioned perpendicular to the incident 
monochromatic x-ray beam. The data-acquisition time of the HPGe detector was set a few 
seconds. An example of energy profile acquired at a data point by the imaging system is 
shown in Fig. 10. We can observe three peaks, i.e., the iodine-fluorescence, the Compton, 
and the Thomson peaks. The net counts in an energy window centered at the characteristic 
x-ray fluorescent spectral line of 28.3 keV at each projection point constitute the CT 
projections. Projections are acquired at constant angular steps using a translation-rotation 
motion of the subject over 180 degrees in a conventional CT configuration. Also, the imaging 
setup can simultaneously obtain Compton scatter CT image as well as FXCT image, because 
the measurement process of Compton scatter is the same as that of fluorescent x-ray (Yuasa, 
et al., 1997; Golosio, et al., 2003). Although through this article synchrotron x ray is 
supposed as incident beam, currently a bench-top FXCT system using a diagnostic energy 
range polychromatic (i.e. 110 kVp) pencil-beam source is being developed (Cheong, et al., 
2010; Jones, et al., 2011). 
 
Fig. 10. Schematic of fluorescent x-ray CT system 
The experiments for evaluating quantitativeness of SR-FXCT were performed using a 10 
mm-diameter acrylic phantom with 3 mm holes to evaluate the contrast detectability 
corresponding to iodine concentrations of 200, 100, 50, 25 and 15 mg ml-1 (Fig. 11). Using the 
contrast-resolution phantom, we confirmed that the FXCT could visualize a 0.005 mg ml-1 
iodine solution at 0.25 mm in-plane spatial resolution and 0.5 mm slice thickness. There was 
an excellent linear correlation between pixel value in the FXCT image and the iodine 
concentration (Fig. 12). From this graph we observed satisfactory quantitativeness and thus 
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Fig. 11. Acrylic phantom and an example of FXCT image. 
 
Fig. 12. Relationship between actual iodine concentration and FXCT pixel value. 
3.4.2 Ex Vivo imaging of hamster’s heart 
With FXCT using synchrotron radiation, we successfully imaged the myocardial fatty acid 
metabolism in normal rat and cardiomyopathic hamster with BMIPP (127I-BMIPP) labelled 
with non-radioactive iodine, where the BMIPP is a potential tracer for detecting the fatty 
acid metabolism in current clinical SPECT imaging (Thet-Thet-Lwin, et al., 2007; —, 2008). In 
this study the myocardial fatty acid metabolism in cardiomyopathic hamster and age-
matched normal hamster were quantitatively analyzed using FXCT images, and the FXCT 
images were compared with optical microscope images with Masson’s trichrome (MT) stain. 
A 20 week J2N-k cardiomyopathic hamster and an age matched J2N-n normal hamster were 
imaged in this study. Under anesthesia (pentobarbital 40 mg kg-1 weight), hearts were 
extracted after 5 min intravenous injection of 127I-BMIPP (0.08 mg g-1 weight). The hearts 
labeled with BMIPP were fixed by formalin and then imaged by FXCT, placing them in an 
acrylic cell under the same data acquisition parameters as for the phantom study. Here, five 
short-axis slices of heart in cardiomyopathy and three short-axis slices in normal hamster 
were imaged by FXCT. After FXCT imaging, specimens were cut into 0.02 mm thick slices. 
The degree of fibrosis and its area were evaluated by optical microscopy (Biozero, Keyence 
Co., Japan) with MT stain, because fibrotic tissue does not uptake BMIPP. 
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FXCT images revealed that BMIPP was distributed homogeneously in normal myocardium, 
whereas it was distributed heterogeneously in cardiomyopathic myocardium. In normal 
hamster, the mean BMIPP uptake value of each slice was not statistically different among 
the three short-axis images: 177.2  18.5, 180.1 17.9 and 179.1  18.0. In cardiomyopathic 
hamster, the mean BMIPP uptake value of each slice was also not statistically significant 
among the five short-axis images: 151.1  26.5, 164.6  25.8, 157.8 ± 23.1, 150.0 ± 24.7 and 
149.0 ± 25.6. The mean BMIPP uptake value of each slice in cardiomyopathic hamster heart 
was lower than that in normal heart and its standard deviation was larger than that of 
normal heart. Short-axis images of the mid-ventricular level in normal and cardiomyopathic 
hamsters (Figs. 13 (a) and (b)) were analyzed in detail for regions of each slice. In these 
images the mean BMIPP uptake in normal myocardium was 1.2 times higher than that in 
cardiomyopathic myocardium (177.2 ± 18.5 mg ml-1 versus 151.1 ± 26.5 mg ml-1). In the same 
slices as used for the FXCT image, optical microscopy with MT stain depicted no fibrosis in 
normal myocardium and only a slight interstitial fibrosis in cardiomyopathic myocardium 
(Figs. 13 (c) and (d)). An area of 12.0% was observed as interstitial fibrosis in the whole 
short-axis slice of the mid-left ventricle. Areas of this interstitial fibrosis partially 
corresponded to that of reduced BMIPP uptake in the FXCT images (Table 1). In addition, 
morphological structures such as papillary muscle, wall thickness and left ventricle 
diameter were also approximately visualized in the FXCT images. Ventricular dilatation and 
mild thinning of the myocardial wall were observed in the cardiomyopathic myocardium 
cases. 
 
Fig. 13. FXCT images of (a) normal myocardium and (b) cardiomyphathic myocardium. 
Optical microscope pictures with MT stain of (c) normal and (d) cardiomyopathic 
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hamster, the mean BMIPP uptake value of each slice was not statistically different among 
the three short-axis images: 177.2  18.5, 180.1 17.9 and 179.1  18.0. In cardiomyopathic 
hamster, the mean BMIPP uptake value of each slice was also not statistically significant 
among the five short-axis images: 151.1  26.5, 164.6  25.8, 157.8 ± 23.1, 150.0 ± 24.7 and 
149.0 ± 25.6. The mean BMIPP uptake value of each slice in cardiomyopathic hamster heart 
was lower than that in normal heart and its standard deviation was larger than that of 
normal heart. Short-axis images of the mid-ventricular level in normal and cardiomyopathic 
hamsters (Figs. 13 (a) and (b)) were analyzed in detail for regions of each slice. In these 
images the mean BMIPP uptake in normal myocardium was 1.2 times higher than that in 
cardiomyopathic myocardium (177.2 ± 18.5 mg ml-1 versus 151.1 ± 26.5 mg ml-1). In the same 
slices as used for the FXCT image, optical microscopy with MT stain depicted no fibrosis in 
normal myocardium and only a slight interstitial fibrosis in cardiomyopathic myocardium 
(Figs. 13 (c) and (d)). An area of 12.0% was observed as interstitial fibrosis in the whole 
short-axis slice of the mid-left ventricle. Areas of this interstitial fibrosis partially 
corresponded to that of reduced BMIPP uptake in the FXCT images (Table 1). In addition, 
morphological structures such as papillary muscle, wall thickness and left ventricle 
diameter were also approximately visualized in the FXCT images. Ventricular dilatation and 
mild thinning of the myocardial wall were observed in the cardiomyopathic myocardium 
cases. 
 
Fig. 13. FXCT images of (a) normal myocardium and (b) cardiomyphathic myocardium. 
Optical microscope pictures with MT stain of (c) normal and (d) cardiomyopathic 






Table 1. Mean BMIPP uptake, and percentile area of reduced BMIPP uptake and fibrosis for 
each myocardinal region of the mid-left ventricle (Thet-Thet-Lwin, et al., 2007; —, 2008). 
3.4.3 Ex Vivo and In Vivo imaging of mouse’s brain 
Using x-ray fluorescent computed tomography (FXCT), the in vivo and ex vivo cerebral 
distribution of a stable-iodine-labeled cerebral perfusion agent, iodoamphetamine analog 
(127I-IMP), has been recorded in the brains of mice (Takeda et al., 2009). In vivo cerebral 
perfusion in the cortex, hippocampus and thalamus was depicted at 0.5 mm in-plane spatial 
resolution. Ex vivo FXCT images at 0.25 mm in-plane spatial resolution allowed the 
visualization of the detailed structures of these regions. The quality of the FXCT image of 
the hippocampus was comparable with the 125I-IMP autoradiogram. These results highlight 
the sensitivity of FXCT and its considerable potential to evaluate cerebral perfusion in small 
animals without using radioactive agents. 
We obtained images from seven living mice, weighing 20–24 g with heads of diameter about 
20 mm, after we employed a 10 mm-diameter contrast-resolution acrylic phantom to assess 
the contrast resolution in an ex vivo brain. The phantom consisted of three 5 mm-diameter 
axial cylindrical channels filled with three different iodine solutions, their concentrations 
ranging from 0.005 to 0.1 mg ml-1. We used non-radioactive 127I-labeled N-isopropyl-p-
iodoamphetamine (127I-IMP containing 0.38 mg iodine) for in vivo imaging of the brain, 
while radioactive 123I-IMP is commonly employed to evaluate cerebral perfusion in clinical 
SPECT studies. Imaging started 5 min after intravenously injecting 127I-IMP into a mouse 
anesthetized with pentobarbital; this dose is similar to that used by others in animal SPECT 
studies. The head of the mouse was set in the vertical direction to the pencil beam, fixed by 
an animal head holder to suppress any movement. Since the amount of IMP in the brain 
declined gradually with the approximate half-life time of 1.5 h, we surgically removed the 
brain of another mouse for the ex vivo experiments 5 min after intravenously injecting the 
127I-IMP and fixed it in the formalin. Then it was set within a formalin-filled acrylic cell, and 
imaged by FXCT at 0.5 mm and 0.25 mm in-plane spatial resolution. The FXCT image of the 
phantom was obtained at 0.25 mm in-plane spatial resolution. For comparison, we obtained 
autoradiograms with radioactive 125I-IMP from two other mice. Their brains were removed 
surgically 5 min after injecting 125I-IMP (15 kBq kg-1), fixed in formalin, and cut into 0.02 mm 
slices. These samples were exposed on an imaging plate (IP) for 48 h, and the plate was read 
by a BAS 5000 (Fuji) IP reader at 0.05 mm scan steps and 16-bit depths. 
The in vivo FXCT image at a 0.5 mm in-plane spatial resolution revealed the cerebral 
perfusion of 127I-IMP throughout the brain of the mouse (Fig. 14), whereas absorption-
contrast x-ray transmission CT (XTCT) discriminated only between the soft tissue and the 
bony structures of the skull. Cerebral perfusion in the cortex and hippocampus was more 
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clearly visualized in the 0.5 mm in-plane spatial resolution FXCT image than in the 1 mm in-
plane resolution image, while the anatomical features of the skull bone were clearly 
demonstrated by XTCT. Furthermore, the superimposed image (FXCT and XTCT) 
demonstrated the correspondence between anatomical features and cerebral perfusion 
(Zeniya, et al., 2001). The measured SNR of the FXCT image in cerebral cortex, hippocampus 
and thalamus was about 12.3, 11.7 and 21.1, respectively. We calculated that the mouse 
experienced a radiation-absorbed dose of about 0.36 Gy for the FXCT imaging experiment. 
 
Fig. 14. In vivo FXCT, TCT and superimposed images of normal mouse brains obtained at 
0.5 mm in-plane spatial resolution (Takeda et al., 2009). 
 
Fig. 15. FXCT image of formalin-fixed (ex vivo) mouse brain set within an acrylic cell filled 
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FXCT clearly imaged the formalin-fixed brain in an acrylic cell both at a 0.5 mm and a 0.25 
mm in-plane spatial resolution, while, in contrast, the XTCT image discriminated only the 
margin of the acrylic cell, and failed to distinguish the rain from its surrounding solution 
(Fig. 15). An ex vivo FXCT image was obtained in the same slice level; however, the FXCT 
image at 0.25 mm in-plane spatial resolution clearly differentiated the detailed structures, 
such as the cortex, hippocampus and thalamus, with almost the same quality as an 
autoradiogram with radioactive 125I-IMP. The IMP dose was approximately 27.3, 23.8 and 
50.3 mg g-1 in the cortical surface, hippocampus and thalamus, respectively. 
4. SR-FXCT based on sheet beam geometry 
As for in vivo imaging, FXCT has a problem: the conventional FXCT takes a huge amount of 
measurement time to acquire a single tomographic image because it adopts the sequential 
data collection scheme with a pencil beam, which is the first generation of data acquisition 
scheme in CT. Although it is desirable to collect as much data as possible for a high-quality 
image, the whole measurement must be completed under anesthesia and then the number 
of data points is severely restricted. Therefore, we have not yet attained the potential spatial 
resolution for in vivo imaging. 
4.1 SR-FXCT imaging system with sheet beam geometry 
The long measurement time of conventional FXCT based on pencil beam geometry is due to 
sequential data acquisition, and for faster measurements simultaneous or parallel 
acquisition of a single projection is indispensable. Figure 16 shows a schematic diagram of 
the proposed imaging geometry (Huo, et al., 2008; —, 2009). An incident monochromatic 
sheet beam, where the photon fluxes are parallel to one another, impinges on the object as it 
covers the width of the object cross section. Contrast agents, such as iodine, are thus excited 
and then isotropically emit x-ray fluorescence photons on de-excitation. A linear array of 
detectors, where N solid-state detectors operating in a photon counting mode with energy 
resolution are equally spaced, is positioned perpendicular to the beam propagation in the 
plane of polarization for the lowest Compton scatter contribution in the spectrum, due to 
the property of linear polarization. A long slit-like collimator is installed in front of each  
 
Fig. 16. FXCT based on sheet-beam geometry (Huo, et al., 2008).  
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detector element in order to restrict the regions emitting x-ray fluorescence incident on the 
detector surface and to reduce the amount of stray radiation being detected. As a result, the 
detector array from the 1st to the Nth detectors simultaneously acquires projection data in a 
direction perpendicular to the beam propagation. Translational scans are therefore no longer 
required during the collection of a set of projections, though some translational scans may 
still be necessary to obtain a single complete projection, because each detector is partitioned 
by a collimator and no data are obtained at the collimator’s septal walls. The overall 
measurement time will still be drastically reduced, as a set of projections can be collected 
through rotational and fewer translational scans. 
4.2 Formulation and reconstruction 
We set the x1x2-coordinate fixed to the object, and suppose that the sheet beam accompanied 
with the detectors array is rotated around the origin O, where the collimators in front of the 
array are omitted so as to see easily the diagram. The hatched region means the incident 
sheet-beam irradiation. We derive the formula representing fluorescent x-ray photons 
measured by a single detector, or the ith detector among N detectors of the array. First, we 
pay attention to a single incident ray among the sheet beam. The points, P, Q, S and R in Fig. 
17 represent the intersection of the single incident ray with the object’s surface, the point of 
interest, an intersection of a single emitted fluorescent x ray with the object’s surface, and an 
intersection of line QS with the object’s surface, respectively. We denote the iodine 
concentration distribution to be estimated, the distribution of the linear attenuation 
coefficient for the energy of the incident X-ray, and that of the fluorescent X-ray as d(x), aI(x) 
and aF(x) must be known in advance by the usual x-ray CT using the CCD camera. Next, let 
us consider the process in which a single incident ray with an initial intensity I0, at the point, 
P, arrives at the point, Q, and the fluorescent subsequently emitted x ray from the iodine 
atoms excited at the point, Q, reaches the ith detector. We partitioned the process into three 
steps. Here, 1S  and 1S   are unit vectors parallel and vertical to the single ray of 
interest. 
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detector element in order to restrict the regions emitting x-ray fluorescence incident on the 
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array are omitted so as to see easily the diagram. The hatched region means the incident 
sheet-beam irradiation. We derive the formula representing fluorescent x-ray photons 
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Step 1: The x-ray flux rate, I(x), reaching the point, Q, is given by 
  0( ) exp ( )( , )II x I Da x     (18) 
where 
0
( )( , ) ( ) 

 I IDa x a x t dt . 
Step 2: The fluorescent x-ray is emitted isotropically with an intensity proportional to the 
product of the absorbed x-ray flux rate at the point, Q, ph I(x)  and the iodine 
concentration, d(x), where ph is the photoelectric linear attenuation coefficient of iodine, and 
 is the differential volume at Q. Accordingly, the flux rate of the fluorescent x ray emitted 
from the point, Q, and reaching the ith detector, f(x), is given by 
 ( ) ( ) ( ) 4phf x I x d x
     (19) 
where  and  are the yield of the fluorescent x ray and the solid angle at which the point, 
Q, is viewed by the ith detector, respectively. 
Step 3: Following a fluorescent x-ray emitted from the point, Q, crossing the object toward 
the ith detector, it is attenuated along the line segment QS; it reaches the ith detector with a 
flux rate given by 
 ( ) exp ( )( , ) ( )d FI x Da x f x
      (20) 
where  
0
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  F FDa x a x t dt . 
Here, we obtained the contribution from the single incident ray into the ith detector. The 
formula holds for other rays among the sheet beam. The total flux rate of the fluorescent x-
ray reaching the ith detector for the sheet beam x-ray is obtained by integrating with respect 
to x along line RS, x• = s, where s is a distance between origin O and line RS: 
  ( , ) exp ( )( , ) ( )a Fx sR f s Da x f x dx 


      (21) 
Thus, the measurement process by the FXCT based on sheet beam geometry leads to the 
attenuated Radon transform. The inversion for  ag R f  was given by Natterer (Natterer, 
2001) as 
  11( ) Re exp ( )( , ) ( , )4
h h
FS
f x div Da x e He g x d    

       (22) 
where 1 2( ) Fh I iH Ra  , and H and R are the Hilbert transform and Radon transform, 
respectively. We can obtain the exact iodine density d(x) by first applying the exact inversion 
formula straightforwardly to Eq. (22), and then by applying Eq. (19) to the resulting f(x). In 
the sheet-beam geometry, the analytical solution is exactly feasible. 
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4.3 Preliminary experiments 
In order to prove the concept of this imaging protocol, we constructed a preliminary 
imaging system for simulating the proposed imaging geometry using a single HPGe SSD. 
4.3.1 Imaging setup 
The preliminary imaging system was constructed at the BLNE-5A bending-magnet beam 
line (6.5 GeV), KEK in Japan. A white x-ray beam from a source was monochromatized 
using a Si (220) monochromator at 37 keV. The photon flux rate in front of the object was 
approximately 9.3 107 photons/mm2/s for a beam current of 40 mA. The 
monochromatized beam was shaped to a sheet beam of 2.0 cm wide 1.0 mm thick using an 
x-ray slit. Figure 18 shows the schematic of the preliminary detection system for simulating 
a sheet-beam geometry, consisting of an HPGe detector operating in photon counting mode 
to detect emitted fluorescent photons and a long Pb slit collimator installed in front of the 
detector surface. We prepared two types of collimators: one coarse (1.0 mm height 0.5 mm 
width  100 mm long) and the other fine (1.0 mm height 0.25 mm width 100 mm long). 
The distance between the sample surface and the collimator tip was set at 12 mm. First the 
sample was scanned translationally along the beam direction and, after the translational 
scan, the sample was rotated. Although the data collection scheme is sequential, the dataset 
finally obtained corresponds to that acquired using a linear array of detectors. Projection 
data at the data point was generated from the Kpeak by summing the fluorescent-photon 
counts in the energy window with the center at 28.3 keV and width of 2 keV.  
 
Fig. 18. Schematic of a lead collimator and a solid state detector. 
4.3.2 Phantom imaging 
To confirm the efficacy, we performed an imaging experiment using a physical phantom, 
which is a 10-mm-diameter acrylic cylinder with three 3-mm-diameter holes filled with 
iodine solutions at different concentrations (200, 100, and 50 μg/ml). The sample was 
imaged twice. First, it was scanned using the coarse collimator translationally and 
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a data point was 5 s, and dead-time rate was less than 10%. Second, it was done using the 
fine collimator translationally and rotationally at 0.25-mm steps and 2 step over 180, 
respectively. The measurement time for a data point was 5 s and dead-time rate was less 
than 5%. The reconstructed images for the coarse and fine collimators are shown in Figs. 19 
(a) and (b), respectively. In both the images, the three circles corresponding to the regions 
including the iodine solution are successfully delineated, but the image for the coarse 
collimator is more blurred than that for the fine collimator. Figure 19 suggests that pixel 
values in the iodine regions depend on the actual iodine concentration. So, we investigated 
the imaging scheme quantitatively using the physical phantom. For this, we imaged the 
phantom while changing the iodine concentrations, and then compared the actual iodine 
concentrations with the average pixel values in the iodine regions set in the reconstructed 
images. Figure 20 shows the relationship. A good correlation was observed between the 
pixel value in the reconstructed image and the iodine concentration (R = 0.99). We can use 
the result as the calibration line for quantitative measurement. 
  
Fig. 19. FXCT image of a 10-mm-diameter acrylic cylindrical phantom which has three 
channels (3 mm) filled with three different concentrations of iodine solution: (a) coarse 
collimator, (b) fine collimator (Huo, et al., 2009). 
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4.3.3 Ex Vivo imaging of mouse’s brain 
We imaged a normal mouse brain ex vivo in order to confirm the suitability of the technique 
for biomedical imaging. Under anesthesia, the brain of a mouse was extracted after 5 min 
intravenous injection of non-radioactive iodine labeled 127I-IMP (about 0.05 mg/ml) and 
fixed by formalin. This experiment was approved by the Medical Committee for the Use of 
Animals in Research of the University of Tsukuba, Japan. The brain was fixed in an acrylic 
cylinder filled with formalin and was put on the stage (Fig. 21). The sample was imaged 
twice. First, it was scanned using the coarse collimator translationally and rotationally at 0.5-
mm steps and 2 step over 180, respectively. The measurement time for a data point was 20 
s and dead-time rate was less than 10%. Second, it was done using the fine collimator 
translationally and rotationally at 0.25-mm steps and 2 step over 180, respectively. The 
measurement time for a data point was 20 s and dead-time rate was less than 5%. The 
reconstructed images for the coarse and fine collimators are shown in Figs. 22 (a) and (b), 
respectively. The reconstructed image for the coarse collimator is more blurred than that for 
the fine collimator. However, in the both images, the cortex and thalamus can be identified 
anatomically, and the iodine content of the brain is estimated to be about 20.0 μg/ml on 
average using the calibration line in Fig. 20. The iodine content approximately coincides 
with that obtained using the system based on a pencil-beam geometry. From these results 
we can conclude that the proposed scheme can also offer quantitative biomedical 
information related to cerebral perfusion at a high spatial resolution. 
 
Fig. 21. Extracted mouse brain put in an acrylic cylinder filled with formalin. 
 
Fig. 22. Ex vivo FXCT images of normal mouse brain: (a) coarse collimator, and (b) fine 
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Here, we investigate the differences between FXCTs based on pencil-beam and sheet-beam 
geometries in their imaging properties by considering each measurement process in detail. 
As shown in Fig. 23 (a), in the pencil-beam geometry a thin incident beam impinges on an 
object and excites imaging agents on the incident beam line, and then fluorescent x-ray 
photons are isotropically emitted from the imaging agents. Pay attention to the point Q 
inside the object in order to consider the measurement process in a more detail. The 
measurement process is broadly divided into three steps in the following: 
A. The incident flux travels from P to Q while being attenuated by the object. 
B. The fluorescent flux of X-ray photons is isotropically emitted at Q in proportion to the 
product of the incident intensity and the concentration of imaging agents at Q. Of the 
photons, only those that propagate toward the detective surface ST are detected. 
C. The fluorescent flux travels from Q to the detector surface ST while being attenuated by 
the object. Here, the amount of attenuation depends on the propagation direction. For 
example, while the fluorescent flux reaching points W and X on the detector surface ST 
is attenuated by segments QU and QV, respectively, the amount of attenuation is 
different. 
 
Fig. 23. Schematics of measurement process: (a) pencil-beam geometry, and (b) sheet-beam 
geometry. 
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Since the fluorescent flux obtained above is a contribution from the point Q, the total 
detected photons can be obtained by integration through PR. The measurement process of 
the pencil beam geometry is very complex, and hence the attenuation correction also is very 
complex. In sheet-beam geometry, concerning the measurement by the ith detector along 
path P→Q→S in Fig. 23 (b), the measurement process is divided into three steps: 
A. The incident flux is attenuated by an object during the propagation from points P to Q. 
B. The x-ray fluorescence photons are isotropically emitted at point Q, whose number is 
proportional to both the incident flux rate and the iodine quantity at point Q. 
C. The fluorescent flux travels toward the detector while being attenuated by the object 
during the propagation from point Q to S. 
As each point on line RS is similarly subjected to the above process, the number of 
fluorescent photons detected by the ith detector is obtained by integrating the contributions 
from all the points on RS. The measurement process of the sheet-beam geometry is very 
simple, and therefore the attenuation correction is relatively simple. 
 
Fig. 24. Example of energy profile: (a) pencil-beam geometry, and (b) sheet-beam geometry 
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First, we consider signal quality based on the above specification on the measurement 
process. Figures 24 (a) and (b) show the energy profile obtained from the identical physical 
phantom using the systems based on pencil- and sheet-beam geometry, respectively. In both 
the figures, fluorescence, Compton scatter, and Thomson scatter peaks are observed from 
the left to the right. The first point to notice is that the counts in a region between the 
fluorescent and the Compton peaks, which correspond to multiple scatter components, in 
the pencil-beam geometry is more than those in the sheet-beam geometry, although the 
energy profiles are very similar in appearance. In the pencil-beam geometry, the detector 
collects a great deal of multiply scattered components from various directions because of the 
use of a large area of the detector surface. On the other hand, in the sheet-beam geometry, 
the detection efficiency of fluorescence is remarkably low because of the use of the slit-like 
collimator. However, the collimator in turn suppresses the scattered components maximally. 
Therefore, the system based on sheet-beam geometry can measure fluorescence under less 
dead-time ratio of the detector, and thus it can collect data more reliably than the system 
based on pencil-beam geometry. 
 
Fig. 25. Example of energy profile around the fluorescent peak: (a) pencil-beam geometry, 
and (b) sheet-beam geometry (Huo, et al., 2009). 
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Figures 25 (a) and (b) show the enlarged energy profiles around the fluorescent peaks for 
the pencil- and sheet-beam geometry, respectively, where Figs. 25 (a) and (b) are 
respectively generated from Figs 24 (a) and (b). From Fig. 25 (a), in the pencil-beam 
geometry, we can see that the multiply scattered components overlap with the fluorescent 
peak. In contrast, the background noise in the fluorescence region is not observed in Fig. 25 
(b). Therefore, we can conclude that the system based on the sheet beam geometry can 
detect data at a higher signal-to-noise ratio than that on the pencil-beam geometry. The 
higher quantitative results described earlier can be attributed to the above factors. 
Next, we consider a relationship between the spatial resolution and the measurement time. 
In the sheet-beam geometry, the spatial resolution of the reconstructed image mainly 
depends on the slit width of the collimator installed in front of the detector, as discussed 
earlier. In principle, the measurement time depends less on the resolution, because a single 
projection is obtained simultaneously or in parallel. On the other hand, in the pencil beam 
geometry, the resolution depends on the cross section of the thin incident beam. Reduction 
of the beam cross section for higher resolution leads to reduction of the translational step, 
and therefore the measurement time to acquire a single projection increases. Therefore, the 
sheet-beam geometry is indispensable for compatibility of the measurement time with the 
resolution. 
Finally, we estimate the measurement time. Using an array of 100 energy-resolved detectors, 
each with a detector surface 0.25 mm in width and arrayed equally 0.25 mm apart, three 
translations at steps of 0.25 mm can produce a single complete projection of 25 mm in width. 
On the assumption that the time for a single measurement is 5 s and the rotational step is 2 
over 180, the total time is 900 (= 5 × 2 × 90) s, plus the time required for the mechanical 
scans. Thus, we can image a single object in about 15 min. If the detector elements are two-
dimensionally arrayed, we can obtain a 3-D CT image by piling up the 2-D tomographic 
images. 
6. Conclusion 
In this chapter, we first introduced FXCT of the first generation based on pencil-beam, 
which offers excellent imaging properties, such as high spatial resolution, high sensitivity, 
and high quantitativeness. Especially, spatial resolution can be improved up to the microns 
range by decreasing cross-section of incident-beam. However, the measurement time 
increases because a decrease in beam cross-section causes a reduction of step size in 
translationally scanning incident beam, leading to an increase in the number of data, and 
further an increase in the measurement time. Therefore, in FXCT based on pencil-beam the 
measurement time and the spatial resolution have a trade-off relationship, since it collects 
data sequentially. Long measurement time is fatal to in vivo imaging, i.e., molecular 
imaging. 
Then, in order to circumvent the above problem, we proposed the parallel data-acquisition 
scheme based on sheet-beam geometry. This method collects a set of data in a single 
projection at once, and thus drastically reduces the total measurement time. We 
experimentally proved the feasibility by demonstrating reconstructed images of a physical 
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The proposed method based on sheet-beam geometry also preserves the excellent imaging 
properties. Also, we take notice of the fact that the sheet-beam geometry offers the exact 
analytical solution. In addition, the FXCT system can acquire not only functional 
information but also morphological one. If the CCD camera is placed downstream of the 
object, we can simultaneously obtain a transmission image which can provide auxiliary data 
for attenuation correction and morphological information. The proposed FXCT can, 
therefore, simultaneously obtain both morphological and functional information, while 
PET/CT requires separate measurements to obtain the two kinds of images. 
7. A view to the future 
The problem left is how to reconstruct 3-D image. PET and SPECT produce 3-D images. If 
FXCT gives only 2-D images in spite of a good spatial resolution, FXCT ranks with PET and 
SPECT. However, the problem can be solved using 2-D detectors array and a volumetric 
parallel incident beam. If we treat the volumetric beam as an accumulation of sheet beams in 
a vertical direction, we can apply the proposed data-acquisition scheme and the 
reconstruction algorithm to each supposed sheet-beam straightforwardly. Finally, we 
construct a 3-D image by accumulating the reconstructed 2-D images in a vertical direction. 
The measurement time in 3-D case is the same as that in 2-D case. For this purpose, we need 
a 2-D detectors array with energy resolution. However, presently it is still too expensive, 
and has an insufficient size of each detector element. Advent of 2-D detectors array with 
energy resolution and with each detective surface area sufficiently fine will accelerate 
development of the FXCT system for molecular imaging. 
8. Take-home-message 
FXCT is a hybrid from x-ray fluorescent analysis and computed tomography. FXCT imaging 
system has excellent properties as follows: 
1. use of non-radioactive imaging agent, i.e., non-inner exposure inspection, 
2. non-destructive measurement, 
3. high sensitivity, 
4. high spatial resolution, 
5. high quanatitativeness, and 
6. simultaneous acquisition of functional and morphological information. 
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1. Introduction 
Understanding how signal inputs and outputs are organised in membrane protein 
signalling networks is an important question in biology. The current goal is to derive 
methods that would allow the 'watching' of these network proteins in action and at atomic 
resolution to see details of their structure. This requires the addition of a 'time' dimension to 
structural biology so that the spatio-temporal parameters of all atoms in each protein can be 
described in detail. This is a huge challenge that in cell-free systems has begun to be 
partially addressed through dynamic experiments combined with molecular simulations. 
However, in cells, the functions of particular structural motifs are not just constrained by 
Brownian motions, energy landscapes and thermodynamics, but also by the local 
availability of partners in subcellular compartments and the boundary constraints imposed 
by cell environments, for example in the plasma membrane, with its 2D dimensionality, 
local curvature and electric fields. To understand protein function in cells, observations have 
to be made in the only physiologically-relevant 'laboratory', the cell. This adds levels of 
complexity to an already vast challenge.  
Using molecular biology techniques in combination with optical methods, we can now 
annotate individual genes and gene products, screen for protein-protein, protein-DNA and 
small molecule interactions, and quantify dynamic changes. However, only the combination 
of fluorescence imaging, fluorescence resonance energy transfer (FRET) and single molecule 
detection currently offers sensitive spatio-temporal detection in cells for low abundance 
protein interactions. This is beginning to bridge the gap between protein structure and 
function by allowing real-time quantitative observations of structural details, 
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conformational intermediates, association and dissociation constants, diffusion rates, and 
rare events. Previous information on complex protein networks, such as the human 
epithelial growth factor receptor (HER) bio-system, has been derived generally from high-
throughput screens and/or single cell models using ensemble (averaged) technologies such 
as biochemical extraction followed by mass spectrometric analysis. Here we describe 
examples of how single molecule and ensemble fluorescence microscopy methods can offer 
the means to understand and predict in cells the structure-function relationships of proteins 
in the input layer of the HER signalling network, from the changes in complex interactions 
between their microscopic molecular components to their response to perturbations. 
2. The human epidermal growth factor receptor (HER) family  
HER molecules are prototypical examples of the growth factor receptor tyrosine kinase 
(RTK) super-family, which also comprises 18 sub-groups of cell surface receptors for many 
growth factors, cytokines and hormones (Schlessinger 2000). The HER family consists of 
four homologous receptors, known in cells of human origin as HER1, HER2, HER3 and 
HER4 (Citri & Yarden 2006). The HER1 molecule (also known as Epidermal Growth Factor 
Receptor (EGFR)) is the founding member of the RTK family (Fig. 1). In other mammals 
HER molecules are known as ErbB receptors (ErbB1-4). This name originates from an 
oncogenic erythroblastosis retrovirus (v-erbB) which encodes a mutated homologue of 
HER1 (Downward et al. 1984).  
HER molecules are encoded as single pass trans-membrane proteins (Fig. 1). The primary 
structure of HER1, which is shared with all receptor tyrosine kinases, consists of a single 
polypeptide chain (1,186 amino acids) of 170 kD, containing a heavily glycosylated 622-
amino acid residue amino-terminal extracellular ligand binding domain that is connected to 
the cytoplasmic domain by a single transmembrane (TM) helix of 23 residues. The 542-
residue cytoplasmic domain contains a conserved 250-amino acid tyrosine kinase core 
(Ullrich et al. 1984). The kinase domain is the locus of the enzymatic activity of the receptor 
and at the core of its signalling function in the cell. 
Mature HER molecules are translocated to the plasma membrane lipid bilayer, which is the 
outer boundary of the cell separating the extracellular and intracellular environments 
(Hillier & Hoffman 1953), were they are able to accept signalling cues from their 
environment (Fig. 1). In the HER family signalling cues are provided by 13 potential ligands 
(reviewed in Yarden & Sliwkowski 2001; Citri et al. 2003; Citri & Yarden 2006). These 
ligands, known as epidermal growth factor (EGF)-related peptides, can be classified in three 
functional groups according to their specific binding targets (Olayioye et al. 2000): EGF, 
transforming growth factor alpha (TGF), amphiregulin and epigen bind HER1; 
betacellulin, epiregulin and heparin binding EGF-like growth factor bind HER1 and HER4; 
neuregulins 1 to 4 (NRG, also known as heregulins), bind either both HER3 and HER4 
(NRG-1 and NRG-2) or HER4 alone (NRG-3 and NRG-4). HER2 is thought to be an orphan 
receptor, with none of the EGF family of ligands discovered so far being able to bind and 
activate it (Baselga & Swain 2009; Olayioye et al. 2000).  
EGF-related peptide growth factors are synthesised as cell membrane associated precursors 
in the plasma membrane. The extracellular domains of membrane-bound growth factors are 
subsequently shed via the action of members of a family of proteases known as a disintegrin  
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Fig. 1. A cartoon of a 2:2 EGF/HER1 dimer complex showing the initial stages of effector 
recruitment and signalling. Shown are the external domains of HER1 bound to EGF (black 
spheres) derived from crystallographic data (Garret et al. 2002; Ogiso et al. 2002; Ferguson et 
al. 2003). In the cytoplasm the two tyrosine kinase domains of the HER1 dimer form an 
asymmetric dimer (Zhang et al. 2006). Following recruitment and phosphorylation of 
effectors like Grb2, recruitment of Sos leads to the activation of Ras via exchange of GTP for 
GDP to activate the Ras mediated signalling pathway (Zhang & Liu 2002). 
and metalloproteases (ADAMs) family. As indicated by their name, these proteolytic 
enzymes are zinc-dependent trans-membrane metalloproteases (Zhou et al. 2005). Other 
members of the ADAMs family also shed extracellular domains of other cytokines and 
receptors (Edwards et al. 2008). Growth factor shedding is critical for the production of 
soluble functional HER ligands that can activate cell signalling via paracrine and autocrine 
mechanisms. Growth factors that remain membrane-bound can bind HER molecules on 
adjacent cells leading to juxtacrine signalling (Riese & Stern 1998). 
3. Ligand-induced receptor dimerisation 
An essential step in HER activation and signalling is achieved via ligand-induced receptor 
dimerisation (Schlessinger 2000). Ligand molecules bind the extracellular region of their 
cognate receptor in specific sites promoting dimerisation and interactions between two 
receptor monomers (Fig. 1). If two receptors are of the same type (e.g. HER1-HER1 dimer) 
the process is known as homo-dimerisation. For receptors of two different types (e.g. HER1-
HER3) the process is known as hetero-dimerisation. Inactive receptors are believed to exist 
mainly as monomers, although unliganded (inactive) HER dimers have also been detected 
in cells (Martin-Fernandez et al. 2002; Clayton et al. 2005).  
A defining characteristic of the HER family is that only HER1 and HER4 can bind ligands 
and also signal autonomously via homo-dimerisation and trans-activation of their tyrosine 
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Fig. 1. A cartoon of a 2:2 EGF/HER1 dimer complex showing the initial stages of effector 
recruitment and signalling. Shown are the external domains of HER1 bound to EGF (black 
spheres) derived from crystallographic data (Garret et al. 2002; Ogiso et al. 2002; Ferguson et 
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dimerisation (Schlessinger 2000). Ligand molecules bind the extracellular region of their 
cognate receptor in specific sites promoting dimerisation and interactions between two 
receptor monomers (Fig. 1). If two receptors are of the same type (e.g. HER1-HER1 dimer) 
the process is known as homo-dimerisation. For receptors of two different types (e.g. HER1-
HER3) the process is known as hetero-dimerisation. Inactive receptors are believed to exist 
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A defining characteristic of the HER family is that only HER1 and HER4 can bind ligands 
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discussed above, HER2 lacks the intrinsic ability to interact with known ligands, whereas 
the kinase of HER3 is defective (reviewed in Citri et al. 2003). HER2 and HER3 can therefore 
only initiate signals through hetero-dimer formation. The following interacting pairs have 
been reported in the literature: HER1-HER1, HER4-HER4, HER1-HER2, HER1-HER3, HER1-
HER4, HER2-HER3, HER2-HER4 and HER3-HER4 (reviewed in (Bublil & Yarden 2007)). 
HER2-HER2 and HER3-HER3 homo-dimers may also exist, but this is less certain. Despite 
having no soluble ligand, HER2 is important because it is the preferred hetero-dimerisation 
partner of the other ligand-bound family members (GrausPorta et al. 1997). In addition, 
there are also reports of higher order homo-oligomers of HER1 (such as tetramers) (Clayton, 
et al. 2005; Clayton et al. 2008).  
4. HER signalling in cancer 
Aberrant behaviour of HER family members has been implicated in many cancers (Sharma 
et al. 2007). Research has shown that in adulthood, excessive HER signalling upsets the 
balance between cell growth and apoptosis resulting in the development of a wide variety of 
solid tumours (reviewed in Bublil & Yarden 2007). In particular, the level of expression 
and/or activation of HER1 and HER2 are altered in many tumours of epithelial origin, and 
clinical studies indicate that HER1 and HER2 have important roles in tumour aetiology and 
progression (Hynes & Lane 2005). For example, deregulated signalling by cell surface HER1 
receptors (e.g. via activating mutations in the HER1 gene) is implicated in a substantial 
percentage of lung cancers (Paez et al. 2004). Gene amplification leading to HER1 
overexpression is also often found in other human cancers like glioblastoma and esophageal 
squamous cell carcinoma (Ohgaki et al. 2004; Sunpaweravong et al. 2005). As activation of 
HER molecules has been shown to result in the growth and progression of the malignancy, 
the HER family is an important target of the pharmaceutical industry and there have been 
considerable research efforts directed toward the development of effective inhibitors of HER 
signalling. Two important types of HER inhibitor are in clinical use: Humanized antibodies 
directed against the extracellular domain of HER1 or HER2, which elicit an immune 
response and/or block ligand-binding and dimerisation, and small-molecule tyrosine-kinase 
inhibitors (TKIs) that compete with ATP in the tyrosine-kinase domain of the receptor 
inhibiting its intrinsic tyrosine kinase activity (Hynes & Lane 2005). Some of these TKIs have 
already demonstrated substantial clinical activity against several cancers (e.g. targeting of 
HER1 and HER2 are in different stages of pre-clinical and clinical trials) (Bublil & Yarden 
2007; Citri & Yarden 2006; Hynes & Lane 2005). 
5. Structural insights on the HER family: The extracellular domain 
The original paradigm proposed for the activation of HER molecules was that the binding of 
ligand induced the dimerisation of monomeric unliganded receptors via ligand-crosslinking 
of two receptor moieties (Schlessinger 2000). Contrary to these expectations, crystallographic 
studies of HER1 ectodomain fragments bound to two types of ligands, EGF and TGF, have 
shown quasi-symmetric 2:2 ligand-receptor dimers where each ligand binds simultaneously 
to subdomains I and III of one of the monomers (Fig. 2). These HER1 dimer structures 
therefore clearly showed that the dimerisation of this receptor was not directly mediated by 
the binding of ligand but achieved exclusively via receptor-receptor contacts via subdomain 
II (Garrett et al. 2002; Ogiso et al. 2002) (Fig. 2).  
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Crystal structures of unliganded HER1, HER3 and HER4 monomers show that these are 
held in a closed conformation by an intramolecular tether formed by loops in subdomains II 
and IV (Bouyain et al. 2005; Ferguson et al. 2003; Hyun-Soo & Leahy 2002). These data 
suggest that ligand binding and dimerisation involves major extracellular structural 
rearrangements in HER1, HER3 and HER4 molecules because in ligand-occupied receptor 
dimers the intramolecular tether is broken and the receptor is opened into an extended 
conformation which interacts with another monomer to form a back-to-back dimer (Burgess 
et al. 2003; Ferguson, et al. 2003). Interestingly, unliganded HER2 has an extended 
configuration that resembles the structure of ligand-bound ‘activated’ HER1 (Cho et al. 
2003). This may explain the unique properties of HER2, which has no known ligand and can 
cause cell transformation (and tumorigenesis) by simple overexpression (Yu & Hung 2000). 
The latter appears to force the equilibrium towards spontaneous HER2 homodimer 
formation, which leads to receptor activation in the absence of ligands. This is the situation 
observed in a variety of human cancers. 
 
Fig. 2. A structural model of the 2:2 EGF/HER1 complex. Shown are the four subdomains 
(I–IV) of the HER1 ectodomain (Garret et al. 2002; Ogiso et al. 2002; Ferguson et al. 2003) and 
the TM helices. In the cytoplasm, the two tyrosine kinase domains form an asymmetric 
dimer (Zhang et al. 2006). The EGF ligands are shown in yellow. Fragments known from 
crystallography or NMR are coloured, while the pale grey sections denote regions of 
uncertain structure, including the extracellular JM linker, the intracellular JM domain (Jura 
et al. 2009a; Brewer et al. 2009), and the C-terminal tails. On the latter, purple spheres 
indicate known auto-phosphorylation sites. Figures have been prepared using visual 
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The typical high-resolution representation of ligand-bound HER1 dimeric holoreceptors is 
depicted in Fig. 2. This generally accepted model has been derived by putting together the 
available structural information on extracellular and intracellular fragments (Garrett et al. 
2002; Ogiso et al. 2002; Ferguson et al. 2003; Brewer et al. 2009; Jura et al. 2009a; Jura et al. 
2009b; Zhang et al. 2006). In this model, the extracellular domains are oriented with respect 
to the membrane based on the historical view that receptors are protruding from the plasma 
membrane as antennae.  
6. Structural insights into the HER family: The intracellular domain  
Ligand binding and the dimerisation of HER1 extracellular domain leads across the plasma 
membrane to the formation of an asymmetric dimer by the two associated intracellular 
kinases (Zhang et al. 2006) that is stabilised by the inner juxtamembrane (JM) region (Brewer 
et al. 2009; Jura et al. 2009a) (Fig. 2). Kinase activation follows through an allosteric 
mechanism in which the C-lobe of one kinase (activator) “pushes” the N-lobe of the other 
kinase (receiver) in an interaction that is highly reminiscent of the activation of CDK2 by 
binding of cyclin A (Jeffrey et al. 1995). Active kinases in the homodimer (and possibly 
heterodimer) then proceed to phosphorylate in trans tyrosine residues in the C-terminal tail 
of the partner receptor (Zhang et al. 2006). Fig. 2 depicts the C-termini of a HER1-HER1 
dimer (for which there is no structural data), showing the location of tyrosine amino acid 
residues. These tyrosine residues are phosphorylated by the addition of a phosphate group 
(PO43-). When phosphorylated these sites act as docking sites for a large repertoire of 
intracellular adaptors and enzymes containing Src homology 2 (SH2) domains (Pawson 
2004). These include Grb2 (Fig. 1), GAP, Shc (Pai & Tarnawski 1998), phospholipase 
C(PLC) (Katan 1998), and phosphatidylinositol 3’-kinase (PI3K) (Vanhaesebroeck et al. 
2001), which regulate Ras/Rho-like GTPases (Ridley 2001), Ca2+ second messenger 
production (Defize et al. 1989), and the Ras-activated MAP/SAP kinase pathways (Zhang & 
Liu 2002). In this way, HER molecules start the intracellular signalling cascades that lead to 
cell proliferation, changes in cell morphology, trafficking, and the termination of signals via 
endocytosis of the receptor-ligand complexes (Carpenter 2000; Sorkin 2001).  
The pattern of phosphorylated tyrosine motifs is specific to each HER homo and hetero pair 
(Schulze, Deng, & Mann 2005a). This is the way by which intracellular effector proteins can 
selectively be recruited by different HER pairs at the plasma membrane to initiate different 
signalling events and cascades in the cell (reviewed in (Citri & Yarden 2006)). The 
combinatorial variety of homo/hetero HER1-4 complexes therefore provides a mechanism 
by which different cell responses can be induced via recruitment of different combinations 
of signalling effectors to phosphorylated homo and hetero HER complexes, activating 
intracellular pathways for signal attenuation (receptor desensitisation, down-regulation, 
endocytosis and trafficking), signal amplification and cell growth, death signals (apoptosis) 
and other signal processing pathways (Yarden & Sliwkowski 2001). This may explain how 
subtle differences in the expression pattern of HER1-4 and their ligands may ultimately 
regulate development and homeostasis in many tissue types. 
7. Towards a systems biology perspective  
A glimpse of the true complexity in the HER network has only been obtained recently in the 
light of high-throughput screens and proteomic assays. These have added hundreds of 
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putatively assigned new interactions and several new signal regulators in different cellular 
compartments to an already complicated picture, making the network increasingly difficult 
to describe. The burgeoning of data is facilitating the emergence of a cellular systems level 
perspective (Jones et al. 2006; Schulze, Deng, & Mann 2005b) which is beginning to uncover 
non-intuitive features of HER signalling, such as the high biological potency of a low-
affinity mutant of EGF (Schoeberl et al. 2002). The emerging view is that of a complex ‘fail-
safe’ robust network system (Citri & Yarden 2006), which is able to maintain some degree of 
function through embedded layers of functional degeneracy, modularity, redundancy, 
buffering and signalling controls, even if some components are damaged. The robustness of 
the HER signalling network is underlined by its bi-stability (ligand-regulated ON/OFF 
states) and its ‘bow-tie’ configuration, in which multiple positive cues (ligand binding) and 
negative cues (receptor trafficking) are fanned out through an intermediate core processing 
unit. The core consists of multiple isoforms of interconnected effector units and signalling 
cascades, intertwined with densely coupled subnetworks (e.g. the phosphoinositide and 
Ca2+ networks and the endocytic machinery; see (Sorkin 2001)). The number of intracellular 
proteins that form part of this core is vast, including not only the HER1 effectors outlined 
above, but also entire families of adaptors and enzymes of (e.g. Grb2 and Shc) (Pai & 
Tarnawski 1998), ubiquitin ligases (e.g. the E3 ubiquitin ligase c-Cb) (reviewed (Thien & 
Langdon 2005)), lipid and protein kinases (e.g. PI3K, Akt; reviewed (Vanhaesebroeck, et al. 
2001)), GTPases (Ridley 2001) (e.g. Ras, Rho) and phospholipases (e.g. PLC-γ (Katan 1998)). 
More recently, the activation of the small RhoGTPase Cdc42 by HER1 signalling has also 
been established (El-Sibai et al. 2007; Feng et al. 2006; Kurokawa et al. 2004). HER signalling 
also results in the specific induction of outputs through transcription factors (Grandis et al. 
1998) (e.g. STAT3) which, depending on the exact combination recruited through the core 
and the cellular context, ultimately lead to different cell fates, including proliferation, 
survival, adhesion, migration and differentiation (Oda et al. 2005). 
8. Multi-colour labelling of signalling proteins in the HER network 
Because of the complexity of the HER signalling network (Oda, et al. 2005), the systems-level 
perspective provides a useful framework to describe network behaviour and to expose and 
predict the fragility of network activity centres. However, the bottleneck in mathematical 
‘Systems’ modelling is incomplete biological understanding. This is mainly due to the 
difficulties of obtaining quantitative kinetic/dynamic data and structure-function 
relationships in the cellular environment. To gain a better understanding of HER signalling 
that can facilitate a systems perspective it is necessary, for example, to devise better means 
of obtaining structural data on the input layer of the HER signalling network. It is also 
necessary to obtain much more information on the dynamic rules of engagement between 
HER network proteins in vivo and to understand the positive and negative feedback-loops 
regulating the HER network that allow functioning under perturbation.  
Fluorescence microscopy methods provide a convenient approach to study protein 
conformation and dynamic interactions between HER network members at the plasma 
membrane of living cells. This method is non-invasive and allows several types of proteins 
to be specifically tagged and observed simultaneously. For example, heteromeric pan-HER 
interactions can in principle be measured in living cells by using a combination of 
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(Fig. 3) and then employing FRET and/or multicolour single molecule tracking to follow 
their interactions in real-time (see below). These methods can in principle be extended in 
cells bio-engineered to express specific combinations of interacting fluorescent 
ligand/HER1-4/adaptor/inhibitor variants.  
 
Fig. 3. A cartoon showing the HER1 homo-dimer and hetero-dimers at the plasma 
membrane. (The intracellular domains of hetero-dimers are not shown for simplicity). 
Different colour labels are targeted to the extracellular domains (small colour spheres). 
Intracellular proteins can be labelled using fluorescence proteins such as GFP. 
One strategy to label HER molecules is to use their cognate ligands (e.g. EGF or small 
affibodies) as delivery vehicles for the fluorophores (Fig. 3). For this, fluorophores of 
different colours can be bound in a 1:1 ratio to different activating and non-activating 
ligands, each specific for one of the receptor types. Once these ligands bind their cognate 
receptors, each receptor type will be tagged with a different colour molecule. This means 
that each receptor type is colour-coded and will appear in a different colour channel. Other 
strategies include chemical synthesis of fluorescent ACP- (a 6 kDa, acyl carrier protein), 
MCP- (a mutant version of ACP), SNAP- and CLIP-tag substrates, fluorescence protein 
fusions to HER C-termini, N/C-termini of scaffolds and effectors (Fig. 2) and cell permeant 
benzylguanine (BG) or benzylcytosine (BC) dye derivatives (Banala, Arnold, & Johnsson 
2008), including BG and BC conjugated to TMRstar (which can fluorescently label any O6-
alkylguanine-DNA alkyltransferase (AGT)-tagged, i.e. SNAP or CLIP tagged, intracellular 
proteins in live cells).  
The remainder of this chapter shows steps taken in our laboratory towards the development 
of an integrated experimental approach that can provide data on multi-molecular 
interactions towards a system-focused approach. These steps have so far consisted of 
developing the tools to extract structural and dynamic information on the HER bio-system 
in the cellular context by gathering information on conformational changes, receptor 
interactions and the dynamic rules of engagement in HER signalling.  
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9. Investigating HER protein-protein interactions by FRET 
FRET is a phenomenon by which the excited-state energy of an optically excited fluorescent 
molecule (donor) is transferred to a neighbouring fluorescent molecule (acceptor) non-
radiatively via intermolecular Van der Waals (dipole-dipole) interactions (Stryer & 
Haugland 1967). For FRET to occur the electronic levels of donors and acceptors must 
overlap. FRET depends on the distance between donors and acceptors as the inverse of the 
sixth power and is therefore very sensitive to short inter-molecular distances in the range 
~2-8 nm. It can therefore be a useful tool to investigate molecular interactions.  
FRET observations can be made either in the steady-state, by detecting the quenching of the 
fluorescence emitted by the donor as energy is transferred to the acceptor, or time-resolved, 
by measuring the shortening of the fluorescence lifetime of the donor. FRET imaging 
between fluorescent EGF derivatives bound to HER1 molecules in cells has been widely 
employed to investigate HER1 homo-dimerisation (Gadella & Jovin 1995; Sako et al. 2000; 
Martin-Fernandez et al. 2002; Clayton et al. 2005; Clayton et al. 2008). A popular strategy for 
this was to measure the efficiency of FRET between donor and acceptor fluorophores bound 
to the N-termini of receptor-bound EGF ligands. Although distances shorter than ~8 nm 
(averaged over the receptor population) were ubiquitously reported by FRET in these 
conditions in cells, it should be noted that the preferred (back-to-back) crystallographic 
dimer shows N-terminal inter-ligand distances of >11 nm (Fig. 3). This distance is too large 
to be detected by FRET and will remain so even when extreme deformations are applied to 
this crystal structure; for example, by changing the angle between domains I and III and 
domain II and/or applying extreme perturbations along low frequency normal modes. The 
FRET results therefore suggest that other interfaces between receptor monomers not yet 
found by crystallographic methods must also occur at the plasma membrane of cells.  
 
Fig. 4. The back-to-back / head-to-head / back-to-back tetramer on the plasma membrane 
(Kästner et al. 2009). The grey- stick models are the atomistically modelled lipid molecules 





(Fig. 3) and then employing FRET and/or multicolour single molecule tracking to follow 
their interactions in real-time (see below). These methods can in principle be extended in 
cells bio-engineered to express specific combinations of interacting fluorescent 
ligand/HER1-4/adaptor/inhibitor variants.  
 
Fig. 3. A cartoon showing the HER1 homo-dimer and hetero-dimers at the plasma 
membrane. (The intracellular domains of hetero-dimers are not shown for simplicity). 
Different colour labels are targeted to the extracellular domains (small colour spheres). 
Intracellular proteins can be labelled using fluorescence proteins such as GFP. 
One strategy to label HER molecules is to use their cognate ligands (e.g. EGF or small 
affibodies) as delivery vehicles for the fluorophores (Fig. 3). For this, fluorophores of 
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strategies include chemical synthesis of fluorescent ACP- (a 6 kDa, acyl carrier protein), 
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The remainder of this chapter shows steps taken in our laboratory towards the development 
of an integrated experimental approach that can provide data on multi-molecular 
interactions towards a system-focused approach. These steps have so far consisted of 
developing the tools to extract structural and dynamic information on the HER bio-system 
in the cellular context by gathering information on conformational changes, receptor 
interactions and the dynamic rules of engagement in HER signalling.  
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Attempts to understand the origin of FRET between donor/acceptor EGF ligands bound to 
HER1 include the pioneering work by Clayton et al. in intact BaF/3 cells, a murine 
interleukin-3 dependent pro-B cell line which do not overexpress ErbB1 (the mammal HER1 
equivalent). Using fluorescence correlation microscopy, this work showed the presence in 
cells of tetramers of activated cell surface EGF/ErbB1 complexes. FRET in turn showed the 
presence of very short distances (< 4 nm) between ErbB1-bound EGF ligands (Clayton, et al. 
2005). It was postulated that these short distances could explain the presence of FRET in the 
context of a tetramer formed by two back-to-back crystallographic dimers. These short 
distances between EGF ligands bound to HER1 were subsequently found in human A431 
epithelial cells by single pair FRET imaging (Webb et al. 2008). This work provided 
additional evidence for HER1-HER1 interfaces in cells other than that described in the back-
to-back crystallographic structure.  
The work of Clayton et al. 2005 and Webb et al. 2008 set the basis for two new models of 
HER1 activation: In one model tetramers were generated through side-by-side contacts 
between two adjacent back-to-back dimers; however, there is no crystallographic evidence 
yet for this arrangement. In the second model (Fig. 4) tetramers were made of two back-to-
back dimers joined by a weak, asymmetric ‘‘head-to-head’’ interface seen in crystal 
structures (Garret et al. 2002). This interface also results in short distances between the N-
termini of the two bound EGF molecules of < 4 nm. Molecular dynamics (MD) simulations 
showed that the head-to-head interaction stabilises appreciably when the tetramer is relaxed 
on the membrane (its interface area increased from 443 Å2 seen in the crystal structure to 604 
Å2) (Kastner, et al. 2009). In this tetramer the two dimers remained stable but lost the 
approximate 2-fold symmetry of the crystal structure. The average dimerisation interface 
area rose from 1,197 Å2 to 1,483 Å2, largely as a result of additional interactions between the 
N-terminus and the dimerisation arm, while the two ligands buried 1,166 Å2 and 1,211 Å2 at 
distinct binding sites.  
Interestingly, the ligand-membrane distances predicted by the tetramer in Fig. 4 are 
significantly shorter than those predicted by the crystallographic back-to-back dimers 
standing upright from the membrane (Fig. 3), a hypothesis that can be tested using FRET 
(see section 11). Initial measurements by Webb et al. (2008) were consistent with the short 
ligand-membrane distances proposed by the model in Fig. 4 (see section 11). 
10. Investigating the origin of ligand – Binding heterogeneity to HER1  
Possibly the main disappointment of the HER crystal structures is that they did not explain 
a 30-year old puzzle in the HER signalling field, namely the origin of the characteristic 
heterogeneity in EGF-binding affinity to cell-surface HER1 molecules. This heterogeneity 
was first detected in EGF binding kinetic experiments in cells, as these display characteristic 
concave-up Scatchard plots (Magun et al. 1980; Shoyab et al. 1979). As HER1 is expressed as 
a single translation product (Ullrich & Schlessinger 1990), the concave-up EGF-binding 
Scatchard plots were interpreted as indicating the presence of two receptor populations: a 
small minority of high-affinity receptors with dissociation constants (KD) of <1 nM that 
mediate most signalling events, and a majority of low affinity receptors with KD of >1 nM 
(Defize et al. 1989; Friedman et al. 1984). When crystallographic structural data became 
available ~ 10 years ago, the high- and low-affinity populations were initially expected to be 
extended HER1 dimers and tethered HER1 monomers, respectively; however, in this model 
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stabilization of the extended dimer configuration by one ligand molecule would facilitate 
the binding of a second ligand to the remaining unliganded receptor in the dimer, resulting 
in positive cooperativity and therefore concave-down Scatchard plots (Mattoon et al. 2004). 
Using global modelling of ligand-binding data as a function of receptor number, Macdonald 
and Pike subsequently showed that EGF-binding heterogeneity could be accounted for by 
negative cooperativity in HER1 dimers (Macdonald & Pike 2008). However, negative 
cooperativity requires that ligand binding to one subunit of the HER1 dimer decreases the 
ligand affinity of the other subunit. This would, in turn, require the interactions between 
ligand and the two subunits of the receptor dimer to be asymmetric, inconsistent with the 
symmetry observed in the back-to-back structure of HER1. A series of recent 
crystallographic structures recently showed that in the drosophila counterpart of HER1 
(known as drosophila EGFR or dEGFR) the extracellular domain asymmetry is induced by 
the binding of the first ligand growth factor to the dEGFR dimer, which structurally 
restrains the unoccupied binding site, reducing the affinity for binding of the second ligand 
(Alvarado et al. 2010). Interestingly, concave-up Scatchard plots were observed in 
preparations of the isolated extracellular region of the dEGFR, in direct contrast with its 
human counterpart, in which concave-up plots are observed only when ligands bind to full-
length receptors in cells. These differences suggest that other receptor regions, 
conformations, and/or other unknown cellular components must be involved in the 
regulation of ligand affinity in HER1 in the cellular environment. A better understanding of 
the conformation of HER1 in the plasma membrane environment is therefore required to 
understand the origin of the heterogeneity of EGF-binding. 
11. Using FRET microscopy to report in situ protein conformation 
Besides ligand-ligand interactions, FRET can also be employed to investigate the 
conformation of proteins at the plasma membrane, for example by measuring the distance 
from a specific site in the protein of interest (e.g. the binding site of a growth factor 
ligand) to the cell surface (Fig. 5). Protein-membrane distances can be determined from 
the variation of the efficiency of FRET between fluorescent donors attached to the protein 
of interest and acceptors labelling the cell surface, measured as a function of acceptor 
surface density (Fig. 5). When crystal structures of the protein and/or protein fragments 
are available, protein-membrane distances derived from FRET can be used to constrain 
the disposition of protein structures with respect to the plasma membrane to inform on 
protein conformation in situ.  
Analytical expressions describing the energy transfer process between random distributions 
of donors (e.g. in specific sites in proteins) and acceptors on lipid membrane surfaces have 
been derived for a number of geometries (see for example Wolber & Hudson 1979). The 
solutions to these equations are the distance of closest approach between the protein-bound 
fluorescent donor probe and a lipid acceptor chromophore at the plasma membrane. 
Examples using this FRET method include an investigation to derive the mean distance 
between the EGF binding site of HER1 and the plasma membrane of cells in suspension 
(Carraway et al. 1990), changes in conformation of 4-Integrin during activation (Chigaev et 
al. 2003), and the minimum separation between the protein portion of GPI-anchored 
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Fig. 5. A cartoon illustrating the FRET problem in two dimensions. Two receptor dimers are 
depicted bound to donor-labelled EGF (green spheres). The plasma membrane is labelled 
with lipid acceptors (red). Many distances are possible between each donor and the 
acceptors in the membrane. By varying the concentration of acceptors at the plasma 
membrane the vertical distance from donors to the cell surface can be calculated (Tynan et 
al. 2011). 
The three examples cited were derived from cell-averaged steady-state intensity 
measurements (e.g., flow cytometry). The efficiency of FRET between a random distribution 
of donors and acceptors can also be determined using fluorescence lifetime imaging 
microscopy (FLIM). This method images with optical resolution the shortening of the 
fluorescence decay time of donor-labelled EGF induced by the lipid acceptors. Being a time-
resolved assay, FLIM has the advantage of being able to directly measure the time between 
the absorption and emission of individual photons in the FRET donor fluorophores, 
providing results largely free from artefacts such as photobleaching and radiative transfer 
which can increase the errors in the measurement (Martin-Fernandez et al. 2002).  
Using the combination of FLIM and FRET to measure protein-membrane distances, Webb et 
al obtained initial evidence for two types of EGF/HER1 complexes, tilted and upright with 
respect to the cell surface, that are associated to high-affinity and low-affinity EGF binding, 
respectively (Webb, et al. 2008). Subsequently, using MD simulations Kästner et al. showed 
that, with minor rearrangements, the HER1 back-to-back dimer can be aligned almost flat on 
the cell membrane, leading to conformational changes which further stabilize the 
extracellular dimer (Kästner et al. 2009). This work also showed that alignment on the cell 
surface and the interactions between the HER1 dimer and the upper leaflet of the membrane 
that follow break the pseudo-2-fold symmetry of the HER1 extracellular region, resulting in 
a highly asymmetric HER1 dimer structure. 
12. HER1 can adopt key features of dEGFR asymmetry 
To investigate the relevance of the MD-derived asymmetric model of the HER1 dimer 
relaxed on the membrane (Kastner et al. 2009) to EGF-binding heterogeneity and negative 
cooperativity (Macdonald & Pike 2008)), Tynan et al extended the FLIM-FRET assay 
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previously reported (Webb et al. 2008) to include FRET titrations as a function of acceptor 
concentration together with a data analysis method based on Monte-Carlo simulations 
(Tynan et al. 2011). This method allowed full quantification of the distance of closest 
approach between HER1-bound ligands and the surface of adherent epithelial cells, the 
assessment of the variation associated to the distance measurement, and also the rejection of 
potential sources of artifacts resulting from non-uniform distributions of FRET donors and 
acceptors.  
Given the known flexibility regions in the accepted crystallographic HER1 ectodomain 
dimer structure, the FRET-derived distance data obtained from HER1 that display high-
affinity for EGF (< 4 nm) could only be reconciled with HER1 structural data if receptors are 
aligned flat on the membrane (Fig. 6). MD simulations of doubly-liganded, singly-liganded 
and unliganded HER1 dimers aligned on a model membrane under the same conditions 
revealed that the asymmetry resulting from alignment on the membrane shares a number of 
key features with the equivalent doubly-liganded and singly-liganded structures observed 
recently in soluble dEGFR (Alvarado et al. 2010). These results suggest that the structural 
basis for negative cooperativity is conserved from invertebrates to humans but that in HER1 
the extracellular region asymmetry requires interactions with the plasma membrane. 
 
Fig. 6. The EGFR ectodomain dimer with two bound ligands, modelled on crystallographic 
structures (Garret et al. 2002; Ogiso et al. 2002; Ferguson et al. 2003) and placed in the 
membrane. Darker green spheres indicate the N termini of the ligands to which donor dyes 






Fig. 5. A cartoon illustrating the FRET problem in two dimensions. Two receptor dimers are 
depicted bound to donor-labelled EGF (green spheres). The plasma membrane is labelled 
with lipid acceptors (red). Many distances are possible between each donor and the 
acceptors in the membrane. By varying the concentration of acceptors at the plasma 
membrane the vertical distance from donors to the cell surface can be calculated (Tynan et 
al. 2011). 
The three examples cited were derived from cell-averaged steady-state intensity 
measurements (e.g., flow cytometry). The efficiency of FRET between a random distribution 
of donors and acceptors can also be determined using fluorescence lifetime imaging 
microscopy (FLIM). This method images with optical resolution the shortening of the 
fluorescence decay time of donor-labelled EGF induced by the lipid acceptors. Being a time-
resolved assay, FLIM has the advantage of being able to directly measure the time between 
the absorption and emission of individual photons in the FRET donor fluorophores, 
providing results largely free from artefacts such as photobleaching and radiative transfer 
which can increase the errors in the measurement (Martin-Fernandez et al. 2002).  
Using the combination of FLIM and FRET to measure protein-membrane distances, Webb et 
al obtained initial evidence for two types of EGF/HER1 complexes, tilted and upright with 
respect to the cell surface, that are associated to high-affinity and low-affinity EGF binding, 
respectively (Webb, et al. 2008). Subsequently, using MD simulations Kästner et al. showed 
that, with minor rearrangements, the HER1 back-to-back dimer can be aligned almost flat on 
the cell membrane, leading to conformational changes which further stabilize the 
extracellular dimer (Kästner et al. 2009). This work also showed that alignment on the cell 
surface and the interactions between the HER1 dimer and the upper leaflet of the membrane 
that follow break the pseudo-2-fold symmetry of the HER1 extracellular region, resulting in 
a highly asymmetric HER1 dimer structure. 
12. HER1 can adopt key features of dEGFR asymmetry 
To investigate the relevance of the MD-derived asymmetric model of the HER1 dimer 
relaxed on the membrane (Kastner et al. 2009) to EGF-binding heterogeneity and negative 
cooperativity (Macdonald & Pike 2008)), Tynan et al extended the FLIM-FRET assay 
Investigating the Conformation of HER Membrane  
Proteins in Cells via Single Molecule and FLIM Microscopy  
 
83 
previously reported (Webb et al. 2008) to include FRET titrations as a function of acceptor 
concentration together with a data analysis method based on Monte-Carlo simulations 
(Tynan et al. 2011). This method allowed full quantification of the distance of closest 
approach between HER1-bound ligands and the surface of adherent epithelial cells, the 
assessment of the variation associated to the distance measurement, and also the rejection of 
potential sources of artifacts resulting from non-uniform distributions of FRET donors and 
acceptors.  
Given the known flexibility regions in the accepted crystallographic HER1 ectodomain 
dimer structure, the FRET-derived distance data obtained from HER1 that display high-
affinity for EGF (< 4 nm) could only be reconciled with HER1 structural data if receptors are 
aligned flat on the membrane (Fig. 6). MD simulations of doubly-liganded, singly-liganded 
and unliganded HER1 dimers aligned on a model membrane under the same conditions 
revealed that the asymmetry resulting from alignment on the membrane shares a number of 
key features with the equivalent doubly-liganded and singly-liganded structures observed 
recently in soluble dEGFR (Alvarado et al. 2010). These results suggest that the structural 
basis for negative cooperativity is conserved from invertebrates to humans but that in HER1 
the extracellular region asymmetry requires interactions with the plasma membrane. 
 
Fig. 6. The EGFR ectodomain dimer with two bound ligands, modelled on crystallographic 
structures (Garret et al. 2002; Ogiso et al. 2002; Ferguson et al. 2003) and placed in the 
membrane. Darker green spheres indicate the N termini of the ligands to which donor dyes 





13. Imaging membrane protein interactions at the nanoscale 
Understanding the structure-function relationships of biological macromolecules ultimately 
requires us to determine molecular structure at a range of resolutions. These include: 
Atomic resolutions (~1 Å) for detailed protein structure, derived from x-ray crystallography 
(Vrielink & Sampson 2003); 1-10 nm for measurement of conformations and inter-molecular 
distances, a range covered by electron microscopy (Agronskaia et al. 2008) and FRET (Stryer 
& Haugland 1967); and 10-20 nm for measurement of inter-unit separation and therefore the 
oligomerisation states of protein complexes. Given the importance of HER homo and hetero-
oligomerisation in signalling, access to distances in the 10-20 nm range is crucial in 
investigation of HER interactions because, as discussed above, structural studies indicate 
that the inter-unit separation in the preferred receptor dimer should be in the region of 10-15 
nm (Fig. 3) (Garrett et al. 2002; Ogiso et al. 2002). However, measurements in this range are 
challenging because these distances fall in a “resolution gap” between FRET and optical 
microscopy, which is diffraction-limited around 200 nm at best.  
In recent years, a number of so-called “super-resolution” optical methods have been 
developed, that break the diffraction limit for light microscopy. These include stimulated 
emission depletion (STED) microscopy (Hell 2003) near-field scanning optical microscopy 
(NSOM) (Dunn 1999), photo-activated localization microscopy (PALM) (Betzig et al. 2006), 
fluorescence imaging with one-nanometre accuracy (FIONA) (Yildiz & Selvin 2005), single-
molecule high resolution imaging with photobleaching (SHRImP) (Balci et al. 2005), 
nanometre-localized multiple single-molecule (NALMS) microscopy (Qu et al. 2004) and 
single-molecule high resolution co-location (SHREC) (Churchman et al. 2005). Theoretically, 
many of these techniques have the potential to measure distances in the required range. 
However, there are challenges in applying them to the cellular environment. NSOM is not 
well-suited to the wet conditions required for living or lightly fixed cells. STED and PALM 
are essentially ensemble imaging techniques that are not easily applied to the measurement 
of the distance between two or more specific molecules in the crowded cell environment. 
SHRImP, SHREC, and NALMS can measure distances between molecules with better than 
10 nm resolution. Like PALM, all these methods “beat” the diffraction limit by imaging 
single molecules, fitting the point spread function (PSF) of the microscope, and locating its 
centre with nanometre accuracy. NALMS uses single molecule detection to count discrete 
steps in traces of fluorescence intensity vs time from diffraction limited spots, each step 
corresponding to the activation or bleaching of a single fluorophore, and measuring the 
change in the PSF of the spot before and after a step. In SHRImP, global fitting is carried out 
on spots before and after bleaching, producing nearly identical results to the sequential 
NALMS method. SHREC again uses PSF fitting, but two different fluorophores with 
different spectral characteristics are used, imaged in distinct channels which must be very 
accurately registered to determine intra-molecular distance. In all these techniques, spatial 
resolution is ultimately limited by the signal-to-noise ratio of the data, which determines the 
precision with which the centre of the PSF can be determined. For this reason, SHRImP, 
SHREC, and NALMS have so far been demonstrated only in “clean” samples such as 
purified, immobilised molecules on glass, and in the presence of antifade reagents. 
The environment of mammalian cells is not conducive to the collection of high signal-to-
noise data. The main source of background noise is intracellular autofluorescence, arising 
from molecules such as NADPH and flavins (Monici 2005). A common approach to reduce 
Investigating the Conformation of HER Membrane  
Proteins in Cells via Single Molecule and FLIM Microscopy  
 
85 
background when looking at membrane proteins is to use total internal reflection (TIRF) 
excitation (Fig. 1) (Axelrod 1989). TIRF creates an evanescent field on the coverslip on which 
the cells are cultured. The field reduces exponentially with depth, and only penetrates 
approximately 300 nm into the sample. Thus, fluorescence is not excited in the bulk of the 
cell, reducing autofluorescence. This enables single molecule detection, as shown in Fig. 7 
(left panel). Single molecules are clearly visible, but there is also a contribution from 
background noise. This results from residual autofluorescence, scattered light, and 
fluorescence from out-of-focus fluorophores.  
In our laboratory we are developing new methods to improve the accuracy of intra-
molecular distance measurement in cells and tissues. We currently achieve sub-10 nm 
positioning resolution in cells by using new data fitting algorithms that perform well in the 
noisy environment of cells (manuscript in preparation). Crucially, our techniques give 
robust estimates of errors, allowing the significance of distance measurements to be 
properly determined. Fig. 7 (right panel) shows typical single molecule traces and 
accompanying position measurement from labelled HER1 complexes in fixed epithelial 
cervical carcinoma HeLa cells. 
   
Fig. 7. Left: Single molecule TIRF image of EGFR in the plasma membrane of HeLa cells. 
EGFR are labelled with their ligand EGF, conjugated with the fluorophore Atto 647N (bar 8 
µm). Right: Traces of single molecule fluorescence intensity (red) vs time for two example 
spots in fixed HeLa cells labelled with EGF-Atto 647N. a) shows a relatively short intra-
molecular distance, b) a longer distance. Fluorophore x and y positions are plotted in black 
and blue, respectively. 
14. Determining dynamic interactions from diffusion at the membrane 
HER molecules interact with each other and with other network proteins while being 
embedded in the lipid bilayer of the plasma membrane, which is composed of neutral, 
charged, saturated and unsaturated lipids (Fig. 1). The lipids in the membrane consist of a 
hydrophilic charged region, the phospholipids heads, which form the extreme outer and 
inner leaflets of the membrane, and hydrophobic C-H chains of different lengths (typically 
from C12 to C20) that forms the core of the bilayer (van Meer 2005). Water molecules 
concentrate on the inner and outer surfaces of the plasma membrane at the boundaries with 
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surface defects created by lipid mismatch. Hydrophilic protein regions are excluded from 
the hydrophobic inner part of the lipid bilayer and stick out from the plasma membrane. 
The simplest membrane model consists of a 2-D liquid model surrounded by a 3-D solvent 
(Singer & Nicolson 1972). In this simple model, membrane proteins diffuse freely in the lipid 
bilayer which is modelled as a viscous liquid. Proteins interact with the surrounding lipid 2-
D ‘liquid’ and diffuse with a speed that depends on lipid viscosity. However, it is observed 
experimentally that the lateral mobility of proteins in biological membranes can be orders of 
magnitude slower than in synthetic membranes. Reasons for this include: 
i. The presence of lipid rafts: The plasma membrane is composed of different lipids (e.g. 
phospholipids, sphingolipids and cholesterol) that can form microdomains of different 
viscosity. These rafts microdomains concentrate certain proteins (including HER 
molecules) and exclude others (see for example (Kusumi et al. 2005; Nagy et al. 2002). 
ii. Intra-membrane barriers: Biological membranes are quite crowded with 15-35% of 
surface area occupied by many different types of proteins which can interact with each 
other affecting diffusion mobility (Scheuring & Sturgis 2005). 
iii. Skeletal interactions: Proteins are able to interact with protein scaffolds and the 
cytoskeletal network beneath the plasma membrane in the intracellular side, which 
have the effect of corralling the membrane proteins in some regions and not others 
(reviewed in Costa et al. 2011).  
 
Fig. 8. Two-colour single molecule tracking of T47D cells. a) White light transmission image; 
b) cells labelled with 0.1 nM anti-ErbB2 affibody-Atto 647N; c) cells labelled with 2 nM anti-
EGFR affibody-Alexa 488; d and e) single molecule tracks (green) from the spots located 
within the boxes marked in b and c. 
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The role of membrane microdomains, intra-membrane barriers and skeletal interactions in 
HER signalling is not yet understood. This role can be investigated using single molecule 
tracking. Advantages of a single molecule approach include the ability to observe dynamic, 
stochastic behaviour, such as compartmentalized diffusion (Andrews et al. 2008; Dahan et 
al. 2003; Fujiwara et al. 2002) that would be masked in ensemble measurements, and the 
ability for localisation of molecules with a precision well below the diffraction limit of light 
(see section 11).  
To investigate protein diffusion and protein-membrane interaction in the HER bio-system 
we have used, for example, a two colour tracking system (Clarke et al. 2011) to follow the 
movements of HER1 and HER2 at the plasma membrane of live T47D cells, a human ductal 
breast epithelial tumour cell line cell model that expresses the four HER receptor types at a 
level between 10,000-30,000 receptors per cell. Fig. 8 shows single molecule images of HER1, 
and HER2 in living cells in their basal state. The receptors are labelled with an anti-HER1 
affibody (Nordberg et al. 2010) conjugated with Alexa 488 an anti-HER2 affibody (Tran et al. 
2007) conjugated with Atto 647N. The data were analysed using Bayesian segmentation 
algorithms and other data analysis methods described in (Rolfe et al. 2011). The resulting 
tracks indicate that HER1 displays in these cells higher mobility at the plasma membrane 
than HER2. We are now developing the methods to extract from these data the different 
mean displacements of each receptor in the plasma membrane from which their co-
localisation kinetics can be derived.  
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15. Towards an integrated approach  
Ultimately, our goal is to use a cross-disciplinary portfolio of experimental and data analysis 
techniques to describe the HER signalling network not just in cell models but also in the real 
world setting. To achieve this we aim at deriving models of ligand-induced behaviour 
exploiting combined single molecule imaging, ensemble FLIM analysis and systems 
predictions. We also aim at establishing how HER signalling is influenced by feed-back 
loops and internal and external perturbations, e.g. HER mutations (seen in human subjects), 
RTK inhibitors and function-blocking antibodies. We also plan to combine experimental 
approaches with molecular dynamics and coarse-grained simulations and to explore data 
mining techniques for exploiting this rich data (Fig. 9). 
16. View to the future: Potential clinical applications and take home message 
We ultimately aim to refine single molecule fluorescence detection to be applicable to 
human tissues. We have already demonstrated single-molecule fluorescence imaging of 
HER receptors in fixed and frozen tissue sections from mouse tumour xenografts and 
human tissue biopsies (manuscript in preparation). This work is being done in collaboration 
with Prof. Peter Parker and colleagues at King’s College London/Guy’s & St Thomas’ NHS 
Foundation Trust. Our aim is to extend the use of fluorescently labelled ligands, affibodies, 
anti-HER monoclonal antibodies (mAbs) and function blocking antibodies from cultured 
cell models to investigations of HER signalling on normal primary cells and tissue sections. 
We also plan to study naturally occurring somatic mutations (e.g. in human lung 
adenocarcinoma, see review on HER1 mutations in: Lynch et al. 2004) and also study cross-
talk interactions with other non-HER receptors in lung and breast cancer tissue. It is hoped 
that these experiments will allow us to obtain further insights into the HER network and 
assess predictions made by our models. Once the methods have been optimised, studies will 
be extended to include other carcinoma cells and tissues, including matched normal tissue. 
Downstream targets of receptor activation will be assessed by western blotting to set the 
baseline population behaviour and ensure specificity of reagents. It is hoped that results 
from these experiments will provide novel insight on how the HER network operates at the 
tissue level and the supra-molecular rules and controls that are necessary to ensure normal 
network function. 
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New drug compounds discovery has moved at an accelerated pace in recent years, with a 
considerable focus on the transition from in vitro to in vivo models. As a result, there has 
been a significant increase in the need to adapt and develop novel non-invasive, high 
resolution in vivo imaging approaches for studying disease development and quantitatively 
determining molecular and cellular events in vivo. Non-invasive imaging methods allow 
continuous monitoring of disease development in vivo. For example, real time spatial-
temporal analysis of tumour growth can reveal the dynamics of cancer progression. 
Furthermore, the effects of therapy can be evaluated non-invasively in vivo. These 
approaches offer the ability to perform repetitive observations and interventions of the 
biological processes underlying disease development and progression.  
Thus, the development of imaging agents with high sensitivity, high specificity, and low 
toxicity is necessary to obtain biochemical functional information for the early 
characterization of the molecular alterations and, in turn, to improve diagnosis and therapy 
for clinical applications. 
Despite significant progress in developing rapid and accurate ex-vivo medical diagnostic 
tests, it is still essential to investigate approaches for in vivo non-invasive imaging because 
many human diseases and the outcomes of therapy not always and not easily can be 
determined by the analysis of blood samples or biopsies. For instance, whether a tumor 
shrinks during cancer therapy has to be determined by bioimaging modalities. In addition, 
non-invasive imaging techniques enable the examination of cellular and biomolecular 
events in locations that are difficult to access by any other means. 
Thus, the development of imaging agents with high sensitivity, high specificity, and low 
toxicity is necessary to improve diagnosis and therapy for clinical applications. 
In this perspective an emerging attractive class of targeting molecules is represented by 
short single-stranded oligonucleotides ligands, named aptamers, being able to bind with 
high affinity to specific protein or non-protein targets by folding into complex tertiary 
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New drug compounds discovery has moved at an accelerated pace in recent years, with a 
considerable focus on the transition from in vitro to in vivo models. As a result, there has 
been a significant increase in the need to adapt and develop novel non-invasive, high 
resolution in vivo imaging approaches for studying disease development and quantitatively 
determining molecular and cellular events in vivo. Non-invasive imaging methods allow 
continuous monitoring of disease development in vivo. For example, real time spatial-
temporal analysis of tumour growth can reveal the dynamics of cancer progression. 
Furthermore, the effects of therapy can be evaluated non-invasively in vivo. These 
approaches offer the ability to perform repetitive observations and interventions of the 
biological processes underlying disease development and progression.  
Thus, the development of imaging agents with high sensitivity, high specificity, and low 
toxicity is necessary to obtain biochemical functional information for the early 
characterization of the molecular alterations and, in turn, to improve diagnosis and therapy 
for clinical applications. 
Despite significant progress in developing rapid and accurate ex-vivo medical diagnostic 
tests, it is still essential to investigate approaches for in vivo non-invasive imaging because 
many human diseases and the outcomes of therapy not always and not easily can be 
determined by the analysis of blood samples or biopsies. For instance, whether a tumor 
shrinks during cancer therapy has to be determined by bioimaging modalities. In addition, 
non-invasive imaging techniques enable the examination of cellular and biomolecular 
events in locations that are difficult to access by any other means. 
Thus, the development of imaging agents with high sensitivity, high specificity, and low 
toxicity is necessary to improve diagnosis and therapy for clinical applications. 
In this perspective an emerging attractive class of targeting molecules is represented by 
short single-stranded oligonucleotides ligands, named aptamers, being able to bind with 
high affinity to specific protein or non-protein targets by folding into complex tertiary 
structures. They discriminate between closely related targets and are characterised by high 
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specificity and low toxicity thus representing a valid alternative to antibodies for in vivo cell 
recognition. Owing to their relatively small size in comparison to antibodies, aptamers 
should be better-suited for rapid target tissue penetration and blood clearance. In addition, 
different from antibodies, aptamers are chemically synthesized at low cost with high batch 
fidelity, are sufficiently stable and can be readily chemically modified to further enhance 
their stability, bioavailability and pharmacokinetics. Moreover, aptamer immunogenicity 
has never been reported. These properties indicate a great potential of aptamers as imaging 
agents, especially when compared to antibodies. 
The present chapter will be dedicated to aptamer-based molecular imaging modalities by 
reviewing the recent application of aptamers as ligands for inflammation imaging, 
thrombus imaging and tumour imaging. 
2. In vivo non-invasive imaging  
The functional imaging techniques developed in the past decades have given raised to 
powerful biomedical imaging tools that permit repeated non-invasive assessment and 
quantification of specific biological and pharmacological processes at the molecular level in 
human and animal (Lyons, 2005). 
By employing medical image modalities one can assess the physiological activities within a 
certain tissue or organ choosing among the imaging platforms available: positron-emission 
tomography (PET), single photon emission computed tomography (SPECT), nuclear 
magnetic resonance imaging (NMRI), optical imaging (OI) and computed tomography (CT). 
2.1 The emission tomography  
The emission tomography is based on the decay process of a specific radioactive element to 
detect the isotope distribution within the body as function of the time. The radionuclide 
concentration changes with time as consequence of the decay events as well as for the 
biochemical processes kinetics. Moreover the concentrations of tracer imaged the given 
tissue metabolic activity, in terms of the specific molecules of interest uptake (Massoud et al. 
2003). Differently from radio-diagnostics methods, more directed towards a morphologic 
analysis, emission tomography hold an essential rule in field of diagnostic and functional 
analysis (heart attack, epilepsy, cardiopathy, Parkinson disease).  
The compound tracer-ligand, which is of interest for its chemical binding properties to 
certain types of tissues, is injected into the body and depending on the nature of the 
radionuclide the decay product can be a photon (SPECT) or a positron (PET).  
The radioactivity profiles obtained are processed by an electronic calculator by means of 
appropriate reconstruction algorithms for the reconstruction of the tomographic image of 
the studied section. 
SPECT imaging is a quite new survey technique by which it is possible to reconstruct 
scintigraphic images related to the spatial and temporal distribution of a radioactive 
substance. SPECT equipment consists of one or more rotational gamma chambers which 
detect gamma rays, in the energy range between 80 KeV and 300 KeV, emitted from gamma-
emitting radioisotopes (99mTc, 111I, 123I, 131I, 125I), previously injected into the patient. The use 
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of targeted radiolabeled ligands to determine the tissue distributions of receptors allows the 
detection of disease upon imaging with a gamma-camera. Multiple 2D image projection can 
be acquired at different angles resulting in the visualization of the 3D biodistribution of the 
radionuclides. The spatial resolution of the reconstructed image depends on the number of 
angular and linear samples selected besides on the collimator and the tomographic 
reconstruction parameters. 
PET is the most extensively used technique in the field of clinical oncology, neurology and 
cardiology (Cantore et al., 2011). In the same way of SPECT, this technique is based on the 
use of radio labelled compounds which are injected into the living subject (usually into 
blood circulation). Especially useful to assess the degree of changes in the cellular 
metabolism as well as in their anatomic structure and in the dimension of the tumor mass, it 
plays a fundamental role in the screening, early detection, diagnosis and treatment of 
neoplasms (Langen et al., 2011). This powerful technique supplies the most advanced and 
outstanding tools on monitoring the early results of a tumor treatment plan giving the 
evidence on the success of the treatment itself and so avoiding useless chemotherapy cycles.  
Radionuclides used in PET scanning, typically isotopes with short half-lives ( 11C, 13N, 15O , 
18F) which undergo positron emission decay, are incorporated either into compounds 
normally used by the body such as, glucose, water, ammonia, or into molecules that bind to 
receptors. PET apparatus is made up of a detector block (scintillator crystal and 
photomultiplier) and a detectors ring which detects the two 511 keV gamma photons 
emitted in coincidence at 180 degrees to each other further to positron-electron annihilation 
events. By this means it is possible to localize their source along a straight line of 
coincidence. Following the radiotracers journey inside the body or the organs it is possible 
to trace its biological pathway and collect data for analysis. During the scan a record of 
tissue concentration is made as the tracer decays. The radiological image obtained is a 
fingerprint of the functionality of the examined organs. Even though PET and SPECT are 
similar there are remarkable differences in terms of efficiency and resolution. Due to the 
detection methodology, since emissions are detected "coincident" in time, PET scanner 
provides more radiation events and localization information, thus giving higher resolution 
images than SPECT, about 4-5mm against 7-8mm. In terms of efficiency only 1 to 10 photons 
upon 10.000 emitted can be detected with SPECT while PET efficiency is about 100 times 
higher (pmoles vs nanomoles).  
Small animals SPECT can provide resolutions up to 200 micrometer (Acton & Kung, 2003). 
Sensitivity, resolution, and field of view are dependent upon the pinhole collimator of the 
instrument. On the other end small animals PET scanner can provide lower spatial 
resolution (0.6 mm). PET is best suited for small molecules and molecules with fast 
kinetics. Moreover PET tracers have lower specific activity, shorter half-lives and are more 
difficult to synthesize. Finally PET radiation dose is 10 fold higher than SPECT (Larobina 
et al., 2006).  
2.2 Nuclear magnetic resonance imaging 
NMRI is a medical imaging technique based on nuclear magnetic resonance to image nuclei 
of atoms inside the body and is able to distinguish pathologic tissue from normal tissue 
(Schellenberger, 2004). This technique is widely used in radiology as it provides good 
Molecular Imaging 96
specificity and low toxicity thus representing a valid alternative to antibodies for in vivo cell 
recognition. Owing to their relatively small size in comparison to antibodies, aptamers 
should be better-suited for rapid target tissue penetration and blood clearance. In addition, 
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reviewing the recent application of aptamers as ligands for inflammation imaging, 
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powerful biomedical imaging tools that permit repeated non-invasive assessment and 
quantification of specific biological and pharmacological processes at the molecular level in 
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The compound tracer-ligand, which is of interest for its chemical binding properties to 
certain types of tissues, is injected into the body and depending on the nature of the 
radionuclide the decay product can be a photon (SPECT) or a positron (PET).  
The radioactivity profiles obtained are processed by an electronic calculator by means of 
appropriate reconstruction algorithms for the reconstruction of the tomographic image of 
the studied section. 
SPECT imaging is a quite new survey technique by which it is possible to reconstruct 
scintigraphic images related to the spatial and temporal distribution of a radioactive 
substance. SPECT equipment consists of one or more rotational gamma chambers which 
detect gamma rays, in the energy range between 80 KeV and 300 KeV, emitted from gamma-
emitting radioisotopes (99mTc, 111I, 123I, 131I, 125I), previously injected into the patient. The use 
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outstanding tools on monitoring the early results of a tumor treatment plan giving the 
evidence on the success of the treatment itself and so avoiding useless chemotherapy cycles.  
Radionuclides used in PET scanning, typically isotopes with short half-lives ( 11C, 13N, 15O , 
18F) which undergo positron emission decay, are incorporated either into compounds 
normally used by the body such as, glucose, water, ammonia, or into molecules that bind to 
receptors. PET apparatus is made up of a detector block (scintillator crystal and 
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tissue concentration is made as the tracer decays. The radiological image obtained is a 
fingerprint of the functionality of the examined organs. Even though PET and SPECT are 
similar there are remarkable differences in terms of efficiency and resolution. Due to the 
detection methodology, since emissions are detected "coincident" in time, PET scanner 
provides more radiation events and localization information, thus giving higher resolution 
images than SPECT, about 4-5mm against 7-8mm. In terms of efficiency only 1 to 10 photons 
upon 10.000 emitted can be detected with SPECT while PET efficiency is about 100 times 
higher (pmoles vs nanomoles).  
Small animals SPECT can provide resolutions up to 200 micrometer (Acton & Kung, 2003). 
Sensitivity, resolution, and field of view are dependent upon the pinhole collimator of the 
instrument. On the other end small animals PET scanner can provide lower spatial 
resolution (0.6 mm). PET is best suited for small molecules and molecules with fast 
kinetics. Moreover PET tracers have lower specific activity, shorter half-lives and are more 
difficult to synthesize. Finally PET radiation dose is 10 fold higher than SPECT (Larobina 
et al., 2006).  
2.2 Nuclear magnetic resonance imaging 
NMRI is a medical imaging technique based on nuclear magnetic resonance to image nuclei 
of atoms inside the body and is able to distinguish pathologic tissue from normal tissue 
(Schellenberger, 2004). This technique is widely used in radiology as it provides good 
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contrast between the different soft tissues of the body in addition to a high images quality. 
Based on the use of strong magnetic fields and non-ionizing radiation, radio frequency 
range, NMRI is completely harmless to the patient. 
Differences of nuclei behavior subject to a strong magnetic field gradient can be recorded to 
construct an image of the scanned area of the body resulting in the visualization of detailed 
internal structures. In the classical representation of an atom nucleus is depicted as a 
rotational sphere along an axis. This rotational motion is associated with a physical quantity 
called: angular momentum (spin). Because of the nuclear composition the so called 
rotational sphere is positively charged resulting in the generation of a magnetic field as a 
consequence of charge motion. By this means nuclei possess an intrinsic angular momentum 
(spin) associated to a magnetic momentum. The spin of a charged particle is associated with 
a magnetic dipole momentum by a proportional factor called gyromagnetic factor. The g-
factor is a characteristic of each nucleus. Allowed values of spin are 0, 1/2, 1, 3/2, 2, etc., 
which corresponds to certain magnetic momentum values according to a specific 
proportional relationship. The sensitivity by which a nucleus can be detected with NMR 
depends on the g-factor. Nuclei with a high gyromagnetic ratio will be easily examined. 
Nuclei with spin value equal to zero, null magnetic momentum, are “transparent” to 
external magnetic field so they can not be analyzed with NMR. Therefore only atoms with 
an odd number of nucleons (protons and/or neutrons) resulting in a nonzero nuclear spin 
can be chosen for this methodic. In the presence of a magnetic field sample nuclear spins, 
randomly arranged, will align along the external field lines (polarization), absorbing and re-
emitting electromagnetic radiation at a specific resonance frequency which depends on the 
strength of the magnetic field and on the magnetic properties of the sample atoms. For a set 
value of magnetic field applied, different nuclei give rise to distinct resonant frequencies 
depending on the strength of applied field. If a sample is placed in a non-uniform magnetic 
field then the resonance frequencies of the sample's nuclei depend on where in the field they 
are located. In the NMRI techniques the polarization of the magnetic nuclear spins is 
achieved by exposing the sample to a constant static magnetic field. The following step is 
the perturbation of this alignment by employing an electro-magnetic, usually radio 
frequency (RF), pulse. The required perturbing frequency is dependent upon the static 
magnetic field and the nuclei of observation. When the RF pulse is turned off nuclear spins 
at different locations relaxes to the equilibrium state with consequent emission of 
characteristic frequencies detectable by the scanner. The electromagnetic signals shifts 
induced by strong field gradients are recorded to construct tridimensional images of studied 
area. To maximize the NMR signal strength the two fields are usually chosen to be 
perpendicular to each other. 
NMRI uses intense applied magnetic fields in order to achieve dispersion and very high 
stability to deliver spectral resolution. The spatial resolution of the imaging technique 
depends on the magnitude of magnetic field gradient. Very high resolution images, on the 
order of one tenth of millimeter, can be achieved with a 3 Tesla scanners.  
For mouse MRI imaging can achieve 10-100 micrometer spatial resolution, with preferably 
at least 7.0 Tesla. To enhance the appearance of blood vessels, tumors or inflammation, 
contrast agents, properly modified, may be injected intravenously acting as specific 
molecular probe. This opens the possibility to monitor in vivo cellular functions as well as 
get information on the spatial distribution of a specific molecular target (Percy et al., 2011). 
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The employment of stable isotopes as contrast agents, diversely from PET methodology, 
gives to this technique the great advantage of supervising metabolic pathways or receptors 
dynamic for infinite time. 
2.3 Optical Imaging  
This non-ionizing imaging technique is based on the use of electromagnetic radiation in the 
near-infrared and visible field to observe single-molecule in living cells. Cost-effective, 
rapid, easy to use, optical imaging can be readily applied to studying disease processes and 
biology in vivo (Luker & Luker, 2008). A charge-coupled device camera (CCD camera) 
detects light emitted allowing for real time 2D imaging and 3D reconstruction. The key 
feature is the different behavior of light interaction with tissues such as adsorption, 
emission, excitation, scattering, fluorescence and luminescence. 
Molecular targets labeled with nanodiamonds, fluorescent dyes, quantum dots, as well as 
bioluminescent, chemiluminescent and fluorescent reporters, would enable biomolecule 
tracking inside cells (Rong Tong et al., 2010). Fluorescently labeled antibodies or biomarkers 
can target and identify tumors or other diseases in in vivo modalities (van der Meel et al., 
2010). Molecular and biochemical events such as transgene expression, transforming 
phenotype and enzyme activity can be detected by means of fluorescent probes. Tumor 
cells, stem cells, immunological cells can be transfected to overexpress luminescent or 
fluorescent proteins (Pomper, 2005). Widely used in animal models trial for low costs and 
good sensitivity (pmol concentrations, few cells), optical labeling technology scanner has an 
anatomical resolution relatively poor (1mm) due to scattering of light in tissue (Hickson, 
2009). OI has a minimal use in clinic owing to limited depth profiling (couple of centimeters 
in tissue depth) (Leblond et al., 2010). 
2.4 Computed tomography 
X-ray computed tomography (CT) is a radiological technique which provides high spatial 
resolution (less than 1 mm) of morphological imaging; three-dimensional anatomical 
images. Axial sections of well-defined depth are imaged upon differential x-ray absorption 
by different tissues. CT is based on detection of an X-ray beam by means of detectors system 
which converts the attenuated beam intensity into electric pulse of equivalent value.  
By interaction with electrons of the material probed, photons are removed from the incident 
beam. The total energy of the resulting beam is then attenuated. The higher the electron 
density, the more interaction of X-ray with the sample material occurs and the more 
attenuated is the final energy. Because of the inherent high-contrast resolution of CT, 
differences between tissues that differ in physical density by less than 1% can be 
distinguished. The CT methodology is widely use in medicine as a diagnostic tool: detailed 
studies of bone and joint structure, bone metastasis scans, measurement of tumor size and 
location, and visualization of airway structure in the lungs, can be assess with high 
resolution. The major drawback of the technology is the high radiation dose which can be 
lethal or mutagenic. For imaging systems dedicated to in vivo studies in animal models, the 
optimal resolution is 50–100 micrometer. Specimen instruments have resolutions down to 
less than 10 micrometer and can visualize e.g. trabecular bone structure. 
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contrast between the different soft tissues of the body in addition to a high images quality. 
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range, NMRI is completely harmless to the patient. 
Differences of nuclei behavior subject to a strong magnetic field gradient can be recorded to 
construct an image of the scanned area of the body resulting in the visualization of detailed 
internal structures. In the classical representation of an atom nucleus is depicted as a 
rotational sphere along an axis. This rotational motion is associated with a physical quantity 
called: angular momentum (spin). Because of the nuclear composition the so called 
rotational sphere is positively charged resulting in the generation of a magnetic field as a 
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The employment of stable isotopes as contrast agents, diversely from PET methodology, 
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3. Aptamers as excellent targeting molecules for in vivo imaging
Aptamers are single-stranded oligonucleotides (DNA or RNA) that like peptides or 
monoclonal antibodies, bind to their targets by complementary shape interactions. Indeed, 
aptamers function by folding into unique globular three-dimensional conformation that 
dictates high-affinity and specificity binding to a variety of targets, each structure being 
unique and determined by the sequence of the nucleic acid (Figure 1 A). As discussed in this 
chapter, the advantages of using nucleic acid aptamers for imaging/therapy are their 
favourable pharmacokinetic properties (rapid renal clearance) and their excellent affinity 
and specificity for their targets. These properties render aptamers useful targeting molecules 
for in vivo imaging allow obtaining high-resolution images with high signal-to-noise ratios 
and decreasing non-specific targeting thus reducing toxicity to non-target tissues (Tavitian 
et al., 1998, 2009; Perkins & Missailidis, 2007). 
 
Fig. 1. The size of each slice is related to the resolution of the indicated technique; the colour 
scale is proportional to the cost (clockwise). 
3.1 Aptamers production 
Aptamers are generated by an in vitro evolutionary selection-amplification scheme, named 
SELEX (Systematic Evolution of Ligands by EXponential enrichment) from libraries of 
random sequence oligonucleotides of large sequence complexity (generally between 1013 
and 1015 members) (Ellington & Szostak, 1990; Tuerk & Gold, 1990). As schematized in 
Figure 1 B, a typical SELEX experiment includes reiterated rounds of: (1) incubating the 
library with the target molecule; (2) partitioning nucleic acids bound specifically to the 
target molecule from unbound sequences; (3) dissociating the nucleic acid-protein 
complexes; and (4) amplifying of the nucleic acids pool enriched for specific ligands. After 
the final round, the PCR products are cloned and sequenced to subsequently identify the 
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best binding sequences. Due to the fact that the specific, three-dimensional arrangements of 
a small number of contact points of the aptamer mediates the target-aptamer interaction, 
rather than a general affinity for the sugar-phosphate backbone of the nucleic acid, aptamers 
can achieve high target selectivity. In addition, the binding characteristics of aptamers can 
be influenced by the type of the experimental system used for the selection and counter-
selection (depletion of aptamers that bind to non-target molecules). As a result, aptamers 
bind their own target with sub-nanomolar affinity thus revealing useful for many of the 
applications for which antibodies are already employed because of their own definite 
characteristics: (i) capacity to discriminate among closely related targets (e.g., will typically 
not bind other proteins from the same gene family); (ii) capacity to quantify the level of 
expression of the protein target; (iii) through binding, may act as inhibitors to block the 
activity of the target product. More important, they are usable not only for in vitro but also 
for in vivo purposes since they are sufficiently stable and can be readily chemically modified 
to further enhance their stability, bioavailability and pharmacokinetics (Esposito et al., 2011; 
Keefe et al., 2008, 2010). 
 
Fig. 2. Schematic representation of SELEX technology. The RNA/DNA aptamer library 
contains a variable region flanked by two constant regions. These constant regions include 
primer sites for PCR amplification and a consensus promoter for the T7-RNA polymerase 
(in the case of an RNA library). The library is used for the selection process. The target can 
be a purified recombinant protein (Protein-SELEX) or a complex target as entire living cells 
(cell-SELEX) 
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3.2 Systemic clearance of the aptamers 
Furthermore, due to their relatively small size (8-15 kDa) in comparison to antibodies (150 
kDa), aptamers should be better suited for rapid tissue penetration and blood clearance, two 
excellent characteristics for contrast agents in imaging. Indeed, when antibodies bind their 
target, their slow clearance may necessitate waiting for days before a significant signal 
emerges from the background of excess unbound ligand. This of course often results in 
organ toxicity and, in addition, limits the usefulness of imaging technology in diagnosing 
acute conditions, and precludes the use of short-lived radionuclides. 
On the contrary, aptamers not conjugated to polyethylene glycol (PEG) are cleared very 
quickly from blood circulation because of renal excretion and hepatobiliary clearance. A 
typical short, nuclease-resistant oligonucleotide administered intravenously exhibits an in 
vivo half-life of <10 min, unless filtration can be blocked by either facilitating rapid 
distribution out of the blood stream into tissues or by increasing the apparent molecular 
weight of the oligonucleotide above the effective size cut-off for the glomerulus. In addition, 
immunogenicity has been found to be either absent or limited when 1000-fold higher doses 
of an aptamer (than would be required clinically) were administered to monkeys (Foy  
et al., 2007). 
This property depends on the fact that antibodies to synthetic oligonucleotides are not 
generally produced and, in addition, the innate immunity response against non-self RNAs 
does not hinder aptamer therapy because 2’-modified nucleotides abrogate Toll-like 
receptors responses (Yu et al., 2009).  
3.3 Stability of the aptamers 
Prerequisites for a successful in vivo application of aptamers as molecular target imaging 
agents are represented by high affinity and selectivity to their target as well by adequate 
stability against in vivo degradation. Since oligonucleotides, especially RNAs, are rapidly 
degraded by nucleases in whole organisms, resulting in a very short half-life in the blood, a 
variety of approaches have been addressed to increase the stability of natural nucleic acids 
in biological media (Keefe & Cload, 2008). 
The most effective modifications to circumvent this limitation are the substitutions at the 2’-
ribose of the pyrimidines that are mainly affected by serum nuclease degradation. Initially, 
attention is focused on ‘post-SELEX modifications’, however, due to the fact that folding 
rules for single-stranded oligonucleotide regions change when these modifications are 
introduced, the binding properties of an aptamer selected in the presence of standard 
nucleotides might be completely different when the same sequence is synthesized with 
nucleotides containing a different 2’-substituent (Blank et al., 2001; Usman & Blatt, 2000; 
Aurup et al., 1992). To circumvent this limitation selections can be performed directly in the 
presence of 2’-modified nucleotides, as long as the modified nucleotides are accepted by T7 
RNA polymerase for the in vitro reaction steps of the selection (Aurup et al., 1992; Ruckman 
et al., 1998). RNA-aptamers containing 2′-fluoro and 2’-amino pyrimidine (2’-F-Py, 2’-NH2-
Py, respectively) can be generated performing the selection in the presence of 2’-modified 
nucleotides (Chelliserrykattil et al., 2004).Analogously, aptamers containing 2′-O-Metyl 
purines (2’-O-Me) have also been developed through post-SELEX modification steps or by 
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starting from 2’-O-Me–containing random sequence libraries during the SELEX process 
itself (Burmeister et al., 2004; Chelliserrykattil & Ellington, 2004). 
Even if 2’-modified nucleotides-containing aptamers show considerable increase in serum 
stability also in the absence of other modifications, changes in the internucleotide linkages 
(such as the use of phosphorothioate) and in the nucleobases (for example, the substitution 
of 5-position of uridine) as well the capping at the oligonucleotide 3′-terminus, have been 
reported (Keefe & Cload, 2008). 
Conformation flexibility is hypothesized to be a major factor limiting the affinity and 
specificity of interactions due to the entropic penalty upon binding. Furthermore, since 
single-stranded regions are the primary site of nuclease attack, the conformational flexibility 
would render the aptamer more accessible to nucleolytic degradation and thus, reduction of 
flexibility would be a key prerequisite for successful in vivo application. One way to stabilize 
aptamers is to increase thermal stability of double-stranded areas located within non-
binding regions. In this respect, the use of locked nucleic acids (LNA), containing a 
methylene bridge to connect the 2′-O to the 4′-C, increases the stability of base pairing 
stabilizing the duplex and enhancing the resistance to nuclease. For example the 
introduction of LNA-modifications in the anti-tenascin C (TN-C) aptamer significantly 
improves its plasma stability of approximately 25% and enhances the tumor uptake 
(Schmidt et al., 2004). 
An interesting application of the SELEX process is based on the selection of RNA aptamers 
binding to the mirror-image of an intended target molecule (e.g. an unnatural D-amino acid 
peptide), followed by the chemical synthesis of the mirror-image of the selected sequence 
(Eulberg & Klussmann, 2003). As a consequence of molecular symmetry, the mirror-image 
aptamer (made from L-ribose) binds to the natural target molecule. Because of the 
substitution of the natural D-ribose with L-ribose, the mirror-image aptamer (named 
Spiegelmer) is totally stable. NOX-A12 and NOX-E36 are two spiegelmers actually in clinical 
trials for the treatment of hematologic tumors and complications of type 2 diabetes, 
respectively (Esposito et al., 2011; Ellington, 2010). 
4. Inflammation imaging with aptamers 
The assessment of precise and reliable methods for the diagnosis of inflammatory processes 
is an important goal in medicine for the effective management of inflammation-related 
diseases. Acute inflammatory diseases are characterized by a significant increase in the 
lymphocytes and neutrophils count in the peripheral blood while chronic inflammatory 
diseases are characterized by infiltration of the target organ by mononuclear cells, such as 
lymphocytes, plasma cells, and macrophages (Weiss, 1989).  
Some inflammatory processes, such as organ-specific autoimmune disorders, are difficult to 
diagnose because they either are asymptomatic or have non-specific symptoms. The 
possibility of diagnosing inflammatory processes during the early stage may allow for early 
therapeutic intervention and possible prevention of the disease. 
During inflammation, levels of several proteolytic enzymes are significantly increased 
including neutrophil elastase that is released by neutrophils accumulated at the site of 
inflammation (Doring, 1994). Aptamers as specific irreversible inhibitors of neutrophil 
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elastase have been isolated by ‘blended SELEX’, a modification of the basic SELEX 
technology that allows to confer high-affinity binding to a weak, covalent inhibitor of an 
enzyme (Smith et al., 1995; Charlton et al., 1997). 
In this process, a randomized nucleic acid library attached covalently to an inhibitory 
compound of elastase (a valyl diphenyl ester phosphonate) was used to select for a 
secondary, stabilizing contact for the target molecule. By iterative selection and 
amplification steps, the nucleic acid sequences that best promote the covalent reaction of the 
valyl phosphonate moiety with the active-site serine of elastase were identified. In addition 
to inhibiting elastase free in solution, these aptamers were highly effective at blocking 
degradation of elastin particles by activated neutrophils. Further, a truncated DNA aptamer 
version, named NX21909, was tested in a rat model of lung inflammation and was found to 
inhibit neutrophil infiltration by 53% at a dose of 40 nmol (Bless et al., 1997). Using 
fluorescent flow cytometry, the aptamer revealed able to bind preferentially to activated 
neutrophils (Charlton et al., 1997).  
The first example of the use of aptamers as in vivo imaging probes is represented by the use 
of NX21909 for diagnostic imaging of inflammation in a rat model of the reverse passive 
Arthus reaction induced by immune complex deposition (Charlton et al., 1997). The aptamer 
was labelled with 99mTc and given by intravenous injection 3.5-4 h after induction of 
inflammation. Rats were imaged on a gamma camera in 10 min frames continuously for 40 
min and additional 10 min frames were taken every hour up to 4 h after administration of 
imaging agent. 
Remarkably, a better signal-to-noise ratio was achieved by the aptamer compared to a 
clinically used IgG-based inflammation imaging agent used as a positive control (for the 
aptamer, a ratio of 4.3 ± 0.6 was achieved at 2 h; for IgG, a ratio of 3.1±0.1 was achieved at 3 
h). This ratio was achieved primarily by the rapid clearance of the aptamer from the 
peripheral circulation. thus indicating that the aptamer technology may be successfully 
applied to diagnostic imaging. 
5. Thrombus imaging with aptamers 
Thrombin is the last enzyme in the clotting cascade functioning to cleave fibrinogen to fibrin 
which forms the fibrin gel of a hemostatic plug or a pathologic thrombus. In addition to its 
role in blood coagulation, it also triggers important anticoagulant and antifibrinolytic 
pathways (Petäjä, 2011). The crystal structure of thrombin has been determined (Bode et al., 
1992; Stubbs & Bode, 1993) thus giving important insight into its structure-function 
relationship. DNA aptamers have been generated that bind to different domains of the 
protein. ODN1 binds to exosite 1, the thrombin substrate binding site, thus competing with 
fibrin for binding to the same site on thrombin (Bock et al., 1992; Wu et al., 1992). 
Conversely, ODN2 reacts with exosite 2, the heparin binding site on thrombin (Tasset et al., 
1997). These aptamers have been extensively characterised for their binding to thrombin and 
ODN1, is currently being evaluated in phase II clinical trials by ARCA 
Biopharma/Archemix Corp. as an anticoagulant for use during acute coronary artery 
bypass surgery. Being unmodified and unstable in vivo the aptamer, designated as Nu172, 
has to be administered by continuous intravenous infusion (Esposito et al., 2011). 
To generate thrombin-dependent images in aptamer-mediated thrombus imaging 
approaches, the radiolabeled aptamer must form a ternary complex with thrombin bound to 
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the fibrin matrix. For this reason ODN 2, but not ODN 1, has been used for thrombus 
imaging (Dougan et al., 2003). 
In vitro experiments showed that ODN2 can form a ternary complex (with thrombin and 
fibrin) in clots, a necessity for thrombus imaging, thus indicating that allosteric interference 
from the fibrin binding site (exosite 1) did not impede ODN 2 binding at exosite 2. 
Thrombin-dependent uptake of ODN 2 was observed with in situ labeling of clots and by 
labeling of preformed clots. Further, the retention of [125I]ODN 2 increased as the thrombin 
content of thrombi was increased whereas the rate of release of ODN 2 out of preformed 
thrombi decreased. Then, the aptamer was tested in vivo, in a rabbit jugular vein model 
using thrombus supplemented with human thrombin,. The labeled aptamer was introduced 
internally with the portion of rabbit blood, or else externally to a preformed unlabeled clot 
via the truncated facial vein and the thrombus area was imaged with a 2D scintigraphic 
camera, or excised for counting. Despite the clearly promising effect in vitro when ODN 2 
was tested in vivo, the uptake was equal to the ovalbumin control and did not reflect 
thrombin content. A possible explanation of the failure of the in vivo thrombin-dependent 
imaging was attributed to the rapid clearance of ODN 2 from blood, combined with slow 
mass transfer in the thrombus. It is conceivable that nucleic acid analogs with extended 
lifetimes in circulation might help overcome this problem. For instance, the clearance rates 
of aptamers can be altered to keep them in circulation by anchoring them to liposome 
bilayers, by coupling them to inert large molecules such as PEG or to other hydrophobic 
groups (Willis et al., 1998; Healy et al., 2004). 
It is noteworthy that the Food and Drug Administration (FDA)-approved aptamer, 
Macugen, as well as all the aptamers in clinical trials, except for Nu172, have been 
conjugated with PEG to enhance their half-life in vivo (Esposito et al., 2011). 
6. Aptamers as in vivo imaging reagents in cancer 
The aim of this section is to give a detailed overview on the aptamers developed for tumour 
imaging. Pointing out the attention on the structural modification as well as the 
bioconjugation with specific tags, we will focus on the experimental results emphasizing the 
essential requirements for potential application of aptamers as imaging probes for in vivo 
studies: high target specificity and affinity, rapid pharmacokinetics, exclusion of toxic side 
effects, tumour penetration, chemical stability, and high signal-to-noise ratio.  
Five modalities (PET, SPECT, NMRI, CT and OI) are available to the scientist for oncological 
investigations in animals (Lewis et al., 2002; Tavitian, 2003). PET and NMRI technologies 
offer deep tissue penetration and high spatial resolution, but compared with non-invasive 
small animal optical imaging, these techniques are very costly and time consuming to 
implement. Aptamers have been successfully coupled to different targeted radiolabeled 
ligands and contrast agents to generate probes for in vivo medical imaging by using the five 
modalities previously described. 
6.1 Aptamers conjugated with 99mTc for SPECT  
The TTA1 aptamer against TN-C has been generated by a crossover SELEX experiment that 
involves crossing from cell-SELEX on TN-C-positive U251 glioblastoma cells to protein-
SELEX against purified recombinant TN-C (Hicke et al., 2001).  
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elastase have been isolated by ‘blended SELEX’, a modification of the basic SELEX 
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the fibrin matrix. For this reason ODN 2, but not ODN 1, has been used for thrombus 
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To improve stability against plasma nucleases, therefore guarantee a good blood persistence 
leading to sufficient signal-to-noise ratios for imaging, aptamer backbone (2’-F-Py 
containing RNA, 39mer) has been modified with the addition of maximal 2’-OMe purine 
substitutions, a thymidine cap at the 3’ end and LNA in not binding critical stem (Shimdt et 
al., 2004). This TTA1 derivative has been further conjugated with mercapto-acetyl diglycine 
(MAG2) chelate via an hexyl-aminolinker at the 5’ end and labelled with 99mTc for 
performing single photon emission computed tomography (Hicke et al., 2006) . 
To assess the degree of stability, an essential feature to achieve a sufficient targeting and 
blood clearance, combined to low background activity in non-target organs, tumour to 
blood and tissue distribution of 99mTc-labeled aptamer have been examined in murine 
xenograft models of glioblastoma and breast cancer (Hicke et al., 2006). Images of 
glioblastoma and breast tumors were taken at various times after intravenous injection in 
mice using a γ-camera. After 3 h post injection the tumor mass was visible as well as liver 
and bladder. At 18h post injection the two major clearance pathways were entirely clean 
from any radioactivity, as predicted by biodistribution analysis (Table1), and the tumor was 
clearly visualized as blazing structure (Hicke et al., 2006). Data show a rapid renal and 
hepatobiliary clearance, 0.2 %ID/g and 1.5 %ID/g at 3h, respectively and a rapid tumor 
penetration (6% injected dose at 60 min). Tumor retention is durable (2.7% injected dose at 
60 min) and the tumor-to-blood signal is significantly high (Hicke et al., 2006). 
Substitution of DTPA-111In or insertion of a PEG3,400 linker have also been tested for 
biodistribution analysis showing a dramatic alteration of tissue uptake and clearance 
patterns, indicating that simple changes to chelator can have significant effects on tissue 
uptake and clearance patterns. 
DNA-aptamers that target cell-surface mucin 1 glycoprotein (MUC1), generated by Protein-
SELEX against purified MUC1 peptides (Ferreira et al., 2006), have also been labeled with 
99mTc (Ferreira et al., 2006). The aptamers, named AptA and AptB, have been selected 
against the protein core or the glycosylated protein, respectively. Various chelating agents 
have been conjugated to the aptamers and multi aptamer complexes have shown increased 
retention of the complex in circulation without increasing the immunogenicity of the 
complex or adversely altering its tumor penetration properties. The biodistribution data of 
the labeled products have shown differences that depend on the size of the conjugate and 
the type of ligand (Borbas et al., 2007). Four types of chelators have been coupled to anti-
MUC1 aptamers to generate a novel complex for diagnostic imaging with improved 
properties: MetCyc, MAG3, DOTA and 4 (Figure 3).  
Differently from the monomeric Tc-MetCyc-Apt and Tc-MAG3-Apt, the tetrameric 
compounds, DOTA and 4, conjugate with 99mTc are able to grab four aptamer molecules 
modified at 5’ by insertion of amine groups to facilitate coupling with the ligands carboxylic 
terminations and 3’ ends to protect against nuclease degradation. Both tetrameric and 
monomeric aptamers were tested in nude mice bearing xenografted MCF7 breast cancer 
tumor. Compared to the monomeric biomarker composites, DOTA and 4 showed an 
increased retention in the circulation by means of their largest molecular weight. Despite the 
tetrameric complexes showed improved tumor retention and pharmacokinetic properties 
compared to the monomeric compounds, biodistribution studies have exhibited presence of 
free technetium in the stomach and large intestine highlighting some kind of lack in the Tc-
aptamer binding (Borbas et al., 2007). 
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Fig. 3. Schematic representation of monomeric and tetrameric aptamer bioconjugates (see 
text for details). 
Anti-MUC1 aptamers have also been successfully conjugated to MAG2chelator and the 
complexes have been labeled with 99mTc (Pieve et al., 2009). Analysis of two aptamer–
radionuclide conjugates, AptA and AptB, biodistribution properties in MCF7 xenograft-
bearing nude mice shows strong 99mTc binding properties (70-80% for AptA and ≥80% for 
AptB) and high stability in vivo, in terms of nuclease degradation and leaking of the metal 
(Table 1). Both aptamers show a maximum tumor uptake after 5h post injection, even 
though Apt B has higher accumulation rate, 0.12 %ID/g (for AptA) and 0.14 %ID/g (for 
AptB), followed by a decrease at 16h, 0.033 %ID/g (for AptA) and 0.016 %ID/g (for AptB) 
and 22h, 0.008 %ID/g (for AptA) and 0.013 %ID/g (for AptB). As pointed out by these data 
AptB releases quicker from the target keeping his activity constant between 16h and 22h, 
whilst AptA activity decreases constantly in time. The activity discrepancy is consequence 
of a different kinetic behaviour upon binding with the molecular target. AptB, in fact, 
internalized in the cancer cell quicker than AptA. Table 1 shows tumour-to-blood ratios 
values, taken at different times post injection, of both oligonucleotide carriers, confirming 
the assumption of Missailidis’s group. The maximum levels of tumour uptake and clearance 
has reached at 5h post injection for AptA and AptB (table 1) but whiles the tumour-to-blood 
ratio trend of AptB, after 5h, is constant in time, AptA decreases drastically at 16 h, reaching 
his minimum value, and increases again at 22h, suggesting that the bound aptamer was not 
internalized.  
Even if the radiolabeled aptamers demonstrate good tumor uptake and clearance, they 
require further optimization before diagnostic use. 
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Target TNC  MUC1 
Aptamer TTA1/2’Fy-RNA AptA/DNA AptB/DNA 
Length(nt) 39 25 25 
Kd (nM) 5 5 5 
Tag 99mTc 99mTc 99mTc 
    
Tumour (%ID/g)    
10 min 5.9±0.6   
1h 2.69±0.30   
3h 1.88±0.10 0.051±0.022 0.044±0.008 
5h  0.12±0.046 0.14±0.040 
16h  0.033±0.034 0.016±0.005 
22h  0.008±0.001 0.013±0.005 
    
Blood (%ID/g)    
10 min 2.27±0.25   
1h 0.11±0.00   
3h 0.03±0.00 0.027±0.002 0.024±0.001 
5h  0.14±0.04 0.19±0.04 
16h  0.005±0.001 0.009±0.001 
22h  0.004±0.001 0.007±0.004 
    
T/Blood    
10 min 2.6   
1h 24.0   
3h 62.6 1.8 1.8 
5h  0.8 0.7 
16h  6.6 1.8 
22h  2 1.8 
Table 1. In vitro characteristics and pharmacokinetics in mice for anti-TNC and anti- MUC1 
aptamers.  
6.2 Nanoparticle-aptamer conjugates for OI and NMRI 
Aptamers were also used to functionalize nanoparticles surface for a potential in vivo cell 
imaging applications (Farokhzad et al., 2004; Javier et al., 2008; Chu et al., 2006; Rong et al., 
2010; Savla et al., 2011). 
Much work has been made by using the two 2’fluoro-pyrimidine (2’Fy)-RNA aptamers (A9 
and A10) that have been generated against the extracellular domain of PSMA (prostate-specific 
membrane antigen), (Lupold et al., 2002). These aptamers bind with high affinity to the acinar 
epithelial cells of prostate cancer tissue. They have been used to deliver nanoparticles, 
quantum dots (QDs), toxin, or siRNA to prostate cancer cells (Cerchia & de Franciscis, 2010). 
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Poly(D,L-lactic acid) (PLA)-PEG-COOH nanoparticles and microparticles, conjugated with 
the A10 RNA aptamer have been developed to target the (PSMA) cells in vivo (Farokhzad et 
al., 2004). 
PLA derivatives exhibit a desirable characteristic by means of their neutral to slightly 
negative surface charge, preserving the aptamers binding characteristic by specific 
interaction with them. On the opposite, particles with a positive surface charge may interact 
non specifically with the negatively charged aptamers affecting their binding properties.  
Moreover the incorporation of PEG containing a terminal hydroxyl and carboxylic acid 
functional groups results essential to maximize nanoparticle circulating half-life and to 
allow the covalent coupling with 3’-NH2–modified aptamer.  
To examine the presence of the aptamer-nanoparticle conjugates on the surface of PSMA-
positive cells, the A10 aptamer has been labeled at 5’end with FITC and uptake by LNCaP 
cells has been evaluated by fluorescent microscopy. Images taken after 2 h and 16 h of 
incubation, showed a massive internalization just after 2h of nanoparticle-aptamer 
compound versus control group (aptamer-treatment of PSMA-negative PC3 cells). 
These aptamer-nanoparticles conjugates have been loaded with docetaxel, anti-cancer 
therapeutic and successfully used for targeted delivery to PSMA-positive cells (Farokhzad et 
al., 2006). 
PSMA has been also labelled using aptamer-quantum dots conjugates (Chu et al., 2006). A 
different anti-PSMA aptamer, A9, has been selected and conjugated to luminescent CdSe 
and CdTe nanocrystals for cell labelling.  
Quantum dots (QD) represent the most promising fluorescent markers and delivery 
vehicles. These semiconductor particles have nanometre size and offer revolutionary 
fluorescence performance over traditional fluorescence dyes such as long-term 
photostability for live-cell imaging and dynamics studies, brilliant colors for simple, single-
excitation multicolor analysis, fixability for follow-up immunofluorescence after in vivo 
studies, narrow and symmetrical emission spectra for low interchannel crosstalk. 
Before conjugation the synthesized aptamer was biotinylated at its 3’-end by periodate 
oxidation and conjugation to biotin hydrazide (Qin & Pyle, 1999). 
Labeling experiments were carried out for fixed and live cells and live cells embedded in a 
collagen matrix. The A9 aptamer-QD conjugates showed specific in vitro labeling for the 
selected target exhibited a good capacity to penetrate keep into tissues.  
QD has also been conjugated with MUC1 aptamer and doxorubicin (QD-MUC1-DOX), via 
acid labile hydrazine bond, for in vivo imaging and drug delivery (Salva et al., 2011). In 
vitro and in vivo studies confirmed that the complex QD-MUC1-DOX accumulate 
predominately in the tumor and effectively release inside cancer cells (Salva et al., 2011). 
A novel, multifunctional, thermally cross-linked superparamagnetic iron oxide nanoparticle 
(TCL-SPION) which can detect prostate cancer (PCa) cells and deliver targeted 
chemotherapeutic drugs has been developed (Wang et al., 2008). TCL-SPION nanoparticle 
has been conjugated with A10 aptamer and the complex so obtained has been tested for PCa 
imaging, using a single-sided NMR probe, and therapy, loading the bioconjugate with DOX. 
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vitro and in vivo studies confirmed that the complex QD-MUC1-DOX accumulate 
predominately in the tumor and effectively release inside cancer cells (Salva et al., 2011). 
A novel, multifunctional, thermally cross-linked superparamagnetic iron oxide nanoparticle 
(TCL-SPION) which can detect prostate cancer (PCa) cells and deliver targeted 
chemotherapeutic drugs has been developed (Wang et al., 2008). TCL-SPION nanoparticle 
has been conjugated with A10 aptamer and the complex so obtained has been tested for PCa 
imaging, using a single-sided NMR probe, and therapy, loading the bioconjugate with DOX. 
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NMR studies confirm the potential of the TCL-SPION-Apt complex as a targeted MR 
contrast showing that the bioconjugate can detect PSMA-expressing PCa cells with high 
sensitivity. The Dox-loaded TLC-SPION-Apt compound has been tested for antiproliferative 
activity against both the LNCaP and PC3 cell lines. Results showed selective delivery to 
PSMA-expressing cells without loss in cytotoxicity (Wang et al., 2008).  
Further, PLA nanoparticles containing stably incorporated cyanine dyes have been tested 
for in vitro and in vivo imaging applications (Tong et al., 2010). Cy5-PLA/A10 aptamer 
nanoparticles have been found to only bind to and get internalized by LNCaP and canine 
prostate adenocarcinoma cells (PSMA-positive), but not to PC3 cells (PSMA-negative). Then, 
conjugates have been intravenously administered to balb/c mice and in vivo biodistribution 
evaluated by using the LI-COR Odyssey scanner. Accumulation of Cy5-PLA NP within 
visceral organs allows for greater than >10-fold increase in fluorescent intensity in 
comparison with background autofluorescence. Splenic accumulation of Cy5-PLA NP is the 
greatest for all visceral organs examined (spleen, liver, kidney, lung, and heart).  
Another application of the anti-PSMA A9 aptamer as molecular-specific contrast agents for 
prostate cancer imaging has been developed by Javier et al (Javier et al., 2008). The aptamer 
has been conjugated by using an extended aptamer design where the extension is 
complementary to an oligonucleotide sequence attached to the surface of gold nanoparticles. 
Binding of nanoparticle-aptamer bioconjugates to prostate LNCaP cells has been valuated 
by reflectance imaging of the labeled cells with confocal microscopy in reflectance mode. 
More recently, in vivo imaging of tumor has been performed by using the DNA aptamer sgc8, 
generated by cell-SELEX on human acute lymphoblastic leukaemia cells and identified to 
interact with protein tyrosine kinase-7 (PTK7) (Shi et al., 2011). The aptamer has been modified 
in order to generate an activatable probe consisting of the binding site of the aptamer (A-
strand), a poly-T linker and a short DNA sequence complementary to a part of the A-strand, 
with a fluorophore and a quencher attached at either terminus. In the absence of binding, the 
aptamer is in a hairpin structure resulting in a quenched fluorescence. When the probe binds 
to cell-surface receptors, it changes conformation resulting in an activated fluorescence signal. 
This molecule was intravenously injected into tumor-bearing mice and fluorescence images 
were collected. Compared to always-on aptamer probes, the activatable aptamer showed 
significantly enhanced image contrast and shortened diagnosis time to 15 min.  
6.3 Nanoparticle-aptamer conjugates for in vivo multimodal imaging  
Recently, a multimodal cancer-targeted imaging system capable of simultaneous in vivo 
fluorescence imaging, radionuclide imaging and magnetic resonance imaging in mice, has 
been reported by using the AS1411 aptamer as targeting molecule (Hwang et al., 2010). 
AS1411 aptamer is a 26-mer guanine-rich oligonucleotide (GRO), which in solution folds 
into quadruplex structures, that make it very stable and resistant to degradation by serum 
enzymes. This aptamer that binds to nucleolin, a protein that is often over-expressed on the 
surface of cancer cells, is currently in Phase II of clinical development (Bates et al., 1999, 
2009; Mongelard & Bouvet, 2010). In this study, the aptamer was conjugated with a cobalt-
ferrite nanoparticle surrounded by fluorescent rhodamine, and the resulting particle was 
bound with 2-(p-isothio-cyanatobenzyl)-1,4,7-triazacyclonane-1,4,7-triacetic acid (p-SCN-bn-
NOTA) chelating agent and further labeled with radionuclide gallium citrate Ga-67. 
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The purified nanoparticles, designated MFR-AS1411, were intravenously injected into a 
mice xenografted with nucleolin-expressing C6 rat glioma cells and radionuclide images 
were acquired at 1, 6, and 24 h after injection. Scintigraphic images of C6 tumors in mice that 
received MFRAS1411 showed that tumors had accumulated MFR-AS1411 at 24 h after 
injection whereas the mutant, not functional, MFR-AS1411 administration revealed rapid 
clearance via the bloodstream. 
Further, bioluminescence images analysed using IVIS200 system in the C6 cells, stably 
expressing the luciferase gene, illustrated the in vivo distribution. MR images of the same 
mice injected with MFR-AS1411 showed dark T2 signals inside the tumor region, compared 
with the MRI signal of the tumor region injected with mutant MFR-AS1411 particles. 
Taken together, the above results by means of multifunctional imaging modality platforms 
demonstrate that MFR-AS1411 specifically targeted cancer cells. 
7. Future perspectives 
To date only few aptamers have been developed as targeting agents in imaging modalities, 
as discussed in the present chapter and schematized in figure 4, nevertheless, their low 
immunogenicity, good tumor penetration, rapid uptake and fast systemic clearance, indicate 
a great potential of these molecules as imaging agents especially when compared to 
antibodies. Given the nature of the aptamers and their discrimination and targeting 
capacities, the majority of the aptamers not bound to the target tissues is cleared rapidly 
from the system. In comparison, intact radiolabelled antibodies remain in circulation for a 
very long time, often resulting in organ toxicity.  
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Further, the continuous advances in SELEX technology allow now to easily generate 
aptamers against virtually any protein and it is plausible speculate that the global market 
demand for nucleic acid aptamers will increase in the next few years opening the aptamer 
field for development for therapy, diagnosis and drug development imaging. 
8. Take-home-message 
Some molecule, most notably those found in nature, have the ability to reach out and grab 
other molecules and bound to them. Aptamers appear to fulfill this criterion and have been 
identified as excellent candidates for targeting specific epitopes in clinical diagnosis and 
therapy of different diseases. Further, because of their high specificity and low toxicity 
aptamers may reveal as the compound of choice for in vivo cell recognition as delivery 
agents for nanoparticles, small interfering RNAs bioconjugates, chemotherapeutic cargos 
and molecular imaging probes (Cerchia & de Franciscis, 2010). 
There have been significant technological advances in cell-SELEX and in vivo-SELEX 
strategies. Although aptamers are relatively new to the clinic, the fact that they can act as 
specific recognition ligands to target cells in vivo suggests that these molecules will have a 
considerable impact in patient care in the near future. 
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1. Introduction
Fluorescence diffuse optical tomography (fDOT) is an imaging modality which goes beyond
well-established techniques such as 2D fluorescence imaging and fluorescence microscopy.
Being a 3D tomographic modality, it seeks to overcome limitations of 2D systems as are: (i)
the determination of the depth of fluorescent objects and (ii) a correction of the broadening of
the fluorescence signal due to the massive scattering of photons.
Compared to high-resolution tomography systems such as CT and MRI, fDOT has the
particular advantage that the optical activity of many fluorophores is influenced by the
chemical milieu in which they are located and, thus, by the biological surrounding.
Researchers have already shown the dependency on the oxygenation of the tissue (Longmuir
& Knopp (1976); Shives et al. (2002)), the pH value (Gannot et al. (2004); Mordon et al. (1992)),
or the temperature (Chen & Wood (2009)), for example. This influence on metabolic processes
and states offers information beyond the visualization of anatomical structures and, therefore,
is termed functional imaging.
In comparison to 2D in-vivo imaging, 3D sensing of fluorescent particles in biological
specimen imposes additional problems:
• Light of lower wavelength (blue and green) is absorbed by many biologically relevant
materials such as hemoglobin. In order to excite deep fluorophore-structures, excitation
light in the far red and near infrared (NIR) range has to be used, which requires suitable
(i.e. NIR-excitable) fluorescent targets.
• Visible and NIR-light is heavily scattered in biological tissue. This compromises the
achievable resolution especially in comparison to CT and MR and requires special
treatment during image reconstruction.
• The light intensity decays exponentially with the probing depth, which infers a
depth-dependent maximum resolution.
The outline of this chapter is as follows: In section 2 the optical properties of tissue
will be introduced. Section 3 deals with possible hardware setups for 3D sensing.
Mathematical models for light propagation are described in section 4. In section 5 nonlinear
image reconstruction methods are compared. An overview about clinical and pre-clinical
applications is given in section 6 and section 7 concludes with an outlook.
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2 Will-be-set-by-IN-TECH
2. Optical properties of tissue
For the determination of the 3D distribution of fluorescent particles inside biological samples,
it is necessary to describe light propagation in tissue with mathematical models. This in
turn requires to quantify typical light-tissue interaction processes in terms of measurable
quantities. The most common processes are certainly absorption and scattering of photons
as well as fluorescence and phosphorescence phenomena.
2.1 Absorption
Absorption is the extinction of a photon, whose energy is stored by the absorbing medium
via excitation of an electron or in rotational or vibrational states of atoms. This physical
processes are stochastic in their nature and therefore should be described by a probability
density measure. However, for most models it is sufficient to give the average occurrence rate
of an absorption event per photon path length. This leads to the definition of the absorption
coefficient μa given in units of inverse length; frequently in cm−1 or mm−1. It specifies
the average number of photons being absorbed when traveling a given distance inside an
absorbing medium. An absorption coefficient of 0.2 cm−1 would mean an average of two
absorption events per 10 cm which the photon travels inside the object. In other words, a
photon can on average travel μ−1a (= 5 cm for the former example) without being absorbed.
The latter quantity is called the mean absorption-free path length.
2.2 Scattering
Scattering is the deflection of a photon out of its original trajectory into a new direction. In
analogy to absorption, the scattering coefficient μs gives the average number of scattering
events per length of travel. The inverse μ−1s is the average length a photon can propagate
in tissue without being scattered and is thus known as mean scattering-free path length. To
fully quantify the scattering behavior of some medium, it is not sufficient to know only how
often scattering happens but also the direction into which the photon will be deflected is
of importance. The latter is given by the scattering phase function Θ(ŝ, ŝ�), which is the
probability for a photon arriving from direction ŝ to be scattered into a new direction ŝ�. Two
possible scattering phase functions are depicted in Figure 1. If every scattered direction ŝ�
has the same probability, the scattering is said to be isotropic. This ideal case is not valid
in biological media, where scattering is usually strongly forward biased as displayed on the
right in Figure 1. At this point, it is also worth noticing that most tissue types are much more
scattering than absorbing. Exceptions to this rule are well perfused tissues such as liver and
highly transparent liquids as liquor, for example.
2.3 Scattering anisotropy factor
For many real-world applications the description of the scattering distribution by the
scattering phase function is much too complicated to be useful. Instead, one seeks to
approximate the anisotropic scattering with a scattering coefficient μs through an isotropic
model with another scattering coefficient μ�s. To this end, the scattering anisotropy factor g is
introduced which is the mean value of the cosine of the scattering angle. This factor is in the
range from -1 to 1. Positive values indicate a preference for forward-scattering while negative
values indicate an imbalance towards photons which are back-scattered. In the isotropic case
g is equal to 0.
118 Molecular Imaging 3D Optical Imaging of Fluorescent Agents in Biological Tissues 3
Fig. 1. Visualization of two scattering phase functions. The incoming photons with direction
ŝ are drawn in black, the scattered ones having a direction ŝ� in red. Left: The scattering
angles are equally distributed; the scattering is isotropic. Right: Nearly all photons are
scattered in a forward direction which is true for most biological tissues.
With the definition of the anisotropy coefficient, one can define the reduced scattering
coefficient μ�s as μ�s := (1 − g)μs. The idea is to approximate anisotropic (forward-directed)
scattering with probability μs and anisotropy g by isotropic scattering with a smaller scattering
coefficient μ�s. This working principle is illustrated in Figure 2. The true path of a scattered
photon is sketched with small arrows. If the anisotropy coefficient of the tissue was g = 0.875,
every (1 − 0.875)−1 = 8 anisotropic steps would be combined into one isotropic step. Thus,
the number of scattering events per length of travel decreases and the mean scattering-free
path length increases. The approximated scattering can be assumed to be isotropic.
Fig. 2. Principle of the anisotropy coefficient: The short arrows represent the path of a
scattered photon in tissue. Each arrow is of length μ−1s , which is the mean scattering-free
path length. Assuming g = 0.875, every eight anisotropic scattering events are approximated
by one isotropic scattering event which is drawn with red arrows. The isotropic scattering
has a reduced scattering coefficient μ�s = (1 − g)μs, i.e. the isotropic mean scattering-free path
length is larger than the anisotropic one.
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2.4 Diagnostic window
The tissue’s ability to absorb photons is a highly wavelength-dependent property. In the so
called diagnostic window around 650–1300 nm, most tissues are sufficiently weak absorbers
and light can penetrate deepest. The lower wavelength boundary of this wavelength range
is made up by oxygenated and de-oxygenated hemoglobin; the upper boundary is due to the
absorption of water.
3. Hardware
Since the early days of fDOT a number of different systems has been built, most of them
for research purposes, but meanwhile also commercial systems are available. Regarding
the details of implementation the systems differ considerably, for a good review see e.g.
Leblond et al. (2010). A basic distinction can be made concerning the operation mode in
terms of its temporal behavior. For some applications the reconstruction of intensity images
is sufficient and then the system can operate in continuous-wave (CW) mode, thus leading
to CW fluorescence tomography (CWFT). If, however, also the fluorescence lifetime ought
to be imaged, the response of the sample to either very short light pulses (usually shorter
than 100 ps) or harmonically modulated light with modulation frequencies between several
tens of MHz up to several GHz must be acquired. The respective technologies are termed
time domain fluorescence tomography (TDFT) or frequency domain fluorescence tomography (FDFT).
All three modes can also be used spectroscopically, which requires in addition a dispersive
element or a tunable filter at the detector side.
While the idea of TDFT is intuitively clear (direct measurement of the decay of the light
signal), FDFT is more indirect. It relies on the fact that the complete time domain information
can be recovered from quasi-stationary measurements with sinusoidally modulated light at
many modulation frequencies—thus sampling in Fourier space—and transforming back to
time domain by an inverse Fourier transform. However, the relevant bandwidth of the
time domain signals is up to several GHz (Gibson et al. (2005)) and frequency domain
systems allow sufficiently accurate operation only up to approximately 1 GHz (Chance et al.
(1998)). Thus, currently the equivalence cannot be exploited from the instrumentation point
of view. Typical modulation frequencies range from less than 100 MHz up to little more than
1 GHz (Durduran et al. (2010); Masciotti et al. (2009); Reynolds et al. (1997)). Assuming a
mono-exponential fluorescence decay the lifetime can be recovered from measurements at a
single frequency because a single exponential is Fourier transformed to a low pass of first
order and thus the knowledge of modulus and phase of the light signal is sufficient.
All systems realized so far share three main components: A light source, a sample holder and
a light detection system.
3.1 Light sources
The light source can have a wide spectral range (e.g. xenon arc lamps) in combination with
filters but narrowband sources like lasers and LEDs are increasingly popular due to their
versatility and the relative ease of producing either short pulses or properly modulated light.
As for standard tomography the light should be concentrated to different locations on the
sample surface, collimated beams are required, which favors the use of lasers. In any case the
spectrum of the light source should be matched to the absorption spectrum of the fluorophore,
but in the case of e.g. small Stokes shifts the excitation wavelength may be chosen somewhat
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below the absorption maximum in order to account for the limited steepness of excitation and
emission filters. In order to keep the hardware flexible, usually filter wheels with selectable
cutoff wavelengths are provided in case of wideband sources so as to adapt the system to
different fluorophores.
For CWFT practically any light source with appropriate power and spectral content can be
used. As FDFT typically requires modulation up to several 100 MHz, classical wideband
sources require a fast optical shutter (electro-optic or acousto-optic, see e.g. Lakowicz (2006))
but such technologies are increasingly replaced by laser diodes which can be easily modulated
up to 1 GHz in a useful power range (typically several tens of mW for in vivo applications).
Even wideband sources based on lasers (supercontinuum lasers) and tunable diode lasers
with external cavity are now available. The highest demands on the source are posed by
TDFT. Currently the short light pulses are typically generated by Ti:sapphire lasers but
also diode lasers are available which can deliver sufficiently short pulses (Lakowicz (2006)).
Ti:sapphire lasers provide the unique feature of being tunable, see e.g. Kumar et al. (2008),
where 150 fs-pulses are generated with a repetition rate of 80 MHz in a tuning range between
750 nm and 850 nm. In the same publication the spectral range could still be extended to
500 nm by the use of a super-continuum source based on a poly-crystalline fiber. The 80 MHz
repetition rate is widely used and has also been adopted for pulsed laser diodes, e.g. in
Soloviev et al. (2009).
3.2 Detectors
On the detector side also a large variety of different realizations can be found. Again a
major difference exists between CWFT, TDFT and FDFT. While there is no special restriction
in CW operation, TDFT requires very fast and precise time-gating of the detector or single
photon counting and precise time correlation between excitation and detection (so called time
correlated single photon counting, TCSPC).
The most sensitive and versatile devices are certainly photomultiplier tubes (PMTs),
photomultipliers with microchannel plates (MCP-PMTs) and image intensifiers based on
MCPs with either optical readout on a phosphor screen or electrical readout on a multi-anode
grid. Though comparatively expensive, all these variants of photomultiplier devices offer
wide dynamic range and frequently also single photon counting capabilities thus enabling
TDFT with TCSPC. The possible photon counting rate is primarily limited by the recovery
time after arrival of one pulse which may last several ns.
Avalanche photodiodes (APDs) are also useful detectors but have some limitations: The
aperture is small compared to that of PMTs, therefore yielding poorer light collection
properties. As APDs exhibit a long tail in their pulse response special active quenching of
the avalanche process is necessary in order to arrive at high counting rates. So called single
photon avalanche photodiodes (SPADs) are able to detect single photons and most recently
imaging arrays have been developed for time-resolved optical imaging with a time resolution
of about 100 ps (Li et al. (2010); Niclass et al. (2004); Pavia et al. (2011)).
A very appealing but somewhat exotic detector is the streak camera which, in principle, is
a PMT with an electron deflection stage and a phosphor screen. This allows to distribute
narrowly spaced subsequent pulses on the screen and thus provides an unrivaled high
effective counting rate. Such devices have been used in some instances for spectrally resolved
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photon counting and precise time correlation between excitation and detection (so called time
correlated single photon counting, TCSPC).
The most sensitive and versatile devices are certainly photomultiplier tubes (PMTs),
photomultipliers with microchannel plates (MCP-PMTs) and image intensifiers based on
MCPs with either optical readout on a phosphor screen or electrical readout on a multi-anode
grid. Though comparatively expensive, all these variants of photomultiplier devices offer
wide dynamic range and frequently also single photon counting capabilities thus enabling
TDFT with TCSPC. The possible photon counting rate is primarily limited by the recovery
time after arrival of one pulse which may last several ns.
Avalanche photodiodes (APDs) are also useful detectors but have some limitations: The
aperture is small compared to that of PMTs, therefore yielding poorer light collection
properties. As APDs exhibit a long tail in their pulse response special active quenching of
the avalanche process is necessary in order to arrive at high counting rates. So called single
photon avalanche photodiodes (SPADs) are able to detect single photons and most recently
imaging arrays have been developed for time-resolved optical imaging with a time resolution
of about 100 ps (Li et al. (2010); Niclass et al. (2004); Pavia et al. (2011)).
A very appealing but somewhat exotic detector is the streak camera which, in principle, is
a PMT with an electron deflection stage and a phosphor screen. This allows to distribute
narrowly spaced subsequent pulses on the screen and thus provides an unrivaled high
effective counting rate. Such devices have been used in some instances for spectrally resolved
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TCSPC in phase fluorometers but also to generate tomographic slice images in diffuse optical
tomography (Hebden et al. (1997)).
Several research groups (e.g. Nothdurft et al. (2009); Patwardhan & Culver (2008); Soloviev
et al. (2009); Zhang & Badea (2009)) are using ultrafast time-gated image intensified CCD
cameras (ICCD) which allow to sample photons within 300 ps at repetition rates up to
110 MHz. Such cameras can acquire a sequence of time-delayed frames from which the time
spread function can be approximately reconstructed. The time resolution is not as good
as with TCSPC but the data quality is sufficient for many applications. As reported by
Patwardhan & Culver (2008), the Fourier transform can then provide the equivalent frequency
domain data up to modulation frequencies of more than 1 GHz.
The detectors also differ in their spectral sensitivity. While most PMTs have a high quantum
efficiency at the shorter wavelengths of the visible spectrum (VIS) and even at UV they
perform comparatively poorly in the NIR range, especially above 850 nm. APDs based on
silicon technology are typically more sensitive in the NIR range and can be used up to
1100 nm.
Both TDFT and FDFT require special electronics after the detectors. FDFT is less demanding
and uses either heterodyne or homodyne demodulation of the radio-frequency (RF) signal
which can be achieved with a fast detector (e.g. PMT) and subsequent downmixing in
an RF stage (for basic concepts see Chance et al. (1998)). Alternatively, the downmixing
can also be accomplished directly in the detector by modulating its gain with the local
oscillator frequency. This approach is the method of choice when using image intensifiers
with phosphor screen because due to the afterglow they are too slow for transmitting
the high frequencies. Gain modulation, however, is easily possible at the photocathode,
though precautions have to be made with respect to modulation depth because many
photocathodes exhibit significant heating at high frequencies due to ohmic losses. Systems
operating with this concept usually apply homodyne demodulation (see e.g. Godavarty et al.
(2003); Reynolds et al. (1997); Sevick-Muraca & Rasmussen (2008)). Also slow detectors in
combination with an electro-optic or acousto-optic shutter can be thought of, but their poorer
modulation characteristics usually precludes the use of this technique.
The design of a TSCPC circuitry is non-trivial and comprises two input stages for the reference
light pulse and the sample pulse. The arrival times of the pulses are determined by a so-called
constant fraction discriminators (CFD) and then passed to a time to voltage converter which
is read out by a subsequent analog/digital converter. Only pulses within a certain peak
height window are counted, thus excluding pulses arising from thermal emission and cosmic
rays. TSCPC boards are commercially available and nowadays fairly compact, even for
multidimensional TSCPC with up to 16 channels at prices in the range of several tens of k$,
depending on the specification. The currently fastest commercial boards are specified with
useful count rates up to 20 MHz. As in single photon counting the excitation light levels are
chosen in a way that no more than 1 % of the excitation pulses lead to a detected photon,
the limit is currently posed by the laser pulse repetition rate which is typically 80 MHz. The
required count rate is then at least 800 000 per second, thus current TSCPC speed is more than
sufficient.
Especially older tomographic systems employ PMTs or PMTs with multiple anodes,
(e.g. Schmidt et al. (2000)) and fiber-optic coupling to the specimen. Also fiber-coupling
and cameras as detectors was reported (Godavarty et al. (2003)). However, the coupling is
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a significant source of systematic errors and thus the trend goes towards so-called free-space
systems without any physical contact to the sample (Schulz et al. (2004)). An early hybrid
solution was reported by Graves et al. (2003) where only the excitation side was fiber-coupled.
Free-space systems can still be based on single PMTs, but the light is then collected via
collimators or focusing lenses at a distance of several cm from the object surface (Kepshire
et al. (2009)). Most instruments, however, employ cameras together with an external or
built-in image intensifier. Due to the large number of pixels available on the camera chip,
the number of possible detectors is much higher than in PMT-based systems and hence the
information content in the data is enhanced.
3.3 Sample holder/manipulation stages
Steering of the light beam can be achieved in different ways. The most common ones are
galvanometer-controlled mirrors (galvo scanners, see e.g. Zhang et al. (2009)), movable laser
diode assemblies or bundles of optically multiplexed fibers (Davis et al. (2008)). While fibers
require a more or less direct coupling with the surface of the object/animal, galvo scanners
and movable laser diodes provide free-space scanning. Fiber-based systems usually do not
move the animal but many free-space systems employ rotational and/or linear stages to move
the animal so as to image it from different sides. A recently developed free-space system (Li
et al. (2009)) includes a conical mirror which partially encloses the sample and thus collects
significantly more light than a camera alone or systems with flat mirrors (see e.g. Chaudhari
et al. (2005) in a non-fluorescent application). The conical mirror makes a rotational stage
unnecessary because light can be collected from nearly all sides of the sample at once. The
excitation beam is coupled to the sample via a galvo scanner and auxiliary optics. In addition,
some systems include a laser-based surface scanner in order to provide the outer boundary
shape of the animal under investigation (e.g. Li et al. (2009); Zavattini et al. (2006)).
3.4 Multispectral imaging
Multi- and hyperspectral imaging can improve the depth resolution of fDOT systems due to
the strong wavelength dependence of absorption and scattering properties of tissue (Zavattini
et al. (2006)). Multispectral means the collection of several (e.g. up to 10) different wavelengths
while hyperspectral means the acquisition at many (e.g. 100) different wavelengths (Chaudhari
et al. (2005)). Also excitation spectroscopy, i.e. the use of many excitation wavelengths,
has been proposed and is even considered as preferable because the dependence of the
absorption coefficient on the wavelength is stronger at shorter wavelengths, i.e. on the
excitation side (Chaudhari et al. (2009)). While many fDOT systems developed so far operate
at more than one excitation wavelength, spectroscopic detection is still not very widespread
in tomographic systems. Recent examples were published by Zavattini et al. (2006), Li et al.
(2009) and Zacharakis et al. (2011). Culver et al. (2003) developed a hybrid CW/frequency
domain fDOT system for breast cancer imaging. This system needs a matching fluid and
coupling of 45 detector fibers to the volume under investigation. Excitation is achieved with
four selectable laser diodes with the wavelengths 650, 690, 786 and 830 nm, each of which can
be modulated sinusoidally at 70 MHz. Nine fibers carry light to a PMT based demodulation
stage while simultaneously a transmission image is captured with a CCD camera in CW
mode. Li et al. (2009) published a CW system with two excitation lasers at 650 and 785 nm.
Detection is possible at 9 spectral bands, which are spaced between 680 nm to 840 nm and
have a width of 20 nm, thus allowing for excitation spectroscopy. Zavattini et al. (2006)
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the strong wavelength dependence of absorption and scattering properties of tissue (Zavattini
et al. (2006)). Multispectral means the collection of several (e.g. up to 10) different wavelengths
while hyperspectral means the acquisition at many (e.g. 100) different wavelengths (Chaudhari
et al. (2005)). Also excitation spectroscopy, i.e. the use of many excitation wavelengths,
has been proposed and is even considered as preferable because the dependence of the
absorption coefficient on the wavelength is stronger at shorter wavelengths, i.e. on the
excitation side (Chaudhari et al. (2009)). While many fDOT systems developed so far operate
at more than one excitation wavelength, spectroscopic detection is still not very widespread
in tomographic systems. Recent examples were published by Zavattini et al. (2006), Li et al.
(2009) and Zacharakis et al. (2011). Culver et al. (2003) developed a hybrid CW/frequency
domain fDOT system for breast cancer imaging. This system needs a matching fluid and
coupling of 45 detector fibers to the volume under investigation. Excitation is achieved with
four selectable laser diodes with the wavelengths 650, 690, 786 and 830 nm, each of which can
be modulated sinusoidally at 70 MHz. Nine fibers carry light to a PMT based demodulation
stage while simultaneously a transmission image is captured with a CCD camera in CW
mode. Li et al. (2009) published a CW system with two excitation lasers at 650 and 785 nm.
Detection is possible at 9 spectral bands, which are spaced between 680 nm to 840 nm and
have a width of 20 nm, thus allowing for excitation spectroscopy. Zavattini et al. (2006)
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described a CW system with one moving excitation laser at 640 nm and a CCD camera based
spectrograph. The spectrograph consists of a grating and an entrance slit which allows
for a spectral resolution of 3 nm. The camera provides x-λ images, i.e. spatial information
along one dimension (x) and spectral information between 400 nm to 1000 nm. A translational
stage allows scanning along the second spatial dimension (y). Another recently published
CW system comprises a CCD camera and a Czerny-Turner spectrograph as detection unit
while exciting the animal at relatively short wavelengths, i.e. the 488 and 514 nm lines of
an Argon laser (Zacharakis et al. (2011)). Zhang & Badea (2011) presented an improvement
of the system developed by Zhang et al. (2009), thus not only allowing for time-gated time
domain acquisition but also for multi-wavelength-excitation by the introduction of a tunable
Ti:sapphire laser. The tuning range from 690 to 1040 nm provides the unique possibility of
time resolved excitation spectroscopy, though in Zhang & Badea (2011) still no use was made
of the tuning option.
3.5 Hybrid systems: Combining high resolution modalities with fDOT
fDOT images exhibit low resolution due to the massive scattering of photons in most
biological tissues. The integration of good regularizing priors based on anatomical data,
provided by e.g. CT or MRI, can lead to significant improvement of the image quality
(Panagiotou et al. (2009); Zhang et al. (2009)) and is mandatory when following recent trends.
This motivates the development of bimodal imaging systems which combine fDOT with
high-resolution methods.
A laboratory system was described in da Silva et al. (2007); Silva et al. (2009), comprising
an X-ray generator and a flat panel detector as well as a krypton laser (752 nm) and a CCD
camera. The sample is rotated and translated in order to form the projections. In addition,
the laser beam is steered via a movable mirror. A similar concept was used by Aguirre et al.
(2008), i.e. a single laser diode with 675 nm a CCD camera, an X-ray source and flat panel
detector as well as a galvo scanner. In contrast to (da Silva et al. (2007)) all components were
mounted on a rotating gantry with 360° angular steering range.
More recently the optical units were integrated into commercial micro-CT devices: Schulz
et al. (2010) reported a hybrid fDOT-CT system, which employs a free-space CW-fDOT
equipment on the rotating gantry of a micro-CT device. Two fiber-coupled laser diodes (670
and 750 nm) are used as sources, the animal is scanned with an x-y-stage. The detector is a
cooled CCD camera with a 50 mm macro-lens.
Yang et al. (2010) developed an fDOT-CT dual-modality system with a flat panel
detector-based micro-CT for small animals. The CW-fDOT part relies on a 748 nm diode laser
and a cooled CCD camera mounted orthogonally to the micro-CT and the projection images
were acquired without rotation of the sample. Similarly, Lin et al. (2010) employed an X-ray
CT system with 2 lasers at 785 and 803 nm as well as a cooled CCD camera on a rotating
gantry.
All these XCT-fDOT systems operate only in CW-mode.
Only a few attempts have been made so far to build hybrid devices employing MRI as the
high-resolution modality. Some pioneering work was already done in the field of DOT,
e.g. by Ntziachristos et al. (2000) involving a fiber-optic interface for the investigation of the
human breast inside of an MRI scanner. The optical instrumentation comprised a PMT-based
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single-photon counting system. Masciotti et al. (2009) published an 9.4 T MRI small animal
scanner with an animal coil (38 mm diameter) and a fiber-optic interface with 13 source fibers
and 27 detection fibers. The system comprises two lasers at 757 and 828 nm, which can be
modulated up to about 1 GHz. Homodyne demodulation is performed with a modulated
ICCD. Davis et al. (2008) designed a spectroscopic CW fDOT unit, which is coupled to the
animal bed inside a 3 T-MRI body scanner via fibers (8 detectors, 16 sources). The excitation
laser operates at 690 nm. The animal bed is placed inside a specially designed rodent coil for
MR-acquisition.
3.6 Advanced hardware concepts
As scanning time is an important issue in fDOT, reducing the required time for data
acquisition is a challenging task. Wang et al. (2010) applied spatial encoding of the excitation
light in order to reduce the time needed to create different excitation patterns. Several
laser diodes are switched on in a particular pattern and moved in axial direction during the
scanning process.
A completely different approach avoids source multiplexing completely, thus reducing
hardware complexity significantly. In contrast to usual spatial encoding by various
combinations of source/detector locations, only a single macro-illumination light source with
a broad spectrum and a tunable excitation filter is used. The required spatial encoding
is achieved by varying the excitation wavelength and exploiting the frequency-dependent
sensitivity distribution inside of the target for the image reconstruction. A prototype (Klose
& Pöschinger (2011)) consists of a commercial 2D-small animal imager with a white light
source, a tunable filter and a cooled CCD camera. The excitation wavelength was varied
in nine steps from 590 to 660 nm with a bandwidth of 10 nm per step. Fluorescence light
was collected at 700 nm. The price paid for the simpler hardware setup is a more complex
reconstruction algorithm which must contain a valid model of frequency-dependent light
propagation in moderately absorbing tissues, which requires extensions of the popular
diffusion approximation of the radiative transfer equation.
3.7 Comparison of technologies
It is intuitively clear that CW systems do not allow fluorescence lifetime imaging (FLIM) but
besides it is also not possible to separately identify the absorption and scattering coefficients
of the medium under investigation (Arridge & Lionheart (1998)). More sophisticated
investigations thus require either the use of FDFT or TDFT. As the instrumentation is
significantly less expensive and demanding for FDFT it would be desirable to contrast the
two approaches in the context of information content and data quality. As mentioned, the
information content is theoretically equal for both modalities when the same sources and
detectors are applied and when the number of frequencies in FD corresponds to the number of
time steps in TD. However, in time domain spectroscopy there are two apparent advantages
from the instrumentation point of view. These are in particular: (i) Dark noise and PMT gain
noise can be eliminated very effectively which is not the case for FDFT. (ii) Artifacts arising
from e.g. reflections can be frequently sorted out prior to any subsequent data processing just
by time-gating.
A rigorous comparison of the methods is difficult because it should include adequate
noise models and cutting-edge reconstruction techniques, which exploit all the information
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described a CW system with one moving excitation laser at 640 nm and a CCD camera based
spectrograph. The spectrograph consists of a grating and an entrance slit which allows
for a spectral resolution of 3 nm. The camera provides x-λ images, i.e. spatial information
along one dimension (x) and spectral information between 400 nm to 1000 nm. A translational
stage allows scanning along the second spatial dimension (y). Another recently published
CW system comprises a CCD camera and a Czerny-Turner spectrograph as detection unit
while exciting the animal at relatively short wavelengths, i.e. the 488 and 514 nm lines of
an Argon laser (Zacharakis et al. (2011)). Zhang & Badea (2011) presented an improvement
of the system developed by Zhang et al. (2009), thus not only allowing for time-gated time
domain acquisition but also for multi-wavelength-excitation by the introduction of a tunable
Ti:sapphire laser. The tuning range from 690 to 1040 nm provides the unique possibility of
time resolved excitation spectroscopy, though in Zhang & Badea (2011) still no use was made
of the tuning option.
3.5 Hybrid systems: Combining high resolution modalities with fDOT
fDOT images exhibit low resolution due to the massive scattering of photons in most
biological tissues. The integration of good regularizing priors based on anatomical data,
provided by e.g. CT or MRI, can lead to significant improvement of the image quality
(Panagiotou et al. (2009); Zhang et al. (2009)) and is mandatory when following recent trends.
This motivates the development of bimodal imaging systems which combine fDOT with
high-resolution methods.
A laboratory system was described in da Silva et al. (2007); Silva et al. (2009), comprising
an X-ray generator and a flat panel detector as well as a krypton laser (752 nm) and a CCD
camera. The sample is rotated and translated in order to form the projections. In addition,
the laser beam is steered via a movable mirror. A similar concept was used by Aguirre et al.
(2008), i.e. a single laser diode with 675 nm a CCD camera, an X-ray source and flat panel
detector as well as a galvo scanner. In contrast to (da Silva et al. (2007)) all components were
mounted on a rotating gantry with 360° angular steering range.
More recently the optical units were integrated into commercial micro-CT devices: Schulz
et al. (2010) reported a hybrid fDOT-CT system, which employs a free-space CW-fDOT
equipment on the rotating gantry of a micro-CT device. Two fiber-coupled laser diodes (670
and 750 nm) are used as sources, the animal is scanned with an x-y-stage. The detector is a
cooled CCD camera with a 50 mm macro-lens.
Yang et al. (2010) developed an fDOT-CT dual-modality system with a flat panel
detector-based micro-CT for small animals. The CW-fDOT part relies on a 748 nm diode laser
and a cooled CCD camera mounted orthogonally to the micro-CT and the projection images
were acquired without rotation of the sample. Similarly, Lin et al. (2010) employed an X-ray
CT system with 2 lasers at 785 and 803 nm as well as a cooled CCD camera on a rotating
gantry.
All these XCT-fDOT systems operate only in CW-mode.
Only a few attempts have been made so far to build hybrid devices employing MRI as the
high-resolution modality. Some pioneering work was already done in the field of DOT,
e.g. by Ntziachristos et al. (2000) involving a fiber-optic interface for the investigation of the
human breast inside of an MRI scanner. The optical instrumentation comprised a PMT-based
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single-photon counting system. Masciotti et al. (2009) published an 9.4 T MRI small animal
scanner with an animal coil (38 mm diameter) and a fiber-optic interface with 13 source fibers
and 27 detection fibers. The system comprises two lasers at 757 and 828 nm, which can be
modulated up to about 1 GHz. Homodyne demodulation is performed with a modulated
ICCD. Davis et al. (2008) designed a spectroscopic CW fDOT unit, which is coupled to the
animal bed inside a 3 T-MRI body scanner via fibers (8 detectors, 16 sources). The excitation
laser operates at 690 nm. The animal bed is placed inside a specially designed rodent coil for
MR-acquisition.
3.6 Advanced hardware concepts
As scanning time is an important issue in fDOT, reducing the required time for data
acquisition is a challenging task. Wang et al. (2010) applied spatial encoding of the excitation
light in order to reduce the time needed to create different excitation patterns. Several
laser diodes are switched on in a particular pattern and moved in axial direction during the
scanning process.
A completely different approach avoids source multiplexing completely, thus reducing
hardware complexity significantly. In contrast to usual spatial encoding by various
combinations of source/detector locations, only a single macro-illumination light source with
a broad spectrum and a tunable excitation filter is used. The required spatial encoding
is achieved by varying the excitation wavelength and exploiting the frequency-dependent
sensitivity distribution inside of the target for the image reconstruction. A prototype (Klose
& Pöschinger (2011)) consists of a commercial 2D-small animal imager with a white light
source, a tunable filter and a cooled CCD camera. The excitation wavelength was varied
in nine steps from 590 to 660 nm with a bandwidth of 10 nm per step. Fluorescence light
was collected at 700 nm. The price paid for the simpler hardware setup is a more complex
reconstruction algorithm which must contain a valid model of frequency-dependent light
propagation in moderately absorbing tissues, which requires extensions of the popular
diffusion approximation of the radiative transfer equation.
3.7 Comparison of technologies
It is intuitively clear that CW systems do not allow fluorescence lifetime imaging (FLIM) but
besides it is also not possible to separately identify the absorption and scattering coefficients
of the medium under investigation (Arridge & Lionheart (1998)). More sophisticated
investigations thus require either the use of FDFT or TDFT. As the instrumentation is
significantly less expensive and demanding for FDFT it would be desirable to contrast the
two approaches in the context of information content and data quality. As mentioned, the
information content is theoretically equal for both modalities when the same sources and
detectors are applied and when the number of frequencies in FD corresponds to the number of
time steps in TD. However, in time domain spectroscopy there are two apparent advantages
from the instrumentation point of view. These are in particular: (i) Dark noise and PMT gain
noise can be eliminated very effectively which is not the case for FDFT. (ii) Artifacts arising
from e.g. reflections can be frequently sorted out prior to any subsequent data processing just
by time-gating.
A rigorous comparison of the methods is difficult because it should include adequate
noise models and cutting-edge reconstruction techniques, which exploit all the information
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available in the data for both modalities. Moreover, parameters like the effective aperture
of the detectors, power of the light sources and effective measurement time must be taken
into account for a fair comparison. One attempt was made for diffuse optical tomography
(DOT) by Nissilä et al. (2006) where the authors compared the time domain system of the
University College London (UCL) (Schmidt et al. (2000)) and a frequency domain system
developed at Helsinki University of Technology (HUT) (Nissilä et al. (2005)). Both systems
are fiber-coupled but differ in the number of source and detector positions. Both systems
operate in the NIR range at very similar wavelengths, i.e. 780 and 815 nm (UCL) and 760
and 830 nm (HUT), respectively. As the HUT system operates only at one single modulation
frequency of 100 MHz a comparison can only be made in the context of time harmonic image
reconstruction, i.e. in terms of magnitude and phase. Considering this limitation the noise
data of both systems are similar, yielding an amplitude noise of 1.7 % and 0.5 % and a phase
noise of 0.2 and 0.5°, respectively at a detected light power of 1 pW. However, the laser
power was different (8 mW for HUT and 40 mW for UCL) and the acquisition speed was
somewhat shorter in the HUT system. The authors of the article also list some data of
other frequency domain systems and show that the HUT and UCL systems, at that time,
had comparatively good noise performance and could thus serve as reference systems. The
analysis also comprises image reconstruction results from data generated with both systems,
but only based on a frequency domain approach. Therefore, this comparison cannot be
generalized because it neither takes into account the full information content of time domain
data nor the specific advantages of optimized time domain reconstruction algorithms. A
more rigorous and comprehensive comparison including realistic noise models and adequate
solvers for all modalities is still lacking.
4. Mathematical description of light transport
Before we can discuss reconstruction methods to find the fluorophore distribution inside
an object, it is necessary to describe mathematical methods to model how light spreads
inside an object. Nowadays, three models are commonly used which are—with decreasing
accuracy—the Monte Carlo method, the radiative transport equation and its diffusion
approximation.
4.1 Random-walk Monte Carlo method
Random-walk Monte Carlo (MC) methods for solving the forward model have a rather long
tradition in optics and have been implemented in different flavors. In the most simple form,
the path of a single photon throughout the tissue is simulated in every run. As most of the
physical processes like the change of the polarization state or the absorption of photons by
electron excitation are stochastic in their nature, MC methods are well suited to model these
effects. Furthermore, it is comparatively easy to incorporate tissue inhomogeneities, reflection
and refraction at internal boundaries due to variations in the index of refraction, anisotropic
scattering phase functions and so on.
The drawback of MC methods is their slow convergence which is proportional to the square
root of the number of runs. In order to achieve reliable results for three dimensional objects, it
is often necessary to simulate the propagation of millions of photons. The convergence is also
poor when a certain physical process has a very low probability, say it occurs only once in one
thousand trials.
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A series of strategies for speeding up the simulations has been developed, for example,
simulating photon packets rather than individual particles (Wang et al. (1995)) and running
photons in parallel using modern graphics hardware (Fang & Boas (2009)). Still, the
comparatively high computational effort limits the applicability of Monte Carlo methods for
reconstructing fluorophore properties.
4.2 Transport equation
A deterministic solution for light propagation can be found in Boltzmann’s transport equation
which is also frequently called the radiative transport equation (RTE). Rather than modeling each
particle independently, which can be done with Monte Carlo methods, the RTE deals with an
ensemble of photons in an infinitesimal volume. To be more precise, the RTE is a balance
equation for the number of photons per unit volume (i.e. the photon density) Φ(�x, ŝ, t) at a
spatial location �x traveling into an infinitesimal solid angle around a direction ŝ at a time





+ ŝ · ∇Φ(�x, ŝ, t) + (μa(�x) + μs(�x))Φ(�x, ŝ, t)
= qint(�x, ŝ, t) + μs(�x)
∫
S2
Θ(ŝ�, ŝ)Φ(�x, ŝ�, t) dŝ� in Ω, (1)
together with the boundary condition
Φ(�x, ŝ, t) = qbc(�x, ŝ, t) ∀ŝ : ŝ · n̂ < 0 on Γ, (2)
where ν is the speed of light in the tissue, μa and μs are the absorption and scattering
coefficients, respectively, and Θ(ŝ�, ŝ) is the scattering phase function which states the
probability that a photon traveling in direction ŝ� will be deflected into direction ŝ. In this
equation, S2 is the surface of the unit sphere and thus the integral is taken over all possible
directions. The term qint models sources inside the domain.
The left-hand side of equation (1) models the decrease in photon density due to movement
and absorption, while the right-hand side incorporates the photon gain caused by scattering
and an internal source.
The boundary condition imposes restrictions on the solution only for inward-pointing
directions, i.e. for all ŝ with ŝ · n̂ < 0 where n̂ is the outward-pointing unit normal of the
domain. It states that no light can enter the domain from the outside except at locations where
a boundary source is present, i.e. where qbc(�x, ŝ, t) �= 0.
A limitation of the transport equation is that it cannot handle wave effects. As a consequence,
the wavelength of the light must be much smaller than the dimensions of the structures in the
domain (Gibson et al. (2005)). Furthermore, varying indices of refraction are not included in
equation (1) but can be incorporated.
Despite these insufficiencies, the transport equation would be well suited for biomedical
optics. It is able to handle many different types of tissue whether they are highly scattering
like muscle, as absorbing as the liver or as transparent as liquor, for example. Furthermore,
the boundary equation is physically meaningful.
The reason why the RTE is frequently avoided is the high computational effort required for
calculating an accurate solution. The photon density Φ(�x, ŝ, t) has to be discretised in the
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available in the data for both modalities. Moreover, parameters like the effective aperture
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(DOT) by Nissilä et al. (2006) where the authors compared the time domain system of the
University College London (UCL) (Schmidt et al. (2000)) and a frequency domain system
developed at Helsinki University of Technology (HUT) (Nissilä et al. (2005)). Both systems
are fiber-coupled but differ in the number of source and detector positions. Both systems
operate in the NIR range at very similar wavelengths, i.e. 780 and 815 nm (UCL) and 760
and 830 nm (HUT), respectively. As the HUT system operates only at one single modulation
frequency of 100 MHz a comparison can only be made in the context of time harmonic image
reconstruction, i.e. in terms of magnitude and phase. Considering this limitation the noise
data of both systems are similar, yielding an amplitude noise of 1.7 % and 0.5 % and a phase
noise of 0.2 and 0.5°, respectively at a detected light power of 1 pW. However, the laser
power was different (8 mW for HUT and 40 mW for UCL) and the acquisition speed was
somewhat shorter in the HUT system. The authors of the article also list some data of
other frequency domain systems and show that the HUT and UCL systems, at that time,
had comparatively good noise performance and could thus serve as reference systems. The
analysis also comprises image reconstruction results from data generated with both systems,
but only based on a frequency domain approach. Therefore, this comparison cannot be
generalized because it neither takes into account the full information content of time domain
data nor the specific advantages of optimized time domain reconstruction algorithms. A
more rigorous and comprehensive comparison including realistic noise models and adequate
solvers for all modalities is still lacking.
4. Mathematical description of light transport
Before we can discuss reconstruction methods to find the fluorophore distribution inside
an object, it is necessary to describe mathematical methods to model how light spreads
inside an object. Nowadays, three models are commonly used which are—with decreasing
accuracy—the Monte Carlo method, the radiative transport equation and its diffusion
approximation.
4.1 Random-walk Monte Carlo method
Random-walk Monte Carlo (MC) methods for solving the forward model have a rather long
tradition in optics and have been implemented in different flavors. In the most simple form,
the path of a single photon throughout the tissue is simulated in every run. As most of the
physical processes like the change of the polarization state or the absorption of photons by
electron excitation are stochastic in their nature, MC methods are well suited to model these
effects. Furthermore, it is comparatively easy to incorporate tissue inhomogeneities, reflection
and refraction at internal boundaries due to variations in the index of refraction, anisotropic
scattering phase functions and so on.
The drawback of MC methods is their slow convergence which is proportional to the square
root of the number of runs. In order to achieve reliable results for three dimensional objects, it
is often necessary to simulate the propagation of millions of photons. The convergence is also
poor when a certain physical process has a very low probability, say it occurs only once in one
thousand trials.
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A series of strategies for speeding up the simulations has been developed, for example,
simulating photon packets rather than individual particles (Wang et al. (1995)) and running
photons in parallel using modern graphics hardware (Fang & Boas (2009)). Still, the
comparatively high computational effort limits the applicability of Monte Carlo methods for
reconstructing fluorophore properties.
4.2 Transport equation
A deterministic solution for light propagation can be found in Boltzmann’s transport equation
which is also frequently called the radiative transport equation (RTE). Rather than modeling each
particle independently, which can be done with Monte Carlo methods, the RTE deals with an
ensemble of photons in an infinitesimal volume. To be more precise, the RTE is a balance
equation for the number of photons per unit volume (i.e. the photon density) Φ(�x, ŝ, t) at a
spatial location �x traveling into an infinitesimal solid angle around a direction ŝ at a time
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together with the boundary condition
Φ(�x, ŝ, t) = qbc(�x, ŝ, t) ∀ŝ : ŝ · n̂ < 0 on Γ, (2)
where ν is the speed of light in the tissue, μa and μs are the absorption and scattering
coefficients, respectively, and Θ(ŝ�, ŝ) is the scattering phase function which states the
probability that a photon traveling in direction ŝ� will be deflected into direction ŝ. In this
equation, S2 is the surface of the unit sphere and thus the integral is taken over all possible
directions. The term qint models sources inside the domain.
The left-hand side of equation (1) models the decrease in photon density due to movement
and absorption, while the right-hand side incorporates the photon gain caused by scattering
and an internal source.
The boundary condition imposes restrictions on the solution only for inward-pointing
directions, i.e. for all ŝ with ŝ · n̂ < 0 where n̂ is the outward-pointing unit normal of the
domain. It states that no light can enter the domain from the outside except at locations where
a boundary source is present, i.e. where qbc(�x, ŝ, t) �= 0.
A limitation of the transport equation is that it cannot handle wave effects. As a consequence,
the wavelength of the light must be much smaller than the dimensions of the structures in the
domain (Gibson et al. (2005)). Furthermore, varying indices of refraction are not included in
equation (1) but can be incorporated.
Despite these insufficiencies, the transport equation would be well suited for biomedical
optics. It is able to handle many different types of tissue whether they are highly scattering
like muscle, as absorbing as the liver or as transparent as liquor, for example. Furthermore,
the boundary equation is physically meaningful.
The reason why the RTE is frequently avoided is the high computational effort required for
calculating an accurate solution. The photon density Φ(�x, ŝ, t) has to be discretised in the
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spatial and angular domain which requires five variables for a 3D problem (three coordinates
and two angles). If too little angular directions are chosen for the discretisation, the resultant
photon field favors propagation along these directions resulting in star-like patterns, where
one would expect a radial symmetric distribution instead. To illustrate the influence of the
angular discretisation on the computational effort, imagine a rather coarse discretisation of
only 32 divisions for both the azimuth and the inclination. This results in 1024 angular
directions, which have to be multiplied by the number of mesh points used for the spatial
discretisation.
4.3 Diffusion approximation
Due to the shortcomings of the previously mentioned models, the most common description
for photon migration is the diffusion approximation. This is a reduced form of the RTE
which first expands the direction-dependent quantities Φ, Θ, qint and qbc into spherical
harmonics. Then, all spherical harmonics except the first one are neglected, i.e. only the
isotropic propagation of photons is considered. Some additional constraints are imposed on
the photon flux and the scattering phase function Θ. A thorough derivation is found in the
review article by Arridge (1999). The model is valid in the regime where photon propagation
is diffuse, which is the case in tissues which are much more scattering than absorbing, at a
sufficient distance from the source. Problems arise if the tissue is either strongly absorbing
such as in the liver or nearly transparent as in liquor. Furthermore, the model is inaccurate
near the light source, where the photon propagation is not yet diffuse due to the small number
of scattering events, and at places where the optical properties jump which might be the case
at the boundary of organs, for example (Gibson et al. (2005)).
In its frequency domain form, the diffusion approximation is a partial differential equation
(PDE) which reads






ϕ(x) = qint(x), in Ω, (3)





on Γ \ Γbc, (4)
where ϕ is the fluence, κ = (3 (μ�s + μa))
−1 the diffusion coefficient of the tissue, μ�s the
reduced scattering coefficient and μa the absorption coefficient. ω is the modulation frequency
of the excitation light source with the special case of ω = 0 s−1 for CW excitation with a
constant intensity. The injected light can be modeled by an internal source qint ,which is
frequently used for collimated beams, or a boundary source qbc, which is suitable for spatially
extended sources on a part Γbc of the boundary Γ. � is a reflection coefficient to incorporate the
reflections at the boundary Γ of the domain Ω due to the differences in the indices of reflection.
4.4 Diffusion approximation for fDOT
For fDOT, the diffusion approximation has to be extended as now two different photon
distributions with different wavelengths have to be simulated: (i) excitation light due to the
illumination of the sample and (ii) emission light which has been generated by a fluorophore
inside the sample by conversion from the excitation wavelength. As the optical parameters
of tissue vary with the chosen wavelength, we distinguish them by sub-scripts x and m for
excitation and emission, respectively. Furthermore, these coefficients have to depend on the
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Fig. 3. Simulation of the fluences ϕx(x) (top row) and ϕm(x) (bottom row) due to three
different boundary sources positioned at angles of 11.25° (left), 56.25° (middle) and 146.25°
(right). The color encodes the logarithm of the amplitude of the photon densities.
fluorophore concentration c(x) which one seeks to reconstruct from measurements in a known
manner. If the concentration is fairly small, it can be seen as an additional absorber and the
effective absorption coefficients can be written in the form








where μa,0,i, i ∈ {x, m}, is the background absorption of the tissue in the absence of
fluorescent agent and �x, �m are the molar extinction coefficients which relate the fluorophore’s
concentration to its absorption coefficients. With these definitions the diffusion approximation
for fDOT can be written as a two-state model (Sevick-Muraca et al. (2003)):
−∇ · (κx(x)∇ϕx(x)) + μx(x)ϕx(x) = qint(x), in Ω, (7)
−∇ · (κm(x)∇ϕm(x)) + μm(x)ϕm(x) = η1 + iωτ �x c(x)ϕx(x), in Ω, (8)
with the boundary conditions





on Γ \ Γbc, (9)
�m ϕm(x) + κm(x)n̂ · ∇ϕm(x) = 0, on Γ. (10)
The conversion efficiency of the fluorophore is denoted by the constant η and its fluorescent
lifetime by τ. A typical simulation result is depicted in Figure 3.
The measurement data is gathered by illuminating the sample with differently positioned
light sources and recording the photons leaving the boundary. The simplest type of
measurement is to record the photons leaving the boundary at a certain location, i.e. to
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spatial and angular domain which requires five variables for a 3D problem (three coordinates
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Fig. 3. Simulation of the fluences ϕx(x) (top row) and ϕm(x) (bottom row) due to three
different boundary sources positioned at angles of 11.25° (left), 56.25° (middle) and 146.25°
(right). The color encodes the logarithm of the amplitude of the photon densities.
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The detector function χ can also incorporate linear transfer characteristics of the system
such as a weighting due to an oblique viewing angle when using a camera. Other types of
measurements based on the logarithm of the intensity, for example, have been reported in
e.g. Arridge (1995); Arridge & Schweiger (1993); Sevick & Chance (1991).
As for a tomographic measurement Ns light sources and Nd detectors are used, the data can
be written in a matrix M of size Nd × Ns. The emission field ϕm depends on the fluorophore
concentration c, which makes the measurement matrix dependent on c and we write M(c) to
emphasize this fact.
5. Image reconstruction
The aim of fluorescence tomography is to reconstruct the fluorophore concentration and/or
the fluorophore’s lifetime inside a 3D object from intensity measurements performed on
the object’s boundary. In the previous section, methods have been described to simulate
the photon propagation inside an object, where the tissue and fluorophore properties
are known exactly. This is called the direct or forward problem. The estimation of
the fluorophore distribution from measurement data is known as the inverse problem of
fluorescence tomography. An overview about the whole reconstruction process is displayed
in Figure 4. In the following, more details will be provided for solving this problem. For the
sake of simplicity, the focus is put on FDFT-systems, whose mathematics is easier to grasp.
Furthermore, one can Fourier-transform time domain data and apply FDFT-algorithms.
Last but not least, CW-reconstructions are a special case of FDFT-reconstructions with a
modulation frequency of ω = 0 s−1.
Mathematically the problem can be formulated as follows: Let Mδ denote a light
measurement taken at the object’s surface, which is usually perturbed by noise bounded
by δ coming from different origins, e.g. detector noise, discretisation errors and modeling
errors. Then, one seeks to find a fluorophore concentration c such that the data mismatch∥∥∥M(c)−Mδ
∥∥∥2 is minimized.
5.1 Ill-posedness of the inverse problem
Fiber-coupled fDOT systems usually result in a limited amount of data. Configurations
with approximately 16 sources and 16 detectors are common which gives a set of 256
measurements. The inverse problem is under-determined in this case: there is much less
measurement data than the number of voxels (typically in the order of ten-thousands) in
which we would like to compute the fluorophore concentration.
The situation is different for the free-space arrangement. The camera can take images of the
whole surface (which depends quadratically on the object’s dimension d). If also the excitation
beam can be positioned everywhere at the surface, one would get measurement combinations
in the order of d2 × d2 = d4 but needs to reconstruct only d3 voxels. In this case more
measurement data is available than there are unknown parameters and the problem is said
to be over-determined.
However, we cannot expect to reconstruct high-resolution images similar to CT from
fluorescence tomography data. In CT the X-ray beams pass the object under investigation in
nearly straight lines as illustrated in Figure 5(a). If the X-ray hits an absorbing object (the small
30 Molecular Imaging 3D Optical Imaging of Fluorescent Agents in Biological Tissues 15
Fig. 4. Typical image reconstruction process: With the help of appropriately discretized
mathematical models the simulated measurement data M(c) is computed. The simulated
measurements have to be close to the true data Mδ gathered from experiments. A
regularization term R(c) has to be created from a-priori knowledge, which is needed to
stabilize the algorithm. Finally, the image is reconstructed by minimizing the sum of the data
mismatch and the penalty term.
ball), it is partly absorbed which casts a “shadow” in the recorded intensity projection I. In
fDOT the photons are massively scattered and spread throughout the whole object. Figure 5(b)
shows the distribution of the light emitted by a fluorescent ball when a small part of the
surface at the top is illuminated with light. A camera looking at the object’s bottom records a
much more diffuse light intensity pattern compared to the CT detector. The interface between
the fluorescent object and the background cannot be determined from these measurements
directly.
An important quantity for the solution of the inverse problem is the so-called sensitivity. It
measures the influence of a change in an image voxel onto a detector datum. This concept
is illustrated for CT and fDOT in Figure 6: The sensitive area of an X-ray beam which is
generated by a source S and detected by D consists of all voxels along the line which the
X-ray passes. Analogously, an fDOT measurement is sensitive in that region which photons
generated by the source S and recorded by the detector D traverse. Due to the massive
scattering, the resulting fDOT sensitivity profile is much broader than the one from CT. In
other words, a single fDOT measurement incorporates information from nearly the whole
sample volume, while a CT datum only measures along a line.
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measures the influence of a change in an image voxel onto a detector datum. This concept
is illustrated for CT and fDOT in Figure 6: The sensitive area of an X-ray beam which is
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Fig. 5. Comparison between CT (a) and fDOT (b). In a CT system the X-ray beams pass the
sample in nearly straight lines. The intensity I decreases if an absorbing object is
encountered resulting in a “shadow” projection. In fDOT the emission light (shown in color)
spreads throughout the sample although the surface is excited at a very small patch only. The
intensity profile which a camera would record from the bottom is much more diffuse than
the CT projection.
Fig. 6. Sensitivity profile for a single CT- and fDOT-measurement. (a) The voxels to which a
CT measurement is sensitive lie along the line which the X-ray beam passes. (b) The photons
in fDOT have a much larger coverage than an X-ray beam which leads to a broadening of the
sensitivity profile.
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An elegant way to compute the sensitivity mathematically is through the use of adjoint fields.
These fields are generated by formally treating the detectors as sources which generate an
adjoint photon distribution. The adjoint field is a spatially resolved measure for the detection
efficiency of a sensor. The sensitivity at a certain position in the sample is then the product of
the forward field (the photon distribution due to the light source) times the adjoint field (the
distribution of the photon collection efficiency). It is highest at locations which are reached by
many photons from the source and from which many photons are collected by the detector at
the same time.
The adjoint system to the forward system (7)–(10) is another system of PDEs which reads
−∇ · (κm(x)∇ψm(x)) + μm(x)ψm(x) = 0 in Ω (12)
−∇ · (κx(x)∇ψx(x)) + μx(x)ψx =
η
1 − iωτ �x c(x)ψm(x) in Ω (13)
�mψm(x) + κm(x)n̂ · ∇ψm(x) = �mχ(x) on Γ (14)
�xψx(x) + κx(x)n̂ · ∇ψx(x) = 0 on Γ. (15)
























h ϕx(qj)ψm(χi) dx. (16)
In this equation, we used the notation ϕ(qj) and ϕ(χi) to emphasize the dependencies of the
forward field on the excitation source qj and the adjoint field on the detector χi, respectively.
When solving the inverse problem, one seeks to reconstruct the parameters in the sensitive
area from the measurement data. Looking at Figure 6, it is intuitively clear that this task is
much easier for CT, where one can simply distribute a measurement datum back along the
line which the X-ray beam passed, than for fDOT, where every recording has to be distributed
in the whole sample. This lack of information is valid for both fiber-based and free-space
arrangements. The reconstruction problem is said to be ill-posed.
5.2 The role of prior information
To deal with the ill-posedness of the inverse problem, additional knowledge has to be
incorporated into the reconstruction algorithm which is known as regularization. This
means that unphysical or undesired images are penalized while images featuring certain
characteristics are favored. Using regularization terms of Tikhonov-type, one can state the
image reconstruction as an optimization problem, where one seeks to minimize the functional
Lα(c) := 12
∥∥∥M(c)−Mδ
∥∥∥2 + αR(c). (17)
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In this equation, R(c) is a penalty for unwanted fluorophore distributions. With the parameter
α it is possible to adjust between sticking to the data (α = 0, which means no regularization
at all) and reconstructing a concentration according to the prior information (α → ∞, which
means that the simulated and the measured data can diverge arbitrarily). As the problem (17)
is non-linear, one can choose e.g. Newton methods to solve it. If the Hessian (i.e. the second















where the parameter α can vary in every iteration. This is known as the iteratively regularized
Gauß-Newton algorithm and is treated in detail elsewhere (Bakushinskiı̆ (1992); Blaschke et al.
(1997); Engl et al. (1996)). In this context, M�∗ means the adjoint of the sensitivity operator
M� and its exact meaning depends on the chosen discretisation. R�(ck) and R̃��(ck) are the
first and approximated second derivatives of the regularization term evaluated for the current
concentration ck. Besides the Gauß-Newton method, other algorithms are available such
as the Levenberg-Marquardt method (Marquardt (1963)), the Newton-Landweber method
(Kaltenbacher (1997)) and the truncated Newton-CG method (Hanke (1997)). Applications
to the field of optical tomography are e.g. Egger & Schlottbom (2011); Jiang (1998); Joshi
et al. (2004); Roy & Sevick-Muraca (1999); Schweiger et al. (2005). A good overview of
reconstruction methods applied to fluorescence tomography is given by Sevick-Muraca et al.
(2003).
Unfortunately, there is no one-size-fits-all-type regularization method. Instead, R(c) has to
be chosen with respect to the application and the expected outcome. In the following, typical
regularization methods are discussed.
5.2.1 Quadratic regularization terms
The probably most often used regularization term is the L2-norm of the concentration,
which is a penalty for large concentrations such as outliers. Thus, smaller values for
the concentration in the whole domain are preferred. The dominance of this particular
regularization term in many engineering applications is most likely not not due to its physical
meaning but rather due to its simplicity and speed, both in implementation and evaluation.
If we denote the identity operator with I, the regularization term and its derivatives can be
written as
R(c) = 12�c�2, R�(c) = c, R��(c) = I. (19)
If one can provide an a-priori guess c0 for the fluorophore distribution, it is advantageous to
penalize the difference between the prior guess and the current concentration, i.e. to use a
regularization term of the form
R(c) = 12�c − c0�2. (20)
Another quadratic regularization term is based on the H1-semi-norm instead of the L2-norm.
This semi-norm does not penalize higher concentration values but it penalizes variations
in the reconstructed fluorophore distribution and thus enforces the resultant images to be
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smooth. From a physical point of view, this is most often more meaningful than to suppress
outliers. The regularization functional is defined as
R(c) = 12�∇c�2, R�(c)h = �∇c,∇h� ,
〈R��(c)h1, h2
〉
= �∇h1,∇h2� . (21)
5.2.2 Total-variation regularization
Although the H1-semi-norm is physically meaningful, it faces the problem that large gradients
of the fluorophore concentration are still penalized which prevents steep transitions (jumps)
from an object to the background. However, if one knows a-priori that the fluorophore is
well localized (e.g. inside a localized tumor) and piecewise constant, the total-variation (TV)
regularization might be an option. Although this method also measures the gradient of the





Using the L1-norm, the penalty grows linearly with the gradient (instead of quadratically), i.e.
larger gradients are allowed to some extent.
Unfortunately, the TV functional is not differentiable at points where ∇c(�x) = 0. A possible

















β + |∇c(�x)|2 d�x (23)
where a scalar β > 0 has been introduced to smooth the square-root around the origin.
Note also that R̃�� is just an approximation of the true Hessian, because the derivative of
the denominator has been neglected.
5.2.3 Level-set method
Another possibility of regularization is through the use of level-set methods, which have
been used for diffuse optical tomography (Alvarez et al. (2009); Schweiger et al. (2008)). The
principle is that if the background fluorescence and the fluorescence inside and object are
constant, the reconstruction problem reduces to finding the interface which separates the
inclusions from the background. This interface can be described using level-set methods:
The level-set function φ(�x),�x ∈ Ω is negative inside the inclusion and positive outside. Thus,
the separating interface consists of all points where the level-set function is zero, i.e. it is the
zero-level set {�x : φ(�x) = 0}. Applying the Heaviside function
H(z) :=
{
1, z ≥ 0,
0, else,
(24)
one can express the concentration distribution as the sum
c(�x) = cin + H(φ(�x))(cout − cin), (25)
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constant, the reconstruction problem reduces to finding the interface which separates the
inclusions from the background. This interface can be described using level-set methods:
The level-set function φ(�x),�x ∈ Ω is negative inside the inclusion and positive outside. Thus,
the separating interface consists of all points where the level-set function is zero, i.e. it is the
zero-level set {�x : φ(�x) = 0}. Applying the Heaviside function
H(z) :=
{
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0, else,
(24)
one can express the concentration distribution as the sum
c(�x) = cin + H(φ(�x))(cout − cin), (25)
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Fig. 7. Comparison of reconstructions of (a) four fluorescent objects with a concentration of
10 μM each. The reconstructions are based on (b) the L2-norm, (c) the H1-norm (d) the
total-variation. Also the results from a method of level-set type with cout = 10 μM are
presented with two different levels for the concentration inside the object: (e) cin = 10 μM
and (f) cin = 50 μM.
where cout and cin are the two scalar fluorophore concentrations in the background and inside
the inclusion.
Unfortunately, the numerical effort for the computation of the evolution of the level-set
function is comparatively high. The reason is again the non-differentiability of the Heaviside
function. A mitigation has been studied as a method of level-set type in Frühauf et al. (2005)
and Egger & Leittão (2009). The idea is to parametrize the concentration c by a nonlinear,
smooth, monotonically increasing function Hβ(φ) and to reconstruct the level-set function φ
which is done by minimizing the objective function
Lφα = 12�F(Hβ(φ))�2 + αR(φ). (26)














This parametrization restricts the concentration by the lower and upper bounds cout and cin,
respectively, but still allows values in between. Furthermore, it has a smooth derivative which
is useful for the Gauß-Newton algorithm.
Example reconstructions using the different kinds of regularization methods, which have been
presented in this chapter, are shown in Figure 7.
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5.2.4 Multi-modality regularization
When combining fDOT with a high-resolution modality such as CT or MRI, it is advantageous
to use information from the highly resolved anatomical images to improve the quality of
fDOT-reconstructions. In the following, some attempts for incorporating this information are
listed.
In the work by Davis et al. (2007), the anatomical images were segmented and the
regularization term R(c) was constructed such that it allows larger variations between voxels
from different segments but keeps variations between voxels from the same segment small.
Although only applied to DOT, Douiri et al. (2007) used a-priori edge information (which
could be obtained from CT, for example) together with an anisotropic diffusion model which
preserves sharp edges in the reconstructed optical properties. This method could also be
extended to fDOT to constrain the leakage of fluorescent agent in the reconstruction across
anatomical boundaries.
Another approach, which uses segmented images from a high-resolution modality like MRI
or CT, was presented by Hyde et al. (2010). Their algorithm first uses only one fluorescence
concentration for each segment (thus reducing the dimension of the reconstruction problem)
and creates a spatially-varying regularization matrix from the low-dimensional reconstruction
in a second step.
5.3 Regularisation parameter and stopping criterion
The choice of the regularization parameter α in equation (17) has attracted quite some
interest. The basic problem is that this parameter balances the goodness of fit, i.e. how well
the mathematical model approximates the measured data, and the stability of the inversion.
For the iteratively regularized Gauß-Newton algorithm, typically exponentially decaying
sequences are suggested (Blaschke et al. (1997); Engl et al. (1996)).
Another problem is the stopping criterion for the iterative reconstruction. Most often these
criteria are implemented using heuristics. For example, one can set a lower limit for the
regularization parameter or stop if stagnation occurs and the residual no longer changes as
done by Dehghani et al. (2008). Note that for the latter approach a good choice for the step
length is mandatory. Otherwise, the residual will decrease very slowly which triggers the
stopping criterion even when no (local) minimum of the objective functional has been reached.
An objective stopping criterion is given by Morozov’s discrepancy principle (Morozov (1966)).
It states that the residual shall not be smaller than the error in the measurement. Thus, if the
true measurement without any noise is denoted as M, α should be chosen such that
�M(cα)−Mδ� ≈ �M−Mδ�, (28)
where cα denotes the reconstructed fluorophore distribution with regularization parameter α.
In other words, the difference between the simulated measurement and the noisy data should
be approximately the same as the difference between the (inaccessible) measurement values
and the noisy data. Unfortunately, the expression on the right-hand side cannot be evaluated
in practice as the true measurements M are not known. Thus, one has to deduce this quantity
by other means based on the distribution of the noise, for example.
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6. Recent developments for pre-clinical and clinical applications
2D fluorescence imaging in pre-clinical sciences is a well-established technology. In this
section, we would like to give an overview about applications of truly three-dimensional
fluorescence imaging. There are many publications showing the potential of fDOT in
phantoms or ex-vivo while the number of in-vivo studies is still very limited. However, as
in-vivo molecular imaging is probably the most attractive future field of application, this
subchapter summarizes some important in-vivo results.
From the technological point of view, we can observe two major groups of applications, the
first of which serves for the non-quantitative visualization of molecular or cellular processes,
mostly evaluating quantum yield data. The second group tackles the more challenging
field of quantitative imaging, frequently exploiting both quantum yield and fluorescence
lifetime imaging (FLIM). The reconstruction of the fluorescence lifetime is of particular interest
because it yields more reliable information about the chemical interaction of the probe with
its environment than the fluorophore’s quantum efficiency (Lakowicz (2006)).
In the first group we find e.g. the use of a cathepsin-activatable fluorescence probe by Niedre
et al. (2008) to monitor a mouse lung tumor and by Haller et al. (2008) for the visualization
of pulmonary inflammation. Another example is the visualization of macrophage infiltration
of infarcted mycardium in a mouse model by Sosnovik et al. (2007), who compared MRI,
planar fluorescence imaging and fluorescence tomography. Kozloff et al. (2007) investigated
the feasibility of localizing bone mineralization/demineralization processes with a specific
fluorescent probe in mice. So-called far-red fluorescent pamidronate (FRFP) was proven to
specifically bind to bone mineral sites and fDOT images made with a commercial system
enabled the visualization of deep mineralizing structures including the growth plates in the
femoral heads. Biswal et al. (2011) developed a 2-nitroimidazole-ICG probe for monitoring
tumor hypoxia and present images of tumors of sizes of a few millimeter, however, without
assessing the accuracy of the tumor location and size in the reconstructions. Tan et al. (n.d.)
used fluorescence tomography to monitor stem cells in Drosophila Pupae by the expression
of a DsRed reporter.
In the second group (FLIM) we find a paper by Nothdurft et al. (2009) who were the
first to show in-vivo life-time tomography on mice, where they imaged agarose gel
implants as well as a cypate-labeled tumor. Gaind et al. (2010) showed the feasibility
of reconstructing fluorescence resonance energy transfer (FRET) parameters, including the
nanometer donor-acceptor distance, also from deep tissue regions in a mouse. 3D-studies
of inter- and intra-molecular FRET could be of high importance for the investigation of
diseases like Alzheimer’s and some cancers related to protein misfolding. McGinty et al.
(2011) presented FLIM in combination with Förster resonance energy transfer (FRET). In their
experiment, a mouse genetically expressed a eGFP-mCherry-FRET probe.
So far there are only very few attempts to apply fluorescence tomography in human
applications. The main reasons are certainly (i) the limited penetration depth of light in tissue
which precludes the application of fDOT in extended parts of the body and (ii) the lack of
approval for human use of most fluorescent labels known in molecular imaging. Corlu et al.
(2007) presented a proof-of-concept study utilizing fluorescence tomography for detecting
breast cancer in women using ICG as fluorescent agent. An interesting recent application
for breast cancer imaging was reported by Mastanduno et al. (2011). The authors combined
breast DCE-MRI, diffuse optical tomography and fDOT for imaging nine healthy volunteers
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and one patient with breast cancer. fDOT was used for the reconstruction of autofluorescence
from protoporphyrine IX, thus no extrinsic labeling agents were applied. The results, though
lacking statistical power, suggest that combined application of all three modalities may
provide improved information on malignancy when compared with DCE-MRI alone.
7. Trends and outlook
In this chapter, we addressed hardware-issues and reconstruction principles for fluorescence
tomography and presented promising applications especially for pre-clinical sciences.
In the near future, we expect that more compact fluorescence tomography hardware will be
developed e.g. through the replacement of photomultiplier tubes by silicon APDs. Another
development will focus on hybrid devices such as fDOT/CT and fDOT/MRI combinations to
use all the information from different modalities.
The reconstruction algorithms will on the one hand follow the hardware development,
i.e. reliable strategies for the incorporation of a-priori information from CT and MRI into
fDOT-images will be needed. On the other hand, the recent developments in commodity
parallel computing architectures, such as modern graphics hardware with NVIDIA’s CUDA
toolkit or the OpenCL framework, will certainly aid the implementation of advanced
algorithms including e.g. non-linear image regularization.
fDOT so far appears difficult to be used for human imaging. However, if autofluorescence
could be used for producing diagnostically relevant contrasts, some niche-applications may
arise. A recent example is the work by Mastanduno et al. (2011) which may open a new
application window in breast imaging. Another important decisive issue is whether new
fluorescent contrast agents will be approved for the use in humans.
In the field of pre-clinical imaging fDOT has been demonstrated to be feasible and the
availability of commercial devices will certainly increase its use and importance. Current
challenges are quantification and 3D lifetime imaging. As FLIM paves the way for 3D sensing
of chemical analytes, this could be a new attractive field of research. Some pioneering work
was already done by Shives et al. (2002) who showed the feasibility of FLIM-based oxygen
sensing in-vitro and there is certainly potential for future developments towards in-vivo
applications.
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1. Introduction 
Focal modulation microscopy (FMM) is an emerging single-photon fluorescence microscopy 
technique that can provide superior image contrast with sub-micron spatial resolutions at 
large penetration depths in highly scattering media such as biological tissues, mainly by 
preserving the signal-to-background ratio (SBR). To achieve this, FMM utilizes the 
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The next section of this book chapter will cover some of the implementations of FMM since 
it was invented in year 2008. Notably, two phase modulation schemes - double reflecting 
mirrors, and FMM based on acousto-optical modulators that are significantly progressive in 
term of stability and image performance will be described in details. Some of the images 
acquired using our FMM systems will also be compared side-by-side with confocal images 
to demonstrate the improvement in image qualities. We have tested on a wide collection of 
biological specimens, including but not limited to chicken chondrocytes, mouse brain 
vasculatures, Drosophila fruitfly as well as tissue phantom. Various fluorescence probes are 
also being utilized with FMM, proving its compatibility for the study of most fluorescence-
related biological parameters. 
For a concluding remark, we give a glimpse of future development of FMM, with emphasis 
on its applications in addressing basic problems in biomedical researches and 
understanding the pathophysiology of human diseases. 
2. Challenges and potential impacts of deep tissue imaging 
The desire to probe even deeper into biological specimens while resolving microstructural 
details and observing specific molecular events has grown over the last decade. This is 
largely because the knowledge obtained by looking at the biological system continuously 
over the entire entity coupled with functional information, as compared to individual 
snapshots via tiny-sectioned specimens, could greatly empower the understanding of 
cellular biology as well as diagnosis and prognosis of many diseases. However, the 
penetration depth that can be achieved in visualizing biological specimens is usually quite 
shallow compared to the total tissue volume, and is not absolutely defined mainly because 
image degradation by background and noise is a gradual process. Here, we briefly overview 
the current state of deep tissue imaging. 
First and foremost, the achievable penetration depth depends largely on the optical 
properties of the specimen – how transparent, scattering, or opaque it is (Oheim, 
Beaurepaire et al. 2001). For instance in the case of zebrafish Danio rerio, one can see entirely 
through an embryo or larva with basic light and fluorescence microscopy and hence 
zebrafish has become a model organism in developmental genetics and neuroscience 
(Detrich, Westerfield et al. 2010). Similarly, other organisms that are virtually transparent, 
such as early-stage roundworm Caenorhabditis elegans and fruit fly Drosophila melanogaster 
are also popular for the in vivo study of many biological processes. In particular, fruit fly 
Drosophila melanogaster has been valuable in identifying genes that control embryonic 
development, as well as the formation of the nervous system. Nevertheless, many other 
organisms and their body parts are so opaque that it is impossible for the current state-of-
arts microscopy techniques to achieve more than  penetration depth with 
uncompromised image quality. As an example, one can resolve little or no cellular details 
within the cerebral cortex without first drilling holes on the skull of mammals. Very often, 
this is done with an invasive biocompatible window opened on the skull of a mouse brain to 
allow an imaging depth up to  (Kleinfeld, Mitra et al. 1998; Svoboda, Helmchen et al. 
1999), which corresponds to the cortical layers 1-3 (Theer, Hasan et al. 2003), yet is still very 
shallow. 
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Fig. 1. Image stack of Drosophila pupa expressing elav-GFP to label CNS (brain and ventral 
nerve cord). The images were acquired with a confocal microscope Zeiss 5 live (10x 
objective). 
Secondly, the imaging depth is also fundamentally limited by the onset of out-of-focus 
fluorescence generation due to light scattering near the top of the sample (Ying, Liu et al. 
1999). At large imaging depths, this out-of-focus background fluorescence would gradually 
overwhelm the in-focus signal. As a consequence, a loss of image contrast will be observed 
(Theer, Hasan et al. 2003). Thus, it is generally difficult to preserve the quality of image 
when imaging at depth more than a few scattering mean free path1(MFP). One specific 
example on how scattering has hindered the study of developmental biology in Drosophila 
fruitfly model is illustrated in the Fig. 1. It is clearly seen that the blurriness of brain 
hemispheres (bh) and ventral nerve cord (vnc) in deeper tissue sections ( ) in contrast 
to better resolving capability of the confocal microscope at shallower region (i.e. ). The 
poor contrast at large penetration depth is due to the attenuation of the fluorescence 
emission as well as multiple scattering. 
This severe limitation of penetration depth of high-resolution optical imaging techniques 
that can only applied to physically sectioned biological samples through laborious 
sectioning procedures, or to natural transparent live specimens, such as organisms at very 
early stages of development, outlined the urgent need to improve in vivo visualization 
capability in thick biological tissues. For instance, current high-resolution intravital imaging 
techniques could permit visualization of tumor microstructure and vascular morphology 
superficially (  depth), which is over volumetric regions that are a small fraction 
of the total tumor volume in small animal models (Vakoc, Lanning et al. 2009), thus very 
much limited our understanding on the tumor microenvironment over multistate and 
multiscale level. 
High-resolution optical techniques with large penetration depth can be proved vital in 
biomedical applications as they allow observation of enormous biological processes within 
large tissue volumes especially for in vivo visualization of dynamic phenomenons in 
developing organism to address some of the basic problems in development biology, such 
as understanding the development phase of central nervous system in Drosophila fruitfly 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
1 The average distance between each scattering event. 
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over the whole body volume, as depicted by Fig. 1. Visualization beyond penetration limit 
of modern microscopy techniques will not only open new pathways in understanding the 
signaling and interactions of tissues with drugs and environmental factors in adult model 
organisms but also could potentially useful for noninvasive imaging and spectroscopy of 
intact biological tissues of human subjects, including but not limited to nondestructive 
diagnosis of major human diseases such as early cancer detection (Zeng, Vangveravong et al. 
2007; Pavlova, Williams et al. 2008). Specifically, the capability to visualize tissue 
microstructures at penetration depth up to  in biological tissues will be clinically 
important in in vivo diagnosis of skin melanomas in dermatology. We further highlight that 
deep imaging could also assist in dissecting tumor pathophysiology of intact tumor 
microenvironment (Jain, Munn et al. 2002; Vakoc, Lanning et al. 2009), as well as 
understanding how the single cells respond to the damage of the nervous system in 
neuropathology (Misgeld and Kerschensteiner 2006) of living animal models, just to list a few.  
In summary, the development of optical techniques with large penetration depth will have 
great impacts in revolutionizing the usages of optical techniques in biomedical and clinical 
applications. 
3. Current optical techniques for deep tissue imaging 
This section gives a brief review of some optical microscopy techniques that are being 
important for observation of thick biological specimens. The principles of each technique are 
being described along with their advantages and disadvantages, in an attempt to give a 
snapshot of current capabilities in deep tissue imaging.  
3.1 Confocal microscopy 
The invention of confocal microscopy (CM) (Minsky 1961; Minsky 1988; Pawley 2006) has 
radically transformed optical imaging in biology research as it provides diffraction-limited 
spatial resolution with unprecedented optical sectioning capability to eliminate from images 
the background caused by out-of-focus light and scatter (Conchello and Lichtman 2005). 
This is achieved through a small pinhole (point) aperture or single-mode fiber being used in 
the detection/image plane which acts as a spatial filter/angular gate to block highly 
scattered out-of-focus light (see Fig. 2). This removal of undesired out-of-focus light not only 
enhanced the image contrast but more importantly also allowed three-dimensional imaging 
as images of thin slices can be acquired over thick specimens. The pinhole also rejects the 
scattered halo of light around the illumination spot if the pinhole size is small enough (i.e. 
about the size of Airy disk) (Conchello and Lichtman 2005), optimizing the point spread 
function for good resolution. In other words, the pinhole with appropriate size can 
effectively ensure that most of the ballistic photons contribute mostly of the signals being 
collected. 
Nonetheless, this selective detection mechanism becomes less effective when the focal points 
moves deeper into the specimens or thick samples are being used, as multiple scattered 
stray photons will eventually leak through the pinhole (Kempe, Thon et al. 1994; Schmitt, 
Knuttel et al. 1994; Kempe, Rudolph et al. 1996), eroding the image contrast and signal-to-
noise ratio (Dunn, Smithpeter et al. 1996). Furthermore, in most cases for deep tissue 
imaging, larger pinhole aperture radius are preferred to allow more photons to be collected 
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Fig. 2. Schematic diagram for a confocal reflection microscope. Dotted line represents the 
path for the light coming from out-of-focus areas in the sample; which will be blocked by 
the pinhole with appropriate size. 
to compensate for the signal lost by attenuation, which could further deteriorate the imaging 
performance. This is because increasing the pinhole aperture size though will marginally 
improve the signal-to-noise ratio but will also drastically reduce the depth discrimination 
power (i.e. optical sectioning capability) of the microscope, leading to diminishing image 
contrast. Hence, very often, it is the trade-off between the signal level and background 
scattered-light rejection that places a fundamental limit on the sectioning capability of the 
microscope (Schmitt, Knuttel et al. 1994) as well as the imaging depth (Smithpeter, Dunn et 
al. 1998; Theer and Denk 2006). As the scattering effects gradually dominate at larger depth, 
image contrast of CM will eventually lost and thus limit its usefulness at near the tissue 
surface (less than �00���) (Conchello and Lichtman 2005). In fact, imaging of CM in turbid 
media such as living tissue is usually performed at imaging depth up to few tens of microns 
only due to limited contrast at higher depth aforementioned.  
By combining with other mechanism to reject the multiple-scattered photons (Gan, Schilders 
et al. 1997), it is possible to improve the penetration depths of CM. Notably, optical 
coherence microscopy (OCM) combines the coherence gating mechanism of optical 
coherence tomography (OCT) and the pinhole effect of the CM to enhance the selection of 
ballistic photons for image reconstruction. Significant improvement in optical sectioning 
capability and penetration depths has been demonstrated (Izatt, Hee et al. 1994). 
Nevertheless, OCM is only sensitive to back-scattered light and not applicable for 
visualization of fluorescence, thus severely limited its biological applications.  
In term of spatial resolution, CM could provide superior lateral (� ��� � improvement) and 
axial (� ��0� � improvement) resolution compared to conventional widefield microscopy 
(Sheppard and Wilson 1980; Gu 1996). However, this improvement in spatial resolutions is 
only appreciable when infinitesimal pinhole is being used which preclude any signal 
collections. Therefore, optimal pinhole size between 60% and 80% of the diameter of the 
diffraction-limited spot (Sandison, Piston et al. 1995) are generally used, with further 
adjustment on the pinhole size to accommodate for desired optical sectioning capability and 
signal level. 
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3.2 Two-photon microscopy 
Another promising optical techniques for subcellular spatial resolution in vivo deep tissue 
imaging is nonlinear two-photon fluorescence microscopy (Denk, Strickler et al. 1990; 
Helmchen and Denk 2005; Svoboda and Yasuda 2006). Two-photon fluorescence 
microscopy is very similar to CM in term of the system design except that it uses ‘higher-
order’ light-matter interactions to generate fluorescence excitation in which two low-energy 
photons arrive ‘simultaneously’ (within ~0.5 femtoseconds, see Fig. 3A) at a fluorescence 
molecule combine their energies to promote the molecule to an excited state, which then 
proceeds along the normal fluorescence-emission pathway.  
 
Fig. 3. Single-photon and two-photon process. A. Jablonski diagrams for one-photon 
excitation and two-photon excitation. B. Schematics of one-photon versus two-photon 
fluorescence emission. 
The process of two-photon absorption requires extremely high concentration of excitation in 
spatial and temporal domain. Hence, very expensive pulse lasers that emit ‘ultrashort’ 
pulses in the range of hundreds femtoseconds with correspondingly high peak intensities 
have to be used with a high NA objective to focus the light beam into a diffraction-limited 
volume. A highly enhanced two-photon fluorescence system in focused laser enable vast 
majority of the fluorescence excitation occurs in a focal volume that can be as small as 
~ . This localization of excitation will limit the out-out-focus fluorescence excitation 
because even the excitation beam illuminated the sample like the case of CM (i.e. over the 
illumination cone as illustrated in Fig. 3B), the out-of-focus excitation light are too weak to 
generate appreciable two-photon fluorescence. Thus, intrinsic optical sectioning and high-
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contrast imaging can be achieved. As all the fluorescence photons are assumed generated 
from the focal region and can be collected as useful signals for imaging, spatial filters in the 
detection path (i.e. the detector pinhole in the CM) is not necessary, allowing higher 
collection efficiency (i.e. for greater signal level) and unprecedented imaging depths (Deng 
and Gu 2003). In particular, imaging up to a depth of  for vasculature and  for 
neuron of mouse brain has been achieved with femtosecond mode-locked Titanium: 
Sapphire (Ti: S) oscillators (Helmchen and Denk 2005).  
It is worth to mention that these penetration depths are achieved partly due to the use of 
near-infrared excitation light that reduces light scattering, however, the achievable lateral 
and axial resolution are both slightly worse due to longer wavelength light sources are 
being used. Furthermore, two-photon fluorescence microscope uses very expensive pulse 
laser that may not be easily affordable for most research groups. Another concern for 
application of two-photon microscopy is the photo-damage/photobleaching at the focal 
volume, mainly due to the high intensity pulse laser to elicit fluorescence at the focus point. 
It is further claimed that the photobleaching that occurs at the focus is higher for two-
photon absorptions than it is for single photon absorptions for comparable emission yields 
(Patterson and Piston 2000; Dittrich and Schwille 2001). This is undesirable for functional 
imaging as photobleaching at the focus is likely to be more detrimental than bleaching at 
plane above and below the focus. On top of that, the optical indicators that can be used with 
two-photon microscopy are only a small subset of the indicators that can be used with 
single-photon excitation microscopy, mainly due to the limited availability of fluorescence 
probes with large “two-photon absorption cross-section”. This limitation could severely 
constrain the types of biological parameters and processes that can be studied using two-
photon fluorescence microscopy. 
Regardless of the superiority of nonlinear mechanism to inhibit the generation of out-of-
focus fluorescence, the performance of two-photon microscopy could still be affected by 
multiple scattering. At extended depths, the ability of excitation light to reach the focus 
unscattered (ballistic excitation photons) and of emitted fluorescence to arrive at the 
detector, with generation of out-of-focus fluorescence near the surface, are placing a 
fundamental limit on how deep two-photon microscopy can probe (Theer and Denk 2006; 
Kobat, Durst et al. 2009). Recent efforts on improving the penetration depths of two-photon 
microscopy by using longer wavelength excitation (Kobat, Durst et al. 2009) or by reducing 
the pulse width of excitation laser (Theer, Hasan et al. 2003) (to increase two-photon 
fluorescence excitation yield) has been very successful with imaging depths over  
being reported (Theer, Hasan et al. 2003; Kobat, Durst et al. 2009). Still, those techniques are 
very selective on the availability of fluorescence probes that can be excited using near-
infrared light and are still very technically demanding (Kobat, Durst et al. 2009) to be 
adopted by most biological research groups. 
3.3 Optical coherence tomography 
Coherence optical tomography (OCT) (Huang, Swanson et al. 1991; Fujimoto 2003) is an 
emerging biomedical optical imaging technique that is capable of considerable high 
resolution and cross-sectional tomographic imaging of microstructures in biological 
systems. Typically, OCT can provide micron-range axial resolution for an imaging depth up 
to  in tissue depending on the optical scattering (Fujimoto, Brezinski et al. 1995).  
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3.2 Two-photon microscopy 
Another promising optical techniques for subcellular spatial resolution in vivo deep tissue 
imaging is nonlinear two-photon fluorescence microscopy (Denk, Strickler et al. 1990; 
Helmchen and Denk 2005; Svoboda and Yasuda 2006). Two-photon fluorescence 
microscopy is very similar to CM in term of the system design except that it uses ‘higher-
order’ light-matter interactions to generate fluorescence excitation in which two low-energy 
photons arrive ‘simultaneously’ (within ~0.5 femtoseconds, see Fig. 3A) at a fluorescence 
molecule combine their energies to promote the molecule to an excited state, which then 
proceeds along the normal fluorescence-emission pathway.  
 
Fig. 3. Single-photon and two-photon process. A. Jablonski diagrams for one-photon 
excitation and two-photon excitation. B. Schematics of one-photon versus two-photon 
fluorescence emission. 
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illumination cone as illustrated in Fig. 3B), the out-of-focus excitation light are too weak to 
generate appreciable two-photon fluorescence. Thus, intrinsic optical sectioning and high-
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and axial resolution are both slightly worse due to longer wavelength light sources are 
being used. Furthermore, two-photon fluorescence microscope uses very expensive pulse 
laser that may not be easily affordable for most research groups. Another concern for 
application of two-photon microscopy is the photo-damage/photobleaching at the focal 
volume, mainly due to the high intensity pulse laser to elicit fluorescence at the focus point. 
It is further claimed that the photobleaching that occurs at the focus is higher for two-
photon absorptions than it is for single photon absorptions for comparable emission yields 
(Patterson and Piston 2000; Dittrich and Schwille 2001). This is undesirable for functional 
imaging as photobleaching at the focus is likely to be more detrimental than bleaching at 
plane above and below the focus. On top of that, the optical indicators that can be used with 
two-photon microscopy are only a small subset of the indicators that can be used with 
single-photon excitation microscopy, mainly due to the limited availability of fluorescence 
probes with large “two-photon absorption cross-section”. This limitation could severely 
constrain the types of biological parameters and processes that can be studied using two-
photon fluorescence microscopy. 
Regardless of the superiority of nonlinear mechanism to inhibit the generation of out-of-
focus fluorescence, the performance of two-photon microscopy could still be affected by 
multiple scattering. At extended depths, the ability of excitation light to reach the focus 
unscattered (ballistic excitation photons) and of emitted fluorescence to arrive at the 
detector, with generation of out-of-focus fluorescence near the surface, are placing a 
fundamental limit on how deep two-photon microscopy can probe (Theer and Denk 2006; 
Kobat, Durst et al. 2009). Recent efforts on improving the penetration depths of two-photon 
microscopy by using longer wavelength excitation (Kobat, Durst et al. 2009) or by reducing 
the pulse width of excitation laser (Theer, Hasan et al. 2003) (to increase two-photon 
fluorescence excitation yield) has been very successful with imaging depths over  
being reported (Theer, Hasan et al. 2003; Kobat, Durst et al. 2009). Still, those techniques are 
very selective on the availability of fluorescence probes that can be excited using near-
infrared light and are still very technically demanding (Kobat, Durst et al. 2009) to be 
adopted by most biological research groups. 
3.3 Optical coherence tomography 
Coherence optical tomography (OCT) (Huang, Swanson et al. 1991; Fujimoto 2003) is an 
emerging biomedical optical imaging technique that is capable of considerable high 
resolution and cross-sectional tomographic imaging of microstructures in biological 
systems. Typically, OCT can provide micron-range axial resolution for an imaging depth up 
to  in tissue depending on the optical scattering (Fujimoto, Brezinski et al. 1995).  
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Fig. 4. Standard OCT scheme based on a low time-coherence Michelson interferometer. The 
intensity �� of the interferometer exit depends on the sample response ���� �� convolved 
with the source coherence function Γ��������� . LS = low time-coherence light source; PC = 
personal computer. Adapted from (Fercher, Drexler et al. 2003). 
OCT uses coherence gating (i.e. interference between the back-scattered light and a reference 
beam) to improve the detection of backscattered light for image reconstruction. OCT can 
generate good contrasts as only the backscattered light that has a well-defined optical path 
length and polarization state will interfere constructively with the reference beam to 
generate strong fringe signals for image reconstruction (see Fig. 4) (Fercher, Drexler et al. 
2003). The intensity of the interferometer exit �� can be represented by: 
  ����� �� � �� � �� � ����Γ��������� � ���� ���  (1) 
where �� and �� are the intensity at the sample and reference arms respectively, Γ������ being 
the source coherence function and ���� �� is the sample response function (i.e. determined 
by the sample geometry and reflectivity due to refractive index mismatches). 
Due to its relatively larger penetration depths, OCT has found applications in 
ophthalmology and dermatology (Prati, Regar et al. 2010). Specifically, OCT has been 
heavily applied for diagnosis of various eye diseases such as age-related macular 
degeneration and glaucoma (Fercher 2010; Prati, Regar et al. 2010) On top of that, OCT has 
also been applied in functional imaging such as spectroscopic imaging of tissue properties, 
Doppler blood flow measurement and quantification of blood oxygenation or tissue 
birefringence (Fujimoto 2003). Recently, second generation OCT, termed optical frequency 
domain imaging (OFDI) (Vakoc, Lanning et al. 2009) has been very successful for the 


















Focal Modulation Microscopy: Principle and Techniques 153 
Although substantially high-resolution at imaging depth up to  is readily achievable 
using OCT, its lack of molecular contrast especially incompatibility with fluorescence 
microscopy has restricted its applications for the study of many other biological processes.  
3.4 Photo-acoustic tomography 
Photo-acoustic tomography (PAT) (Wang, Xu et al. 2002; Wang, Ku et al. 2004), being one of 
the fastest-growing area of biomedical imaging technology over the last decade, offers high-
resolution three-dimensional imaging with rich optical contrast in vivo at depths beyond the 
optical transport mean free path (i.e.  in human skin) (Wang 2009). In the 
photoacoustic phenomenon, excitation light (short-pulsed laser is normally used for efficient 
ultrasound generation) is absorbed by a material and converted to heat, and the subsequent 
thermoelastic expansion generates an acoustic wave. This acoustic wave can then be 
detected by using an ultrasonic detector for the reconstruction of ultrasound image. In 
fluorescence mode, ultrasonic detection of pressure waves generated by the absorption of 
pulse light by fluorescence proteins in elastic media enable high-resolution visualization of 
fluorescent proteins few millimetres deep within highly light-scattering living organisms.  
PAT combines the optical imaging and ultrasound imaging, enabling rich optical contrast 
and high ultrasonic resolution imaging modality. Typically, the ultrasonic scattering 
coefficient in biological tissue is  orders of magnitude less than the optical equivalent. 
Hence, PAT can detect the ultrasonic waves even at a depth of multiple folds larger 
compared to existing high-resolution optical imaging techniques, such as confocal 
microscopy and two-photon microscopy, thus enabling deeply penetrating functional 
(Wang, Pang et al. 2003; Yang, Xing et al. 2007) and molecular (Li, Zemp et al. 2007; Li, Oh et 
al. 2008) imaging in biological samples. For instance, highly optimized PAT could enable 
visualization of fluorescent proteins few millimeters deep within highly light-scattering 
living organisms.  
Nevertheless, the in-plane spatial resolution of the photo-acoustic images achievable is 
fundamentally limited by the effective bandwidth of the ultrasonic detector MHz , 
leading to diffraction limited resolution and even worse for axial resolution 
(Razansky, Distel et al. 2009). Recent higher lateral resolution around  has been 
reported but at a much shallower penetration depth of  (Wang 2009), which is not 
better than current techniques such as two-photon microscopy. Furthermore, very often the 
specimens have to be immersed in acoustic medium for better coupling of the propagation 
of acoustic wave to the ultrasonic detector, which might not be suitable for all types of living 
biological specimens.  
3.5 Others recent developments 
Another very promising technique, termed single plane illumination microscopy (SPIM) 
(Huisken, Swoger et al. 2004) or light-sheet-based fluorescence microscopy (Keller, Schmidt 
et al. 2010) in which a single plane in specimen is quickly scanned with a thin laser beam 
while a 2D camera-based detection arm records a fluorescence image at a right-angle to the 
illumination axis. Light-sheet-based microscopy could greatly enhance the image acquisition 
speed and the image contrast while limited the photobleaching and phototoxicity on the 
specimens (Keller, Schmidt et al. 2008; Keller and Stelzer 2008). However, this technique 
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Although substantially high-resolution at imaging depth up to  is readily achievable 
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the fastest-growing area of biomedical imaging technology over the last decade, offers high-
resolution three-dimensional imaging with rich optical contrast in vivo at depths beyond the 
optical transport mean free path (i.e.  in human skin) (Wang 2009). In the 
photoacoustic phenomenon, excitation light (short-pulsed laser is normally used for efficient 
ultrasound generation) is absorbed by a material and converted to heat, and the subsequent 
thermoelastic expansion generates an acoustic wave. This acoustic wave can then be 
detected by using an ultrasonic detector for the reconstruction of ultrasound image. In 
fluorescence mode, ultrasonic detection of pressure waves generated by the absorption of 
pulse light by fluorescence proteins in elastic media enable high-resolution visualization of 
fluorescent proteins few millimetres deep within highly light-scattering living organisms.  
PAT combines the optical imaging and ultrasound imaging, enabling rich optical contrast 
and high ultrasonic resolution imaging modality. Typically, the ultrasonic scattering 
coefficient in biological tissue is  orders of magnitude less than the optical equivalent. 
Hence, PAT can detect the ultrasonic waves even at a depth of multiple folds larger 
compared to existing high-resolution optical imaging techniques, such as confocal 
microscopy and two-photon microscopy, thus enabling deeply penetrating functional 
(Wang, Pang et al. 2003; Yang, Xing et al. 2007) and molecular (Li, Zemp et al. 2007; Li, Oh et 
al. 2008) imaging in biological samples. For instance, highly optimized PAT could enable 
visualization of fluorescent proteins few millimeters deep within highly light-scattering 
living organisms.  
Nevertheless, the in-plane spatial resolution of the photo-acoustic images achievable is 
fundamentally limited by the effective bandwidth of the ultrasonic detector MHz , 
leading to diffraction limited resolution and even worse for axial resolution 
(Razansky, Distel et al. 2009). Recent higher lateral resolution around  has been 
reported but at a much shallower penetration depth of  (Wang 2009), which is not 
better than current techniques such as two-photon microscopy. Furthermore, very often the 
specimens have to be immersed in acoustic medium for better coupling of the propagation 
of acoustic wave to the ultrasonic detector, which might not be suitable for all types of living 
biological specimens.  
3.5 Others recent developments 
Another very promising technique, termed single plane illumination microscopy (SPIM) 
(Huisken, Swoger et al. 2004) or light-sheet-based fluorescence microscopy (Keller, Schmidt 
et al. 2010) in which a single plane in specimen is quickly scanned with a thin laser beam 
while a 2D camera-based detection arm records a fluorescence image at a right-angle to the 
illumination axis. Light-sheet-based microscopy could greatly enhance the image acquisition 
speed and the image contrast while limited the photobleaching and phototoxicity on the 
specimens (Keller, Schmidt et al. 2008; Keller and Stelzer 2008). However, this technique 
Molecular Imaging 154 
usually requires dedicated image post-processing to improve the spatial resolutions (for 
instance, deconvolution) (Verveer, Swoger et al. 2007; Keller, Schmidt et al. 2010) and no 
penetration depths over  have been reported up to date. 
Other high-resolution optical imaging techniques such as 4-Pi (Hell, Stelzer et al. 1994) and I5M 
(Gustafsson, Agard et al. 1999) microscopy based on coherent collection of fluorescence using 
a pair of diametrically opposed objectives which could enhance the axial resolution by a factor 
of 3-7 along the optical axis; far-field optical microscopy such as stimulated emission depletion 
(STED) microscopy (Dyba and Hell 2002) uses superlocalized depletion of the excited state by 
stimulated emission with few tens nanometers spatial resolution being demonstrated 
(probably the highest resolution using optical techniques for living cells) and total internal 
reflection fluorescence microscopy (TIRF) (Axelrod 2003) that uses decaying evanescent wave 
are all severely limited in penetration depth and thus not extensively reviewed here. 
3.6 Summary 
There is a considerable large gap in the development for optical microscopy techniques that 
can achieve high penetration depth with subcellular spatial resolution, for vast applications 
in biomedical researches. Table 1 summarizes the strengths and limitations of some of the 
imaging modalities for subcellular-resolution deep imaging being described in this book 
chapter. Therefore we developed Focal Modulation Microscopy (FMM) (Chen, Wong et al. 
2008), a novel technique that aims for imaging depth greater than but not limited to  
with subcellular spatial resolution and molecular specificity. The principle of FMM will be 
further elaborated in the next section.  
 




High-resolution with optical sectioning. 
Much cheaper laser source than two-
photon imaging.  
Shallow penetration depths 





Optical sectioning. Reduced 
photobleaching and photodamage with 
large penetration depths up to . 
High cost of ultrashort-
pulsed laser and limited 





Large penetration depth up to  and 
ease of implementation. 
Lack of molecular contrast 
due to incompatibility with 
fluorescence imaging and 
high level of speckle noise. 
Photoacoustic 
Tomography 
Good penetration depths up to few mm 
and compatible with fluorescence 
imaging.  
Poorer spatial resolutions 





Optical sectioning. Better penetration 
depths than confocal microscopy using 
cheaper continuous-wave laser. Can work 
in fluorescence and reflectance mode. 
Photobleaching (same as 
confocal microscopy). 
Table 1. A comparison of optical imaging modalities with good resolution and penetration 
depths. 
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4. Principle of focal modulation microscopy 
Focal modulation microscopy (FMM) (Chen, Wong et al. 2008; Wong, Chong et al. 2009) is a 
novel optical microscopy technique based on single photon excited fluorescence. It can 
provide sub-micron spatial resolution at large penetration depth in living tissues mainly by 
preserving the SBR of the image. In FMM, a phase modulator is employed to sinusoidally 
phase modulate (or frequency shifting) half of the spatial extent of the excitation beam. As 
the beam being tightly focused by the objective lens, interference of the both half-beams 
generates an intensity modulation at the designated frequency around the focal volume. 
This modulated excitation focus thus results in a modulated fluorescence signal from the 
focal volume. Although both the ballistic and scattered photons could reach the focal plane, 
only the ballistic photons contribute to the oscillatory excitation, as they have well-defined 
phase and polarization. Therefore, in principle, “out-of-focus” fluorescence emission should 
not be modulated as they are originated from scattered excitation. Subsequently, a simple 
lock-in technique can be implemented to retrieve the fluorescence signal excited by ballistic 
light and to reject the contribution from diffusive-light-excited fluorescence.  
4.1 Excitation beam modulation 
Here we present the principle of FMM in mathematical model. As FMM is a technique that 
employs a spatiotemporal phase modulator to sinusoidally modulate a spatial fraction of the 
excitation beam, we can define the excitation field: 
  ������ � ������� � �������������  (2) 
in which �� is the spatial coordinates and the ��������� term describe the fraction of the 
excitation field being phase modulated with a periodic function ����� (at the frequency �) in 
contrast to the unmodulated fraction ���. The corresponding excitation intensity around the 
focal spot is thus given by: 
  ������ � |������|� � ������ � ��∗���� � ���� � ����������� � ���� � �����������∗  (3) 
Expanding the Eqn. 3, we obtained: 
������ � ��������∗ � ���������������������∗ � ���������������∗ � ���������������∗ � |���|� � |���|� � 
 ����������∗ �������� � |���|� � |���|� � �|������∗ | cos����� � arg� ������∗ ��  (4) 
We could observe from the last line of Eqn. 4 that the first two terms are the fraction of 
excitation intensity which is unchanged over time whereas the last term corresponds to 
oscillatory intensity at the modulation frequency �. In a FMM system, the unmodulated 
field ������� and the modulated field ������� are generally spatially separated, due to 
spatiotemporal phase modulation at the objective aperture. The excitation intensity is 
therefore a constant except at locations around the focal point, in which there is a significant 
overlapping between ������� and �������. At the focal point, ������� and ������� are usually in 
phase so that arg�������∗ � � �. The maximal excitation intensity is reached when cos� ����� �1 (in phase), 
  ��������� � |���|� � |���|� � �|������∗ |  (5) 
The minimal excitation intensity is :  
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usually requires dedicated image post-processing to improve the spatial resolutions (for 
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penetration depths over  have been reported up to date. 
Other high-resolution optical imaging techniques such as 4-Pi (Hell, Stelzer et al. 1994) and I5M 
(Gustafsson, Agard et al. 1999) microscopy based on coherent collection of fluorescence using 
a pair of diametrically opposed objectives which could enhance the axial resolution by a factor 
of 3-7 along the optical axis; far-field optical microscopy such as stimulated emission depletion 
(STED) microscopy (Dyba and Hell 2002) uses superlocalized depletion of the excited state by 
stimulated emission with few tens nanometers spatial resolution being demonstrated 
(probably the highest resolution using optical techniques for living cells) and total internal 
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3.6 Summary 
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with subcellular spatial resolution and molecular specificity. The principle of FMM will be 
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novel optical microscopy technique based on single photon excited fluorescence. It can 
provide sub-micron spatial resolution at large penetration depth in living tissues mainly by 
preserving the SBR of the image. In FMM, a phase modulator is employed to sinusoidally 
phase modulate (or frequency shifting) half of the spatial extent of the excitation beam. As 
the beam being tightly focused by the objective lens, interference of the both half-beams 
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phase and polarization. Therefore, in principle, “out-of-focus” fluorescence emission should 
not be modulated as they are originated from scattered excitation. Subsequently, a simple 
lock-in technique can be implemented to retrieve the fluorescence signal excited by ballistic 
light and to reject the contribution from diffusive-light-excited fluorescence.  
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excitation beam, we can define the excitation field: 
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  ���������� � |���|� � |���|� � 2|������∗ |  (6) 
which corresponds to ��������� � ����The difference between the in-phase and off-phase 
intensities provides the measure of peak-to-peak value of intensity modulation at the focal 
point. 
4.2 Excitation point spread function of FMM 
We can find the illumination intensity point spread function (PSF) of the FMM using the 
scalar diffraction theory. For an aberration-free lens of circular aperture, the illumination 
intensity distribution is given by (Gu 2000): 




  (7) 
in which �� denotes the zero-order Bessel function and � � ������ and � � �� ���� ���
� � are 
radial and axial normalized optical coordinates with the wavenumber � � 2� �⁄ . The 
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phase-shift varying from ������ with respect to the excitation beam passed through the inner 
circle. Hence, the pupil function ���� that describes the field distribution at the lens aperture 
can be described as: 
  ���� � � �� ����� � � �
√2 2�
�������� ���� √2 2� � � � �
  (8) 
where � is the normalized aperture diameter of the objective lens. 
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When the phase profile over the aperture is uniform (i.e. ), the intensity 
distribution along the optical axis is identical to the illumination point spread function of 
CM; on the other hand, when , there will be a strong destructive interference of the 
beams at the focal spot, leading to the off-phase intensity profile (dashed) as shown in Fig. 5 
(Left). The difference between these two excitation intensity profiles is the effective 
illumination point spread function in FMM.  
The excitation intensity distribution of the CM and FMM along the lateral direction is plot in 
Fig. 5 (Right). It is worth to mention that due to the differential mechanism of FMM, there 
are negative sidelobes in the excitation IPSF of the FMM, albeit with relatively smaller 
magnitude compared to that of lateral IPSF. In order to extract the FMM signal, an aperture 
pinhole of size slightly smaller that the central lobe is to be used, in order to exclude the 
negative side lobes being included in the retrieved signal. These negative side lobes, if being 
included in the detected signal, will dramatically reduce the FMM signal.  
4.3 Signal-to-background ratio in FMM 
While the basic principle of FMM is straightforward and its performance has been 
experimentally demonstrated (Chen, Wong et al. 2008), it is desirable to conduct theoretical 
studies to gain further insight into this technique. In this section, we present a theoretical 
model that combines the scalar diffraction theory (Gu 2000) with Monte Carlo simulation 
(Schmitt, Knuttel et al. 1994), in which the dependence of SBR on penetration depth are 
examined and compared for both FMM and CM.  
 
Fig. 6. Model geometry of a FMM/CM setup. Annular aperture with (shaded region) and 
without phase modulation is studied. L1 and L2 are lens with focal length . DM is the 
dichroic mirror and PMT is the photomultiplier tube. 
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4.3.1 Model geometry 
We consider a system geometry shown in Fig. 6. The collimated excitation laser beam is 
focused by the objective lens L1 to a point located in a slab of turbid medium. The refractive 
indices are assumed to be matched across the medium surface. The system includes lenses 
L1 and L2 (Diameter , focal length 9 mm), a dichroic mirror (DM), a pinhole 
 in diameter, a spatiotemporal phase modulator, and a PMT. The optical properties 
(absorption coefficient , scattering coefficient , anisotropy factor 
) of the turbid medium are typical for biological soft tissues. Fluorescent molecules 
are homogeneously distributed and are the only absorptive substance in the medium. 
4.3.2 Excitation rate for confocal microscopy 
The excitation light, once entering the turbid medium, is separated into a ballistic 
component and a scattered component due to scattering events. The fluorescence excitation 
rate for CM consists of ballistic (CMB) and scattered (CMS) components:  
    (9) 
where  and  are the locations of the focal point and 
fluorescent molecules, respectively. The scalar diffraction theory is used to calculate the 
ballistic excitation rate (in polar coordinates): 
    (10) 
Here  denotes the zero-order Bessel function. The normalized optical coordinates 
 and  are related to the normalized radius 
 and ,  is the wave number, and the numerical 
aperture , with  being the radius of the diffraction aperture at the plane of 
the objective lens. The constant  is used to normalize the total excitation power to unity. 
Attenuation of the ballistic component depends on the extinction coefficient  
and the penetration depth . 
Monte Carlo simulation (Schmitt, Knuttel et al. 1994) is employed to obtain the scattered 
excitation rate . Given the focal point , photon packets with an initial 
weight of one are launched at the air-turbid medium interface . Their initial position 
and direction are randomly assigned with the probability density function satisfying the 
following conditions: a) The excitation beam intensity is uniform over the aperture of L1, and 
b) the photon packets would converge to the focal point if there is no scattering. Then the 
trajectory of each photon packet is randomly generated following the standard propagation 
and interaction approach. The weight of a photon packet is adjusted after each interaction: 
    (11) 
At the same time, the ‘lost’ weight is deposited into that position grid as considered as being 
absorbed by the fluorescence molecules. A simulated trajectory ends when the photon 
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escape from the slab surface or the weight drops below a preset threshold. A large number 
(10�) of photons are traced to find the average excitation rate �������� ��� for each focal 
depth. The contribution from the first interaction is attributed to ballistic light and thus 
excluded from �������� ���. 
4.3.3 Excitation rate for focal modulation microscopy 
For FMM, the equivalent excitation rate is associated with the ballistic light only:  
�������� ��� � 












�  (12) 
The first term in the above equation (i.e. enclosed in first modulus function) is the excitation 
intensity when ���� � �0 and the second term corresponds to excitation intensity when 
���� � ��. 
In Fig. 7 , the excitation rates are compared for an imaging depth of �00���. Fig. 7 (a) shows 
FMM excitation rate (absolution value) as a function of the radial displacement and defocus, 
while Fig. 7 (b) is the ballistic excitation rate in the CM setup. They are highly concentrated 
around the focal point and decay rapidly outside of the focal volume. Such a behaviour is 
desirable for optimal optical sectioning and high-resolution imaging. On the contrary, the 
diffusive excitation rate for the CM setup (Fig. 7 (c)) is distributed in a rather large volume, 
although the peak value is about 2 orders of magnitude smaller than that of ballistic 
excitation rate.  
 
Fig. 7. Ballistic and diffusive excitation rates for an imaging depth of ������. 
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4.3.4 Detection point-spread-function 
As CM and FMM have the same detection optics, their fluorescence detection efficiencies are 
identical. For the ballistic fluorescence light, the detection efficiency is given by: 




  (13) 
where the two-dimensional integration is over S, the image of the pinhole in the medium 
and centered at ��. The optical coordinates ��and �� are normalized radial and axial 
distances between �� and the point ��� �� ��� within �. The first term of Eqn. 13, �������  is the 
solid angles of the detection cone where � is half of the angular aperture of L1. 
Scattered fluorescence photons are again simulated by the use of Monte Carlo method. 
Photon packets are launched from a point �0� 0� ��� with the initial directions uniformly 
sampled. Trajectory of propagation and scattering steps for each photon is generated using 
the standard Monte Carlo approaches. Photons emerging from the surface without 
scattering are discarded. Scattered photons, once crossed the upper medium surface, are 
traced using geometric optics. In order to enhance the simulation efficiency by reusing the 
trajectories, we actually deploy an array of detectors after L2. The detector array consists of 
101 planes along the optical axis, corresponding to focal depths sampled every 10��� from 
0 to 1000��� in the medium. Each detection plane has a sensing area 1� � in diameter and 
it is divided into a grid of 1��� by 1��� pixels. A photon captured by the pixel at ���� adds a 
normalized weight to the scattered detection efficiency: 
  ������ ��� � ������ ��� � ����   (14) 
Here � is the weight of the photon packet, �� is the pinhole area in ���and � is the total 
number of photons launched, and �� is the conjugate point of ���� in the medium. 
 
Fig. 8. Scattered detection efficiency as a function of (a) focus point or (b) molecular target 
position. 
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Shown in Fig. 8 (a) is ������ �� � �0�0��00���� as a function of �� and ��, obtained with 10� 
simulated photons. The simulation is repeated for the emitter depth range from 0 to 1	��, at an 
incremental step of 10	��. Then the results are combined to generate the spatial distribution as a 
function of �� and ��, for any given focal depth ��. Shown in Fig 8 (b) is 
����� � �0�0��00���� ���, the scattered detection efficiency when the focal point is �00	�� deep.  
4.3.5 Formulation for signal-to-background ratio 
When the excitation and detection optics are focused at ��, the total CM signal can be 
expressed as a sum of four terms: 
 ���	���� � ∭������������ ��� � �������� ���� � ������� ��� � ������ ���� � 	 ��������� � 
 ��������� � ����� ���� � ����� ����  (15) 
Here ��������� � ∭����������� ��� � ������ ��� is related to ballistic excitation and ballistic 
fluorescence photons, and is the desired signal. All the three-dimensional integrals are over 
the entire volume of the turbid medium. The other three terms contribute to a background 
����� � ����� � ����� � ����� , that is related to scattered photons. The signal to background ratio 
(SBR) is thus defined as:  
  ����� � ���
��
�����  (16) 
in which 
����� �������������� ��������� ��� � �������� ��������� ��� � �������� ��������� ���� � 
 ����� � ����� � �����  (17) 
The total FMM signal is given by 
 �������� �∭������������ ��������� ��� � �������� ��������� ���� � 
 ������ ���� � ������ ����  (18) 
while the signal to background ratio is simply 




∭�����������������������  (19) 
4.3.6 Discussions and summary 
Various CM and FMM signals are compared in Fig. 9 (a). ����� and ������  decay exponentially 
with the focal depth as expected. ������  is slightly weaker than ����� because the modulation 
depth is always less than one. The CM background is dominated by ����� , which is related to 
scattered excitation and scattered emission photons. It overwhelms ����� for imaging depths 
over 200	��. In contrast, the FMM background ������  is significantly lower than the FMM 
signal ������ . The SBR ratios are plotted as functions of penetration depth in Fig. 9 (b). It is 
evident that FMM provides a much more superior SBR than CM even for small imaging 
depths. For a large imaging depth up to 1 mm, ������ is maintained at around 20	dB.  
Molecular Imaging 160 
4.3.4 Detection point-spread-function 
As CM and FMM have the same detection optics, their fluorescence detection efficiencies are 
identical. For the ballistic fluorescence light, the detection efficiency is given by: 




  (13) 
where the two-dimensional integration is over S, the image of the pinhole in the medium 
and centered at ��. The optical coordinates ��and �� are normalized radial and axial 
distances between �� and the point ��� �� ��� within �. The first term of Eqn. 13, �������  is the 
solid angles of the detection cone where � is half of the angular aperture of L1. 
Scattered fluorescence photons are again simulated by the use of Monte Carlo method. 
Photon packets are launched from a point �0� 0� ��� with the initial directions uniformly 
sampled. Trajectory of propagation and scattering steps for each photon is generated using 
the standard Monte Carlo approaches. Photons emerging from the surface without 
scattering are discarded. Scattered photons, once crossed the upper medium surface, are 
traced using geometric optics. In order to enhance the simulation efficiency by reusing the 
trajectories, we actually deploy an array of detectors after L2. The detector array consists of 
101 planes along the optical axis, corresponding to focal depths sampled every 10��� from 
0 to 1000��� in the medium. Each detection plane has a sensing area 1� � in diameter and 
it is divided into a grid of 1��� by 1��� pixels. A photon captured by the pixel at ���� adds a 
normalized weight to the scattered detection efficiency: 
  ������ ��� � ������ ��� � ����   (14) 
Here � is the weight of the photon packet, �� is the pinhole area in ���and � is the total 
number of photons launched, and �� is the conjugate point of ���� in the medium. 
 
Fig. 8. Scattered detection efficiency as a function of (a) focus point or (b) molecular target 
position. 
Focal Modulation Microscopy: Principle and Techniques 161 
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Fig. 9. Normalized intensity and signal-to-background ratio for various depths. (a) FMM signals 
 (dashed-dotted) and  (asterisks) compared with CM signals  (solid),  (dashed), 
 (diamonds),  (circles), and  (pluses); (b) SBR for FMM (circles) and CM (asterisks). 
In this section, the advantage of FMM is well explained with the theoretical model 
combining the scalar diffraction theory and Monte Carlo methods. The SBR ratio of FMM is 
evaluated with such a model and is compared with that of CM. It is obvious that SBR is not 
a limiting factor for an imaging depth as large as . Our model can also be used to 
analyse other performances such as spatial resolution and SBR ratio of FMM. 
4.4 Effect of aperture configurations on the modulation depth of FMM 
Another important parameter in FMM is the modulation depth, which can be defined as the 
ratio of the intensity of the modulated fluorescence signal (i.e. the ac component) to the 
average intensity (approximately the dc component) collected by the aperture pinhole. The 
modulation depth is crucial in designing illumination aperture for FMM because it 
determines the efficiency of FMM signal generation with respect to the total excitation 
power deposited on the sample. Principally, a larger modulation depth will give us 
enhanced FMM signal and therefore improved signal to noise ratio. In addition, a larger 
modulation depth allows us to reduce the threshold of excitation power for optical image 
quality when probing deep into thick living specimens, which is crucial in minimizing the 
probability of photobleaching and phototoxicity resulted from higher excitation power. In 
this section, we first define the modulation depth and an analytical expression for its 
calculation in FMM. In particular, various aperture designs are being considered to compare 
their effectiveness in generating high modulation depth. The spatial resolutions correspond 
to each aperture are also presented with some concluding remarks at the end. 
4.4.1 Definition of modulation depth for FMM 
The modulation depth of FMM can be defined as the ratio of the intensity of the modulated 
fluorescence signal (i.e. ac component) to the average intensity (i.e. dc component) collected 
by the aperture pinhole when exciting a fluorescence-stained sample: 
    (20) 
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Here � denotes the signal intensity at the pinhole detector. In FMM, the illumination 
apertures consists of, non-modulated and modulated zones, as shown in Fig. 10, in which 
the green regions having a constant phase delay while the light passing through the blue 
regions is subject to a time-varying phase delay. The relative phase delay ���� between the 
green and blue regions varies from 0 to � phase shift. All the apertures are designed such 
that the total area of the modulated regions equal to that of the unmodulated regions, in 
order to have the maximum modulation efficiency. 
In previous section, we already described the 3D illumination point spread function (IPSF) 
after the objectives based on scalar diffraction theory. Assuming the wavefront of the 
illumination beams is uniform before spatial phase modulator, we can obtain the IPSF of 
CM and FMM using the following equation in Cartesian coordinates: 






  (21) 
where � is the open area of the aperture and ���,, �,, �� is the instantaneous phase profile of 
the spatial phase modulator, which varies with time � according to designated modulation 
frequency. The lateral and axial coordinates �, �, and � are in the image space while �, and �, 
indicate the position in the aperture �. The wavenumber � is related to the wavelength of 
the illumination � as � � � ���  and � is the focal length of the objective. Then, the intensity on 
the detector ���� can be expressed as: 
  ���� �∭���, �, �, �� � �|����, �, ��|� ⊗� ���, ��� ������  (22) 
where ����, �, ��is the amplitude point spread function of the detection optics, ���, �� is the 
sensitivity function for the detector and is related to the size of the aperture pinhole in front 
of the detector. Thus, when the phase over the apertures is uniform (i.e. ���� � 0�, a strong 
constructive interference at the focal spot of the objectives is expected and the detected 
signal at the central focal spot will reach the maximum, which is also identical to that of CM. 
For CM, the phase profile is uniform (i.e. ���,, �,, �� � �) and thus the IPSF is simply: 






  (23) 
Then, the detected signal of CM at the focal spot is: 
  ��� �∭�����, �, �� � �|����, �, ��|� ⊗� ���, ��� ������  (24) 
On the other hand, when the relative phase delay of the modulated and unmodulated 
beams ���� is equal to �, a strong destructive interference will occur at the central spot of 
the point spread function of the illumination beams (i.e. within the first zeroth of the IPSF of 
FMM) and the detected intensity approximately reach the minimum (i.e. ����), with high-
intensity side lobes appearing immediately outside the central focal spot. At such, we can 
define the effective FMM intensity point spread function as the difference of the intensity at 
the central focal spot for illumination with uniform phase (i.e. ����) and that of modulated 
phase apertures (i.e. ����); which can be easily shown to be proportionally equal to the FMM 
intensity detected using heterodyne detection in real implementation. Here, we outline the 
equations for the illumination PSF of FMM: 
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Fig. 9. Normalized intensity and signal-to-background ratio for various depths. (a) FMM signals 
 (dashed-dotted) and  (asterisks) compared with CM signals  (solid),  (dashed), 
 (diamonds),  (circles), and  (pluses); (b) SBR for FMM (circles) and CM (asterisks). 
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    (20) 
Focal Modulation Microscopy: Principle and Techniques 163 
Here � denotes the signal intensity at the pinhole detector. In FMM, the illumination 
apertures consists of, non-modulated and modulated zones, as shown in Fig. 10, in which 
the green regions having a constant phase delay while the light passing through the blue 
regions is subject to a time-varying phase delay. The relative phase delay ���� between the 
green and blue regions varies from 0 to � phase shift. All the apertures are designed such 
that the total area of the modulated regions equal to that of the unmodulated regions, in 
order to have the maximum modulation efficiency. 
In previous section, we already described the 3D illumination point spread function (IPSF) 
after the objectives based on scalar diffraction theory. Assuming the wavefront of the 
illumination beams is uniform before spatial phase modulator, we can obtain the IPSF of 
CM and FMM using the following equation in Cartesian coordinates: 






  (21) 
where � is the open area of the aperture and ���,, �,, �� is the instantaneous phase profile of 
the spatial phase modulator, which varies with time � according to designated modulation 
frequency. The lateral and axial coordinates �, �, and � are in the image space while �, and �, 
indicate the position in the aperture �. The wavenumber � is related to the wavelength of 
the illumination � as � � � ���  and � is the focal length of the objective. Then, the intensity on 
the detector ���� can be expressed as: 
  ���� �∭���, �, �, �� � �|����, �, ��|� ⊗� ���, ��� ������  (22) 
where ����, �, ��is the amplitude point spread function of the detection optics, ���, �� is the 
sensitivity function for the detector and is related to the size of the aperture pinhole in front 
of the detector. Thus, when the phase over the apertures is uniform (i.e. ���� � 0�, a strong 
constructive interference at the focal spot of the objectives is expected and the detected 
signal at the central focal spot will reach the maximum, which is also identical to that of CM. 
For CM, the phase profile is uniform (i.e. ���,, �,, �� � �) and thus the IPSF is simply: 






  (23) 
Then, the detected signal of CM at the focal spot is: 
  ��� �∭�����, �, �� � �|����, �, ��|� ⊗� ���, ��� ������  (24) 
On the other hand, when the relative phase delay of the modulated and unmodulated 
beams ���� is equal to �, a strong destructive interference will occur at the central spot of 
the point spread function of the illumination beams (i.e. within the first zeroth of the IPSF of 
FMM) and the detected intensity approximately reach the minimum (i.e. ����), with high-
intensity side lobes appearing immediately outside the central focal spot. At such, we can 
define the effective FMM intensity point spread function as the difference of the intensity at 
the central focal spot for illumination with uniform phase (i.e. ����) and that of modulated 
phase apertures (i.e. ����); which can be easily shown to be proportionally equal to the FMM 
intensity detected using heterodyne detection in real implementation. Here, we outline the 
equations for the illumination PSF of FMM: 
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Then, the FMM intensity is simply: 
  ���� �∭������, �, �� � �|����, �, ��|� ⊗� ���, ��� ������  (26) 
Finally, the modulation depth of FMM can be easily calculated using equations. It is 
important to understand that the total intensity loading on the focal plane inside the sample 
(as well as the whole sample) is always uniform regardless of the relative phase-delay of the 
patterned illumination beam, and the detection pinhole (as well as its size) is crucial in 
collecting only the intensity-modulated fluorescence emission from the focal volume. Else, 
the amplitude of FMM signal over the focal plane would drop significantly. 
4.4.2 Simulation results 
The simulation results based on analytical expressions described in the previous section are 
presented here. Typical system parameters are being used in our simulation. The laser 
wavelength is ���	��. For simplicity, we assume the objective lens L1 and the collection lens 
L2 are identical and have the same numerical aperture of 0.55, and the excitation and 
emission lights have same wavelength as well. The pinhole diameter used is 0.�	��, about 
0.������ (����� is the diameter of Airy disk). Eight apertures (see Fig. 10), which includes 
three annular apertures, three fan-shaped apertures and two stripe-shaped apertures, are 
investigated. These apertures are selected partly due to their ease of fabrication. 
 
Fig. 10. Configurations of SPM apertures that are being investigated. The areas with green 
color are non-modulated, and those with blue are modulated. According to the first principle 















�  for 6-zone annular aperture. 
Similarly, the widths for stripe apertures are � � 0.�0�� for 4-zone stripe aperture and 
�� � 0.��5�, �� � 0.���� for 6-zone stripe aperture. � is the external radius of aperture. 
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The effective illumination IPSFs for different apertures calculated using equations described 
in section 4.4.1 are presented in Fig. 11. They are displayed as enface (upper row) and cross-
sectional (lower row) 2D images of around the focal point. Fig. 11 (a) are the effective IPSFs 
for annular apertures of two zones (left column), four zones (middle column), and six zones 
(right column), respectively. The results for fan-shaped and stripe-shaped apertures are 
arranged in a similar way in Fig 11 (b) and (c). The coordinates of the Figs ,  and  are 
related to the practical coordinates , , and  by ,  and  
with  the numerical aperture of objective lens,  the semi-angle aperture of the objective 
lens. The illumination IPSFs of FMM can be negative for some regions outside central focal 
volume due to differential excitation mechanism of FMM. If these negative side lobes are 
allowed to be included in the FMM image formation (i.e. by enlarging the detection 
pinhole), the FMM signals will diminish and become ineffective (Chen, Wong et al. 2008). 
 
Fig. 11. IPSFs for (a) annular, (b) fan shape and (c) stripe shape apertures. In (a) and (b) the 
first, second and third columns are corresponding to two, four, and six zones. In (c) The 
result of two zones is omitted because it is the same as the two-zone fan-shape aperture. The 
icon on the top-right of each graph is the corresponding aperture shape. 
From the IPSFs in Fig 11, we can calculate the modulation depth using the method described 
in previous section. The calculated modulation depth for the investigated apertures is 
shown in Table 2. Additionally, the lateral and axial spatial resolutions achievable are also 
expressed in term of full width half maximum (FWHM) of the simulated IPSFs (see Table 3), 
which is the diameter of the central spot where the intensity drops beyond half of the 
maximum. Basically, there are no significant differences between the achievable spatial 
resolutions in both lateral and axial directions. 
Molecular Imaging 164 







Then, the FMM intensity is simply: 
  ���� �∭������, �, �� � �|����, �, ��|� ⊗� ���, ��� ������  (26) 
Finally, the modulation depth of FMM can be easily calculated using equations. It is 
important to understand that the total intensity loading on the focal plane inside the sample 
(as well as the whole sample) is always uniform regardless of the relative phase-delay of the 
patterned illumination beam, and the detection pinhole (as well as its size) is crucial in 
collecting only the intensity-modulated fluorescence emission from the focal volume. Else, 
the amplitude of FMM signal over the focal plane would drop significantly. 
4.4.2 Simulation results 
The simulation results based on analytical expressions described in the previous section are 
presented here. Typical system parameters are being used in our simulation. The laser 
wavelength is ���	��. For simplicity, we assume the objective lens L1 and the collection lens 
L2 are identical and have the same numerical aperture of 0.55, and the excitation and 
emission lights have same wavelength as well. The pinhole diameter used is 0.�	��, about 
0.������ (����� is the diameter of Airy disk). Eight apertures (see Fig. 10), which includes 
three annular apertures, three fan-shaped apertures and two stripe-shaped apertures, are 
investigated. These apertures are selected partly due to their ease of fabrication. 
 
Fig. 10. Configurations of SPM apertures that are being investigated. The areas with green 
color are non-modulated, and those with blue are modulated. According to the first principle 















�  for 6-zone annular aperture. 
Similarly, the widths for stripe apertures are � � 0.�0�� for 4-zone stripe aperture and 
�� � 0.��5�, �� � 0.���� for 6-zone stripe aperture. � is the external radius of aperture. 
Focal Modulation Microscopy: Principle and Techniques 165 
The effective illumination IPSFs for different apertures calculated using equations described 
in section 4.4.1 are presented in Fig. 11. They are displayed as enface (upper row) and cross-
sectional (lower row) 2D images of around the focal point. Fig. 11 (a) are the effective IPSFs 
for annular apertures of two zones (left column), four zones (middle column), and six zones 
(right column), respectively. The results for fan-shaped and stripe-shaped apertures are 
arranged in a similar way in Fig 11 (b) and (c). The coordinates of the Figs ,  and  are 
related to the practical coordinates , , and  by ,  and  
with  the numerical aperture of objective lens,  the semi-angle aperture of the objective 
lens. The illumination IPSFs of FMM can be negative for some regions outside central focal 
volume due to differential excitation mechanism of FMM. If these negative side lobes are 
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Fig. 11. IPSFs for (a) annular, (b) fan shape and (c) stripe shape apertures. In (a) and (b) the 
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result of two zones is omitted because it is the same as the two-zone fan-shape aperture. The 
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From the IPSFs in Fig 11, we can calculate the modulation depth using the method described 
in previous section. The calculated modulation depth for the investigated apertures is 
shown in Table 2. Additionally, the lateral and axial spatial resolutions achievable are also 
expressed in term of full width half maximum (FWHM) of the simulated IPSFs (see Table 3), 
which is the diameter of the central spot where the intensity drops beyond half of the 
maximum. Basically, there are no significant differences between the achievable spatial 
resolutions in both lateral and axial directions. 
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Aperture pattern Number of zones 2 4 6 
Annular 0.446 0.757 0.865 
Fan 0.361 0.602 0.762 
Stripes 0.361 0.691 0.814 
Table 2. Modulation depths for various aperture patterns. 
 Lateral Axial 
Aperture pattern Number of zones 2 4 6 2 4 6 
Annular 2.666 2.689 2.692 6.692 7.699 7.898 
Fan 2.694 2.697 2.697 8.057 8.056 8.057 
Stripes 2.694 2.696 2.696 8.057 8.060 8.059 
Table 3. Lateral and axial spatial resolution for various aperture patterns. 
4.4.3 Discussions 
We have investigated the effectiveness of various aperture patterns in achieving higher 
modulation depth for FMM that are important for efficient generation of intensity 
modulation at the focal spot. We compare the resultant modulation depths and achievable 
spatial resolutions for these aperture patterns through analytical calculations, with several 
comments can be made. 
First, with the number of zones increasing from 2 to 6, the modulation depths of the three 
types of apertures increase from 0.3~0.4 to 0.75~0.85, as shown in Table 2. As explained 
earlier, there are negative side lobes in the effective IPSFs as FMM is based on differential 
excitation mechanism (see Fig. 11). In the cases for an aperture with two zones, the negative 
side lobes appear very close to the positive central main lobe and their absolute peak values 
are greater than 0.4 (normalized to the main lobe peak value). Such behaviour lead to 
reduced FMM signal if these negative side lobes are included in FMM image formation 
when the pinhole size is too large. Alternatively, we can implement smaller detection 
pinhole to exclude these negative side lobes, which at the same time reduced FMM signals 
from central spot. By increasing the number of zones in the SPM aperture, however, we can 
disperse the negative side lobes, moving their peak positions slightly away from the focus 
and at the same time reducing their magnitudes. Thus, we have greater flexibility in 
selecting larger detection pinhole to capture maximum FMM signals from central focal spot. 
This is generally true for annular, fan-shape, and stripe-shape apertures.  
Second, it is observed that there is slight degradation (from 6.7 to 7.9) for the axial resolution 
of annular aperture when the modulation depth is being increased by increasing the number 
of zones from 2 to 6, and almost no influence to the axial resolutions of other type of 
apertures, which is shown in Table 3. Previously, it has been shown that CM with an 
annular aperture and a point detector will result in improvement of lateral spatial resolution 
at the cost of degradation of optical sectioning strength (i.e. axial resolution) (Sheppard and 
Gu 1991). However, using a finite sized pinhole, annular aperture could give us 
improvement of axial resolution (Gu and Sheppard 1991). The effect of size of pinhole 
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detector on the axial resolution of FMM with annular aperture as the number of zones 
increase is thus worth to be further investigated in future.   
Last but not least, from the standpoint of modulation depth and axial resolution, the annular 
apertures are superior to the fan shape and stripe shape apertures, while the achievable 
lateral resolutions are approximately the same for all types of apertures. This is expected 
because neither the fan-shape nor the stripe-shape apertures have noticeable negative side 
lobes in the axial direction (Fig. 11 (b) and (c)), except the annular aperture that results in 
strong negative side lobes along the optical axis (Fig. 11 (a)), but has been taken care off by 
the pinhole. There are strong side lobes in the focal plane for the fan-shaped and stripe-
shaped apertures due to their circular asymmetry and therefore better resolving power is 
expected in certain directions, such as, along  direction for fan shape and stripe shape 
apertures (see Fig. 11 (b) and (c)). Nevertheless, the poorest resolution along the lateral 
directions are being chosen as comparison. At such, we found no significant improvement 
of the lateral resolution for all apertures. 
5. Implementations of focal modulation microscopy 
Here, we describes on the implementations of two spatiotemporal phase modulation 
schemes for focal modulation microscope - double reflecting mirrors as well as FMM based 
on acousto-optical modulators that are significantly progressive in term of stability and 
image performance.  
5.1 Double-reflecting mirror 
5.1.1 System design 
Shown in Fig. 12 is the schematic diagram of the first prototype FMM system developed at 
the Optical Bioimaging Lab, National University of Singapore. The light source is a   
solid state single frequency laser, whose 25 mW output beam is expanded to about  in 
diameter. When passing through the spatial phase modulator, the beam is split into two 
spatially separated half-beams, which are parallel and subject to different phase delays. The 
spatiotemporal phase modulation is implemented with two parallel mirrors (M1 and M2) 
inside the dashed box. M1 is mounted on a stationary base while M2 is mounted on a 
piezoelectric actuator. A sinusoidal voltage signal of a single frequency  
superimposed on an appropriate dc bias is applied to the actuator to induce a relative phase 
shift periodically between 0 and . The spatiotemporal phase modulated excitation beam is 
reflected by a dichroic mirror and is then directed by a two-dimensional fast steering mirror 
to a 20X objective. Fluorescence emission is collected by the same objective and de-scanned 
is performed by the same fast steering mirror. A long pass emission filter is used to further 
reject the excitation light already suppressed by the DM. The cut-on wavelength for both the 
DM and the long pass filter is between 667 and 670 . Then the fluorescence light is 
focused by an achromat and coupled into a single mode (SM) optic fiber. A photomultiplier 
tube (R928, Hamamatsu Photonics Co.) converts the weak light signal to an electrical signal, 
which is digitized and sampled by a DAQ card in a personal computer (PC). The acquired 
photoelectrical signal contains a constant DC component and a time-varying AC component 
at 5 kHz due to modulated excitation. A Fast Fourier Transform (FFT) is performed on the 
PC to retrieve both FMM and CM signals respectively.  
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detector on the axial resolution of FMM with annular aperture as the number of zones 
increase is thus worth to be further investigated in future.   
Last but not least, from the standpoint of modulation depth and axial resolution, the annular 
apertures are superior to the fan shape and stripe shape apertures, while the achievable 
lateral resolutions are approximately the same for all types of apertures. This is expected 
because neither the fan-shape nor the stripe-shape apertures have noticeable negative side 
lobes in the axial direction (Fig. 11 (b) and (c)), except the annular aperture that results in 
strong negative side lobes along the optical axis (Fig. 11 (a)), but has been taken care off by 
the pinhole. There are strong side lobes in the focal plane for the fan-shaped and stripe-
shaped apertures due to their circular asymmetry and therefore better resolving power is 
expected in certain directions, such as, along  direction for fan shape and stripe shape 
apertures (see Fig. 11 (b) and (c)). Nevertheless, the poorest resolution along the lateral 
directions are being chosen as comparison. At such, we found no significant improvement 
of the lateral resolution for all apertures. 
5. Implementations of focal modulation microscopy 
Here, we describes on the implementations of two spatiotemporal phase modulation 
schemes for focal modulation microscope - double reflecting mirrors as well as FMM based 
on acousto-optical modulators that are significantly progressive in term of stability and 
image performance.  
5.1 Double-reflecting mirror 
5.1.1 System design 
Shown in Fig. 12 is the schematic diagram of the first prototype FMM system developed at 
the Optical Bioimaging Lab, National University of Singapore. The light source is a   
solid state single frequency laser, whose 25 mW output beam is expanded to about  in 
diameter. When passing through the spatial phase modulator, the beam is split into two 
spatially separated half-beams, which are parallel and subject to different phase delays. The 
spatiotemporal phase modulation is implemented with two parallel mirrors (M1 and M2) 
inside the dashed box. M1 is mounted on a stationary base while M2 is mounted on a 
piezoelectric actuator. A sinusoidal voltage signal of a single frequency  
superimposed on an appropriate dc bias is applied to the actuator to induce a relative phase 
shift periodically between 0 and . The spatiotemporal phase modulated excitation beam is 
reflected by a dichroic mirror and is then directed by a two-dimensional fast steering mirror 
to a 20X objective. Fluorescence emission is collected by the same objective and de-scanned 
is performed by the same fast steering mirror. A long pass emission filter is used to further 
reject the excitation light already suppressed by the DM. The cut-on wavelength for both the 
DM and the long pass filter is between 667 and 670 . Then the fluorescence light is 
focused by an achromat and coupled into a single mode (SM) optic fiber. A photomultiplier 
tube (R928, Hamamatsu Photonics Co.) converts the weak light signal to an electrical signal, 
which is digitized and sampled by a DAQ card in a personal computer (PC). The acquired 
photoelectrical signal contains a constant DC component and a time-varying AC component 
at 5 kHz due to modulated excitation. A Fast Fourier Transform (FFT) is performed on the 
PC to retrieve both FMM and CM signals respectively.  
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Fig. 12. Schematic diagram of the prototype focal modulation microscopy system. The 
spatial phase distribution of the 6�0��� excitation beam (red) is modulated by the use of 
two parallel mirrors, M1 (stationary) and M2 (oscillating axially at � kHz). The fluorescence 
emission (purple) from the focal volume is collected by a fiber based confocal detection 
system, and then the oscillatory component at � kHz is retrieved for image formation. The 
personal computer is used for data acquisition and analysis, lateral scanning with the fast 
steering mirror, and axial scanning with the 3D stage. 
5.1.2 Experiments and results 
To demonstrate the capability of our method for in vivo imaging of cellular and sub-cellular 
structure and function, we used chicken cartilage as a sample tissue to evaluate the 
performance of FMM. Chondrocytes are the only cells found in cartilage. The cells are 
usually of a rounded or bluntly angular form, lying in groups of two or more in a glandular 
or almost homogeneous matrix. Chicken cartilage was cut into slices around ��mm in 
thickness and stained with DiD (DiIC18 (5), Invitrogen Corp.), a lipophilic tracer for cell 
membrane labeling. The laser power was attenuated by 10 � 1000 times to avoid fast 
photobleaching. Fig. 13 (a) and 13 (b) are CM and FMM images acquired at a depth around 
��0���.  
One can easily see that optical sectioning is not effective in the confocal image (Fig 13(a)). 
Fluorescence signals from layers other than the focal plane cast shadows in the image, 
resulting in overlapping structures and blurred cellular shapes. On the contrary, the FMM 
image (Fig. 13 (b)) shows uncompromised quality. The upper-central area was then scanned 
with a four times finer step (about 100 nm) and the high magnification images are displayed 
in Fig. 13 (c) and (d). The FMM image (Fig. 13 (d)) provides detailed information with sub-
micron spatial resolution and excellent contrast, which are not available from the CM image 
(Fig. 13 (c)). We then pushed further to test the maximal penetration depth of our prototype 
FMM system. Shown in Fig 13. (e) and (f) are FMM images from 500 and 600 �� in depth. It 
is evident that resolution is still high enough to visualize cellular structures. Beyond 600 ��, 
the shot noise associated with the background will gradually overwhelm the FMM signal.  
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To the best of our knowledge, the penetration depth we report here has never been achieved 
by one photon fluorescence based microscopy when imaging optically dense biological 
tissues. However, there might be still room for further improvements. The tissue samples in 
our experiments were uniformly stained. As a result, the superficial layers strongly 
absorbed the excitation light and generated intense background emissions. For certain 
applications where only the deep region of interest is stained, an even larger penetration 
depth should be possible. More photostable and brighter fluorescent labels (e.g., quantum 
dots) can also help further increase the imaging depth. 
 
Fig. 13. Fluorescence images of chondrocytes obtained from chicken cartilage. Confocal images 
((a) and (c)) were acquired simultaneously with the corresponding FMM images ((b) and (d)) 
at a depth of 280 ��. (e) and (f) are FMM images obtained from 500 and �00��� in depth. 
The imaging depth mentioned above was achieved with a relatively long excitation 
wavelength of ��0���. For excitation light of shorter wavelength, such as UV or blue light, 
the achievable imaging depth is expected to be smaller due to stronger scattering. On the 
other hand, near infrared fluorescence dyes (Indocyanine Green, for example) would allow 
the use of an even longer excitation wavelength (�80���) and deeper imaging. The imaging 
speed of this prototype FMM is limited by the spatiotemporal phase modulator consisting of 
two mirrors. The minimal dwelling time at each pixel is 0.2 ms, significantly longer than the 
typical 10 microsecond pixel dwelling time for commercial CM and MPM systems.  
5.1.3 Discussions 
The imaging depth demonstrated here is related to a relatively long excitation wavelength 
of 640 nm. Generally the scattering coefficient of biological tissue decreases with increasing 
wavelength, and in many situations the attenuation of ballistic light is dominated by 
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our experiments were uniformly stained. As a result, the superficial layers strongly 
absorbed the excitation light and generated intense background emissions. For certain 
applications where only the deep region of interest is stained, an even larger penetration 
depth should be possible. More photostable and brighter fluorescent labels (e.g., quantum 
dots) can also help further increase the imaging depth. 
 
Fig. 13. Fluorescence images of chondrocytes obtained from chicken cartilage. Confocal images 
((a) and (c)) were acquired simultaneously with the corresponding FMM images ((b) and (d)) 
at a depth of 280 ��. (e) and (f) are FMM images obtained from 500 and �00��� in depth. 
The imaging depth mentioned above was achieved with a relatively long excitation 
wavelength of ��0���. For excitation light of shorter wavelength, such as UV or blue light, 
the achievable imaging depth is expected to be smaller due to stronger scattering. On the 
other hand, near infrared fluorescence dyes (Indocyanine Green, for example) would allow 
the use of an even longer excitation wavelength (�80���) and deeper imaging. The imaging 
speed of this prototype FMM is limited by the spatiotemporal phase modulator consisting of 
two mirrors. The minimal dwelling time at each pixel is 0.2 ms, significantly longer than the 
typical 10 microsecond pixel dwelling time for commercial CM and MPM systems.  
5.1.3 Discussions 
The imaging depth demonstrated here is related to a relatively long excitation wavelength 
of 640 nm. Generally the scattering coefficient of biological tissue decreases with increasing 
wavelength, and in many situations the attenuation of ballistic light is dominated by 
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achievable imaging depth should be smaller. On the other hand, near infrared fluorescence 
dyes (Indocyanine Green, for example) would allow the use of an even longer excitation 
wavelength (780 nm) and deeper imaging. In our future research, we will systematically 
study the dependence of imaging depth on excitation wavelength and fluorescence dye 
properties. The imaging speed of our prototype FMM is limited by the modulation 
frequency. The minimal dwelling time at each pixel is , significantly longer than the 
typical  pixel dwelling time for commercial CM and MPM systems. We plan to develop 
electro-optical material based spatial phase modulators that can be modulated at a 
frequency more than a few MHz. Near-real-time FMM imaging (a few frames per second) 
would be possible with such a modulator.  
5.2 FMM using acousto-optical modulators 
We reported our FMM system implemented using tilting plate phase modulator (Wong, 
Chong et al. 2009) where a modulation frequency up to a few tens of kHz can been achieved. 
However, compared to most commercial laser scanning microscopes with microsecond pixel 
dwell time, that modulation frequency is still too low. In this section we describe a near-real-
time FMM with AOMs and demonstrate the improved image acquisition speed and quality. 
Our FMM system is based on an Olympus FV300 confocal microscope 
 
Fig. 14. Setup for a FMM implemented using acousto-optical modulators. Laser beam is split 
by a beam splitter (BS) in which light beam in each arm undergoing frequency shifting by 
two acoustic-optical modulators (AOM) with different resonance frequencies. Phase-shifted 
beams are reflected back to the BS by retroreflectors (R1 and R2). They are aligned in parallel 
non-overlapping manner when being split second times at BS in which one combined beam 
will be used to generate a reference signal while another combined beam is directed to the 
scanning unit of Olympus FV300 to excite the samples through the objective lens (OBJ). PD 
is a photodetector and M is a mirror. 
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5.2.1 Optical setup 
The spatio-temporal phase modulator based on AOMs is shown schematically in see Fig. 14. 
The coherent laser beam is first split by a beam splitter into two beams which then passes 
through two AOMs with slightly different resonance frequencies (i.e. f1 and f2) where they 
undergo zeroth- and first-order diffractions. The first-order diffracted beams which are 
Doppler shifted at the f1 and f2 on each arm. They are reflected with slight lateral 
displacement using retroreflectors to return to the same AOMs and then are recombined at 
beam splitter. It is important to note that the two beams at the moment are Doppler shifted 
at twice the resonance frequencies of the AOMs respectively as they passed through the 
AOMs twice. Part of the combined beam is directed towards a fiber-optic photodetector, 
which generates a reference signal at the optical beating frequency of 2(f1 - f2). The remaining 
part of the modulated laser beam is directed to the scanning unit of a conventional CM 
(Olympus FV300) to excite the biological sample stained with fluorescence probes. 
5.2.2 Detection of FMM signal 
The fluorescence emissions are then detected by the built-in PMT detector (R3896, 
Hamamatsu Photonics Co.) behind a confocal pinhole. The PMT output is preamplified 
before feeding to an I/Q demodulator, where the oscillatory component at the beating 
frequency is picked up by mixing with the reference signal. The demodulated signal is 
further enhanced by the low-frequency amplifier and is then fed to the data acquisition 
device of the FV300 system (see Fig. 15 for the signal processing pathway).  
 
Fig. 15. Flow diagrams showing the signal-processing pathway. 
The two AOMs we are using have resonant frequencies of 75	MHz and 80	MHz, 
respectively, resulting in a modulation frequency of 10	MHz. In principle, such a high 
modulation frequency allows a pixel dwell time as short as 0.1 microseconds. This 
instrument is a significant improvement in term of imaging speed, stability and noise level 
compared with the prototype setup we reported previously (Chen, Wong et al. 2008; Wong, 
Chong et al. 2009). CM and FMM images can be captured simultaneously with the same 
acquisition speed using our current system. The effectiveness of FMM in improving image 
quality is demonstrated by imaging blood vessels in mouse brain labeled with lipophilic 
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carbocyanine dye DiI (‘DiI’; DiIC18(3), Invitrogen), self-made tissue phantom as well as DiD 
stained chicken chondrocytes.  
5.2.3 Experiments and results 
The mouse brain samples were prepared using the established techniques described in the 
literature (Li, Song et al. 2008). A mouse was first sacrificed by overdose with CO2 in a CO2 
chamber. A transverse incision was made to open the abdominal cavity. The diaphragm was 
exposed and cut. The chest was then cut on both sides up to the second rib. The anterior 
chest wall was turned toward the head of the mouse to expose the chest cavity. The butterfly 
needle of the perfusion device was inserted into the left ventricle, and the right atrium was 
punctured. ��� of standard phosphate buffer solution (PBS) was injected from the perfusion 
device at the rate of � � ������� for ����. Then, � � ���� of the DiI solution was injected 
at a rate of � � ������� for � � ��� ��. Successful perfusion was monitored by observing 
color change in the ear, nose and palms of the mouse from pale while to purple. Lastly, the 
fixative (4% paraformaldehyde solution) was injected at a rate of � � ������� for a total of 
5min. It should be ensured that there are no air bubbles in the perfusion device as 
introduction of air into the circulatory system could block blood vessels, resulting in poor 
perfusion. The stained mouse brain was then extracted, and stored in 4% (wt/vol) 
paraformaldehyde solution. The whole fixed mouse brain is mounted by mounting medium 
(Polyvinyl alcohol mounting medium with DABCO®, antifading BioChemika, Sigma-
Aldrich) in a coverslip bottom dish with cover (MatTek Corp) for imaging using our FMM.  
Besides fluorescence imaging, we also apply our FMM system on imaging a cylindrical self-
made tissue phantom slab mainly consisted of epoxy-resin, resin hardener, and titanium 
dioxide (TiO2). The TiO2 powder acts as scattering components and the main contrast agent 
inside the tissue phantom. This tissue phantom was made based on the procedures reported 
in literature (Firbank, Oda et al. 1995) and is commonly used for calibration in diffuse 
optical tomography (DOT) (Mo and Chen 2008). The chicken cartilage sample is prepared in 
the similar way described in section 5.1.2. 
A. Mouse brain vasculatures imaging 
The mouse brain samples were imaged using our FMM system with either objectives 
UPLSAPO 10x/0.40 numerical aperture (NA) or LUCPLANFLN 20x/0.45 NA to evaluate 
our FMM system in term of image quality improvement. Here we show the images captured 
using CM and FMM simultaneously to demonstrate the robustness of FMM in rejecting out-
of-focus fluorescence background and retaining high-resolution features even imaging deep 
inside tissues (depicted by Fig. 16). 
A blood vessel bifurcation imaged using CM (Fig. 16 (a)) and FMM (Fig. 16. (b)) shows that 
much finer features can be visualized by FMM clearly at the penetration depth around 
�����. Fig. 16 (c) and (d) shows the digital magnification near the bifurcation of the main 
blood vessel (indicated by white boxes in Fig. 16 (a) and (b)) which also reveals better 
contrast on the fine structures of the blood vessels by the image captured by FMM as 
compared to CM. From the intensity profiles spanning the both white lines (top-down) in 
the Fig. 16 (c) and (d), we can also observe that the peaks are more clearly visible and 
distinctive from each other’s in the FMM image with sharper valleys, and significant 
reduction in background as well. This indicates that our FMM system can provide better 
image contrast and more structural information of the tissue being studied.  
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Fig. 16. Demonstration of FMM in retaining high-resolution features by rejecting out-of-
focus fluorescence background. A blood vessel bifurcation image acquired with Olympus 
LUCPLANFLN 20x/0.45 NA using (a) CM and (b) FMM shows much finer features can be 
revealed by FMM even at penetration depth up 200um. Fig. 16 (c) and (d) shows the digital 
magnification near the bifurcation of the main blood vessel which reveals much richer 
features on the image captured by FMM. The plot at the bottom of the images shows the 
intensity profiles of the white lines (top-down) in the images. 
B. Tissue phantom imaging 
We also performed imaging in the tissue phantom over the depths of  with 
 increments. A single frame image of a cluster of TiO2 powder (see Fig. 17) embedded 
at  inside the self-made tissue phantom captured using CM and FMM operated in 
reflectance mode.  
Similarly, FMM (see Fig. 17 (b)) could significantly improve the image quality by providing 
superior contrast and sharp edges as compared to CM which are blurred mainly by multiple 
scattering effects. The peaks are also more clearly distinguished from each other in FMM 
despite the TiO2 granules are in close proximity, as shown by the intensity profile spanning 
the white line (left-right), with higher SBR ratio due to lower background intensity.  
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Fig. 17. Image of cluster of TiO2 embedded 320um inside tissue phantom captured with 
Olympus LUCPLANFLN 20x/0.45 NA using (a) CM and (b) FMM. Better image quality is 
achieved using FMM, with less blurring and structures are more clearly distinguishable due 
to sharp boundaries. The plot at the bottom of the images shows the intensity profile of the 
white lines in the images. Peaks are more distinct with better contrast can be observed. 
To perform more quantitative analysis of image quality improvement by FMM, we selected 
a pair of identical region of interest (ROI) from Fig. 17 (a) and (b) respectively and compare 
their normalized spectra (with respect to the dc values). From Fig. 18, we can observe that 
the high frequency components (>1 cycle/µm) in the FMM image are about 13 dB stronger 
than those in the CM image. This can be translated to a 13 dB improvement in the SBR ratio 
provided by FMM. However, our previous theoretical model (Chong, Wong et al. 2010) 
predicted a 20 dB enhancement by FMM at a similar imaging depth of 2 scattering mean free 
paths (the scattering coefficient of our tissue phantom is around 6 cm-1 (Mo and Chen 2008) . 
This discrepancy could be due to slight overlapping of the two excitation beams and the 
resultant residual intensity modulation which can be minimized by improved modulator 
designs. 
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Fig. 18. Normalized spatial spectra (with respect to dc values) of the region of interests 
labeled by square boxes in Fig. 17 (a) and (b) showing the spatial frequency components of 
CM and FMM respectively. 
C. Chicken chondrocytes samples 
We also imaged chondrocytes of the chicken cartilage samples labelled with lipophilic 
carbocyanine dye DiD (DiD’ solid; DiIC18 (5) solid, Invitrogen) using objectives UPLSAPO 
10x/0.40 numerical aperture (NA).  
 
Fig. 19. Comparison of FMM and confocal fluorescence microscopy of chondrocytes of 
chicken cartilages at penetration depth around . (a) The chondrocytes were labeled 
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Generally, it is evident that the FMM image gives us less background than raw confocal 
fluorescence microscopy image (Fig. 19 (a)). The optical contrast of FMM image is also 
greatly improved, whereas the confocal data are blurred as a result of light scattering. The 
removal of scattered light also translated directly into enrichment in information quality, 
revealing features inside the cellular compartments that were obscured in confocal images 
(Fig. 19 b), indicating that FMM can preserve the optical contrast for large penetration depth 
in which the fluorescence background dominates the collected signals. The advantages of 
FMM in terms preserving optical contrast and providing richer subcellular information will 
be important for imaging of subcellular studies of thick specimens such as characterizing the 
morphological changes of nuclei in cancers cells (Yao, Maslov et al. 2010).  
5.2.4 Discussions and summary 
We have validated the capability of FMM in improving image quality at large penetration 
depth by visualizing various specimens. All the images were taken at 512x512 pixels, with a 
pixel dwell times of around 10���, resulting image acquisition time of around ����. We 
emphasized that as the mouse brain samples are specifically stained in which only blood 
vessels void of blood (one of the major absorbers and scatterers inside biological tissues) are 
labeled with DiD, generally less background will be observed while larger penetration 
depth is expected compared to uniformly stained samples. Nevertheless, CM still suffers 
from poor image quality especially in observation of finer features; while FMM can work 
robustly in detecting fluorescence by ballistic photons and rejecting out-of-focus 
fluorescence background even at the large depth. This is an important feature for 
investigations and characterizations of thick tissue with sub-micron spatial resolution when 
confocal pinhole fails to reject majority of the out-of-focus fluorescence background. Better 
characterization of microvasculatures in animal model over large observation volume using 
FMM can be potentially useful especially for quantification of angiogenesis in term of 
density/diameter of blood vessels in live animal cancer model (Lunt, Gray et al. 2010). We 
also highlight that though FMM can reject most of the background, it cannot increase the 
signal level and thus if the FMM signal falls below the shot noise floor at extreme depths, 
other strategies (i.e. denoise image processing and/or extended image acquisition time) may 
be needed to improve the image quality.  
A modulation frequency of 160 MHz can be achieved if only a single AOM is used. 
However, a too high modulation frequency could cause significant attenuation of the FMM 
signals as the signal intensity is proportional to ������ in which ��is the modulation 
frequency and � is the lifetime of fluorescent probes. As most of the fluorescent molecules 
have a typical lifetime of a few nanoseconds, deterioration of the signal-to-noise ratio will 
thus be a serious problem at large penetration depths. The 10 MHz we choose falls in the 
optimal frequency range for fast image acquisition and negligible signal attenuation, and it 
is compatible with available demodulation components. In future, the issues of inherent 
Poisson statistical noise that gradually becoming significant in the case of low intensity 
signal related to deep imaging of biological tissues and further improvement of the image 
quality with the inclusion of Poisson noise removal will be studied. 
6. Conclusions 
It is a seemingly endless endeavour as microscopists seek to push ever deeper into 
biological specimens, while resolving micro-structural details and observing specific 
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molecular events. This book chapter describes the development of high-speed focal 
modulation microscopy and the corresponding technological advancement, in which the 
aim is to extend the penetration depth limit in thick specimens, without the necessity of the 
usage of long wavelength excitation or non-linear effect, i.e. currently two main approaches 
for achieving large penetration depth in biological specimens. FMM has thus far proved to 
be a significant improvement over the conventional confocal microscopy in term of SBR 
ratio at large penetration depths and potentially useful for cellular and molecular in vivo 
imaging. Its overall low-cost implementation also means its potential to be widely adopted 
as a basic research tool in biomedical and clinical applications. 
In summary, the principles of FMM is elaborated and two implementations of FMM which 
varies in term of phase modulation schemes – double-mirrors phase modulator and FMM 
based on acousto-optical modulator that are significantly progressive in term of stability and 
image performance as compared to first FMM prototype based on double mirror spatial 
phase modulator (Chen, Wong et al. 2008) are being demonstrated. It is worth to mention 
that the modulation frequency is greatly enhanced from kHz range to MHz range, and the 
accompanied benefits include higher image acquisition speed and possible adaptation to 
fluorescence lifetime imaging. We also demonstrated the capability of FMM in improving 
the imaging contrast of various types of samples over a large penetration depth. We also 
highlight that FMM can operate in both fluorescence and back-scattered/reflectance mode. 
This is contrasted to the non-linear methods such as two-photon microscopy which only 
improve the imaging depth in fluorescence mode. FMM can switch between fluorescence 
and back-scattered/reflectance mode by enabling/disabling the phase modulation 
components in the illumination arm, thus allowing observation of surface topology and 
tissue morphology based on the back-scattered/reflectance mode as well as rich functional 
and molecular-specific information through the fluorescence mode.  
6.1 Future directions 
We believe FMM technique will be useful for many biological applications, which large 
penetration depth is required. Future works to combine the technique of FMM with multi-
photon microscopy and microendoscopy are underway to further improve the penetration 
depth achievable by optical techniques through better rejection of background fluorescence; 
and for clinical usage to help in early disease detection and diagnosis. On top of that, the 
application of adaptive optics in FMM to pre-conditioning the beam profile of the excitation 
beam will further improve the modulation efficiency of FMM, which currently hampered by 
optical aberrations due to biological samples inhomogeneity. Much stronger FMM signal 
can be obtained if these optical aberration effects can be dampened which allows better 
focusing at the focal region and more efficient generation of intensity modulation. The 
development of FMM microendoscopy, thanks to the technological advancement in 
miniature fiber-optics and micro-mechanical scanning mechanism, will be invaluable for in 
vivo cellular-level imaging of tissues in regions that are otherwise inaccessible by bench-top 
microscope, such as the lung, bladder, cervix, uterus, colon, and peritoneum (Sabharwal, 
Rouse et al. 1999; Flusberg, Cocker et al. 2005). This ability enables determination of 
abnormalities localized on the surface or those being more aggressive (i.e. invading below 
the surface) which will be crucial for early cancer detection. 
In addition, the high modulation frequency of FMM based on acousto-optical modulators 
can also be further developed for fluorescence lifetime imaging. Fluorescence lifetime 
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We have validated the capability of FMM in improving image quality at large penetration 
depth by visualizing various specimens. All the images were taken at 512x512 pixels, with a 
pixel dwell times of around 10���, resulting image acquisition time of around ����. We 
emphasized that as the mouse brain samples are specifically stained in which only blood 
vessels void of blood (one of the major absorbers and scatterers inside biological tissues) are 
labeled with DiD, generally less background will be observed while larger penetration 
depth is expected compared to uniformly stained samples. Nevertheless, CM still suffers 
from poor image quality especially in observation of finer features; while FMM can work 
robustly in detecting fluorescence by ballistic photons and rejecting out-of-focus 
fluorescence background even at the large depth. This is an important feature for 
investigations and characterizations of thick tissue with sub-micron spatial resolution when 
confocal pinhole fails to reject majority of the out-of-focus fluorescence background. Better 
characterization of microvasculatures in animal model over large observation volume using 
FMM can be potentially useful especially for quantification of angiogenesis in term of 
density/diameter of blood vessels in live animal cancer model (Lunt, Gray et al. 2010). We 
also highlight that though FMM can reject most of the background, it cannot increase the 
signal level and thus if the FMM signal falls below the shot noise floor at extreme depths, 
other strategies (i.e. denoise image processing and/or extended image acquisition time) may 
be needed to improve the image quality.  
A modulation frequency of 160 MHz can be achieved if only a single AOM is used. 
However, a too high modulation frequency could cause significant attenuation of the FMM 
signals as the signal intensity is proportional to ������ in which ��is the modulation 
frequency and � is the lifetime of fluorescent probes. As most of the fluorescent molecules 
have a typical lifetime of a few nanoseconds, deterioration of the signal-to-noise ratio will 
thus be a serious problem at large penetration depths. The 10 MHz we choose falls in the 
optimal frequency range for fast image acquisition and negligible signal attenuation, and it 
is compatible with available demodulation components. In future, the issues of inherent 
Poisson statistical noise that gradually becoming significant in the case of low intensity 
signal related to deep imaging of biological tissues and further improvement of the image 
quality with the inclusion of Poisson noise removal will be studied. 
6. Conclusions 
It is a seemingly endless endeavour as microscopists seek to push ever deeper into 
biological specimens, while resolving micro-structural details and observing specific 
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molecular events. This book chapter describes the development of high-speed focal 
modulation microscopy and the corresponding technological advancement, in which the 
aim is to extend the penetration depth limit in thick specimens, without the necessity of the 
usage of long wavelength excitation or non-linear effect, i.e. currently two main approaches 
for achieving large penetration depth in biological specimens. FMM has thus far proved to 
be a significant improvement over the conventional confocal microscopy in term of SBR 
ratio at large penetration depths and potentially useful for cellular and molecular in vivo 
imaging. Its overall low-cost implementation also means its potential to be widely adopted 
as a basic research tool in biomedical and clinical applications. 
In summary, the principles of FMM is elaborated and two implementations of FMM which 
varies in term of phase modulation schemes – double-mirrors phase modulator and FMM 
based on acousto-optical modulator that are significantly progressive in term of stability and 
image performance as compared to first FMM prototype based on double mirror spatial 
phase modulator (Chen, Wong et al. 2008) are being demonstrated. It is worth to mention 
that the modulation frequency is greatly enhanced from kHz range to MHz range, and the 
accompanied benefits include higher image acquisition speed and possible adaptation to 
fluorescence lifetime imaging. We also demonstrated the capability of FMM in improving 
the imaging contrast of various types of samples over a large penetration depth. We also 
highlight that FMM can operate in both fluorescence and back-scattered/reflectance mode. 
This is contrasted to the non-linear methods such as two-photon microscopy which only 
improve the imaging depth in fluorescence mode. FMM can switch between fluorescence 
and back-scattered/reflectance mode by enabling/disabling the phase modulation 
components in the illumination arm, thus allowing observation of surface topology and 
tissue morphology based on the back-scattered/reflectance mode as well as rich functional 
and molecular-specific information through the fluorescence mode.  
6.1 Future directions 
We believe FMM technique will be useful for many biological applications, which large 
penetration depth is required. Future works to combine the technique of FMM with multi-
photon microscopy and microendoscopy are underway to further improve the penetration 
depth achievable by optical techniques through better rejection of background fluorescence; 
and for clinical usage to help in early disease detection and diagnosis. On top of that, the 
application of adaptive optics in FMM to pre-conditioning the beam profile of the excitation 
beam will further improve the modulation efficiency of FMM, which currently hampered by 
optical aberrations due to biological samples inhomogeneity. Much stronger FMM signal 
can be obtained if these optical aberration effects can be dampened which allows better 
focusing at the focal region and more efficient generation of intensity modulation. The 
development of FMM microendoscopy, thanks to the technological advancement in 
miniature fiber-optics and micro-mechanical scanning mechanism, will be invaluable for in 
vivo cellular-level imaging of tissues in regions that are otherwise inaccessible by bench-top 
microscope, such as the lung, bladder, cervix, uterus, colon, and peritoneum (Sabharwal, 
Rouse et al. 1999; Flusberg, Cocker et al. 2005). This ability enables determination of 
abnormalities localized on the surface or those being more aggressive (i.e. invading below 
the surface) which will be crucial for early cancer detection. 
In addition, the high modulation frequency of FMM based on acousto-optical modulators 
can also be further developed for fluorescence lifetime imaging. Fluorescence lifetime 
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measurements are independent of fluorophores concentrations and thus insensitive to 
wavelength-dependent light scattering, making it attractive especially in certain scenario 
such as when uniform illumination for visualization of fluorescent probes deep in tissues 
cannot be easily achieved over the area of interest owing to its irregular surface (Sun, Phipps 
et al. 2009). 
6.2 Take home message 
It is always a trade-off between the penetration depths limit and spatial resolutions when 
adopting an optical microscopy technique in visualization of thick biological specimens. 
Depending on the applications, it is important to balance the overall cost and imaging 
qualities to maximize the research outputs. With the advancement of optical engineering, 
faster scanning mechanisms and higher–performance photodetector, it is expected that 
biomedical imaging will be benefited with higher-throughput and larger penetration 
depths.    
7. References 
Axelrod, D. (2003). "Total internal reflection fluorescence microscopy in cell biology." 
Biophotonics, Pt B 361: 1-33. 
Chen, N., C. H. Wong, et al. (2008). "Focal modulation microscopy." Opt Express 16(23): 
18764-18769. 
Chen, N., C. H. Wong, et al. (2008). "Focal modulation microscopy." Optics Express 16(23): 
18764-18769. 
Chong, S. P., C. H. Wong, et al. (2010). "Focal modulation microscopy: a theoretical study." 
Optics letters 35(11): 1804-1806. 
Conchello, J. A. and J. W. Lichtman (2005). "Optical sectioning microscopy." Nature methods 
2(12): 920-931. 
Deng, X. and M. Gu (2003). "Penetration depth of single-, two-, and three-photon 
fluorescence microscopic imaging through human cortex structures: Monte Carlo 
simulation." Applied Optics 42(16): 3321-3329. 
Denk, W., J. H. Strickler, et al. (1990). "Two-photon laser scanning fluorescence microscopy." 
Science 248(4951): 73-76. 
Detrich, H. W., 3rd, M. Westerfield, et al. (2010). "The zebrafish: cellular and developmental 
biology, part A. Preface." Methods Cell Biol 100: xiii. 
Dittrich, P. S. and P. Schwille (2001). "Photobleaching and stabilization of fluorophores used 
for single-molecule analysis with one- and two-photon excitation." Applied Physics 
B-Lasers and Optics 73(8): 829-837. 
Dunn, A. K., C. Smithpeter, et al. (1996). "Sources of contrast in confocal reflectance 
imaging." Applied Optics 35(19): 3441-3446. 
Dyba, M. and S. W. Hell (2002). "Focal spots of size lambda/23 open up far-field 
fluorescence microscopy at 33 nm axial resolution." Physical review letters 88(16): 
163901. 
Fercher, A. F. (2010). "Optical coherence tomography - development, principles, 
applications." Zeitschrift Fur Medizinische Physik 20(4): 251-276. 
Fercher, A. F., W. Drexler, et al. (2003). "Optical coherence tomography - principles and 
applications." Reports on Progress in Physics 66(2): 239-303. 
Focal Modulation Microscopy: Principle and Techniques 179 
Firbank, M., M. Oda, et al. (1995). "An improved design for a stable and reproducible 
phantom material for use in near-infrared spectroscopy and imaging." Physics in 
Medicine and Biology 40(5): 955-961. 
Flusberg, B. A., E. D. Cocker, et al. (2005). "Fiber-optic fluorescence imaging." Nat Methods 
2(12): 941-950. 
Fujimoto, J. G. (2003). "Optical coherence tomography for ultrahigh resolution in vivo 
imaging." Nature biotechnology 21(11): 1361-1367. 
Fujimoto, J. G., M. E. Brezinski, et al. (1995). "Optical Biopsy and Imaging Using Optical 
Coherence Tomography." Nature Medicine 1(9): 970-972. 
Gan, X., S. Schilders, et al. (1997). "Combination of annular aperture and polarization gating 
methods for efficient microscopic imaging through a turbid medium: Theoretical 
analysis." Microscopy and Microanalysis 3(6): 495-503. 
Gu, M. (1996). Principles of three dimensional imaging in confocal microscopes. Singapore ; 
River Edge, NJ, World Scientific. 
Gu, M. (2000). Advanced optical imaging theory. Berlin ; New York, Springer. 
Gu, M. and C. J. R. Sheppard (1991). "3-Dimensional Imaging in Confocal Fluorescent 
Microscopy with Annular Lenses." Journal of Modern Optics 38(11): 2247-2263. 
Gustafsson, M. G., D. A. Agard, et al. (1999). "I5M: 3D widefield light microscopy with 
better than 100 nm axial resolution." Journal of microscopy 195(Pt 1): 10-16. 
Hell, S. W., E. H. K. Stelzer, et al. (1994). "Confocal Microscopy with an Increased Detection 
Aperture - Type-B 4pi Confocal Microscopy." Optics Letters 19(3): 222-224. 
Helmchen, F. and W. Denk (2005). "Deep tissue two-photon microscopy." Nature methods 
2(12): 932-940. 
Huang, D., E. A. Swanson, et al. (1991). "Optical coherence tomography." Science 254(5035): 
1178-1181. 
Huisken, J., J. Swoger, et al. (2004). "Optical sectioning deep inside live embryos by selective 
plane illumination microscopy." Science 305(5686): 1007-1009. 
Izatt, J. A., M. R. Hee, et al. (1994). "Optical coherence microscopy in scattering media." 
Optics letters 19(8): 590-592. 
Jain, R. K., L. L. Munn, et al. (2002). "Dissecting tumour pathophysiology using intravital 
microscopy." Nature Reviews Cancer 2(4): 266-276. 
Keller, P. J., A. D. Schmidt, et al. (2010). "Fast, high-contrast imaging of animal development 
with scanned light sheet-based structured-illumination microscopy." Nature 
methods 7(8): 637-U655. 
Keller, P. J., A. D. Schmidt, et al. (2008). "Reconstruction of Zebrafish Early Embryonic 
Development by Scanned Light Sheet Microscopy." Science 322(5904): 1065-1069. 
Keller, P. J. and E. H. Stelzer (2008). "Quantitative in vivo imaging of entire embryos with 
Digital Scanned Laser Light Sheet Fluorescence Microscopy." Current opinion in 
neurobiology 18(6): 624-632. 
Kempe, M., W. Rudolph, et al. (1996). "Comparative study of confocal and heterodyne 
microscopy for imaging through scattering media." Journal of the Optical Society of 
America a-Optics Image Science and Vision 13(1): 46-52. 
Kempe, M., A. Thon, et al. (1994). "Resolution Limits of Microscopy through Scattering 
Layers." Optics Communications 110(5-6): 492-496. 
Molecular Imaging 178 
measurements are independent of fluorophores concentrations and thus insensitive to 
wavelength-dependent light scattering, making it attractive especially in certain scenario 
such as when uniform illumination for visualization of fluorescent probes deep in tissues 
cannot be easily achieved over the area of interest owing to its irregular surface (Sun, Phipps 
et al. 2009). 
6.2 Take home message 
It is always a trade-off between the penetration depths limit and spatial resolutions when 
adopting an optical microscopy technique in visualization of thick biological specimens. 
Depending on the applications, it is important to balance the overall cost and imaging 
qualities to maximize the research outputs. With the advancement of optical engineering, 
faster scanning mechanisms and higher–performance photodetector, it is expected that 
biomedical imaging will be benefited with higher-throughput and larger penetration 
depths.    
7. References 
Axelrod, D. (2003). "Total internal reflection fluorescence microscopy in cell biology." 
Biophotonics, Pt B 361: 1-33. 
Chen, N., C. H. Wong, et al. (2008). "Focal modulation microscopy." Opt Express 16(23): 
18764-18769. 
Chen, N., C. H. Wong, et al. (2008). "Focal modulation microscopy." Optics Express 16(23): 
18764-18769. 
Chong, S. P., C. H. Wong, et al. (2010). "Focal modulation microscopy: a theoretical study." 
Optics letters 35(11): 1804-1806. 
Conchello, J. A. and J. W. Lichtman (2005). "Optical sectioning microscopy." Nature methods 
2(12): 920-931. 
Deng, X. and M. Gu (2003). "Penetration depth of single-, two-, and three-photon 
fluorescence microscopic imaging through human cortex structures: Monte Carlo 
simulation." Applied Optics 42(16): 3321-3329. 
Denk, W., J. H. Strickler, et al. (1990). "Two-photon laser scanning fluorescence microscopy." 
Science 248(4951): 73-76. 
Detrich, H. W., 3rd, M. Westerfield, et al. (2010). "The zebrafish: cellular and developmental 
biology, part A. Preface." Methods Cell Biol 100: xiii. 
Dittrich, P. S. and P. Schwille (2001). "Photobleaching and stabilization of fluorophores used 
for single-molecule analysis with one- and two-photon excitation." Applied Physics 
B-Lasers and Optics 73(8): 829-837. 
Dunn, A. K., C. Smithpeter, et al. (1996). "Sources of contrast in confocal reflectance 
imaging." Applied Optics 35(19): 3441-3446. 
Dyba, M. and S. W. Hell (2002). "Focal spots of size lambda/23 open up far-field 
fluorescence microscopy at 33 nm axial resolution." Physical review letters 88(16): 
163901. 
Fercher, A. F. (2010). "Optical coherence tomography - development, principles, 
applications." Zeitschrift Fur Medizinische Physik 20(4): 251-276. 
Fercher, A. F., W. Drexler, et al. (2003). "Optical coherence tomography - principles and 
applications." Reports on Progress in Physics 66(2): 239-303. 
Focal Modulation Microscopy: Principle and Techniques 179 
Firbank, M., M. Oda, et al. (1995). "An improved design for a stable and reproducible 
phantom material for use in near-infrared spectroscopy and imaging." Physics in 
Medicine and Biology 40(5): 955-961. 
Flusberg, B. A., E. D. Cocker, et al. (2005). "Fiber-optic fluorescence imaging." Nat Methods 
2(12): 941-950. 
Fujimoto, J. G. (2003). "Optical coherence tomography for ultrahigh resolution in vivo 
imaging." Nature biotechnology 21(11): 1361-1367. 
Fujimoto, J. G., M. E. Brezinski, et al. (1995). "Optical Biopsy and Imaging Using Optical 
Coherence Tomography." Nature Medicine 1(9): 970-972. 
Gan, X., S. Schilders, et al. (1997). "Combination of annular aperture and polarization gating 
methods for efficient microscopic imaging through a turbid medium: Theoretical 
analysis." Microscopy and Microanalysis 3(6): 495-503. 
Gu, M. (1996). Principles of three dimensional imaging in confocal microscopes. Singapore ; 
River Edge, NJ, World Scientific. 
Gu, M. (2000). Advanced optical imaging theory. Berlin ; New York, Springer. 
Gu, M. and C. J. R. Sheppard (1991). "3-Dimensional Imaging in Confocal Fluorescent 
Microscopy with Annular Lenses." Journal of Modern Optics 38(11): 2247-2263. 
Gustafsson, M. G., D. A. Agard, et al. (1999). "I5M: 3D widefield light microscopy with 
better than 100 nm axial resolution." Journal of microscopy 195(Pt 1): 10-16. 
Hell, S. W., E. H. K. Stelzer, et al. (1994). "Confocal Microscopy with an Increased Detection 
Aperture - Type-B 4pi Confocal Microscopy." Optics Letters 19(3): 222-224. 
Helmchen, F. and W. Denk (2005). "Deep tissue two-photon microscopy." Nature methods 
2(12): 932-940. 
Huang, D., E. A. Swanson, et al. (1991). "Optical coherence tomography." Science 254(5035): 
1178-1181. 
Huisken, J., J. Swoger, et al. (2004). "Optical sectioning deep inside live embryos by selective 
plane illumination microscopy." Science 305(5686): 1007-1009. 
Izatt, J. A., M. R. Hee, et al. (1994). "Optical coherence microscopy in scattering media." 
Optics letters 19(8): 590-592. 
Jain, R. K., L. L. Munn, et al. (2002). "Dissecting tumour pathophysiology using intravital 
microscopy." Nature Reviews Cancer 2(4): 266-276. 
Keller, P. J., A. D. Schmidt, et al. (2010). "Fast, high-contrast imaging of animal development 
with scanned light sheet-based structured-illumination microscopy." Nature 
methods 7(8): 637-U655. 
Keller, P. J., A. D. Schmidt, et al. (2008). "Reconstruction of Zebrafish Early Embryonic 
Development by Scanned Light Sheet Microscopy." Science 322(5904): 1065-1069. 
Keller, P. J. and E. H. Stelzer (2008). "Quantitative in vivo imaging of entire embryos with 
Digital Scanned Laser Light Sheet Fluorescence Microscopy." Current opinion in 
neurobiology 18(6): 624-632. 
Kempe, M., W. Rudolph, et al. (1996). "Comparative study of confocal and heterodyne 
microscopy for imaging through scattering media." Journal of the Optical Society of 
America a-Optics Image Science and Vision 13(1): 46-52. 
Kempe, M., A. Thon, et al. (1994). "Resolution Limits of Microscopy through Scattering 
Layers." Optics Communications 110(5-6): 492-496. 
Molecular Imaging 180 
Kleinfeld, D., P. P. Mitra, et al. (1998). "Fluctuations and stimulus-induced changes in blood 
flow observed in individual capillaries in layers 2 through 4 of rat neocortex." Proc 
Natl Acad Sci U S A 95(26): 15741-15746. 
Kobat, D., M. E. Durst, et al. (2009). "Deep tissue multiphoton microscopy using longer 
wavelength excitation." Optics Express 17(16): 13354-13364. 
Li, L., R. J. Zemp, et al. (2007). "Photoacoustic imaging of lacZ gene expression in vivo." 
Journal of Biomedical Optics 12(2): 020504. 
Li, M. L., J. T. Oh, et al. (2008). "Simultaneous molecular and hypoxia imaging of brain 
tumors in vivo using spectroscopic photoacoustic tomography." Proceedings of the 
Ieee 96(3): 481-489. 
Li, Y., Y. Song, et al. (2008). "Direct labeling and visualization of blood vessels with 
lipophilic carbocyanine dye DiI." Nature protocols 3(11): 1703-1708. 
Lunt, S. J., C. Gray, et al. (2010). "Application of intravital microscopy in studies of tumor 
microcirculation." Journal of Biomedical Optics 15(1): 011113. 
Minsky, M. (1961). Microscopy Apparatus. US. 
Minsky, M. (1988). "Memoir on Inventing the Confocal Scanning Microscope." Scanning 
10(4): 128-138. 
Misgeld, T. and M. Kerschensteiner (2006). "In vivo imaging of the diseased nervous 
system." Nature reviews. Neuroscience 7(6): 449-463. 
Mo, W. and N. Chen (2008). "Fast time-domain diffuse optical tomography using 
pseudorandom bit sequences." Opt. Express 16(18): 13643-13650. 
Oheim, M., E. Beaurepaire, et al. (2001). "Two-photon microscopy in brain tissue: parameters 
influencing the imaging depth." J Neurosci Methods 111(1): 29-37. 
Patterson, G. H. and D. W. Piston (2000). "Photobleaching in two-photon excitation 
microscopy." Biophysical journal 78(4): 2159-2162. 
Pavlova, I., M. Williams, et al. (2008). "Understanding the biological basis of 
autofluorescence imaging for oral cancer detection: high-resolution fluorescence 
microscopy in viable tissue." Clinical cancer research : an official journal of the 
American Association for Cancer Research 14(8): 2396-2404. 
Pawley, J. B. (2006). Handbook of biological confocal microscopy. New York, NY, Springer. 
Prati, F., E. Regar, et al. (2010). "Expert review document on methodology, terminology, and 
clinical applications of optical coherence tomography: physical principles, 
methodology of image acquisition, and clinical application for assessment of 
coronary arteries and atherosclerosis." European Heart Journal 31(4): 401-415. 
Razansky, D., M. Distel, et al. (2009). "Multispectral opto-acoustic tomography of deep-
seated fluorescent proteins in vivo." Nat Photon 3(7): 412-417. 
Sabharwal, Y. S., A. R. Rouse, et al. (1999). "Slit-scanning confocal microendoscope for high-
resolution in vivo imaging." Applied Optics 38(34): 7133-7144. 
Sandison, D. R., D. W. Piston, et al. (1995). "Quantitative Comparison of Background 
Rejection, Signal-to-Noise Ratio, and Resolution in Confocal and Full-Field Laser-
Scanning Microscopes." Applied Optics 34(19): 3576-3588. 
Schmitt, J. M., A. Knuttel, et al. (1994). "Confocal Microscopy in Turbid Media." Journal of 
the Optical Society of America a-Optics Image Science and Vision 11(8): 2226-
2235. 
Focal Modulation Microscopy: Principle and Techniques 181 
Schmitt, J. M., A. Knuttel, et al. (1994). "Confocal microscopy in turbid media." Journal of 
the Optical Society of America. A, Optics, image science, and vision 11(8): 2226-
2235. 
Sheppard, C. J. R. and M. Gu (1991). "3-Dimensional Optical Transfer-Function for an 
Annular Lens." Optics Communications 81(5): 276-280. 
Sheppard, C. J. R. and T. Wilson (1980). "Image-Formation in Confocal Scanning 
Microscopes." Optik 55(4): 331-342. 
Smithpeter, C. L., A. K. Dunn, et al. (1998). "Penetration depth limits of in vivo confocal 
reflectance imaging." Applied Optics 37(13): 2749-2754. 
Sun, Y., J. Phipps, et al. (2009). "Fluorescence lifetime imaging microscopy: in vivo 
application to diagnosis of oral carcinoma." Opt Lett 34(13): 2081-2083. 
Svoboda, K., F. Helmchen, et al. (1999). "Spread of dendritic excitation in layer 2/3 
pyramidal neurons in rat barrel cortex in vivo." Nat Neurosci 2(1): 65-73. 
Svoboda, K. and R. Yasuda (2006). "Principles of two-photon excitation microscopy and its 
applications to neuroscience." Neuron 50(6): 823-839. 
Theer, P. and W. Denk (2006). "On the fundamental imaging-depth limit in two-photon 
microscopy." Journal of the Optical Society of America. A, Optics, image science, 
and vision 23(12): 3139-3149. 
Theer, P., M. T. Hasan, et al. (2003). "Two-photon imaging to a depth of 1000 microm in 
living brains by use of a Ti:Al2O3 regenerative amplifier." Opt Lett 28(12): 1022-
1024. 
Theer, P., M. T. Hasan, et al. (2003). "Two-photon imaging to a depth of 1000 mu m in living 
brains by use of a Ti : Al2O3 regenerative amplifier." Optics Letters 28(12): 1022-
1024. 
Vakoc, B. J., R. M. Lanning, et al. (2009). "Three-dimensional microscopy of the tumor 
microenvironment in vivo using optical frequency domain imaging." Nat Med 
15(10): 1219-1223. 
Verveer, P. J., J. Swoger, et al. (2007). "High-resolution three-dimensional imaging of large 
specimens with light sheet-based microscopy." Nature methods 4(4): 311-313. 
Wang, L. V. (2009). "Multiscale photoacoustic microscopy and computed tomography." 
Nature photonics 3(9): 503-509. 
Wang, X., Y. Pang, et al. (2003). "Noninvasive laser-induced photoacoustic tomography for 
structural and functional in vivo imaging of the brain." Nature biotechnology 21(7): 
803-806. 
Wang, X., Y. Xu, et al. (2002). "Photoacoustic tomography of biological tissues with high 
cross-section resolution: reconstruction and experiment." Medical Physics 29(12): 
2799-2805. 
Wang, X. D., G. Ku, et al. (2004). "Non-invasive functional photoacoustic tomography of 
blood oxygen saturation in the brain." Photons Plus Ultrasound: Imaging and 
Sensing 5320: 69-76. 
Wong, C. H., S. P. Chong, et al. (2009). "Simple spatial phase modulator for focal modulation 
microscopy." Applied Optics 48(17): 3237-3242. 
Yang, S., D. Xing, et al. (2007). "Functional imaging of cerebrovascular activities in small 
animals using high-resolution photoacoustic tomography." Medical Physics 34(8): 
3294-3301. 
Molecular Imaging 180 
Kleinfeld, D., P. P. Mitra, et al. (1998). "Fluctuations and stimulus-induced changes in blood 
flow observed in individual capillaries in layers 2 through 4 of rat neocortex." Proc 
Natl Acad Sci U S A 95(26): 15741-15746. 
Kobat, D., M. E. Durst, et al. (2009). "Deep tissue multiphoton microscopy using longer 
wavelength excitation." Optics Express 17(16): 13354-13364. 
Li, L., R. J. Zemp, et al. (2007). "Photoacoustic imaging of lacZ gene expression in vivo." 
Journal of Biomedical Optics 12(2): 020504. 
Li, M. L., J. T. Oh, et al. (2008). "Simultaneous molecular and hypoxia imaging of brain 
tumors in vivo using spectroscopic photoacoustic tomography." Proceedings of the 
Ieee 96(3): 481-489. 
Li, Y., Y. Song, et al. (2008). "Direct labeling and visualization of blood vessels with 
lipophilic carbocyanine dye DiI." Nature protocols 3(11): 1703-1708. 
Lunt, S. J., C. Gray, et al. (2010). "Application of intravital microscopy in studies of tumor 
microcirculation." Journal of Biomedical Optics 15(1): 011113. 
Minsky, M. (1961). Microscopy Apparatus. US. 
Minsky, M. (1988). "Memoir on Inventing the Confocal Scanning Microscope." Scanning 
10(4): 128-138. 
Misgeld, T. and M. Kerschensteiner (2006). "In vivo imaging of the diseased nervous 
system." Nature reviews. Neuroscience 7(6): 449-463. 
Mo, W. and N. Chen (2008). "Fast time-domain diffuse optical tomography using 
pseudorandom bit sequences." Opt. Express 16(18): 13643-13650. 
Oheim, M., E. Beaurepaire, et al. (2001). "Two-photon microscopy in brain tissue: parameters 
influencing the imaging depth." J Neurosci Methods 111(1): 29-37. 
Patterson, G. H. and D. W. Piston (2000). "Photobleaching in two-photon excitation 
microscopy." Biophysical journal 78(4): 2159-2162. 
Pavlova, I., M. Williams, et al. (2008). "Understanding the biological basis of 
autofluorescence imaging for oral cancer detection: high-resolution fluorescence 
microscopy in viable tissue." Clinical cancer research : an official journal of the 
American Association for Cancer Research 14(8): 2396-2404. 
Pawley, J. B. (2006). Handbook of biological confocal microscopy. New York, NY, Springer. 
Prati, F., E. Regar, et al. (2010). "Expert review document on methodology, terminology, and 
clinical applications of optical coherence tomography: physical principles, 
methodology of image acquisition, and clinical application for assessment of 
coronary arteries and atherosclerosis." European Heart Journal 31(4): 401-415. 
Razansky, D., M. Distel, et al. (2009). "Multispectral opto-acoustic tomography of deep-
seated fluorescent proteins in vivo." Nat Photon 3(7): 412-417. 
Sabharwal, Y. S., A. R. Rouse, et al. (1999). "Slit-scanning confocal microendoscope for high-
resolution in vivo imaging." Applied Optics 38(34): 7133-7144. 
Sandison, D. R., D. W. Piston, et al. (1995). "Quantitative Comparison of Background 
Rejection, Signal-to-Noise Ratio, and Resolution in Confocal and Full-Field Laser-
Scanning Microscopes." Applied Optics 34(19): 3576-3588. 
Schmitt, J. M., A. Knuttel, et al. (1994). "Confocal Microscopy in Turbid Media." Journal of 
the Optical Society of America a-Optics Image Science and Vision 11(8): 2226-
2235. 
Focal Modulation Microscopy: Principle and Techniques 181 
Schmitt, J. M., A. Knuttel, et al. (1994). "Confocal microscopy in turbid media." Journal of 
the Optical Society of America. A, Optics, image science, and vision 11(8): 2226-
2235. 
Sheppard, C. J. R. and M. Gu (1991). "3-Dimensional Optical Transfer-Function for an 
Annular Lens." Optics Communications 81(5): 276-280. 
Sheppard, C. J. R. and T. Wilson (1980). "Image-Formation in Confocal Scanning 
Microscopes." Optik 55(4): 331-342. 
Smithpeter, C. L., A. K. Dunn, et al. (1998). "Penetration depth limits of in vivo confocal 
reflectance imaging." Applied Optics 37(13): 2749-2754. 
Sun, Y., J. Phipps, et al. (2009). "Fluorescence lifetime imaging microscopy: in vivo 
application to diagnosis of oral carcinoma." Opt Lett 34(13): 2081-2083. 
Svoboda, K., F. Helmchen, et al. (1999). "Spread of dendritic excitation in layer 2/3 
pyramidal neurons in rat barrel cortex in vivo." Nat Neurosci 2(1): 65-73. 
Svoboda, K. and R. Yasuda (2006). "Principles of two-photon excitation microscopy and its 
applications to neuroscience." Neuron 50(6): 823-839. 
Theer, P. and W. Denk (2006). "On the fundamental imaging-depth limit in two-photon 
microscopy." Journal of the Optical Society of America. A, Optics, image science, 
and vision 23(12): 3139-3149. 
Theer, P., M. T. Hasan, et al. (2003). "Two-photon imaging to a depth of 1000 microm in 
living brains by use of a Ti:Al2O3 regenerative amplifier." Opt Lett 28(12): 1022-
1024. 
Theer, P., M. T. Hasan, et al. (2003). "Two-photon imaging to a depth of 1000 mu m in living 
brains by use of a Ti : Al2O3 regenerative amplifier." Optics Letters 28(12): 1022-
1024. 
Vakoc, B. J., R. M. Lanning, et al. (2009). "Three-dimensional microscopy of the tumor 
microenvironment in vivo using optical frequency domain imaging." Nat Med 
15(10): 1219-1223. 
Verveer, P. J., J. Swoger, et al. (2007). "High-resolution three-dimensional imaging of large 
specimens with light sheet-based microscopy." Nature methods 4(4): 311-313. 
Wang, L. V. (2009). "Multiscale photoacoustic microscopy and computed tomography." 
Nature photonics 3(9): 503-509. 
Wang, X., Y. Pang, et al. (2003). "Noninvasive laser-induced photoacoustic tomography for 
structural and functional in vivo imaging of the brain." Nature biotechnology 21(7): 
803-806. 
Wang, X., Y. Xu, et al. (2002). "Photoacoustic tomography of biological tissues with high 
cross-section resolution: reconstruction and experiment." Medical Physics 29(12): 
2799-2805. 
Wang, X. D., G. Ku, et al. (2004). "Non-invasive functional photoacoustic tomography of 
blood oxygen saturation in the brain." Photons Plus Ultrasound: Imaging and 
Sensing 5320: 69-76. 
Wong, C. H., S. P. Chong, et al. (2009). "Simple spatial phase modulator for focal modulation 
microscopy." Applied Optics 48(17): 3237-3242. 
Yang, S., D. Xing, et al. (2007). "Functional imaging of cerebrovascular activities in small 
animals using high-resolution photoacoustic tomography." Medical Physics 34(8): 
3294-3301. 
Molecular Imaging 182 
Yao, D. K., K. Maslov, et al. (2010). "In vivo label-free photoacoustic microscopy of cell 
nuclei by excitation of DNA and RNA." Opt Lett 35(24): 4139-4141. 
Ying, J., F. Liu, et al. (1999). "Spatial distribution of two-photon-excited fluorescence in 
scattering media." Appl Opt 38(1): 224-229. 
Zeng, C., S. Vangveravong, et al. (2007). "Subcellular localization of sigma-2 receptors in 
breast cancer cells using two-photon and confocal microscopy." Cancer research 
67(14): 6708-6716. 
0
Automated Segmentation and Morphometry
of Cell and Tissue Structures. Selected
Algorithms in ImageJ
Dimiter Prodanov and Kris Verstreken
Bioelectronic systems group, BIONE, Imec
Belgium
1. Introduction
This chapter covers selected aspects of the segmentation and measurements of spatial or
temporal features (i.e. morphometry) of biological objects in biomedical (non-optical)1 and
microscopic images. The term measurement refers to a succinct quantitative representation
of image features over space and time. This implies the application of the act of geometric
measurement to the raw imaging data, i.e. "morphometry". Measurements arise in a defined
experimental context.
1.1 Information complexity aspects
The life science experimentation strives to answer defined research questions via quantitative
analysis of multiple experimental trials. This process can be described by a workflow2 which
starts by defining the research hypotheses or questions (Fig. 1). During the last stage the
images are transformed into measurements, which are finally interpreted in the light of the
original research question (Fig. 1).
A substantial decrease of the volume of output data occurs at each step of the so-described
processing workflow. In contrast, this decrease is translated into an increase of the complexity
of generated information (e.g. derived data). For example, if one takes a microscopic image
representing a cell and measures its shape, then the raster image data (supposedly a matrix of
width x height) transforms into a set of shape parameters, each one having a different semantic
context (for example, neurite length, orientation, cell size). While in the raster data set the
biological object is only implicitly present, in the derived data the representation of at least
one attribute of the object under study is explicitly constructed (for example, the cell size).
At this stage, the explicit information contained in the raw image about the illumination and
staining distribution is lost. Therefore, the process of object (i.e. pattern) recognition and
reconstruction is accompanied by irreversible reduction of the input information. At each
step of the workflow the information in the previous step is transformed into contextual data,
1 The bioluminescence imaging methods will not be discussed here.
2 A workflow provides an abstracted view over the experiment being performed. It describes what
procedures need to be enacted, but not necessarily all the details of how they will be executed.
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Fig. 1. The experimental workflow in life science imaging
The experimental workflow in life sciences aims at answering the initially- posed research
question via quantitative analysis of multiple experimental trials. It starts with definition
of experimental design and assignment of subjects (samples) to the experimental groups.
Upon completion of the manipulations, the final specimens are collected and the raw data
are acquired. Subsequent process of analysis leads to a decrease of the volume of the input
data and an increase in their structural complexity.
called meta data. In such manner, the information complexity increase is also mapped to an
increase of the complexity of the data structure.
Measurements, therefore, are reduced representations of the image features of interest, which
have higher information complexity compared to the raw data. Due to the irreversible
information loss introduced by the process of measurement, in order to be able to replicate
the measurements given the original data, one needs an instance of the applied algorithm.
Therefore, measurements are only implicitly "present" in images.
1.2 Biomedical imaging modalities
Processing and extraction of information from images have become indispensable aspects of
the experimental workflow in life science research. Two major branches of imaging methods
in life sciences can be discerned: microscopic imaging and biomedical imaging 3.
Biomedical imaging integrates aspects of medicine, medical physics, biomedical engineering,
and computer science. Notably, pre-clinical imaging comprises an assembly of techniques
exploiting different physical modalities4: (i) micro-ultrasound, (ii) micro Photoacoustic
tomography μPAT, (iii) micro Magnetic Resonance Imaging μMRI, (iv) micro Computed
Tomography μCT, (v) micro Positron Emission Tomography μPET and (vi) micro Single
Photon Emission Computed Tomography μSPECT.
3 The biomedical imaging can be narrowly defined as an assembly of imaging methods developed
for the study of human disorders and diseases for the purposes of mechanism characterization and
development of treatments in model organisms, i.e. pre-clinical imaging.
4 Since most of the work with animal models is done in rodent species the mirco aspect of the techniques
is emphasized.
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1.3 Drivers for biomedical imaging software development
The continuous improvement of biomedical imaging hardware enables development of novel
imaging methods for acquisition and visualization. Novel imaging techniques progress in 3
main aspects: improvement of the signal-to-noise ratio, improvement of the spatial resolution,
or adding new physical modalities to images. In microscopy, examples of the former can
be given in laser scanning confocal (van Meer et al., 1987; White et al., 1987), spinning disc
confocal (Nakano, 2002), wide-field deconvolution (Hiraoka et al., 1987) and multiphoton
microscopes (Denk et al., 1990) ubiquitously used in cell and developmental biology. In
non-optical imaging for example, the resolution in μMRI reached the order of 150 um,
while different super-resolution microscopic approaches brought up the spatial resolution of
microscopes to the order of 100 nm. Images having more than 3 dimensions (i.e. 3 spatial
plus time, wavelength, orientation, decay times, etc) have become ubiquitous in biomedical
imaging and life science microscopy.
Some examples can be also given in time-lapse microscopy, confocal microscopy (Canaria
& Lansford, 2010), hyperspectral imaging (Marcsisin et al., 2010) and non-invasive imaging,
such as MRI and PET. For example, contemporary tract reconstruction techniques in MRI
require computations on 5D image datasets, representing position and orientation (Jonasson
et al., 2005). As a result, developing novel image processing, data mining and database tools
gained an increasing focus in the scientific community (Peng, 2008).
2. Biomedical imaging software
Each step of the experimental workflow typically requires the use of different hardware
and software tools. Ideally, obtained raw data should be directly available for use in other
applications either by remote instrument read-out or by transfer of the data upon application
request. However, such ideal situation is far from reality and is inherently restricted by
the heterogeneity of meta data describing different experiments. Other impeding factors
are the limited interoperability between equipment vendor applications and the frequent
incompatibility between proprietary data storage formats. As a result, the field of biomedical
imaging suffers from considerable segmentation. There are numerous proprietary and
open-source software products.
2.1 Proprietary software
Proprietary software for pre-clinical imaging is usually distributed with the specialized data
acquisition hardware, such as MRI or PET scanners. Without being exhaustive, we could give
several examples:
The Paravision R© package of Bruker is used to operate the BiospinTM MR scanner. The
software performs image reconstruction, 3D visualization of the reconstructed images,
computation of parametric image maps and morphometry.
The IMALYTICS R© package of Philips is used to analyze ultrasound, PET, CT, SPECT and
MRI images (Fischer & Paulus, 2010). The package is targeted at the pharmaceutical
industry and provides project-based workflows, rigid registration, segmentation and
visualization. Advanced options are non-rigid registration, pharmacokinetic modeling
and analysis of SPECT data.
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Amira is a general purpose package for imaging data rendering and 3D modeling
and analysis. Among its processing capabilities can be included image filtering,
segmentation, registration and morphing, deconvolution and tensor computation. Among
its measurement capabilities can be included spatial measurements, densitometry,
co-localization and statistics. Its functionality to an extent matches the one offered by the
Fiji distribution of ImageJ.
Pre-clinical imaging systems usually do not comply with any specific standard regarding raw
data storage. In contrast, each manufacturer usually develops a proprietary storage format,
which makes it difficult to share data and distribute data processing efforts.
In the field of imaging for microscopy there are also several powerful commercial systems
distributed by the microscopic equipment manufacturers; for example the AxioVisionTM and
ZENTM systems of Carl Zeiss (Germany) or the Cell-RTM system of Olympus (Japan). They all
provide image processing and measurement features to a varying extent. The most-popular
specialized morphometry software packages are listed in the paragraphs below:
Huygens is a package specialized in deconvolution, rendering and visualization developed
by Scientific Volume Imaging, The Netherlands. Its advanced characteristics include
estimation of the 3D point spread function from images and simulation of microscopic
image formation.
Image-Pro Plus is a package specialized in 2D and 3D image processing, enhancement,
and analysis developed by Media Cybernetics, USA. Among its advanced capabilities
can be counted image fusion, extended depth of view, object tracking, thresholding of
color images and morphological segmentation. Its functionality closely matches the one
developed in ImageJ.
Imaris is a package for image rendering and visualization of 3D and 4D microscopy datasets
of Bitplane Scientific Software, Switzerland. Its advanced capabilities include object fusion,
illumination, segmentation and volume rendering. Its functionality to an extent matches
the one offered by the Fiji distribution of ImageJ.
MetaMorph is an advanced system for image processing and morphometry developed
by Molecular Devices, USA. The advantages of the system include different filtering
and segmentation algorithms and the integration between measurements and display of
results. Its functionality closely matches the one developed in ImageJ.
Volocity is a package of PerkinElmer (USA) for microscopic image rendering, interactive
exploration, and analysis. Among the analysis options can be included colocalization,
ratioed images, Fluorescence Recovery After Photobleaching (FRAP) and Fluorescence
Resonance Energy Transfer (FRET). Its functionality closely matches the one offered by
the McMaster’s distribution of ImageJ.
In addition, general purpose data-processing languages, such as IDL R© (ITT Visual
Information Solutions, USA) and Matlab R© (The Mathworks Inc, USA) computational
environments are also used by the community.
A substantial and usual shortcoming of proprietary software is that the researcher is forced
to use the offered package as a black box. In contrast, open-source implementations
allow the researcher to critically examine the used approaches and the correctness of the
implementation. Due to this, open-source solutions typically have faster development cycles
including faster bug fixing. Consequently, to the authors’ understanding they are preferable
for development of new image processing and morphometric algorithms.
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2.2 Open source software
There are numerous open-source programs for biomedical image processing. This can
be attributed in part to the fact that in the past every imaging center developed its own
analysis tools. Traditionally, many image processing algorithms were developed in C or C++.
Attempts to overcome the fragmentation of the field of C/C++ programs were funded in
1990s by NIH in USA, which lead to the development of the general-purpose platforms for
image visualization – VTK (Visualization Toolkit), and image registration and filtering – ITK
(Insight Toolkit) which are currently supported by Kitware Inc (Ibanez et al., 2005). Both sets
of libraries are implemented in C++ and require sophisticated building systems. However,
their use in life-science microscopy is very limited.
While C/C++ platforms dominated the field before the year 2000, the evolution of Java and
the continuous improvement of its performance in the last 10 years made it a language
of choice for scientific software. Among the advantages of Java can be counted its
portability across platforms; the richness of the available functionality; the extended user base
including academic, commercial and community end-users and developers; its automated
multi-threading and its object-oriented architecture.
The analysis packages having more extensive functionality are listed in Table 1 (Ciliberti,
2009). For didactic purposes, the open-source packages can be classified into analysis suites,
which are suitable for comprehensive analytical tasks, and specialized toolsets, which focus
into a limited number of processing and analysis tasks.
name web site platform language
Mango http://ric.uthscsa.edu/mango/ JAMA Java
Seg3D http://www.sci.utah.edu/SCIRunDocs/index.php/CIBC:Seg3D ITK/VTK C++
MedINRIA http://www-sop.inria.fr/asclepios/software/MedINRIA/ ITK/VTK C++
BioImage Suite http://www.bioimagesuite.org/ ITK/VTK C++
3D Slicer http://www.slicer.org/ ITK/VTK Tcl/Tk
FSL http://www.fmrib.ox.ac.uk/fsl/fsl/list.html FMRIB C++
FreeSurfer http://surfer.nmr.mgh.harvard.edu/ FMRIB C++
Table 1. Some popular open source biomedical imaging programs
2.2.1 Analysis suites
BioImage Suite provides image editing, voxel classification, deformable user-interactive
segmentation, rigid and non-rigid registration, modules for Diffusion Tensor Imaging
(DTI) analysis and General Linear Model (GLM) functionality for fMRI analysis
(Papademetris et al., 2008).
Seg3D is a volume segmentation and processing tool, which is distributed under the MIT
License and is developed by the NIH Center for Integrative Biomedical Computing at the
University of Utah. The data are organized in multiple layered volumes supporting either
manual or filter-based segmentation and annotation.
3D Slicer is a software package for visualization and image annotation (Pieper et al., 2004).
Present versions of 3D Slicer provide a workflow engine, command-line and GUI interfaces
and scripting. The packages is distributed under BSD-style license.
Mango is a Java 3D-based program which supports image registration, surface rendering
and analysis (statistics and profiling) (Lancaster & Martinez, 2007). It also provides
extensibility via plugins and high level API.
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FSL is a set of command line and GUI image analysis and statistical tools for fMRI, structural
MRI and DTI analysis (Smith et al., 2004). FSL is written mainly by members of the
Analysis Group, FMRIB, Oxford University, UK. It is distributed under non for profit use
license.
2.2.2 Specialized tool-sets
Among the specialized tools, two main application areas can be discerned: DTI analysis and
fMRI.
Diffusion Tensor Imaging – MedINRIA is a program based on VTK and ITK, which is
developed by INRIA in France (Fillard et al., 2009). It is specialized in DTI and fiber
tracking, tensor visualization and image registration.
fMRI – SPM is a software package designed for the analysis of brain imaging data sequences.
The sequences can be a series of images from different cohorts, or time-series from the same
subject. The current release is designed for the analysis of fMRI, PET and SPECT data. SPM
is developed by the Functional Imaging Laboratory at University College London, UK
(Ashburner et al., 2010). It is based on the proprietary MATLAB R© (The MathWorks, Inc)
environment. The FreeSurfer program provides reconstruction of the brain cortical surface
from structural MRI data, and overlay of functional MRI maps. CARET is a software
program for the structural and functional analysis of the cerebral and cerebellar cortex. The
name is an abbreviation from Computerized Anatomical Reconstruction Toolkit. AFNI is
an environment for processing and displaying functional MRI data5.
3. ImageJ in the big picture
ImageJ is a public domain image processing program written in Java. Since its inception
in 1997 ImageJ has evolved to become a standard analytical tool in life science imaging. It
has an open architecture providing extensibility via 3rd party Java modules (called plugins)
and scripting macros. It is developed by Wayne Raspband since 1997 and expanded via
contributed software code by an international group of contributors (Abramoff et al., 2004;
Collins, 2007). Plugins are distributed together with their source code under various licences
determined by the pluing authors. Occasionally, some plugins are included in the main body
of the program.
ImageJ supports a large number of file formats either natively or through the plugin
extensions, for example using the Bio-Formats library 6.
There are several popular plugin distributions and collections. The most popular distributions
are listed in the next paragraphs:
NIH’s plugin collection is historically the 1st plugin collection. It is hosted on the ImageJ
web site itself 7. Main categories include acquisition, analysis, color processing, filters,
segmentation, graphics, input/output, stacks, utilities and links to developers’s sites.
Fiji is a plugin distribution aimed at microscopic applications in Neuroscience. It is
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Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany. The collection
includes plugins and libraries for neurite tracing (Longair et al., 2011), 3D reconstructions,
trainable interactive segmentation (Schindelin, 2008) and mathematical morphology
(Prodanov et al., 2006). It also comes with several additional scripting engines such
as Jython and JRuby and Java enhancements like Java 3D. Every plugin included in the
collection has a user manual.
The McMaster’s University plugin collection8 is aimed at fluorescent microscopy
applications. There are specialized plugins for collocalization analysis, spectral and
iterative deconvolution for image denoising (Dougherty, 2005) including parallel
implmentations9. The distribution includes a user manual.
The CRP Tudor’s plugin collection is structured around the documentation Wiki web site10
and is hosted and maintained with the support of the Public Research Centre Henri Tudor,
Luxembourg. It is a general purpose collection. Different categories include: filtering,
color processing, morphometry and processing, segmentation and others. Every plugin
included in the collection has a user manual and a history page.
It should be noted that some of the contributed plugins are present in all plugin distributions;
while others are only distribution-specific.
While developed more for microscopic analysis ImageJ can be also used as a tool for
visualization and measurements of pre-clinical imaging data. Key features of ImageJ are
its support of (i) different modes of segmentation, (ii) the advanced image editing, (iii)
the advanced filtering and processing capabilities and (iv) the well-established user and
developer communities.
ImageJ can also produce derived results plots. Supported modalities are linear and surface
plots. The basic measurement types in ImageJ are: areas, diameters, perimeters, angles,
circularity, coordinates in 2D and 3D, intensities, and calibrated pixel values. Finally, ImageJ
can also produce image and measurement statistics. A complete user guide of ImageJ is
maintained by T. Ferreira and W. Rasband since 2010 (Ferreira & Rasband, 2010). What makes
ImageJ superior to most of the specialized biomedical imaging programs are its capabilities:
• to support add-on functionality via plugins;
• to implement several scripting languages, such as its native macro script and JavaScript;
• to provide extensive measurement functions (e.g. morphometry and statistics).
• to run without modification on multiple operation systems.
4. Applications of ImageJ in MRI
Although historically analysis of non-optical biomedical images was one of the first
applications of ImageJ there are still not so many algorithms for such types of images. Recently,
however, with the spread of common non-optical biomedical imaging modalities the demand
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The most common MRI techniques map the distribution of hydrogen atoms in different
tissues. The primary contrast mechanisms exploit relaxation of the atomic magnetization:
spin-lattice relaxation, characterized by the relaxation time T1, i.e T1-contrast, and spin-spin
relaxation, characterized by the relaxation time T2, i.e. T2-contrast. MRI can be used for
non-invasive monitoring of models of human diseases, such as traumatic brain edema, stroke
or spinal cord injury. Such monitoring requires development of differential contrasting
techniques either for T1 or for T2.
Parametric mapping functionality for ImageJ 3D and 4D datasets is provided by the MRI
Processor plugin made available from the ImageJ documentation Wiki website (Prodanov
et al., 2010). The plugin calculates parametric maps based on reconstructed MR images.
Such parametric maps are derived images where each pixel value represents a parametric
fit to time varying data sequence. Parametric maps are, for example, T1, T2 and proton
density maps. Data fitting is available using either the Levenberg-Marquardt or the Simplex
algorithm. Currently supported types are T2 and T1 maps. Unique features of the plugin are
(i) the possibility to fit multicomponent exponential models, (ii) the support of 4D data sets
and (iii) the support of arbitrary closed Regions of Interest (ROIs). The T2-map functionality
has been already validated against the Paravision 4.0 software.
Fig. 2. Operation of the MRI Processor plugin
A – UI of the MRI Processor. The user can select different types of maps and fitting algorithms.
B – Computed T2 map. The image was colorized using the royal LUT. The calibration is given
in ms. Scale bar – 2 mm.
The T2 maps are computed by fitting of the MRI dataset to the equation:
Mxy(t) = Mxy(0)e−t/T2 + ε (4.1)
where Mxy is the transverse field magnetization component and ε is the offset term introduced
by the unsigned pixel representation. The T1 maps are computed by fitting of the dataset to
the equation:
Mz(t) = Mz,eq(0)(1 − 2 e−t/T1 ) + ε (4.2)
where Mz is the longitudinal field magnetization component and ε is the offset term
introduced by the unsigned pixel representation.
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5. Selected Morphometric algorithms
Cell and tissue structures can be segmented in a variety of ways. For a successful image
segmentation it is important to have prior knowledge of the image composition, i.e. the
texture properties of the background and the objects of interest. In general, a typical algorithm
includes the following stages:
• preprocessing steps, which decrease the spatial variation of the image
• thresholding, which produces one or more binary masks
• masking or Region of interest (ROI) selection
• postprocessing steps, for example including second thresholding or parametric fitting
• final measurement of volume, area, angles, etc.
Image processing algorithms can be classified based on the spatial (temporal) transformations
which they introduce into the image. Point operations transform an input pixel into an
output value. An example for such an operation can be given by histogramming or contrast
adjustment. Zonal operations transform all the pixels in a certain spatially- or temporally-
connected neighborhood into some output. Such neighborhoods are, for example, defined by
structuring elements or convolution kernels. Map operations compute output image based
on 2 or more input images. For example masking, addition and subtraction of images are such
operations.
In the next sections we describe protocols based on granulometric filtering (a class of
morphological filters), differential contrast enhancement, area thresholding, or distance map
transforms.
5.1 Thresholding
Thresholding is performed using a labeling operator Tr. By definition, Tr labels a pixel in the
image only if its intensity g exceeds certain value Tmin:
Trα [g(x) ≥ Tmin] : g(x) → 1(x)
where 1 is the binary pixel label denoting the foreground value and g – the pixel intensity at
the co-ordinates vector x. There are different ways to propose a Tmin value based on zonal
or regional statistical variables. Some of the most popular methods include Otsu, maximal
entropy and percentile thresholding. A good review on thresholding techniques can be found
in Sezgin & Sankur (2004).
5.2 Local area thresholding
The local area thresholding is a regional image operation depending on the parameter α. If it
is assumed that this ROI represents predominantly the image texture, α acts as a sensitivity
parameter that determines the overall proportion of the "noise" pixels in the ROI. If so
determined threshold level is extended to the overall image then a signal to noise ratio, SNR





where ḡ is the mean intensity of the image.
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The action of a parametric thresholding operator Trα is conditioned on the ratio between the
area of the labeled pixels and the total ROI area:
Trα
[
x ∈ ROI| HROI (Tmin)
AROI
≥ 1 − α
]
: g(x) → 1(x) (5.4)
where AROI denotes the ROI area, Tmin is the locally-computed threshold level and H() the
cumulative histogram of the ROI (Prodanov & Feirabend, 2008).
5.3 Granulometric filtering
The algorithm is implemented as an ImageJ plugin. Particles of different sizes can be extracted
from an image if two images from a granulometric image sequence are subtracted (see
Appendix 12). Accordingly, the granulometric filtering is defined as:
D = I ◦ SE[dlow]− I ◦ SE[dhigh]
where ◦ denotes morphological opening and SE is a structuring element defining the
neighborhood around a pixel.
5.4 Differential Contrast Enhancement
The algorithm assumes that one of the images samples only background Ibackground while
the other samples background and objects of interest Iobjects. Further, it is assumed that the
histograms of the background and the objects overlap to an extent so that it is not-possible to
separate them by thresholding. The contrast of the image (channel) of interest is rescaled with
a coefficient assuring that 0 /∈ Con f idence95[Ibackground − Iobjects]. This condition is achieved if





where P95 denotes the 95th percentile of the empirical pixel intensity distribution and E[]
denotes the expectation. Next, to obtain the objects, the contrast-rescaled image is subtracted
from the objects image in order to produce an output image R.
R = Iobjects − kb · Ibackground (5.6)
5.5 Distance map transformations
Distance map are produced from binary images. The map is an image derived from the
original image where every pixel in the background is assigned the shortest possible distance
to a foreground pixel given a certain metrics. The most popular distance maps are derived
from the city-block (e.g. having diamond equidistant contours), the chessboard (e.g. having
square equidistant contours) or the euclidean (e.g. having circular equidistant contours)
metrics. In mathematical terms:
D(x) = minp{dist(x, p) | g(p) = 1}
92 Molecular Imagi Automated Segmentation and Morphometry of Cell and Tissue Structures. Selected Algorithms in ImageJ 11
where 1 denotes the foreground label, x and p denote pixel coordinates, and g denotes
intensity. From this equation a naive implementation can be derived directly. However, its
execution time scales very badly with the image size and is of little practical use. ImageJ
implements an approximate Euclidean distance map algorithm as part of its EDM plugin. The
EDM algorithm is similar to the 8SSEDT in Leymarie & Levine (1992). The algorithm provides
a fast approximation of the EDM, with the deviation from a full calculation being between
-0.09 and 0.
6. Spatial distribution of labeled cells around a lesion site
Distance distribution of cell structures around an object can be used to demonstrate
spatially-distributed effects or interactions. The distance from an arbitrary pixel set (for
example a connected ROI representing the objects of interest) can be computed using the
(approximate) Euclidean distance map transformation. In such case, the quantity of the effect
(e.g. the amount of immuno-reactivity) can be given by the support volume. Since the area
of a ring enclosed by two equidistant levels in the distance map increases monotonously
with distance, to allow for comparison one needs to normalize the integral intensity by the
ring area. Such normalization produces so called support volume density, having the same








h(g) · g (6.7)
where Ar denotes the are of the ring.
The algorithm is demonstrated on images produced from transversal cortical histological
slices stained for ED1 (microglial cell marker) and GFAP (astrocytic cell marker). The principle
of the algorithm is similar to the previous work of Blacher et al. (2001), which employed
distance maps to determine the effects of small molecules (Blacher et al., 2001) or enzymes
(Chabottaux et al., 2006) on vascularization. In contrast to the works of Blacher et al., we did
not attempt segmenting individual glial cells, since their processi form an overlapping mesh.
The application, which is presented here, is the measurement of the amount and distribution
of glial cells in a histological section encompassing an implanted microelectrode. Following
chronic implantation, the brain matter around the electrode forms glial scar spanning about
500 um from the electrode (review in Polikov et al. (2005)). Shortly after implantation, the
astroglial and microglial cells undergo activation and hypertrophy and invade the region of
primary injury. The distribution of glial cells around a lesion in the brain can be used to
measure the extent of reactive gliosis and compare effects of treatments with anitinflammatory
agents after such an implantation. In particular, such distributions can be used to study the
brain tissue response to chronically implanted silicon microelectrode arrays (Welkenhuysen,
2011).
6.1 Imaging protocol
Tissue slices were stained using the following protocol: preincubation - 4h in 10 % normal
goat serum, containing 0.1 % Triton-X 100; incubation - rabbit GFAP antibody (1:500,
Dakocytomation) + mouse ED1 (1:200, Abcam) overnight at room temperature. Following
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secondary incubation with antibodies for 4h with a cocktail of anti-mouse Alexa-444 and
Alexa-568 (1:500, Molecular Probes) in blocking buffer, the sections were cover-slipped with
Vectashield-DAPI (Vector Labs) mounting medium.
Confocal images were acquired on LSM5 Pascal confocal microscope (Carl Zeiss
Microimaging GmbH, Germany) using Plan Apochromat 5x/0.16 objective. The images were
composed of 2 acquisition channels (having 8-bit dynamic range each) for demonstration of
Alexa-444 (green LUT) and Alexa-568 emission (red LUT), respectively. The implant side
was centered in the field of view (Fig. 3A). Exposure times were optimized to provide best
compromise between cell contrast and saturation fraction. Images were imported in ImageJ
using the LSM Reader plugin.
6.2 Outline of the algorithm
The following algorithm was used for computation of the binary mask from the ED1 image:
1. Perform Gaussian filtering, kernel diameter 5 pixels;
2. Perform morphological erosion with SE of d=5 pixels;
3. Perform morphological dilation with SE of d=10 pixels;
4. Do median thresholding (Doyle, 1962) (Fig. 3B).
5. Do magic wand selection from a point in the lesion site.
6. Clear the non selected area.
7. This mask is then transformed by Euclidean distance mapping and serially thresholded at
increasing distances.
The resulting ring-like images are then overlaid in turn onto the GFAP image (Fig. 3D).
Proposed approach can be used to investigate the factors which contribute to the loss of signal
in chronic microelectrode recordings. From the side of the brain this phenomenon can be
caused by (i) spatial shift caused by the formation of the glial scar, (ii) neuronal cell death
around the implanted probe or (iii) silencing of the surrounding neurons (review in Braeken
& Prodanov (2010)). Activation of microglial cells results in a substantial increase in their
phagocytic capacity. So-described process could lead to changes of the neuronal activity of
the remaining neurons and may lead to atrophy or cell death of the neuronal cell bodies and
axons, respectively. This in turn increases the variability of recorded bioelectrical signals and
impedes the interpretation of the acquired physiological data. Moreover, the glial scar in the
brain has growth-inhibitory properties for the regenerating axons, which could additionally
impede the signal readout.
7. Morphometry of cultured neurons
To establish the dose- or time- dependence of a specific pharmacological effect often a large
number of different experimental groups are needed. This rapidly increases the number
of individual samples to be evaluated. Because of the high variability of the localizations
of synapses on dendrites and the clustering of boutons, the stereological assumption of
homogeneity of spatial distribution is violated. Therefore, complete dendritic trees are
counted. To facilitate counting in cell cultures we have developed a reproducible and robust
method for automatic identification and morphometry of synaptic boutons (Prodanov et al.,
2006). The method is further illustrated with identification of synaptic boutons marked for
synapsin I immuno-fluoresecence from micro-island cultures of neocortical neurons.
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Fig. 3. Spatial distribution of GFAP immunoreactivity around an electrode insertion track
A – ED1-labeled neuronal cell bodies (red) overlaid on GFAP-positive glial cells (green). The
electrode insertion track can be recognized as the tissue defect in the center of the image.
B – mask of the insertion track segmented as a background object in the center of the image;
C – Euclidean distance map of the insertion track. The closest distance to a point on the track
border is represented by the intensity value of the pixel. D – concentric equidistant regions
overlaid on the GFAP-image. Original image resolution 1.217 pixels/μm; scale bar – 100 μm.
7.1 Imaging protocol
Micro island cortical cultures were prepared from embryonic day 18 murine embryos.
Cultures were stained with antibodies against a marker for dendrites, microtubule-associated
protein 2 (MAP-2), and a marker for synaptic vesicles, synapsin I. Cultures were fixed by
4% paraformaldehyde, washed with 0.1M Phosphate buffered saline (PBS) and incubated in
0.1% Triton X-100 followed by 4% fetal calf serum for 20 minutes. After washing with PBS,
cultures were incubated for 1 hour at room temperature in a mixture containing 0.1% Triton
X-100, mouse monoclonal anti-MAP-2, 1:200 (Boehringer, Alkmaar, The Netherlands) and
rabbit polyclonal anti-synapsin I, 1:1000 antibodies diluted in PBS. After washing with PBS,
the cells were incubated for 1 hour at room temperature in secondary antibodies conjugated to
anti-rabbit-Cy5 or anti-mouse-Alexa546 (Molecular Probes, Oregon, USA). Finally, the slides
were washed in PBS and cover-slipped with Dabco-Mowiol (Prodanov et al., 2006).
Samples were analyzed on a Zeiss 510 Meta confocal microscope (Carl Zeiss, Heidelberg,
Germany). A set of high-resolution digital images of different cultures was recorded at a
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secondary incubation with antibodies for 4h with a cocktail of anti-mouse Alexa-444 and
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Alexa-444 (green LUT) and Alexa-568 emission (red LUT), respectively. The implant side
was centered in the field of view (Fig. 3A). Exposure times were optimized to provide best
compromise between cell contrast and saturation fraction. Images were imported in ImageJ
using the LSM Reader plugin.
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2. Perform morphological erosion with SE of d=5 pixels;
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resolution of 4.45 pixels per μm. Images were acquired on 2 channels - cyan, comprising
anti-synapsin staining and red, comprising anti-MAP-2 staining.
7.2 Outline of the algorithm
The algorithm employed in the study can be outlined in the following main steps:
1. Perform granulometry of the image and compute its granulometric size density G(d)
(Appendix 12).
2. Identify the scale of interest by the pattern of the peaks in G(d); select low bound Ilow =
S ◦ Elow and high bound images Ihigh = S ◦ Ehigh and subtract the images.
3. Construct the binary "mask" using the k-means clustering segmentation algorithm.
4. Delete irrelevant structures by superimposing the mask on the original image using
bit-plane logical AND operation (masking).
5. Threshold the resulting image using the area thresholding (Sec. 5.2).
6. Construct disjoint grains from the pixels that are above the threshold based on their
8-connected neighborhoods.
7. Enumerate and measure the grains constructed in this way. Produce derivative images
where the identification numbers of the positive fibers are visible.
The algorithm was applied to the synapsin channel of every image. The identified
boutons were numbered and their areas, equivalent diameters, and planar co-ordinates were
automatically measured and recorded. The final measurements were uploaded in the LabIS








Fig. 4. Illustration of the granulometric filtering technique on a real image. A -
Co-localization of synapsin I (cyan) and MAP-2 (red); B - co-localization of the detected
synaptic boutons (red outline) with the inverted image from A. Scale bar - 5 μm.
As the fluorescent patches in the real images were round, granulometry was performed with a
family of flat disk-shaped SEs ranging from d=1 to d=25 (0.2 μm - 5.6 μm). For the construction
of Ilow values of either dlow=3 or dlow=5 were selected depending on the amount of debris in
an image; dhigh=11 was selected as a parameter for Ihigh. Based on the discrimination of dark
background, auto-fluorescing cell mass, and synapsin positive grains three brightness classes
were used during k-means clustering. During the area thresholding, sufficient overlap of the
thresholded particles with the actual synapsin grains was typically achieved for α = 0.8. The
brightest class was selected for the construction of the mask. A typical result of the detection
procedure is presented in Fig. 4B.
An advantage of the proposed automated approach is that, apart from the number of
synaptic boutons in a light microscopic image, it also allows to be measured morphological
characteristics such as area, circularity, and maximal diameter.
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8. Spatial mapping of tracer-filled axons
Specific populations of myelinated nerve fibers can be investigated by retrograde tracing from
a muscle followed by morphometric assessment of the labeled fibers at different anatomical
levels. Transversal sections of so-labeled nerves would then represent spatial maps of the
specific muscle representations (Fig. 5). To facilitate such mapping studies we have developed
a reproducible approach for image segmentation and morphometry (Prodanov & Feirabend,
2008).
Gastrocnemius muscles of adult rats were injected under anesthesia with the retrograde tracer
Fluoro-Gold. After a survival period of 3 days, the sciatic nerves and spinal roots were
harvested and fixed in 4% paraformaldehyde.
8.1 Imaging protocol
The samples were sectioned at 14 μm, mounted on glass slides and inspected on an Axioplan
(Carl Zeiss Microimaging GmmbH, Germany) fluorescence microscopes. The fluorescent
signal from the specimens was recorded on 2 channels. Fluoro-Gold signal was recorded
using a standard filter set for DAPI (4’,6-Diamidino-2-phenylindole) detection (excitation
320 - 370 nm), see Fig. 5/Fluoro-Gold. The signal from the myelin sheaths (comprising
autofluorescence) was recorded using a standard filter set for FITC (Fluorescein) detection
(excitation 450 - 490 nm), see Fig. 5/FITC. Tracer-positive axonal profiles were isolated
from the resulting images by means of Differential Contrast Enhancement and Granulometric
filtering.
The following procedure was employed to identify the Fluoro-Gold-positive fibers. Due to
the excitation characteristics of Fluoro-Gold its signal was absent from the FITC channel (Fig.
5/FITC). Therefore, it was possible to isolate the Fluoro-Gold using the DCE implemented
as the Channel Filter plugin. For the optimal differential brightness enhancement a thin
rectangle ROI was drawn across the image and the intensities of the pixels were averaged
in the direction perpendicular to the larger side of the rectangle and the input images were
transformed according to Eq. 5.6.
8.2 Outline of the algorithm
The algorithm employed in the study can be outlined in the following main steps:
1. Perform DCE (Sec. 5.4).
2. Perform granulometry on the resulting image and compute G(d).
3. Identify the scale of interest by the pattern of the peaks in G(d); select Ilow = S ◦ Elow and
Ihigh = S ◦ Ehigh and subtract the images.
4. Interactively threshold the resulting image.
5. Construct disjoint grains from the pixels that are above the threshold based on their
8-connected neighborhoods.
6. Enumerate and measure the grains constructed in this way. Produce derivative images
where the identification numbers of the positive fibers are visible.
Spatial maps obtained in this way were uploaded to LabIS using the SQL Results plugin. The
data were imported to Matlab and the spatial distribution of the Fluoro-Gold-positive axons
was further studied on demand using custom code (Prodanov & Feirabend, 2008; Prodanov
et al., 2007).
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The algorithm employed in the study can be outlined in the following main steps:
1. Perform DCE (Sec. 5.4).
2. Perform granulometry on the resulting image and compute G(d).
3. Identify the scale of interest by the pattern of the peaks in G(d); select Ilow = S ◦ Elow and
Ihigh = S ◦ Ehigh and subtract the images.
4. Interactively threshold the resulting image.
5. Construct disjoint grains from the pixels that are above the threshold based on their
8-connected neighborhoods.
6. Enumerate and measure the grains constructed in this way. Produce derivative images
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Spatial maps obtained in this way were uploaded to LabIS using the SQL Results plugin. The
data were imported to Matlab and the spatial distribution of the Fluoro-Gold-positive axons
was further studied on demand using custom code (Prodanov & Feirabend, 2008; Prodanov
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Fig. 5. Gastrocnemius topography in the sciatic and tibial nerves revealed by the Differential
Contrast Enhancement algorithm (Prodanov & Feirabend, 2008)
Left pane: FITC – showing the myelin sheath auto-fluorescence; FG – showing Fluoro-Gold
fluorescence and Enhanced – showing the subtraction of the other two. Images are
composed of several "stitched" complete microscopical fields. Stitching was performed
semi-automatically using the the 2D stitching plugin (Preibisch et al., 2009). Fascicle borders
are enhanced by dotted lines. Enhanced image was generated by the Channel Filter plugin.
Right pane: Gastrocnemius axons inside a fascicle of the tibial nerve (top - Tibial/FG) and a
microscopic field in the sciatic nerve (bottom - Inset/FG). The corresponding inset is outlined
in the Enhanced image. Tibial/FG – the Gastrocnemius fascicle borders are outlined by a
dotted line. Scale bars – 100 μm.
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9. Outlook
Presented algorithms can be developed further in two directions.
Parallelization: As the sizes of available images increase and the parallel computer
architectures become increasingly available a logical step would be the development
of parallel implementations. Such parallelizations can be especially useful in zonal
and map algorithms where the same elementary operations are repeated multiple times
on different pixels. Notably we expect substantial speedups for image convolutions
and morphology operations. Parallelization can be implemented either using general
purpose semi-automatic parallelization libraries, or optimized at a low level for the specific
algorithms.
Multidimensionality: Another direction for future development is the support of
multidimensional kernels and structuring elements in zonal operations. Multidimensional
imaging data are increasingly used in life sciences but at present they are not
well supported by the data model in ImageJ, which assumes at best a collection
of loosely-coupled 2D images. Such support can be achieved by development of
a multidimensional data model in combination with generic zonal image transform
algorithms.
It is expected that the development and support of ImageJ will continue in the future as the
user and developer base of the program is growing and there are structured institutional
efforts to sustain and support this trend. Therefore, both directions will be pursued further
in the context of ImageJ and the developed plugins and libraries will be made available to the
user community.
10. Management of the information flow
Until recently, management of the data produced along the life science workflow (Fig. 1) was
not perceived as a pressing issue in the academic environments. Traditionally, the scientific
publications were considered as the only sufficient reports of the experimental findings.
However, the scale of current imaging experiments and the volumes of data generated by
them would also require persistent data management and collaboration solutions. This is a
situation already recognized in brain mapping studies (Bjaalie, 2002). On the second place,
sharing of raw data and code gains momentum in Neuroscience. The exchange of raw
imaging data between groups offers the opportunity to differently re-analyze previously
collected data and encourage new interpretations (Eckersley et al., 2003). While something
new for Neurosciences such practices are common in other fields like Physics and to
some extend in Bioinformatics, i.e. in Proteomics. With the increase of experimental
complexity and the article size restrictions imposed by the scientific publishers, frequently
essential experimental details are omitted from the final peer reviewed publications. This
eventually impedes the reproduction of the original experiments and could eventually lead
to unnecessary reproduction of experiments and waste of time and resources. In contrast,
data sharing can reduce the experimental and analytical errors. However, both high-level
data archiving and the raw data sharing will have limited utility if they are not backed by
information system solutions on the research laboratory level.
In the following sections we present an integrated information system for image
measurements, LabIS. The system was publicly demonstrated for the first time at the
6th FENS Forum of European Neuroscicence, although developmental versions existed since
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2004. Previous versions of the system supported data analyzed in publications about:
motor endplate distributions in (Prodanov, 2006; Prodanov et al., 2005); synaptic boutons
morphometry in (Prodanov, 2006; Prodanov et al., 2006); peripheral axon spatial distributions
in (Prodanov, 2006; Prodanov & Feirabend, 2008; Prodanov et al., 2007). Development of LabIS
has the objectives to automate (i) the process of storage, annotation and querying of image
measurements and (ii) to provide means for data sharing with 3rd party applications utilizing
measurement data (Prodanov, 2008). A developmental snapshot of the system is available
through the website Sourceforge.net at http://labinfsyst.sourceforge.net/.
10.1 System realization
LabIS realizes 3-tier architecture with a relational database back-end and an application logic
middle tier realizing web-based user interface for reporting and annotation and a web service
communication layer. LabIS is a distributed Internet and intranet application. It can be
accessed (i) through the web user interface by a web browser, (ii) through web-service or
(iii) database clients (Fig. 6). LabIS is based on commonly-accepted open-source software
technologies and open communication and data storage protocols. In order to enforce data
organization in a structured manner, LabIS realizes a centralized data storage model. LabIS is
designed and developed in a modular manner and the data model for communication with
3rd party applications is also extendable.
Interaction with users is executed via dynamically-generated web pages. All user-interface
modules are organized in a similar manner: users can generate reports, enter data or annotate
already present database records. The Project planning module is used for management of the
records of research projects. The users can perform tasks, such as deployment of new and/or
changing the state or the attributes of ongoing projects. Groups of results can be organized
in results collections. The Subject management module manages the records for experimental
animals. The users can perform tasks, such as registration of new subjects/animals, editing
of records, introduction of new species etc. The subjects can be assigned to projects and
to experimental groups. Dynamic reports can be generated for arbitrary periods. The
Manipulation management module manages the records for performed manipulations. The
users can perform tasks, such as registration and editing of manipulations. Dynamic reports
can be generated for arbitrary periods. The Image Measurements and Morphometry module
manages uploaded measurement records. Uploaded measurements can be associated to a
project, an experimental subject, experimental group, sample, result collection, or paired
to other measurements. The measurements can be queried by the name of the measured
image, by the internal ID or simply browsed. There are possibilities for flexible reporting
of the performed measurements. The Administration module manages the user roles, the
maintenance of the database, and the system configuration. The users can also define custom
ontologies.
It should be noted that LabIS is not a raw image database. The raw images are let to reside
in remote repositories, such as on a local client file system or 3rd party file server, while only
references to them are stored centrally. In contrast, the imaging meta data and the produced
measurements are stored centrally in the relational database. Such an approach provides a
definite advantage for the integration of 3rd party imaging data, such as large scale digital
atlases. It also increases the portability of the system since its entire database can be easily
copied from one host to another. Most notable characteristics of LabIS are the possibilities to
annotate and collate measurements and its interoperability with 3rd party software. In this
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Fig. 6. LabIS user interface and data upload clients
The information system can be accessed through the web user interface by a web browser.
The user interface of the ImageJ SQL access plugin for measurement upload and annotation is
overlaid onto a web browser window displaying the Morphometry module.
context, interactions with LabIS are executed either by exchange of structured messages over
the web or by database queries in an intranet.
10.2 Annotations of measurements
Measurement type annotations Uploaded measurements can be annotated by ontology
entries. Support of 3rd party ontologies is provided using the publicly available Ontology
Lookup Service (OLS) registry web site 11. This support is realized on 2 levels: (i)
individual measurement types can be annotated with ontology keys, for example using
the Unit Ontology; (ii) the complex measurement objects can be annotated using terms of
any of the ontologies supported by OLS. The integration with OLS is transparent for the
user and is realized using a cascade of client and 3rd party server calls. This is an example
of mixed client-server interoperability.
Spatial annotations LabIS provides also atlas mapping and registration functionality. Major
features include the possibility to associate a Results collection to an atlas and to map
individual measurement entries of the collection to the atlas imaging space. An example is
demonstrated in Fig. 7 where some measurements are mapped to a rat coronal histological
11 http://www.ebi.ac.uk/ontology-lookup/
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Interaction with users is executed via dynamically-generated web pages. All user-interface
modules are organized in a similar manner: users can generate reports, enter data or annotate
already present database records. The Project planning module is used for management of the
records of research projects. The users can perform tasks, such as deployment of new and/or
changing the state or the attributes of ongoing projects. Groups of results can be organized
in results collections. The Subject management module manages the records for experimental
animals. The users can perform tasks, such as registration of new subjects/animals, editing
of records, introduction of new species etc. The subjects can be assigned to projects and
to experimental groups. Dynamic reports can be generated for arbitrary periods. The
Manipulation management module manages the records for performed manipulations. The
users can perform tasks, such as registration and editing of manipulations. Dynamic reports
can be generated for arbitrary periods. The Image Measurements and Morphometry module
manages uploaded measurement records. Uploaded measurements can be associated to a
project, an experimental subject, experimental group, sample, result collection, or paired
to other measurements. The measurements can be queried by the name of the measured
image, by the internal ID or simply browsed. There are possibilities for flexible reporting
of the performed measurements. The Administration module manages the user roles, the
maintenance of the database, and the system configuration. The users can also define custom
ontologies.
It should be noted that LabIS is not a raw image database. The raw images are let to reside
in remote repositories, such as on a local client file system or 3rd party file server, while only
references to them are stored centrally. In contrast, the imaging meta data and the produced
measurements are stored centrally in the relational database. Such an approach provides a
definite advantage for the integration of 3rd party imaging data, such as large scale digital
atlases. It also increases the portability of the system since its entire database can be easily
copied from one host to another. Most notable characteristics of LabIS are the possibilities to
annotate and collate measurements and its interoperability with 3rd party software. In this
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Fig. 6. LabIS user interface and data upload clients
The information system can be accessed through the web user interface by a web browser.
The user interface of the ImageJ SQL access plugin for measurement upload and annotation is
overlaid onto a web browser window displaying the Morphometry module.
context, interactions with LabIS are executed either by exchange of structured messages over
the web or by database queries in an intranet.
10.2 Annotations of measurements
Measurement type annotations Uploaded measurements can be annotated by ontology
entries. Support of 3rd party ontologies is provided using the publicly available Ontology
Lookup Service (OLS) registry web site 11. This support is realized on 2 levels: (i)
individual measurement types can be annotated with ontology keys, for example using
the Unit Ontology; (ii) the complex measurement objects can be annotated using terms of
any of the ontologies supported by OLS. The integration with OLS is transparent for the
user and is realized using a cascade of client and 3rd party server calls. This is an example
of mixed client-server interoperability.
Spatial annotations LabIS provides also atlas mapping and registration functionality. Major
features include the possibility to associate a Results collection to an atlas and to map
individual measurement entries of the collection to the atlas imaging space. An example is
demonstrated in Fig. 7 where some measurements are mapped to a rat coronal histological
11 http://www.ebi.ac.uk/ontology-lookup/
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atlas. This is achieved by integration with public atlas datasets, for example those available
at Brain Maps web site12 (Mikula et al., 2007) .
10.3 Interoperability
Interoperability with 3rd party software is realized both on the client and server sides.
ImageJ can directly upload measurements to LabIS via specialized plugin clients. In such way,
the entire image processing functionality of ImageJ can be made available to the end user.
The user can perform arbitrary measurements using any type of built-in or customized
Fig. 7. Spatial annotation and atlas registration
Three types of atlas annotations are demonstrated in the figure. A ROI annotation delineating
a region in the frontal cortex is displayed in solid blue, Nissl stating, source Brain Maps,
contributed by Edward Jones, 2007. In red are demonstrated provisional annotations produced
by mouse clicks on the client side. In black are demonstrated measurements already stored on
the server. Spatial annotation storage and retrieval can be done using the user interface in the
bottom left part of the web page. Spatial navigation in the atlas dataset can be done using the
icons in the top left part of the web page.
12 http://brainmaps.org/
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ImageJ plugins. After the end of the measurement session this object together with a
JPEG-encoded thumbnail view of the active image are upload either using the SQL client or
using the web service client. Known measurement unit types are associated automatically
to terms in 3rd party ontologies, i.e. the Unit Ontology. If a new measurement type is
encountered it is also automatically included in the database. Such a new type can be later
annotated using the web UI and the ontology terms lookup service. The GUI front-end
clients were implemented as a set of plugins: the SQL Results plugin and web-service
plugins SOAP Results and JSON Results plugins. The SQL-plugin implements a MySQL
client that interacts directly with the database server. It is intended for use in intranet
environments. The web-service plugins interact with the Object Server interfaces of LabIS
(Fig. 6). This functionality is an example of interoperability on the client side.
Matlab R© can directly query LabIS via its web-service interface. Since its R2007 version,
Matlab R© provides client functionality for web services. The generation of client scripts
is fully automated and transparent to the end-user by the service discovery mechanisms.
On the application level, advantages of the system are the use of open communication
standards and the integration of server and client technologies, which are transparent for
the end-user. On the system level, advantages of LabIS are the extendable data model, the
independence of a particular programming language and the scalability of the component
technologies. On the level of exploitation and deployment, advantages of the system are the
use of open-source platforms, which are available as standard hosting options in the most web
hosting services.
11. Summary
This chapter presents several techniques for morphometry of microscopic and non-optical
images. The main focus of the manuscript is the automation of image processing and
measurement steps along the experimental workflow. Main algorithms are implemented as
either plugins or macros for the public domain image processing program ImageJ. We present
several generic processing and segmentation techniques, which can be used in a variety of
applications.
Notably, the utility of mathematical morphology was demonstrated in several image filtering
and segmentation algorithmic steps. Morphology-based Granulometric filtering was used to
facilitate segmentation of globular structures, such as synaptic boutons or cross sections of
axons. In the first application, morphological granulometry was used to estimate size of
synaptic boutons, which are then segmented by means of granulometric filtering followed
by thresholding. Using this approach quantitative effects of different treatments of cell
cultures can be measured. In the second application, Differential Contrast Enhancement and
granulometry were used to segment images of fluorescent tracer filled axons. An additional
application of the morphological image simplification were the preprocessing steps in the
analysis of astroglial distribution.
The computation of spatial parametric maps was demonstrated in the context of MRI data
sets. Such maps are produced by parametric fitting to time-varying spatial measurements.
The utility of the Local Area Thresholding was demonstrated in the context of segmentation
of histological images. The Differential Contrast Enhancement algorithm can be used to reduce
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encountered it is also automatically included in the database. Such a new type can be later
annotated using the web UI and the ontology terms lookup service. The GUI front-end
clients were implemented as a set of plugins: the SQL Results plugin and web-service
plugins SOAP Results and JSON Results plugins. The SQL-plugin implements a MySQL
client that interacts directly with the database server. It is intended for use in intranet
environments. The web-service plugins interact with the Object Server interfaces of LabIS
(Fig. 6). This functionality is an example of interoperability on the client side.
Matlab R© can directly query LabIS via its web-service interface. Since its R2007 version,
Matlab R© provides client functionality for web services. The generation of client scripts
is fully automated and transparent to the end-user by the service discovery mechanisms.
On the application level, advantages of the system are the use of open communication
standards and the integration of server and client technologies, which are transparent for
the end-user. On the system level, advantages of LabIS are the extendable data model, the
independence of a particular programming language and the scalability of the component
technologies. On the level of exploitation and deployment, advantages of the system are the
use of open-source platforms, which are available as standard hosting options in the most web
hosting services.
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This chapter presents several techniques for morphometry of microscopic and non-optical
images. The main focus of the manuscript is the automation of image processing and
measurement steps along the experimental workflow. Main algorithms are implemented as
either plugins or macros for the public domain image processing program ImageJ. We present
several generic processing and segmentation techniques, which can be used in a variety of
applications.
Notably, the utility of mathematical morphology was demonstrated in several image filtering
and segmentation algorithmic steps. Morphology-based Granulometric filtering was used to
facilitate segmentation of globular structures, such as synaptic boutons or cross sections of
axons. In the first application, morphological granulometry was used to estimate size of
synaptic boutons, which are then segmented by means of granulometric filtering followed
by thresholding. Using this approach quantitative effects of different treatments of cell
cultures can be measured. In the second application, Differential Contrast Enhancement and
granulometry were used to segment images of fluorescent tracer filled axons. An additional
application of the morphological image simplification were the preprocessing steps in the
analysis of astroglial distribution.
The computation of spatial parametric maps was demonstrated in the context of MRI data
sets. Such maps are produced by parametric fitting to time-varying spatial measurements.
The utility of the Local Area Thresholding was demonstrated in the context of segmentation
of histological images. The Differential Contrast Enhancement algorithm can be used to reduce
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bleed-through artifacts from a background channel to a signal channel. Presented algorithm
was used in the context of image enhancement in fluorescent tracer studies.
The utility of distance transform for analysis of spatial distribution of objects was
demonstrated in the context of estimation of radial distributions of the glial fraction of the
neuropil.
In addition, we also present an information system, which is capable of managing the
measurements uploaded from ImageJ. The system provides a structured information context
for querying and retrieval of primary morphometric information, which goes beyond
acquisition metadata. In such way, the increase of the information complexity along the
experimental workflow is supported. The system is a step towards providing the link




Mathematical morphology is a branch of mathematics applicable to image processing.
Morphology operators are a class of zonal operations where the pixels of a certain
neighborhood (Structure Element) are combined to produce a single output value. Principal
operations in mathematical morphology are erosion, dilation, opening and closing (Matheron,
1975; Serra, 1982).
Grey level images can be represented by 3D geometric bodies (called umbras) where the
elevation conventionally signifies intensity. Morphology operations of gray level images can
be constructed from ordering and ranking of the pixels. If S(x) is the umbra of the image S
and E(x) is a Structuring Elements (SEs) set, erosion (�) and dilation (⊕) are defined by:
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S (x − b)− Ê (b)]
}
(12.9)
where Ê is the complement of the structure element and x or b denote vector coordinates.
Opening is defined as I ◦ E = (I � E)⊕ E and closing as I • E = (I � E)⊕ E.
An example of the four major morphological operations is given in Fig. 8.
As seen from their definition, erosion and closing increase the number of dark pixels and
decrease image brightness, while dilation and opening do the opposite.
Sizes of different objects present in an image can be collectively studied by the operation of
granulometry, introduced by Matheron (1975).
In a way similar to sieving grains, pixels comprising an image are "sieved" according to their
connectivity imposed by a certain SE. Granulometry is formally defined as a set of openings
by a family of SEs, characterized by certain scale parameter d. In the case of closings, the set
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Fig. 8. Prinicipal morphological operations
Fig. 9. Granulometry of a synthetic image
Granulometric image sequence; from left to right: original image, d=5; d=10, d=15, d=20, d=25





I ◦ (d · E) (12.10)
where d denotes the proportionality parameter of the homothety. By convention G0(S) = S
and for negative d opening is replaced by closing.
For greyscale images, the measure of the interaction with SE is the support volume removed
after opening. This can be expressed by the granulometric (size) density distribution:
GSD (d) =
V[I ◦ dE]− V[I ◦ (d − 1)E]
V[I]
(12.11)
where g is the intensity. The support volume is estimated from the image histogram H =






Gray-level morphological operations erosion, dilation, opening and closing are implemented
as a plugins for ImageJ.
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Nowadays, new imaging modalities such as molecular imaging have enabled both 
practitioners and researchers to visualize, trace and measure biological processes at the level of 
cells or even single molecules. Instruments of nuclear medicine, like Positron Emission 
Tomography (PET), Single-Photon Emission Computed Tomography (SPECT) and gamma 
scintigraphy have largely contributed to the evolving and promising era of personalized 
medicine. Such recently introduced molecular imaging techniques take advantage of an 
additional potential for broad application in imaging molecular or cellular events in vivo: 
gene/protein function and regulation, signal transduction, transcriptional regulation and 
characterization of transgenic animals (Jacobs et al., 2003). Most importantly, molecular 
imaging will render possible the identification of potential molecular therapeutic targets, in the 
development of new treatment strategies, and in their successful implementation into clinical 
application (Jacobs et al., 2003). As a description, molecular imaging is a process of getting 
signals originating from live organisms after the administration of specific agents that target 
specific markers found at tissue or cellular level. Such nuclear imaging is the most well-known 
instrument of all molecular imaging methods and has been set as the gold standard. 
In this chapter, the authors will discuss PET and other more recent molecular imaging 
techniques such as near infrared fluorescence (NIRF). Moreover, we will put emphasis on 
the application of molecular imaging in visualization of stem cell transplantation as a 
ground breaking treatment modality for neurodegenerative and other neurological diseases.  
The authors stand among the very first who has implemented recently introduced 
molecular imaging techniques into experimental research and clinical practice.  
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2. Cell therapy 
Cell therapy, as a promising method using live components of human tissue for treatment of 
neurological diseases, is one of the mainstays of the wide field of regenerative medicine.. 
Among stem cell sources available up to date, mesenchymal stem cells (MSCs) have 
generated a great deal of interest because of their potency in terms of regeneration and 
tissue engineering (Wislet-Gendebien et al., 2012). 
Neurodegenerative disease is a term which encompasses a wide range of acute and chronic 
neurological diseases such as Parkinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis (ALS), Alzheimer's disease, multiple sclerosis (MS), stroke, and spinal cord injury. 
Because of the fact that central nervous system reveals limited capacity of regeneration and 
tissue replacement, cell therapy and tissue regeneration of injured or degenerated tissue, as 
a potential new therapeutic modality, draws lots of attention (Wislet-Gendebien et al., 2012). 
Stem cells have the potential to differentiate into many different cell types. Recent research 
has concerned an exciting opportunity to apply MSCs especially in the management of 
neurodegenerative diseases, because of their potential to differentiate into neurons (Lee et 
al., 2010).  
It has been shown that the injection of MSCs could be profitable in the treatment of 
neurodegenerative diseases such as Parkinson’s disease (Levy et al.), Spinal Stroke and 
cerebral ischemia (Sieber-Blum, 2010), Alzheimer's disease (Lee et al., 2010), Multiple 
Sclerosis (Grigoriadis et al., 2011), Huntington's Disease (Snyder et al., 2010). The 
advantages of using stem cells for regenerative medicine are not only the eases of harvesting 
from bone marrow or other donor sites but also the minimal risk of tissue rejection because 
of the application of autologous cells. 
Interestingly, recent data suggest that intravenously injected MSCs could migrate into the 
brain and pass blood-brain barrier (BBB), which is basically formed by brain microvascular 
endothelial cells (BMECs), and restrict the passage of immune cells and different molecules 
into the brain. The exact mechanism of this phenomenon, whether it is based on Integrin-
mediated adhesion or is matrix metalloproteinase dependent extracellular matrix 
degradation, is yet not clear (Krampera et al., 2007, Matsushita et al., 2011). 
One of the main clinical problems of stem cell transplantation is the difficulty of detection, 
localization, and examination of the stem cells in vivo at both cellular and molecular levels 
(Sandu et al.). State-of-the-art molecular imaging techniques provide new superior means of 
noninvasive, repeated, and quantitative tracking of stem cell implants or transplants (Sandu 
et al.). From initial deposition to the survival, migration, and differentiation of the 
transplant/implanted stem cells, current molecular imaging methods allow monitoring of 
the infused cells in the same live recipient bed over time (Sandu et al.). 
3. Positron Emission Tomography (PET) 
Over the past two decades, PET has been introduced and applied widly in the milieu of 
diagnosis including head and neck diseases. Along with a growing interest to use PET in 
tracing different types of molecules such as amino acids, receptor ligands, glucose and other 
metabolic substrates which follow specific metabolic pathways have been utilized to assess 
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different tissue functions, especially in neoplasms (Cornelius et al., 2011). The main 
substances for radio-labeling are fluorine-18 (F), gadolinium-68 (Ga) and Carbon-11 (C). The 
advantages that they confer upon other positron emitting isotopes such as O, N and C are 
their longer half-life time which results in superior tissue distribution and consequently a 
dynamic imaging of higher accuracy (de Langen et al., 2008, Keiding et al., 2010, Floeth et 
al., 2011, Henze et al., 2005). 
Among metabolic substrates, F-fluorodeoxyglucose is the most renowned molecular tracer 
in oncology. It has been shown that F-FDG uptake may increase in neoplasmic cells which 
are believed to be indicative of an increased glycolysis and a subsided respiratory rate of 
tumoral tissues (Di Chiro et al., 1987). It has been demonstrated that amino acid synthesis is 
up regulated in tumor cells in comparison to normal tissues. Until now, F-Tyrosine and C-
Methionine uptakes are studied at different grades of oncologic tumors such as 
meningimoma (Cremerius et al., 1997).  
C-colin, another marker which represents phospholipid synthesis, is hiked in malignant 
tumors. It has been shown that the metabolism and proliferation of C-colin are strongly 
correlated with breast and prostate cancers, indicating high uptake as a measurement of 
cellular proliferation (Cornelius et al., 2011). Other markers, with a better theoretical profile, 
have also been introduced in neuroscience but are mostly used only in a limited number of 
experiments, so that no knowledge is about their potential for imaging stem cell 
transplantation. 
4. Near-InfRared Fluorescence (NIRF) imaging 
NIRF confers similar capability for tracing of imaging agents as PET. NIRF dyes are 
chemically conjugated on targeting molecule such as antibodies, carbohydrates and 
peptides. After administration into tissues, the dye molecules are excited by the radiation of 
tissue penetrating NIR excitation light (750-900nm). 
Considering radioactive decay, a photon of lower energy which has a higher wavelength is 
emitted and the fluorescent dye relaxes back to its basic state, ready to repeat the same 
process. Each fluorescent dye absorb excitation light and afterward, just in a nanosecond, 
produce fluorescent light. Accordingly, each fluorescent dye molecule provides about 
100,000,000 photons per second for collection and image formation. As a consequence, low-
energy fluorescent photons are slightly absorbed and maximally scattered, reduced by the 
tissues between the targeted tissue and the tissue surface before being collected by detectors 
in a few milliseconds. In contrast with radionuclides, a fluorescent dye has no physical half-
life. Moreover, this methodology is not clinically approved yet and no devices is available 
for human imaging with NIRF contrast agents, and NIRF contrast imaging agents do not 
posses approval for human study as well. Interestingly, some investigators utilized NIRF 
imaging for human applications such as functional lymphatic imaging, sentinel lymph node 
mapping, activated probes, and promising advances in 3D imaging (Sevick-Muraca EM, 2012). 
5. Potential clinical applications of molecular imaging
Many surgical techniques are mainly based on histological grading of the tumor. Molecular 
imaging enables surgeons to have the gross picture of these tumors. Pre-surgical molecular 
Molecular Imaging 212 
2. Cell therapy 
Cell therapy, as a promising method using live components of human tissue for treatment of 
neurological diseases, is one of the mainstays of the wide field of regenerative medicine.. 
Among stem cell sources available up to date, mesenchymal stem cells (MSCs) have 
generated a great deal of interest because of their potency in terms of regeneration and 
tissue engineering (Wislet-Gendebien et al., 2012). 
Neurodegenerative disease is a term which encompasses a wide range of acute and chronic 
neurological diseases such as Parkinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis (ALS), Alzheimer's disease, multiple sclerosis (MS), stroke, and spinal cord injury. 
Because of the fact that central nervous system reveals limited capacity of regeneration and 
tissue replacement, cell therapy and tissue regeneration of injured or degenerated tissue, as 
a potential new therapeutic modality, draws lots of attention (Wislet-Gendebien et al., 2012). 
Stem cells have the potential to differentiate into many different cell types. Recent research 
has concerned an exciting opportunity to apply MSCs especially in the management of 
neurodegenerative diseases, because of their potential to differentiate into neurons (Lee et 
al., 2010).  
It has been shown that the injection of MSCs could be profitable in the treatment of 
neurodegenerative diseases such as Parkinson’s disease (Levy et al.), Spinal Stroke and 
cerebral ischemia (Sieber-Blum, 2010), Alzheimer's disease (Lee et al., 2010), Multiple 
Sclerosis (Grigoriadis et al., 2011), Huntington's Disease (Snyder et al., 2010). The 
advantages of using stem cells for regenerative medicine are not only the eases of harvesting 
from bone marrow or other donor sites but also the minimal risk of tissue rejection because 
of the application of autologous cells. 
Interestingly, recent data suggest that intravenously injected MSCs could migrate into the 
brain and pass blood-brain barrier (BBB), which is basically formed by brain microvascular 
endothelial cells (BMECs), and restrict the passage of immune cells and different molecules 
into the brain. The exact mechanism of this phenomenon, whether it is based on Integrin-
mediated adhesion or is matrix metalloproteinase dependent extracellular matrix 
degradation, is yet not clear (Krampera et al., 2007, Matsushita et al., 2011). 
One of the main clinical problems of stem cell transplantation is the difficulty of detection, 
localization, and examination of the stem cells in vivo at both cellular and molecular levels 
(Sandu et al.). State-of-the-art molecular imaging techniques provide new superior means of 
noninvasive, repeated, and quantitative tracking of stem cell implants or transplants (Sandu 
et al.). From initial deposition to the survival, migration, and differentiation of the 
transplant/implanted stem cells, current molecular imaging methods allow monitoring of 
the infused cells in the same live recipient bed over time (Sandu et al.). 
3. Positron Emission Tomography (PET) 
Over the past two decades, PET has been introduced and applied widly in the milieu of 
diagnosis including head and neck diseases. Along with a growing interest to use PET in 
tracing different types of molecules such as amino acids, receptor ligands, glucose and other 
metabolic substrates which follow specific metabolic pathways have been utilized to assess 
Molecular Imaging of Stem Cells: A New Area for Neuroscience 213 
different tissue functions, especially in neoplasms (Cornelius et al., 2011). The main 
substances for radio-labeling are fluorine-18 (F), gadolinium-68 (Ga) and Carbon-11 (C). The 
advantages that they confer upon other positron emitting isotopes such as O, N and C are 
their longer half-life time which results in superior tissue distribution and consequently a 
dynamic imaging of higher accuracy (de Langen et al., 2008, Keiding et al., 2010, Floeth et 
al., 2011, Henze et al., 2005). 
Among metabolic substrates, F-fluorodeoxyglucose is the most renowned molecular tracer 
in oncology. It has been shown that F-FDG uptake may increase in neoplasmic cells which 
are believed to be indicative of an increased glycolysis and a subsided respiratory rate of 
tumoral tissues (Di Chiro et al., 1987). It has been demonstrated that amino acid synthesis is 
up regulated in tumor cells in comparison to normal tissues. Until now, F-Tyrosine and C-
Methionine uptakes are studied at different grades of oncologic tumors such as 
meningimoma (Cremerius et al., 1997).  
C-colin, another marker which represents phospholipid synthesis, is hiked in malignant 
tumors. It has been shown that the metabolism and proliferation of C-colin are strongly 
correlated with breast and prostate cancers, indicating high uptake as a measurement of 
cellular proliferation (Cornelius et al., 2011). Other markers, with a better theoretical profile, 
have also been introduced in neuroscience but are mostly used only in a limited number of 
experiments, so that no knowledge is about their potential for imaging stem cell 
transplantation. 
4. Near-InfRared Fluorescence (NIRF) imaging 
NIRF confers similar capability for tracing of imaging agents as PET. NIRF dyes are 
chemically conjugated on targeting molecule such as antibodies, carbohydrates and 
peptides. After administration into tissues, the dye molecules are excited by the radiation of 
tissue penetrating NIR excitation light (750-900nm). 
Considering radioactive decay, a photon of lower energy which has a higher wavelength is 
emitted and the fluorescent dye relaxes back to its basic state, ready to repeat the same 
process. Each fluorescent dye absorb excitation light and afterward, just in a nanosecond, 
produce fluorescent light. Accordingly, each fluorescent dye molecule provides about 
100,000,000 photons per second for collection and image formation. As a consequence, low-
energy fluorescent photons are slightly absorbed and maximally scattered, reduced by the 
tissues between the targeted tissue and the tissue surface before being collected by detectors 
in a few milliseconds. In contrast with radionuclides, a fluorescent dye has no physical half-
life. Moreover, this methodology is not clinically approved yet and no devices is available 
for human imaging with NIRF contrast agents, and NIRF contrast imaging agents do not 
posses approval for human study as well. Interestingly, some investigators utilized NIRF 
imaging for human applications such as functional lymphatic imaging, sentinel lymph node 
mapping, activated probes, and promising advances in 3D imaging (Sevick-Muraca EM, 2012). 
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Many surgical techniques are mainly based on histological grading of the tumor. Molecular 
imaging enables surgeons to have the gross picture of these tumors. Pre-surgical molecular 
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imaging of neurological tumors enables us to establish better surgical procedure and 
strategy. Also, it would allow physicians to have a better pre-assessment of prognosis and 
risk benefit ratio. Moreover, PET might be helpful in the early discovery of molecular-level 
changes, which are undetectable in CT and MRI. Also, within a specific tumor, the most 
metabolically active and aggressive tumor areas could be mapped. 
Intriguingly, emerging data suggest that molecular imaging could be used as an outcome 
assessment tool for different treatment modalities. For instance, a recent study compared 
MRI response assessment with metabolic O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET 
response assessment during antiangiogenic treatment in patients with recurrent high-grade 
glioma (see table 1). Good results are already known for (18)FDG-PET, but results revealed 
that (18)F-FET PET, on the other hand, seems also to be predictive of treatment failure in 
that it contributes important information to response assessment based only on MRI and 








Table 1. (18)F-FDG Positron Emission Tomography with a Gold Standard of Biopsy or 
Radiography Follow-up (Schaller et al., 2008) 
6. Stem cell imaging at neurodegenerative pathways and pathologies 
Regenerative medicine is a developing era that seeks to restore or replace damaged tissue 
and organs via natural or bioengineered tools. Regenerative medicine via stem cells is 
considered as one of the most promising means to repair tissues. Stem cells could be isolated 
from both adult human and embryonic tissues. There is a great body of evidence 
demonstrating successful cases of expanded stem cell in vitro and then grafted in vivo for 
regenerative purposes at different tissues such as bone, cartilage, and myocardium.  
It seems that inflammation and degeneration are the two main aspects of CNS pathogenesis. 
It seems that there is an intrinsic connection between these two phenomena because in 
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several cases inflammation trigger degeneration. Also, endogenous neural stem cells, which 
have the capacity of renewing cells of CNS, may migrate to the affected area and robust the 
process of repair. This scenario drives scientists to seek a natural healing framework based 
on Trans stem cell therapy. In fact, it may improve the efficacy and decrease the toxicity of 
treatment modalities which are the main concepts of personalized medicine. 
7. Molecular imaging in Alzheimer’s disease 
Alzheimer’s disease (AD) is describes as a chronic and complex progressive 
neurodegenerative disorder, and is the most common cause of dementia among the elderly. 
A great body of evidences indicates that neuronal degeneration in AD progresses in a 
certain way while the pathology advances over several decades. Establishing an accurate 
dynamic map of this sequence is vital for the understanding and mapping the complex 
endophenotype of AD, providing a basis for successful treatments designed to resist or 
prevent disease progression. 
PET scanning has long been used to trace alterations in cerebral blood flow and metabolism 
in AD, and is useful for the differential diagnosis of dementia in individual patients. For 
instance, hypometabolism of the posterior cingulate cortex could be observed early in AD 
using fluoro-deoxyglucose (FDG) PET scanning, even while MRI results are normal (Ewers 
et al., 2011, Mosconi et al., 2004). As disease progresses, there is diminished cerebral 
metabolism and perfusion in posterior cingulate and association cortices, but the basal 
ganglia and thalamus, cerebellum, and primary sensorimotor cortices are largely spared 
until later stages of the disease. Some studies have tracked AD with PET, using new 
molecular probes sensitive to amyloid-beta (Aβ) or neurofibrillary tangle pathology, or both 
types of pathology (Braskie et al., 2010, Klunk et al., 2004, Mintun et al., 2006, Small et al., 
2006). 
8. Stem cell in Multiple Sclerosis (MS) 
Multiple sclerosis appears to result from defective innate and adaptive immune system 
actions in the CNS, likely begins with a kind of autoimmune response that leads to 
demyelination and neuronal degeneration. It seems that auto activity of immune system 
followed by neuroinflamation gradually causes death of oligodendrocytes. Increasing body 
of evidence represents that the brain’s inability to repair is one of the main factors that make 
this disease irreversible and causes permanent damages. This claim is in accordance with 
the fact that the progression of disease and state of remyelination is different in every 
patient. Consistently, Patrikios et al. (Patrikios et al.), recently performed 51 autopsies of MS 
patients with different clinical courses and disease durations and traced variable extents of 
remyelination. In 20% of patients – both relapsing and progressive patients – the extent of 
remyelination was extensive with 60–96% of the global lesion area remyelinated.  
Several attempts have been made since about four decades to replace demieylinated cells 
with myelin forming cells; however, as neural cells are highly differentiated and have 
limited ability for growth and expansion, these efforts have been mostly abortive in vivo. 
With the advent of stem cell regenerative medicine, scientists further discovered the 
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remyelination was extensive with 60–96% of the global lesion area remyelinated.  
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with myelin forming cells; however, as neural cells are highly differentiated and have 
limited ability for growth and expansion, these efforts have been mostly abortive in vivo. 
With the advent of stem cell regenerative medicine, scientists further discovered the 
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functional and special characteristics of adult stem cells and attempted to utilize them for 
the treatment of neurodegenerative multiple sclerosis. 
Adult stem cells have not only provided us with a readily available cell source for cell 
therapy but also with much safer and far less toxic tumor treatment measures. There are two 
basic routes for cell administration including in-site cell transplantation or blood injection 
(circulation). Tangible examples for the former include Parkinson’s disease, acute spinal 
cord injury and brain trauma. For multifocal diseases such as MS and epilepsy, the model of 
in-site injection is not effective; rather blood circulation or cerebrospinal fluid circulation 
should be used. There are several studies demonstrating successful results with the 
transplantation of hematopietic, mesenchymal and neural stem cells into the CNS injured 
areas in MS, SCI, epilepsy, and stroke cases (Pluchino et al., 2009). 
9. Mechanisms of Stem Cell Repairing 
A great amount of data demonstrates that HSCs have a great capacity to differentiate into 
different cell types including muscle, skin, neural tissue and lung (Pluchino et al., 2009). 
Several studies used HSCs injection as a treatment modality for hematological malignancies 
and shows that HSCs have the capability of entering the brain and as well as differentiating 
and producing new neural cells including neurons and microglia; these findings were in 
concordance by the detection of Y chromosome- positive Purkinje cells in the cerebellum of 
female rats who have undergone bone marrow transplantation from male donors (Koshizuka 
et al., 2004 2005). In addition, in an animal studies on rats suffering from a demyelinated lesion 
of the spinal cord, intravenous or intraparenchimal HSCs therapy lead to different degrees of 
remyelination  which  was proportional to the number of injected stem cells (Akiyama et al., 
2002a 2002, Inoue et al, 2003, Akiyama et al., 2002b 2002, Inoue et al, 2003). 
Several studies have challenged the idea of cell replacement in stem cell regeneration 
theories. Despite the fact that MSCs can exert various therapeutic effects, some data suggest 
that they protect immune system from demyelination via alternative mechanism to cell 
replacement.  
The suggested therapeutic effect is based on the intrinsic capacities of such cells to secret a 
large number of cytokines and chemokines. It has been shown that the pattern of secretion 
changes as early as transplanted stem cell encounter new (micro) environment in vivo. Some 
studies have shown that mesenchymal stem cells mainly act by suppressing inflammation, 
via cell-to-cell contact as well as through the activation of anti-inflammatory pathways; and 
consequently the proliferation, migration and differentiation of endogenous progenitor cells 
are enhanced. 
Utilizing fluorescent dyes and imaging modalities in humans is not possible due to limited 
depth of tissue penetration.  On the other hand, magnetic resonance imaging (MRI) and 
positron emission tomography (PET) have shown promising value and also great feasibility 
for treatment via stem cell. As well as above PET scan imaging, stem cells could be tagged 
with ferromagnetic material or with gadolinium rhodamine dextran and then detect via  
MRI (Brekke et al., 2007) (Carney and Shah, 2011). These imaging modalities along with 
alteration of genes via genetic engineering  and consequent labeling methods, enabled 
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scientists to monitor  different phase of repair and stem cell therapy. This allows not only 
the imaging in real time of stem cell migration, but also its integration, and therapeutic 
effects at the single cell level. Also, the above-mentioned capacities for tracing and 
monitoring of grafted stem cell behavior, enable us to assess both quantitatively and 
qualitatively the interaction between stem cell and its environment.  
10. View to the future 
Molecular imaging will gain more and more importance in neurosciences. PET is currently 
the gold standard and that will not change very soon. However, the different methods have 
different advantages and disadvantages, but it is not only for the researcher but also for the 
physician important to know this differences. In the near future, imaging on the molecular 
but also on the cellular level will not be an exception, as it is still now, but rather the rule. 
Such improvements open widely the door to a personalized medicine, a fact that has special 
importance in neurosciences. 
11. Take-home-message 
Molecular imaging has gained step-by-step importance in neuroscience. To know this 
method in detail is demanding but important in the area of personalized medicine. 
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1. Introduction 
Atherosclerosis and its consequences contribute to more than 50% of mortality in Europe, 
the United States of America and many developed or developing countries (Schafers et al., 
2010). The main pathologic substrate in atherosclerosis is the atherosclerotic lesion. The 
classical high-risk plaque is characterized by a large lipid core, a thin fibrous cap and many 
macrophages in the shoulder regions of the plaque (Falk et al., 1995; Stary et al., 1995). 
Rupture of the fibrous cap or, more subtle, erosion leads to exposure of the thrombogenic 
sub-endothelial matrix to blood leading to thrombus formation. Recurrent thrombosis or 
major atherothrombosis may lead to an acute cardiovascular event via sub(total) occlusion 
of the vessel of interest. Macrophages are the key mediators of plaque inflammation and 
progression (Lusis, 2000; Ross, 1999). Inflammatory activity can be evaluated at the cellular 
(macrophages and neutrophils) or sub-cellular (secreted enzymes, membrane-bound 
proteins) level. Sensitive and specific biomarkers of plaque inflammation and instability are 
highly desired for more accurate definition of high-risk plaques in high risk patient 
populations. At present, serologic markers do not accomplish this need sufficiently. 
Therefore, there is a need for noninvasive imaging techniques for identification and 
quantification of local plaque biomarkers, which can direct interventional cardiologists and 
vascular surgeons to diseased sites and can monitor therapeutic response.  
2. Atherosclerosis 
Atherosclerosis is characterized by various more or less orderly processes taking place 
during the development from a fatty streak to a rupture-prone or ruptured plaque (Ross, 
1999). Several morphological stages of plaque development related to risk of rupture were 
described by the American Heart Association (Stary et al., 1995). However, recently other 
plaques than the classical vulnerable plaque with a large lipid core and thin fibrous cap 
were also recognized as high-risk plaque, like highly calcified and obstructive plaques 
(Naghavi et al., 2003a, 2003b). During the process of atherogenesis, inflammation aggravates 
endothelial dysfunction and vice versa. First, low density lipoproteins are deposited in the 
subintima, where rare neutrophils and macrophages produce myeloperoxidase. This  
leads to generation of tyrosyl radicals and aldehydes resulting in oxidation of LDL. 
Oxidized LDL (ox-LDL) irritates endothelial cells which become dysfunctional, leading to 
inflammatory cell migration and activation. Macrophage activation leads to release of 
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inflammatory cell migration and activation. Macrophage activation leads to release of 
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matrix metalloproteinases, cathepsins and other matrix degrading enzymes. Activated 
macrophages also release factors that eventually cause apoptosis of smooth muscle cells, 
endothelial cells and macrophages themselves. Fibrous cap thinning, lipid core growth, 
formation of fragile intra-plaque neovasculature, intra-plaque hemorrhage and finally 
fibrous cap rupture may be the result of these processes. Fibrous cap rupture leads to 
exposure of the tissue under the broken endothelial barrier to the blood stream which 
activates coagulation. Subsequent formation of a thrombus may cause an acute thrombotic 
event (Libby, 2002; Lusis, 2000; Ross, 1999) .  
All these processes can serve as the target of molecular imaging techniques, at the cellular or 
subcellular/molecular level. The next section describes an overview of the available 
methods for in vivo molecular imaging of atherosclerosis. 
3. Molecular imaging techniques for atherosclerosis 
Various noninvasive imaging techniques are available for evaluation of the levels of the 
above inflammation-related cells, proteins or enzymes. Fluorescence imaging (FI), 
ultrasound (US), computed tomography (CT), positron emission tomography (PET), single-
photon-emission computed tomography (SPECT) and magnetic resonance imaging (MRI) 
are all imaging modalities with in vivo applicability that could play a role in molecular 
imaging of plaque inflammation (I.Y. Chen & Wu, 2011).  
Because light attenuation by tissue is wavelength dependent, fluorescent proteins with more 
red-shifted emission wavelength have been developed to maximize FI sensitivity and 
specificity. The advent of quantum dot technology alleviates the problems associated with 
protein-based optical reporters, e.g. photobleaching, low quantum yield, low absorbance 
and broad emission band. However, because of the limited imaging depth an intravascular 
catheter is needed for clinical application (Calfon et al., 2010). Further, cytotoxicity of 
quantum dots needs to be addressed and a second imaging modality (MRI or CT) is needed 
for anatomic colocalization before FI with quantum dots may be clinically implemented (Iga 
et al., 2007).  
Ultrasound with targeted micro-bubbles is restricted to the endothelial molecular targets, 
because the size of the bubbles (~1-10 µm) precludes their extravasation (I.Y. Chen & Wu, 
2011). Other disadvantages of US include the high degree of operator dependency, low 
micro-bubble adhesion efficiency and poor ability to image past bony structures.  
Recently, an iodinated CT contrast agent was used for imaging of macrophage activity in 
atherosclerotic plaques (Hyafil et al., 2007). The unknown toxicity of the high concentrations 
of organometallics needed for effective imaging, limited differentiation between diverse soft 
plaque constituents and the high radiation exposure limit clinical application of molecular 
CT.  
After intravenous administration of the PET-tracer F-18-fluorodeoxyglucose, metabolically 
active cells may take up this tracer. This has been shown useful for PET/CT imaging of 
atherosclerotic plaque inflammation in carotid, iliac and femoral arteries of patients (Rudd 
et al., 2007). PET and SPECT are techniques allowing imaging of disease processes in vivo 
with nanomolar/picomolar sensitivity (Massoud & Ghambir, 2003). SPECT was applied for 
imaging of plaque apoptosis in an atherosclerotic rabbit model (Kolodgie et al., 2003), and 
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lipid-rich lesions of mice and rabbits via an epitope on ox-LDL (Tsimikas et al., 2000). PET 
and SPECT lack definition of anatomical structure and have limited spatial resolution, and 
therefore need to be combined with an imaging modality (CT or MRI), which can define 
anatomic structure.  
In terms of broad clinical applicability and availability, MRI is the most versatile technique. 
MRI does not involve ionizing radiation, has a high penetration depth, is safe and non-
invasive, suitable as a screening tool, which can be repeated at will and provides both 
anatomical and physiological information. Disadvantages of MRI are relatively long 
acquisition times and poor suitability for patients, who are claustrophobic. Molecular MRI 
of coronary artery plaque is difficult due to motion caused by respiration and cardiac 
contractions. These motions pose an upper limit to the time window of MRI signal 
acquisition during the cardiac cycle. However, development of more efficient pulse 
sequence protocols may reduce these problems in future. 
Molecular MRI employs contrast agent carriers to which antibodies, peptides or receptor 
(ant)agonists with affinity for the target of interest are conjugated (Mulder et al., 2007a). 
Larger carriers can harbor a higher payload of MR contrast generating Gd or iron oxides 
and can therefore have higher relaxivity. However, carriers which are very large may not 
enter the plaque due to the limited size of endothelial cell fenestrations. In atherosclerosis 
these fenestrations may exceed the regular size of 5 nm by far. In the apoE-/- mouse model 
neo-intimal thickening of the carotid artery induced by a constrictive collar could be 
visualized with paramagnetic liposomes which could pass the endothelial barrier despite a 
mean diameter of 90 nm (Mulder et al., 2006). In another study the effect of size of the 
contrast agent on plaque permeation was investigated (Van Bochove et al., 2011). This effect 
was tested in apoE-/- mice in which a tapered cast around the right carotid artery generated 
thin cap fibroatheromas and non-thin cap fibroatheromas as published previously (Cheng et 
al. 2006). Low molecular weight Gd-chelates (Gd-HP-DO3A) and micelles led to plaque 
enhancement which was highest with the longest retention in the non-thin cap 
fibroatheromas, whereas liposomes did not accumulate in any of the plaques (Van Bochove 
et al., 2011). These results implicate that targeted liposomes are most suitable for the 
imaging of plaque-associated endothelial markers, whereas micelles, which accumulate 
extravascularly on a long timescale, are suited for imaging of less abundant markers inside 
plaques. Low molecular weight compounds may be employed for target-specific imaging of 
highly abundant extravascular plaque-associated targets. 
4. Molecular MRI of atherosclerosis 
4.1 Extracellular matrix proteins 
The potential for in vivo molecular imaging of plaque collagen using a liposome 
functionalized with a collagen adhesion protein, CNA35, has been suggested after a series of 
in vitro tests (Sanders et al., 2009). Indirectly, quantification of collagen using this method 
could provide information about plaque phenotype, in particular plaque stability.  
Another extracellular matrix protein of plaque, which has potential for noninvasive 
assessment of plaque burden by molecular MRI in vivo is elastin. Changes in elastin content 
and the high abundance of elastin during plaque development make it a good quantitative 
marker of plaque burden, which was recently confirmed in a mouse model of 
Molecular Imaging 222 
matrix metalloproteinases, cathepsins and other matrix degrading enzymes. Activated 
macrophages also release factors that eventually cause apoptosis of smooth muscle cells, 
endothelial cells and macrophages themselves. Fibrous cap thinning, lipid core growth, 
formation of fragile intra-plaque neovasculature, intra-plaque hemorrhage and finally 
fibrous cap rupture may be the result of these processes. Fibrous cap rupture leads to 
exposure of the tissue under the broken endothelial barrier to the blood stream which 
activates coagulation. Subsequent formation of a thrombus may cause an acute thrombotic 
event (Libby, 2002; Lusis, 2000; Ross, 1999) .  
All these processes can serve as the target of molecular imaging techniques, at the cellular or 
subcellular/molecular level. The next section describes an overview of the available 
methods for in vivo molecular imaging of atherosclerosis. 
3. Molecular imaging techniques for atherosclerosis 
Various noninvasive imaging techniques are available for evaluation of the levels of the 
above inflammation-related cells, proteins or enzymes. Fluorescence imaging (FI), 
ultrasound (US), computed tomography (CT), positron emission tomography (PET), single-
photon-emission computed tomography (SPECT) and magnetic resonance imaging (MRI) 
are all imaging modalities with in vivo applicability that could play a role in molecular 
imaging of plaque inflammation (I.Y. Chen & Wu, 2011).  
Because light attenuation by tissue is wavelength dependent, fluorescent proteins with more 
red-shifted emission wavelength have been developed to maximize FI sensitivity and 
specificity. The advent of quantum dot technology alleviates the problems associated with 
protein-based optical reporters, e.g. photobleaching, low quantum yield, low absorbance 
and broad emission band. However, because of the limited imaging depth an intravascular 
catheter is needed for clinical application (Calfon et al., 2010). Further, cytotoxicity of 
quantum dots needs to be addressed and a second imaging modality (MRI or CT) is needed 
for anatomic colocalization before FI with quantum dots may be clinically implemented (Iga 
et al., 2007).  
Ultrasound with targeted micro-bubbles is restricted to the endothelial molecular targets, 
because the size of the bubbles (~1-10 µm) precludes their extravasation (I.Y. Chen & Wu, 
2011). Other disadvantages of US include the high degree of operator dependency, low 
micro-bubble adhesion efficiency and poor ability to image past bony structures.  
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and the high abundance of elastin during plaque development make it a good quantitative 
marker of plaque burden, which was recently confirmed in a mouse model of 
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atherosclerosis with an elastin-specific MR contrast agent (Makowski et al., 2011). The 
strong MRI signal change provided by this agent allowed for imaging with high spatial 
resolution, not only resulting in accurate assessment of plaque burden, but also plaque 
characterization by quantification of intra-plaque elastin content using signal intensity 
measurements (Makowski et al., 2011).  
Gadofluorine M is an amphiphile with perfluorinated side chains, which forms micelles 
with a diameter of 5 to 6 nm in aqueous solution. Accumulation of Gadofluorine M micelles 
in atherosclerotic plaque has been attributed to the enhanced vessel-wall permeability and 
also to its affinity for both extracellular matrix proteins (Meding et al. 2007) and plaque 
lipids (Barkhausen et al., 2003).  
4.2 Cholesterol deposition 
Antibody-conjugated paramagnetic micelles have been used for targeted MRI of specific 
epitopes of ox-LDL in atherosclerotic plaque. At 72 and 96 hours after intravenous injection 
of ox-LDL-targeted micelles in apoE-/- mice, specific MRI signal enhancement of aortic 
plaque was observed. MRI signal enhancement was significantly lower after injection of 
control non-conjugated micelles and nonspecific IgG-conjugated micelles (Briley-Saebo et 
al., 2008). Despite this success in the preclinical setting, clinical application of the ox-LDL 
targeted micelles may be hampered by the long blood circulation times (>14 hours) and high 
liver uptake (20% of the injected dose). Cell apoptosis (Hak et al., 2009; Ide et al. 2005) and 
nephrogenic systemic fibrosis in patients with renal dysfunction (Pedersen, 2007) have been 
implied to be caused by gadolinium (Gd) released from paramagnetic MRI contrast agents. 
Therefore, excessive and prolonged retention of Gd-chelates in organs needs to be avoided.  
Ox-LDL in the plaque of apoE-/- mice has also been targeted with functionalized lipid-
coated ultra-small superparamagnetic iron particles (LUSPIOs) (<20 nm) (Briley-Saebo et al., 
2011). The aortic wall was enhanced on gradient echo images after injection in apoE-/- mice 
using a positive contrast method (GRASP). In contrast, no enhancement was observed after 
injection of control non-targeted LUSPIOs and larger (~40 nm) LSPIOs. In vivo specificity of 
the particles to ox-LDL increased after coating of the particles with lipids which prevented 
ingestion by macrophages.  
Another targeted imaging approach which features interaction with plaque cholesterol is the 
use of HDL-like particles. These particles have the advantages of being endogenous and 
biodegradable, do not trigger immune reactions and are not recognized by the RES 
(Cormode et al., 2008, 2009; Frias et al., 2006; Skajaa et al., 2010). Other attractive biological 
properties of HDL-like particles are that HDL enables reverse cholesterol transport from the 
plaque, has anti-atherothrombotic properties, and reduces oxidation and plaque 
inflammation (Skajaa et al., 2010). Various versions of HDL-mimicking nanoparticles have 
been designed for plaque imaging: reconstituted HDL-like spherical or discoid particles, 
fully synthetic HDL-like particles and fully synthetic nanocrystal HDL (Cormode et al., 
2009a; Skajaa et al., 2010). Spherical HDL-like particles were made up by apoA-I, extracted 
from human plasma, and reconstituted with commercially available phospholipids and Gd-
conjugated lipids (Frias et al., 2004). The signal intensity of the aortic wall of mice was 
highest at 24 hours after injection of the above particles and returned to baseline levels at 48 
hours after injection (Frias et al., 2004). Cheaper and easier manufacturing procedures 
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would facilitate the use of HDL-like particles. Two different methods of preparation of 
reconstituted HDL discs were compared for their in vivo efficacy of imaging aortic wall in 
apoE-/- mice (Frias et al., 2006). Both types of discs showed highest signal intensity of 
macrophage-rich plaques at 24 hours after injection, while advanced plaques containing 
more cholesterol crystals and less macrophages revealed most enhancement at 72 hours 
after injection (Frias et al., 2006). Two fully synthetic HDL-like disks based on two synthetic 
lipid-binding apo A-I mimicking peptides, 37pA and the cheaper and easier synthesized 
18A, were compared for their potential for in vivo MR enhancement. At 24 hours after 
injection both HDL disks provided similar plaque enhancement in the aorta of 
atherosclerotic mice (Cormode et al., 2008). In nanocrystal HDL the natural HDL core is 
replaced by inorganic nanocrystals while retaining the phospholipid coating. Via 
modification of both their core and their corona, these particles can be made suitable for 
multimodality imaging. In one study Gd-chelates were incorporated in the corona while the 
nanocrystal core was chosen to be based on gold for CT detection, quantum dots for optical 
imaging or iron oxide (FeO) for MRI visualization (Cormode et al., 2008). In vivo MRI 
showed positive enhancement of plaque when the core consisted of gold or quantum dot, 
whereas a significant decrease in signal was observed when the core contained FeO. 
Histology revealed at least partial colocalization with plaque macrophages (Cormode et al., 
2008). Additionally, all mentioned MRI-visible HDL-like nanoparticles might be useful to 
study the role of HDL in plaque progression (Skajaa et al., 2010).  
As mentioned earlier, Gadofluorine M is supposed to have affinity for plaque lipids 
(Barkhausen et al., 2003) and extracellular matrix proteins. In a rabbit model of 
atherosclerosis injection of Gadofluorine M led to a high contrast-to-background ratio on T1-
weighted MR images of aortic plaque (Barkhausen et al., 2003). The contrast-enhanced 
regions corresponded with Sudan-positive lipid-rich aortic wall segments on histological 
slices (Barkhausen et al., 2003). 
4.3 Endothelial cells 
Endothelial cells respond to several stimuli with increased expression of cell adhesion 
molecules. The inflammatory mediators, IL-1 and TNFα, are among these stimuli and lead 
to increased expression of ICAM-1, VCAM-1 and P-selectin by endothelial cells (Libby, 
2002). Oxidized low-density lipoproteins, accumulating in plaque during atherogenesis, 
represent a stimulus for enhanced expression of VCAM-1 by endothelial cells (Libby, 2002; 
Lusis, 2000; Ross, 1999). Leukocytes extravasate after interaction of VCAM-1 with very late 
antigen-4 (VLA-4) on the leukocyte membrane surface (Libby, 2002).  
The binding capacity of microparticles of iron oxide conjugated with antibodies directed 
against VCAM-1 (diameter ~4.5 µm) to TNFα-stimulated mouse endothelial cells was 
demonstrated in vitro (McAteer et al., 2010). These VCAM-1-targeted microparticles were 
applied for in vivo imaging of inflammation in peritubular capillaries in murine kidneys 
after ischemia reperfusion injury (Akhtar, 2010). VCAM-1 expression on dysfunctional 
endothelial cells of cholesterol-fed apoE-/- mouse aorta was targeted with a cross-linked 
iron oxide (CLIO) fluorescent nanoparticle conjugated to a peptide sequence with homology 
to the a-chain of VLA-4 for both MRI and fluorescence imaging (Kelly et al., 2005). Higher 
signal amplification of atherosclerotic mouse aorta was anticipated and found by this group 
using newly developed second-generation VCAM-1-targeted magnetic nanoparticles that 
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using a positive contrast method (GRASP). In contrast, no enhancement was observed after 
injection of control non-targeted LUSPIOs and larger (~40 nm) LSPIOs. In vivo specificity of 
the particles to ox-LDL increased after coating of the particles with lipids which prevented 
ingestion by macrophages.  
Another targeted imaging approach which features interaction with plaque cholesterol is the 
use of HDL-like particles. These particles have the advantages of being endogenous and 
biodegradable, do not trigger immune reactions and are not recognized by the RES 
(Cormode et al., 2008, 2009; Frias et al., 2006; Skajaa et al., 2010). Other attractive biological 
properties of HDL-like particles are that HDL enables reverse cholesterol transport from the 
plaque, has anti-atherothrombotic properties, and reduces oxidation and plaque 
inflammation (Skajaa et al., 2010). Various versions of HDL-mimicking nanoparticles have 
been designed for plaque imaging: reconstituted HDL-like spherical or discoid particles, 
fully synthetic HDL-like particles and fully synthetic nanocrystal HDL (Cormode et al., 
2009a; Skajaa et al., 2010). Spherical HDL-like particles were made up by apoA-I, extracted 
from human plasma, and reconstituted with commercially available phospholipids and Gd-
conjugated lipids (Frias et al., 2004). The signal intensity of the aortic wall of mice was 
highest at 24 hours after injection of the above particles and returned to baseline levels at 48 
hours after injection (Frias et al., 2004). Cheaper and easier manufacturing procedures 
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would facilitate the use of HDL-like particles. Two different methods of preparation of 
reconstituted HDL discs were compared for their in vivo efficacy of imaging aortic wall in 
apoE-/- mice (Frias et al., 2006). Both types of discs showed highest signal intensity of 
macrophage-rich plaques at 24 hours after injection, while advanced plaques containing 
more cholesterol crystals and less macrophages revealed most enhancement at 72 hours 
after injection (Frias et al., 2006). Two fully synthetic HDL-like disks based on two synthetic 
lipid-binding apo A-I mimicking peptides, 37pA and the cheaper and easier synthesized 
18A, were compared for their potential for in vivo MR enhancement. At 24 hours after 
injection both HDL disks provided similar plaque enhancement in the aorta of 
atherosclerotic mice (Cormode et al., 2008). In nanocrystal HDL the natural HDL core is 
replaced by inorganic nanocrystals while retaining the phospholipid coating. Via 
modification of both their core and their corona, these particles can be made suitable for 
multimodality imaging. In one study Gd-chelates were incorporated in the corona while the 
nanocrystal core was chosen to be based on gold for CT detection, quantum dots for optical 
imaging or iron oxide (FeO) for MRI visualization (Cormode et al., 2008). In vivo MRI 
showed positive enhancement of plaque when the core consisted of gold or quantum dot, 
whereas a significant decrease in signal was observed when the core contained FeO. 
Histology revealed at least partial colocalization with plaque macrophages (Cormode et al., 
2008). Additionally, all mentioned MRI-visible HDL-like nanoparticles might be useful to 
study the role of HDL in plaque progression (Skajaa et al., 2010).  
As mentioned earlier, Gadofluorine M is supposed to have affinity for plaque lipids 
(Barkhausen et al., 2003) and extracellular matrix proteins. In a rabbit model of 
atherosclerosis injection of Gadofluorine M led to a high contrast-to-background ratio on T1-
weighted MR images of aortic plaque (Barkhausen et al., 2003). The contrast-enhanced 
regions corresponded with Sudan-positive lipid-rich aortic wall segments on histological 
slices (Barkhausen et al., 2003). 
4.3 Endothelial cells 
Endothelial cells respond to several stimuli with increased expression of cell adhesion 
molecules. The inflammatory mediators, IL-1 and TNFα, are among these stimuli and lead 
to increased expression of ICAM-1, VCAM-1 and P-selectin by endothelial cells (Libby, 
2002). Oxidized low-density lipoproteins, accumulating in plaque during atherogenesis, 
represent a stimulus for enhanced expression of VCAM-1 by endothelial cells (Libby, 2002; 
Lusis, 2000; Ross, 1999). Leukocytes extravasate after interaction of VCAM-1 with very late 
antigen-4 (VLA-4) on the leukocyte membrane surface (Libby, 2002).  
The binding capacity of microparticles of iron oxide conjugated with antibodies directed 
against VCAM-1 (diameter ~4.5 µm) to TNFα-stimulated mouse endothelial cells was 
demonstrated in vitro (McAteer et al., 2010). These VCAM-1-targeted microparticles were 
applied for in vivo imaging of inflammation in peritubular capillaries in murine kidneys 
after ischemia reperfusion injury (Akhtar, 2010). VCAM-1 expression on dysfunctional 
endothelial cells of cholesterol-fed apoE-/- mouse aorta was targeted with a cross-linked 
iron oxide (CLIO) fluorescent nanoparticle conjugated to a peptide sequence with homology 
to the a-chain of VLA-4 for both MRI and fluorescence imaging (Kelly et al., 2005). Higher 
signal amplification of atherosclerotic mouse aorta was anticipated and found by this group 
using newly developed second-generation VCAM-1-targeted magnetic nanoparticles that 
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undergo internalization and trapping in endothelial cells and macrophages that express 
VCAM-1 (Nahrendorf et al., 2006). 
P-selectin expression by endothelial cells has been imaged with a slow-clearing blood-pool 
MRI contrast agent functionalized with sulfate groups with homology to the P-selectin 
binding region of P-selectin glycoprotein ligand-1 (Alsaid et al., 2009). Application of this P-
selectin-targeted paramagnetic agent led to specific plaque enhancement in apoE-/- mice 
between 10 and 30 minutes after intravenous injection. Ex vivo fluorescence microscopy 
confirmed specific binding of the agent to P-selectin (Alsaid et al., 2009). 
4.4 Neovascularization 
The reason for the development of neovasculature in atherosclerotic plaques is uncertain. 
One theory emphasizes the hypoxia in the thickened intimal layer (>500 µm) as a stimulant 
for neoangiogenesis (Sluimer & Daemen, 2009). Another theory however states that 
neovascularization may exist early on during atherogenesis and promotes plaque 
inflammation and progression by facilitating extravasation of inflammatory cells (Dunmore 
et al., 2007). Intraplaque hemorrhage of the fragile neovasculature has also been related to 
rapid carotid atherosclerotic plaque growth (Takaya et al., 2005). 
Dynamic contrast enhanced (DCE) MRI was applied first for quantitative assessment of 
neovasculature in tumors, but has been exploited more recently for quantification of human 
carotid plaque neovasculature (Yuan et al., 2002). DCE-MRI uses serial MRI acquisitions 
with high temporal resolution enclosing a time window around the injection of a low 
molecular weight Gd-containing contrast agent. Differentiation between fibrous tissue 
(enhancement ~80%) and lipid core (enhancement ~30%) by virtue of the neovessel density 
in fibrous tissue has been demonstrated (Yuan et al., 2002). Quantitative information on 
plaque uptake kinetics of contrast agent, amount of neovascularization and vessel 
permeability may be provided by appropriate modeling of the signal intensity time course 
in the plaque (Calcagno et al., 2010). 
Recently, Gadofluorine M uptake in the balloon-injured aorta of New Zealand White rabbits 
has been found to correlate with plaque neovessel and macrophage density (Sirol et al., 
2009). Histological evaluation showed that plaque neovessels, lipid-rich regions and 
Gadofluorine M co-localized. However, non-specificity of Gadofluorine M, which also has 
affinity for other plaque constituents like extracellular matrix proteins and lipids, will 
complicate mathematical modeling of quantitative parameters. 
Also targeted approaches have been used for the molecular MR imaging of plaque 
neovascularization. The αvβ3 integrin is expressed amongst others by endothelial cells on 
angiogenic vessels in plaque. A low molecular weight peptidomimetic of Arg-Gly-Asp 
conjugated to Gd-DTPA led to enhancement of aortic plaque in apoE-/- mice which was 
diminished after “presaturation” with the MRI-silent, Europium-chelated analogue of the 
Gd-conjugated compound (Burtea et al., 2008).  
Targeting of proteins expressed on the outer endothelial cell membrane indicative for 
neovascularization has the distinct advantage that the contrast agent does not need to enter 
the plaque. This approach allows for the use of large, very potent, nanoparticulate MR 
contrast agents, like Gd-containing perfluorocarbon emulsion nanoparticles with a size of 
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about 250 nm (Anderson et al., 2000). Transgenic rats with a mutation in the leptin receptor 
represent a model for metabolic syndrome, resulting in abdominal obesity, atherosclerosis 
and myocardial lesions. The Gd-containing perfluorocarbon emulsion targeted towards the 
αvβ3 integrin was used for imaging neovessels in aortic plaques of these rats (Cai et al., 
2010). Additionally, the effect of treatment with the anorectic and hypolipidemic drug 
benfluorex on plaque neovascularization was studied. Treated animals displayed an overall 
lower and patchy plaque enhancement in comparison to non-treated ones, indicative for a 
decreased angiogenic vessel density in the plaque (Cai et al., 2010). So, modulation of 
neovascularization by therapeutics could be studied using this molecular MRI approach. 
The same αvβ3-targeted perfluorocarbon emulsion was used to monitor collateral formation 
after treatment with angiogenic L-arginine in a rabbit femoral artery ligation model (Winter 
et al., 2010). The results achieved in these diverse studies argue against a straightforward 
interpretation of MR imaging results in atherosclerosis using αvβ3-targeted nanoparticles. 
Molecular MRI of neovascularization with these nanoparticles may not discriminate 
between adverse plaque neovascularization and beneficial sprouting of collaterals. At the 
time, pharmacokinetic profiling information on αvβ3-targeted and non-targeted 
perfluorocarbon nanoparticles has been obtained in rabbits with in vivo MRI and blood 
samples (Neubauer et al., 2008). 
4.5 Macrophages 
Macrophages play a key role in the inflammatory process of atherosclerosis. Therefore, they 
are most extensively studied using molecular MRI. Previously, superparamagnetic particles 
of iron oxide were used for lymph node imaging in the context of tumor staging and 
detection of focal liver lesions (Schmitz, 2003). During a phase III trial which investigated 
the use of the ultra-small dextran-coated counterparts of these particles (USPIOs, diameter 
18-30 nm) for discrimination between healthy lymph nodes and lymph node metastases, 
these USPIOs were found by co-incidence to be ingested by aortic plaque macrophages 
(Schmitz et al., 2001). Since then these USPIOs have been extensively studied for their 
potential to monitor inflammation in atherosclerosis in patients and regression after 
treatment with aggressive lipid-lowering therapy (Tang et al., 2009).  
The versatility of these USPIOs for imaging of both lymph nodes and atherosclerotic plaque 
constitutes an important drawback of these USPIOs. Lymph nodes often develop in close 
proximity to the inflamed plaque lesion. We have shown that differentiation between peri-
vascular lymph nodes and aortic wall in atherosclerotic mouse models may be difficult 
using USPIOs (Te Boekhorst et al., 2010a). Successful visualization will depend on spatial 
resolution and the imaging sequence (Te Boekhorst et al., 2010a). Recently, a newly 
developed positive contrast technique for (U)SPIOs, “GRASP”, has been shown capable to 
differentiate between peri-vascular lymph nodes and atherosclerotic vessel wall (Briley-
Saebo et al., 2011).  
Apart from this cellular MRI approach, also specific macrophage membrane proteins have 
been targeted. Among others targeting of the macrophage scavenger receptor-A (MSR-A) 
has been achieved in a mouse model of atherosclerosis with paramagnetic Gd-containing 
micelles (Amirbekian et al., 2007). Plaques in the aortic wall of apoE-/- mice displayed a 
79% increase in signal intensity upon injection of the MSR-A-targeted micelles, whereas 
control micelles resulted in 34% signal increase (Amirbekian et al., 2007). MSR-A together 
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undergo internalization and trapping in endothelial cells and macrophages that express 
VCAM-1 (Nahrendorf et al., 2006). 
P-selectin expression by endothelial cells has been imaged with a slow-clearing blood-pool 
MRI contrast agent functionalized with sulfate groups with homology to the P-selectin 
binding region of P-selectin glycoprotein ligand-1 (Alsaid et al., 2009). Application of this P-
selectin-targeted paramagnetic agent led to specific plaque enhancement in apoE-/- mice 
between 10 and 30 minutes after intravenous injection. Ex vivo fluorescence microscopy 
confirmed specific binding of the agent to P-selectin (Alsaid et al., 2009). 
4.4 Neovascularization 
The reason for the development of neovasculature in atherosclerotic plaques is uncertain. 
One theory emphasizes the hypoxia in the thickened intimal layer (>500 µm) as a stimulant 
for neoangiogenesis (Sluimer & Daemen, 2009). Another theory however states that 
neovascularization may exist early on during atherogenesis and promotes plaque 
inflammation and progression by facilitating extravasation of inflammatory cells (Dunmore 
et al., 2007). Intraplaque hemorrhage of the fragile neovasculature has also been related to 
rapid carotid atherosclerotic plaque growth (Takaya et al., 2005). 
Dynamic contrast enhanced (DCE) MRI was applied first for quantitative assessment of 
neovasculature in tumors, but has been exploited more recently for quantification of human 
carotid plaque neovasculature (Yuan et al., 2002). DCE-MRI uses serial MRI acquisitions 
with high temporal resolution enclosing a time window around the injection of a low 
molecular weight Gd-containing contrast agent. Differentiation between fibrous tissue 
(enhancement ~80%) and lipid core (enhancement ~30%) by virtue of the neovessel density 
in fibrous tissue has been demonstrated (Yuan et al., 2002). Quantitative information on 
plaque uptake kinetics of contrast agent, amount of neovascularization and vessel 
permeability may be provided by appropriate modeling of the signal intensity time course 
in the plaque (Calcagno et al., 2010). 
Recently, Gadofluorine M uptake in the balloon-injured aorta of New Zealand White rabbits 
has been found to correlate with plaque neovessel and macrophage density (Sirol et al., 
2009). Histological evaluation showed that plaque neovessels, lipid-rich regions and 
Gadofluorine M co-localized. However, non-specificity of Gadofluorine M, which also has 
affinity for other plaque constituents like extracellular matrix proteins and lipids, will 
complicate mathematical modeling of quantitative parameters. 
Also targeted approaches have been used for the molecular MR imaging of plaque 
neovascularization. The αvβ3 integrin is expressed amongst others by endothelial cells on 
angiogenic vessels in plaque. A low molecular weight peptidomimetic of Arg-Gly-Asp 
conjugated to Gd-DTPA led to enhancement of aortic plaque in apoE-/- mice which was 
diminished after “presaturation” with the MRI-silent, Europium-chelated analogue of the 
Gd-conjugated compound (Burtea et al., 2008).  
Targeting of proteins expressed on the outer endothelial cell membrane indicative for 
neovascularization has the distinct advantage that the contrast agent does not need to enter 
the plaque. This approach allows for the use of large, very potent, nanoparticulate MR 
contrast agents, like Gd-containing perfluorocarbon emulsion nanoparticles with a size of 
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about 250 nm (Anderson et al., 2000). Transgenic rats with a mutation in the leptin receptor 
represent a model for metabolic syndrome, resulting in abdominal obesity, atherosclerosis 
and myocardial lesions. The Gd-containing perfluorocarbon emulsion targeted towards the 
αvβ3 integrin was used for imaging neovessels in aortic plaques of these rats (Cai et al., 
2010). Additionally, the effect of treatment with the anorectic and hypolipidemic drug 
benfluorex on plaque neovascularization was studied. Treated animals displayed an overall 
lower and patchy plaque enhancement in comparison to non-treated ones, indicative for a 
decreased angiogenic vessel density in the plaque (Cai et al., 2010). So, modulation of 
neovascularization by therapeutics could be studied using this molecular MRI approach. 
The same αvβ3-targeted perfluorocarbon emulsion was used to monitor collateral formation 
after treatment with angiogenic L-arginine in a rabbit femoral artery ligation model (Winter 
et al., 2010). The results achieved in these diverse studies argue against a straightforward 
interpretation of MR imaging results in atherosclerosis using αvβ3-targeted nanoparticles. 
Molecular MRI of neovascularization with these nanoparticles may not discriminate 
between adverse plaque neovascularization and beneficial sprouting of collaterals. At the 
time, pharmacokinetic profiling information on αvβ3-targeted and non-targeted 
perfluorocarbon nanoparticles has been obtained in rabbits with in vivo MRI and blood 
samples (Neubauer et al., 2008). 
4.5 Macrophages 
Macrophages play a key role in the inflammatory process of atherosclerosis. Therefore, they 
are most extensively studied using molecular MRI. Previously, superparamagnetic particles 
of iron oxide were used for lymph node imaging in the context of tumor staging and 
detection of focal liver lesions (Schmitz, 2003). During a phase III trial which investigated 
the use of the ultra-small dextran-coated counterparts of these particles (USPIOs, diameter 
18-30 nm) for discrimination between healthy lymph nodes and lymph node metastases, 
these USPIOs were found by co-incidence to be ingested by aortic plaque macrophages 
(Schmitz et al., 2001). Since then these USPIOs have been extensively studied for their 
potential to monitor inflammation in atherosclerosis in patients and regression after 
treatment with aggressive lipid-lowering therapy (Tang et al., 2009).  
The versatility of these USPIOs for imaging of both lymph nodes and atherosclerotic plaque 
constitutes an important drawback of these USPIOs. Lymph nodes often develop in close 
proximity to the inflamed plaque lesion. We have shown that differentiation between peri-
vascular lymph nodes and aortic wall in atherosclerotic mouse models may be difficult 
using USPIOs (Te Boekhorst et al., 2010a). Successful visualization will depend on spatial 
resolution and the imaging sequence (Te Boekhorst et al., 2010a). Recently, a newly 
developed positive contrast technique for (U)SPIOs, “GRASP”, has been shown capable to 
differentiate between peri-vascular lymph nodes and atherosclerotic vessel wall (Briley-
Saebo et al., 2011).  
Apart from this cellular MRI approach, also specific macrophage membrane proteins have 
been targeted. Among others targeting of the macrophage scavenger receptor-A (MSR-A) 
has been achieved in a mouse model of atherosclerosis with paramagnetic Gd-containing 
micelles (Amirbekian et al., 2007). Plaques in the aortic wall of apoE-/- mice displayed a 
79% increase in signal intensity upon injection of the MSR-A-targeted micelles, whereas 
control micelles resulted in 34% signal increase (Amirbekian et al., 2007). MSR-A together 
Molecular Imaging 228 
with MSR-B is responsible for 75-90% of ox-LDL uptake by macrophages. Ex vivo targeting 
of MSR-B in dissected human aortic atherosclerotic plaque has been achieved with 125-nm-
diameter lipid-based nanoparticles (Lipinski et al., 2009). However, the potential of these 
MSR-B-targeted nanoparticles for in vivo targeting has still to be demonstrated. Bimodal 
micelles for MSR (A and B) containing both Gd and an optical label (rhodamine-conjugated 
lipid or a quantum dot) led to a signal increase of aortic wall in apoE-/- up to 200% (Mulder 
et al., 2007b). MSR-targeted rhodamine micelles could be detected with fluorescence 
microscopy and were found to be associated with macrophages. Quantum dots allowed ex 
vivo detection of aortic macrophage-rich regions with UV illumination (Mulder et al., 2007b).  
Plaque macrophages express the ox-LDL receptor LOX-1 and binding of ox-LDL induces 
apoptosis, expression of adhesion molecules and release of MMPs (Ross, 1999; Li et al., 
2010). Paramagnetic liposomes conjugated to anti-LOX-1 antibodies were injected in 
LDL-R-/- mice. Aortic plaques were specifically enhanced on T1 weighted MR images, 
while no enhancement was observed on MR images from double knockout LDL-R-/- 
LOX-1-/- mice or from LDL-R-/- mice injected with nonspecific IgG-conjugated liposomes 
(Li et al., 2010). Histological analyses revealed that most LOX-1 co-localized with 
macrophages, apoptotic cells and MMP-9 and only a small proportion with proliferated 
smooth muscle cells.  
The use of antibodies for making contrast agents target specific has important 
disadvantages: the high costs of antibodies, their immunogenicity and difficulty in handling 
and preparation. Application of other specific targeting moieties of non-antibody origin is 
therefore attractive. An example is the use of phosphatidylserine (PS) incorporated in self-
assembled lipid-based contrast agents. PS is expressed on apoptotic cells and is specifically 
recognized by macrophages. PS-containing paramagnetic liposomes showed in vitro 
specificity for RAW cells (mouse macrophages) and significant MR enhancement of aortic 
plaques during the first 4 hours after injection in apoE-/- mice (Maiseyeu et al., 2009). 
Another targeted approach avoiding the use of antibodies employs a potent synthetic 
agonist (HU-308) of the peripheral cannabinoid receptor (CB2-R) (Te Boekhorst et al., 
2010b). T-lymphocytes and macrophages in advanced mouse and human atherosclerotic 
plaque CB2-R have been shown to express this CB2-R (Steffens et al., 2005). Activation of 
CB2-R by HU-308 results in amelioration of plaque phenotype in atherosclerotic mice 
(Steffens et al., 2005). The suggested mechanism is an immune system modulating effect 
through CB2-R, which involves a regulatory negative feedback effect dampening the 
inflammatory process in advanced plaques (Steffens et al., 2005). Self-assembly of polymeric 
micelles was easily achieved by mixing HU-308, which has a 7-carbon tail and a hydrophilic 
head group, with Gd-containing and PEG-ylated lipids (Te Boekhorst et al., 2010b). T1-
weighted inversion recovery fast spin echo MR images revealed in vivo plaque enhancement 
in the aortas of double knockout apoE-/-, eNOS-/- mice between 36 and 48 hours after 
injection of CB2-R-targeted micelles (Te Boekhorst et al., 2010c).  
The earlier mentioned flexible HDL platform could be easily functionalized for more specific 
retention into plaques. A third example of targeted approach avoiding the application of 
antibodies concerns incorporation of an apoE-derived lipopeptide into HDL particles 
enriched with Gd-based lipids (W. Chen et al., 2008). Application of this material led to both 
higher association with mouse macrophages in vitro and more pronounced in vivo 
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enhancement of aortic plaque in mice relative to reconstituted HDL without incorporation 
of the apoE-derived lipopeptide (W. Chen et al., 2008). 
Furthermore, hyaluronic acid, which targets the CD44 receptor on activated macrophages, 
has been conjugated to a lipid coating enclosing iron oxide nanoparticles (Kamat et al., 
2010). In vitro experiments have revealed ingestion by activated THP-1 macrophages, 
suggesting potential for in vivo imaging of plaque inflammation (Kamat et al., 2010). 
Transient cellular location of the HDL particles was suggested by a series of Prussian blue 
stainings for iron. Despite these promising findings, the in vivo potential of these 
macrophage-targeted iron oxides for MRI of plaque inflammation has still to be confirmed. 
Apart from direct targeting of macrophages, one can also address released macrophage 
products. An example of an extracellular released enzyme in atherosclerotic plaque is 
represented by the matrix metalloproteinases (MMPs). Increased activity of MMPs 
produced by smooth muscle cells and macrophages has been reported to be related to 
plaque rupture (Vink & Pasterkamp, 2002; Schafers et al., 2010). A small peptide with 
affinity for MMPs was conjugated to Gd-DOTA and employed for in vivo MR imaging of 
plaque (Lancelot et al., 2008). The plasma half-life of this small peptide was only 30 minutes 
and the concentrations in artery specimens were 3 times as high as those after injection of 
Gd-DOTA, with prolonged retention at least until 22 hours after injection (Lancelot et al., 
2008). The mentioned peptide has affinity for various MMPs. However, the MMP family is 
large and the role of each MMP member is not entirely known. It has been shown, that 
expression of MMP-2 and MMP-9 is upregulated in shoulder regions of human vulnerable 
plaques (Galis & Khatri, 2002). The advent of specific inhibitors of MMP-9 and -2 and their 
application in small paramagnetic peptides may improve specificity for unstable plaque.  
Another protein that has been linked to adverse cardiovascular events in patients after 
carotid endarterectomy surgery is neutrophil gelatinase-associated lipocalin-2 (NGAL) (Te 
Boekhorst et al., 2011). NGAL is produced and released particularly by macrophages, 
although first discovered in neutrophils (Hemdahl et al., 2006). MMP-9 activity is prolonged 
and degradation prevented after binding to NGAL. Apart from forming a stable and 
biologically active complex with MMP-9, NGAL mediates inflammatory activity through 
binding to formyl-methionyl-leucyl-phenylalanine (fMLP; a chemotactic peptide), 
leukotriene B4, and platelet-activating factor (Hemdahl et al., 2006). In vivo MRI of severely 
advanced atherosclerotic plaques of the double knockout apoE-/-, eNOS-/- mouse was 
performed at 24 and 72 hours after injection of 24p3(mouse homologue of NGAL)-targeted 
micelles and IgG isotype antibody-conjugated micelles (Te Boekhorst et al., 2011). Both 
24p3-targeted and control micelles led to an increased average Normalized Enhancement 
Ratio (NER) at 24 hours after injection (~1.45 versus ~1.30 respectively), while at 72 hours 
after injection of 24p3-targeted micelles average NER further increased and after injection of 
control micelles average NER had decreased (~1.70 versus ~1.20) (Te Boekhorst et al., 2011). 
Histology revealed that micelles co-localized with 24p3 and partially with macrophages. 
The results of this study are summarized in Figure 1A-H. 
Targeting of extracellular located molecules such as MMPs and NGAL has the advantage 
over intracellular targets that the target is readily available. On the other hand, it may carry 
the drawback that the contrast agent is easily washed out from the plaque, together with the 
target, into the blood. Nevertheless, imaging of intact excreted proteins and particularly 
their activity could provide important insights in the inflammatory state of the plaque. For   
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with MSR-B is responsible for 75-90% of ox-LDL uptake by macrophages. Ex vivo targeting 
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2010). Paramagnetic liposomes conjugated to anti-LOX-1 antibodies were injected in 
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while no enhancement was observed on MR images from double knockout LDL-R-/- 
LOX-1-/- mice or from LDL-R-/- mice injected with nonspecific IgG-conjugated liposomes 
(Li et al., 2010). Histological analyses revealed that most LOX-1 co-localized with 
macrophages, apoptotic cells and MMP-9 and only a small proportion with proliferated 
smooth muscle cells.  
The use of antibodies for making contrast agents target specific has important 
disadvantages: the high costs of antibodies, their immunogenicity and difficulty in handling 
and preparation. Application of other specific targeting moieties of non-antibody origin is 
therefore attractive. An example is the use of phosphatidylserine (PS) incorporated in self-
assembled lipid-based contrast agents. PS is expressed on apoptotic cells and is specifically 
recognized by macrophages. PS-containing paramagnetic liposomes showed in vitro 
specificity for RAW cells (mouse macrophages) and significant MR enhancement of aortic 
plaques during the first 4 hours after injection in apoE-/- mice (Maiseyeu et al., 2009). 
Another targeted approach avoiding the use of antibodies employs a potent synthetic 
agonist (HU-308) of the peripheral cannabinoid receptor (CB2-R) (Te Boekhorst et al., 
2010b). T-lymphocytes and macrophages in advanced mouse and human atherosclerotic 
plaque CB2-R have been shown to express this CB2-R (Steffens et al., 2005). Activation of 
CB2-R by HU-308 results in amelioration of plaque phenotype in atherosclerotic mice 
(Steffens et al., 2005). The suggested mechanism is an immune system modulating effect 
through CB2-R, which involves a regulatory negative feedback effect dampening the 
inflammatory process in advanced plaques (Steffens et al., 2005). Self-assembly of polymeric 
micelles was easily achieved by mixing HU-308, which has a 7-carbon tail and a hydrophilic 
head group, with Gd-containing and PEG-ylated lipids (Te Boekhorst et al., 2010b). T1-
weighted inversion recovery fast spin echo MR images revealed in vivo plaque enhancement 
in the aortas of double knockout apoE-/-, eNOS-/- mice between 36 and 48 hours after 
injection of CB2-R-targeted micelles (Te Boekhorst et al., 2010c).  
The earlier mentioned flexible HDL platform could be easily functionalized for more specific 
retention into plaques. A third example of targeted approach avoiding the application of 
antibodies concerns incorporation of an apoE-derived lipopeptide into HDL particles 
enriched with Gd-based lipids (W. Chen et al., 2008). Application of this material led to both 
higher association with mouse macrophages in vitro and more pronounced in vivo 
Molecular MRI of Atherosclerosis 229 
enhancement of aortic plaque in mice relative to reconstituted HDL without incorporation 
of the apoE-derived lipopeptide (W. Chen et al., 2008). 
Furthermore, hyaluronic acid, which targets the CD44 receptor on activated macrophages, 
has been conjugated to a lipid coating enclosing iron oxide nanoparticles (Kamat et al., 
2010). In vitro experiments have revealed ingestion by activated THP-1 macrophages, 
suggesting potential for in vivo imaging of plaque inflammation (Kamat et al., 2010). 
Transient cellular location of the HDL particles was suggested by a series of Prussian blue 
stainings for iron. Despite these promising findings, the in vivo potential of these 
macrophage-targeted iron oxides for MRI of plaque inflammation has still to be confirmed. 
Apart from direct targeting of macrophages, one can also address released macrophage 
products. An example of an extracellular released enzyme in atherosclerotic plaque is 
represented by the matrix metalloproteinases (MMPs). Increased activity of MMPs 
produced by smooth muscle cells and macrophages has been reported to be related to 
plaque rupture (Vink & Pasterkamp, 2002; Schafers et al., 2010). A small peptide with 
affinity for MMPs was conjugated to Gd-DOTA and employed for in vivo MR imaging of 
plaque (Lancelot et al., 2008). The plasma half-life of this small peptide was only 30 minutes 
and the concentrations in artery specimens were 3 times as high as those after injection of 
Gd-DOTA, with prolonged retention at least until 22 hours after injection (Lancelot et al., 
2008). The mentioned peptide has affinity for various MMPs. However, the MMP family is 
large and the role of each MMP member is not entirely known. It has been shown, that 
expression of MMP-2 and MMP-9 is upregulated in shoulder regions of human vulnerable 
plaques (Galis & Khatri, 2002). The advent of specific inhibitors of MMP-9 and -2 and their 
application in small paramagnetic peptides may improve specificity for unstable plaque.  
Another protein that has been linked to adverse cardiovascular events in patients after 
carotid endarterectomy surgery is neutrophil gelatinase-associated lipocalin-2 (NGAL) (Te 
Boekhorst et al., 2011). NGAL is produced and released particularly by macrophages, 
although first discovered in neutrophils (Hemdahl et al., 2006). MMP-9 activity is prolonged 
and degradation prevented after binding to NGAL. Apart from forming a stable and 
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target, into the blood. Nevertheless, imaging of intact excreted proteins and particularly 
their activity could provide important insights in the inflammatory state of the plaque. For   






Fig. 1. MR images and histological stainings of atherosclerotic plaque after intravenous 
injection of NGAL/24p3-targeted micelles. Pre- and post-injection (0, 24 and 72 h) MR 
images of aortic wall in apoE-/-/eNOS-/- mice injected with control (A-C) and NGAL/24p3-
targeted (E-G) micelles and immunohistochemistry at 72 hours for micelle-conjugated rat 
antibodies in control micelles (D) and NGAL/24p3-targeted micelles (H). P=plaque, 
LN=lymph node. NER= Normalized Enhancement Ratio. The post-injection MR images 
show increased signal intensity at 24 hours for both NGAL/24p3-targeted micelles and 
control micelles, while signal intensity at 72 hours stays at the higher level for NGAL/24p3-
targeted micelles but returned to baseline for control micelles. Note that the signal intensity 
of the peri-aortic lymph node, which was removed during harvesting of the aorta, is also 
increased after injection. Histology of the mouse aorta at 72 hours after injection revealed no 
staining of micelles for injections with control micelles and extensive red staining for 
injections with NGAL/24p3-targeted micelles.. H: scale bar = 100µm (original magnification: 
100x) (Te Boekhorst et al., 2011). 
example, peroxidase-based hematologic profiling has been shown to predict adverse cardiac 
events during a follow-up of 1 year (Brennan et al., 2010). In order to prevent washout of the 
agent, Bogdanov and coworkers have designed an activatable (smart) low-molecular weight 
Gd-containing probe for imaging of myeloperoxidase, an enzyme released by macrophages 
that is responsible for oxidation of LDL via the formation of reactive oxygen species (J.W. 
Chen et al., 2004). Activation of the probe by myeloperoxidase leads to polymerization, 
increasing its size and relaxivity, and prolonging its retention in the target region – hence 
providing an indirect readout of enzyme activity. This probe enabled MR imaging of 
increased myeloperoxidase activity in plaques in the aorta of rabbits, as is summarized in 
Figure 2A-G (Ronald et al., 2009). 
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Fig. 2. Imaging of diseased aortas of cholesterol-fed rabbits before and after injection of an 
activatable MPO sensor.  
Imaging before and 2 hours after injection of DTPA-Gd (A,D), before and 2 hours after 
injection of bis-tyr-DTPA-Gd (B,E) which is a nonactivatable analog of MPO-Gd, and before 
and 2 hours after injection of the functional agent MPO-Gd (C,F). Histology of the rabbit 
aorta after injection of MPO-Gd revealed focal MPO presence in the plaque and confirmed 
the MR findings (G). Printed with permission from (Ronald et al., 2009).  
4.6 Apoptotic cells 
When cells become apoptotic, phosphatidylserine (PS), initially mainly found in the inner 
leaflet of the viable cell membrane, is also expressed on the outer leaflet of the cell. The 
expression of PS can be detected with molecular MRI using the protein annexin A5 as a 
targeting ligand. Annexin A5 binds specifically to PS in the presence of calcium (Gerke et al., 
2002). Apoptosis in atherosclerotic plaques in the aorta of apoE-/- mice was studied using 
Gd-containing micelles conjugated to annexin A5. T1-weighted MR images showed at 24 
hours after injection a slight, but significant, increase of plaque intensity relative to control 
non-conjugated micelles (Van Tilborg et al., 2010).  
Phage display may identify small peptides with specific affinity to selected targets. One 
study employed a PS-specific peptide, identified by phage display and conjugated to 
Gd-DTPA, for detection of apoptotic cells in aortic plaques of apoE-/- mice at 30 minutes 
after injection (Burtea et al., 2009). The use of such small peptides has certain advantages 
above proteins or antibodies in terms of reduced immunogenicity and a cheaper and easier 
production process.  
However, studies with apoptosis-directed agents in a number of apoptosis-associated 
pathologies have also revealed the limitation of apoptosis-targeted contrast agents. The 
publication of a SPECT study reporting visualization of apoptosis of cardiomyocytes in 
patients with acute myocardial infarction (Hofstra et al., 2000) may serve as an example. 
Apoptosis may not be useful for targeted imaging of vulnerable plaque in the coronary 
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arteries, due to the possibly overwhelming background signal of enhanced cardiac muscle 
in a compromised patient group. 
4.7 Activated platelets and thrombus 
Activated platelets play a crucial role in the formation of repetitive micro-thrombi, which 
suddenly may result in a major thrombus, followed by an acute cardiovascular event 
(Naghavi et al., 2003a, 2003b; Stary et al., 1995). Therefore, early recognition of a high 
incidence of micro-thrombi by molecular imaging of activated platelets has important 
prognostic value.  
Activated platelets express αIIbβ3 integrin, which has been targeted with cyclic arginine–
glycine–aspartic acid (RGD) peptides, which are specific for the αIIβ3 integrin among 
others, and are conjugated to ultra-small particles of iron oxide for T2* weighted MRI 
(Johansson et al., 2001). Unfortunately, the resolution, which was achieved with RGD-
USPIO-enhanced MRI, was too low to detect thrombus in vivo (Johansson et al., 2001). 
Chemical conjugation to nanoparticles typically results in the loss of antibody functionality. 
A biochemically robust, highly reproducible and site-specific coupling method using the 
Staphylococcus aureus sortase A enzyme for the conjugation of single-chain antibodies 
(scFv) to amine-coated superparamagnetic iron oxide nanoparticles was developed (Ta et 
al., 2011). Conjugation efficiency ranged between 50 and 70% and the bioactivity of the scFv 
with specific affinity to activated platelets was preserved after conjugation. In vivo MRI 
showed that these scFv-conjugated SPIOs effectively bound to activated platelets on FeCl3 
induced thrombus in carotid arteries of mice (Ta et al., 2011). 
Fibrin-targeted small peptides conjugated to Gd-DTPA have been employed successfully in 
pigs, showing the feasibility of MRI to differentiate between acute and subacute (1-3 days 
old) coronary thrombus (Botnar, 2004a, 2004b). More recently, MR enhancement of 
thrombus has been achieved in a phase II trial using these peptides in patients, with a 
diagnosed symptomatic thrombus in vessel territories potentially associated with stroke 
(Spuentrup et al., 2008). 
Gd-perfluorocarbon nanoparticles functionalized with fibrin-targeted peptides were also 
applied for MR imaging of in vitro human thrombus (Winter et al., 2003). These 
perfluorocarbon nanoparticles can be used for T1-weighted proton MRI as well as for 19F 
hot-spot MR imaging. The advantage of the latter feature is the natural absence of 
background signal precluding the necessity of a baseline scan, which is attractive for clinical 
application from a logistical point of view.  
Also contrast agents based on the paramagnetic chemical exchange saturation transfer 
(PARACEST) mechanism have been employed for MR imaging of fibrin. This technique has 
been pioneered by the group of Balaban et al. (Ward et al., 2000). PARACEST agents have 
exchangeable protons (–NH, –OH, etc.) that resonate at a chemical shift position that is 
distinguishable from the bulk water signal. When an RF pulse is applied at the resonance 
frequency of the exchangeable protons, these protons will be saturated. Transfer into the 
bulk water pool will lead to reduced equilibrium magnetization. This so-called saturation 
transfer effect can be switched ‘‘on’’ and ‘‘off’’ by simply changing the pulse sequence. The 
PARACEST agents are potentially attractive for in vivo use, because contrast can be switched 
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on and off by selective RF pulse saturation, avoiding the need for baseline imaging and 
spatial registration of images acquired hours or days apart. The main disadvantage of 
PARACEST agents, however, is low sensitivity, which hampers the ability to image 
molecular targets. One method of increasing the sensitivity of paraCEST agents is to 
incorporate multiple metal chelates into a macromolecular scaffold. Proof of concept CEST 
imaging of fibrin was provided in vitro for fibrin clots, using a fibrin-specific 
perfluorocarbon nanoparticle containing multiple PARACEST units (Winter et al., 2006). 
This first generation PARACEST nanoparticle agent, however, introduced a large cationic 
charge on the particle surface. Cationic particles can cause significant in vivo toxicity and 
are not suitable for biomedical applications. In a recent study, a neutral lipid conjugated 
PARACEST chelate was incorporated onto the surface of PFC nanoparticles leading to a 
negative surface charge. PARACEST and 19F MRI showed a linear increase in both 
PARACEST contrast to noise ratio and the 19F signal with increasing nanoparticle 
concentration. Artificial fibrin clots were efficiently targeted using these nanoparticles and 
imaged using PARACEST and 19F MRI (see Figure 3) with detection limits of 2.30 nM and 




Fig. 3. Dual PARACEST and 19F MR imaging of a clot treated with fibrin-targeted 
PARACEST nanoparticles.  
PARACEST contrast to noise ratio map (A) and 19F image (B) collaboratively show 
nanoparticles bound to the surface of the clot. The grayscale color bar represents the 
PARACEST CNR depicted in (A). (C) The nanoparticle concentration (nM) is color-coded 
and overlaid onto the PARACEST subtraction image to demonstrate colocalization of these 
two definitive signals. Printed with permission from (Cai et al., 2011). 
Various products of the coagulation cascade may serve as targets for molecular MRI as well. 
Very recently, a thrombin inhibitor was conjugated to perfluorocarbon nanoparticles for 
localized in vivo control of thrombus in the common carotid artery of a mouse after acute 
photochemical injury (Myerson et al., 2011). The modified nanoparticles outperformed heparin 
and the free thrombin inhibitor according to the activated partial thromboplastin time. 
The earlier mentioned fibrin-targeted small-peptide MR contrast agents have low sensitivity 
for the estimation of thrombus age. Specific targeting of earlier phases of thrombus 
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localized in vivo control of thrombus in the common carotid artery of a mouse after acute 
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and the free thrombin inhibitor according to the activated partial thromboplastin time. 
The earlier mentioned fibrin-targeted small-peptide MR contrast agents have low sensitivity 
for the estimation of thrombus age. Specific targeting of earlier phases of thrombus 
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formation could help into this respect. Activated factor XIII cross-links fibrin chains and 
covalently cross-links α2-antiplasmin to fibrin, with a rapid decline in catalytic activity. 
Therefore, the potential of an α2-antiplasmin-based peptide labeled with rhodamine and Gd 
for specific detection of early thrombus was investigated both in vitro and in vivo (Miserus et 
al., 2009). Thrombus was induced via application of FeCl3 to the carotid artery of mice. In 
one group the contrast agent was injected seconds after thrombus formation, while in 
another group injection was postponed 24 to 48 hours after thrombus formation. Only early 
thrombus was enhanced using this contrast agent while thrombus with an age of 24 -48 
hours was not enhanced (Miserus et al., 2009). 
5. View-to-future 
As described above, MRI is capable of providing detailed cellular and molecular imaging 
information, which combined with the wealth of anatomical and functional MRI readouts, 
makes MR imaging of atherosclerosis a very powerful asset to study plaque vulnerability, 
progression and to evaluate effects of treatment. A potential limitation of MRI, however, is 
the limited sensitivity of the technique in the detection of low concentrations of targeted 
contrast agent.  
Development of improved MR techniques may enhance the sensitivity of detection. 
Hyperpolarization of nuclear spins through dynamic nuclear polarization (DNP) has 
recently attracted considerable attention for increasing the signal-to-noise ratio in an NMR 
experiment by several orders of magnitude (Ragavan et al., 2011). However, application of 
this technique to larger molecules has so far proven challenging. Recently, a full length 
protein was hyperpolarized at low temperature and dissolved for NMR signal acquisition in 
the liquid state in mixtures of organic solvent and water. Signal enhancements of 300-2000 
are obtained in partially deuterated polypeptide when hyperpolarized on 13C and of 30-180 
when hyperpolarized on 1H (Ragavan et al., 2011). Additionally, low-field (1 T) compact 
benchtop MRI systems (ASPECT, IconBruker) are ideally suited to take advantage of the 
higher relaxivity of Gd-based contrast agents at low magnetic fields.  
Although MRI-based single cell detection with the use of iron oxides has been reported, in 
general, much higher doses are needed as compared to for example the nuclear imaging 
techniques (Leuschner et al., 2011). Moreover the effect of covalent binding of 
peptides/lipids to Gd on the pharmacokinetics and biodistribution of the various contrast 
agent ingredients is uncertain. This complicates rapid approval of Gd-based MR contrast 
agents and its carriers for human application by the Food and Drug Administration (FDA 
(USA)) and European Medicines Agency (EMEA (Europe)), because of the concerns about 
retention in the body and toxicity. Issues are, amongst others, the unknown metabolic fate of 
the carrier material in the body, transmetallation of Gd3+ with native metal-ions in the 
body (Hak et al., 2009), and worries about Gd-induced nephrogenic systemic fibrosis 
(Pedersen, 2007). In this respect, nanocrystal HDL-like particles with iron oxide cores 
(Cormode et al., 2008; Mulder Acc Chem Res 2009; Skajaa et al., 2011) are very promising 
MR contrast agent candidates for clinical application because they seem to avoid most of 
these toxicity concerns. Figure 4 shows a schematic depiction of a nanocrystal HDL-like 
nanoparticle and summarizes some results achieved with it (Skajaa et al., 2011). 
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Fig. 4. Nanocrystal HDL with FeO core. Schematic depiction of FeO-HDL (a). (b) In vivo T2*-
weighted (TR = 10 ms, TE = 4 ms) MR image of abdominal region of an apoE-/- mouse, 24 h 
post-injection of FeO-HDL. The white arrow denotes the black rim (black spot) in the aortic 
wall observed after FeO-HDL administration. (A, aorta, V, inferior cava vein). (c) Ex vivo 
confocal laser microscopy of excised aorta section. Nuclei are shown in blue via DAPI 
staining, FeO-HDL in red (rhodamine), green color marks macrophages, stained with Alexa 
647-CD68 and yellow marks co-localization of FeO-HDL and macrophages. (d) In vitro TEM 
images of FeO-HDL in buffer. (e) In vitro negative staining TEM image of FeO-HDL, 
showing that each iron oxide (IO) particle is coated with a single monolayer of 
phospholipids. (f, g) TEM and negative staining TEM of blood samples 5 min after the 
administration of FeO-HDL revealed individually dispersed particles, i.e. no aggregation 
and that the lipid coating is intact. Printed with permission from (Skajaa et al., 2011). 
The use of frequency-selective paraCEST agents or perfluorocarbon nanoparticles in 
principle permits imaging of various target species simultaneously. Although in vitro proof 
of principle has been provided, in vivo application has been limited so far. Problems for 
paraCEST agents are related to low sensitivity and susceptibility artifacts, whereas 19F 
imaging also suffers from relatively low sensitivity. Concerning clinical translation, the iron 
oxides are most promising, since they enable the most sensitive detection with MRI while 
toxicity is low. The larger iron oxides provide sensitive hypointense contrast on T2-weighted 
images, whereas small iron oxides (~5 nm) can also be used for T1-weighted imaging with 
hyperintense contrast (Taboada et al., 2007). 
The application of both diagnostic and therapeutic MR agents for monitoring of drug 
delivery and therapeutic responses is very promising. Gd-containing liposome-encapsulated 
prednisolone phosphate was injected in atherosclerotic rabbits and delivery at the balloon-
injured aorta was imaged with MRI (Lobatto et al., 2010). The therapeutic anti-inflammatory 
and anti-angiogenic effects of the glucocorticoid were monitored with DCE MRI (Lobatto et 
al., 2010). Another study employed paramagnetic ανβ3-targeted fumagillin-loaded 
perfluorocarbon nanoparticles, releasing fumagillin via “contact facilitated drug delivery” 
(only upon ligand-directed binding) (Winter et al., 2006). These nanoparticles resulted after 
1 week in a significant reduction in degree and spatial distribution of MR enhancement. This 
effect was not observed when no drug or non-targeted fumagillin-loaded nanoparticles 
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imaging also suffers from relatively low sensitivity. Concerning clinical translation, the iron 
oxides are most promising, since they enable the most sensitive detection with MRI while 
toxicity is low. The larger iron oxides provide sensitive hypointense contrast on T2-weighted 
images, whereas small iron oxides (~5 nm) can also be used for T1-weighted imaging with 
hyperintense contrast (Taboada et al., 2007). 
The application of both diagnostic and therapeutic MR agents for monitoring of drug 
delivery and therapeutic responses is very promising. Gd-containing liposome-encapsulated 
prednisolone phosphate was injected in atherosclerotic rabbits and delivery at the balloon-
injured aorta was imaged with MRI (Lobatto et al., 2010). The therapeutic anti-inflammatory 
and anti-angiogenic effects of the glucocorticoid were monitored with DCE MRI (Lobatto et 
al., 2010). Another study employed paramagnetic ανβ3-targeted fumagillin-loaded 
perfluorocarbon nanoparticles, releasing fumagillin via “contact facilitated drug delivery” 
(only upon ligand-directed binding) (Winter et al., 2006). These nanoparticles resulted after 
1 week in a significant reduction in degree and spatial distribution of MR enhancement. This 
effect was not observed when no drug or non-targeted fumagillin-loaded nanoparticles 
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were administered (Winter et al., 2006), thus providing evidence for the specific therapeutic 
effect of the targeted, drug-loaded nanoparticles. 
6. Clinical application 
In patient studies iron oxide particles and Gadofluorine M have already been successfully 
applied for MRI of inflammation. The use of MRI with these particles combined with MRI 
assessment of cardiovascular function and myocardial tagging in selected patient 
populations with specific co-morbidity that increases risk for atherosclerotic disease may 
further stratify cardiovascular risk groups. Clinical application of self-assembling Gd-based 
molecular contrast agents is difficult due to the large amounts needed for detection and 
toxicity issues, especially in patients with kidney disease. Molecular targeted iron oxide 
nanoparticles conjugated to small peptides, recognized by phage display have lower 
immunogenicity when compared to full antibodies but toxicity may still hamper clinical 
application. Into this respect, the use of synthetic (ant)agonists or peptidomimetics for 
conjugation to MR visible nanoparticles combined with MRI of plaque targets in selected 
patient groups is anticipated to be more successful. Clinical application of perfluorocarbon 
nanoparticles for imaging of intravascular targets (endothelial cell markers and 
thrombus/activated platelets) employing the zero-background 19F signal is attractive. The 
safety of fluorine and the high payload of 19F which counterbalances low sensitivity of 19F 
MRI, make these perfluorocarbon nanoparticles (without Gd) useful contrast agents with 
clinical potential for targeted imaging of intravascular targets. However, first the 
pharmokinetic profiling information obtained in rabbits (Neubauer et al., 2008) needs to be 
expanded and should be obtained in patients. Activatable Gd- or iron oxide-based contrast 
agents sensing plaque enzyme activity may be used for detection of enzymes available at 
nM concentrations owing to enhanced relaxivity related to oligomerization of substrates or 
coupling of them to proteins (Tu et al., 2011). This approach is interesting in the scope of 
clinical application because it measures activity instead of presence of enzymes and lower 
toxicity is anticipated because lower Gd (or iron oxide) concentrations are needed for a 
certain degree of enhancement. The endogenous nature of the lipid coat of FeO-HDL-like 
nanoparticles, the easy incorporation of natural or synthetic lipids for increased 
accumulation in plaque macrophages, and the low toxicity of FeO makes these nanoparticles 
an attractive contrast agent for clinical MRI of atherosclerotic plaque. Clinical application of 
a specific molecular MRI method will also depend on costs of the contrast agent for a 
specific target of interest, the versatility of that agent and the contribution of this MRI 
approach to clinical decision making. 
7. Conclusion 
A number of strategies for cellular and molecular MRI of atherosclerosis were successfully 
developed. Proof of concept clinical application was already established for imaging of 
macrophages using non-targeted iron oxides and at a more immature stage for the 
fibrin-targeted small-molecule peptides conjugated to Gd-DTPA. Future studies will have to 
clarify whether the targeted contrast agents have diagnostic or prognostic added value in 
the evaluation of atherosclerotic plaque progression/rupture in humans. Promising new 
developments include activatable contrast agents, which are able to report on enzyme 
activity, perfluorocarbon nanoparticles exploiting the zero-background 19F signal, as well as 
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the use of modified MRI-visible endogenous nanoparticles, such as HDL and LDL, for 
imaging of atherosclerosis and specific plaque components. 
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It is generally believed that the coronary plaques with lipid-laden thin fibrous cap and a 
large lipid core beneath are vulnerable and imaging methods such as intravascular 
ultrasonography1, optical coherence tomography2, and angioscopy3-5 are clinically employed 
to detect this type of plaques. However, the coronary plaques that have a thin cap composed 
of tight calcium layers are frequently observed during post-mortem examinations3. 
Moreover, plaques wherein the deposition of lipids and macrophages is confined to just the 
superficial layers and in which a lipid core is not present also exist3,6. These evidences 
indicate the necessity of detailed molecular characterization for the detection of vulnerable 
plaques.   
Oxidized low-density lipoprotein (ox-LDL) plays an important role in the initiation, 
progression and destabilization of atherosclerotic plaques by inducing the proliferation and 
elongation of survival of macrophages7,8.  
Normal collagen fibers (CFs) that contain collagen-I in abundance protect the coronary 
plaques against mechanical stress. During plaque growth, collagen-I is replaced by 
collagen-III, -IV and/or -V9-11, and CFs are degenerated, disrupted, and finally destroyed 
by matrix metalloproteinases released by macrophages12. During this process, 
macrophages accumulate lipids such as cholesteryl esters (CEs) and ox-LDL13,14 and 
become foam cells while simultaneously producing ceramide within themselves15; their 
death results in formation of the lipid core. Therefore, demonstrating the lack of collagen-I 
which is mainly contained in normal CFs, deposition of lipids and existence of ox-LDL 
and the substances that comprising ox-LDL is an essential requisite for the detection of 
vulnerable plaques, but in-vivo clinical tools to visualize them in the coronary plaques are 
lacking.  
Structurally, ox-LDL is composed of cortex and core. The cortex is composed of 
lysophosphatidylcholine (LPC), free cholesterol (C) and Shiff base derived by oxidation 
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collagen-III, -IV and/or -V9-11, and CFs are degenerated, disrupted, and finally destroyed 
by matrix metalloproteinases released by macrophages12. During this process, 
macrophages accumulate lipids such as cholesteryl esters (CEs) and ox-LDL13,14 and 
become foam cells while simultaneously producing ceramide within themselves15; their 
death results in formation of the lipid core. Therefore, demonstrating the lack of collagen-I 
which is mainly contained in normal CFs, deposition of lipids and existence of ox-LDL 
and the substances that comprising ox-LDL is an essential requisite for the detection of 
vulnerable plaques, but in-vivo clinical tools to visualize them in the coronary plaques are 
lacking.  
Structurally, ox-LDL is composed of cortex and core. The cortex is composed of 
lysophosphatidylcholine (LPC), free cholesterol (C) and Shiff base derived by oxidation 
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from apolipoprotein B (apoB), and the core is composed of triglyceride (TG), cholesteryl 
esters (CEs), and proteins (Figure 1).  
High-density lipoprotein (HDL) is composed of the same substances except Apo B, and 
plays a key role in reverse cholesterol transport but also stimulates prostacyclin release, 
enhances endothelial repair, inhibits monocyte recruitment into the arterial wall, and 
inhibits progression of and enhances regression of atherosclerosis16, 17. 
LPC itself is a pro-inflammatory substance, and plays a critical role in the atherogenic 
activity of ox-LDL. This substance is generated by lipoprotein-associated phospholipase A2 
18; induces vascular endothelial cell dysfunction19; causes endothelial cell apoptosis by DNA 
fragmentation20; stimulates adhesion and activation of lymphocytes and initiates chemotaxis 
of macrophages21; causes transformation of vascular smooth muscle cells that is 
characteristic of atherosclerosis.  
Apolipoprotein B-100 (apo B-100) is a major protein of low density lipoprotein (LDL)22. 
Serum Apo B-100 is elevated in patients with type 2 diabetes mellitus23 as well as in those 
with coronary artery disease24. Apo B-100 and apo B-100/apo A-1 ratio predict not only 
coronary artery disease25 but also other cardiovascular disease26, and metabolic syndrome27. 
Medical treatments have been directed to lower Apo B-10028.  
TG is also considered an important risk of cardiovascular disease, but lowering TG levels 
remains difficult to achieve29, 30. 
Although these substances in serum are measureable, measurement of these substances in 
the atherosclerotic plaques is difficult. If they become visible in patients in-vivo, initiation, 
progression and destabilization, and the effects of medical and interventional therapies on 
atherosclerotic plaques can be objectively evaluated.  
Based upon the knowledge about the pathophysiology of atherosclerosis, in-vitro and in-vivo 
animal studies and clinical trials have been performed using different tracers for plaque 
imaging studies, including radioactive-labelled lipoproteins, components of the coagulation 
system, cytokines, mediators of the metalloproteinase system, cell adhesion receptors, and 
even whole cells, or antibodies of the substances composing atherosclerotic plaques. 
However the majority of them are still not applicable clinically. 
Spectroscopy has been attempted intensively for molecular imaging of lipids within the 
atherosclerotic lesions in-vitro31,32. However, its clinical application started only recently33. 
Also, magnetic resonance imaging or computed tomography has been attempted for lipid 
imaging, however their clinical application is yet not established34,35. 
Although invasive, angioscopy is a clinically established high resolution technique, which 
enables direct, colored and three-dimensional imaging of the coronary arterial wall. 
Recently, fluorescent angioscopy, both color and near-infrared, was developed and is used 
for molecular imaging of the substances within the human coronary plaques not only in-
vitro36-39 but also in patients in-vivo36,37. 
The present article reviews recent advances in molecular imaging of the substances 
comprising atherosclerotic coronary plaques by fluorescent angioscopy.  
Molecular Imaging of Atherosclerotic Coronary Plaques by Fluorescent Angioscopy 249 
 
TG: triglyceride. apo B: apolipoprotein B . PC: phosphatidylcholine. LPC: lysophosphatidylcholine. 
Fig 1. Schematic Representation of Structure of Low-density Lipoprotein (LDL) and 
Oxidized Low-density Lipoprotein (Ox-LDL). 
2. Fluorescent angioscopy system 
a. Color fluorescent angioscopy 
The color fluorescent angioscopy (CFA) system is composed of a fluorescence-excitation 
unit, an angioscope, a fluorescence-emission unit and a camera. The fluorescence-excitation 
unit is composed of a mercury-xenon lamp and seven sets of band-pass filter (BPF) discs, 
exchangeable by rotation for selection of the desired wave length of light ranging from 320- 
to 760-nm. The remaining single disc, which did not have any filter, was used to  irradiate 
white light for carrying out conventional angioscopy.  The angioscope (modified VecMover, 
Clinical Supply Co, Gifu, Japan) was composed of a 2.5-F fiberscope which contained 6000 
quartz fibers for the image guide and 300 quartz fibers for the light guide. This fiberscope 
was incorporated in a 5-F guiding balloon catheter and was steerable along a 0.014-inch 
guide wire; it also enabled observation of a coronary segment up to 7 cm in length by a 
single saline flush. This angioscope was approved for clinical use by the Japanese Ministry 
of Health and Labor and Welfare, and is widely used clinically in Japan.  
The fluorescence-emission unit is composed of seven sets of dichroic membrane (DM) and 7 
sets of band-absorption filter (BAF) discs which receive light ranging from 360- to 880-nm 
and is connected to a 3CCD digital camera (C7780, Hamamatsu Photonics, Hamamatsu). 
The obtained images are displayed on a computer screen through a camera controller 
(C7780, Hamamatsu Photonics, Hamamatsu). 
To observe the vascular lumen, the light and image guides are connected to the excitation 
and emission units, respectively. After selecting the desired BPF and BAF, the light is 
irradiated through the BPF and the light guide toward the target. A pair of BPF of 345±15 
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nm and BAF of 420 nm (“A” imaging), and another pair of 470±20 nm BPF and BAF of 515 nm 
(“B” imaging) are usually used for imaging The evoked fluorescence is received by the digital 
camera through the DM and BAF for successive three-dimensional imaging at an adequate 
time-interval from 0.01 to 1 s. The details of this CFA system are described elsewhere.41  
The intensity of the fluorescence images is arbitrarily defined as strong, weak and absent 
when the exposure-time required for imaging is within 0.5, more than 0.5 and within 1 and 
more than 1 s, respectively (Figure 2).                                                                
 
Cited from Ref. 41, with permission. 
Fig. 2. Schematic Representation of A Fluorescent Angioscopy System 
b. Near-infrared fluorescent angioscopy (NIRFA) 
For NIRFA, the BPF and BAF of the angioscopy system used for color fluorescent 
angioscopy system are replaced by a 710±25 nm BPF disc and 780-nm BAF disc by rotation, 
respectively, and color CCD camera is replaced by an intensified CCD camera (C3505, 
Hamamatsu Photonics)37. 
3. Color fluorescence of major substances that comprising atherosclerotic 
plaques examined by fluorescent microscopy  
a. Autofluorescence at “A”-imaging 
Among the major substances that constitute atherosclerotic plaques, collagen-I and -IV 
exhibit blue and light blue autofluorescence, respectively whereas collagen-III and -V did 
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not. Blue or light blue auto-fluorescence was not exhibited by other substances. Calcium 
phosphate, ceramide, and β -carotene which co-exists with lipid in the vascular wall, 
exhibited white, purple and orange auto-fluorescence, respectively (Figure. 3; Table 1) 
In the presence of β-carotene, collagen-I and -IV exhibited green fluorescence, collagen-III 
and -V showed white fluorescence, cholesterol (C) exhibited yellow fluorescence and 





From A to D: “A”-imaging of and E to H: “B”-imaging of collagens-I, -III, -IV and -V, respectively. By 
“A”-imaging, blue fluorescence was seen in collagen-I, no fluorescence in collagen-III, light blue 
fluorescence in collagen-IV and no fluorescence in collagen-V.  I: β-carotene (10-5 M) showing orange in 
fluorescence color by “A”-imaging. J: mixture of collagen-I and β-carotene showing green in 
fluorescent color by “A”-imaging. K: mixture of collagen-III and β-carotene showing white-to-light 
blue in fluorescence by “A”-imaging. Horizontal bar of each panel: 100μm. cited from Ref. 36, with 
permission. 
Fig. 3. Fluorescence of Collagen Subtypes Visualized by “A”- and “B”-Imagings of Color 
Fluorescent Microscopy (CFM) Before and After Mixing with β-Carotene. 
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AF: autofluorescence. EB: Evans blue. TB: Trypan blue. NB: Nile blue. Ho: Homidium chloride. 
“A” : “A”-imaging. 
“B” : “B”-imaging. 
LDL: low-density lipoprotein. Ox-LDL: oxidized low-density lipoprotein.   VLDL: very low-density 
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lipoprotein. HDL: high-density lipoprotein. LPC: lysophosphatidylcholine. PC: phosphatidylcholine. 
TG: triglyceride. Apo: apolipoprotein. MMP: matrix metalloproteinase. Chole: cholesteryl.  7-Keto chol: 
7-ketocholesterol.  
B: blue. Br: brown. G: green. Go: gold. LB: light blue. LY: light yellow. O: orange. P: purple. R: red. RBr: 
reddish brown. SB: sky blue. V: violet. W: white. Y: yellow.  - : no significant fluorescence. 
Underlined colors are characteristic for the corresponding substances. 
Table 1. Fluorescence Color of the Major Substances That Comprising Atherosclerotic 
Plaques 
b. Autofluorescence at “B”-imaging 
Collagen I and IV exhibit green autofluorescence whereas collagen III and V not. Calcium 
phosphate, ceramide and β-carotene exhibit yellow, yellow and orange autofluorescence, 
respectively. Other major subtances comprising atherosclerotic plaques do not exhibit auto-
fluorescence (Table 1).  
c. Color fluorescence of major substances that comprising atherosclerotic plaques evoked by 
markers 
Evans blue dye (EB) has been clinically used for intravascular imaging41-43, and its beneficial 
effects proved44.  
Oxidized low-density lipoprotein (ox-LDL) does not show autofluorescence, but presents a 
violet and a reddish brown fluorescence in the presence of EB by “A”- and “B”-imaging, 
respectively (Figure 4). This combination of fluorescent colors is not exhibited by any other 
major substances in the atherosclerotic plaques, indicating that this combination of 
fluorescent colors is due to ox-LDL (Table 1). 
TB has been clinically applied for treatment of Tripanosoma parasitemia many years ago45, 46. 
Although LPC and TB do not exhibit autofluorescence independently, a red fluorescence is 
evoked at both “A”- and “B”-imaging when they are mixed together. PC exhibits a pink and 
an orange fluorescence by “A”- and “B”-imaging, respectively38 (Figure 4).    
Nile blue dye (NB), which has been used as a electromechanical biosensor of DNA47. 
Apolipoprotein B-100 (apo B-100) exhibits no fluorescence at “A”-imaging but exhibits a 
golden fluorescence in the presence of NB at “B”-imaging (Figure 4, Table 1). 
In the presence of a mixture of homidium chloride (Ho) and TB, ox-LDL and LDL exhibit a 
golden fluorescence whereas LPC and apo B-100 a red fluorescence at “B”-imaging (Table 1). 
Since not exhibited by other major substances comprising atherosclerotic plaques, these 
fluorescent colors can be used for identification of the substances mentioned above. 
4. Near-infrared fluorescence (NIRF) of major substances that comprising 
atherosclerotic plaques 
Cholesterol, cholesteryl esters and calcium phosphate (Ca) individually do not exhibit NIRF 
but exhibit NIRF in the presence of β-carotene which is known to coexists with lipids in the 
vascular wall. The other substances that are contained in atherosclerotic plaques did not37 
(Figure 5; Table 2). 
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EB: Evans blue. TB: Trypan blue. NB: Nile blue. Ho+TB: Homidium chloride and Trypan blue.  
Fig. 4. Fluorescent Colors of Major Lipid Components Evoked by Biocompartible Markers 
Examined by Microscopy  














Images before (upper panels) and after mixing with β-carotene (lower panels); From A to D: collagen I, 
free cholesterol, cholesteryl oleate, calcium phosphate, respectively; From A-1 to D-1: corresponding 
NIRFM images evoked after mixing with β-carotene (10-5M). Horizontal bar in each panel: 100μm. Cited 
from Ref. 37, with permission. 
Fig. 5. Near-infrared Fluorescent Microscopy (NIRFM) Images of Collagen I, Cholesterol, 
Choresteryl Oleate and Calcium Phosphate. 
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from Ref. 37, with permission. 
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Table 2. Near-infrared Fluorescence (NIRF) of the Major Substances That Comprising 
Atherosclerotic Plaques 
5. Color fluorescent angioscopy of excised human coronary plaques  
a. Detection of vulnerable coronary plaques based on collagen subtype imaging 
Excised human coronary plaques exhibit blue, green, white-to-light blue, or yellow-to-
orange fluorescence. Fluorescent microscopic studies revealed that collagen subtypes, 
cholesterol, cholesteryl esters, calcium and β-carotene determine the fluorescent color of the 
plaques36. Histological examinations revealed abundant CFs without lipids in blue plaques; 
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CFs and lipids in green plaques; meager CFs and abundant lipids in white-to-light blue 
plaques; and the absence of CFs and deposition of lipids, calcium and macrophage foam 
cells in the thin fibrous cap in yellow-to-orange plaques, indicating that the yellow-to-






From A to D: conventional angioscopic images of coronary plaques. From A-1 to D-1: corresponding 
CFA images using “A” imaging. From A-2 to D-2: corresponding CFM scanned images using “A” 
imaging. Horizontal bar:100μm. A: a white plaque observed during conventional angioscopy (arrow) 
exhibited blue fluorescence by CFA (arrow in A-1) and CFM scan (A-2). B: a yellow plaque observed 
during conventional angioscopy (arrow) exhibited green fluorescence seen during CFA (arrow in B-1) 
and CFM scan (arrow in b-2).  C: a yellow plaque observed during conventional angioscopy (arrow) 
exhibited white-to-light blue fluorescence seen during CFA (C-1) and deposition of yellow substances in 
the white-to-light blue area (arrow in C-2). D: a yellow plaque observed during conventional 
angioscopy (arrow) exhibited yellow fluorescence observed during CFA (D-2) and deposition of orange 
(white arrowhead), white (white arrow) and blue (yellow arrow) substances in the area of no 
fluorescence by CFM scanning. Cited from Ref. 36, with permission. 
Fig. 6. Relationships between Images of Coronary Plaques Produced by Conventional 
Angioscopy, Color Fluorescent Angioscopy (CFA) and Color Fluorescent Microscopy (CFM) 
Scanning    
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From A-3 to D-3: microscopic images after Oil-red O and methylene blue staining obtained from the 
same plaques in A, B, C and D as shown in Figure. 6, respectively. Red: lipids. Black: calcium. LC: lipid 
core. Horizontal bar: 100μm. From A-4 to D-4: CFs stained by silver staining. No normal CFs in D-4. 
Arrow in D-4: plaque debris. Horizontal bar: 20μm. From A-5 to D-5: images of ceramide in    
macrophage foam cells obtained by “B” imaging of CFM after Ziel-Neelsen staining. Orange 
fluorescence (arrows): ceramide. Arrowhead in C-5: residual CFs. Horizontal bar: 20μm. A-3: a plaque 
without lipids, with abundant normal CFs (A-4) and without macrophage foam cells (A-5). B-3: a 
plaque with lipids, with thick CFs (B-4) but without macrophage foam cells (b-5).  C-3: a plaque with 
lipid deposition and cavity formation, meager CFs (C-4) and disseminated macrophage foam cells 
(arrow inC-5). D-3: a plaque with a thin fibrous cap with lipids and calcium (arrow in D-3), without CFs 
(D-4) and with multiple macrophage foam cells (arrows inD-5). Cited from Ref. 36, with permission.  
Fig. 7. Lipids, Calcium Compounds, Collagen Fibers (CFs), and Macrophage Foam Cells in 
the Same Plaques as Those Shown in Figure. 6.  
b. Oxidized low-density lipoprotein (Ox-LDL) imaging 
After the administration of EB in an ex-vivo study, not only the yellow plaques but also the 
white plaques studied by conventional angioscopy frequently presented a violet 
fluorescence by “A”-imaging and a reddish brown fluorescence by “B” imaging, indicating 
the existence of ox-LDL (Figure 8). The distribution of this fluorescence appeared in a patchy 
or diffuse manner. There was a tendency for this fluorescent color to appear more frequently 
in yellow plaques rather than the white plaques classified by conventional angioscopy36. By 
scanning microscopy, a violet and a reddish brown fluorescence distributed diffusely or in 
web-like configuration, indicating plaque to plaque differences in deposition pattern of ox-
LDL36.  







A: a white plaque imaged by conventional angioscopy. Arrow: the portion observed by CFA.  B: “A”-
image of the same plaque before administration of EB. The plaque showed green autofluorescence, 
indicating existence of collagens-I and/or -IV (Table 1). B-1: CFA image after administration of EB. The 
plaque showed diffuse and violet fluorescence. C: “B”-image of the same plaque, showing green 
autofluorescence. C-1: “B”-image after administration of EB, showing reddish brown fluorescence. This 
combination of EB-evoked fluorescent color indicates the existence of ox-LDL. Cited from Ref. 36, with 
permission. 
Blue fluorescence (arrowhead in A-1) and green fluorescence(arrowhead in B-1) indicate collagen I 
and/or IV.  
Fig. 8. Ox-LDL in An Excised Coronary Plaque Imaged by Color Fluorescent Angioscopy 
(CFA)  
c. Lysophosphatidylcholine (LPC) imaging 
The red fluorescence of LPC was investigated by color fluorescent angioscopy in the excised 
human coronary plaques. This fluorescent color both at “A”-and “B”-imaging was detected 
frequently by color fluorescent angioscopy in both white and yellow plaques that were 
classified by conventional angioscopy using white light (Figure 9). As in case of ox-LDL, this 
fluorescent color was found to be distributed in web-like or diffuse configuration by color 
fluorescent microscopic scanning38 (Figure 10). 
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A: a yellow plaque imaged by conventional angioscopy. Arrow: the portion observed by CFA.  B and C: 
CFA images of the same plaque before administration of TB. The plaque showed green and blue 
fluorescence in mosaic pattern by “A” imaging, and green and yellow fluorescence in mosaic pattern by 
“B” imaging, indicating the  co-existence of collagen I and/or IV and lipids. B-1 and C-1: CFA images 
after administration of TB. The plaque showed red fluorescence by both” A”-and “B”-imaging, 
indicating the existence of LPC. Cited from Ref. 38, with permission. 
Fig. 9. Lysophosphatidylcholine (LPC) in A Coronary Plaque Imaged by Color Fluorescent 
Angioscopy (CFA) 
 
A: yellow plaque imaged by conventional angioscopy.  B and B-1: CFM  scanned luminal surface of the 
same plaque after the application of TB, showing wed-like distribution of red fluorescence and therefore  
web-like deposition of LPC (arrows).  Horizontal bar in B-1: 100μm. This bar is also applicable to B. 
Cited from Ref. 38, with permission. 
Fig. 10. Distribution Patterns of Lysophosphatidylcholine (LPC) in A Coronary Plaque by 
Color Fluorescent Microscopy (CFM) Scanning  
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d. Apo B-100 imaging 
In the presence of NB, golden fluorescence, diffuse, spotty or web-like configuration, was 
observed in excised human coronary arteries by “B”-imaging, indicating deposition of apo 
B-100. However, the relationship between deposition patterns of this substance and plaque 
structure by histology is not clarified. 
e. Triglyceride (TG) imaging 
Imaging of TG, a major component of the core of ox-LDL, by CFA is yet not successful 
because of a lack in appropriate biocompartible markers.   
f. HDL and LDL imaging 
Selective imaging of HDL and LDL by fluorescent angioscopy is yet not successful as in case 
of TG.    
 
A: Yellow plaque imaged by conventional angioscopy. Arrow: the  portion observed by CFA  A-1 and 
A-2: CFA images of the same plaque before and after administration of Ho and TB solution (Ho+TB), 
respectively. The plaque showed greenish yellow autofluorescence before (arrow in A-1) and red 
(arrowheads in A-2) and golden fluorescence (arrow in A-2) in a mosaic pattern after the administration 
of Ho and TB, indicating co-existence of ox-LDL and/or  LDL, and LPC and /or apo B-100.  B: Yellow 
plaque by conventional angioscopy (arrow). B-1 and B-2: CFA images before and after administration of 
Ho and TB solution (Ho+TB), respectively. The plaque showed yellow autofluorescence (arrow in B-1) 
before and red fluorescence (arrow in  B-2) after the administration of Ho and TB solution, indicating 
deposition of LPC and/or apo B-100. 
Cited from Ref. 39, with permission. 
Fig. 11. Oxidized Low-density Lipoprotein (Ox-LDL), LDL, Lysophosphatidylcholine (LPC), 
and Apolipoprotein (ApoB) in Coronary Plaques Imaged by Color Fluorescent Angioscopy 
(CFA)  
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g. Simultaneous imaging of oxidized low-density lipoprotein (Ox-LDL), low-density lipoprotein 
(LDL), lysophosphatidylcholine (LPC) and apolipoprotein B-100 (apo B-100) 
By “B”-imaging, ox-LDL and LDL (group A) exhibit golden fluorescence, while LPC and 
apo B-100 (group B) exhibit red fluorescence. By color fluorescent angioscopy, coronary 
plaques frequently exhibited red and golden fluorescence in a mosaic pattern, indicating co-
deposition of A and B. Red fluorescence was also observed in a small number of plaques, 
indicating solitary deposition of B39 (Figure 11).  
 
From A to D: the images of coronary plaques by conventional angioscopy.  
From A-1 to D-1: corresponding NIRFA images of the same plaques. From A-2 to D-2 : corresponding 
NIRFM scanned images of the cut wall surface of the same specimens . From A-3 to D-3: corresponding 
histological images after staining with Oil Red-O and methylene blue. Red and black portions indicate 
lipids and calcium, respectively. Horizontal bar at the left upper corner of each panel: 100 μm. 
A: a white plaque. From B to D: yellow plaques. A-1 and B-1: homogenous type. Arrows: homogenous 
NIRF; C-1: doughnut-shaped type. Arrow: NIRF absent portion surrounded by strong NIRF region; D-1: 
spotty type. Arrow: spots. A-2 and B-2: homogenous NIRF (arrows); C-2 : necrotic core lacking NIRF 
(arrow) surrounded by strong NIRF region; D-2: fibrous cap with strong NIRF spots (arrow). A-3: 
homogenous deposition of lipids deep in the plaque (arrow); B-3: lipid deposition in entire plaque. C-3: 
lipid-deposited fibrous cap with a necrotic core (NC) belowD-3: calcium particles distributed within a 
lipid-laden fibrous cap. Red: lipids. Black: calcium compounds (arrow).   
Horizontal bar: 100μm. Cited from Ref. 37, with permission. 
Fig. 12. Relationships Among Conventional Angioscopic, Near-infrared Fluorescent 
Angioscopic (NIRFA), and Near-infrared Fluorescent Microscopic (NIRFM) Scanned Images 
and Histological Changes in Excised Human Coronary Plaques. 
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6. Near-infrared fluorescent angioscopy of excised human coronary plaques 
a. Cholesterol (C) and cholesteryl ester (CE) imaging 
In an ex-vivo study, excised human coronary plaques were classified as those with NIRF 
and those without. The former plaques were classified into homogenous, doughnut-shaped 
and spotty types37.  
Histological examinations revealed that these image patterns were determined by the 
differences in the locations of cholesterol, cholesteryl esters and Ca, and that those deposited 
within 700μm in depth from plaque surface were imaged by NIRFA37 (Figure 12).  
7. Clinical application of fluorescent angioscopy 
a. Oxidized low-density lipoprotein (ox-LDL) 
In our catheterization laboratory, CFA was performed during routine coronary angioscopy 
in patients with coronary artery disease.  
After selective injection of the EB solution into the coronary artery, not only the plaques but 
also the apparently normal coronary segments frequently exhibited a reddish brown 
fluorescence by “B”-imaging, indicating the existence of ox-LDL36 (Figure 13).  
 
Reddish brown fluorescence observed in a non-stenotic proximal segment of the left anterior 
descending coronary artery after the intracoronary injection of EB in a patient with stable angina 
pectoris. 
 A: an angiogram of the left coronary artery. Arrows a to b: the proximal segment observed by CFA. The 
wall of the segment was uneven but significant stenosis was not found. 
From .B to E: CFA images of the same segment obtained after injecting EB, by advancing the angioscope 
distally from a to b of panel A.  Reddish brown portions indicate ox-LDL. The luminal surface was  
uneven, indicating early stage of atherosclerosis. Cited from Ref. 36, with permission. 
Fig. 13. Ox-LDL Imaged by “B”-imaging of Color Fluorescent Angioscopy (CFA) in the 
Coronary Artery in A Patient with Angina Pectoris 
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Fig. 13. Ox-LDL Imaged by “B”-imaging of Color Fluorescent Angioscopy (CFA) in the 
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b) Cholesterol and cholesteryl esters 
The present authors examined coronary plaques by NIRFA during coronary angiography in 
25 patients with coronary artery disease. Figure 14 shows a yellow plaque by conventional 
angioscopy. This plaque exhibited homogenous NIRF, indicating homogenous deposition of 
cholesterol and/ or choresteryl esters. Homogenous, doughnut-shaped or spotty NIRFA 
images were also observed in patients37. 
 
 
From A to C: angiogram, conventional angioscopic image and NIRFA image of a plaque in the proximal 
segment of the left anterior descending coronary artery (arrow in A). The yellow plaque (arrow in B) 
presented a homogenous type NIRF image (B-1). Arrowhead: guide wire. 
Cited from Ref. 37, with permission. 
Fig. 14. Near-infrared Fluorescent Angioscopy (NIRFA) Study in a 61-year-old Male with 
Stable Angina.  
8. Discussion 
The use of an antibody of individual components that comprising vessel wall is a more 
specific indicator for their imaging in-vivo. However, there are many limitations to its 
clinical application. Therefore, the use of a low molecular weight substance that selectively 
binds to individual components and presents specific fluorescence color is another option 
that can be used for the imaging of individual lipid components.  
In the present study, low molecular weight dyes with, EB, TB, NB, Ho+TB were found to 
evoke fluorescence specific to ox-LDL and its components except TG and Schiff base. Thus, 
visualization of ox-LDL and its major components in a given plaque was achieved, enabling 
analysis of the differences in their deposition patterns in human coronary plaques. The 
mechanisms by which these dyes evoked fluorescence are not known. One possibility is that 
dyes became conjugated to the target substances to form an adduct to provoke a fluorescent 
color specific to individual substances.  
Ox-LDL, which plays an important role in the initiation, progression and destabilization of 
atherosclerotic plaques, became visible for the first time by CFA in patients. Furthermore, 
the substances that comprising ox-LDL became visible by CFA or NIRFA in excised human 
coronary arteries. 
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However, CFA and NIRFA have been limited to collagen subtypes, ox-LDL, cholesterol and 
cholesteryl esters in clinical situations. Imaging of other substances by CFA or NIRFA in 
patients is yet not performed because clinical applicability of biocompartible markers other 
than EB is not established.  
Fluorescent angioscopy faced some shortcomings; (1) The visualization by CFA is limited only 
to the substances deposited within 200μm from the vascular luminal surface and by NIRFA 
within 700 μm (Table 3). Therefore deposits in the deeper layers can not be analyzed by this 
system of CFA and NIRFA.（2) Differing in function to antibodies, biomarkers employed in 
CFA do not selectively bind to the target substance, and therefore, there may be other 
unknown substances which exhibit the same fluorescent color in the presence of the markers 
used. (3) Because a lens is used, the pictures obtained by CFA and NIRFA are fish-eye images 
and therefore quantitative assessment of the target substance is difficult (Table 3).     
 
CFA: color fluorescent angioscopy. NIRFA: near-infrared fluorescent angioscopy. 
Table 3. Advantages and Disadvantages of Angioscopy 
At present, imaging by fluorescent angioscopy is limited to several substances that comprise 
coronary plaques. By selecting adequate biomarkers, the substances other than those 
mentioned above may become visible. 
Fluorescent angioscopy was established only recently and therefore its clinical application is 
limited to a few laboratories. As in spectroscopy, this technique will become prevalent when 
clinically applicable biomarkers for the substances comprising atherosclerotic lesions 
become complete. 
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9. Conclusion 
LDL has cortex and core. The cortex is composed of PC, free cholesterol  and apo B-100, and 
the core is composed of TG and cholesteryl esters. Ox-LDL is derived from LDL by 
oxidation of its component PC into LPC and apo B-100 into Shiff base, and plays an 
important role in the initiation, progression and destabilization of atherosclerotic plaques by 
inducing the proliferation and elongation of survival of macrophages.  
We succeeded in molecular imaging of ox-LDL not only in the excised human coronary 
plaques but also in coronary arteries in patients in-vivo by CFA using EB as a biomarker. Also, 
LPC, apo B-100, free cholesterol, and cholesteryl esters in human coronary plaques became 
visible by either CFA or NIRFA. These imaging techniques will give us much information 
which is otherwise not obtainable on the mechanisms of atherosclerosis in clinical situation.  
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9. Conclusion 
LDL has cortex and core. The cortex is composed of PC, free cholesterol  and apo B-100, and 
the core is composed of TG and cholesteryl esters. Ox-LDL is derived from LDL by 
oxidation of its component PC into LPC and apo B-100 into Shiff base, and plays an 
important role in the initiation, progression and destabilization of atherosclerotic plaques by 
inducing the proliferation and elongation of survival of macrophages.  
We succeeded in molecular imaging of ox-LDL not only in the excised human coronary 
plaques but also in coronary arteries in patients in-vivo by CFA using EB as a biomarker. Also, 
LPC, apo B-100, free cholesterol, and cholesteryl esters in human coronary plaques became 
visible by either CFA or NIRFA. These imaging techniques will give us much information 
which is otherwise not obtainable on the mechanisms of atherosclerosis in clinical situation.  
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1. Introduction 
Molecular imaging has recently been defined by the Society of Nuclear Medicine as ‘the 
visualization, characterization, and measurement of biological processes at the molecular 
and cellular levels in humans and other living systems’ (Mankoff 2007). It usually exploits 
specific labeled molecular probes, as well as intrinsic tissue characteristics as the source of 
image contrast, and uses a number of molecular imaging modalities, including magnetic 
resonance imaging, optical imaging, targeted ultrasound, single photon emission 
tomography and positron emission tomography (Massoud and Gambhir 2003). 
Angiogenesis is the development of new vasculature from pre-existing blood vessels and/or 
circulating endothelial calls (Bergers and Benjamin 2003). It is well established that 
angiogenesis is one of the key aspects in the growth and metastasis of solid tumors 
(Folkman 1995; Ferrara and Kerbel 2005). Typically tumor-associated angiogenesis goes 
through two phases, an avascular and a vascular phase that are separated by the ‘angiogenic 
switch’. The avascular phase of tumors corresponds to small and occult lesions that stay 
dormant and subsist on diffusion of nutrients from the host microvasculature. After 
reaching a certain size (usually around 1-2mm), a small subset of dormant tumors enter the 
vascular phase in which exponential tumor growth ensues. Angiogenesis is a complex 
multistep process regulated by many factors. At the onset of angiogenesis, a number of pro-
angiogenic growth factors (e.g. vascular endothelial growth factors, platelet derived growth 
factor, fibroblast growth factors) and proteolytic enzymes (e.g. metalloproteinases, cathepsin 
cysteine proteases, plasmin) are secreted into the interstitium. This leads to degradation of 
basal membrane surrounding the pre-existing vasculature, along with proliferation and 
migration of smooth muscle and endothelial cells. All these events lead to the alignment and 
organization of endothelial cells to form new vessels and a vascular network within the 
tumor (Ferrara and Kerbel 2005).  
Tumor angiogenesis is not simply the production of an increased number of blood vessels to 
serve a growing mass. Although the main purpose of tumor angiogenesis can be considered 
to maintain a cancer’s blood supply, the process occurs in an unmitigated fashion, and the 
resultant vascular network is highly abnormal. This profoundly aberrant vasculature 
dramatically alters the tumor microenvironment and influences heavily the ways in which 
cancers grow and progress, escape the host’s immune system, metastasize, and respond to 
anticancer therapies. 
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cysteine proteases, plasmin) are secreted into the interstitium. This leads to degradation of 
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serve a growing mass. Although the main purpose of tumor angiogenesis can be considered 
to maintain a cancer’s blood supply, the process occurs in an unmitigated fashion, and the 
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dramatically alters the tumor microenvironment and influences heavily the ways in which 
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The heterogeneity in vessel distribution and haphazard anatomical arrangement of the 
vasculature cause spatial and temporal heterogeneity in blood flow, with areas of 
hypervasularity adjacent to hypovascular ones (Tong, Boucher et al. 2004). Also, the 
structural abnormalities of the tumor vasculature lead to a marked increase in vessel 
leakiness. As a consequence, there is a protein and fluid build-up in the tumor interstitium. 
This excess extravasation of protein increases the extravascular oncotic pressure, dragging 
further fluid into the interstitial space (Stohrer, Boucher et al. 2000; Tong, Boucher et al. 
2004). Furthermore, there is an absence of functional intratumoral lymphatic vessels, 
resulting in the impaired clearance of extracellular fluid and hence interstitial hypertension 
within tumors. The raised intratumoral interstitial fluid pressure (IFP) reduces the 
hydrostatic pressure gradient between the intravascular and extravascular compartments 
such that the two essentially equilibrate, which reduces transvascular flow. Also, the 
mechanical stress from the solid mass of proliferating cancer cells and the matrix is able to 
collapse tumor vessels, closing the lumen through compressive forces (Padera, Stoll et al. 
2004). This combination of regional poor perfusion, raised IFP, and areas of vascular 
collapse produces regional hypoxia and acidosis within tumors (Helmlinger, Yuan et al. 
1997). Aberrations in the tumor vasculature have great implications for tumor sensitivity to 
therapy. Hypoxia is a well-known mediator of cancer cell resistance to conventional 
radiotherapy and cytotoxics (Teicher 1996; Wouters and Brown 1997). Moreover, the poor 
blood supply and raised intratumoral IFP (leading to a reduction in transvacular flow) 
impair the delivery of systemically administered therapies to tumors such as conventional 
cytotoxics and monoclonal antibodies (Jain 1989; Tong, Boucher et al. 2004). 
With the discovery of vascular endothelial growth factor (VEGF) as a major driver of tumor 
angiogenesis, efforts were focused on novel therapeutics aimed at inhibiting VEGF activity, 
with the goal of regressing tumors by starvation. Unfortunately, clinical trials of anti-VEGF 
monotherapy in patients with solid tumors have been largely negative (Jain, Duda et al. 
2006). Intriguingly, the combination of anti-VEGF therapy with conventional chemotherapy 
has improved survival in cancer patients compared with chemotherapy alone (Sandler, Gray 
et al. 2006; Saltz, Clarke et al. 2008). In 2001, a ‘vascular normalization’ hypothesis was 
proposed to explain this paradox (Jain 2001). The normalization hypothesis suggests that by 
correcting the abnormalities in structure and function of tumor vessels (rather than 
destroying vessels completely) we can normalize the tumor microenvironment and 
ultimately control tumor progression and improve response to other therapies (Jain 2005). 
Non-invasive imaging of tumor angiogenesis will allow for much earlier detection of tumors 
and also the development of surrogate markers for assessing response to treatment.  
2. Imaging of angiogenesis 
Imaging angiogenesis has been focused into three different arenas: 1) kinetic imaging using 
dynamic tracking of contrast administration; 2) steady state blood volume determinations of 
neovascular density; and 3) specific molecular markers of angiogenesis. 
2.1 Kinetic imaging using dynamic tracking of contrast material 
Dynamic contrast-enhanced imaging is a noninvasive technique that can provide 
parameters related to tissue perfusion and permeability for examination of the tumor 
vasculature.  
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2.1.1 Dynamic contrast-enhanced ultrasound 
Contrast-enhanced ultrasound (CEU) imaging is based on the reception, analysis and 
display of acoustic signals produced by reflection or backscatter of sound (echo) with use of 
contrast agents. The most commonly used contrast agent are microbubbles that are gas-
liquid emulsions consisting of a gaseous core (e.g. perfluorocarbon, sulfur hexfluoride, or 
nitrogen) that is enclosed by a shell composed of biocompatible materials (albumin, 
galactose, lipids, polymers). The gaseous core of the microbubbles causes a very high 
echogenic response following insonification with ultrasound, resulting in high contrast-to-
tissue background ratio. Owing to their micron size (usually ranging in size between 1 and 4 
m in diameter), these microbubbles stay within the vascular compartment, and do not leak 
out into the extra-vascular space (Deshpande, Pysz et al. 2010). Thus, microbubbles are 
highly suitable for imaging angiogenic markers that are over expressed on tumor vascular 
endothelial cells (Deshpande, Needles et al. 2010). 
Following intravenous administration, microbubbles do not coalesce to form emboli, but 
dissolve leaving remnants that are easily metabolized or excreted. Further, biodistribution 
studies revealed that microbubbles have low circulation residence times as they are rapidly 
removed by the reticuloendothelial system (Perkins, Frier et al. 1997; Weskott 2008; 
Willmann, Cheng et al. 2008). To increase the circulation time of the microbubbles in serum, 
additional coatings, such as polyethylene glycol polymer arms are added onto the 
microbubble shell. Additionally these coatings help stabilize the microbubble by providing 
additional steric protection, preventing aggregation and help escape immune surveillance 
by the body (Klibanov 2009).  
To make ultrasound a molecular imaging tool, contrast microbubbles can be functionalized 
with ligands such as antibodies or peptides that bind molecular marker of interest with high 
affinity (Klibanov, Hughes et al. 1999). These binding ligands can either be coupled to the 
microbubbles using non-covalent attachment, or chemical conjugation (Klibanov 2005), or 
they can be integrated into the microbubble shell directly during the production process or 
after manufacturing (Pochon, Tardy et al. 2010; Pysz, Foygel et al. 2010). 
The huge benefit of using microbubbles is that the microcirculation can be detected. Since 
the nonlinear signals from microbubbles occur regardless of their motion and equally when 
they are stationary, CE US detects the capillary bed, which is by far the largest part of the 
microcirculation. Of course, its spatial resolution is limited, so that individual capillaries 
cannot be discerned, but the microbubble content gives rise to a signal ‘wash’ whose 
intensity is proportional to the microbubble concentration and thus to the blood volume in 
that portion of tissue (Figure 1).  
To estimate or measure perfusion, the essential tool is the transit or wash-in, wash-out 
curve, often referred to as the time-intensity curve (TIC) in which the time course of the 
transit of the microbubbles across a region of interest (ROI) is measured (Cosgrove and 
Lassau 2010). Two families of information are available from these TICs, those that depend 
on timing events, such as the arrival time and the time to peak enhancement, and those that 
depend on the amount of enhancement detected, such as the peak enhancement and the 
area under the TIC. These indices are rather more complex as they rely on a number of key 
assumptions. One is that the signal strength is proportional to the microbubble 
concentration (Blomley, Albrecht et al. 1997; Claassen, Seidel et al. 2001). Another 
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The heterogeneity in vessel distribution and haphazard anatomical arrangement of the 
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2.1.1 Dynamic contrast-enhanced ultrasound 
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assumption is that all the non-linear signals in the ROI do emanate from the microbubbles, 
rather than from tissue.  
 
Fig. 1. Four images from a patient with pathologic proven rectal neuroendocrine tumor that 
is metastatic to the right lobe of the liver. (a) & (b) are conventional ultrasound images of the 
right lobe of the liver which demonstrates a well circumscribed, hypoechoic mass. (c) & (d) 
are contrast mode rapid ultrasound following injection of 3 x 10-8 microbubbles that are 
approximately 2.5 microns in size in a volume of 2.4mL. Panels (c) and (d) demonstrate 
different timepoints which demonstrate enhancement of the tumor fairly homogenously in 
(c), and in (d) washout of the tumor with enhancement of the hepatic venous system. 
(Figure from Dhyani & Samir et. al. unpublished data) 
The other way to generate boluses of contrast depends on the unique interaction between 
the imaging beam and the contrast agent: microbubbles are destroyed by higher intensity 
ultrasound which causes them to oscillate wildly and in complex patterns such that the gas 
escapes and the contrast effect is lost. The readiness with which this happens depends on 
the robustness of the shell, but for the commonly used clinical agent it is well within those 
licensed by regulatory agencies (usually a mechanical index (MI) of 1.9 is allowable). In a 
typical set-up, an infusion of microbubbles is used to achieve a steady blood concentration, 
and then a series of pulses at high MI is sent into the ROI before the system is switched back 
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to a low MI microbubble-specific mode for imaging (Wei, Jayaweera et al. 1998). The 
progressive inflow of the microbubbles in the cleared region can then be observed and the 
accumulation plotted. It takes the form of a rising exponential whose initial slope, , is 
related to the flow rate and whose maximum value, A, is related to the equilibrium 
concentration of the microbubbles, also known as the fractional vascular volume. The 
formula that is usually deployed is: 
 R = A (1-e (-t))  (1) 
though other approximations can be used (Lucidarme, Kono et al. 2003). An important 
difference between ultrasound and most other contrast agents should be stressed here: 
because of their relatively large size, microbubbles do not diffuse across the endothelium 
and into the interstitial space, unlike the ionic agents used for CT and MR. Advantages of 
this ‘destruction reperfusion’ method are its ready repeatability and the clean inflow 
function – there is no blurring effect from the upstream circulation as occurs following an iv 
bolus.  
The breast was one of the first tumors studies when contrast agents became available and 
striking differences between benign and malignant masses were reported (Kedar, Cosgrove 
et al. 1995). Not only was there more enhancement in malignancies but also the pattern was 
more chaotic. A rather crude attempt to evaluate transit times in the masses suggested that 
the cancers had earlier enhancement and retained the contrast for longer. Subsequent 
studies of breast masses have been less positive, with only poor enhancement and little 
differences between benign and malignant lesions as well as false positives where highly 
vascular fibroadenomas caused confusion (Rizzatto, Martegani et al. 2001; Jung, Jungius et 
al. 2005). In a more recent study of 50 consecutive patients with histological proof, QLab 
software was used to calculate features from TICs after bolus injections of SonoVue 
(Barnard, Leen et al. 2008). The area under the curve (AUC) and the peak enhancement were 
larger in malignant than benign lesions. 
The prostate has also been studied from early after the introduction of microbubbles, both to 
improve detection of cancers and to assess response to antiandrogen therapy (Eckersley, 
Sedelaar et al. 2002). Again, the techniques were crude, exploiting what was available. More 
recently, microbubble-specific modes and more durable microbubbles have become 
available, and reports of their usefulness in targeting biopsies promise to reduce the high 
proportion of negative biopsies (Frauscher, Klauser et al. 2003; Wink, Frauscher et al. 2008). 
A study found that DCE US was a useful method for evaluating the neovascularization of 
gastric carcinomas, and enhanced intensity (enhanced intensity is equal to peak intensity 
minus baseline intensity) had a strongly positive linear correlation with microvessel density 
(MVD) (Shiyan, Pintong et al. 2009). Another study found that DCE US was a valuable 
method for evaluating angiogenesis in colorectal tumors in vivo (Zhuang, Yang et al. 2011). 
This study also found that the area under the curve (AUC) had a positive linear correlation 
with MVD and could form a new index for assessing angiogenesis and the biological 
behavior of colorectal tumors. A recent study also found that the peak intensity and AUC 
reflected the MVD in ovarian tumors (Wang, Lv et al. 2011). 
In summary, DCE US is a powerful tool for studying neovascularization and the effect of 
anti-angiogenic therapy, with minimal morbidity. 
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2.1.2 CT perfusion 
CT perfusion (CTP) is a theoretical tool able to objectively quantify (with the use of 
mathematical models and dedicated software) the ‘real’ perfusion of tissues in that it only 
measures the density difference produced by the contribution of contrast material (and 
therefore of blood) to tissues. CTP is based on two indispensable technical requirements. 
 
Fig. 2. Effect of treatment on tumors in patients who completed entire combined treatment 
regimen, and surgery. (a) Endoscopic and pathological evaluation of rectal tumors. Surgical 
specimens showed grade II tumor regression in patients 1-5 and grade III in patients 6, by 
Mandard criteria. Endoscopic image (instead of surgical specimen) was taken for patients 6, 
3.5 weeks before surgery. BV, bevacizumab. (b) Representative functional CT images of 
blood perfusion before treatment (day 0), after bevacizumab (day 12) and after completion 
of treatment (day 104) in patient 5. (c) Tumor FDG uptake before treatment (pretreatment), 
12d after bevacizumab treatment and 6-7 weeks after completion of all neoadjuvant therapy 
(presurgery). Saggital projections of FDG-PET scans for patient 1 are shown. Tumor is 
outlined in box, posterior to the bladder. (Reprinted with permission from Nature Medicine, 
10(2), Willet et al. Direct evidence that the VEGF-specific antibody bevacizumab has 
antivascular effects in human rectal cancer., 145-7, Copyright 2004) 
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The first is the performance of repeated CT scans of the volume being analyzed (also known 
as dynamic, cine or perfusion scans). These need to be acquired before, during and after 
intravenous administration of iodinated contrast material to enable the study of density 
variations over time. The density measured by CT in the unit volume (voxel) is directly 
proportional to the quantity of contrast material present within it (Lee, Purdie et al. 2003). 
The contrast material contained within the tissue volume being studied is due to contrast 
material in vessels and contained in the extravascular/cellular space (or more simply, 
interstitial space) due to passive diffusion (Cenic, Nabavi et al. 2000). The second 
requirement is the selection of the arterial input. Placement of an ROI on an artery (arterial 
input) makes it possible to obtain a density/time curve, expressed in Hounsfield units (HU) 
per second (s), which is compared with the density/time curve of the tissues being studied, 
which is also obtained with placement of an ROI. Thanks to the comparison, the quantity of 
contrast material within vessels (vascular component) can be distinguished from contrast 
material within the interstitium (extravascular/cellular component). Lastly, with the use of a 
number of kinetic models, perfusion parameters can be calculated that quantify perfusion of 
the tissues being studied (Figure 2). 
Two-compartment (or Patlak) analysis sees the vascular compartment and the 
extravascular/cellular compartment as distinct, and quantifies exchange between them 
(Patlak, Blasberg et al. 1983). It provides an estimate of blood volume (BV) within the 
microvasculature and the extraction fraction (EF), also known as the transit constant (Ktrans), 
which is the sum of the flow within the microvasculature and capillary permeability. One-
compartment analysis (or slope method) enables the calculation of perfusion with short-
duration perfusion scans. Perfusion can be calculated as the ratio between the maximum 
slope of the density/time curve of tissue and the peak density reached by the artery selected 
as arterial input. The main advantage of this method is that it allows the calculation of 
perfusion with short-duration scans, in that the density/time curve of tissues reaches its 
maximum slope well before peak density. Short-duration scans are defined to include only 
the first pass of contrast material to avoid blood recirculation from interfering with 
perfusion quantification. In addition, they offer the advantage of being able to be performed 
in conditions of breath-hold in critical regions, thus limiting the possibility of motion 
artifacts. Nonetheless, this kinetic model is by its nature highly sensitive to noise present in 
the acquired images in that images are analyzed in a ‘discontinuous’ manner. Perfusion is, 
in fact, calculated by using only four images: the baseline image, the image obtained at peak 
density of the artery and the two subsequent images that show the greatest differences in 
tissue density. The presence of noise in one of these images can invalidate perfusion 
quantification (Miles and Griffiths 2003). 
Deconvolution-based perfusion analysis applies a mathematical operation of deconvolution 
to compare the density/time curve obtained from the arterial input and from the tissue 
being studied to obtain a theoretical concentration curve (of contrast material in the tissue 
being studied/time), known as the residual impulse response function (IRF) (Bronikowski, 
Dawson et al. 1983). Using the first part of the concentration curve, it can reasonably be 
assumed that the contrast material lies solely within the vascular compartment. In this 
fashion, blood flow (BF), BV and mean transit time (MTT) of blood within the 
microvasculature can be calculated according to the central volume principle, whereby BF = 
BV/MTT. In reality, the contrast material is distributed in the vascular compartment only 
exclusively in the brain parenchyma (where the blood-brain barrier hinders it passage into 
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the extravascular/cellular component), in the testicle and in the retina. In all other organs, 
the contrast material spreads via capillaries into the interstitium. Nonetheless, most contrast 
material diffuses in the interstitium late, and the amount that diffuses during the first pass is 
small. It can therefore be theoretically assumed that the contrast material is only in the 
vascular compartment in all other parenchyma if only the early scans are used for perfusion 
analysis (within the first 45-60s from contrast administration), with a maximum error of 
15%(Purdie, Henderson et al. 2001). Using the last part of the curve and the St. Lawrence 
and Lee adiabatic approximation, passage of contrast material into the interstitium can be 
quantified, with inclusion in the perfusion analysis of the CT scan performed after the first 
phase (therefore known as the interstitial phase). Calculating the permeability surface area-
product (PS) is done according to the following equation: 
 PS = -BF [in(1-E)],  (2) 
where E is the fraction of contrast that leaks into the interstitium from the vascular space 
(EF) (Petralia, Preda et al. 2010). 
A study of 23 patients with colorectal adenocarcinoma found that tumor permeability 
surface-area product and blood volume correlate positively with MVD and may reflect the 
microvascularity of colorectal tumors (Goh, Halligan et al. 2008). A study in 6 patients with 
primary or locally advanced adenocarcinoma of the rectum found that after a single infusion 
of bevacizumab (a VEGF-specific antibody) there was a significant decrease in tumor blood 
flow (40-44%) and blood volume (16-39%), which was accompanied by a significant 
decreased in tumor MVD (Willett, Boucher et al. 2004). A study of 20 patients with 
resectable soft tissue sarcoma treated with neoadjuvant bevacizumab and radiotherapy 
found that the BV, BF and PS decreased by 62-72% (Yoon, Duda et al. 2010). A study in 
patients treated with antiangiogenic therapy for metastatic renal cell carcinoma found that 
the baseline perfusion parameters were higher in responders than in stable patients, and 
that after the first cycle of treatment there was a significant decrease in BF and BV in 
patients receiving antiangiogenic treatment. They concluded that perfusion parameters 
determined with DCE CT could help predict biological response to antiangiogenic drugs 
before beginning therapy and help detect an effect after a single cycle of treatment 
(Fournier, Oudard et al. 2010). A further study in patients with advanced lung 
adenocarcinoma found that BF, BV and permeability values were higher in responding 
patients than in the other patients, with a significant difference at second follow-up for BF, 
BV and permeability (Fraioli, Anzidei et al. 2011). A study in patients with advanced HCC 
treated with bevacizumab initially and then in combination with gemcitabine and 
oxaliplatin, found that there was a significant decrease in BF, BV, and PS and an increase in 
MTT from baseline. They also found that tumors with higher baseline MTT values 
correlated with favorable clinical outcome and had better 6 months progression-free 
survival. The baseline Ktrans of responders was significantly higher than that of 
nonresponders. They concluded that CTP was a more sensitive image biomarker for 
monitoring early antiangiogenic treatment effects as well as in predicting outcome at the 
end of treatment and progression-free survival as compared with RECIST and tumor 
density (Jiang, Kambadakone et al. 2011). Another study found that perfusion MDCT can 
detect focal blood changes even when the tumor is shrinking, possibly indicating early 
reversal of tumor responsiveness to antiangiogenic therapy (Sabir, Schor-Bardach et al. 
2008).  
Molecular Imaging of Tumor Angiogenesis 277 
2.1.3 Dynamic contrast enhanced MRI 
Functional dynamic contrast enhanced MRI (DCE-MRI) relies on the “leaky” nature of 
angiogenic blood vessels associated with malignancy. DCE-MRI is the acquisition of serial 
images before, during, and after the administration of an intravenous contrast agent, which 
produces time series images that enable pixel-by-pixel analysis of contrast kinetics within 
the tumor. PK models provide a means of summarizing contrast enhancement data in terms 
of parameters that relate to underlying vascular anatomy and physiology. Commonly used 
PK models assume that the contrast agent resides in and exchanges between two 
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Fig. 3. Axial MR images from a patient with known metastatic renal cell carcinoma metastatic 
to retroperitoneal lymph nodes. (a) Overlying T1 weighted post contrast images are 
parametric permeability (Ktrans) images derived from bolus injection of gadolinium DTPA 
mathematically derived from analysis schemes as described in section 2.1.3. Please note the 
increased permeability throughout the metastatic lymph node. (b) Parametric images 
representing the apparent diffusion coefficient (ADC) at approximately the same level. Please 
note the homogeneous decreased signal intensity on ADC maps throughout the metastatic 
lymph node. One week following sunitinib therapy, there is dramatically decreased 
permeability within the metastatic lymph node on the superimposed Ktrans map (c), and there 
is heterogeneously increased ADC within the metastatic lymph node (d), both of which 
correspond to physiologic response to therapy. Figure from Rosen et al (unpublished data).  
Molecular Imaging 276 
the extravascular/cellular component), in the testicle and in the retina. In all other organs, 
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The majority of DCE-MRI studies are performed with small molecule, FDA approved 
Gadolinium based contrast agents. By mapping the T1 relaxation constant parametrically, 
and dynamically “following” the distribution of the contrast agent through the tumor 
microvasculature utilizing volumetric T1 weighted imaging, one can model the permeability 
and other parameters that may serve as surrogate biomarkers of angiogenesis (Figure 3 and 
4). To do this, the change in tumor concentration with time is governed by the differential 
equation: 
  dCtumor/dt=KtransCp-kepCtumor  (3) 
where Ctumor and Cp are the concentration of the agent in the EES and plasma space, 
respectively, Ktrans is the transfer constant between the plasma and the EES, and Kep + 
Ktrans/ve, where ve is the fraction of tumor volume occupied by the EES. Thus the 
concentration of contrast agent within the tumor is determined by the blood plasma 
concentration curve and the two parameters, Ktrans, the transfer constant, and the EES 








Fig. 4. (a) Maps of Ktrans, a measure of blood-brain barrier permeability. (b) T1-weighted 
anatomic images after intravenous administration of a contrast agent (gadolinium-DTPA), 
demonstrating a region of bright signal corresponding to the recurrent brain tumor in the 
left frontal lobe. Note the reduction in Ktrans following Gd-DTPA injection and kinetic 
analysis, and the accompanying shrinkage of the mass after injection of Cediranib (VEGF 
inhibitor). Figure from Jennings et. al. (unpublished data).  
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In relating the shape of the enhancement curve obtained from dynamic MRI studies, Ktrans 
controls the height of the Ctumor curve and kep = Ktrans/ve controls the shape of the curve; the 
smaller kep, the more delayed the enhancement. Ktrans is a function of flow (perfusion) and 
permeability; the greater the flow and permeability, the greater the Ktrans (Choyke, Dwyer et 
al. 2003) (Figure 5).  
 
Fig. 5. T1-weighted MRI of mice with pseudocolorized VVF maps superimposed through 
the center of the tumor within the right flank for each treatment arm (rapamycin (a), 
sorafenib (b), and control (c)) at baseline and at the end of therapy. Note the heterogeneity of 
signal intensity and color spread throughout the cohorts at baseline, with marked decrease 
in vascularity in the rapamycin (a) and sorafenib (b) treated animals as compared to control 
(c). Of note, only 3 mice survived all 3 weeks of treatment within the rapamycin treated arm. 
VVF was quantified each week in each cohort and graphed (mean +/- SEM) (d). Note the 
parallel, rapid decrease in VVF in both the sorafenib and rapamycin treated cohorts as 
compared to control with a statistically significant decrease in VVF (p<0.001) at week 3 in 
both cohorts relative to control. Although there was a decrease in mean VVF in control mice, 
there was no statistically significant difference in VVF comparing week 3 to baseline 
measurements in control mice. Figure from Guimaraes et. al. (unpublished data). 
Utilizing this approach in humans suffering from breast cancer, Hulka et al demonstrated a 
sensitivity of 86% and specificity of 93% for the diagnosis of malignancy (Hulka, Smith et al. 
1995; Hulka, Edmister et al. 1997; Tofts, Brix et al. 1999). Knopp et al expanded on these 
results and were able to demonstrate, by correlative analysis with VEGF and CD31 analysis, 
significantly faster enhancement characteristics between histologic subtypes (invasive ductal 
carcinoma, invasive lobular carcinoma and ductal carcinoma in situ)(Knopp, Weiss et al. 
1999). Subsequently, various groups have demonstrated, in vivo, in animal models and 
clinical trials, statistically significant differences in permeability transfer constants following 
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results and were able to demonstrate, by correlative analysis with VEGF and CD31 analysis, 
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1999). Subsequently, various groups have demonstrated, in vivo, in animal models and 
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the administration of angiogenesis inhibitors (Pham, Roberts et al. 1998; Morgan, Thomas et 
al. 2003). Morgan et al demonstrated a rapid reduction in enhancement within 26 to 33 
hours after the first dose of the VEGF inhibitor PTK 787/ZK 222584 in a liver metastasis 
from colorectal carcinoma. This substantial reduction in enhancement is evident across all 
dose groups on day 2, with a mean reduction in permeability transfer constant of 43% 
(Morgan, Thomas et al. 2003). 
Despite these sophisticated models and encouraging results, pharmacokinetics modeling 
has been utilized with varying success to calculate blood volume of fractional plasma 
volume, with reported values demonstrating a correlation coefficient of R^2 0.61, and most 
studies indicate high sensitivity (>90%), but wide variability in specificity, with published 
values as low as 30% (Piccoli 1997). This variability is demonstrated well in a study by Su et 
al who performed DCE MRI on 105 patients with breast cancer and correlated it to VEGF 
serum marker levels as well as microvascular density as assessed post CD31 staining. 
Although patients with increased VEGF demonstrated higher CD31 microvascular densities, 
no significant association between MRI parameters and these other surrogate markers was 
demonstrated (Su, Cheung et al. 2003). In a study of 38 patients with advanced 
hepatocellular carcinoma treated with sunitinib, the investigators found significant 
decreases in Ktrans and Kep to approximately half. Moreover, the extent of decrease in Ktrans in 
patients who experienced partial response/stable disease was significantly greater (two-fold 
on average) compared with patients with progressive disease or who died during the first 
two cycles of therapy (Zhu, Sahani et al. 2009).  
DCE-MRI, in summary, has exciting potential to study the early effects of anti-angiogenic 
therapy in various organ systems.  
2.1.4 Positron emission tomography 
PET has been used in some studies to assess tumor blood flow with H2 15O as a biological 
endpoint of response to antiangiogenic agents (Herbst, Mullani et al. 2002). The principal 
advantage of H2 15O is that it is a ‘freely diffusible’ tracer, meaning that its uptake by the 
tumor is not limited by vascular permeability. H2 15O PET has been used to measure blood 
flow in several tumor types, including breast (Beaney, Lammertsma et al. 1984) and brain 
tumors (Ito, Lammertsma et al. 1982). The first report of the use of PET to measure vascular 
pharmacodynamics in humans was part of a phase 1 dose-escalation study of the tumor 
vascular targeting agent combretastatin A4 phosphate (CA4P) (Anderson, Yap et al. 2003). 
H2 15O PET was used to measure tumor and normal tissue perfusion and blood volume, 
before and after the administration of CA4P. Significant reductions in tumor perfusion were 
measured 30 minutes after administration of CA4P. However, there are potential 
limitations. H2 15O has a short half-life (2 minutes) and therefore studies require an on-site 
cyclotron and a separate tracer synthesis for each injection. In small tumors, partial volume 
effects may be significant if the tumor size is less than twice the resolution of the scanner. 
Second, there is a phenomenon known as ‘spill over’ or ‘spill in’ of counts from surrounding 
structures with high blood flow, such as the heart and the aorta, or within areas of relatively 
high blood flow, such as the liver, therefore limiting the use of this technique in the lung, 
liver and mediastinum.  
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2.2 Steady state blood volume determinations of neovascular density 
2.2.1 Magnetic resonance imaging 
Ultrasmall super paramagnetic iron oxide (a.k.a. magnetic nanoparticle (MNP)) is a steady 
state blood pool agent that creates contrast through magnetic susceptibility variations 
proximal to the vascular network (Enochs, Harsh et al. 1999; Tropres, Grimault et al. 2001; 
Corot, Robert et al. 2006; Persigehl, Bieker et al. 2007), which results in changes in inherent 
and induced transverse relaxation times defined as T2 and T2*, respectively. Accurate 
evaluation of R2* (1/T2*) or R2 (1/T2) necessitate defining two or more points on the natural 
or induced transverse relaxation decay curve. Addition of contrast agent increases R2* 
(1/T2*) thus causing limits on sampling as the T2* is shortened. It can be shown that: 
  R2* or R2  log [Spost/Spre] (4) 
where, Spre and Spost are pre- and post-contrast MRI signal intensity (Brown and Giaccia 
1998). The change in transverse relaxation rate R2 (1/T2) and changes in effective 
transverse relaxation rate R2* (1/T2*) caused by the contrast agent are proportional to 
tumor blood volume (BV) fraction (Belliveau, Rosen et al. 1990; Dennie, Mandeville et al. 
1998; Ostergaard, Smith et al. 1998). Therefore, the capability of MNP to modulate the 
effective transverse relaxation rate, R2*, is exploited where the difference of R2* before and 
after administration of MNP will be useful in determining microvessel density (Hyodo, 
Chandramouli et al. 2009).  
Bremer et al first utilized intravital microscopy to determine whether a prototype magnetic 
nanoparticle (MION) agent truly had intravascular distribution in tumor microenvironment 
(Bremer, Mustafa et al. 2003). For these experiments a green fluorescent protein expressing 
9L tumor model was utilized, in which tumor microvasculature is clearly outlined against 
fluorescent tumor cells, even at very high spatial resolution, which demonstrated that 
MION selectively enhanced the vascularity without any significant leakage into tumor 
interstitium during time of observation (30 minutes). They also found that steady state 
measures of vascular volume fraction (VVF) with MRI allow a volumetric, in vivo, non-
invasive assay of microvascular density in experimental tumor models. 
Pancreatic adenocarcinoma xenograft lines were subcutaneously implanted into nude mice, 
which were then therapies targeted to 3 loci of the sonic hedgehog signaling pathway. MRI 
imaging was performed 1 week after therapy, pre and post injection of MION-47. Following 
treatment, tumors showed a significant decrease in VVF compared to controls (Guimaraes, 
Rakhlin et al. 2008). A study on fibrosarcoma-bearing nude mice which were injection with a 
thrombogenic vascular targeting agent (VTA) found that the R2* values were significantly 
reduced shortly after treatment initiation and concluded that USPIO-enhanced MR imaging 
enable early monitoring of antiangiogenic treatment of tumors (Persigehl, Bieker et al. 2007).  
A recently published study on rhabdomyosarcoma-bearing mice treated with bevacizumab 
or saline as control, found that multiecho R2* MR relaxometry allowed an early and 
quantitative assessment of tumor vascularization changes in response to an antiangiogenic 
treatment (Ring, Persigehl et al. 2011). Another study on renal cell carcinoma-bearing mice 
treated with rapamycin (mTOR inhibitor), sorafenib (VEGF inhibitor) or saline control, VVF 
correlated with MVD and that the VVF in all treatment arms differed from control and 
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declined weekly with treatment. They also reported that VVF changes with rapamycin were 
similar to high-dose sorafenib (Guimaraes, Ross et al. 2011). 
Although not FDA approved, MNP enhanced MRI measures allow for interrogation of 
altered tumor microvascular morphology, and may serve as a robust means of evaluating 
the microstructural microvascular changes associated with anti-angiogenic therapy in 
humans.  
2.3 Specific molecular markers of angiogenesis 
Advances in knowledge of tumor angiogenesis have resulted in the identification of several 
molecules in tumor angiogenic signaling. These molecules have been exploited for their use 
as targets for molecular imaging and quantification of tumor angiogenesis. Furthermore, 
discovery of these molecules has led to realization of the concept that tumor vessels can be 
selectively targeted for therapy. Non-invasive molecular imaging of tumor angiogenesis can 
allow for much easier diagnosis and better prognosis of cancer, as well as more accurate 
treatment monitoring, which will eventually lead to personalized molecular medicine.  
2.3.1 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is one of the key factors regulating angiogenesis. 
Most of the vasculogenic and angiogenic effects of VEGF are mediated through two 
endothelium-specific receptor tyrosine kinases, VEGF receptor 1 (VEGFR-1) and VEGF 
receptor 2 (VEGFR-2)(Millauer, Wizigmann-Voos et al. 1993). VEGFR-1 is critical for 
physiologic and developmental angiogenesis, and VEGFR-2 is the major mediator of the 
mitogenic, angiogenic, and permeability-enhancing effects of VEGF (Ferrara 2004). In the 
imaging studies reported to date, however, specificity for ether VEGFR-1 or VEGFR-2 has 
rarely been achieved, because most of the tracers are based on VEGFA isoforms, which bind 
to both VEGFRs. Because of a high level of VEGFR-1 expression, rodent kidneys can take up 
a significant amount of a VEGFA-based tracer, a fact that often makes the kidneys the dose-
limiting organ. Because VEGFR-2 is generally accepted to be more functionally important 
than VEGFR-1 in cancer progression, this limits the use of current techniques. 
Recently, in vivo CE US imaging of VEGF/VEGFR expression has been reported. In 2 
murine tumor models, microbubbles conjugated to anti-VEGFR-2 monoclonal antibodies 
were used to image VEGFR-2 expression (Willmann, Paulmurugan et al. 2008). The targeted 
microbubbles produced a significantly higher average signal intensity than control 
microbubbles, and the signal intensity was significantly lower when anti-VEGFR-2 
antibodies (blocking antibodies) were used, demonstrating target specificity. 
99mTc-labelled human VEGF121 (one of the homodimeric isoforms of VEGFRA) has been used 
as a molecular imaging marker of VEGFR expression in an orthotopic mouse model of 
mammary adenocarcinoma, and for the imaging of tumor vasculature before and after 
tumoricidal cyclophosphamide treatment (Blankenberg, Backer et al. 2006). [123I]VEGF165 has 
also been reported as a potential tumor marker (Cornelissen, Oltenfreiter et al. 2005), but 
despite the high receptor affinity of this tracer, biodistribution in melanoma tumor-bearing 
mice indicated poor tumor-to-background ratios, most likely due to the low metabolic 
stability (deiodination) of the compound. Nonetheless, biodistribution, safety, and absorbed 
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dose of [123I]VEGF165 was studied in patients with pancreatic carcinoma (Li, Peck-
Radosavljevic et al. 2004). Following IV administration, sequential images were recorded 
during the initial 30 minutes after injection. Although a majority of primary pancreatic 
tumors and their metastases were visualized by the [123I]VEGF165 scan, the organ with the 
highest absorbed dose was the thyroid, indicating severe deiodination of the probe. 
To target the VEGFR-2, Backer et al (Backer, Patel et al. 2006) used single chain VEGF 
(scVEGF) with an N-terminal cysteine-containing tag (Cys-tag), which can be used for site 
specific attachment of various agents (Backer, Levashova et al. 2008). The scVEGF-based 
family of probes has been validated to target the VEGF receptor in vitro and in vivo tumor 
angiogenesis (Blankenberg, Backer et al. 2006; Levashova, Backer et al. 2008) 
64Cu-labelled VEGF121 has been used for PET imaging of tumor angiogenesis and VEGFR 
expression (Cai, Chen et al. 2006). DOTA-VEGF121 (where DOTA denotes 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) exhibits nanomolar receptor affinity in vitro. 
In an animal model, microPET imaging revealed rapid, specific, and prominent uptake of 
[64Cu]DOTA-VEGF121 in highly vascularized small xenografts (high VEGFR-2 expression) 
but significantly lower and sporadic uptake in large tumors (low VEGFR-2 expression). 
Substantial tracer uptake in the kidneys was also observed, most likely due to the high 
VEGFR-1 expression in this organ. 
A VEGFR-2-specific PET tracer based on mutant VEGF121 has been recently developed 
(Wang, Cai et al. 2007). The D63AE64AE67A mutant of VEGF121 (VEGFDEE), compared with 
VEGF121 had an affinity for binding to VEGFR-1 that was 20-fold lower, without a significant 
reduction in VEGFR-2-binding affinity. 
HuMV833, a humanized mouse monoclonal anti-VEGF antibody was labeled with 124I for 
PET imaging of solid tumors in phase 1 trial cancer patients (Jayson, Zweit et al. 2002). 
Antibody distribution and clearance were markedly heterogeneous between and within 
patients and between and within individual tumors, suggesting that dose escalation design 
of phase 1 studies with antiangiogenic antibodies such as HuMV833 would be problematic.  
2.3.2 Integrins 
Integrins are a family of cell adhesion molecules consisting of two noncovalently bound 
transmembrane subunits ( and ) that pair to create heterodimers with distinct adhesive 
capabilities. Integrin 3 mediates the migration of endothelial cells through the basement 
membrane during blood-vessel formation (Josephs, Spicer et al. 2009). Imaging of integrin 
3 expression is promising for the assessment of angiogenesis, as integrin 3 is 
significantly up-regulated on endothelium during angiogenesis, but not an quiescent 
endothelium (Brooks, Clark et al. 1994). In addition, in healthy tissue, expression of integrin 
3 is highly restricted with significant amounts only observed in osteoclasts (van der Flier 
and Sonnenberg 2001). Integrin 3, which mediates the migration of endothelial cells 
through the basement membrane during blood-vessel formation, binds to peptides 
containing the amino-acid sequence arginine-glycine-aspartic acid (RGD) within the 
interstitial matrix (Haubner 2006). By labeling these peptides with 125I, 111In, 64Cu, 99mTc, 18F 
or fluorescence dyes, specific binding of imaging agents to integrin 3 in tumors has been 
demonstrated (Haubner, Wester et al. 1999; van Hagen, Breeman et al. 2000; Haubner, 
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molecules in tumor angiogenic signaling. These molecules have been exploited for their use 
as targets for molecular imaging and quantification of tumor angiogenesis. Furthermore, 
discovery of these molecules has led to realization of the concept that tumor vessels can be 
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Most of the vasculogenic and angiogenic effects of VEGF are mediated through two 
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a significant amount of a VEGFA-based tracer, a fact that often makes the kidneys the dose-
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99mTc-labelled human VEGF121 (one of the homodimeric isoforms of VEGFRA) has been used 
as a molecular imaging marker of VEGFR expression in an orthotopic mouse model of 
mammary adenocarcinoma, and for the imaging of tumor vasculature before and after 
tumoricidal cyclophosphamide treatment (Blankenberg, Backer et al. 2006). [123I]VEGF165 has 
also been reported as a potential tumor marker (Cornelissen, Oltenfreiter et al. 2005), but 
despite the high receptor affinity of this tracer, biodistribution in melanoma tumor-bearing 
mice indicated poor tumor-to-background ratios, most likely due to the low metabolic 
stability (deiodination) of the compound. Nonetheless, biodistribution, safety, and absorbed 
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(scVEGF) with an N-terminal cysteine-containing tag (Cys-tag), which can be used for site 
specific attachment of various agents (Backer, Levashova et al. 2008). The scVEGF-based 
family of probes has been validated to target the VEGF receptor in vitro and in vivo tumor 
angiogenesis (Blankenberg, Backer et al. 2006; Levashova, Backer et al. 2008) 
64Cu-labelled VEGF121 has been used for PET imaging of tumor angiogenesis and VEGFR 
expression (Cai, Chen et al. 2006). DOTA-VEGF121 (where DOTA denotes 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) exhibits nanomolar receptor affinity in vitro. 
In an animal model, microPET imaging revealed rapid, specific, and prominent uptake of 
[64Cu]DOTA-VEGF121 in highly vascularized small xenografts (high VEGFR-2 expression) 
but significantly lower and sporadic uptake in large tumors (low VEGFR-2 expression). 
Substantial tracer uptake in the kidneys was also observed, most likely due to the high 
VEGFR-1 expression in this organ. 
A VEGFR-2-specific PET tracer based on mutant VEGF121 has been recently developed 
(Wang, Cai et al. 2007). The D63AE64AE67A mutant of VEGF121 (VEGFDEE), compared with 
VEGF121 had an affinity for binding to VEGFR-1 that was 20-fold lower, without a significant 
reduction in VEGFR-2-binding affinity. 
HuMV833, a humanized mouse monoclonal anti-VEGF antibody was labeled with 124I for 
PET imaging of solid tumors in phase 1 trial cancer patients (Jayson, Zweit et al. 2002). 
Antibody distribution and clearance were markedly heterogeneous between and within 
patients and between and within individual tumors, suggesting that dose escalation design 
of phase 1 studies with antiangiogenic antibodies such as HuMV833 would be problematic.  
2.3.2 Integrins 
Integrins are a family of cell adhesion molecules consisting of two noncovalently bound 
transmembrane subunits ( and ) that pair to create heterodimers with distinct adhesive 
capabilities. Integrin 3 mediates the migration of endothelial cells through the basement 
membrane during blood-vessel formation (Josephs, Spicer et al. 2009). Imaging of integrin 
3 expression is promising for the assessment of angiogenesis, as integrin 3 is 
significantly up-regulated on endothelium during angiogenesis, but not an quiescent 
endothelium (Brooks, Clark et al. 1994). In addition, in healthy tissue, expression of integrin 
3 is highly restricted with significant amounts only observed in osteoclasts (van der Flier 
and Sonnenberg 2001). Integrin 3, which mediates the migration of endothelial cells 
through the basement membrane during blood-vessel formation, binds to peptides 
containing the amino-acid sequence arginine-glycine-aspartic acid (RGD) within the 
interstitial matrix (Haubner 2006). By labeling these peptides with 125I, 111In, 64Cu, 99mTc, 18F 
or fluorescence dyes, specific binding of imaging agents to integrin 3 in tumors has been 
demonstrated (Haubner, Wester et al. 1999; van Hagen, Breeman et al. 2000; Haubner, 
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Wester et al. 2001; Janssen, Oyen et al. 2002; Chen, Conti et al. 2004; Beer, Lorenzen et al. 
2008). 
Targeted ultrasound imaging of integrin 3 during tumor angiogenesis has been reported 
(Ellegala, Leong-Poi et al. 2003). In a rat model of human glioblastoma, CEU was performed 
with microbubbles coated with echistatin, an RGD-containing disintegrin, which binds 
specifically to integrin 3. The CEU signal was found to be highest at the periphery of 
tumors, where integrin expression was most prominent as indicated by 
immunohistochemistry, and correlated well with tumor microvascular blood volume.  
Gd3+-containing paramagnetic liposomes (300-350nm in diameter) have been used for MRI 
of integrin 3 expression (Sipkins, Cheresh et al. 1998). In that study, mMRI of squamous 
cell carcinomas in a rabbit model was achieved with LM609, a mouse antihuman integrin 
3 monoclonal antibody, as the targeting ligand. Peptidomimetic integrin 3 antagonist-
conjugated magnetic magnetic nanoparticles were tested in a Vx-2 squamous cell carcinoma 
model with the common clinical field strength of 1.5 T(Winter, Caruthers et al. 2003). The 
targeted nanoparticles increased the MR signal dramatically in the periphery of the tumor at 
2 hours after injection. Despite their relatively large size (~270nm in diameter), these 
nanoparticles penetrated into the leaky tumor neovasculature but did not migrate into the 
interstitum in appreciable amounts. In a later report, athymic nude mice bearing human 
melanoma tumors were successfully imaged with systemically injected integrin 3-
targeted paramagnetic nanoparticles (Schmieder, Winter et al. 2005). Very small regions 
(about 30mm3) of angiogenesis associated with nascent melanoma tumors were visualized 
by this technique, which may enable phenotyping and staging of early melanomas in 
clinical settings. 
Integrin 3-targeted ultrasmall SPIO nanoparticles were used with a 1.5T RI scanner for 
the noninvasive differenciation of tumors with large and small fractions of integrin 3–
positive tumor vessels (Zhang, Jugold et al. 2007). After injection of RGD peptide-
conjugated small SPIO nanoparticles, T2*-weighted MR images revealed the heterogeneous 
distribution of integrin –positive tumor vessels, as evidenced by an irregular signal intensity 
decrease. In contrast, the signal intensity decreased homogeneously in the control tumor, 
with predominantly small and uniformly distributed vessels. 
In recent years, many fluorescently labeled cyclic RGD peptides have been developed for 
near infrared fluorescence imaging like RGD-Cy7, RGD-Cy5.5, RGD-QD705 (Chen, Conti et 
al. 2004; Cai, Shin et al. 2006; Wu, Cai et al. 2006) and cyclic RGD coupled to IRDye 800CW-
labeled peptide which is even more shifted towards the infrared parts of the spectrum 
resulting in ideal fluorescent characteristics for in vivo use (Adams, Ke et al. 2007). Mulder 
et al (Mulder, Koole et al. 2006; Mulder, Castermans et al. 2009) recently described 
paramagnetic lipid-encapsulated quantum dots with RGD presented at the outside and a 
green fluorescent quantum dot at the inside of the micellar shell. These targeted particles are 
both suitable for fluorescence imaging as well as MRI, thus providing unique opportunities 
for the use of multimodality molecular imaging. 
Several groups have improved 3 integrin specificity, binding affinity, and possible 
targeted delivery of therapeutics, by coupling multiple RGD motifs on a backbone molecule 
(Kok, Schraa et al. 2002; Cheng, Wu et al. 2005; Mulder, Koole et al. 2006; Jin, Josserand et al. 
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2007; Mulder, Castermans et al. 2009). Although, many types of tumor cells are positive for 
3 integrin, RGD-modified proteins mainly localize at the tumor endothelium and not in 
the tumor itself (Schraa, Kok et al. 2002). 
The commercially available near infrared fluorescent (NIRF) probe IntegriSense (Visen 
Medical) consists of a small molecule nonpeptide 3 antangonist fused to the VivoTg-S680 
near infrared fluorophore. IntegriSense has a much higher specificity for 3 integrin 
compared to RGD-based probes. Unlike RGD-based probes, extravasation of IntegriSense 
does occur and the probe localizes at both the surface of 3 integrin positive endothelial 
cells and the surface 3 integrin positive tumor cells. Furthermore, IntegriSense is 
internalized by the 3 integrin positive tumor cells leading to a slower clearance of the 
probe from tumors compared to the surrounding tissues. A drawback of the slower 
clearance from the tumor is the practical upper limit on the possible frequency of repeated 
measurements (Kossodo, Pickarski et al. 2010). 
A dimeric RGD peptide E[c(RGDyK)]2 (abbreviated as FRGD2) has been labeled with 18F. A 
high accumulation of 18F-FRGD2 in integrin 3 –rich tumors was demonstrated with a 
high tumor/background ratio at late time points of imaging (Zhang, Xiong et al. 2006). A 
glycopeptides based on c(RGDyK) was later labeled with 18F and the resulting 18F-galacto-
RGD was found to be safely administered to patients and allowed detection of integrin-
positive tumors (Haubner, Weber et al. 2005). Despite the successful translation of 18F-
galacto-RGD into clinical trials however, several key issues remain to be resolved, such as 
tumor-targeting efficacy, pharmacokinetics, and the ability to quantify integrin 3 density 
in vivo. Indeed, other promising multimetric RDG peptides are being investigated and may 
give better localization than galacto-RGD (Cai, Niu et al. 2008) 
Etaracizumab, a humanized murine monoclonal antibody against human integrin 3 has 
been conjugated with a chelating agent DOTA and labeled with 64Cu. The resulting 
[64Cu]DOTA-etaracizumab correlated well with integrin 3 in tumor xenografts via PET 
imaging (Cai, Wu et al. 2006). MicroPET studies revealed avid [64Cu]DOTA-etaracizumab 
uptake in integrin 3 -positive tumors. The receptor specificity of [64Cu]DOTA-
etaracizumab was confirmed by effective blocking of tumor uptake with co-administration 
of non-radioactive etaracizumab. 
A nanoparticle-based probe has been used for both MRI and optical imaging of integrin 
3. MRI-detectable and fluorescent liposomes carrying RGD peptides were evaluated for 
in vivo tumor imaging (Mulder, Strijkers et al. 2005). Both RGD-conjugated liposomes and 
RAD ( a control peptide that does not bind to integrin 3)-conjugated liposomes provided 
enhanced T1-weighted MR contrast. Ex vivo fluorescence microscopy revealed that RGD-
conjugated liposomes were specifically associated with the activated tumor endothelium, 
whereas RAD-conjugated liposomes were located in the extravascular compartment. 
A quantum dot (QD)-based probe for NIRF imaging and PET of integrin 3 has been 
developed (Cai, Chen et al. 2007). QD surface modification with RGD peptides allowed for 
integrin 3 targeting, and DTA conjugation enabled PET after 64Cu labeling. It was found 
that the majority of the probe in the tumor was within the vasculature, as evidenced by 
excellent overlay of the QD fluorescence signal and vasculature integrin 3 staining. This 
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immunohistochemistry, and correlated well with tumor microvascular blood volume.  
Gd3+-containing paramagnetic liposomes (300-350nm in diameter) have been used for MRI 
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targeted nanoparticles increased the MR signal dramatically in the periphery of the tumor at 
2 hours after injection. Despite their relatively large size (~270nm in diameter), these 
nanoparticles penetrated into the leaky tumor neovasculature but did not migrate into the 
interstitum in appreciable amounts. In a later report, athymic nude mice bearing human 
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conjugated small SPIO nanoparticles, T2*-weighted MR images revealed the heterogeneous 
distribution of integrin –positive tumor vessels, as evidenced by an irregular signal intensity 
decrease. In contrast, the signal intensity decreased homogeneously in the control tumor, 
with predominantly small and uniformly distributed vessels. 
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al. 2004; Cai, Shin et al. 2006; Wu, Cai et al. 2006) and cyclic RGD coupled to IRDye 800CW-
labeled peptide which is even more shifted towards the infrared parts of the spectrum 
resulting in ideal fluorescent characteristics for in vivo use (Adams, Ke et al. 2007). Mulder 
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paramagnetic lipid-encapsulated quantum dots with RGD presented at the outside and a 
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Medical) consists of a small molecule nonpeptide 3 antangonist fused to the VivoTg-S680 
near infrared fluorophore. IntegriSense has a much higher specificity for 3 integrin 
compared to RGD-based probes. Unlike RGD-based probes, extravasation of IntegriSense 
does occur and the probe localizes at both the surface of 3 integrin positive endothelial 
cells and the surface 3 integrin positive tumor cells. Furthermore, IntegriSense is 
internalized by the 3 integrin positive tumor cells leading to a slower clearance of the 
probe from tumors compared to the surrounding tissues. A drawback of the slower 
clearance from the tumor is the practical upper limit on the possible frequency of repeated 
measurements (Kossodo, Pickarski et al. 2010). 
A dimeric RGD peptide E[c(RGDyK)]2 (abbreviated as FRGD2) has been labeled with 18F. A 
high accumulation of 18F-FRGD2 in integrin 3 –rich tumors was demonstrated with a 
high tumor/background ratio at late time points of imaging (Zhang, Xiong et al. 2006). A 
glycopeptides based on c(RGDyK) was later labeled with 18F and the resulting 18F-galacto-
RGD was found to be safely administered to patients and allowed detection of integrin-
positive tumors (Haubner, Weber et al. 2005). Despite the successful translation of 18F-
galacto-RGD into clinical trials however, several key issues remain to be resolved, such as 
tumor-targeting efficacy, pharmacokinetics, and the ability to quantify integrin 3 density 
in vivo. Indeed, other promising multimetric RDG peptides are being investigated and may 
give better localization than galacto-RGD (Cai, Niu et al. 2008) 
Etaracizumab, a humanized murine monoclonal antibody against human integrin 3 has 
been conjugated with a chelating agent DOTA and labeled with 64Cu. The resulting 
[64Cu]DOTA-etaracizumab correlated well with integrin 3 in tumor xenografts via PET 
imaging (Cai, Wu et al. 2006). MicroPET studies revealed avid [64Cu]DOTA-etaracizumab 
uptake in integrin 3 -positive tumors. The receptor specificity of [64Cu]DOTA-
etaracizumab was confirmed by effective blocking of tumor uptake with co-administration 
of non-radioactive etaracizumab. 
A nanoparticle-based probe has been used for both MRI and optical imaging of integrin 
3. MRI-detectable and fluorescent liposomes carrying RGD peptides were evaluated for 
in vivo tumor imaging (Mulder, Strijkers et al. 2005). Both RGD-conjugated liposomes and 
RAD ( a control peptide that does not bind to integrin 3)-conjugated liposomes provided 
enhanced T1-weighted MR contrast. Ex vivo fluorescence microscopy revealed that RGD-
conjugated liposomes were specifically associated with the activated tumor endothelium, 
whereas RAD-conjugated liposomes were located in the extravascular compartment. 
A quantum dot (QD)-based probe for NIRF imaging and PET of integrin 3 has been 
developed (Cai, Chen et al. 2007). QD surface modification with RGD peptides allowed for 
integrin 3 targeting, and DTA conjugation enabled PET after 64Cu labeling. It was found 
that the majority of the probe in the tumor was within the vasculature, as evidenced by 
excellent overlay of the QD fluorescence signal and vasculature integrin 3 staining. This 
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dual-modality (PET/NIRF imaging) probe can confer sufficient tumor contrast at a 
concentration much lower than that required for in vivo NIRF imaging, significantly 
reduces the potential toxicity of cadmium-based QDs, and may hasten the future translation 
of QD-based imaging agents to clinical and biomedical applications. 
2.3.3 Transforming growth factor 
Transforming growth factor  (TGF-) signaling plays a role in several biological processes, 
including embryonic development, carcinogenesis, wound healing, and angiogenesis 
(Bernabeu, Lopez-Novoa et al. 2009). In normal cells, the TGF- pathway restricts cell 
growth, differentiation and cell death. In contrast, in malignant cells, various components of 
the TGF- signaling pathway become mutated thereby exploiting the ability of TGF- to 
modulate growth promoting processes, including cell invasion and angiogenesis. TGF- 
signaling is mediated by TGF- binding to TGF- receptors, of which, there are three classes: 
Type I and II are heterodimeric receptor whereas type III are homodimeric receptors . 
CD105, also known as endoglin, is a TGF- type III receptor that has been shown to 
participate in signaling angiogenesis. Endoglin is predominantly expressed on proliferating 
endothelial cells (Fonsatti, Altomonte et al. 2003), and inhibition of its expression has been 
shown to restore the growth suppressing signals of the TGF- signaling pathway (Ma, 
Labinaz et al. 2000). Thus, endoglin is an attractive molecular target of angiogenesis since it 
is over-expressed on tumor-associated endothelium (Bernabeu, Lopez-Novoa et al. 2009). 
Avidin (Av) was incorporated into the shell of perfluorocarbon-exposed sonicated dextrose 
albumin micobubbles (Av-MBs) to anchor biotinylated monoclonal antibodies (mAbs) 
(Korpanty, Grayburn et al. 2005). A rat anti-mouse CD105 mAb (MJ7/18) and an isotype-
matched control mAb were investigated for biotinylation, microbubbles incorporation, and 
cellular studies. It was found that MJ7/18-conjugated microbubbles bound specifically to 
endothelial cells but not fibroblasts, while the control mAb-conjugated Av-MBs did not 
exhibit CD105-specific targeting. After demonstrating the proof-of-principle, a follow-up 
study was carried out to follow the vascular response of therapy in mouse models of 
subcutaneous and orthotopic pancreatic adenocarcinoma (Korpanty, Carbon et al. 2007). For 
comprehensive investigation of angiogenesis in tumor-bearing mice treated with anti-VEGF 
mAbs and/or gemcitabine (a nucleoside analog with known activity against pancreatic 
adenocarcinoma), the localization of microbubbles targeting CD105, VEGFR-2, or VEGF-
activated blood vessels 9the VEGF-VEGFR complex) was monitored by ultrasound (Di 
Marco, Di Cicilia et al. 2010). In the subcutaneous model, receptor-targeted microbubbles 
gave significantly better enhancement of tumor vasculature than the non-targeted or control 
mAbs-conjugated microbubbles. In addition, video intensity from targeted microbubbles 
correlated with the level of target expression (CD105, VEGFR-2, or the VEGF-VEGFR 
complex), as well as with MVD in tumors under either anti-angiogenesis or cytotoxic 
therapy. 
One study investigated the applicability of a human umbilical vein endothelial cell 
(HUVEC)-based in vitro model to mimic physiological and angiogenic vasculature (Vag, 
Schramm et al. 2009). High fluorescence signal was observed in proliferating HUVECs due 
to CD105 expression. 
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Molecular MRI of CD105 expression in tumor-bearing rats was achieved with Gd-DTPA-
containing stabilized liposomes (Gd-SLs) (Zhang, Feng et al. 2009). A series of targeted and 
non-targeted MRI contrast agents were compared in glioma-bearing rats: Gd-DTPA, Gd-
SLs, Gd-SLs conjugated to anti-CD105 mAbs (CD105-Gd-SLs), and Gd-SLs conjugated to 
control mAbs (IgG-Gd-SLs). Serial T1-weighted MRI before and after contrast agent 
administration revealed that the area with enhanced MRI contrast was restricted for CD105-
Gd-SLs but not for the other three groups. In addition, the degree of contrast enhancement 
over time also varied between different groups. For example, Gd-DTPA gave an early 
contrast enhancement which peaked at 30 minutes and declined to baseline values at 60 
minutes, while the signal intensity for CD105-Gd-SLs continued to increase over a period of 
120 minutes. The signal intensity of IgG-Gd-SLs and Gd-SLs both peaked at 60 minutes 
followed by a decline, yet the rate of decrease was quite different. Ex vivo histology further 
revealed that the enhancement in the CD105-Gd-SLs group resulted mainly from new 
microvessels. However, both mature microvessels and new microvasculature were 
responsible for contrast enhancement in the other three groups.  
A study investigated an 111In-labeled anti-CD105 mAb (MJ7/18) and compared its 
neovascular binding, tumor accumulation, and in vivo behavior in an isotype-matched 
control mAb (Bredlow, Lewin et al 2000) In a B16 melanoma model, the tumors in animals 
receiving 111In-labelled MJ7/18 were more easily identified than animals receiving the 
radiolabeled control mAb. However, the tumor contrast was only modest. Ex vivo 
autoradiography and histology experiments of the tumor sections corroborated the different 
patterns of in vivo tumoral accumulation for the two antibodies. MJ7/18 exhibited intense 
activity in the peripheral region of the tumor, where the highest concentration of vessels 
was found, and much lower activity in the tumor center. On the other hand, little 
accumulation of activity could be found in tumors of mice that had been injected with 111In-
labeled control mAb.  
Another study tested a 125I-labeled anti-CD105 mAb (MAEND3) in a canine mammary 
carcinoma model (Fonsatti, Jekunen et al. 2000). After demonstrating differential expression 
of CD105 on human breast cancer and endothelial cells, two dogs with spontaneous 
mammary tumors were intravenously injected with 125I-laveled MAEND3 and imaged eight 
hours later. Rapid and intense uptake of the radiolabeled mAb with excellent tumor-to-
background ratio was observed in the tumor areas of both dogs, which were confirmed as 
ductal mammary adenocarcinoma after surgical excision ten days later. Another study also 
explored the use of 125I-labeled anti-CD105 mAb for radioimmunotherapy applications in 
mouse tumor models (Tabata, Kondo et al. 1999). Significant growth suppression of the 
tumors was observed while a 125I-labeled control mAb did not show any significant anti-
tumor efficacy.  
A 99mTc-labelled anti-CD105 mAb (E9) was investigated in freshly excised kidneys from 
renal carcinoma patients (Costello, Li et al. 2004). After perfusion of 99mTc-E9 through the 
renal artery, immunoscintigraphy revealed the presence of well-defined radioactive hot 
spots, which matched the positions of the tumors as identified by pre-surgery MRI and 
subsequent histology. Gamma-counting revealed that the median values of radioactivity 
uptake per gram of wet weight were > 10 fold higher in the tumors than in normal kidney 
tissues. Not only was CD105 specificity of the tracer confirmed by blocking studies, 
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dual-modality (PET/NIRF imaging) probe can confer sufficient tumor contrast at a 
concentration much lower than that required for in vivo NIRF imaging, significantly 
reduces the potential toxicity of cadmium-based QDs, and may hasten the future translation 
of QD-based imaging agents to clinical and biomedical applications. 
2.3.3 Transforming growth factor 
Transforming growth factor  (TGF-) signaling plays a role in several biological processes, 
including embryonic development, carcinogenesis, wound healing, and angiogenesis 
(Bernabeu, Lopez-Novoa et al. 2009). In normal cells, the TGF- pathway restricts cell 
growth, differentiation and cell death. In contrast, in malignant cells, various components of 
the TGF- signaling pathway become mutated thereby exploiting the ability of TGF- to 
modulate growth promoting processes, including cell invasion and angiogenesis. TGF- 
signaling is mediated by TGF- binding to TGF- receptors, of which, there are three classes: 
Type I and II are heterodimeric receptor whereas type III are homodimeric receptors . 
CD105, also known as endoglin, is a TGF- type III receptor that has been shown to 
participate in signaling angiogenesis. Endoglin is predominantly expressed on proliferating 
endothelial cells (Fonsatti, Altomonte et al. 2003), and inhibition of its expression has been 
shown to restore the growth suppressing signals of the TGF- signaling pathway (Ma, 
Labinaz et al. 2000). Thus, endoglin is an attractive molecular target of angiogenesis since it 
is over-expressed on tumor-associated endothelium (Bernabeu, Lopez-Novoa et al. 2009). 
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(HUVEC)-based in vitro model to mimic physiological and angiogenic vasculature (Vag, 
Schramm et al. 2009). High fluorescence signal was observed in proliferating HUVECs due 
to CD105 expression. 
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Molecular MRI of CD105 expression in tumor-bearing rats was achieved with Gd-DTPA-
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microvessels. However, both mature microvessels and new microvasculature were 
responsible for contrast enhancement in the other three groups.  
A study investigated an 111In-labeled anti-CD105 mAb (MJ7/18) and compared its 
neovascular binding, tumor accumulation, and in vivo behavior in an isotype-matched 
control mAb (Bredlow, Lewin et al 2000) In a B16 melanoma model, the tumors in animals 
receiving 111In-labelled MJ7/18 were more easily identified than animals receiving the 
radiolabeled control mAb. However, the tumor contrast was only modest. Ex vivo 
autoradiography and histology experiments of the tumor sections corroborated the different 
patterns of in vivo tumoral accumulation for the two antibodies. MJ7/18 exhibited intense 
activity in the peripheral region of the tumor, where the highest concentration of vessels 
was found, and much lower activity in the tumor center. On the other hand, little 
accumulation of activity could be found in tumors of mice that had been injected with 111In-
labeled control mAb.  
Another study tested a 125I-labeled anti-CD105 mAb (MAEND3) in a canine mammary 
carcinoma model (Fonsatti, Jekunen et al. 2000). After demonstrating differential expression 
of CD105 on human breast cancer and endothelial cells, two dogs with spontaneous 
mammary tumors were intravenously injected with 125I-laveled MAEND3 and imaged eight 
hours later. Rapid and intense uptake of the radiolabeled mAb with excellent tumor-to-
background ratio was observed in the tumor areas of both dogs, which were confirmed as 
ductal mammary adenocarcinoma after surgical excision ten days later. Another study also 
explored the use of 125I-labeled anti-CD105 mAb for radioimmunotherapy applications in 
mouse tumor models (Tabata, Kondo et al. 1999). Significant growth suppression of the 
tumors was observed while a 125I-labeled control mAb did not show any significant anti-
tumor efficacy.  
A 99mTc-labelled anti-CD105 mAb (E9) was investigated in freshly excised kidneys from 
renal carcinoma patients (Costello, Li et al. 2004). After perfusion of 99mTc-E9 through the 
renal artery, immunoscintigraphy revealed the presence of well-defined radioactive hot 
spots, which matched the positions of the tumors as identified by pre-surgery MRI and 
subsequent histology. Gamma-counting revealed that the median values of radioactivity 
uptake per gram of wet weight were > 10 fold higher in the tumors than in normal kidney 
tissues. Not only was CD105 specificity of the tracer confirmed by blocking studies, 
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immunoscintigraphy with 99mTc-E9 was also able to identify tumors that were not detected 
during pre-surgery MRI. 
2.3.4 Matrix metalloprotienases 
Expression of matrix metalloproteinases (MMPs) is associated with the removal of the 
extracellular matrix (ECM) barrier to allow cancer cells ad endothelial cells to invade the 
basement membrane. A number of MMPs are also specifically involved in angiogenesis, 
including MMPs 1, 2, 3, 9, and 14 (Stollman, Ruers et al. 2009).  
One approach for monitoring MMP activity in tumor-bearing animal models is the use of 
‘smart’ fluorescence probes that are bound to a synthetic graft copolymer consisting of a 
cleavable backbone that can act as an MMP substrate. When placed in close proximity, these 
polymeric fluorochromes quench each other and are not detectable. On enzymatic cleavage 
of the backbone by MMPs, the fluorochromes are spatially dissociated and begin to 
fluoresce (Bremer, Bredow et al. 2001) 
3. Clinical relevance of the finding 
The development of anti-angiogenic agents has been rapid to date. Although demonstrating 
provocative physiologic effects, the results to date have not demonstrated any significant 
improvements in patient outcome. This may be a result of various factors including a better 
understanding of the timing associated with the greatest changes occurring physiologically 
or morphologically within the microvasculature, a better understanding of whether the 
hypothesis of vascular normalization (Jain 2001; Jain 2005) (Goel, Duda et al. 2011) has 
bearing and may be a window into the introduction of other targeted cytotoxic agents, and 
improved, translatable targeted molecular imaging approaches to interrogating the tumor 
microenvironment. As these methods evolve in parallel, one may see come to fruition a true 
clinical benefit to the outstanding insight proposed from Dr. Folkman’s (Folkman 1971) 
seminal article many years ago.  
4. View to the future 
In order to bridge this gap in understanding the effects of angiogenesis, significant 
improvements and developments will have to occur within the following areas: 1) 
improvements in quality assurance and quality control associated with the physiologic 
measurements on interrogate the permeability, blood flow, and blood volume values that 
MRI, CT and PET; 2) improvements in targeted, molecular imaging approaches that may 
reflect the molecular changes that are occurring following administration of extant and 
novel anti-angiogenic or vascular disrupting agents, and lastly; 3) utilizing both of these 
approaches to better investigate and have a more comprehensive understanding of the 
validity and regulation of vascular normalization as a hypothesis for improved 
chemotherapeutic delivery is crucial.  
Perfusion imaging with MRI, CT or PET provides a unique window into the vascular 
morphology and physiologic changes associated with agents that disrupt the tumor 
microenvironment or microvasculature. As we have noted in this chapter thus far, these 
have had a profound impact on the initial evaluation of agents that target the tumor 
microvasculature. If performed with proper quality assurance/quality control, and critical 
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understanding of baseline variance, measures will allow for a more robust understanding of 
the true effects of agents targeted to the tumor microvasculature. Although many studies 
have demonstrated that there is in general good concordance with preclinical data and with 
other angiogenesis biomarkers, and if studies are performed well, the observations gleaned 
from these studies might improve the biologic understanding of the mechanism of drug 
action, potential drug interactions, and the duration of effects, however, the high variance 
demonstrated in many of these studies (>20% in some instances), makes proper 
determination of biologic effect sometimes suspect. This fact becomes more important as we 
go forward trying to study the correlation of these physiologic changes with clinical 
outcomes and relevant serum biomarkers. 
MRI molecular imaging may play a role in improving some of these problems illustrated 
above. As noninvasive molecular imaging methods evolve, there will be an increasing 
possibility to personalization of therapy. For instance, imaging of MRI reporter-labeled stem 
cells or endothelial progenitor cells will provide new insights into their role in tumor 
angiogenesis, as these cell types have been implicated in tumor vascularization and 
potential poor response to antiangiogenic therapies (Monzani and La Porta 2008) (van der 
Schaft, Seftor et al. 2004). Exciting developments have been made in identification of tumor 
vascular specific receptors, which opens up possibilities for imaging but also monitoring 
using nanodevices the delivery of therapeutic agents, or gene delivery. Likewise, similar 
advances have been made in siRNA technology, where image-guided delivery to tumor 
microvasculature, visualization of this delivery via liposome technology or other 
nanocarriers, and detection of a therapeutic response are well within the realm of current 
imaging capabilities (Pathak, Penet et al. 2010). Yet, these technologies to this point remain 
preclinical and successful translation to the clinic remains a hurdle.  
With all of the advances in imaging technology demonstrating effects and possible benefits 
of antiangiogenic therapy, the future of this kind of work remains unclear. One concept that 
has come to the fore and deserves mention is that of vascular normalization. A concept 
introduced by Rakesh Jain (Izumi, Xu et al. 2002), which describes the morphologic and 
physiologic changes that occur to tumor microvasculature accompanying anti-angiogenic 
therapy. This factor may be key in modulating the proangiogenic and anti-angiogenic forces 
ongoing in maintenance of the tumor microenvironment in addition to providing key 
insights into potential temporal windows for the introduction of cytotoxic agents. These 
questions remain the key to further improvements in the delivery of chemotherapeutic 
agents. “As a result, the presence and timing of therapy-induced normalization must be 
carefully studied in a range of human tumors, and novel therapeutics are needed. This will 
in part be informed by preclinical work, and also by development and validation of 
noninvasive biomarkers that survey the normalization phenotype. Only then will treatment 
be applied in a rational and judicious fashion with the intent of maximizing therapeutic 
outcomes” (Goel, Duda et al. 2011). 
5. Take home message 
The studies and techniques described attest to the validity of these extant and novel imaging 
techniques to probe the microstructural and morphologic microvascular changes that occur 
both as a result of tumor angiogenesis, and more importantly, soon after the delivery of anti-
angiogenic therapy. These can be performed indirectly, by measuring hemodynamic 
Molecular Imaging 288 
immunoscintigraphy with 99mTc-E9 was also able to identify tumors that were not detected 
during pre-surgery MRI. 
2.3.4 Matrix metalloprotienases 
Expression of matrix metalloproteinases (MMPs) is associated with the removal of the 
extracellular matrix (ECM) barrier to allow cancer cells ad endothelial cells to invade the 
basement membrane. A number of MMPs are also specifically involved in angiogenesis, 
including MMPs 1, 2, 3, 9, and 14 (Stollman, Ruers et al. 2009).  
One approach for monitoring MMP activity in tumor-bearing animal models is the use of 
‘smart’ fluorescence probes that are bound to a synthetic graft copolymer consisting of a 
cleavable backbone that can act as an MMP substrate. When placed in close proximity, these 
polymeric fluorochromes quench each other and are not detectable. On enzymatic cleavage 
of the backbone by MMPs, the fluorochromes are spatially dissociated and begin to 
fluoresce (Bremer, Bredow et al. 2001) 
3. Clinical relevance of the finding 
The development of anti-angiogenic agents has been rapid to date. Although demonstrating 
provocative physiologic effects, the results to date have not demonstrated any significant 
improvements in patient outcome. This may be a result of various factors including a better 
understanding of the timing associated with the greatest changes occurring physiologically 
or morphologically within the microvasculature, a better understanding of whether the 
hypothesis of vascular normalization (Jain 2001; Jain 2005) (Goel, Duda et al. 2011) has 
bearing and may be a window into the introduction of other targeted cytotoxic agents, and 
improved, translatable targeted molecular imaging approaches to interrogating the tumor 
microenvironment. As these methods evolve in parallel, one may see come to fruition a true 
clinical benefit to the outstanding insight proposed from Dr. Folkman’s (Folkman 1971) 
seminal article many years ago.  
4. View to the future 
In order to bridge this gap in understanding the effects of angiogenesis, significant 
improvements and developments will have to occur within the following areas: 1) 
improvements in quality assurance and quality control associated with the physiologic 
measurements on interrogate the permeability, blood flow, and blood volume values that 
MRI, CT and PET; 2) improvements in targeted, molecular imaging approaches that may 
reflect the molecular changes that are occurring following administration of extant and 
novel anti-angiogenic or vascular disrupting agents, and lastly; 3) utilizing both of these 
approaches to better investigate and have a more comprehensive understanding of the 
validity and regulation of vascular normalization as a hypothesis for improved 
chemotherapeutic delivery is crucial.  
Perfusion imaging with MRI, CT or PET provides a unique window into the vascular 
morphology and physiologic changes associated with agents that disrupt the tumor 
microenvironment or microvasculature. As we have noted in this chapter thus far, these 
have had a profound impact on the initial evaluation of agents that target the tumor 
microvasculature. If performed with proper quality assurance/quality control, and critical 
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understanding of baseline variance, measures will allow for a more robust understanding of 
the true effects of agents targeted to the tumor microvasculature. Although many studies 
have demonstrated that there is in general good concordance with preclinical data and with 
other angiogenesis biomarkers, and if studies are performed well, the observations gleaned 
from these studies might improve the biologic understanding of the mechanism of drug 
action, potential drug interactions, and the duration of effects, however, the high variance 
demonstrated in many of these studies (>20% in some instances), makes proper 
determination of biologic effect sometimes suspect. This fact becomes more important as we 
go forward trying to study the correlation of these physiologic changes with clinical 
outcomes and relevant serum biomarkers. 
MRI molecular imaging may play a role in improving some of these problems illustrated 
above. As noninvasive molecular imaging methods evolve, there will be an increasing 
possibility to personalization of therapy. For instance, imaging of MRI reporter-labeled stem 
cells or endothelial progenitor cells will provide new insights into their role in tumor 
angiogenesis, as these cell types have been implicated in tumor vascularization and 
potential poor response to antiangiogenic therapies (Monzani and La Porta 2008) (van der 
Schaft, Seftor et al. 2004). Exciting developments have been made in identification of tumor 
vascular specific receptors, which opens up possibilities for imaging but also monitoring 
using nanodevices the delivery of therapeutic agents, or gene delivery. Likewise, similar 
advances have been made in siRNA technology, where image-guided delivery to tumor 
microvasculature, visualization of this delivery via liposome technology or other 
nanocarriers, and detection of a therapeutic response are well within the realm of current 
imaging capabilities (Pathak, Penet et al. 2010). Yet, these technologies to this point remain 
preclinical and successful translation to the clinic remains a hurdle.  
With all of the advances in imaging technology demonstrating effects and possible benefits 
of antiangiogenic therapy, the future of this kind of work remains unclear. One concept that 
has come to the fore and deserves mention is that of vascular normalization. A concept 
introduced by Rakesh Jain (Izumi, Xu et al. 2002), which describes the morphologic and 
physiologic changes that occur to tumor microvasculature accompanying anti-angiogenic 
therapy. This factor may be key in modulating the proangiogenic and anti-angiogenic forces 
ongoing in maintenance of the tumor microenvironment in addition to providing key 
insights into potential temporal windows for the introduction of cytotoxic agents. These 
questions remain the key to further improvements in the delivery of chemotherapeutic 
agents. “As a result, the presence and timing of therapy-induced normalization must be 
carefully studied in a range of human tumors, and novel therapeutics are needed. This will 
in part be informed by preclinical work, and also by development and validation of 
noninvasive biomarkers that survey the normalization phenotype. Only then will treatment 
be applied in a rational and judicious fashion with the intent of maximizing therapeutic 
outcomes” (Goel, Duda et al. 2011). 
5. Take home message 
The studies and techniques described attest to the validity of these extant and novel imaging 
techniques to probe the microstructural and morphologic microvascular changes that occur 
both as a result of tumor angiogenesis, and more importantly, soon after the delivery of anti-
angiogenic therapy. These can be performed indirectly, by measuring hemodynamic 
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parameters associated and related to blood volume, permeability and blood flow through 
imaging. These measures have been indispensible in the rapid and noninvasive 
interrogation of the microvascular changes accompanying antiangiogenic therapy. As 
existing techniques (e.g. DCE-MRI, CT perfusion, DCE-US) become more refined and 
validated by multi-institutional trials, the associated biomarkers may play a more pro-active 
role in the personalized approach that oncology is likely to engender. Furthermore, with the 
recent development of novel hybrid MRI PET devices, the realization and translation of 
more novel, targeted imaging approaches that probe the altered signaling pathways 
associated with angiogenesis, may become a reality in humans.  
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1. Introduction 
1.1 PET and SPECT imaging 
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography 
(SPECT) based functional imaging utilize radiolabeled tracers to provide information for 
real time visualization of physiological or biological processes in live animals or humans. 
Disease-related biomarkers involved in initiation and/or progression of a pathological 
condition are imaged by these nuclear imaging technologies which lead to early detection of 
abnormalities prior to the appearance of morphological changes visualized by other imaging 
modalities such as CT or MRI (1-3). Additional advantages of nuclear imaging approaches 
are high sensitivity of detection and high spatial resolution. Further they are either non- or 
minimally invasive and highly quantitative (4). Together, these characteristics of PET and 
SPECT make them an invaluable technique for monitoring some diseases and disorders.  
There are significant differences between PET and SPECT, some of which are highlighted 
below. A major advantage of PET over SPECT is its 2-3 orders of magnitude greater sensitivity 
and quantitative capability (5). PET utilizes radioisotopes that decay via emission of positrons, 
whereas, SPECT radioisotopes decay by electron capture and/or gamma emission (5). Table 1 
lists some of the most commonly used PET and SPECT radioisotopes and their physical 
properties. The synthetic chemistry behind development of these radioisotopes as tracers for 
imaging is dependent on the half-lives. For example, the short decay half-lives (2 – 20 min) of 
the PET radioisotopes: carbon-11, nitrogen-13 and oxygen-15 requires that radiotracer 
synthesis with these radioisotopes be conducted in close proximity to a cyclotron (3-5). On the 
other hand, radioisotopes such as fluorine-18, copper-64, indium-111, iodine-123 and iodine-
124 are sufficiently long-lived to allow transportation from regional commercial sites (3-5). 
Additionally, the radioisotopes gallium-68, copper-62 and technetium-99m can be 
conveniently obtained from an in-house generator (3-5). At the present time, clinical SPECT 
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imaging is more prevalent than PET imaging due to both its cost effectiveness and the greater 
availability of SPECT scanners at most nuclear medicine clinics. 
Isotope Imaging Mode Production 
Method 
Half-Life Decay Mode(s) 
11C PET Cyclotron 20.4 min β+ (99+%) 
13N PET Cyclotron 10 min β+ (100%) 
15O PET Cyclotron 2.03 min β+ (99.9%) 
18F PET Cyclotron 110 min β+ (97%) 
EC (3%) 
124I PET Accelerator 4.2 days EC (74.4%) 
β+ (25.6%) 
68Ga PET Generator 68.3 min β+ (90%) 
EC (10%) 
62Cu PET Generator 9.73 min β+ (98%) 
EC (2%) 
64Cu PET Reactor 12.7 hours β+ (61%) 
β- (39%) 
99mTc SPECT Generator 6.02 hours IC (100%) 
111In Gamma 
Scintigraphy 
Accelerator 2.8 days EC (100%) 
123I SPECT Accelerator 13.3 hours β+ (100%) 
192Ir SPECT Reactor 73.8 days EC (4.9%) 
β- (95.1%) 
201Tl SPECT Cyclotron 73 hours EC (100%) 
82Rb PET Generator 1.27 min β+ (100%) 
89Zr PET Cyclotron 3.3 days β+ (100%) 
β+ = positron emission; EC = electron capture; IC = isomeric conversion, β- = electron emission  
Table 1. Common PET and SPECT Radioisotopes  
In recent years, an effort has been made to combine anatomical imaging modalities (such as 
CT and MRI) with molecular imaging modalities in order to capitalize on the strengths of 
both techniques. These multi-modality approaches can provide both high structural detail 
and high detection sensitivity of pathophysiological changes giving greater insight into the 
dynamic processes of tumor growth and progression. Advances in this field have already 
been made and PET-CT technology is now available for use in many clinics (6-8). Further, 
the recent approval by the US Food and Drug Administration (FDA) of the first PET-MRI 
machine for clinical imaging (9) is a major step forward in multimodal imaging. Compared 
with PET-CT technology, PET-MRI scans demonstrate higher structural detail, especially of 
soft tissues, and additionally permit the use of MRI techniques such as perfusion imaging 
and MR spectroscopy (10). Furthermore, MRI scans (in PET-MRI) use magnetic fields 
instead of x-rays, thereby decreasing patient radiation doses in comparison to PET-CT scans 
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(10). Boss et al. showed the effectiveness and reliability of PET-MRI in scanning intracranial 
tumors using [11C] methionine or [68Ga] DOTATOC (11). 
The past decade has seen the investigation and validation of several radiotracers with 
particular emphasis in oncology. These targets include molecular biomarkers such as 
growth factor receptors, protein kinases, specific receptor over-expression or biological 
events such as angiogenesis, apoptosis, hypoxia and tumor proliferation (1-3). This review 
will highlight recent PET and SPECT radiotracer development for angiogenesis imaging 
with a major focus on their application in oncology. 
1.2 Biology of angiogenesis 
Angiogenesis, the formation of new blood vessels, plays a central role in growth of tumors 
beyond 1-2 mm3 as neovascularization is required to supply oxygen and nutrients and for 
removal of cellular wastes(12-14). Further, neo-angiogenesis is critical to the metastatic 
potential of tumors as it aids in the dispersion of cancer cells to distant organs. Recent 
advances in cellular and molecular biology have led to the identification of novel angiogenic 
biomarkers and molecular dissection of their signaling pathways(13, 15). One of the key 
signaling pathways involved in initiation of new tumor blood vessels is mediated by 
vascular endothelial growth factor (VEGF) and its receptor tyrosine kinase (VEGFR)(16-18). 
Pro-angiogenic signaling mediated by VEGF/VEGFR is critical when tumors outgrow their 
existing blood supply and frequently display oxygen deficiency (hypoxia). Hypoxia is 
known to trigger the secretion of VEGF (19-22). Binding of VEGF to its receptor initiates a 
signaling cascade that promotes the proliferation, migration and survival of endothelial 
cells, ultimately leading to angiogenesis (23-25). The angiogenic effects of the VEGF family 
are believed to be primarily mediated through VEGF-A. To date, VEGF-A (also referred to 
as VEGF) and its receptors are the most characterized signaling pathways in developmental 
and tumor angiogenesis(24, 26-35). 
Alternative splicing of RNA has revealed the existence of at least nine different molecular 
isoforms for VEGF-A, comprising 121, 145, 148, 162, 165, 165b, 183, 189 or 206 amino 
acids(36-43). The angiogenic actions of VEGF-A are mediated primarily via two closely 
related endothelium-specific receptor tyrosine kinases (VEGFR-1 and VEGFR-2)(44-46). All 
of the VEGF-A isoforms bind to both VEGFR-1 and VEGFR-2, of which, VEGFR-2 is the 
major mediator of proliferation and angiogenesis (14). Thus, a variety of solid tumor cells 
overexpress VEGFR-2, which serves as poor prognostic marker for the survival of cancer 
patients (47, 48). Therefore, new therapies based on humanized monoclonal antibodies that 
inhibit VEGF-A are used to treat cancers of colorectal, lung, kidney and eye origin and there 
are many newer therapies under various stages of development (27, 49)  
2. Molecular targets and ligands for PET/SPECT imaging of angiogenesis 
2.1 VEGF receptor and ligands 
PET imaging of VEGFR expression in vivo was first demonstrated using VEGF121 
radiolabeled with 64Cu. Radiolabeling was achieved via 64Cu chelation to a DOTA-VEGF121 
conjugate (DOTA is an abbreviation for 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-
tetraacetic acid). In vivo evaluation of 64Cu-DOTA-VEGF121 using microPET imaging of 
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imaging is more prevalent than PET imaging due to both its cost effectiveness and the greater 
availability of SPECT scanners at most nuclear medicine clinics. 
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athymic nude mice bearing U87MG human glioblastoma xenografts showed rapid and high 
specific accumulation of the radioligand in small U87MG tumors (16% injected dose per 
gram [ID/g]) at 4 h post-injection. Larger tumors showed significantly lower uptake (1 – 3% 
ID/g). Differences in tumor localization between large and small tumors showed a good 
correlation with tumor VEGF receptor expression (VEGFR-2). In vivo VEGFR-2 specificity of 
the radioligand was also confirmed by pharmacological blocking experiments and ex vivo 
studies (immunofluorescence staining, western blot analysis). This study also demonstrated 
the dynamic nature of VEGFR signaling during tumor growth and proliferation. 
Subsequently, these authors also reported on the development of a 64Cu-labeled 
vasculature-targeting fusion toxin (VEGF121/rGel) composed of a VEGF121 linked 
recombinant plant toxin gelonin construct (rGel) for multimodality imaging and therapy of 
glioblastoma. Sustained tumor accumulation and high signal-to-noise ratios were 
demonstrated by this radioligand in mice bearing glioblastoma xenografts up to 48 h post-
injection. Based on the pharmacokinetic information obtained from the imaging studies, 
therapeutic administration of VEGF121/rGel to mice bearing orthotopic U87MG 
glioblastomas revealed specific tumor neovasculature damage by histological analysis after 
a multiple dose treatment regimen. 
Apart from their role in tumor angiogenesis, VEGF/VEGFR signaling plays a key role in 
other human pathologies. For example, myocardial infarction (MI) is known to activate 
VEGF/VEGFR signaling. PET imaging studies conducted in a rat model of MI with 64Cu-
DOTA-VEGF121 revealed a 3 - 4 higher myocardial uptake of radioactivity for up to 2 weeks 
following infarction as compared to controls (50, 51). In addition, PET imaging of VEGFR 
expression with 64Cu-DOTA-VEGF121 in a rat stroke model showed peak tracer uptake in the 
stroke border zone at approximately 10 days post-surgery indicating neovascularization as 
confirmed by histopathology studies(52).  
111In-labeled recombinant VEGF isoform VEGF165 (111In-hn-Tf-VEGF) was reported by Chan 
and coworkers as a tumor angiogenic marker in experimental mice models. VEGF165 was 
fused through a flexible polypeptide linker to the n-lobe of human transferrin(53). The latter 
construct permitted labeling of the radioligand with 111In at a site remote from the VEGF 
receptor-binding domain. In radioligand stability studies, 111In-hn-Tf-VEGF demonstrated a 
moderate loss of 111In to transferrin in human plasma in vitro over a 72 h period (21.3% ± 
3.4% per day). Radioligand biodistribution studies and whole-body gamma camera imaging 
were conducted in athymic mice bearing subcutaneous U87MG human glioblastoma 
xenografts. 111In-hn-Tf-VEGF displayed tumor and blood radioactivity accumulations of 6.7 
± 1.1 %ID/g and 1.6 ± 0.4 %ID/g, respectively, at 72 h post-injection. Co-administration of a 
100-fold excess of VEGF led to a 15-fold decrease in tumor uptake of radioactivity. High 
uptake of radioactivity was also observed in liver (45.5 ± 7.5 %ID/g), kidneys (39.4 ± 7.0 
%ID/g) and spleen (35.6 ± 4.4 %ID/g) at this time interval. The authors present evidence to 
indicate that uptake of radioactivity in these organs is due to 111In-hn-Tf-VEGF and not due 
to 111In-transferrin via transchelation of 111In from the radioligand to transferrin. 
Along with labeling VEGF-A and its isoforms, efforts have also been made to create anti-
VEGF-A antibodies for imaging and therapeutic purposes. Success in this field was achieved 
with the creation of bevacizumab, a humanized monoclonal antibody that blocks VEGF-
induced endothelial cell proliferation. A radiolabeled form of bevacizumab, 89Zr-
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bevacizumab, was demonstrated to have high tumor uptake in small animal PET imaging 
(54, 55). A phase 1 clinical trial with 124I-labelled HuMV833 showed promising findings as 
well establishing the utility of radiolabeled antibodies in imaging VEGF(56, 57).  
2.2 αVβ3 integrins and RGD peptide 
An indirect approach to angiogenesis imaging has focused on radioligands targeting the 
αvβ3 class of cell adhesion molecule integrins. Integrin αvβ3 receptors are significantly up-
regulated in endothelial cells during angiogenesis but not in mature vessels or non-
neoplastic epithelium (Brooks PC, Science 1994; Pasqualini R, Nat Biotechnol, 1997). Integrin 
αvβ3 is also expressed in a variety of tumor cells, including melanoma, late-stage 
glioblastoma, ovarian, breast and prostate cancer. The ability to visualize and quantify 
integrin αvβ3 expression in vivo would allow for appropriate selection of patients for anti-
integrin treatment and also monitor treatment efficacy in such patients. 
Radioligand development for αvβ3 imaging has focused primarily on small RGD peptide 
antagonists. The tripeptide sequence motif, arginine-glycine-aspartate (RGD), is found in 
proteins of the extracellular matrix. Many integrins, including αvβ3, link the intracellular 
cytoskeleton of cells with the extracellular matrix via recognition and binding to this RGD 
motif. [18F]GalactoRGD was the first radiotracer used for successful PET imaging of tumor 
αvβ3 expression in patients. Subsequently, a hydrophilic D-amino acid containing 
tetrapeptide analog was also developed which demonstrated improved pharmacokinetics 
and proteolytic stability. Wu and coworkers have reported on the enhanced αvβ3 receptor 
binding characteristics of dimeric and multimeric RGD peptides over monomeric peptides 
which has been attributed to an increased local concentration of RGD domains at the 
receptor vicinity (polyvalency effect). Accordingly, several [18F]- and [64Cu]-labeled dimeric 
and tetrameric RGD peptide analogs have been recently synthesized and evaluated by this 
group for integrin-targeted imaging in lung, brain and breast cancer. As an example, 
microPET imaging studies with a dimeric RGD peptide coupled to 4-[18F]Fluorobenzoate 
{[18F]-FB-E[c(RGDyK)]2} showed predominantly renal excretion and twice as much tumor 
uptake in the same animal model as the monomeric analog [18F]-FB-c(RGDyK). Binding 
potentials derived from tracer kinetic modeling studies showed good correlation with tumor 
integrin expression levels as measured by SDS-PAGE/autoradiography in the six tumor 
models tested. 
Recently, a disulfide-based cyclic RGD called iRGD (internalizing RGD) was reported that 
showed binding affinity to the αvβ3 integrin and neurophilin-1 (NRP-1) receptor and 
portrayed the ability to penetrate tumor tissue for both imaging and drug-delivery 
purposes(58). These characteristics of the peptide iRGD (CRGDKGPDC) are achieved 
through a sequence of steps. Initially, iRGD binds to the αvβ3 integrins expressed on the 
endothelium of tumor cells through its RGD motif(59). Subsequently, the peptide is 
proteolytically cleaved producing a C-terminal RGDK/R sequence that both increases the 
peptide’s affinity to NRP-1 and decreases its binding activity to αvβ3 due to the CendR 
motif(59). This newfound affinity to NRP-1 provides iRGD its tumor penetrating 
capabilities(60). Not surprizingly, iRGD has become a major target for in vivo imaging as it 
can both home to tumor cells and also be internalized making the peptide a more effective 
imaging agent compared with other RGD peptides. iRGD imaging has been achieved using 
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to 111In-transferrin via transchelation of 111In from the radioligand to transferrin. 
Along with labeling VEGF-A and its isoforms, efforts have also been made to create anti-
VEGF-A antibodies for imaging and therapeutic purposes. Success in this field was achieved 
with the creation of bevacizumab, a humanized monoclonal antibody that blocks VEGF-
induced endothelial cell proliferation. A radiolabeled form of bevacizumab, 89Zr-
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bevacizumab, was demonstrated to have high tumor uptake in small animal PET imaging 
(54, 55). A phase 1 clinical trial with 124I-labelled HuMV833 showed promising findings as 
well establishing the utility of radiolabeled antibodies in imaging VEGF(56, 57).  
2.2 αVβ3 integrins and RGD peptide 
An indirect approach to angiogenesis imaging has focused on radioligands targeting the 
αvβ3 class of cell adhesion molecule integrins. Integrin αvβ3 receptors are significantly up-
regulated in endothelial cells during angiogenesis but not in mature vessels or non-
neoplastic epithelium (Brooks PC, Science 1994; Pasqualini R, Nat Biotechnol, 1997). Integrin 
αvβ3 is also expressed in a variety of tumor cells, including melanoma, late-stage 
glioblastoma, ovarian, breast and prostate cancer. The ability to visualize and quantify 
integrin αvβ3 expression in vivo would allow for appropriate selection of patients for anti-
integrin treatment and also monitor treatment efficacy in such patients. 
Radioligand development for αvβ3 imaging has focused primarily on small RGD peptide 
antagonists. The tripeptide sequence motif, arginine-glycine-aspartate (RGD), is found in 
proteins of the extracellular matrix. Many integrins, including αvβ3, link the intracellular 
cytoskeleton of cells with the extracellular matrix via recognition and binding to this RGD 
motif. [18F]GalactoRGD was the first radiotracer used for successful PET imaging of tumor 
αvβ3 expression in patients. Subsequently, a hydrophilic D-amino acid containing 
tetrapeptide analog was also developed which demonstrated improved pharmacokinetics 
and proteolytic stability. Wu and coworkers have reported on the enhanced αvβ3 receptor 
binding characteristics of dimeric and multimeric RGD peptides over monomeric peptides 
which has been attributed to an increased local concentration of RGD domains at the 
receptor vicinity (polyvalency effect). Accordingly, several [18F]- and [64Cu]-labeled dimeric 
and tetrameric RGD peptide analogs have been recently synthesized and evaluated by this 
group for integrin-targeted imaging in lung, brain and breast cancer. As an example, 
microPET imaging studies with a dimeric RGD peptide coupled to 4-[18F]Fluorobenzoate 
{[18F]-FB-E[c(RGDyK)]2} showed predominantly renal excretion and twice as much tumor 
uptake in the same animal model as the monomeric analog [18F]-FB-c(RGDyK). Binding 
potentials derived from tracer kinetic modeling studies showed good correlation with tumor 
integrin expression levels as measured by SDS-PAGE/autoradiography in the six tumor 
models tested. 
Recently, a disulfide-based cyclic RGD called iRGD (internalizing RGD) was reported that 
showed binding affinity to the αvβ3 integrin and neurophilin-1 (NRP-1) receptor and 
portrayed the ability to penetrate tumor tissue for both imaging and drug-delivery 
purposes(58). These characteristics of the peptide iRGD (CRGDKGPDC) are achieved 
through a sequence of steps. Initially, iRGD binds to the αvβ3 integrins expressed on the 
endothelium of tumor cells through its RGD motif(59). Subsequently, the peptide is 
proteolytically cleaved producing a C-terminal RGDK/R sequence that both increases the 
peptide’s affinity to NRP-1 and decreases its binding activity to αvβ3 due to the CendR 
motif(59). This newfound affinity to NRP-1 provides iRGD its tumor penetrating 
capabilities(60). Not surprizingly, iRGD has become a major target for in vivo imaging as it 
can both home to tumor cells and also be internalized making the peptide a more effective 
imaging agent compared with other RGD peptides. iRGD imaging has been achieved using 
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optical fluorescent and MRI agents, but a nuclear imaging agent has yet to be developed for 
this promising peptide(58, 59). 
2.3 Matrix Metalloproteinases (MMP) 
Matrix metalloproteinases (MMP’s), a family of zinc- and calcium-dependent 
endopeptidases, facilitate endothelial cell migration during angiogenesis via the enzymatic 
degradation of connective tissue(61). Within the family of MMP’s, MMP-2 and MMP-9 have 
been most associated with tumor aggressiveness and metastatic potential(62). Consequently, 
several MMP-specific peptides as well as small-molecule inhibitors (MMPI’s) have been 
radiolabeled with 125I, 123I, 64Cu, or 18F for PET or SPECT imaging of angiogenesis(63). For 
example, Koivunen et al. discovered that the decapeptide cyclo(Cys-Thr-His-Trp-Gly-Phe-
Thr-Leu-Cys)(CTT) selectively inhibited MMP-2 and MMP-9 thus suppressing the migration 
of endothelial and tumor cells(63, 64). Subsequent radiolabeling with 64Cu and chelation to 
DOTA showed low tracer accumulation in tumors(63). Studies on other MMP imaging 
agents have shown similar results calling into question their utility for angiogenesis imaging 
due to their low tumor targeting capabilities, nonspecific activity in preclinical trials, and in 
vivo instability(62). 
2.4 Nucleolin and F3 peptide 
It is now commonly believed that different organs and tissues may have a distinct 
vasculature, and molecular profiling studies have revealed that this heterogeneity stems 
from expression of distinct functional biomarkers in endothelial cells and its milieu. 
Similarly, molecular dissections of tumor and tumor vasculature have revealed that the 
angiogenic network of blood vessels in tumor is unique both structurally and 
physiologically. Tumor vasculature expresses unique biomarkers that distinguish it from 
normal blood vessels and allow targeting of cargo of therapeutic or imaging agents (14).  
Phage display peptide libraries contain peptide motifs that can home to the tumor 
vasculature and bind directly to the molecules expressed on tumor vessels (65, 66). Utilizing 
in vivo phage display technology, Ruoslahti's group identified F3 peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) as a sequence that specifically binds to 
tumor and its angiogenic endothelial cells (67). Later studies identified Nucleolin, as the 
receptor for F3 peptide. Nucleolin is localized both within the nucleus and the cytoplasm 
and is involved in RNA transport and processing. However, in proliferating tumor cells, it is 
cyclically transported from the nucleus to cell surface and back by a specific shuttle 
mechanism (68). Subcellular distribution of fluorescently-labeled F3 peptide shadowed 
nucleolin localization both in vitro and in vivo (Figure 1, (69, 70)). Further, we recently 
performed meta-analysis of microarray data from tumor samples and found that Nucleolin 
is upregulated in brain, head and neck and lung cancers when compared with respective 
normal tissue. Taken together, the overexpression of nucleolin and its unique localization at 
cell surface, suggest that nucleolin may be targeted for tumor imaging and delivery of 
therapeutic agents. 
F3 peptide has been used to deliver fluorescent tags, siRNA, and therapeutic radionuclides 
to tumors (44, 71-75). We have recently demonstrated that this peptide sequence can carry a 
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pay load of 80 nm multifunctional nanoparticles in a tumor specific manner (76) and that 
these reside at the tumor sites longer than the untargeted nanoparticles. Several groups have 
generated a variety of distinct F3-targeted nanoparticles and shown their efficacy in 
targeting mouse tumors or human xenografts in mouse (44, 71-75, 77). We recently reported 
the development of an new F3 peptide with cysteine at the c-terminus. Fluorescently or 
[125I]-labeled conjugates of this peptide localized to tumors in a mouse model, when 











Fig. 1. Subcellular localization of Fluorescent-labeled F3Cys peptides shadows that of 
nucleolin. MDA-MB-435 cells, in optically clear bottom dishes, cultured in either serum free 
or serum containing media were stained with AF532-F3Cys, counterstained with DAPI and 
monitored under a fluorescent microscope. In cells grown in media containing 10% serum,  
cell surface and nuclear staining of F3Cys was observed while serum starved cells showed 
predominantly nuclear staining without significant membrane staining. This suggests that 
F3Cys localizes to cell surface in actively growing cells.  
AF532-F3Cys 
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pay load of 80 nm multifunctional nanoparticles in a tumor specific manner (76) and that 
these reside at the tumor sites longer than the untargeted nanoparticles. Several groups have 
generated a variety of distinct F3-targeted nanoparticles and shown their efficacy in 
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F3Cys localizes to cell surface in actively growing cells.  
AF532-F3Cys 











Fig. 2. Fluorescent or SPECT imaging using tagged F3-cys peptide.  Mice bearing A549 (A) 
xenografts were injected i.v. via the tail vein with either AF647-F3Cys or AF647-Control 
peptide and fluorescence images were acquired over time. Tumor specific uptake at 2 h was 
observed only with AF647-F3Cys but not with AF647-Control peptide (A).  Ex vivo 
fluorescence imaging of tumor, kidney and liver harvested 2 h after AF647-F3Cys peptide 
injection in animals bearing A549 Tumor xenografts show that F3 peptide is taken up by 
tumor, kidney and liver while AF647-Control peptide shows no tumor specific fluorescence 
(B). Tumor specific uptake was also seen with MDA-MB-435 (melanoma cancer cells) 
xenografts when AF647-F3Cys and not AF647-Control peptide was administered (C). 
SPECT imaging studies conducted following  i.v. administration of  [125I]IBMF3 to nude 
mice bearing MDA-MB-435 tumor xenografts showed distinct uptake of radioactivity in 
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2.5 Miscellaneous alternate targets 
Prostate-specific membrane antigen (PSMA) is expressed on the neovascular endothelium 
of a majority of solid type tumors and not on endothelial cells of normal tissue. Thus, 
radiolabelled PSMA may be utilized in the detection of tumor-specific angiogenesis(78-
80). For the detection of nodal metastasis in prostate cancer, the FDA approved 
ProstaScint, a PSMA antibody labeled with 111In (81, 82). Another 111In-labeled PSMA 
antibody (J591) in a phase I clinical trial was reported to accumulate in malignant sites of 
tumors associated with kidney, liver, colon, breast and melanomas suggesting a potential 
of PSMA in imaging angiogenesis(81-84).. In a preclinical study, a 11C-labeled small 
molecule ligand for prostate-specific antigen was shown to localize to prostate cancer in 
experimental animal models. 
A number of extracellular matrix (ECM) proteins have also been targeted in the imaging of 
angiogenesis as some of the antigens in ECM have been discovered to be associated with 
neoangiogenic sites. Extra domain B of fibronectin and extra domain C of tenascin have 
been targeted in preclinical model systems to detect neoangiogenesis in malignant sites (63, 
85, 86) 
3. Clinical relevance of imaging angiogenesis 
Radiotracer imaging techniques such as PET and SPECT offer unique advantages for 
investigation of angiogenesis in patients at the molecular level by virtue of its high 
sensitivity and adequate spatial and temporal resolution. At the clinical level, such 
approaches could be useful for lesion detection, to select patients likely to respond to 
therapies directed at such targets, to confirm successful targeting and dose optimization as 
well as treatment monitoring. Additionally, nuclear imaging techniques could also aid in the 
development of new angiogenesis-targeted drugs and their validation. For example, PET 
imaging can provide rapid characterization of a drugs pharmacokinetics and 
pharmacodynamic behavior in both pre-clinical studies and clinical trials thereby improving 
the speed, efficiency and cost of drug development. Taken together, these exciting 
developments will likely play an important clinical role in the management of human 
malignancies. 
3.1 Future outlook on angiogenesis radiotracer design  
The past decade has seen major advances in the field of PET and SPECT radiotracer 
development for visualizing the molecular events associated with angiogenesis. A vast 
majority of these approaches have either focused on radiolabeled analogs of vascular 
endothelial growth factor (VEGF) or RGD small peptide antagonists of the αvβ3 class of cell 
adhesion molecule integrins. Despite these achievements, there is still a need for 
improvements in synthetic strategies for existing radiotracers and the development of 
alternate radiotracers for angiogenesis imaging. For example, approaches using radiolabeled 
VEGF are complicated by several factors such as the presence of multiple VEGF isoforms, 
high renal expression of VEGF receptors and the mitogenic activity of VEGF. Additionally, 
clinical trials conducted with RGD-based radiotracers have shown wide heterogeneity in 
tumor binding both within the same patient and between patients (87). Furthermore, RGD 
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2.5 Miscellaneous alternate targets 
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of a majority of solid type tumors and not on endothelial cells of normal tissue. Thus, 
radiolabelled PSMA may be utilized in the detection of tumor-specific angiogenesis(78-
80). For the detection of nodal metastasis in prostate cancer, the FDA approved 
ProstaScint, a PSMA antibody labeled with 111In (81, 82). Another 111In-labeled PSMA 
antibody (J591) in a phase I clinical trial was reported to accumulate in malignant sites of 
tumors associated with kidney, liver, colon, breast and melanomas suggesting a potential 
of PSMA in imaging angiogenesis(81-84).. In a preclinical study, a 11C-labeled small 
molecule ligand for prostate-specific antigen was shown to localize to prostate cancer in 
experimental animal models. 
A number of extracellular matrix (ECM) proteins have also been targeted in the imaging of 
angiogenesis as some of the antigens in ECM have been discovered to be associated with 
neoangiogenic sites. Extra domain B of fibronectin and extra domain C of tenascin have 
been targeted in preclinical model systems to detect neoangiogenesis in malignant sites (63, 
85, 86) 
3. Clinical relevance of imaging angiogenesis 
Radiotracer imaging techniques such as PET and SPECT offer unique advantages for 
investigation of angiogenesis in patients at the molecular level by virtue of its high 
sensitivity and adequate spatial and temporal resolution. At the clinical level, such 
approaches could be useful for lesion detection, to select patients likely to respond to 
therapies directed at such targets, to confirm successful targeting and dose optimization as 
well as treatment monitoring. Additionally, nuclear imaging techniques could also aid in the 
development of new angiogenesis-targeted drugs and their validation. For example, PET 
imaging can provide rapid characterization of a drugs pharmacokinetics and 
pharmacodynamic behavior in both pre-clinical studies and clinical trials thereby improving 
the speed, efficiency and cost of drug development. Taken together, these exciting 
developments will likely play an important clinical role in the management of human 
malignancies. 
3.1 Future outlook on angiogenesis radiotracer design  
The past decade has seen major advances in the field of PET and SPECT radiotracer 
development for visualizing the molecular events associated with angiogenesis. A vast 
majority of these approaches have either focused on radiolabeled analogs of vascular 
endothelial growth factor (VEGF) or RGD small peptide antagonists of the αvβ3 class of cell 
adhesion molecule integrins. Despite these achievements, there is still a need for 
improvements in synthetic strategies for existing radiotracers and the development of 
alternate radiotracers for angiogenesis imaging. For example, approaches using radiolabeled 
VEGF are complicated by several factors such as the presence of multiple VEGF isoforms, 
high renal expression of VEGF receptors and the mitogenic activity of VEGF. Additionally, 
clinical trials conducted with RGD-based radiotracers have shown wide heterogeneity in 
tumor binding both within the same patient and between patients (87). Furthermore, RGD 
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peptides may have limitations for tumor imaging due to the limited number of αvβ3 integrin 
receptors available per tumor cell and their low binding affinity (87). Thus, new radiotracers 
with improved targeting efficacy and pharmacokinetics are indispensible for successful 
clinical translation.  
Angiogenesis is involved in a multitude of biological processes including, embryogenesis, 
female reproductive cycle, tissue remodeling and wound healing (88). Furthermore, 
imbalances or upregulation of angiogenic processes are observed in numerous disorders 
including rheumatoid arthritis, psoriasis, cardiac restenosis and diabetic retinopathy. 
Accordingly, the future availability of clinically-validated angiogenesis imaging radiotracers 
could have broad applicability in disease management beyond that of oncology.  
4. Summary 
In this review, we have focused on recent developments in the design of new PET and 
SPECT radiotracers for imaging the tumor angiogenic process and their biological 
evaluation in pre-clinical animal models and initial clinical studies. Radiotracers based on 
VEGF and the cell adhesion molecule integrin αvβ3 currently form the major focus for 
imaging agent development. Additionally, alternate approaches that focus on radiolabeled 
matrix metalloproteinase and prostate specific membrane antigen (PSMA) inhibitors as well 
as the tumor-homing F3 peptide are described. Molecular imaging techniques such as PET 
and SPECT continue to play an increasingly important role in both disease diagnosis at the 
presymptomatic stage and the monitoring of its progression and response to therapeutic 
intervention. The future availability of improved imaging biomarkers for angiogenesis and 
appropriate animal models for their validation will be crucial for unraveling this complex 
process in health and disease and could lead to important advances in the treatment of 
cancer. 
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1. Introduction 
During the last decade, there has been enormous progress in understanding both 
multipotent stem cells such as hematopoietic stem cells and pluripotent stem cells such as 
embryonic stem cells and induced pluripotent stem cells. However, it has been challenging 
to study developmental potentials of these stem cells because they reside in complex cellular 
environments and aspects of their distribution, migration, engraftment, survival, 
proliferation, and differentiation often could not be sufficiently elucidated based on limited 
snapshot images of location or environment or molecular markers (Jang et al., 2011). 
Therefore, reliable imaging methods to monitor or track the fate of the stem cells are highly 
desirable. Both short-term and more permanent monitoring of stem cells in cultures and in 
live organisms have benefited from recently developed imaging approaches that are 
designed to investigate cell behavior and function. Transmission electronic microscopy 
(TEM) and series of noninvasive imaging technologies enable us to investigate cell behavior 
in the context of a live organism. In turn, the knowledge gained has brought our 
understanding of stem cell biology to a new level. 
Cell based therapeutics are emerging as powerful regimens. To better understand the 
migration and proliferation mechanisms of implanted cells, a means to track cells in living 
subjects is essential, and to achieve that, a number of cell labeling techniques have been 
developed. Nanoparticles, with their superior physical properties, have become the 
materials of choice in many investigations along this line. Owing to inherent magnetic, 
optical or acoustic attributes, these nanoparticles can be detected by corresponding imaging 
modalities in living subjects at a high spatial and temporal resolution. These features allow 
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1. Introduction 
During the last decade, there has been enormous progress in understanding both 
multipotent stem cells such as hematopoietic stem cells and pluripotent stem cells such as 
embryonic stem cells and induced pluripotent stem cells. However, it has been challenging 
to study developmental potentials of these stem cells because they reside in complex cellular 
environments and aspects of their distribution, migration, engraftment, survival, 
proliferation, and differentiation often could not be sufficiently elucidated based on limited 
snapshot images of location or environment or molecular markers (Jang et al., 2011). 
Therefore, reliable imaging methods to monitor or track the fate of the stem cells are highly 
desirable. Both short-term and more permanent monitoring of stem cells in cultures and in 
live organisms have benefited from recently developed imaging approaches that are 
designed to investigate cell behavior and function. Transmission electronic microscopy 
(TEM) and series of noninvasive imaging technologies enable us to investigate cell behavior 
in the context of a live organism. In turn, the knowledge gained has brought our 
understanding of stem cell biology to a new level. 
Cell based therapeutics are emerging as powerful regimens. To better understand the 
migration and proliferation mechanisms of implanted cells, a means to track cells in living 
subjects is essential, and to achieve that, a number of cell labeling techniques have been 
developed. Nanoparticles, with their superior physical properties, have become the 
materials of choice in many investigations along this line. Owing to inherent magnetic, 
optical or acoustic attributes, these nanoparticles can be detected by corresponding imaging 
modalities in living subjects at a high spatial and temporal resolution. These features allow 
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implanted cells to be separated from host cells; and have advantages over traditional 
histological methods, as they permit non-invasive, real-time tracking in vivo (Bhird et al., 
2011).  
Superparamagnetic iron oxide nanoparticles and magnetic resonance imaging provide a 
non-invasive method to detect and label hematopoietic stem cells. These nanoparticles 
exhibit unique properties of superparamagnetism and can be utilized as excellent molecular 
probes for magnetic resonance imaging. Neumaier et al., (2008) related that cell labeling by 
iron oxide nanoparticles has emerged as a potentially powerful tool to monitor trafficking of 
a large number of cells in the cell therapy field. Magnetic resonance imaging and iron 
magnetic nanoparticles are able to increase the accuracy and the specificity of imaging and 
represent new imaging opportunities in preclinical and translational research (Neumaier et 
al., 2008). 
Superparamagnetic behaviour of the marker used (magnetic fluid), composed of iron oxide 
(Fe3O4), comes from particles where the magnetization is free to re-orient itself due to 
thermal fluctuations (Sastry et al. 1995), characterizing the presence of electron-dense 
granules detectable by TEM. As described above, the nanoparticles can also be detected by 
magnetic resonance techniques, both in vitro and in vivo. The fundamental state of the free 
ion (Fe3+) has an electronic configuration of 3d5, having all its 5 spins bound (S=5/2 and 
total momentum orbital=null), giving a 6S configuration for the fundamental state, 6 times 
degenerated, forming 3 pairs of Kramers levels separated by the local electrical field (Stark 
effect). Since Fe3+ is an ion with an odd number of unpaired electrons, the duplet’s 
degeneration can only be possible by a magnetic field and then the electronic paramagnetic 
resonance (EPR) can be observed.  
CD133 antigen is a surface molecule with unknown functions expressed by more primitive 
CD34+ hematopoietic progenitor cells (HPCs) (Miraglia et al., 1997). The presence of antigen 
CD133 on a subset of very primitive HPCs such as CD34/CD133 cells points to this marker 
as an attracting tool to isolated human HPCs for biologic studies and clinical purposes 
(Peichev et al., 2000). 
In humans, CD133 is expressed in stem cells (Yin et al., 1997) and in several cellular 
progenitors (Yin et al., 1997), including those derived from the hematopoietic and nervous 
systems (Yin et al., 1997; Miraglia et al, 1997). CD133 expression is also detected in other 
primitive cells (Gehling et al., 2000) and in some tumors, such as retinoblastoma, 
glioblastoma, and medulloblastoma (Yin et al., 1997; Pfenninger et al., 2007).  
Human cord blood has been described as an excellent source of CD133+ HPCs with a large 
application potential (Rubinstein et al., 1998; Kuci et al., 2003).  
A large number of studies on stem cell biology and HPCs transplantation indicate that 
umbilical cord blood (UCB) is a suitable source of transplantable human HPCs (Gluckman 
et al. 1997; Rocha et al., 2001).  
BONANNO et al. (2004) described the clinical isolation and functional characterization of 
cord blood CD133+ HPCs with high hematopoietic activity and in vitro mesenchymal 
potential (differentiation mesoderm). Thus, the authors suggest that large-scale isolation of 
CD133+ cells from human UCB could represent a primary step to again access to a stem pool 
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useful for therapeutic hematopoietic transplants, stem cell expansion for clinical purposes 
and pre-clinical research on tissue regenerating therapies. 
In 2007, the same group (BONANNO et al.) related another therapeutic use of CD133+ cells 
from human UCB. They suggested the use of these cells as a treatment for myocardium 
ischemia due their potential to differentiate into endothelial and cardiomyocyte-like cells in 
vitro. In vivo studies showed vasculogenic potential of CD133+ cells from UCB in response to 
ischemia in an animal injury model (Finney et al., 2005; Ma et al., 2005). 
CD133+ cells can be isolated in vitro with monoclonal antibody anti-CD133 bound to 
magnetic beads that are composed of superparamagnetic nanoparticles (Miltenyi Biotec) 
and purified by MACS (magnetic activated cell sorting).  
The low levels of toxicity of the magnetic nanoparticles binding to magnetite (Fe3O4) used in 
the process of cellular selection (MACS - Miltenyi Biotec) can also be observed through 
studies that used hematopoetic stem cells obtained by the same selection procedure, in 
transplants of patients with cancer, obtaining satisfactory therapeutic results (Lang et al., 
2003; Richel, et al., 2000). 
This manuscript presents the study of molecular imaging on CD133+ hematopoietic stem 
cells from human umbilical cord blood.   
2. Materials and methods 
2.1 Collection and selection of the CD133+ hematopoetic stem cells from human 
umbilical cord blood (UCB) 
The collection of the umbilical cord blood was obtained in the Obstetric Centre of the Albert 
Einstein Israelita Hospital, São Paulo, Brazil, from pregnancies at term (n=5) with written 
permission from the mother. The collection was performed with sterile equipment through a 
puncture of the umbilical cord vein, at the moment of birth and after the cord was cut. 
Blood bags with a maximum volume of 250mL with 2mL of anticoagulant were used. The 
volume of the collected blood varied between 70 and 120mL. A sample of 80µL of blood was 
separated for cell count. The blood was then diluted in 1:2 proportion in a RPMI (Gibco) 
culture medium and the limpho-mononuclear cells were separated by the Ficoll-PaqueTM 
Plus (Amersham – GE Healthcare) density gradient in a 1:3 proportion (Lehner & Holter, 
2002). After 35 minutes in a 400g centrifuge, the fraction of the limpho-mononuclear cells 
were carefully isolated with the help of a 10mL pipette and washed in RPMI.  
The CD133+ cell population was purified following the separation protocol by MiniMACS 
microbeads affinity chromatography using anti-CD133 bound to magnetic beads (Miltenyi 
Biotec). 
The cells were filtrated in 30µm nylon filters and the number of these cells were determined 
by the cell count in an automatic counter (Coulter), after which they were centrifuged (400g 
for 5 minutes) and resuspended in the proportion of 300µL of solution for each 108 cells in a 
PBS solution containing 2mM EDTA and 0.5% BSA (solution 1). For each 108 cells, 100µL of 
FcR blocker and 100µL of magnetic micro-spheres with CD133+ antibodies (6°C) were 
added. The labelled cells were centrifuged and resuspended in solution 1 to be separated in 
the chromatography column to isolate only the CD133+ cells.   
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2.2 Flow cytometry 
After CD133+ cell separation, the cell population was characterized by flow cytometry using 
the following monoclonal antibodies (Becton Dickinson, San Jose, CA) and (Miltenyi Biotec): 
CD34 (clone: 581) FITC-conjugated, CD45 (clone: 2D1) PerCP Cy-5.5-conjugated and 
CD133/2 (clone: AC141) APC-conjugated and the respective isotype controls IgG1 FITC-
conjugated, IgG1 PerCP Cy-5.5-conjugated and IgG1 APC-conjugated. 
Cells were incubated with antibodies at 4oC, on dark for 30 minutes, and then washed with 
PBS and fixed with 1% paraformaldehyde. A total of 105 fluorescent cellular events were 
acquired on the FACSARIA flow cytometry (BD Bioscience) and analyzed by FACSDIVA 
software. Briefly, the analysis was performed by gating the cell population on forward 
scatter (FSC) versus side scatter (SSC) followed by gating only the CD45+ cells. Within the 
CD45+ cell population, cells were analyzed for expression of CD34 and CD133 markers.   
2.3 Transmission Electron Microscopy (TEM) 
CD133+ cell population (107 cells) was fixed in 0,5% glutaraldehyde in 0,2M cacodylate 
buffer for two hours at 4°C. Two 15 minute washes in cacodylate buffer followed this 
process. Post-fixation was performed in 1% osmium tetroxide for one hour at 4°C, followed 
by another two 15 minute washes in the same buffer. For contrast, the material was 
immersed in a solution of uranyl acetate in acetone for 30 minutes. After dehydration, the 
material was embedded in Epon resin diluted in acetone (1:1) and incubated at 4°C with 
agitation for 24 hours. The material was then transferred to pure Epon resin and incubated 
at 60° C for 72 hours, until completely polymerized. Semi and ultrathin sections were 
obtained with the aid of a Porter Blum ultramicrotome. The semithin sections were stained 
with azur II (1%) and methylene blue (1%). The ultrathin sections were placed on copper 
grids and stained with uranyl acetate and lead citrate. The grids were studied and 
photographed in a transmission electron microscope, PHILLIPS CM100. 
2.4 Electron Paramagnetic Resonance (EPR) 
In order to corroborate with the referred marking of the CD133+ cells bound to iron oxide 
superparamagnetic nanoparticles the EPR technique was used. 
The EPR signal of the iron oxide nanoparticles (iron markers Fe3O4) describe a peculiar 
absorption curve of approximately g= 2,0 where the curve area (double integral of the EPR 
spectrum) is proportional to the concentration of the sample nanoparticles. 
To perform a quantitative analysis of the Fe3O4 concentration, a calibration curve was first 
built based on different known concentrations between 2,6µm and 0,6mM. 
The sample preparation was obtained from a suspension of 107 stem cells (CD133+), bound 
to iron oxide nanoparticles, in 0,5% glutaraldehyde fixative in a 2µL quartz tube. Following 
this, the EPR measurements were performed. The methodology of the quantification 
calibration was already described in previous studies Gamarra et al. (2007); Sadeghiani et 
al., (2005); Lacava et al., (2002). 
The EPR measurements were taken using 20.166mW power, 1,6x105 receiver gain, 4 
scanning and the measurements were taken at room temperature. The spectral composition 
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of EPR absorption was obtained with a Bruker homodyne spectrophotometer, model EMX, 
operating with a frequency of 9,2 GHz in the band X and modulated to 100 kHz, utilizing 
one cavity of a rectangular microwave in the operating mode of the dominant cavity TE102.  
3. Results
3.1 Characterization by flow cytometry of CD133+ stem cells from UCB  
After selection of CD133+ cells with monoclonal antibodies bound to superparamagnetic 
nanoparticles, flow cytometry analysis revealed that about 82% of the population is 
comprised by CD34+/CD133+ cells, most of them expressing CD133 (Figure 1). After this 
first analysis, the ultrastructural characterization of the CD133+ cells was performed. 
 
Fig. 1. (A) The Flow Cytometry graph shows that CD133+/CD34+ (82,0%), CD133/CD34+ 
(1,6%) and CD34+CD133- (9,2%). (B) Isotype control graph shows that wasn’t unspecific 
staining.   
3.2 Identification and ultrastructural characterization of CD133+ stem cells labelled 
with nanoparticles 
Under the electron microscopy, ultrastructural analysis highlighted the presence of 
electrondense granules in the cell surface. This demonstrates the presence of anti-CD133 
monoclonal antibodies bound to superparamagnetic nanoparticles recognizing the CD133 
membrane protein (Figures 2A, B, C, D). This does not occur in the cells of the control group 
(CD133-) (Figures 3C, D) since similar electrondense signal surrounding cellular membrane 
of CD133- cells (control group) were not detected (Figures 3C, D).  
Electrondense signals related to superparamagnetic nanoparticles were also observed in the 
cell cytoplasm, suggesting their internalization through the process of the endocytosis 
(pinocytosis) of nanoparticles bound to the antibodies (Figures 2C, D; 3A, B). CD133+ cells 
incorporated superparamagnetic nanoparticles through its small cytoplasmic projections 
forming the pinocytics vesicles, as shown in the figures 2C and 3B.  
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Fig. 2. Transmission electronic microscopy of CD133+ stem cells. n = nucleus, c = cytoplasm, 
arrow = electrondense granules or magnetic nanoparticles, pv = pinocytics vesicles. Scale: 
A) 1µm; B) 0,5µm; C) 0,25µm; D) 0,125 µm.  
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Fig. 3. (A, B) Transmission electronic microscopy of CD133+ stem cells. (C, D) Transmission 
electronic microscopy of CD133- stem cells (control). n = nucleus, mi = mitochondria, mt = 
microtubules, arrow A = electrondense granules or magnetic nanoparticles, arrow B = 
absence of the electrondense granules or magnetic nanoparticles, pv = pinocytics vesicles, li 
= lipids, v = vacuoles. Scale: A) 1µm; B) 0,5µm; C) 0,25µm; D) 0,25µm.  
3.3 Electron Paramagnetic Resonance (EPR) of the superparamagnetic nanoparticles 
labelled of CD133+ stem cells 
To clearly show the expression of CD133 antigenic marker of the cell population under 
study, an EPR spectrum was first performed only with monoclonal antibodies anti-CD133 
bound to magnetic nanoparticles composed of superparamagnetic nanoparticles. A 
resonance in g=2.0 (Figure 4) was observed, derived from Fe3+ spins that interact with 
themselves, but with a supermagnetic behavior that characterizes the presence of 
agglomerates (Gamarra et al., 2005; Hseih et al., 2002; Sharma & Waldner, 1977). This signal 
consists of a strong absorption, while the large width is attributed to the strong interaction 
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3.3 Electron Paramagnetic Resonance (EPR) of the superparamagnetic nanoparticles 
labelled of CD133+ stem cells 
To clearly show the expression of CD133 antigenic marker of the cell population under 
study, an EPR spectrum was first performed only with monoclonal antibodies anti-CD133 
bound to magnetic nanoparticles composed of superparamagnetic nanoparticles. A 
resonance in g=2.0 (Figure 4) was observed, derived from Fe3+ spins that interact with 
themselves, but with a supermagnetic behavior that characterizes the presence of 
agglomerates (Gamarra et al., 2005; Hseih et al., 2002; Sharma & Waldner, 1977). This signal 
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Fig. 4. EPR spectra, showing the resonance absorption curve of the superparamagnetic 
nanoparticles, labelled cells (CD133+), unlabelled cells (CD133-) and glutaraldehyde 0,5% 
fixative. The spectra are shown in the inset.  
EPR spectrum of the labelled cells (CD133+) was then performed, observing a resonance line 
in g=2.0 showing the presence of the magnetic nanoparticles bound to the cells, which were 
immersed in glutaraldehyde 0,5% fixative. This fixative was removed by centrifugation of 
the labelled cells and it was analyzed using the EPR spectrum. This spectrum showed the 
absence of resonance in glutaraldehyde fixative thus evidencing the absence of iron oxide 
superparamagnetic nanoparticles in the fixative. 
As expected, the EPR spectrum of unlabelled cells (CD133-), used as negative controls, did 
not present a resonance line.  
4. Discussion  
Modern imaging technologies that allow for in vivo monitoring of cells in intact research 
subjects have opened up broad new areas of investigation. In the field of hematopoiesis and 
stem cell research, studies of cell trafficking involved in injury repair and hematopoietic 
engraftment have made great progress using these new tools. Multiple imaging modalities 
are available, each with its own advantages and disadvantages, depending on the specific 
application. For mouse models, clinically validated technologies such as magnetic resonance 
imaging (MRI) and positron emission tomography (PET) have been joined by optical 
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imaging techniques such as in vivo bioluminescence imaging (BLI) and fluorescence 
imaging, and all have been used to monitor bone marrow and stem cells after 
transplantation into mice. Each modality requires that the cells of interest be marked with a 
distinct label that makes them uniquely visible using that technology. For each modality, 
there are several labels to choose from. Finally, multiple methods for applying these 
different labels are available (Duda et al., 2007). 
In this work was described the molecular imaging on CD133+ hematopoietic stem cells from 
human umbilical cord blood through the nanobiotechnological applications. We were able to 
distinguish CD133+ from CD133- cells by TEM, based on their attachment to nanoparticles, as 
well as by signal analysis of EPR generated by these nanoparticles. Our findings indicate 
potential nanobiotechnological applications for in vivo cell imaging and therapy. 
In the hematopoietic system, CD133 is especially expressed in stem cells and progenitor cells 
found in the bone marrow, peripheral blood and human umbilical cord blood, which was 
used as the cellular source for this study (Yin et al., 1997; Miraglia et al. (1997). Recent data 
suggest that CD133+ cells, besides having extensive hematopoietic plasticity (Wynter et al., 
1998), can be used in different clinical applications, being an alternative in the utilization of 
CD34+ cells, more commonly used in transplant protocols (Handgretinger et al., 2003). 
CD133+ cellular fraction of bone marrow harbors precursors of granulocytes/macrophages 
and dendritic cells (Yin et al., 1997). 
Studies performed by Gehling et al. (2000) demonstrated that CD133+ cells have the capacity 
to differentiate in endothelial cells. After that, other researchers identified an endothelial 
progenitor (CD133+) that co-expresses the receptor for vascular endothelial growth factor 
(VEGFR) (Gill et al., 2001). They also detected functional responses in these cells during 
vascular trauma, suggesting that these CD133+ endothelial progenitors can be mobilized by 
VEFG, being useful in repairing vascular tissue injury (Gill et al., 2001). 
Powell et al. (2005) related diseases of the coronary arteries with the reduction of fractions 
from three different sub-types of CD133+ circulant cells: CD133+CD34+; CD133+CXCR4+ and 
CD133+VEGFR2+. These data indicated that the functional meaning of CD133 positive 
cellular fractions (CD133+) transcends the hematopoietic tissue (Bhatia, 2001). 
In the present study, after the previous analysis of flow cytometry confirming the significant 
expression (82%) of the CD133 cell surface antigen (CD133+ phenotype) in the stem cells of 
the human umbilical cord blood (UCB), the analysis of these cells through Transmission 
Electronic Microscopy (TEM) was performed.  
The electron micrographs highlighted the presence of electrondense granules in the cellular 
membrane, as well as dispersed in the cytoplasm of CD133+ cells, which refers to the 
superparamagnetic nanoparticles bound to anti-CD133 monoclonal antibody. These 
electronic micrographs described an important ultrastructural finding related to the 
presence of vesicles that internalize of nanonoparticles conjugated to anti-CD133 by the 
process of pinocytosis for all antibodies tested. We suggest that in our study the pynocytisis 
occur by receptor-mediated endocytosis. The endocytosis process happens after the 
antibody biding to the receptor, and then a depression arises on the cell membrane which is 
followed by the formation of the pinocytic vesicles. These pinocytic vesicles that are 
surrounded by the cytoplasmic proteins called clatrines, are internalized (Pavon et al., 2010). 
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suggest that CD133+ cells, besides having extensive hematopoietic plasticity (Wynter et al., 
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CD133+ cellular fraction of bone marrow harbors precursors of granulocytes/macrophages 
and dendritic cells (Yin et al., 1997). 
Studies performed by Gehling et al. (2000) demonstrated that CD133+ cells have the capacity 
to differentiate in endothelial cells. After that, other researchers identified an endothelial 
progenitor (CD133+) that co-expresses the receptor for vascular endothelial growth factor 
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Powell et al. (2005) related diseases of the coronary arteries with the reduction of fractions 
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CD133+VEGFR2+. These data indicated that the functional meaning of CD133 positive 
cellular fractions (CD133+) transcends the hematopoietic tissue (Bhatia, 2001). 
In the present study, after the previous analysis of flow cytometry confirming the significant 
expression (82%) of the CD133 cell surface antigen (CD133+ phenotype) in the stem cells of 
the human umbilical cord blood (UCB), the analysis of these cells through Transmission 
Electronic Microscopy (TEM) was performed.  
The electron micrographs highlighted the presence of electrondense granules in the cellular 
membrane, as well as dispersed in the cytoplasm of CD133+ cells, which refers to the 
superparamagnetic nanoparticles bound to anti-CD133 monoclonal antibody. These 
electronic micrographs described an important ultrastructural finding related to the 
presence of vesicles that internalize of nanonoparticles conjugated to anti-CD133 by the 
process of pinocytosis for all antibodies tested. We suggest that in our study the pynocytisis 
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surrounded by the cytoplasmic proteins called clatrines, are internalized (Pavon et al., 2010). 
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Electron Paramagnetic Resonance (EPR) analysis of the CD133+ stem cells from UCB 
detected that the signal (spectrum) generated by the labelled cells comes from the 
superparamagnetic nanoparticles composed of iron oxide bound to these cells. 
For spectrum detection of the EPR of the superparamagnetic nanoparticles it was necessary 
to perform an earlier study of the qualitative visualization through TEM of these 
nanoparticles also bound to CD133+ stem cells. The micrographies showed that the anti-
CD133 antibodies, bound to nanoparticles are bound to the cell surface antigens, thus 
demonstrating that the stem cell morphology, even after the selection process, was 
preserved. In this way the information of the analysis of the quantification by EPR of the 
iron content in the cells was validated (Billotey et al., 2003; Wilhelm et al., 2002), which is 
necessary for the intensity study of the image signal by magnetic resonance (MRI), to obtain 
the molecular image. 
This findings may guide future research in the study of molecular imaging on CD133+ 
haematopoietic stem cells from human umbilical cord blood, highlighting the 
immunolocalization of monoclonal antibodies associated with superparamagnetic 
nanoparticles, as well as the signal detection generated by these nanoparticles (EPR) bound 
to the cells studied, suggest many biomedical applications using new resources in 
nanoscience as they become available. The EPR results, together with ultrastructural 
characterization of immunolocalized nanoparticles, strongly suggest that CD133+ cells 
labelled with nanoparticles can be considered for different nanobiotechnological 
applications, i.e., matter manipulation in a nanometric scale to help areas such as diagnosis, 
therapeutics or even bioengineering (Fargeas et al., 2006). This is because these CD133+ cells 
from human UCB could represent a primary step to again access to a stem pool useful for 
therapeutic hematopoietic transplants, stem cell expansion for clinical purposes and pre-
clinical research on tissue regenerating therapies. 
Recent developments are revolutionizing the understanding about hematopoietic stem-cell 
therapy. Over the past three decades, much knowledge has been accumulated to provide a 
sound basis for the optimal use of this approach in the treatment of hematopoietic cancers, 
especially acute myelogenous leukemia, Hodgkin's disease and other lymphomas and 
multiple myeloma (Verlinden et al., 1998; Thomas; Chift, 1999; Negrin et al., 2000; Childs et 
al., 2000; Sharp et al., 2000). This approach has also been used in the treatment of some solid 
tumors, most notably breast cancer, for which its value is still in dispute because of poor 
accrual in randomized trials and because it takes many years to obtain definitive answers, 
even from well-designed trials (Joshi et al., 2000). Hematopoietic stem-cell therapy is also 
being tried in sickle cell disease and thalassemia and recently in progressive multiple 
sclerosis, systemic scleroderma, severe systemic lupus erythematosus, and rheumatoid 
arthritis with a poor prognosis (Shichishima et al., 1983; Papanikolaou et al., 2011; 
Alderucciro et al., 2011). 
The broadening therapeutic applications of hematopoietic stem cells also reflect an 
increased understanding of how to modulate the cells of the immune system to minimize 
both rejection and graft-versus-host disease and to improve the management of the 
infectious complications of immunosuppression (Verlinden et al., 1998; Sharp et al., 2000). 
While much has been studied about hematopoietic stem-cell therapy several questions 
remain regarding the biology of stem cells in living subjects. For most therapeutic 
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applications of regenerative medicine, critical issues such as stem cell type and delivery 
route of stem cells remain to be elucidated. In addition, after cells are transplanted to the 
living subject, it becomes critical to understand the biology of transplanted cells and how 
they interact with the microenvironment. Recent developments in molecular imaging 
modalities may likely permit investigators to answer some of these questions. Furthermore, 
some of these imaging strategies have the potential to be translated to patients, which makes 
them plausible to be used in the clinics.  
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1. Introduction 
The lymphomas are a heterogeneous group of malignant diseases, which vary with respect 
to their molecular features, genetics, clinical presentations, treatment approaches and 
outcomes. They are divided into two broad groups on the basis of pathology: Hodgkin's 
disease (HD) and non-Hodgkin's lymphoma (NHL). They comprise approximately 5% - 6% 
of all malignancies and are the fifth most frequently occurring type of cancer in the Western 
world (Jemal A et al., 2009). HD and many histological sub-types of NHL are potentially 
curable with appropriate chemotherapy and/or involved-field radiotherapy, and patients 
with disease relapse may be cured by second-line salvage treatments (Hampson FA and AS 
Shaw, 2008). Accurate staging and response assessment are essential to guide treatment 
decisions. Molecular imaging has become an essential tool in the early diagnosis (guiding 
biopsy), initial staging and risk stratification, monitoring response to therapy, and detection 
tumor recurrence of lymphomas. Research in molecular imaging is also contributing to our 
understanding of the disease pathogenesis of lymphomas and helping to direct more 
effective care of patients with the diseases. 
Computed tomography (CT) once was the single imaging modality for staging and 
monitoring morphological changes after treatment. The relatively recent integration of 
positron emission tomography (PET) with the use of [18]F-fluorodeoxyglucose tracer (18F-
FDG) into oncologic imaging has further improved baseline staging and facilitated 
functional evaluation of disease behaviour (such as tumor malignancy grade), metabolic 
response to therapy, and earlier detection of disease recurrence (Ngeow JY et al., 2009; 
Schoder H et al., 2005; Spaepen K et al., 2002). Particularly for conclusions of therapy 
response assessment, FDG-PET has been shown to be considerably more accurate than 
anatomical imaging by CT because of its ability to distinguish between viable tumor and 
necrosis or fibrosis in post-therapy residual masses.  
The specificity of FDG-PET is improved with the addition of CT. Integrated PET/CT, with 
the advantage of combining functional and anatomical information and better attenuation 
correction, is regarded to be the current standard of practice for the management of 
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lymphomas. However, PET/CT is expensive, time-consuming, involves exposure to 
ionizing radiation, and is not widely available because it requires support infrastructure, 
such as cyclotrons and radiochemistry laboratories (Huang B et al., 2009). In contrast, 
magnetic resonance imaging (MRI) provides excellent tissue contrast and high spatial 
resolution, and lack of ionizing radiation. It may be a potential alternative for the 
surveillance of lymphoma patients with multiple follow-up examinations. Moreover, the 
rapidly evolving parallel imaging acquisition technique with multi-channel phased array 
surface coils has enabled a high spatial resolution whole-body MR examination within a 
reasonable time (Lauenstein TC and RC Semelka, 2006). The development of imaging 
modalities, which can encompass the entire body, is of great importance, especially for 
aggressive lymphomas, in which extensive disease involvement is common (Antoch G et al., 
2003; Ghanem N et al., 2006).  
Whole-body MRI has shown advantages for the detection of distant metastatic diseases, 
especially from tumors frequently spreading to the brain, liver, or bone marrow (Kwee TC et 
al., 2009), and it has been introduced as a whole-body bone marrow screening application 
(Schmidt GP et al., 2009). Within this context, whole-body MRI is highly accurate for staging 
of hematologic diseases, such as lymphomas. However, additional bone marrow biopsy is 
still considered mandatory. 
Evaluation of nodal disease by CT and conventional MRI still relies on size criteria, lymph 
nodes with a short-axis diameter greater than 10 mm are generally considered positive. 
However, lymph nodes may be enlarged reactively and even small lymph nodes may be 
infiltrated by malignant cells. Thus, tumor in unenlarged lymph nodes may go undetected. 
Diffusion-weighted MRI (DWI) is a noninvasive technique that probes the random 
microscopic motion of water molecules in vivo (Le Bihan D, 1995). DWI with apparent 
diffusion coefficient (ADC) mapping provides quantitative physiological and functional 
information regarding characterization of lymphomas. Because of their high cellularity and 
high nuclear-to-cytoplasm ratio, aggressive lymphomas have relatively high signal intensity 
on DW images and low ADC values (Sumi M et al., 2007). Recent studies have shown that 
DWI with ADC mapping could distinguish between benign and malignant 
lymphadenopathy (Holzapfel K et al., 2009; Perrone A et al., 2009), and it may have 
prognostic potential in patients with aggressive lymphomas (Wu X, PL Kellokumpu-
Lehtinen et al., 2011). An advantage of DWI over conventional MRI sequences in the 
evaluation of lymphoma is the high lesion-to-background contrast, which make it a valuable 
imaging modality for detecting metastasis and cancer relapse, and it has also been used to 
assess treatment response in various malignancies including lymphomas (Wu X, PL 
Kellokumpu-Lehtinen et al., 2011). Our recent pilot study showed that DWI, in combination 
with whole-body MRI, yielded results comparable with those from integrated PET/CT in 
treatment evaluation of patients with diffuse large B-cell lymphoma (Wu X, PL Kellokumpu-
Lehtinen et al., 2011). DWI and PET/CT share similar applications in the field of clinical 
oncology. This is important when a patient is not suitable for PET/CT exams (e.g. diabetes) 
or PET/CT is not available.  
This chapter will highlight the most important and potential applications of FDG-PET/CT 
and MRI including whole-body MRI and DWI emphasizing the strengths and pitfalls of 
each imaging approach in diagnosis, initial staging, and response assessment of lymphomas.  
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2. Classification of malignant lymphomas 
The lymphoproliferative disorders encompass a collection of lymphoid neoplasms with 
different clinical and histological presentations. The classification of lymphoid malignant 
diseases has been beset by difficulties. In 1994, a census for universal lymphoma 
classification was published in the form of the Revised European-American Lymphoma 
(REAL) classification (Harris NL et al., 1994). The current World Health Organization 
(WHO) classification was derived from the REAL criteria, in which NHL is categorized into 
more than 20 subtypes on the basis of cell origin (B- or T-cell precursor), morphological, and 
immunophenotypic data (Harris NL et al., 2000). Diffuse large B-cell lymphoma and 
follicular lymphoma account for more than 50% of cases of NHL. The WHO classification 
helps to determine not only malignancy grade, but also prognosis. Systems in which NHL is 
grouped into indolent, aggressive, and very aggressive disorders are practically very useful 
(Cronin CG et al., 2010).  
3. Diagnosis, initial staging, and prognosis assessment of malignant 
lymphomas  
Diagnosis is based on an integration of morphological (lymph nodes, blood and bone 
marrow), immunophenotypic, molecular, cytogenetic data, and clinical behavior. Many 
lymphomas have characteristic morphological features, but no specific biomarker is of 
diagnostic value. In patients suspected of malignant lymphoma, a surgical excision biopsy 
of an enlarged lymph node (or extra-nodal site) is mandatory to confirm the diagnosis and 
to define the histological subtypes.  
Once the diagnosis of HD or NHL has been established by biopsy of a particular site, 
accurate determination of disease extent (staging) is crucial for appropriate treatment 
planning and prognosis prediction. In addition, knowing the sites of involvement at time of 
diagnosis makes it possible to accurately restage at the end of therapy and document a 
complete remission. Conventional staging techniques, considered the standard reference, 
include contrast-enhanced CT of the neck, chest, abdomen and pelvis, uni/bilateral bone 
marrow biopsy, and in some cases MRI. CT has been the most commonly used imaging 
modality for initial staging of lymphomas for decades. In patients with aggressive NHL and 
HD, FDG-PET and FDG-PET/CT are increasingly applied for the initial staging. Bone 
marrow biopsy is an invasive procedure and can be subject to sampling errors (Pelosi E et 
al., 2008). Therefore, PET scan should be the first step in lymphoma staging workup so that 
it could be used to guide bone marrow biopsy in the presence of patchy bone marrow lesion 
(Figure 1). The role of FDG-PET in indolent lymphoma is still unclear, and not all indolent 
lymphomas are FDG-avid. In current clinical practice, the use of MRI for staging malignant 
lymphoma is still limited. It is mainly applied as an adjunct to CT in selected cases with soft 
tissue lesions, or suspected involvement of the central nervous system or bone marrow that 
need to be further evaluated (Vermoolen MA et al., 2011).  
Staging of both HD and NHL is based on the Ann Arbor classification, with the inclusion of 
a definition of bulky disease known as the Cotswold modification (Lister TA et al., 1989). 
This staging system encompasses the number of sites of disease involved, the type of 
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Fig. 1. A coronal slice of fused PET/CT image (a), the corresponding PET image (b) and CT 
image (c) in a 62-year-old male patient with diffuse large B-cell lymphoma  
Multiple FDG avid lesions are showing in the cervical, mediastinum, abdominal region, and 
the left iliac on both the fused PET/CT image and the PET image. The iliac lesion was 
neither detected by the corresponding CT image, nor by bone marrow biopsy that was 
performed at the right side of the iliac.  
therefore an indispensable tool. Ann Arbor stage I: Only one lymph node region or extra-
nodal site is affected. Stage II: Multiple lymph node regions are affected, but limited to the 
same side of the diaphragm. Stage III: Involvement of lymph node regions on both sides of 
the diaphragm, which may be accompanied by local extra-nodal extension. Stage IV: Diffuse 
involvement of one or more extra-nodal organs or sites, including bone marrow, liver, and 
lung (Lister TA et al., 1989). Accurate staging is critical for identifying patients with early 
stage (stage I or II) lymphoma, some of which might be treated with involved-field radiation 
therapy. Chemotherapy is performed in patients with more advanced stage disease (stage III 
or IV).  
The International Prognostic Score (IPS) based on seven factors consisting of serum albumin, 
hemoglobin, gender, stage, age, leukocytosis, and lymphocytopenia is used for newly 
diagnosed HD patients. Whereas the International Prognostic Index (IPI) is the most widely 
used prognostic index for adult NHL, which is based on both clinical and imaging findings 
including age, serum lactate dehydrogenase (LDH) level, extent of disease, and performance 
status. The IPI is derived from an additive score of 0 to 5 points to stratify patients as having 
low (0 - 1 point), low-to-intermediate (2 points), high-to-intermediate (3 points), or high (4 - 
5 points) prognostic risk (Shipp MA, 1994). However, considerable variations still remain in 
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the outcome of individual patients within the same prognostic group because of the 
biological and clinical heterogeneity of the diseases. Currently, the paradigm of treatment in 
HD and NHL is moving towards a more risk-adapted therapy based on the individual 
patient’s prognosis by advanced imaging techniques.  
4. Response assessment of malignant lymphomas 
The response to therapy of lymphomas shows a high variability, therefore, it is important to 
have knowledge of early chemotherapy efficacy for individual patient. Furthermore, 
assessment of early- or mid-treatment response to chemotherapy has been shown to be of 
prognostic value in patients with malignant lymphomas (MacManus MP et al., 2007). 
Identification of nonresponders at an early stage allows for the adjustment of chemotherapy 
and radiotherapy regimens promptly and thereby may improve the outcomes and decrease 
the toxicity and costs that associated with ineffective treatment. However, the value of 
altering therapy based on early- or mid-treatment FDG-PET remains to be established 
(Cheson BD et al., 2007). Response assessment at the end of treatment is performed to assess 
whether there is a partial or complete remission, which is important for determining the 
need for additional treatment and for determining prognosis. The International Working 
Group (IWG) criteria, published in 1999, have become the widely accepted standard for 
response assessment in NHL, and were subsequently adopted for HD (Cheson BD et al., 
1999). Although based primarily on CT findings, the IWG criteria take bone marrow biopsy, 
clinical, and biochemical information into account. The IWG criteria have proved extremely 
useful in the standardization of treatment response, but they do have a number of 
limitations. As a consequence of this, together with advances in functional imaging, revised 
criteria that incorporate both CT and FDG-PET were published in 2007 (Cheson BD et al., 
2007). Complete remission indicates disappearance of all evidence of disease, partial 
remission indicates regression of measurable disease and no new sites, stable disease 
indicates failure to attain complete remission or partial remission, and progressive disease 
indicates the appearance of new lesions or increase by ≥50% of previously involved sites 
(Cheson BD et al., 2007). According to the revised criteria, a patient is considered to be 
complete remission even if a residual CT mass is present, provided the mass has changed 
from being FDG avid or PET-positive to PET-negative.  
5. Different imaging modalities  
5.1 Computed tomography  
The introduction of CT in the mid 1970s was a tremendous breakthrough in noninvasive 
imaging, and its potential for staging malignant lymphoma was soon recognized and 
investigated. Since then, CT has gradually become the imaging modality of choice for 
staging malignant lymphomas. CT technology has continuously been developed and 
refined; major milestones include the introduction of spiral (helical) CT, and the advent of 
multi-detector row CT that increases the speed of data collection dramatically. In addition, 
current CT scanners have a faster gantry rotation. These properties enable acquisition of 
high resolution cross-sectional images of the whole-body within only a couple of seconds, 
which minimizes or eliminates breathing artifacts (Kwee TC, Kwee RM et al., 2008; Rydberg 
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the outcome of individual patients within the same prognostic group because of the 
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combination with powered injectors for rapid bolus administration of intravenous contrast 
medium, focal extra-nodal lesions on the order of a few millimeters can be identified (Lucey 
BC et al., 2005; Vinnicombe SJ and RH Reznek, 2003). Intravenous contrast medium 
facilitates nodal recognition in the neck and in the retroperitoneum in patients with a 
paucity of adipose tissue. The importance of adequate bowel opacification with dilute oral 
contrast (so as to avoid confusion with intra-abdominal and pelvic masses) was well 
recognised (Kwee TC, Kwee RM et al., 2008). However, contrast-enhanced CT is not very 
helpful in differentiating normal from malignant lymph nodes. CT has limitations in 
differentiating malignant from benign small lymph nodes or, after treatment, neoplastic 
tissue from fibrosis.  
CT remains the basic imaging modality for initial staging malignant lymphomas because of 
its widespread availability and relatively low cost. However, the limited specificity of CT is 
still a fundamental problem in oncology, e.g. to detect pathological changes in normal-sized 
structures, to detect lesions that have poor contrast with surrounding tissue. At initial 
staging, determination of nodal involvement by CT is based on size criteria. Lymph nodes 
viewed on CT are considered as pathological if the maximum allowed long-axis diameter of 
15 mm is exceeded, and/or if the short-axis diameter is more than 10 mm. In addition, nodal 
involvement is presumed if clustering of normal-sized lymph nodes is present in the 
anterior mediastinum or mesentery, or if lymph nodes of any size are visualized in areas 
where they normally are not observed (Vermoolen MA et al., 2011). CT evaluation on the 
basis of nodal size has historically been regarded as the reference standard imaging tech-
nique for staging, with a reported sensitivity and specificity for nodal disease of 87.5% and 
85.6%, respectively (la Fougere C et al., 2006). General criteria for extra-nodal involvement 
are any focal density alterations or mass lesions involving soft tissues, bones, parenchymal 
organs and serosal cavities (Vermoolen MA et al., 2011). Comparing current with previous 
CT scans may improve diagnostic reliability. Nevertheless, the use of CT alone in restaging 
malignant lymphoma can be limited, since it is not able to differentiate residual viable 
tumor tissue from therapy-induced fibrosis. Following treatment of lymphoma by 
chemotherapy and/or radiation, up to 40% of patients with nodal disease have a residual 
mass on CT. Previous studies have shown that only 10 - 20% of such patients will have 
disease in these residual masses (Hampson FA and AS Shaw, 2008). In early response 
assessment, CT is not an ideal diagnostic tool, as morphological changes may lag behind 
rapid functional changes in response to therapy. Another weakness of CT is the limited 
sensitivity for detecting bone marrow involvement, which, if present, by definition indicates 
stage IV disease (Vinnicombe SJ and RH Reznek, 2003) (Figure 1).  
Major disadvantages of CT are exposure of the patient to ionizing radiation and the 
administration of iodinated contrast agents, which may induce secondary cancers and cause 
allergic reactions, respectively (Kwee TC et al., 2009). Nevertheless, contrast-enhanced 
diagnostic CT remains the base for initial measurements of involved sites and detection of 
complications such as adjacent organ compression, although combined FDG-PET/CT is 
increasingly applied for initial staging of malignant lymphomas.  
5.2 FDG-PET 
Positron emission tomography was developed in the 1970s soon after CT (Phelps ME et al., 
1975). It is based on the use of positron-emitting radiopharmaceuticals and the detection in 
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coincidence of the 2 nearly collinear 511 keV photons emitted following positron 
annihilation with an electron. Fluorodeoxyglucose (FDG), an analogue of glucose; is taken 
up by high-glucose-using cells. After transport into tumour cells, 18F-FDG is phosphorylated 
to 18F-FDG-6-phosphate that cannot be further metabolised. It will take approximately 60 
minutes for the radiotracer to travel through the body and to be absorbed by the organ or 
tissue being studied. Thus, 60 minutes after intravenous injection, the concentrations of 18F-
FDG tracer give tissue glucose metabolic activity, in terms of regional glucose uptake. 
Cancer imaging by 18F-FDG-PET is based on the observation that most cancers, including 
many lymphomas, metabolize glucose at an abnormally high rate (Warburg O, 1956). The 
most aggressive tumors require greater glucose consumption to maintain their accelerated 
growth. Imaging of malignant lymphoma with FDG was first described in the 1980s (Paul R, 
1987), and the first reports on FDG-PET as a whole-body staging method in malignant 
lymphoma was published in the 1990s (Moog F et al., 1997). PET technology has improved 
dramatically since its development. Initial patient imaging units had a system resolution 
greater than 15 mm, whereas current units have a 4 to 5 mm resolution. Raw data should be 
reconstructed by means of iterative expectation maximization algorithms, which provide 
superior signal-to-noise ratio compared with filtered back-projection images (Kwee TC, 
Kwee RM et al., 2008). When one (or both) of the annihilation photos scatters in the body, it 
is prevented to be detected appropriately, which is called attenuation. Attenuation effects 
produce regional nonuniformities, distortions of intense structures, and edge effects. To 
improve anatomical delineation, additional transmission scanning for attenuation correction 
using an external radiation source is required. Attenuation correction also allows for 
semiquantitative evaluation, which offers a more objective way to assess FDG uptake. 
Nonattenuation corrected images should also be evaluated, because the attenuation 
correction itself may also introduce image artifacts (Rohren EM et al., 2004).  
FDG-PET imaging protocols vary from institution to institution, which highlights the need 
for standardization. In the most frequently used protocol, patients fast for 4 - 6 hours prior 
to the injection of FDG. Imaging commences approximately 60 minutes after the injection of 
a typical FDG dose of 370 MBq. Serum glucose levels of less than 150 mg/dl are desirable. 
Patients are also instructed to avoid any kind of strenuous activity prior to the examination 
and following injection of the radioisotope to avoid physiological muscle uptake of FDG.  
Visual analysis of an FDG-PET scan can characterize the intensity of metabolic activity as 
low, moderate or high. In many cases visual image interpretation is sufficient to identify 
malignant lesions. Any focus of visually elevated FDG uptake relative to the background 
(surrounding normal tissue), not located in areas of physiologically increased uptake, is 
regarded as positive for malignant lymphomas (Vermoolen MA et al., 2011). In organs with 
physiological FDG uptake (e.g., spleen and liver), focal or inhomogeneous uptake patterns 
are considered to be indicative of malignant lymphoma (Figure 1). Nevertheless, 
quantitative analysis of FDG uptake may complement visual image interpretation because it 
provides objective criteria, thus minimizing interobserver variability in image 
interpretation. The FDG uptake can also be assessed semiquantitatively using the 
standardized uptake value (SUV). The standardized uptake value, an index of glucose 
metabolism on FDG-PET image, is the ratio between the measured and expected uptake if 
FDG were distributed evenly throughout the body. The maximum standardized uptake 
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coincidence of the 2 nearly collinear 511 keV photons emitted following positron 
annihilation with an electron. Fluorodeoxyglucose (FDG), an analogue of glucose; is taken 
up by high-glucose-using cells. After transport into tumour cells, 18F-FDG is phosphorylated 
to 18F-FDG-6-phosphate that cannot be further metabolised. It will take approximately 60 
minutes for the radiotracer to travel through the body and to be absorbed by the organ or 
tissue being studied. Thus, 60 minutes after intravenous injection, the concentrations of 18F-
FDG tracer give tissue glucose metabolic activity, in terms of regional glucose uptake. 
Cancer imaging by 18F-FDG-PET is based on the observation that most cancers, including 
many lymphomas, metabolize glucose at an abnormally high rate (Warburg O, 1956). The 
most aggressive tumors require greater glucose consumption to maintain their accelerated 
growth. Imaging of malignant lymphoma with FDG was first described in the 1980s (Paul R, 
1987), and the first reports on FDG-PET as a whole-body staging method in malignant 
lymphoma was published in the 1990s (Moog F et al., 1997). PET technology has improved 
dramatically since its development. Initial patient imaging units had a system resolution 
greater than 15 mm, whereas current units have a 4 to 5 mm resolution. Raw data should be 
reconstructed by means of iterative expectation maximization algorithms, which provide 
superior signal-to-noise ratio compared with filtered back-projection images (Kwee TC, 
Kwee RM et al., 2008). When one (or both) of the annihilation photos scatters in the body, it 
is prevented to be detected appropriately, which is called attenuation. Attenuation effects 
produce regional nonuniformities, distortions of intense structures, and edge effects. To 
improve anatomical delineation, additional transmission scanning for attenuation correction 
using an external radiation source is required. Attenuation correction also allows for 
semiquantitative evaluation, which offers a more objective way to assess FDG uptake. 
Nonattenuation corrected images should also be evaluated, because the attenuation 
correction itself may also introduce image artifacts (Rohren EM et al., 2004).  
FDG-PET imaging protocols vary from institution to institution, which highlights the need 
for standardization. In the most frequently used protocol, patients fast for 4 - 6 hours prior 
to the injection of FDG. Imaging commences approximately 60 minutes after the injection of 
a typical FDG dose of 370 MBq. Serum glucose levels of less than 150 mg/dl are desirable. 
Patients are also instructed to avoid any kind of strenuous activity prior to the examination 
and following injection of the radioisotope to avoid physiological muscle uptake of FDG.  
Visual analysis of an FDG-PET scan can characterize the intensity of metabolic activity as 
low, moderate or high. In many cases visual image interpretation is sufficient to identify 
malignant lesions. Any focus of visually elevated FDG uptake relative to the background 
(surrounding normal tissue), not located in areas of physiologically increased uptake, is 
regarded as positive for malignant lymphomas (Vermoolen MA et al., 2011). In organs with 
physiological FDG uptake (e.g., spleen and liver), focal or inhomogeneous uptake patterns 
are considered to be indicative of malignant lymphoma (Figure 1). Nevertheless, 
quantitative analysis of FDG uptake may complement visual image interpretation because it 
provides objective criteria, thus minimizing interobserver variability in image 
interpretation. The FDG uptake can also be assessed semiquantitatively using the 
standardized uptake value (SUV). The standardized uptake value, an index of glucose 
metabolism on FDG-PET image, is the ratio between the measured and expected uptake if 
FDG were distributed evenly throughout the body. The maximum standardized uptake 





metabolic response to therapy, and early detection of disease recurrence (Ngeow JY et al., 
2009; Schoder H et al., 2005; Spaepen K et al., 2002; Wu X, P Dastidar et al., 2011). 
Measurements of metabolic burden, which incorporate both FDG uptake and PET lesion 
volume may prove more useful for risk stratification and response assessment (Berkowitz A 
et al., 2008).  
Owing to its high diagnostic accuracy, FDG-PET has become an established imaging 
modality in addition to CT for the initial staging, response assessment, and detection 
recurrence of lymphomas [4]. Previous studies have demonstrated that FDG-PET is superior 
to CT in staging HD and high-grade NHL, with sensitivity, specificity, and accuracy 
reported at 85 - 98% (Hampson FA and AS Shaw, 2008; la Fougere C et al., 2006). As a 
consequence a significant number of patients will have a change of stage, with many of 
these having their management revised (Hampson FA and AS Shaw, 2008). Most commonly 
this results in the disease being upstaged, since patients with true early stage disease are 
differentiated by FDG-PET from those with otherwise occult advanced disease.  
FDG-PET is useful in lymphoma classification or grading, as well as guiding biopsy. Several 
studies have shown that standardized uptake value correlates with the degree of 
malignancy in lymphomas, and in patients with NHL and an standardized uptake value 
greater than 10 are quite likely to have aggressive disease (Okada M et al., 2010). The degree 
of FDG uptake by lymphoma cells may be a biomarker for disease biology: e.g. different 
histopathological subtypes of HD who have exhibited significantly different levels of FDG 
uptake (Hutchings M et al., 2006). Similarly, grade III follicular lymphomas appear to have 
significantly higher FDG uptake than grade I or II follicular lymphomas (Tang B et al., 2009). 
FDG uptake is lower in indolent lymphoma compared to aggressive lymphoma. 
Histological transformation of indolent lymphoma occurs in 20 – 30% of the patients. Recent 
study has shown that FDG-PET can be used as an accurate guide for biopsies in suspected 
transformed tissues (Bodet-Milin C et al., 2008). The standardized uptake value varies 
considerably in different tumors of the same lymphoma patients, and biopsies should be 
performed in the site with the maximum standardized uptake value of the whole body (the 
highest malignancy) that represents the malignancy of the disease (Bodet-Milin C et al., 2008; 
Wu X, P Korkola et al., 2011). However, histological analysis remains the gold standard to 
confirm the transformation, since there is considerable overlap in the range of maximum 
standardized uptake values for different subtypes of lymphomas.  
The main advantage of FDG-PET over anatomical imaging techniques, such as CT, is its 
ability to detect metabolic changes in malignant lymphoma lesions before structural changes 
become visible. A pretreatment FDG-PET scan may identify additional focal bone marrow 
lesions that would be missed by bone marrow biopsy or CT examination (Figure 1). 
Furthermore, FDG-PET surpasses CT in differentiating residual viable tumor tissue from 
therapy-induced fibrosis, and this allows PET performed at the end of treatment to provide 
a more accurate response classification than assessment by CT. Therefore, when FDG-PET 
results are used to make treatment decisions at initial staging and response assessment, 
outcome may improve, particularly in patients with HD and aggressive NHL. In addition, 
early- and mid-treatment PET studies have been shown to be a good predictor of 
progression-free survival and overall survival. However, the value of FDG-PET for staging 
certain indolent NHLs that are not FDG-avid may be limited, and CT imaging remains the 
modality of choice in these subgroups (Vermoolen MA et al., 2011). Routinely, FDG avid 
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malignant lymphomas (HD, diffuse large B-cell lymphoma, follicular lymphoma, and 
mantle cell lymphoma) are well visualized both in initial staging and restaging. However, 
some subtypes of NHL, predominantly low-grade lymphomas, may have low or even no 
uptake of FDG. Nodal and extra-nodal marginal zone lymphomas, small lymphocytic 
lymphomas, primary duodenal follicular lymphoma, cutaneous T-cell lymphomas, and 
peripheral T-cell lymphomas all have been reported to be possibly FDG negative (Kwee TC, 
Kwee RM et al., 2008). Caution is warranted in these histological subtypes of NHL because a 
negative FDG-PET scan could not rule out malignant lesions. It is also considered 
mandatory to perform a pretreatment FDG-PET scan in these variable FDG avid NHLs, 
since comparison of a post-treatment FDG-PET scan to a pretreatment FDG-PET scan will 
lead to more accurate restaging (Kwee TC, Kwee RM et al., 2008).  
A major drawback of FDG-PET is its lack of detailed anatomical information, which 
impedes precise localization of sites with FDG uptake. In addition, FDG-PET is not cancer 
specific; there is possibility of FDG uptake in benign conditions with increased glycolysis 
such as inflammation and granulomatous disease. Additionally, high physiological uptake 
within the brain, myocardium, gastrointestinal tract, urinary tract, muscle, brown fat, 
salivary glands, and thymus may obscure or mimic the presence of tumor deposits. Caution 
also is warranted in patients receiving chemotherapy in conjunction with cytokines, such as 
granulocyte colony stimulating factor, because these patients may have increased bone 
marrow FDG uptake up to 3 weeks after the last dose of cytokines (Kazama T et al., 2005). 
Therefore, a careful evaluation of FDG-PET findings, along with a patient's accurate history 
and clinical examination, is necessary to minimize the number of false-positive 
interpretations. Another disadvantage of FDG-PET is exposure of the patient to ionizing 
radiation.  
In conclusion, 18F-FDG-PET is the imaging technique of choice for initial staging and end-of-
treatment evaluation. However, 18F-FDG is not specific for tumoral tissue. Several factors 
can make the interpretation of PET studies challenging. Chief among these factors are the 
variable physiological uptake of FDG by normal tissues, FDG uptake related to 
inflammation, occasional malignant lesions with low avidity for FDG, limited resolution of 
small lesions, altered biodistribution of FDG related to hyperglycemia or hyperinsulinemia, 
and, in particular, bone marrow activation commonly encountered in cancer patients after 
treatment. It should be kept in mind that also FDG-negative lymphomas exist, and a 
negative 18F-FDG-PET cannot exclude minimal residual disease. The interpretation of PET 
information requires therefore a thorough understanding of the normal physiological 
distribution of FDG in the body, and one should always correlate PET findings with clinical 
and laboratory data, other imaging modalities, and/or a biopsy.  
5.3 FDG-PET/CT fusion 
Advances in the scanner and computer technology enabled the development of PET/CT 
hybrid systems with a hardware-oriented approach to image fusion. With this type of 
scanner, accurately registered anatomical and functional images can be acquired in a single 
examination, and CT data can be used for attenuation correction of PET images. Although 
performed in one imaging section, the two examinations are by no means performed 
simultaneously. Rather, it is typically for the CT scan to be performed first, and the PET scan 
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distribution of FDG in the body, and one should always correlate PET findings with clinical 
and laboratory data, other imaging modalities, and/or a biopsy.  
5.3 FDG-PET/CT fusion 
Advances in the scanner and computer technology enabled the development of PET/CT 
hybrid systems with a hardware-oriented approach to image fusion. With this type of 
scanner, accurately registered anatomical and functional images can be acquired in a single 
examination, and CT data can be used for attenuation correction of PET images. Although 
performed in one imaging section, the two examinations are by no means performed 
simultaneously. Rather, it is typically for the CT scan to be performed first, and the PET scan 





patient motion between the PET and CT scans would lead to inaccurate attenuation 
correction and unreliable fusion. Several manufacturers are now offering integrated FDG-
PET/CT systems combining different models of high-resolution dedicated PET scanners 
and multidetector-row CT scanners in line with a common imaging bed (Blodgett TM et al., 
2007; von Schulthess GK et al., 2006). A computer platform (workstation) is used to 
reconstruct CT and PET data and create fused PET/CT images in the transaxial, coronal, 
and sagittal planes for interpretation. CT attenuation value and the maximum standardized 
uptake value are calculated at this workstation. PET/CT has been shown to increase both 
the accuracy of interpretation and the confidence level of the readers, and it has already 
been proven as an important diagnostic tool in several cancer types, including lymphomas, 
for initial staging, assessing prognosis, therapy monitoring, as well as detection of 
recurrence.  
FDG-PET and CT provide functional and anatomical information, respectively. Integration 
of both modalities may outperform both FDG-PET alone and CT alone in initial staging and 
restaging of malignant lymphoma. FDG-PET/CT fusion, using a combined PET/CT 
scanner, allows more accurate localization of foci with increased FDG uptake than stand-
alone PET, and this may reduce the problems of physiological FDG uptake being 
misinterpreted as pathological and false localization of disease. An additional advantage of 
combined PET/CT is the use of the CT images for attenuation correction of the PET 
emission data, which reduces whole-body scanning time to 30 minutes. This approach also 
provides low-noise attenuation correction factors compared with those from standard PET 
transmission measurements using an external radiation source, and eliminates bias from 
emission contamination of post-injection transmission scans (Kwee TC, Kwee RM et al., 
2008). A pitfall of CT-based attenuation correction, however, is that the use of concentrated 
CT contrast agents, CT beam-hardening artifacts due to metallic implants, and physiological 
motion can result in the alterations of standardized uptake value in lesions or the 
appearance of artifactual lesions. Thus, images without attenuation correction also should 
be evaluated to avoid misinterpretations (Blodgett TM et al., 2007; von Schulthess GK et al., 
2006). In general, integrated PET/CT without iodinated contrast material or contrast-
enhanced CT without PET is used for initial staging of lymphomas. Previous study has 
shown that PET/CT is more sensitive and specific than contrast-enhanced CT and suggested 
that PET/CT performed without intravenous contrast media is sufficient for staging patients 
with HD and aggressive NHL (Schaefer NG et al., 2004). PET/CT in particular is 
recommended for primary diagnosis and follow-up because it is a whole-body imaging 
modality and provides both anatomical and metabolic information. Furthermore, PET/CT 
allows earlier detection of relapse than does morphological imaging with CT or MRI alone, 
and it is frequently used to detect relapse at follow-up of patients with lymphomas. 
Radiation dose is a point of concern in FDG-PET/CT fusion, although the CT portion of a 
PET/CT scan is usually performed at different settings than a standard diagnostic CT to 
decrease the radiation burden.  
5.4 Whole-body magnetic resonance imaging 
The high spatial resolution and excellent soft-tissue contrast make MRI an ideal tool for the 
detection of parenchymal and osseous lesions. However, because of long imaging time, MRI 
was previously used only as a tool to image limited anatomical areas of the body. Recent 
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improvements in MRI technology have resulted in the availability of sufficiently fast and 
with diagnostic image quality sequences for whole-body MRI. As a result, whole-body MRI 
has become feasible for staging malignancies, including malignant lymphomas (Lauenstein TC 
and RC Semelka, 2006). Similar to MRI of limited body regions, whole-body MRI is sensitive to 
susceptibility artifacts, predominantly in the thoracic region, and motion artifacts in the 
abdomen (breathing and peristalsis) and thorax (breathing and cardiac motion). Image 
acquisition under breath-holding or respiratory triggering should therefore be applied.  
Several studies have shown that whole-body MRI is feasible in both adults and children, 
and it may play an important role in staging and follow-up of various cancers, including 
malignant lymphomas (Kwee TC et al., 2009; Lauenstein TC and RC Semelka, 2006; Schmidt 
GP et al., 2009). A major advantage of whole-body MRI in malignant lymphomas is the 
possibility of completely evaluating the spread of disease throughout the entire body, 
including nodal, extra-nodal, and bone marrow involvement, in one examination 
(Vermoolen MA et al., 2011). A disadvantage of whole-body MRI is that the image quality 
may be inferior to that of MRI examinations of limited body regions because the former 
allows less time to acquire different MRI sequences and imaging planes, and generally 
employs a greater slice thickness and lower spatial resolution. The use of a phased-array 
surface coil is preferred because it provides an increased signal-to-noise ratio and spatial 
resolution compared with an integrated body coil. There is no standard whole-body MRI 
protocol for staging malignant lymphomas yet; data regarding preferred sequence and 
imaging plane are lacking. A commonly recommended approach for tumor staging in 
general is the application of fat-suppressed T1-weighted gradient echo sequences before and 
after the administration of intravenous gadolinium, and fat suppressed T2-weighted 
sequence (Figure 2). Previous studies has shown that the fluid-sensitive fat-suppressed T2-
weighted short-tau-inversion-recovery (STIR) sequence is useful for the assessment of the 
skeletal system and the pelvis (Lauenstein TC and RC Semelka, 2006). STIR is a particularly 
sensitive for detecting parenchymal and bone marrow lesions, which are generally 
visualized as structures of high signal intensity on images acquired with this sequence 
(Kwee TC, Kwee RM et al., 2008). However, malignant lymph nodes can not be 
differentiated from benign nodes on the basis of signal intensity, neither on T1- nor on T2-
weighted images.  
Although MRI inherently provides superior soft-tissue contrast to CT and has the potential 
to characterize lesions on the basis of signal characteristics, assessment of nodal involvement 
is still based on size criteria. General criteria for extra-nodal involvement are any signal 
abnormalities or mass lesions involving soft tissues, bones, parenchymal organs, and serosal 
cavities. MRI is superior to CT for imaging the liver, whereas CT is superior to MRI for the 
assessment of mediastinal and pulmonary lymphomatous lesions (Lauenstein TC and RC 
Semelka, 2006). In addition, CT may be more attractive than MRI in patients with reduced 
health status, as it is a faster study and requires less patient cooperation.  
Whole-body MRI is a feasible technique for staging malignant lymphomas, and whole-body 
MR imaging after gadolinium contrast injection can improve contrast and may facilitate 
detection of nodal and extra-nodal lymphomatous lesions (Schmidt GP et al., 2009). 
However, disadvantages of gadolinium application include increased examination time and 
costs, and the potential risk of developing nephrogenic systemic fibrosis in patients with  
renal failure (Vermoolen MA et al., 2011). In contrast to CT, FDG-PET, and FDG-PET/CT 
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Fig. 2. MR images in a 57 year-old male patient with diffuse large B-cell lymphoma.  
Multiple lymph node lesions in the cervical region are shown: A coronal slice of T2-
weighted image without fat-suppression (a) and the corresponding coronal slice of T2-
weighted image with fat suppression (b). An axial slice of T1-weighted image before 
contrast agent injection and the corresponding axial slice of T1-weighted image with 
contrast enhancement (d). An axial slice of T2-weighted image without fat suppression (e) 
and the corresponding axial slice of T2-weighted image with fat suppression (f).  
especially important in children. However, MRI cannot be performed in patients with 
pacemakers, defibrillators, or other implanted electronic devices, and in case of 
claustrophobia. Another limitation of conventional (anatomical) MRI is the lack of 
functional information, which may result in failure to detect pathological changes in 
normal-sized structures. However, it may be overcome with recently developed functional 
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MRI techniques, such as DWI. DWI highlights areas with restricted diffusion that occurs in 
many malignant tumors, including malignant lymphoma, without using contrast agent 
(Schmidt GP et al., 2009; Wu X, PL Kellokumpu-Lehtinen et al., 2011).  
5.5 Diffusion-weighted imaging  
Diffusion-weighted imaging enables the visualization of the random extra, intra, and 
transcellular motion of water molecules in biological tissues (Le Bihan D, 1995). DWI 
provides information on extracellular space tortuosity, tissue cellularity, and the integrity of 
cellular membranes. It can be used for the detection and characterization of pathological 
processes, including determination of lesion aggressiveness and monitoring response to 
therapy of malignant tumors, and it may therefore be of value in staging and follow-up 
evaluation of malignant lymphomas. The signal properties of DWI indicate both the T2 
relaxation time and water diffusion, and reflect the microstructure and physiological state of 
tissue. Thus, subtle changes in tissue architecture can be seen by DWI. In order to create an 
ADC map, at least two datasets with different degrees of diffusion-weighting (i.e. b-values) 
have to be acquired. The ADC value derived from DWI is independent of the magnetic field 
strength and can overcome the effects of ‘T2 shine-through` (an area with a very high T2 
relaxation time may remain as a high signal in DWI and may be mistaken for restricted 
diffusion), thus allowing a more meaningful comparison of results from different studies. In 
general, malignant tissues tend to be hypercellular, with enlarged hyperchromatic nuclei 
and abundant macromolecular proteins (Wang J et al., 2001). These factors reduce the 
diffusion space for water molecules in the extra and intracellular compartments, resulting in 
a decrease in ADC values (Herneth AM et al., 2003; Sumi M et al., 2007). In contrast, the 
breakdown of diffusion barriers in necrotic tissue allows the relatively unhindered diffusion 
of water molecules, resulting in high ADC values (Herneth AM et al., 2003).  
DWI using single-shot echo-planar imaging (EPI) is a well-established method to examine 
the brain. Extra-cranial DWI, however, did not become a clinical standard because the use of 
EPI was complicated by magnetic susceptibility artifacts and severe image distortion in the 
body (Ichikawa T et al., 1998, 1999; Muller MF et al., 1994). Recently introduced parallel 
imaging techniques, such as sensitivity encoding (Bammer R, 2003; Glockner JF et al., 2005), 
and the development of stronger gradients and multichannel coils have largely overcome 
this problem; DWI of adequate quality can now be performed in the body at b-values of 500 
- 1000 s/mm² (Koh DM and DJ Collins, 2007; Thoeny HC and F De Keyzer, 2007). Despite 
the above-mentioned breakthroughs in DWI, breathhold or respiratory triggered scanning 
was still considered necessary, since it was widely accepted that respiratory motion was an 
impediment for DWI of (moving) visceral organs (Low RN and J Gurney, 2007) .  
DWI can be performed quickly and does not require a contrast agent. DW-MRI is not just 
sensitive to microscopic water movements but also to physiological motions of greater 
magnitude, such as blood, cerebrospinal fluid and ductal flows. At low b-values (< 50 - 100 
s/mm2) bulk water movement will be the predominant factor determining the ADC; at 
higher b-values, bulk water motion has less a role in the continued signal attenuation. Thus, 
it is possible to differentiate between the contributions made by water populations of high 
and low mobility by varying the experimental conditions for calculation of the ADC. It is 
generally accepted that with the high b-values used on clinical scanners (up to 500 - 1000 
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The limitations of DWI include the sensitivity to artifacts (e.g. respiration and peristalsis 
movements), and therefore optimization is required to maximize the signal-to-noise ratio 
and to minimize artifacts. Above all, DWI is not specific to cancer. In order to interpret DWI 
correctly, both DW images and ADC maps should be evaluated with caution and compared 
with corresponding anatomical images when necessary.  
Takahara et al. reported a unique concept of whole-body DWI, called “diffusion-weighted 
whole-body imaging with background body signal suppression” (DWIBS) (Takahara T et al., 
2004). This technique intentionally uses free breathing scanning rather than breathholding 
or respiratory triggering to visualize (moving) visceral organs and their lesions. In a study 
comparing pre- and post-chemotherapy FDG-PET with DWIBS, Kwee et al. found that 
DWIBS has higher spatial resolution for the imaging of patients with lymphomas, although 
it has only limited ability to help detect mediastinal lesions (Kwee TC, T Takahara et al., 
2008). In addition, whole-body DWI offers a high lesion-to-background contrast, making it a 
sensitive technique for the detection of lesions (Kwee TC et al., 2009). When DWIBS is added 
to whole-body MRI, both anatomical and functional information can be provided within a 
single examination. A limitation of DWIBS is that the evaluation of structures close to the 
heart, such as mediastinal lymph nodes and the left liver lobe, may be compromised because 
of signal loss and artifacts due to cardiac motion (Vermoolen MA et al., 2011).  
6. View to future 
6.1 Novel PET tracers  
The development of new tracers and smart probes are the two key points in the 
development of multimodality image and diagnostic imaging in future. FDG is in routine 
diagnostics the most commonly used tracer for lymphoma detection and therapy follow-up, 
but it should be kept in mind that also FDG-negative lymphomas exist. A number of new 
radiotracers have been developed and are under clinical evaluation, e.g. [11C]choline, [18]F-
fluorothymidine (18F-FLT). One characteristic of malignant cells is an increased rate of 
cellular proliferation. There is good evidence that 18F-FLT uptake is closely correlated with 
cellular proliferation (Buck AK et al., 2006). However, high uptake in normal bone marrow 
and the liver may limit the sensitivity of FLT-PET for detection of extra-nodal involvement. 
18F-fluoride is a positron-emitting bone-seeking agent that reflects blood flow and 
remodelling of bone, it is also sensitive for detection of lytic and early marrow-based 
metastases. The instant fusion of increased 18F-fluoride uptake with morphological data of 
CT improves the specificity in cancer patients by accurately differentiating between benign 
and malignant uptake sites (Even-Sapir E et al., 2007).  
6.2 Combination of PET with other modalities than CT: PET/MRI 
Among the above-mentioned imaging techniques, no single modality is perfect and 
sufficient to gain all the necessary information. Therefore, the combination of multiple 
imaging techniques can offer synergistic advantages. Multi-modal imaging can be achieved 
either through the combination of imaging hardware such as PET/CT, through the 
combination of different contrast agents, or through co-registration of images acquired with 
different modalities. With regard to lymphatic imaging, this leads to improved accuracy and 
sensitivity of lymph nodes detection. PET/CT has been matured into an important clinical 
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diagnostic tool. Clinical studies have shown that the combination of anatomical structures 
revealed from CT and the functional information from PET into one image, with high fusion 
accuracy, provides an advanced diagnostic tool and research platform. Although PET/CT is 
already an established clinical tool, it still bears some limitations. A major drawback is that 
CT provides only limited soft tissue contrast and exposes the studied patient to a significant 
radiation dose. Since PET and CT scanner are hard-wired back to back and share a common 
patient bed, PET/CT does not allow simultaneous data acquisition. This temporal mismatch 
causes image artifacts by patient movement or respiration motion between the two scans. To 
overcome these limitations, recent research concentrates on the combination of PET and 
MRI into one single machine. The goal of this development is to integrate the PET detectors 
into the MRI scanner which would allow simultaneous data acquisition, resulting in 
combined functional and morphological images with an excellent soft tissue contrast, good 
spatial resolution of the anatomy, and accurate temporal and spatial image fusion. 
Additionally, since MRI provides also functional information such as DWI, blood 
oxygenation level dependant (BOLD) imaging, or spectroscopy, PET/MRI could even 
provide multi-functional information of pathophysiological processes in vivo. Furthermore, 
the radiation dose for PET/MR will be lower than that for PET/CT, being of particular 
importance for repeated studies aimed to evaluate disease progression and therapy 
response. First experiments with PET/MRI prototypes showed promising results, indicating 
its great potential for clinical imaging (Shao Y et al., 1997; Wagenaar DJ et al., 2006). 
Multimodality imaging techniques will play a leading role in clinical applications and 
development of diagnostic imaging in oncology.  
6.3 High field MRI and new MR contrast agent 
As MRI systems operating at 1.5 T are now widely available and provide high-quality 
whole-body images in a reasonable acquisition time, implementation of whole-body MRI 
into diagnostic protocols for malignant lymphomas is expected in the near future. In 
particular, MRI may be expected to be suitable to replace CT for initial staging and response 
evaluation, as part of radiation-minimizing policies, especially in children and pregnant 
women. Whole-body MRI at higher field strength (3.0 T) may increase the image quality and 
lesion conspicuity with a reduced scan time, since it has higher signal-to-noise ratio. 
However, whole-body MRI at 3.0 T is more sensitive to artifacts and has not yet been proven 
to be diagnostically superior to whole-body MRI at 1.5 T (Schmidt GP et al., 2007).  
Superparamagnetic iron oxide nanoparticles, which are MRI-specific lymphographic agents, 
are currently under investigation and can potentially play a role in staging of malignant 
lymphoma by identifying involved lymph nodes independent of lymph node size (Will O et 
al., 2006).  
7. Conclusion 
In conclusion, making the diagnosis of lymphoma often requires multiple imaging 
modalities, and CT is currently the most commonly used means for staging patients with 
malignant lymphomas. However, CT lacks functional information, which impedes 
identification of disease in normal-sized organs. 18F-FDG-PET and hybrid FDG-PET/CT are 
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fluorothymidine (18F-FLT). One characteristic of malignant cells is an increased rate of 
cellular proliferation. There is good evidence that 18F-FLT uptake is closely correlated with 
cellular proliferation (Buck AK et al., 2006). However, high uptake in normal bone marrow 
and the liver may limit the sensitivity of FLT-PET for detection of extra-nodal involvement. 
18F-fluoride is a positron-emitting bone-seeking agent that reflects blood flow and 
remodelling of bone, it is also sensitive for detection of lytic and early marrow-based 
metastases. The instant fusion of increased 18F-fluoride uptake with morphological data of 
CT improves the specificity in cancer patients by accurately differentiating between benign 
and malignant uptake sites (Even-Sapir E et al., 2007).  
6.2 Combination of PET with other modalities than CT: PET/MRI 
Among the above-mentioned imaging techniques, no single modality is perfect and 
sufficient to gain all the necessary information. Therefore, the combination of multiple 
imaging techniques can offer synergistic advantages. Multi-modal imaging can be achieved 
either through the combination of imaging hardware such as PET/CT, through the 
combination of different contrast agents, or through co-registration of images acquired with 
different modalities. With regard to lymphatic imaging, this leads to improved accuracy and 
sensitivity of lymph nodes detection. PET/CT has been matured into an important clinical 
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diagnostic tool. Clinical studies have shown that the combination of anatomical structures 
revealed from CT and the functional information from PET into one image, with high fusion 
accuracy, provides an advanced diagnostic tool and research platform. Although PET/CT is 
already an established clinical tool, it still bears some limitations. A major drawback is that 
CT provides only limited soft tissue contrast and exposes the studied patient to a significant 
radiation dose. Since PET and CT scanner are hard-wired back to back and share a common 
patient bed, PET/CT does not allow simultaneous data acquisition. This temporal mismatch 
causes image artifacts by patient movement or respiration motion between the two scans. To 
overcome these limitations, recent research concentrates on the combination of PET and 
MRI into one single machine. The goal of this development is to integrate the PET detectors 
into the MRI scanner which would allow simultaneous data acquisition, resulting in 
combined functional and morphological images with an excellent soft tissue contrast, good 
spatial resolution of the anatomy, and accurate temporal and spatial image fusion. 
Additionally, since MRI provides also functional information such as DWI, blood 
oxygenation level dependant (BOLD) imaging, or spectroscopy, PET/MRI could even 
provide multi-functional information of pathophysiological processes in vivo. Furthermore, 
the radiation dose for PET/MR will be lower than that for PET/CT, being of particular 
importance for repeated studies aimed to evaluate disease progression and therapy 
response. First experiments with PET/MRI prototypes showed promising results, indicating 
its great potential for clinical imaging (Shao Y et al., 1997; Wagenaar DJ et al., 2006). 
Multimodality imaging techniques will play a leading role in clinical applications and 
development of diagnostic imaging in oncology.  
6.3 High field MRI and new MR contrast agent 
As MRI systems operating at 1.5 T are now widely available and provide high-quality 
whole-body images in a reasonable acquisition time, implementation of whole-body MRI 
into diagnostic protocols for malignant lymphomas is expected in the near future. In 
particular, MRI may be expected to be suitable to replace CT for initial staging and response 
evaluation, as part of radiation-minimizing policies, especially in children and pregnant 
women. Whole-body MRI at higher field strength (3.0 T) may increase the image quality and 
lesion conspicuity with a reduced scan time, since it has higher signal-to-noise ratio. 
However, whole-body MRI at 3.0 T is more sensitive to artifacts and has not yet been proven 
to be diagnostically superior to whole-body MRI at 1.5 T (Schmidt GP et al., 2007).  
Superparamagnetic iron oxide nanoparticles, which are MRI-specific lymphographic agents, 
are currently under investigation and can potentially play a role in staging of malignant 
lymphoma by identifying involved lymph nodes independent of lymph node size (Will O et 
al., 2006).  
7. Conclusion 
In conclusion, making the diagnosis of lymphoma often requires multiple imaging 
modalities, and CT is currently the most commonly used means for staging patients with 
malignant lymphomas. However, CT lacks functional information, which impedes 
identification of disease in normal-sized organs. 18F-FDG-PET and hybrid FDG-PET/CT are 





malignant lymphomas. MRI techniques such as whole-body MRI and DW-MRI may be 
good radiation-free alternatives to FDG-PET/CT in lymphoma patients with multiple 
follow-up examinations, which may be particularly relevant for children and those who are 
not suitable for PET/CT exams. Furthermore, in assessment of patients with non-FDG-avid 
lymphomas MRI could become the imaging modality of choice. However, well-designed 
studies are needed to validate the accuracy of whole-body MRI and DWIBS for the staging 
and response assessment of malignant lymphomas.  
8. Take home message 
 Computed tomography remains the most commonly used modality for initial staging 
patients with malignant lymphomas because of its widespread availability and 
relatively low cost. 
 FDG-PET and integrated FDG-PET/CT are the established imaging modalities for 
initial staging and response assessment of lymphomas. Integrated PET/CT has higher 
diagnostic accuracy than CT and FDG-PET alone. 
 Whole-body MRI and DW-MRI are emerging radiation-free alternative imaging 
techniques for initial staging and treatment response evaluation of lymphomas. 
However, large studies are needed to determine the value of whole-body MRI and 
DWIBS.  
 MRI at 3 T and combined PET/MRI may have potential for future clinical applications.  
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1. Introduction  
The epidermal growth factor (EGF) receptor (EGFR, HER1, ErbB1) and human epidermal 
growth factor receptor type 2 (HER2, ErbB2) belong to the ErbB family of type I tyrosine 
kinases (TKs). This family of receptor TKs also includes another two closely related 
members HER3/ErbB3 and HER4/ErbB4. The general structure of these cell surface 
receptor proteins contains an extracellular ligand-binding domain, a hydrophobic 
transmembrane domain, an intracellular tyrosine kinase domain and a non-catalytic 
carboxyl terminal tail (Ferguson et al., 2000; Kari et al., 2003; Mitsudomi & Yatabe, 2010; 
Pines et al., 2010). Various ligands for EGFR, HER3 and HER4 have been identified, with 
EGF the most extensively characterized for its binding and activation of EGFR. These ErbB 
proteins are present in the plasma membrane as monomers. Upon ligand binding, the ErbB 
receptors can associate with each other to form different receptor dimers, which may be 
homodimers (e.g., EGFR-EGFR) or heterodimers (e.g., EGFR-HER2). The dimerization 
results in the activation of kinase activity and downstream signaling pathways, which often 
leads to cell proliferation and malignant tumor growth. HER2 is an exception, with no 
compatible ligand identified. However, it is the preferred heterodimerization partner for all 
other ErbB members (Mishani & Hagooly, 2009; Niu et al., 2008; Tzahar et al., 1996; Yarden 
& Sliwkowski, 2001).  
As EGFR and HER2 play important roles in many physiological and pathological processes, 
it is not surprising that deregulation of EGFR and HER2 is associated with various types of 
malignancies (Kari et al., 2003; Niu et al., 2008; Yarden & Sliwkowski, 2001). Both 
overexpression and mutation of EGFR have been identified in various types of cancers, 
while overexpression is a more commonly employed mechanism in the case of HER2 
(Yarden & Sliwkowski, 2001). In these cancer cells, the TK activity is either elevated or 
constitutively activated. EGFR- and HER2-targeted anti-cancer medicines have been 
developed by either targeting the extracellular ligand-binding domain through antibody 
blocking, or by inhibiting the tyrosine kinase activity using low-molecular-weight molecules 
(Baselga, 2006; Pines et al., 2010; Speake et al., 2005). Cetuximab (a humanized mouse 
antibody) and panitumumab (a fully human antibody) have been approved for selected 
EGFR-targeted cancer treatment. Although these antibodies are designed to down-regulate 
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EGF the most extensively characterized for its binding and activation of EGFR. These ErbB 
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homodimers (e.g., EGFR-EGFR) or heterodimers (e.g., EGFR-HER2). The dimerization 
results in the activation of kinase activity and downstream signaling pathways, which often 
leads to cell proliferation and malignant tumor growth. HER2 is an exception, with no 
compatible ligand identified. However, it is the preferred heterodimerization partner for all 
other ErbB members (Mishani & Hagooly, 2009; Niu et al., 2008; Tzahar et al., 1996; Yarden 
& Sliwkowski, 2001).  
As EGFR and HER2 play important roles in many physiological and pathological processes, 
it is not surprising that deregulation of EGFR and HER2 is associated with various types of 
malignancies (Kari et al., 2003; Niu et al., 2008; Yarden & Sliwkowski, 2001). Both 
overexpression and mutation of EGFR have been identified in various types of cancers, 
while overexpression is a more commonly employed mechanism in the case of HER2 
(Yarden & Sliwkowski, 2001). In these cancer cells, the TK activity is either elevated or 
constitutively activated. EGFR- and HER2-targeted anti-cancer medicines have been 
developed by either targeting the extracellular ligand-binding domain through antibody 
blocking, or by inhibiting the tyrosine kinase activity using low-molecular-weight molecules 
(Baselga, 2006; Pines et al., 2010; Speake et al., 2005). Cetuximab (a humanized mouse 
antibody) and panitumumab (a fully human antibody) have been approved for selected 
EGFR-targeted cancer treatment. Although these antibodies are designed to down-regulate 
EGFR signaling by inhibiting ligand-binding, preventing receptor dimerization and 
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accelerating receptor degradation, antibody-dependent cell-mediated cytotoxicity is also 
considered as an important mechanism for IgG1 isotype antibody cetuximab (Cai et al., 
2008; Okamoto, 2010). Trastuzumab (a humanized mouse antibody) is a widely used 
treatment for breast cancer patients with HER2 overexpression (Niu et al., 2008). Because 
TKs depend on ATP to provide phosphate for the phosphorylation process, small molecules 
that bind to the ATP-binding pocket of the kinase domain can inhibit its enzymatic activity. 
These TK inhibitors (TKIs) may bind either reversibly or irreversibly. Reversible TKIs 
erlotinib and gefitinib are EGFR-specific, while lapatinib inhibits both EGFR and HER2 
(Pines et al., 2010).  
Molecular imaging agents with specific targets can provide information regarding biological 
processes at a cellular level before anatomical changes occur. Similar to the approaches used 
to develop EGFR and HER2 therapeutic agents, two strategies could be used for EGFR- and 
HER2-targeted tumor imaging. The first class of imaging agents targets extracellular domain 
of the receptor. Examples of these imaging agents include whole antibodies, antibody 
fragments, affibodies and nanobodies. The EGFR ligands, which bind to EGFR extracellular 
domain at high affinity, could also be used for this purpose. The second class of molecules 
includes TKIs and analogs that bind reversibly or irreversibly to the kinase domain of the 
receptor. Actually, some of the EGFR- and HER2-targeted therapeutic agents mentioned 
above have been used for tumor imaging after labeling with different functional groups, 
such as radionuclides for positron emission tomography (PET) and single-photon emission 
computed tomography (SPECT) imaging, and fluorescent dyes for optical imaging (Mishani 
et al., 2008; Mishani & Hagooly, 2009; Niu et al., 2008).  
2. Imaging agents targeting EGFR  
2.1 Anti-EGFR antibodies  
PET imaging with 64Cu (t1/2 = 12.7 h)-labeled cetuximab (64Cu-DOTA-cetuximab) was 
employed to measure the EGFR expression in seven xenograft tumor models in vivo. The 
data was compared with EGFR levels in the tumors determined by Western blot. A 
reasonable linear correlation (R2 = 0.80) between the tumor uptake of 64Cu-DOTA-cetuximab 
(measured by PET) and the EGFR protein expression level (measured by Western blot) was 
discovered. It was also found that 64Cu-DOTA-cetuximab had increasing tumor 
accumulation over time in EGFR-positive tumors but relatively low uptake in EGFR-
negative tumors (Cai et al., 2007). In a following study, 64Cu-DOTA-cetuximab was used to 
monitor the early response of EGFR degradation induced by 17-allyamino-17-
demethoxygeldanamycin (17-AAG) treatment (Niu et al., 2008). 17-AAG is an Hsp90 
inhibitor, which induces the degradation of EGFR protein (Lang et al., 2007). In a PC-3 
prostate tumor model, 17-AAG treatment induced significant reduction of 64Cu-DOTA-
cetuximab uptake in the tumor. The reduction of 64Cu-DOTA-cetuximab uptake correlated 
well with the lower EGFR protein level in the treated tumor as determined by 
immunofluorescence staining and Western blot (Niu et al., 2008).  
Cetuximab has also been labeled with fluorescent dyes for optical imaging. Cy5.5 (Ex/Em: 
675/695 nm)-labeled cetuximab (cetuximab-Cy5.5) was taken up specifically by head and 
neck squamous cell carcinoma (HNSCC) xenografts. The fluorescence from mouse tumors 
treated with cetuximab-Cy5.5 was significantly higher compared to a control probe IgG1-
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Cy5.5 (Rosenthal et al., 2007). To reduce the background fluorescence signal, a two-step 
activation strategy was designed. EGFR-overexpressing tumors (A431) were pre-targeted 
with biotinylated cetuximab, followed by administration of neutravidin conjugated with 
BODIPY-FL fluorescent dye (nAv-BDPfl). As the fluorescence of nAv-BDPfl increases 
dramatically (~ 10-fold) upon binding to biotin, the nAv-BDPfl signal will be specifically 
activated at the tumor site, where the biotinylated cetuximab was concentrated. Not 
surprisingly, this approach produced a higher tumor-to-background ratio (Hama et al., 
2007). Another activatable probe employed the fluorescence quenching of ICG after 
conjugation with antibodies. The fluorescence could be restored by disrupting the molecular 
interaction between ICG and antibodies either in vitro (SDS plus 2-ME treatment) or in vivo 
(target binding and internalization). ICG-labled panitumumab (labeling ratio 1:5) exhibited 
a 58-fold signal increase upon SDS/2-ME treatment. EGFR-overexpressing tumors (A431 
and MDA-MB-468) could be identified by this probe. Two other antibodies, trastuzumab 
(anti-HER2) and daclizumab (anti-CD25) were also labeled with ICG and used to image 
their respective targets in this study (Ogawa et al., 2009).  
In an attempt to extend EGFR-targeted imaging with cetuximab to clinical scenario, 
cetuximab was labeled with 99mTc (t1/2 = 6 h). The resulting imaging probe 99mTc-EC-C225 
was evaluated by cell uptake assay, and in tumor-bearing mice and rats. SPECT imaging on 
a patient with squamous cell carcinoma visualized the tumor 2 h after 99mTc-EC-C225 
administration (Schechter et al., 2003). Assessment of the radiation dosimetry of this probe 
indicated that it has reasonable dosimetric properties for a diagnostic nuclear medicine 
agent (Schechter et al., 2004).  
EGFR variant III (EGFRvIII) is a common in-frame deletion mutant that lacks a large part of 
the extracellular portion (exons 2-7), including components of the ligand-binding domain 
(Ekstrand et al., 1992). EGFRvIII is constitutively activated, and associated with 
glioblastoma and some other tumors, such as prostate and breast cancer (Wikstrand et al., 
1998). EGFRvIII could be recognized by ch806, a chimeric anti-EGFR antibody that 
selectively binds an EGFR epitope exposed only on mutant, overexpressed, or ligand-
activated forms of the receptor (Panousis et al., 2005). 124I (t1/2 = 4.2d)-labeled ch806 (124I -
IMP-R4-ch806) was able to detect EGFRvIII expressing tumors (U87MG.EGFRvIII) at 24 h 
after probe injection, and prolonged retention was evident up to 168 h post-injection. There 
was a good correlation between in vivo tumor PET quantitation of 124I -IMP-R4-ch806 and ex 
vivo measurement from dissected tissues. Remarkably, this probe was tumor-specific, and 
no significant binding to normal tissue was observed (Lee et al., 2010). This is in contrast to 
cetuximab, which accumulates in EGFR-expressing tissues such as liver (Niu et al., 2008).  
2.2 EGFR-specific antibody fragments 
Due to their large size (~150 kDa), the antibody-based imaging agents suffer from 
drawbacks such as long biodistribution time, poor penetrating capability, and slow 
clearance from the blood and normal tissues, which causes limited imaging contrast early 
post-injection, high background signal and non-uniform tumor penetration (Gong et al., 
2010; Schier et al., 1996). Antibodies could be dissected into minimal monovalent binding 
fragments, such as Fab (~55 kDa) and scFv (~28 kDa), which retain the binding specificity 
(Holliger & Hudson, 2005). These antibody fragments have also been used for molecular 
imaging studies.  
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The Fab fragment of a fully human antibody that recognizes the native extracellular domain 
of EGFR was labeled with 125I (t1/2 =59.4 d). The binding of 125I-Fab to EGFR was confirmed 
by immunoprecipitation (IP) and fluorescence-activated cell sorting (FACS). In an animal 
imaging study, 125I-Fab was able to distinguish the tumors with different levels of EGFR 
expression (Xu et al., 2009). An EGFR-specific scFv was isolated from a phage display 
library, and labeled with either quantum dot (QD) for fluorescence imaging, or magnetic 
iron oxide (IO) for magnetic resonance imaging (MRI). The resulting EGFR-targeted 
nanoparticles were discovered to accumulate in pancreatic xenograft tumors by tissue 
section fluorescence imaging and whole animal MRI (Yang et al., 2009). To achieve site-
specific labeling, an anti-EGFR scFv was fused to the SNAP-tag creating a fusion protein 
425(scFv)SNAP (~48 kDa) (Kampmeier et al., 2010). SNAP-tag is a 20-kDa protein derived 
from the human DNA repair protein O6-alkylguanine-DNA-alkyltransferase (hAGT), which 
reacts with the fluorescent dye conjugated benzylguanine (BG) substrate, leading to 
covalent labeling of the fluorescent dye on the fusion protein (Keppler et al., 2004). The 
fusion protein 425(scFv)SNAP labeled with the near-infrared (NIR) substrate BG-747 
accumulated rapidly and specifically at the tumor site. Due to the efficient clearance, the 
tumor to background ratio (TBR) of this probe was significantly higher compared to the full-
length antibody cetuximab (Kampmeier et al., 2010).  
Camelids contain a unique type of antibodies lacking the light chain (Hamers-Casterman et 
al., 1993). The single variable domain of heavy chain (VHH) has been isolated, and termed 
nanobody (~15 kDa). Several EGFR-specific nanobodies were labeled with 99mTc for SPECT 
imaging. These 99mTc-lableded nanobody molecules showed high specificity towards EGFR-
overexpressing A431 tumors. The clearance from the blood was fast. The probe 
accumulation in the kidney was much higher than that in the liver, indicating a kidney 
clearance route (Gainkam et al., 2008; Huang et al., 2008). We labeled an EGFR-specific 
nanobody molecule (a kind gift from Dr. Paul van Bergen en Henegouwen at Utrecht 
University) with a NIR fluorescent dye IRDye® 800CW (Ex/Em: 774/789 nm) and used it 
for in vivo optical imaging. A431 xenograft tumors could be clearly identified at 1d post-
injection with different dosages (0.4, 0.8 and 1.6 nmol per mouse) (Fig. 1). Consistent with 
SPECT results, the kidney accumulation of this fluorescent probe was high (Gong et al., 
unpublished data). To increase the binding affinity and optimize the pharmacokinetic 
properties, a bivalent form of nanobody molecule was created by fusing two monovalent   
 
Fig. 1. In vivo fluorescence imaging of nude mice bearing A431 tumors using an EGFR-
specific nanobody labeled with IRDye 800CW. Images (dorsal view) were acquired at 1 d 
after injection of 1.6 nmol, 0.8 nmol or 0.4 nmol imaging agents, respectively. Arrows 
indicate A431 tumors. The nanobody was a gift from Dr. Paul van Bergen en Henegouwen, 
Utrecht University.  
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nanobody (EG2) molecules to the human Fc fragment. The resulting molecule, EG2-hFc (80 
kDa) was labeled with the fluorescent dye Cy5.5, and compared with Cy5.5-labeled 
monovalent EG2, and Cy5.5-labeled pentavalent derivative V2C- EG2 (128 kDa). In vivo 
pharmacokinetic and biodistribution studies in mice revealed that the plasma half life of 
EG2-hFc-Cy5.5 was much prolonged compared to the other two probes. The retention of 
EG2-hFc-Cy5.5 in EGFR/EGFRvIII-expressing orthotopic brain tumors was also significantly 
higher, resulting in an improved tumor fluorescence signal (Iqbal et al., 2010).  
2.3 Natural ligand EGF 
EGF (MW: 6045 Da) is a small polypeptide that binds with high affinity to EGFR on the cell 
surface (Stoscheck & King, 1986; Yarden & Sliwkowski, 2001). 111In (t1/2 = 2.8 d)-labeled 
hEGF (111In-DTPA-hEGF) was compared with an 111In-labeled monoclonal antibody (111In-
DTPA-MAb528) for in vivo tumor imaging. The blood clearance of 111In-DTPA-hEGF was 
much faster (< 0.2%ID/g for 111In-DTPA-hEGF vs 3%ID/g for 111In-DTPA-MAb528 in the 
blood at 72 h post injection). The tumor accumulation of 111In-DTPA-hEGF was lower. 
Although both probes could visualize EGFR-expressing tumors, the signal from 111In-DTPA-
MAb528 was more prominent at 72 h post-injection (Reilly et al., 2000). The fast clearance of 
EGF makes it advantageous over antibodies for radionuclides with shorter half-lives such as 
68Ga (t1/2 = 68 min). 68Ga-labeled hEGF (68Ga-DOTA-hEGF) was used in a microPET imaging 
study. A quick localization of radioactivity in tumors (within 5 min) was demonstrated 
(Velikyan et al., 2005).  
Both Cy5.5- and IRDye 800CW-labeled EGF (named as EGF-Cy5.5 and EGF800 respectively) 
have been successfully used for fluorescence optical imaging of EGFR-expressing tumors. 
The specificity of both probes was verified by competition with excess cetuximab (Ke et al., 
2003; Kovar et al., 2006). However, a direct comparison between these two probes revealed 
that EGF800 produced a significantly lower background and a higher tumor-to-background 
ratio, implying that IRDye 800CW is superior to Cy5.5 for this application (Adams et al., 
2007). Analysis of the excised tumors from EGF800-treated mice demonstrated a good 
correlation between tumor wet weight and in vivo tumor fluorescence signal. Repeated 
administration of EGF800 probe allowed for the non-invasive tracking of orthotopic prostate 
tumor growth (Fig. 2) (Kovar et al., 2006). Another study with EGF800 showed that probe 
accumulation in tumors reflected relative EGFR expression and EGFR occupancy by 
cetuximab (Manning et al., 2008).  
QDs have also been used to label EGF for fluorescence optical imaging. An EGFR targeting 
nanoprobe was formed by coupling NIR QDs to EGF. The tumor-specific accumulation of 
this nanoprobe was demonstrated by both whole animal imaging and ex vivo tissue analysis 
(Diagaradjane et al., 2008).  
2.4 EGFR-specific affibody 
Affibody molecules are a class of affinity proteins composed of 58 amino acid residues that 
are derived from one of the IgG-binding domains of staphylococcal protein A. EGFR-
specific affibody molecules (~7 kDa) have been selected by phage display technology 
(Friedman et al., 2007). A head-to-tail dimeric form (ZEGFR:955)2 that has a higher binding 
affinity was labeled with 111In and successfully used for in vivo imaging of A431 tumors 
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nanobody (EG2) molecules to the human Fc fragment. The resulting molecule, EG2-hFc (80 
kDa) was labeled with the fluorescent dye Cy5.5, and compared with Cy5.5-labeled 
monovalent EG2, and Cy5.5-labeled pentavalent derivative V2C- EG2 (128 kDa). In vivo 
pharmacokinetic and biodistribution studies in mice revealed that the plasma half life of 
EG2-hFc-Cy5.5 was much prolonged compared to the other two probes. The retention of 
EG2-hFc-Cy5.5 in EGFR/EGFRvIII-expressing orthotopic brain tumors was also significantly 
higher, resulting in an improved tumor fluorescence signal (Iqbal et al., 2010).  
2.3 Natural ligand EGF 
EGF (MW: 6045 Da) is a small polypeptide that binds with high affinity to EGFR on the cell 
surface (Stoscheck & King, 1986; Yarden & Sliwkowski, 2001). 111In (t1/2 = 2.8 d)-labeled 
hEGF (111In-DTPA-hEGF) was compared with an 111In-labeled monoclonal antibody (111In-
DTPA-MAb528) for in vivo tumor imaging. The blood clearance of 111In-DTPA-hEGF was 
much faster (< 0.2%ID/g for 111In-DTPA-hEGF vs 3%ID/g for 111In-DTPA-MAb528 in the 
blood at 72 h post injection). The tumor accumulation of 111In-DTPA-hEGF was lower. 
Although both probes could visualize EGFR-expressing tumors, the signal from 111In-DTPA-
MAb528 was more prominent at 72 h post-injection (Reilly et al., 2000). The fast clearance of 
EGF makes it advantageous over antibodies for radionuclides with shorter half-lives such as 
68Ga (t1/2 = 68 min). 68Ga-labeled hEGF (68Ga-DOTA-hEGF) was used in a microPET imaging 
study. A quick localization of radioactivity in tumors (within 5 min) was demonstrated 
(Velikyan et al., 2005).  
Both Cy5.5- and IRDye 800CW-labeled EGF (named as EGF-Cy5.5 and EGF800 respectively) 
have been successfully used for fluorescence optical imaging of EGFR-expressing tumors. 
The specificity of both probes was verified by competition with excess cetuximab (Ke et al., 
2003; Kovar et al., 2006). However, a direct comparison between these two probes revealed 
that EGF800 produced a significantly lower background and a higher tumor-to-background 
ratio, implying that IRDye 800CW is superior to Cy5.5 for this application (Adams et al., 
2007). Analysis of the excised tumors from EGF800-treated mice demonstrated a good 
correlation between tumor wet weight and in vivo tumor fluorescence signal. Repeated 
administration of EGF800 probe allowed for the non-invasive tracking of orthotopic prostate 
tumor growth (Fig. 2) (Kovar et al., 2006). Another study with EGF800 showed that probe 
accumulation in tumors reflected relative EGFR expression and EGFR occupancy by 
cetuximab (Manning et al., 2008).  
QDs have also been used to label EGF for fluorescence optical imaging. An EGFR targeting 
nanoprobe was formed by coupling NIR QDs to EGF. The tumor-specific accumulation of 
this nanoprobe was demonstrated by both whole animal imaging and ex vivo tissue analysis 
(Diagaradjane et al., 2008).  
2.4 EGFR-specific affibody 
Affibody molecules are a class of affinity proteins composed of 58 amino acid residues that 
are derived from one of the IgG-binding domains of staphylococcal protein A. EGFR-
specific affibody molecules (~7 kDa) have been selected by phage display technology 
(Friedman et al., 2007). A head-to-tail dimeric form (ZEGFR:955)2 that has a higher binding 
affinity was labeled with 111In and successfully used for in vivo imaging of A431 tumors 
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(Nordberg et al., 2008). To further improve the binding affinity and specificity, the affibody 
was optimized by affinity maturation process (Friedman et al., 2008). The second generation 
of EGFR-specific affibody has been conjugated with various labels, and characterized in 
detail. 
 
Fig. 2. Tracking of orthotopic prostate tumor growth with EGF800. Male NOD/SCID mice 
were injected orthotopically with 22Rv1 tumor cells. Animals were injected with EGF800 at 
different time points and imaged. The left column shows the tumor progression of a 
representative mouse in color-coded fluorescence images superimposed on the white light 
images. In the right column, total fluorescence in an ROI encompassing the tumor region 
was quantified. Fluorescence intensity is color-coded to assist visualization. Adapted from 
(Kovar et al., 2006) with permission.  
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In vivo imaging with 64Cu- or Cy5.5-labeled ZEGFR:1907 showed fast tumor (A431) targeting 
and good tumor-to-normal tissue contrast. Both agents accumulated at a high level in 
tumor, liver and kidney as revealed by biodistribution study (Miao et al., 2010, 2010). A 
dimeric form of EGFR-specific affibody (13.7 kDa) was labeled with IRDye 800CW (named 
as Eaff800), and used to image A431 xenograft tumors. The tumor could be visualized 1 h 
post-injection, and it became most prominent after 1 d (Fig. 3). The binding and uptake of 
Eaff800 was EGFR-specific because it only produced minimal signal when reacted with SK-
OV-3 cells (HER2-overexpressing) in both cell-based assay and in vivo imaging study. It is 
notable that the liver uptake of Eaff800 was high, possibly due to the cross-reaction between 
Eaff800 and murine EGFR expressed in the liver (Gong et al., 2010).  
 
Fig. 3. In vivo optical imaging of nude mice bearing A431 tumors using Eaff800. (A) A 
representative series of whole body images (dorsal view) acquired at different time points 
following injection of 0.5 nmol Eaff800. The tumors were indicated with arrows. (B) Clearance of 
Eaff800 from the tumor and normal tissue. Average signal intensities were quantified using ROIs 
of equivalent sized areas from the tumor sites and contralateral sites at indicated time points. 
Data were presented as mean ± SD of three individual mice. (C) Tumor-to-background ratio 
(TBR) at different time points after probe injection. TBR was calculated by dividing mean tumor 
signal by mean background signal of the contralateral site. Adapted from (Gong et al., 2010) with 
permission.  
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(Nordberg et al., 2008). To further improve the binding affinity and specificity, the affibody 
was optimized by affinity maturation process (Friedman et al., 2008). The second generation 
of EGFR-specific affibody has been conjugated with various labels, and characterized in 
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In vivo imaging with 64Cu- or Cy5.5-labeled ZEGFR:1907 showed fast tumor (A431) targeting 
and good tumor-to-normal tissue contrast. Both agents accumulated at a high level in 
tumor, liver and kidney as revealed by biodistribution study (Miao et al., 2010, 2010). A 
dimeric form of EGFR-specific affibody (13.7 kDa) was labeled with IRDye 800CW (named 
as Eaff800), and used to image A431 xenograft tumors. The tumor could be visualized 1 h 
post-injection, and it became most prominent after 1 d (Fig. 3). The binding and uptake of 
Eaff800 was EGFR-specific because it only produced minimal signal when reacted with SK-
OV-3 cells (HER2-overexpressing) in both cell-based assay and in vivo imaging study. It is 
notable that the liver uptake of Eaff800 was high, possibly due to the cross-reaction between 
Eaff800 and murine EGFR expressed in the liver (Gong et al., 2010).  
 
Fig. 3. In vivo optical imaging of nude mice bearing A431 tumors using Eaff800. (A) A 
representative series of whole body images (dorsal view) acquired at different time points 
following injection of 0.5 nmol Eaff800. The tumors were indicated with arrows. (B) Clearance of 
Eaff800 from the tumor and normal tissue. Average signal intensities were quantified using ROIs 
of equivalent sized areas from the tumor sites and contralateral sites at indicated time points. 
Data were presented as mean ± SD of three individual mice. (C) Tumor-to-background ratio 
(TBR) at different time points after probe injection. TBR was calculated by dividing mean tumor 
signal by mean background signal of the contralateral site. Adapted from (Gong et al., 2010) with 
permission.  
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The monomer ZEGFR:1907 and dimer (ZEGFR:1907)2 were labeled with 111In and 125I, respectively. 
The resulting four variants, 111In-Bz-DTPA-ZEGFR:1907, 111In-Bz-DTPA-(ZEGFR:1907)2, 125I-PIB- 
ZEGFR:1907 and 125I-PIB-(ZEGFR:1907) 2 were compared in A431 tumor bearing nude mice. At 24 h 
after injection, the use of 111In provided higher tumor radioactivity level than did 125I for 
both the monomer and the dimer. It was also discovered that the tumor uptake of monomer 
was higher than that of dimer, despite a superior cellular retention of radioactivity for dimer 
in cell-based assays. The best probe, 111In-Bz-DTPA-ZEGFR:1907, produced a tumor-to-blood 
ratio of 100 at 24 h after injection (Tolmachev et al., 2009). To investigate the effect of injected 
protein dose, an aliquot of labeled affibody 111In-DOTA-ZEGFR:2377 was diluted in different 
amounts of unlabeled affibody before injection to A431 tumor bearing mice. A bell-shaped 
dose-responsive curve was observed. The initial increase in uptake was reasoned to be 
associated with saturation of EGFR in normal tissues, resulting in more 111In-DOTA-
ZEGFR:2377 available for tumor targeting. Further increase in the unlabeled affibody caused the 
competition of EGFR in the tumor site and reduced 111In-DOTA-ZEGFR:2377 uptake 
(Tolmachev et al., 2010).  
2.5 TKI derivatives  
TKIs targeting EGFR are small organic molecules developed based mainly on the 
anilinoquinazoline moiety. These molecules bind to ATP-binding site of the kinase domain 
either reversibly or irreversibly (Mishani & Hagooly, 2009). Reversible TKI agent gefitinib 
was labeled with 18F (t1/2 = 110 min) to image the EGFR status of different cancer cells. 
However it was discovered that [18F]-gefitinib uptake did not correlate with EGFR 
expression levels due to high non-specific cellular uptake (Su et al., 2008). This finding is in 
agreement with other studies showing that most reversible TKIs were inadequate for in vivo 
imaging despite impressive in vitro profile, including high affinity and specificity toward 
EGFR. These radio-labeled reversible agents often exhibit low uptake in targeted tumors 
and high uptake in non-targeted tissues (Mishani & Hagooly, 2009). Nevertheless, a recent 
study with 11C (t1/2 = 20 min)-labeled erlotinib, another reversible TKI, showed that [11C]-
erlotinib accumulated in HCC827 tumors that expresses high level of EGFR and is sensitive 
to erlotinib treatment. HCC827 xenograft tumors could be visualized by micro-PET 
scanning with [11C]-erlotinib, whereas A549 and NCI358 xenografts (both express low level 
of EGFR) could not. However HCC827 cells also harbor an in-frame deletion mutation in 
exon 19 that contributes to the enhanced sensitivity to erlotinib. It is not clear whether this 
mutation causes the accumulation of [11C]-erlotinib in the tumor (Memon et al., 2009).  
To enhance binding efficacy, much effort has been invested in the development of 
irreversible TKIs as therapeutic drugs and imaging agents (Mishani et al., 2008; Mishani & 
Hagooly, 2009). An irreversible TKI-based radiotracer, morpholino-[124I]-IPQA, has been 
developed and characterized. Morpholino-[124I]-IPQA covalently binds to the ATP-binding 
site of the activated (phosphorylated) EGFR, but not the inactive EGFR. A431 tumors on 
immunocompromised rats and mice were successfully visualized by PET imaging with this 
probe (Pal et al., 2006). A newer version of this probe, [18F]F-PEG6-IPQA, which has better 
water solubility, has also been developed. [18F]F-PEG6-IPQA could detect NSCLC xenograft 
tumors harboring L858R activating EGFR mutations, and did not recognize NSCLC 
xenografts expressing either wild type or L858R/T790M dual mutant EGFR (Yeh et al., 
2011). Another irreversible TKI analog ML04 exhibited excellent specificity to EGFR in vitro. 
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However, in vivo biodistribution analysis of [18F]ML04 showed that the probe uptake in 
EGFR-positive tumors was mainly non-specific, suggesting that further optimization of this 
probe is needed (Abourbeh et al., 2007; Mishani et al., 2008). 
3 Imaging HER2-overexpressing tumors 
3.1 Anti-HER2 antibodies  
HER2 amplification was initially observed in human breast cancer and was subsequently 
identified in ovarian cancer and other types of cancers (Niu et al., 2008; Slamon et al., 1989; 
Zhang et al., 1989). HER2 expression is highly conserved between primary breast lesions 
and metastases in lymph node, bone marrow as well as distant locations (Gancberg et al., 
2002; Lopez-Guerrero et al., 2006; Regitnig et al., 2004; Simmons et al., 2009; Simon et al., 
2001; Tapia et al., 2007; Vincent-Salomon et al., 2007); and remains so throughout therapy 
(Carlsson et al., 2004; Gong et al., 2005; Pectasides et al., 2006). Thus, accurate assessment of 
HER2 expression levels is of great interest for identifying breast cancer patients who will 
benefit from HER2-targeted therapy.  
Trastuzumab (Herceptin; Genentech, CA), a recombinant humanized monoclonal antibody 
directed against the extracellular domain of the HER2 protein, was engineered by inserting 
the complementarity determining region of a murine antibody (clone 4D5) into the 
framework of a consensus human IgG1 (Carter et al., 1992). Tratuzumab has been shown to 
be effective in early-stage breast cancer that overexpresses HER2. Clinical trials indicate that 
combining tratuzumab treatment with standard chemotherapy for early-stage HER2 
positive breast cancer reduces the risk of recurrence and death when compared to 
chemotherapy alone, thereby improving disease-free and overall survival rates in patients 
(Baselga et al., 2006; Romond et al., 2005). 
Trastuzumab was radio-labeled with 111In using DTPA as a chelator. 111In-DTPA-
trastuzumab selectively bound to the human HER2 receptor in in vitro analysis. 
Biodistribution and tumor targeting were studied in SK-OV-3 (HER2+) and GLC4 (HER2-) 
tumor-bearing athymic mice. The SK-OV-3 tumor showed substantial uptake of the labeled 
antibody after 5 h. The difference in uptake between SK-OV-3 and GLC4 tumors was even 
more pronounced 3 d after injection. At that time, the SK-OV-3 tumor was clearly visualized 
by radioimmunoscintigraphy (Lub-de Hooge et al., 2004). Research has also demonstrated 
that fluorescent dye-labeled trastuzumab enabled differentiation between breast cancer cells 
expressing high and low levels of HER2. Serial imaging before and during trastuzumab 
therapy revealed a significant reduction in probe uptake with treatment (Gee et al., 2008). 
Trastuzumab was also used to mediate the cellular internalization of pH-activatable 
fluorephores. These probes produced minimal fluorescence outside of the cell, and were 
activated by sensing the pH change in the lysosome after internalization (Urano et al., 2009). 
Other optical imaging based applications include imaging SK-BR-3 tumors with Cy5.5-
labeled trastuzumab (Hilger et al., 2004), and distinguishing between HER2+ pulmonary 
metastases and HER2- pulmonary metastases using rhodamine green-conjugated 
trastuzumab (Koyama et al., 2007).  
Another antibody against HER2 used for imaging applications is pertuzumab, a humanized 
antibody derived from the murine antibody 2C4. Unlike trastuzumab, pertuzumab sterically 
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site of the activated (phosphorylated) EGFR, but not the inactive EGFR. A431 tumors on 
immunocompromised rats and mice were successfully visualized by PET imaging with this 
probe (Pal et al., 2006). A newer version of this probe, [18F]F-PEG6-IPQA, which has better 
water solubility, has also been developed. [18F]F-PEG6-IPQA could detect NSCLC xenograft 
tumors harboring L858R activating EGFR mutations, and did not recognize NSCLC 
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However, in vivo biodistribution analysis of [18F]ML04 showed that the probe uptake in 
EGFR-positive tumors was mainly non-specific, suggesting that further optimization of this 
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that fluorescent dye-labeled trastuzumab enabled differentiation between breast cancer cells 
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Another antibody against HER2 used for imaging applications is pertuzumab, a humanized 
antibody derived from the murine antibody 2C4. Unlike trastuzumab, pertuzumab sterically 
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hinders HER2 hetero-dimerization with EGFR and HER3. Pertuzumab conjugated with 
177Lu showed significant tumor uptake in an in vivo study using gamma camera imaging 
(Persson et al., 2005). 
3.2 HER2-specific antibody fragments 
Trastuzumab-derived antibody fragments Fab and F(ab’)2 have also been employed for 
molecular imaging. 111In- or 99mTc-labeled trastuzumab Fab conjugates were used to detect 
HER2-expressing tumors using whole-body scintigraphy. Tumors were visualized 6 h post-
injection (Tang et al., 2005; Tang et al., 2005). Trastuzumab and trastuzumab-derived Fab 
fragment (Fab4D5) labeled with 111In were compared in a MMTV/HER2 mouse allograft 
model. Although Fab4D5 showed accumulation in the tumor as early as 2 h, rapid wash-out 
through the kidneys was observed by 6 h. On the contrary, trastuzumab was slow for tumor 
deposition and slow for clearance from the normal tissues. To improve the pharmacokinetic 
properties of the Fab fragment, an albumin binding sequence was introduced to generate a 
bifunctional molecule (AB.Fab4D5). Similar to Fab4D5 alone, AB.Fab4D5 visualized the 
tumor at 2 h post-injection, but its presence was sustained beyond 24 h, which resembles 
trastuzumab. Intravital microscopy revealed that tumor cell staining by AB.Fab4D5 was 
more uniform than for Fab4D5 or trastuzumab. The association of AB.Fab4D5 with albumin 
altered the clearance route of the probe, and minimal probe accumulation in the kidney was 
observed (Dennis et al., 2007). In another report, trastuzumab F(ab’)2 fragment labeled with 
68Ga was successfully used to quantify the loss and recovery of HER2 induced by HSP90 
inhibitor 17-AAG in mice bearing BT-474 tumors (Smith-Jones et al., 2004). Table 1 
summarizes trastuzumab-based agents for nuclear, optical and dual-modality imaging. This 
table includes only representative agents in each class, thus is in no way a complete list. The 
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Table 1. Summary of molecular imaging agents based on trastuzumab (Herceptin) or 
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3.3 HER2-specific affibody  
Phage display selection yielded affibody molecules that specifically bind to HER2 extracellular 
domain. One of these molecules, His6-ZHER2:4 (affibody ZHER2:4 linked to a histidine tag) targets 
the extracellular domain of HER2 with an affinity (KD) at about 50 nM. The affibody does not 
interfere with trastuzumab binding to HER2, since the binding sites are different (Wikman et 
al., 2004). The specificity of the affibody was illustrated by the uptake of 125I- His6-ZHER2:4 in 
HER2-overexpressing SK-BR-3 breast cancer cells (Tran et al., 2007; Wikman et al., 2004). A 
bivalent version of the affibody (ZHER2:4)2, which has an increased binding affinity (KD = 3 nM) 
was later created (Steffen et al., 2005). When 125I-labeled (ZHER2:4)2 was investigated in an 
animal study, a tumor-to-blood ratio of about 10:1 was obtained 8 h after injection, and the 
tumor region could be visualized using gamma camera imaging (Steffen et al., 2006). However 
a comparison of 125I-labeled (Tolmachev et al., 2009) or 18F-labeled (Cheng et al., 2008) second 
generation affibody molecules (see below) demonstrated that the monomeric form provided 
better tumor targeting than the dimeric form, which is the same as EGFR-specific affibody 
molecules (Tolmachev et al., 2009).  
The second generation of HER2-specific affibody was generated through a single-library 
affinity maturation step. One of them, ZHER2:342, showed a >2200-fold increase in affinity (22 
pM for ZHER2:342 vs 50 nM for ZHER2:4). SK-OV-3 tumor xenografts were imaged 6 h after 
injection of 125I-labeled ZHER2:342. The tumor uptake at 4 h post-injection was improved by a 
factor of 4 compared to the parental molecule ZHER2:4 (Orlova et al., 2006). Comparison of 
124I-labeled ZHER2:342 and trastuzumab demonstrated that better tumor-to-organ ratios were 
obtained with ZHER2:342 due to the more rapid clearance (Orlova et al., 2009). By changing the 
radioisotope to 111In, the labeled molecule 111In-Benzyl-DTPA- ZHER2:342 maintain a KD of 21 
pM. Detection of SK-OV-3 tumors was achieved at 4 h post-injection with a gamma-camera. 
Biodistribution analysis revealed a tumor-to-blood ratio of 100 (Tolmachev et al., 2006). 
HER2-specific affibody molecules were also labeled with fluorescent dyes. The binding 
affinities and specificities of the conjugated molecules were unchanged or minimally 
affected by the modifications. In vivo NIR optical imaging revealed that affibody fused with 
an albumin-binding domain (ABD-(ZHER2:342)2) exhibited a better performance compared to 
either monomer or dimer alone (Lee et al., 2008).  
Site-specific radio-labeling of ZHER2:342 was achieved by synthetic chemistry. The resulting 
111In-DOTA-ZHER2:342-pep2 has a binding affinity of 65 pM. High contrast gamma camera 
images were obtained in the tumor region as early as 1 h after injection. Although pre-
treatment with trastuzumab did not compete with the binding of 111In-DOTA-ZHER2:342-pep2 in 
tumors, degradation of the HER2 receptor using the heat-shock 90 inhibitor 17-AAG before 
probe administration reduced tumor uptake (Orlova et al., 2007). These data taken together 
indicate that, similar to the first generation affibody ZHER2:4, the binding site of ZHER2:342 is 
different from that of trastuzumab, but specific to the HER2 receptor. Site-specific labeling 
of 99mTc was mediated by incorporation of either histidine tag (His6), natural peptide 
sequences CCG, CGGG, or maGGG, maSSS, maSKS, maESE chelators into the ZHER2:342 
sequence. All 99mTc-labeled probes showed tumor-specific uptake at 6 h post-injection or 
earlier using gamma camera imaging (Engfeldt et al., 2007; Engfeldt et al., 2007; Orlova et 
al., 2006; Tran et al., 2007; Tran et al., 2008).  
111In and 68Ga-labeled ZHER2:342 were tested in patients with recurrent metastatic breast 
cancer. These agents detected 9 out of 11 18F-FDG-positive metastases at 2-3 h after injection, 
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suggesting their potential to localize HER2-positive metastases not amenable to biopsy 
(Baum et al., 2010).  
The HER2-specific affibody was further optimized by reengineering the nonbinding surface 
of ZHER2:342 to improve its properties such as storage stability, surface hydrophilicity, melting 
point and amenability for peptide synthesis. The new generation of affibody was created 
and characterized (Ahlgren et al., 2010; Feldwisch et al., 2010).  
The fact that HER2-specific affibodies and trastuzumab target separate epitopes might be 
advantageous when developing these affibodies as imaging agents. These imaging agents 
will not interfere with trastuzumab binding when being used to monitor the therapeutic 
effect of trastuzumab (Baum et al., 2010; Orlova et al., 2007). One cause of concern of these 
affibody-base imaging agents is the high non-specific kidney accumulation. This is due to 
the small molecular weight of the affibody molecules which renders their clearance mainly 
through the kidney.  
3.4 Dual-labeled trastuzumab  
Probes dual-labeled with a radionuclide and a NIR fluorophore enhance the advantages and 
compensate the disadvantages of each modality, and could offer unique opportunities for 
the combination of non-invasive whole body imaging and subsequent intraoperative 
guidance during surgery. To investigate this possibility, trastuzumab was conjugated with 
either 111In (for SPECT imaging) or 64Cu (for PET imaging), and IRDye 800CW to image 
HER2 overexpression in mouse xenograft tumors (Sampath et al., 2010; Sampath et al., 
2007).  
(111In-DTPA)n-trastuzumab-(IRDye800)m was synthesized using a three step process 
wherein, trastuzumab was first conjugated to DTPA and then with IRDye 800CW. Prior to 
animal imaging, radio-labeling with 111In was performed. The agent was validated for 
binding specificity in vitro using the fluorescence microscopy. High probe uptake in HER2-
overexpressing SKBr3-luc tumors was demonstrated using NIR fluorescence, SPECT and 
planar scintigraphy imaging. The tumor-to-muscle ratios were comparable between optical 
and nuclear imaging modalities, but NIR fluorescence imaging had a higher signal-to-noise 
ratio. Since NIR fluorescence imaging has improved sensitivity due to high photon count, it 
can be used to monitor the lymphatic uptake of the dual-labeled antibody after intradermal 
administration into the dorsal aspect of the foot pad. Accumulation into the lymph nodes 
was observed at picomole doses within 1 h after administration, while clearance was 
observed by 24 h (Sampath et al., 2007).  
To test the ability of dual-labeled (64Cu-DOTA)n-trastuzumab-(IRDye800)m to detect 
metastasis, Balb/c mice bearing 4T1.2/R (murine breast cancer cell, HER-) and 4T1.2neu/R 
(murine breast cancer cell, HER+) tumors were used. The diagnostic capability of this dual-
labeled probe was also compared with PET imaging agent 18FDG. (64Cu-DOTA)n-
trastuzumab-(IRDye800)m showed significantly higher uptake in 4T1.2neu/R primary 
tumors compared to 4T1.2/R tumors, indicating in vivo specificity of the dual-labeled 
imaging agent. In contrast 18FDG did not show any preferential uptake between the two 
tumor types. Lung metastases of HER2-overexpressing 4T1.2neu/R cells were successfully 
detected with whole body PET imaging after administration of (64Cu-DOTA)n-trastuzumab-
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(IRDye800)m. Unfortunately, due to its limited penetration capability, whole body NIR 
fluorescence imaging could not detect lung metastases although it detected superficial skin 
metastases successfully. But agent uptake was evident with ex vivo NIR fluorescence 
imaging. Ex vivo NIR fluorescence imaging also visualized the trafficking of imaging agent 
from the primary tumor to lymph nodes, which was not possible for nuclear imaging with 
64Cu. When 18FDG was investigated, it could not detect metastases under these conditions 
(Sampath et al., 2010). 
In another study, it was found that trastuzumab labeled with both ICG and 111In mimicked 
the cocktail of ICG-trastuzumab and 111In-trastuzumab when injected into 3T3/HER2 
tumor-bearing mice. As the fluorescence of ICG in this probe was only activated after 
binding to the HER2 receptor on the cell surface and being internalized, the HER2-
overexpressing tumor could be visualized with minimal background signal (Ogawa et al., 
2009).  
4 Imaging EGFR and HER2 simultaneously  
4.1 Antibodies labeled with fluorescent dyes  
Fluorescence optical imaging has the advantage of multiple channels, which can be 
employed to image two or more targets simultaneously. Cetuximab and trastuzumab were 
labeled with Cy5.5 and Cy7, respectively. The binding and internalization of cetuximab-
Cy5.5 by A431, and trastuzumab-Cy7 by 3T3/HER2+ cells were confirmed by fluorescence 
microscopy. On the contrary, no binding of cetuximab-Cy5.5 to 3T3/HER2+, and 
trastuzumab-Cy7 to A431 was observed. When mice were injected with a cocktail of 
cetuximab-Cy5.5 and trastuzumab-Cy7, A431 and 3T3/HER2+ tumors could be detected 
distinctly based on the Cy5.5 and Cy7 spectral images (Barrett et al., 2007). In a subsequent 
study three antibodies (cetuximab, trastuzumab and daclizumab) were labeled with three 
different fluorophores (Cy5, Cy7 and AlexaFluor700), respectively. Spectrally resolved 
fluorescence imaging showed that these probes clearly distinguished their respective 
targeting tumors (A431, 3T3/HER2+ and SP2-Tac) based on their distinct optical spectra 
(Koyama et al., 2007).  
4.2 Affibody molecules labeled with fluorescent dyes  
The EGFR- or HER2-specific Affibody molecules were labeled with IRDye 800CW and DY-
682, respectively. The labeled probes, Eaff800 and Haff682, were taken up at high levels by 
EGFR-overexpressing A431 and HER2-overexpressing SK-OV-3 cells, respectively. Whole 
animal imaging showed that Eaff800 mainly accumulated in A431 tumor, while more 
Haff682 signal was found in SK-OV-3 tumor (Fig. 4A). Scanning tissue sections of dissected 
tumors confirmed the in vivo data. The liver uptake of Eaff800 was much higher than that of 
Haff682, suggesting a role of murine liver EGFR in the uptake of Eaff800. When the labeled 
fluorophores on the affibody molecules were exchanged (i.e. EGFR-specific affibody labeled 
with DY-682 and HER-specific affibody labeled with IRDye 800CW), the specificities of the 
affibody molecules were not affected (Fig. 4B). These results demonstrated that the tumor 
uptake of these imaging agents is receptor-mediated, and is independent of the fluorophore 
labeled on the affibody molecules (Gong et al., 2010).  
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Fig. 4. Dual-color in vivo optical imaging with EGFR- and HER2-specific affibody molecules. 
Nude mice bearing A431 and SK-OV-3 tumors on the left side and right side, respectively, 
were injected with 100 μl PBS containing (A) 0.5 nmol Eaff800 and 0.5 nmol Haff682, or (B) 
0.5 nmol Haff800 and 0.5 nmol Eaff682. Whole body images (dorsal view) were acquired at 
1d following agent injection. The green color and red color represent IRDye800CW and DY-
682 fluorescence signals, respectively. The tumors were indicated with arrows. Modified 
from (Gong et al., 2010) with permission.  
5. Closing remarks 
In vivo molecular imaging has become a valuable tool in biomedical research and drug 
development (Weissleder & Pittet, 2008; Willmann et al., 2008). The radionuclide-based 
imaging technology, such as PET and SPECT, has been used in clinical applications. In the 
research field, fluorescence optical imaging is becoming more and more popular due to its 
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low cost, ease of use, longer time window for image capture and ability to track multiple 
probes simultaneously. Compared to fluorophores in the visible spectra, imaging with NIR 
fluorophores could reduce the autofluorescence, maximize tissue penetration, and are 
ideally suitable for non-invasive animal imaging applications (Kovar et al., 2007; Weissleder, 
2001). However, even with NIR fluorophores, the direct clinical application of fluorescence 
imaging may be limited to superficial tissues such as breast and skin, or for visualization 
during endoscopy and image-guided-surgery procedures (Kampmeier et al., 2010).  
EGFR- and HER2-targeted molecular imaging may aid in the selection of patients for 
individualized therapy by noninvasively assessing the expression level of EGFR and HER2 
in tumors, and guide drug dosage and regime by measuring target-drug interaction and 
receptor occupancy. It can also be used to assess the responses to therapy in pre-clinical and 
clinical research, and provide valuable information for drug development and validation 
(Kampmeier et al., 2010).  
EGFR and HER2 mediate a complex network of signaling pathways that interweaves with 
many other signaling networks. Interpretation of therapeutic output based solely on EGFR- 
and HER2-targeted imaging results might be oversimplified. Analysis of downstream 
molecules such as p-Erk1/2 may complement EGFR- and HER2-targeted imaging and 
provide new insights for cancer treatment (Cai et al., 2008). For EGFR-targeted therapy, it is 
not uncommon that drug effects are independent of EGFR expression levels in cancer cells. 
In these situations, targeting activated forms of the receptor instead of total receptor level 
may be a more reliable method to predict drug responsiveness (Pantaleo et al., 2009; 
Pantaleo et al., 2009).  
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fluorophores could reduce the autofluorescence, maximize tissue penetration, and are 
ideally suitable for non-invasive animal imaging applications (Kovar et al., 2007; Weissleder, 
2001). However, even with NIR fluorophores, the direct clinical application of fluorescence 
imaging may be limited to superficial tissues such as breast and skin, or for visualization 
during endoscopy and image-guided-surgery procedures (Kampmeier et al., 2010).  
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individualized therapy by noninvasively assessing the expression level of EGFR and HER2 
in tumors, and guide drug dosage and regime by measuring target-drug interaction and 
receptor occupancy. It can also be used to assess the responses to therapy in pre-clinical and 
clinical research, and provide valuable information for drug development and validation 
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EGFR and HER2 mediate a complex network of signaling pathways that interweaves with 
many other signaling networks. Interpretation of therapeutic output based solely on EGFR- 
and HER2-targeted imaging results might be oversimplified. Analysis of downstream 
molecules such as p-Erk1/2 may complement EGFR- and HER2-targeted imaging and 
provide new insights for cancer treatment (Cai et al., 2008). For EGFR-targeted therapy, it is 
not uncommon that drug effects are independent of EGFR expression levels in cancer cells. 
In these situations, targeting activated forms of the receptor instead of total receptor level 
may be a more reliable method to predict drug responsiveness (Pantaleo et al., 2009; 
Pantaleo et al., 2009).  
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1. Introduction 
In 1853, a surgeon at the London Hospital, Adams J, discovered the first case of prostate 
cancer by histological examination [1]. In the report, he noted that the condition was “a very 
rare disease”. Remarkably, 150 years later, prostate cancer has become a significant health 
problem and disease. Prostate cancer continues to have the highest incidence rate of any 
other type of cancer in male, and it is the second leading cause of cancer deaths in male (in 
the United States), with about 220k new cases diagnosed each year only in US [2-4]. 
Detection rates of prostate cancers vary widely across through the world, with less 
frequently detecting in East and South Asia than in Europe, and especially in the United 
States. Prostate cancer tends to develop in men over the age of fifty, and although it is one of 
the most prevalent types of cancer in men. However, many of those patients never have 
symptoms, while undergo no therapy, and eventually die of other causes. The increased 
incidence of prostate cancer patients has led to remarkable changes in diagnosis and 
treatment over the past decades. Fifty years ago the typical patient was a man in his early 
seventies who was diagnosed with metastases to the bone and/or soft tissues [5]. 
Characteristically, these lesions were bulky and histologically poorly differentiated. 
Diagnosis at such an advanced disease status was a death sentence, with patients dying 
within less than two years. Prostate cancer is currently diagnosed by sector biopsy in men 
presenting with an elevated serum prostate-specific antigen level. As for all biopsies, sector 
biopsy for prostate cancer is invasive and limited by sampling error [6]. Now there is a 
genetic and biochemical framework for understanding the process of both sporadic and 
inherited forms of prostate cancer, especially with the development of the new discipline, 
molecular imaging, a valuable tool for the diagnosis for prostate cancer [7]. At present, 
owing to the use of molecular imaging modality, together with the traditional serum PSA 
screening and improved biopsy techniques, most patients could be diagnosed with prostate 
cancer at a stage when it is potentially curable by surgical and/or radiological approaches . 
As a result, the good news is that the diagnosis of prostate cancer is no longer automatically 
a death sentence [8]. 
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Molecular imaging is a newly emerging field, but has became an indispensable tool in 
cancer research, medical practice and clinical trials, with aims at noninvasive, real-time, 
quantitative visualization of in vivo molecular processes occurring at cellular and 
subcellular levels. Molecular imaging allows physicians and clinicians not only to see where 
a tumor is located in the body, but also to visualize the expression and activity of specific 
molecules (small molecular, or large molecular such as protein, antibody, and etc) and 
biological processes (e.g., apoptosis, metastasis, and angiogenesis) which influence tumor 
behavior and/or its response to therapy. At present, advancement in the molecular imaging 
field is promoted by the development of improved imaging hardware for use in preclinical 
and clinical settings, the identification and validation of new, biologically relevant imaging 
targets, and the development of improved imaging probes derived from novel chemicals. Of 
these three essential factors, which comprise the majority of current molecular imaging 
research, hardware developments and novel target discoveries significantly outpace the 
development and clinical advancement of new molecular imaging probes, particularly with 
respect to cancer imaging [9-12]. Hence, molecular imaging, or diagnostic imaging, could 
provide a full prospect of prostate tumor burden by uncovering recurrent and metastatic 
lesions. 
Hererin, we will focus on the discovery of molecular imaging probes that exist for the use of 
molecular imaging as a platform for prostate cancer, rather than specific details of hardware 
and instrumentation. Since molecular imaging probes may also help to guide oncologists, 
physicians and clinicians to identify those patients that could best benefit from a given 
therapeutic regimen, dose, or duration of drug, we will also outline the existing molecular 
imaging probes and modalities that are currently undergoing preclinical and clinical tests 
and those, which have been described based on the different receiptor of prostate cancer, 
that could be rapidly translated into humans. Meanwhile, we will also discuss possible 
future directions and specific application of these and other potential new imaging 
strategies designed to both diagnosis and treatment for prostate cancer. 
2. Imaging probes for prostate cancer based on androgen receptor (AR) 
Androgens are fundamental for the growth, development and maintenance of the prostate. 
Its effects are exerted via the nuclear androgen receptor (AR) which is a ligand-dependent 
transcription activator involved in cellular proliferation and differentiation and is founded 
in all histologic types of prostate tumors. Pathologic and molecular analyses of AR would 
afford the evidence of the gene expression and increased protein mutation, which 
contributes to a change of function, and ligand-independent activation [13, 14]. Since it is 
particularly imperative to find approaches for assessing prostate cancer comprehensively, 
molecular imaging of AR might provide an unprecedented opportunity for deciphering the 
molecular mechanisms involved in the development and natural progression of prostate 
cancer from a localized process to the hormone-refractory metastatic disease. Such 
understanding will be the key for targeted imaging and therapy, as well as for predicting 
and evaluating treatment response and prognosis [15]. An alternative approach to 
radiolabeled antibodies, such as 111In-labeled prostate-specific membrane antigen (PSMA) 
monoclonal antibody (also named as ProstaScint) was reported, with a focus on the 
development of AR radioligands for positron emission tomography (PET), single photon 
emission computerized tomography (SPECT), and magnatic resonance imaging (MRI)-based 
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imaging of the prostate. Generally speaking, AR radiolabeled ligands can be divided into two 
main structural classes, steroidal (such as 18F-FDHT) and nonsteroidal (such as flutamide and 
bicalutamide), or into two different functional classes, androgenic and antiandrogenic [16, 17].  
2.1 Steroidal AR radioligands for imaging prostate cancer 
Zanzonico P and co-workers discovered a steroidal AR radioligand, 18F-FDHT (16β-
[18F]fluoro-5R-dihydrotestosterone), and carried out some basic research to evaluate it [18, 
19]. FDHT is of a structural analog of 5R-di-hydrotestosterone, a principal intraprostatic 
form of androgen. A study of progressive androgen-independent prostate cancer on seven 
patients indicated that 18F-FDHT may be a promising new radiotracer compare with 18F-
FDG. In the relevant study of fluorinated androgen analogs in baboon, performed by Welch 
group, the uptake of FDHT in the prostate was blocked by coadministration of cold 
tesosterone (reduced about 10-fold) [20]. To date, FDHT appears to bind specifically to 
androgen receptors in vivo and to be of the most favorable targeting properties for 
noninvasive imaging among all receptor-binding radiotracers studied before. In other 
researches, 18F-FDHT present some advantages such as fast tumor uptake and prolonged 
retention of radioactivity observed in human studies. However, limitations such as 















Scheme 1. The chemical structure of Testosterone and 18F-FDHT. 
2.2 Nonsteroidal AR radioligands for imaging prostate cancer 
Nonsteroidal AR radioligands, (R)-[11C]-dimethylaminehydroxy-flutamide derivatives 
(Scheme 2, probe 2, 3, and 4), were designed, synthesized and radiosynthesised by Jacobson O 
et al in 2006 [24]. The preliminary biological evaluations of three novel nonsteroidal flutamide 
derivative androgen ligands demonstrated some significant benefits compared with the 
currently used commercial drugs. These compounds have higher or similar affinities to the AR 
when compared with 3-bromo-hydroxyflutamide and hydroxyflutamide. However, unlike 
other reported nonsteroidal radiolabeled AR ligands, these compounds have an electron-rich 
group (dimethylamine) located on the methyl moiety, which may confer a better stability to 
the molecule. Additionally, they serve as an anchor for carbon-11 labeling in a more 
straightforward approach than labeling with fluorine-18 or bromine-76. Furthermore, some 
other nonsteroidal agents are being evaluated for prostate cancer imaging, based on 
hydroxyflutamide and bicalutamide pharmacophores, for example, as shown in Scheme 2, (R)-
[18F]-hydroxyflutamide (5), 3-[76Br]-bromo-hydroxyflutamide (6), [18F]- bicalutamide (7), 
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Scheme 2. Chemical structures of some nonsteroidal AR radioligands for imaging prostate 
cancer. 
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[76Br]-bromo-bicalutamide (8), and [76Br]-bromo-thiobicalutamide (9) [25, 26]. Additionally, 
[76Br]-bromo-bicalutamide compound has been found  to have an order of magnitude 
higher affinity for AR than that of bicalutamide (Kd of 0.113 μM for [76Br]-bromobica-
lutamide versus to Kd of 1.276 μM for bicalutamide). Also, a series of novel prospective 
SPECT imaging agents has been reported very recently. These 99mTc-containing flutamide 
derivatives (10, 11) were synthesized, characterized, and evaluated, with a significant 
selective uptake by a prostate [27]. Furthermore, Marom H et al reported a new nonsteroidal 
antiandrogen-lanthanoid metal complexes (12) as a potential MRI contrast agent for prostate 
cancer diagnostics [28]. These interesting results demonstrate that AR provides a more 
sensitive imaging-based biologic target for imaging and early assessment of treatment 
response. 
3. Imaging probes for prostate cancer based on PSMA 
Serum prostate-specific antigen (PSA) has long been used as an organ-specific biomarker 
and is currently the most commonly used one for prostate cancer. PSA is a 33 kDa 
androgen-regulated serine protease produced by the prostate gland. However, PSA and 
other related parameters have limited sensitivity and limited specificity to prostate cancer. 
Therefore, it may be affected by a manner unrelated to the effect of the therapy on tumor, 
and is the cause of the patients' great anxiety or overstated diagnostic expectations [29, 30]. 
The prostate-specific membrane antigen (PSMA) is expressed in both the benign and the 
neoplastic prostatic epithelial cells and in other tissues, such as kidney, liver, and brain [31]. 
It is upregulated in hormone-resistant states and in metastatic disease. It is a 
transmembrane, 750 amino acid, type II glycoprotein primarily expressed in normal human 
prostate epithelium but overexpressed in prostate cancer, including metastatic disease. 
Because PSMA is expressed by virtually all prostate cancers and its expression is further 
increased in poorly differentiated, metastatic and hormone-refractory carcinomas, it is a 
very attractive target for prostate cancer imaging and therapy [32, 33]. Recently, researchers 
from Johns Hopkins University presented the preparation of radiolabeled small-molecule 
ligands for PSMA ([125I]DCIT, [11C]DCMC, [18F]DCFBC], as well as seven technetium 
99m- or rhenium-labeled chelating agents attached to an amino-functionalized PSMA 
inhibitor with or without a variable length linker moiety [34-36]. These probes were based 
on potential capitalization on PSMA as a relevant biologic target for imaging and therapy of 
prostate cancer. Other works indicated that biotinylated anti-PSMA antibody conjugated to 
streptavidin-labeled iron oxide nanoparticles could be used as the MRI probe for detection 
of prostate cancer cells [37]. T1-weighted signal was greater for cells with magnetic 
particles bound to cell surface than for cells that internalized the particles, whereas no 
such effect was noted with T2-weighted images. Besides, a low molecular weight PSMA-
based fluorescent imaging agent have been relatively extensively studied in prostate 
cancer. 2-(3-(5-[7-(5-amino-1-carboxy-pentyl-carbamoyl)-heptanoy-amino]-1-carboxy-
pentyl)-ureido) entanedioic acid was conjugated with a commercially available near-
infrared light-emitting dye (IRDye 800CW) to afford 16 in good yield. It has a PSMA 
inhibitory activity of 0.37 nM, which is capable of generating target-to-nontarget ratios of at 
least 10 fold in PSMA-expressing PC3-PIP vs PSMA-negative PC3-flu tumors in vivo. It is 
useful for the study of PSMA-expressing tissue in preclinical models or for intraoperative 
guidance [38].  
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of prostate cancer cells [37]. T1-weighted signal was greater for cells with magnetic 
particles bound to cell surface than for cells that internalized the particles, whereas no 
such effect was noted with T2-weighted images. Besides, a low molecular weight PSMA-
based fluorescent imaging agent have been relatively extensively studied in prostate 
cancer. 2-(3-(5-[7-(5-amino-1-carboxy-pentyl-carbamoyl)-heptanoy-amino]-1-carboxy-
pentyl)-ureido) entanedioic acid was conjugated with a commercially available near-
infrared light-emitting dye (IRDye 800CW) to afford 16 in good yield. It has a PSMA 
inhibitory activity of 0.37 nM, which is capable of generating target-to-nontarget ratios of at 
least 10 fold in PSMA-expressing PC3-PIP vs PSMA-negative PC3-flu tumors in vivo. It is 
useful for the study of PSMA-expressing tissue in preclinical models or for intraoperative 
guidance [38].  
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Scheme 3. Probes for imaging prostate cancer based on PSMA. 
4. Other probes for imaging prostate cancer based on EGF receptor, GRP 
receptor, and integrin αvβ3 
[18F]-fluorodeoxyglucose (FDG) (17) is a well known molecular imaging probe for 
monitoring tissue glucose metabolism in clinical trial [39, 40]. Because of the advantages of 
the known mechanism that most tumors are hypermetabolic with increased glucose 
metabolism (Warburg effect), this probe is more suitable for assessing the glucose 
metabolism for prostate cancer. The upregulation of glucose transporter (GLUT) proteins 
(such as GLUT1 and/or GLUT3) and/or increased enzymatic level of hexokinase (HK) and 
activity (primarily HK-II) have been observed in many cancers. GLUT, which affects the 
rate-limiting step, is very important for glucose metabolism. The whole procedure needs 
energy-independent glucose transport across the cell membrane down the concentration 
gradient. Then, glucose is phosphorylated to glucose-6-phosphate by efficiently using HK-II. 
FDG, with a similar structure to glucose, is phosphorylated to FDG-6-phosphate, but when 
compared with glucose-6-phosphate, it cannot be further metabolized in the glycolytic 
pathway and finally trapped and accumulated in the cell owing to its negative charge [41, 
42]. The GLUT1 mRNA expression was observed by Northern blot analysis in both 
androgen-independent cell lines and the androgen-sensitive prostate cancer cell line [43]. A 
related study from Australia demonstrated that the expression of GLUT12 in human 
prostate cancer cell lines potentially enhanced glucose metabolism in prostate tumor [44]. 
These findings may explain the phenomenon of higher FDG accumulation in prostate 
cancer, especially in malignancy grade. However, there are some limitations: the role of 18F-
FDG PET in prostate cancer is controversial, and the results are heavily influenced by the 
Recent Development and Trends  
in Molecular Imaging Probes for Prostate Cancer 383 
patient selection; The uptake of 18F-FDG is low in tumour tissue. The 60%–70% sensitivity 
of 18F-FDG PET for prostate cancer is not high enough to justify its routine clinical use for 
staging or restaging of this disease [45]. The poor performance of 18F-FDG PET is likely 
related to the low glucose metabolic rate that results from the relatively slow growth of most 
prostate cancers as well as to other factors.  
Another PET tracers, such as 11C- or 18F-labeled acetate (18, 19) and choline (20, 21), have 
been extensively studied in prostate cancer [46, 47]. However, 11C acetate is primarily 
retained in prostate cancer cell lines, due to incorporation of the radiocarbon into 
phosphatidylcholine and neutral lipids of the cells [48]. Meanwhile, because of the alteration 
in several enzymes involved in the metabolism of fatty acids and enhanced beta-oxidation 
pathway, it has been observed that fatty acid metabolism rather than glycolysis may be 
dominant in prostate cancer [49]. Recent studies also confirmed that the involvement of the 
fatty acid synthesis pathway in 11C acetate uptake in prostate tumors is an imaging marker 
for fatty acid synthesis expression [50]. Previous clinical studies with 11C- labeled acetate 
(11C-ACE) have reported improved sensitivity, up to 100%, for detection of primary tumors 
in patients with untreated prostate cancer [51, 52]. However, the potential for widespread 
use of 11C-ACE is limited by the short radioactive half-life (20.4 min) of 11C. Accordingly, 
there is considerable interest in identifying positron-emitting radiopharmaceuticals labeled 
with isotopes with longer half-lives that are suitable for imaging of prostate cancer. One 
such radiopharmaceutical that has been studied is 18F-fluoroethylcholine, which also 
appears to be a cell membrane precursor compound [53, 54]. Another potential agent is the 
acetate analog 18F-fluoroacetate (18F-FAC). Fatty acid synthesis is an important pathway in 
cancer cell, which requires major enzyme for converting carbohydrates to fatty acids, and 
the upregulation of the relevant enzyme plays a key role in tumorigenesis of the prostate in 
the transgenic adenocarcinoma of mouse prostate (TRAMP) model [55]. Recently, 
[11C]acetoacetate (22) has also been evaluated as a potential PET probe of ketone body use 
by prostate tumors [56]. It was found that PC-3 androgen-independent prostate tumors 
display moderated uptake of [11C] acetoacetate with rapidly decreasing background 
activity. Further research would be needed to determine the exact biologic relevance of 
imaging ketone body use to the natural history of prostate cancer and how it may be useful 
in a specific clinical setting. 
The epidermal growth factor receptor (EGFR) is over-expressed in a variety of human 
cancers, including in hormone-refractory prostate carcinomas, in which the EGFR has been 
associated with advanced disease stage, resistance to standard treatment and poor 
prognosis. Therefore, the EGFR is considered to be a promising molecular target for 
molecular imaging and therapy for hormone-refractory prostate cancer. Fozing T reported a 
synthesis an EGF receptor tyrosine kinase (EGFR-TK) inhibitor, 123I-PD153035 (23) as 
potential imaging probes. In vitro studies of 123I-PD153035 was found that it accumulats 
highly in human PC-3 and DU-145 prostate cancer cells cooperating with 123I-mAb425, the 
123I radiolabelled IgG2a antibody [57]. In vivo studies of the human prostate cancer 
xenografts in mouse was accurately visualized after i.v. administration of 123I-PD153035 by 
a gamma camera. These data suggest that 123I-PD153035 are promising candidates as an 
imaging probe for EGFR- positive prostate cancer and warrant further in vivo validations to 
ascertain their potential as imaging agents for clinical used. Another radiolabeled bombesin 
(a target molecular with high affinity for GRP receptors) analogues was synthesized and 
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assessed for SPECT (111In label) and PET (64Cu or 18F label) visualization of prostate cancer 
[58, 59]. However, imaging of the GRP receptor is being under the further investigation to 
determine whether it is useful or not in clinical trial for prostate cancer. 
In relation to tumor angiogenesis, the vascular endothelial growth factor (VEGF) signaling 
pathway and the integrin αvβ3 (a cell adhesion molecule) have been identified to play key 
roles. Molecular imaging of these targets in the tumor vasculature may help tailor targeted 
antiangiogenic therapy [60]. Some of PET probes suitable for integrin receptor imaging have 
been reported, and have shown high specificity in various types of tumors, including 
prostate cancer models [61]. Active research continues in identifying more specific biologic 
markers for interrogating the tumor vessels. These investigations will not only shed more 
light on the biologic basis of the complex signals involved in malignancy-induced 
angiogenesis, but may also help facilitate the design and image-based testing of drugs 
targeted to tumor-specific angiogenesis. 
 
Scheme 4. Other small molecular imaging probes for prostate cancer. 
5. Conclusion  
Molecular imaging probes represent an important, growing class of chemical compounds 
for biology, pharmaceutical sciences, preclinic and clinic studies and further application. In 
conjunction with the imaging modality (such as PET, SPECT, MRI and etc), the 
identification of molecular imaging targets and the development of new labeled molecular 
probes for those targets are crucial for expanding the capability of in vivo molecular 
imaging for biological research, molecular diagnostics and drug discovery. In the post 
genomics era, there is the opportunity to advance probes to the point where they can target 
specific biochemical signatures associated with disease, including prostate cancer. Because 
changes in biochemistry occur before diseases reach an advanced stage, molecular imaging 
probes will foster earlier and more personalized diagnosis of disease. Herein, the abilities of 
various probes to assess different functional and molecular characteristics for prostate 
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cancer are being explored and reviewed. The advantages and limitations of imaging agents 
for prostate cancer were outlined in Table 1.  





Advantages Limitations Reference 
1 fast tumor uptake, prolonged 
retention of radioactivity 
rapid metabolic rate, not 
sensitive enough 
21, 22, 23 
2, 3, 4 stablity, easy for 11C label, 
high affinity 
instability of the 11C 
labeled precursor, low 
radiolabeled yield 
24 
13, 14, 15 easy for synthesization, 
specificity, muti-labeled 
methods 
not specific enough (mouse 
kidneys, also express 
PSMA) 
31, 33, 34, 
35, 36, 
17 clinical use, safety not sensitive enough, low 
cellular uptake 
39, 40, 41 




20, 21 clinical use, high sensitivity 
and specificity, suitable for 
PET (20) 




6. Perspective  
Currently, imaging probes for prostate cancer are focused on the construction that yield an 
increased selectivity and sensitiveness of measurements per examination, thus higher 
resolution and quantification accuracy is required. Due to the complication of case 
difference and personalized conditions, more accurate and more efficient forward and 
inversion problems for improving the quantification accuracy will be speed up. The design, 
synthesis and application of dual- and multi-modality probe will be a hot research area, 
which may be the next generation of probe. The combination of different fuctional modality 
undoubtly will improve the accuracy of diagnosis and analysis to prostate cancer. On the 
other hand, a targeted gene-therapy approach is also being developed to activate the 
immune system to recognize prostate cancer cells. To discovery probes based on labeled 
gene and related macromelecule and these types of approaches might provide a new 
direction of prostate cancer therapies. We believe that such imaging probes will play a vital 
role in our further understanding of prostate cancer, in early detection and in the design of 
effective treatments. 
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